PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HWANG, KC; GRAY, CD; SIVASUBRAMANIAN, N; IM, MJ				HWANG, KC; GRAY, CD; SIVASUBRAMANIAN, N; IM, MJ			INTERACTION SITE OF GTP-BINDING G(H) (TRANSGLUTAMINASE-II) WITH PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; GS-ALPHA; TISSUE TRANSGLUTAMINASE; SIGNAL MEDIATOR; PROTEIN; IDENTIFICATION; PURIFICATION; RECEPTOR; ALPHA(1)-ADRENOCEPTOR; RECONSTITUTION	The GTP binding G alpha(h) (transglutaminase II) mediates the alpha(1B)-adrenoreceptor signal to a 69-kDa phospholipase C (PLC). Thus, G alpha(h) possesses both GTPase and transglutaminase activities with a signal transfer role. The recognition sites of this unique GTP binding protein for either the receptor or the effector are completely unknown. A site on human heart G alpha(h) (hhG alpha(h)) has been identified that interacts with and stimulates PLC. Expressed mutants of hhG alpha(h) with deleted C-terminal regions lost the response to (-)-epinephrine and GTP and failed to coimmunoprecipitate PLC by the specific G(h7 alpha) antibody. The interaction regions were further defined by studies with synthetic peptides of hhG alpha(h) and a chimera in which residues VaL(665)-Lys(672) of hhG alpha(h) were substituted with Ile(707)-Ser(714) residues of human coagulation factor XIIIa. Thus, eight amino acid residues near the C terminus of hhG alpha(h) are critical for recognition and stimulation of PLC.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL FFB37,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM45985] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRCKBICHLER PJ, 1981, P NATL ACAD SCI-BIOL, V78, P5005, DOI 10.1073/pnas.78.8.5005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DAS T, 1993, J BIOL CHEM, V268, P27398; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; ITOH H, 1991, J BIOL CHEM, V266, P16226; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MAY DC, 1988, BIOCHEMISTRY-US, V27, P4888, DOI 10.1021/bi00413a045; MURTAUGH MP, 1983, J BIOL CHEM, V258, P1074; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766	23	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27058	27062		10.1074/jbc.270.45.27058	http://dx.doi.org/10.1074/jbc.270.45.27058			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592956	hybrid			2022-12-25	WOS:A1995TE58300056
J	JIANG, Y; YAN, M; GRALLA, JD				JIANG, Y; YAN, M; GRALLA, JD			ABORTIVE INITIATION AND FIRST BOND FORMATION AT AN ACTIVATED ADENOVIRUS E4 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; MAJOR LATE PROMOTER; TRANSCRIPTION INITIATION; NONPHOSPHORYLATED FORM; BASAL TRANSCRIPTION; ATP REQUIREMENT; INVITRO; PHOSPHORYLATION; HELICASE	Abortive initiation at the adenovirus E4 promoter was studied by following the production of RNA formed from the initiating nucleotides UpA and CTP. Formation of a specific short RNA via a reaction with appropriate alpha-amanitin sensitivity required promoter, activator, and ATP, In the absence of any of these, an alpha-amanitin-resistant reaction led to lower levels of a product of unknown origin. The alpha-amanitin-sensitive reaction required open promoter complexes, as assayed directly by permanganate probing. This reaction was not blocked by the inhibition of polymerase C-terminal domain kinase activity or by the lack of DNA supercoiling. Thus, formation of the initial bond of the mRNA appears to require activator and ATP to open the DNA but not phosphorylation of the polymerase C-terminal domain, In addition, the abortive initiation reaction was strongly suppressed when all elongation substrates were present, suggesting that cycling to produce high amounts of abortive product is strongly disfavored during productive initiation at this promoter.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; JACOB GA, 1994, J BIOL CHEM, V269, P3655; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1994, J BIOL CHEM, V269, P5505; JIANG Y, 1995, J BIOL CHEM, V270, P1277, DOI 10.1074/jbc.270.3.1277; JIANG Y, 1994, NUCLEIC ACIDS RES, V22, P4958, DOI 10.1093/nar/22.23.4958; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	44	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27332	27338		10.1074/jbc.270.45.27332	http://dx.doi.org/10.1074/jbc.270.45.27332			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592996	hybrid			2022-12-25	WOS:A1995TE58300096
J	LEE, NG; SUNSHINE, MG; ENGSTROM, JJ; GIBSON, BW; APICELLA, MA				LEE, NG; SUNSHINE, MG; ENGSTROM, JJ; GIBSON, BW; APICELLA, MA			MUTATION OF THE HTRB LOCUS OF HAEMOPHILUS-INFLUENZAE NONTYPABLE STRAIN-2019 IS ASSOCIATED WITH MODIFICATIONS OF LIPID-A AND PHOSPHORYLATION OF THE LIPO-OLIGOSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE LIPOOLIGOSACCHARIDES; ESCHERICHIA-COLI; NULL MUTATIONS; MULTICOPY SUPPRESSOR; POLYACRYLAMIDE GELS; GENE; LIPOPOLYSACCHARIDES; PLASMIDS; MEDIA	The HtrB protein was first identified in Escherichia coli as a protein required for cell viability at high temperature, but its expression was not regulated by temperature. We isolated an htrB homologue from nontypable Haemophilus influenzae strain (NTHi) 2019, which was able to functionally complement the E, coli htrB mutation, The promoter for the NTHi 2019 htrB gene overlaps the promoter for the rfaE gene, and the two genes are divergently transcribed. The deduced amino acid sequence of NTHi 2019 HtrB had 56% homology to E, coli HtrB, In vitro transcription-translation analysis confirmed production of a protein with an apparent molecular mass of 32-33 kDa, Primer extension analysis revealed that htrB was transcribed from a sigma(70)-dependent consensus promoter and its expression was not affected by temperature, The expression of htrB and rfaE was 2.5-4 times higher in the NTHi htrB mutant B29 than in the parental strain, In order to study the function of the HtrB protein in Haemophilus, we generated two isogenic htrB mutants by shuttle mutagenesis using a mini-Tn3, The htrB mutants initially showed temperature sensitivity, but they lost the sensitivity after a few passages at 30 degrees C and were able to grow at 37 degrees C, They also showed hypersensitivity to deoxycholate and kanamycin, which persisted on passage, SDS-polyacrylamide gel electrophoresis analysis revealed that the lipo-oligosaccharide (LOS) isolated from these mutants migrated faster than the wild type LDS and its color changed from black to brown as has been described for E. coli htrB mutants. Immunoblotting analysis also showed that the LOS from the htrB mutants lost reactivity to a monoclonal antibody, 6E4, which binds to the wild type NTHi 2019 LOS. Electrospray ionization-mass spectrometry analysis of the O-deacylated LOS oligosaccharide indicated a modification of the core structure characterized in part by a net loss in phosphoethanolamine. Mass spectrometric analysis of the lipid A of the htrB mutant indicated a loss of one or both myristic acid substitutions. These data suggest that HtrB is a multifunctional protein and may play a controlling role in regulating cell responses to various environmental changes.	UNIV IOWA, DEPT MICROBIOL, IOWA CITY, IA 52242 USA; UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of Iowa; University of California System; University of California San Francisco					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024616, R01AI024616] Funding Source: NIH RePORTER; NCRR NIH HHS [NCRR BRTP 01614] Funding Source: Medline; NIAID NIH HHS [AI 24616] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUKWAIK Y, 1991, MOL MICROBIOL, V5, P2475, DOI 10.1111/j.1365-2958.1991.tb02092.x; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; CHANDLER MS, 1991, PLASMID, V25, P221, DOI 10.1016/0147-619X(91)90016-P; CLEMENTZ T, 1995, 1995 ANN M AM SOC BI, V9, P1311; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; GIBSON BW, 1993, J BACTERIOL, V175, P2702, DOI 10.1128/JB.175.9.2702-2712.1993; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HELANDER IM, 1992, EUR J BIOCHEM, V185, P541; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE NG, 1995, INFECT IMMUN, V63, P818, DOI 10.1128/IAI.63.3.818-824.1995; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; MELAUGH W, 1992, J BIOL CHEM, V267, P13434; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; RAY MK, 1994, J BACTERIOL, V176, P4243, DOI 10.1128/jb.176.14.4243-4249.1994; Sambrook J, 1989, MOL CLONING LABORATO; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WILLIAM JD, 1988, NUCLEIC ACIDS RES, V16, P6127	30	55	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27151	27159		10.1074/jbc.270.45.27151	http://dx.doi.org/10.1074/jbc.270.45.27151			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592970	hybrid			2022-12-25	WOS:A1995TE58300070
J	SCHMIDT, KN; TRAENCKNER, EBM; MEIER, B; BAEUERLE, PA				SCHMIDT, KN; TRAENCKNER, EBM; MEIER, B; BAEUERLE, PA			INDUCTION OF OXIDATIVE STRESS BY OKADAIC ACID IS REQUIRED FOR ACTIVATION OF TRANSCRIPTION FACTOR NF-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; INTACT-CELLS; FACTOR-ALPHA; PHORBOL ESTER; CALYCULIN-A; PHOSPHORYLATION; INTERLEUKIN-1; TRANSLOCATION; INHIBITORS	The widely used phosphatase 1 and 2A inhibitor okadaic acid is one of the many stimuli activating transcription factor NF-kappa B in cultured cells. Phosphorylation of I kappa B-alpha, one of NF-kappa B's inhibitory subunits, is a prerequisite for I kappa B degradation and the subsequent liberation of transcriptionally active NF-kappa B. This observation suggested that the phosphorylation status of IlcB is influenced by an okadaic acid-sensitive phosphatase. In this study, we provide evidence that the effect of okadaic acid on NF-kappa B activation is indirect and dependent on the production of reactive oxygen intermediates rather than the inhibition of an I kappa B-alpha phosphatase. Okadaic acid was found to be a strong inducer of cellular H2O2 and superoxide production in two distinct cell lines. The structurally unrelated phosphatase inhibitor calyculin A also induced oxidative stress. The delayed onset of reactive oxygen production in response to okadaic acid correlated with the delayed activation of NF-kappa B. Moreover, NF-kappa B induction was optimal at the same okadaic acid concentration that caused optimal H2O2 production. Both reactive oxygen intermediates production and NF-kappa B activation were inhibited by the antioxidant pyrrolidine dithiocarbamate and 8-(diethylamino)octyl-3,4,5-trimethyoxybenzoate, a Ca2+ chelator. Future experiments using phosphatase inhibitors in intact cells must consider that the compounds can act as strong inducers of oxidative stress, which provides one explanation for their tumor-promoting activity.	UNIV FREIBURG, INST BIOCHEM, D-79104 FREIBURG, GERMANY; HANNOVER SCH VET MED, INST CHEM, D-30173 HANNOVER, GERMANY	University of Freiburg; University of Veterinary Medicine Hannover, Foundation								AONUMA S, 1991, MUTAT RES, V250, P375, DOI 10.1016/0027-5107(91)90194-S; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHRISTIANSEN NO, 1986, BIOCHIM BIOPHYS ACTA, V882, P57, DOI 10.1016/0304-4165(86)90055-3; GOPALAKRISHNA R, 1992, BIOCHEM BIOPH RES CO, V189, P950, DOI 10.1016/0006-291X(92)92296-A; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEIER B, 1990, BIOL CHEM H-S, V371, P1021, DOI 10.1515/bchm3.1990.371.2.1021; MENON SD, 1993, J BIOL CHEM, V268, P26805; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYER M, 1993, OXIDATIVE STRESS CEL, P217; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MUROI M, 1994, J BIOL CHEM, V269, P30561; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RIECKMANN P, 1992, BIOCHEM BIOPH RES CO, V187, P51, DOI 10.1016/S0006-291X(05)81457-3; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUZUKI YJ, 1993, FREE RADICAL RES COM, V18, P115, DOI 10.3109/10715769309147348; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; THEVENIN C, 1990, New Biologist, V2, P793; TRAENCKNER BM, 1995, IN PRESS J CELL SCI; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	47	165	170	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27136	27142		10.1074/jbc.270.45.27136	http://dx.doi.org/10.1074/jbc.270.45.27136			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592968	hybrid			2022-12-25	WOS:A1995TE58300068
J	ORA, A; HELENIUS, A				ORA, A; HELENIUS, A			CALNEXIN FAILS TO ASSOCIATE WITH SUBSTRATE PROTEINS IN GLUCOSIDASE-DEFICIENT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; INFLUENZA HEMAGGLUTININ; GLYCOPROTEINS; OLIGOSACCHARIDES; AGGREGATION; MATURATION; MEMBRANE; REMOVAL; INVITRO	Increasing evidence shows that calnexin, a membrane-bound chaperone in the endoplasmic reticulum, is a lectin that binds to newly synthesized glycoproteins that have partially trimmed N-linked oligosaccharides. It specifically attaches to core glycans from which two glucoses have been removed by glucosidases I and II. Several recent reports suggest, however, that it can also bind to proteins devoid of N-linked glycans. To investigate the extent of glycan-independent binding, we have analyzed two mutant cell lines (Lee 23 and Pha(R) 2.7) that are unable to process the core glycans because they lack glucosidase I or glucosidase II, respectively, In contrast to parental cell lines, calnexin binding of substrate proteins was found to be virtually nonexistent in these cells. Neither cellular nor viral proteins associated with the chaperone, It was concluded that glycans are crucial for calnexin association and that the vast majority of substrate proteins are therefore glycoproteins.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University			ora, ari/P-5180-2015		NCI NIH HHS [CA 46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CHEN W, 1994, P NATL ACAD SCI USA, V92, P6229; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; GIBSON R, 1979, J BIOL CHEM, V254, P3600; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELANIUS A, 1994, MOL BIOL CELL, V5, P253; HELENIUS A, 1992, CELL BIOL BIOTECHNOL, P125; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM P, 1995, J CELL BIOL, V12, P29; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; METSIKKO K, 1990, J VIROL, V64, P4678; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RAJOGAPALAN S, 1994, SCIENCE, V263, P387; RAY MK, 1991, J BIOL CHEM, V266, P22818; REITMAN ML, 1982, J BIOL CHEM, V257, P357; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SUH K, 1992, J BIOL CHEM, V267, P21671; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	33	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26060	26062		10.1074/jbc.270.44.26060	http://dx.doi.org/10.1074/jbc.270.44.26060			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592804	hybrid			2022-12-25	WOS:A1995TC97800011
J	KOHZUMA, T; DENNISON, C; MCFARLANE, W; NAKASHIMA, S; KITAGAWA, T; INOUE, T; KAI, Y; NISHIO, N; SHIDARA, S; SUZUKI, S; SYKES, AG				KOHZUMA, T; DENNISON, C; MCFARLANE, W; NAKASHIMA, S; KITAGAWA, T; INOUE, T; KAI, Y; NISHIO, N; SHIDARA, S; SUZUKI, S; SYKES, AG			SPECTROSCOPIC AND ELECTROCHEMICAL STUDIES ON ACTIVE-SITE TRANSITIONS OF THE TYPE-1 COPPER PROTEIN PSEUDOAZURIN FROM ACHROMOBACTER CYCLOCLASTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA AZURIN; ALCALIGENES-FAECALIS S-6; ELECTRON-TRANSFER; RESONANCE RAMAN; NITRITE REDUCTASE; CRYSTAL-STRUCTURE; METHYLAMINE DEHYDROGENASE; POPLAR PLASTOCYANIN; COMPLEX ASSOCIATION; BLUE PROTEIN	The single type 1 copper protein pseudoazurin from Achromobacter cycloclastes gives reversible electrochemical behavior at a (4-pyridyl) disulfide-modified gold electrode. Measurements carried out at 25.0 degrees C indicate a midpoint reduction potential of E(1/2) = 260 mV versus normal hydrogen electrode at pH 7.0 and a peak-to-peak separation of Delta E(p) = 59 mV. The diffusion coefficient and heterogeneous electron transfer rate constant are estimated to be 2.23 x 10(-6) cm(2) s(-1) and 3.7 x 10(-2) cm s(-1), respectively. Also, controlled potential electrolysis indicates a 1-electron transfer process and a formal reduction potential of 259 mV versus normal hydrogen electrode for the Cu(II)/Cu(I) couple. The heterogeneous electron transfer rate constant determined at the (4-pyridyl)disulfide-modified gold electrode at pH 4.6 is 6.7 x 10(-3) cm s(-1), consistent with a slower process at the positively charged electrode surface. At pH 11.3, UV-visible, EPR, and resonance Raman spectra indicate a conversion of the distorted tetrahedral copper geometry to a trigonal structure. The trigonal form has elongated axial bonding and an axial EPR spectrum. At pH 11.3, the reduction potential is further decreased, and Cu-S bands in resonance Raman spectra at 330-460 cm(-1) are shifted to higher energy (similar to 10 cm(-1)), consistent with a stronger Cu-S bond.	UNIV NEWCASTLE UPON TYNE,DEPT CHEM,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; INST MOLEC SCI,OKAZAKI,AICHI 444,JAPAN; OSAKA UNIV,FAC ENGN,DEPT APPL CHEM,SUITA,OSAKA 565,JAPAN; HIROSHIMA UNIV,FAC INTEGRATED ARTS & SCI,DEPT ENVIRONM SCI,HIGASHIHIROSHIMA 724,JAPAN; OSAKA UNIV,FAC SCI,DEPT CHEM,TOYONAKA,OSAKA 560,JAPAN	Newcastle University - UK; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB); Osaka University; Hiroshima University; Osaka University	KOHZUMA, T (corresponding author), IBARAKI UNIV,DEPT CHEM,BUNKYO 2-1-1,MITO,IBARAKI 310,JAPAN.		Kohzuma, Takamitsu/U-2966-2019	Dennison, Christopher/0000-0001-8665-052X; Nakashima, Satoru/0000-0001-8378-1153				ADMAN ET, 1989, J BIOL CHEM, V264, P87; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ANDREW CR, 1994, J AM CHEM SOC, V116, P11489, DOI 10.1021/ja00104a032; ARMSTRONG FA, 1988, ACCOUNTS CHEM RES, V21, P407, DOI 10.1021/ar00155a004; ARMSTRONG FA, 1989, J PHYS CHEM-US, V93, P6485, DOI 10.1021/j100354a041; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BLAIR DF, 1985, J AM CHEM SOC, V107, P5755, DOI 10.1021/ja00306a025; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHRISTENSEN HEM, 1990, INORG CHEM, V29, P2808, DOI 10.1021/ic00340a019; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; DENBLAAUWEN T, 1993, BIOCHEMISTRY-US, V32, P12455, DOI 10.1021/bi00097a025; DENNISON C, 1993, J CHEM SOC DALTON, P1959, DOI 10.1039/dt9930001959; DENNISON C, 1994, J CHEM SOC DALTON, P437, DOI 10.1039/dt9940000437; DESILVA DGAH, 1992, J CHEM SOC DALTON, P2145, DOI 10.1039/dt9920002145; GRAY KA, 1988, J BIOL CHEM, V263, P13987; GROENEVELD CM, 1988, J BIOL CHEM, V263, P167; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HAN J, 1993, J AM CHEM SOC, V115, P4256, DOI 10.1021/ja00063a048; HAN J, 1991, BIOCHEMISTRY-US, V30, P10904, DOI 10.1021/bi00109a014; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; INOUE T, 1994, ACTA CRYSTALLOGR D, V50, P317, DOI 10.1107/S0907444994000260; INOUE T, 1993, J BIOCHEM-TOKYO, V114, P761, DOI 10.1093/oxfordjournals.jbchem.a124251; INOUE T, 1994, THESIS OSAKA U; IWASAKI H, 1973, J BIOCHEM, V73, P659, DOI 10.1093/oxfordjournals.jbchem.a130125; IWASAKI Y, 1992, ELECTROANAL, V4, P765, DOI 10.1002/elan.1140040805; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; KLAULIS P, 1994, J APPL CRYSTALLOGR, V24, P946; KOHZUMA T, 1994, B CHEM SOC JPN, V67, P138, DOI 10.1246/bcsj.67.138; LAPPIN AG, 1979, J AM CHEM SOC, V101, P2302, DOI 10.1021/ja00503a009; LONG JE, 1989, BIOCHEMISTRY-US, V28, P6970, DOI 10.1021/bi00443a029; LOWERY MD, 1993, J AM CHEM SOC, V115, P3012, DOI 10.1021/ja00060a074; LU Y, 1993, J AM CHEM SOC, V115, P5907, DOI 10.1021/ja00067a003; MCGINNIS J, 1988, INORG CHEM, V27, P2306, DOI 10.1021/ic00286a018; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; NICHOLSON RS, 1965, ANAL CHEM, V37, P1351, DOI 10.1021/ac60230a016; PETRATOS K, 1988, ACTA CRYSTALLOGR B, V44, P628, DOI 10.1107/S0108768188008912; RYDEN L, 1984, COPPER PROTEINS COPP, V1, P157; SAKURAI T, 1990, INORG CHEM, V29, P4715, DOI 10.1021/ic00348a026; SEGAL MG, 1978, J AM CHEM SOC, V100, P4585, DOI 10.1021/ja00482a044; SUZUKI S, 1989, INORG CHEM, V28, P802, DOI 10.1021/ic00303a038; SYKES AG, 1990, STRUCT BOND, V75, P175; TAKAHASHI S, 1991, J AM CHEM SOC, V113, P9400, DOI 10.1021/ja00024a073; THAMANN TJ, 1982, P NATL ACAD SCI USA, V79, P6396, DOI 10.1073/pnas.79.20.6396; TOBARI J, 1984, MICROBIAL GROWTH C1, P106; VANDEKAMP M, 1993, EUR J BIOCHEM, V218, P229; VANDEKAMP M, 1990, J AM CHEM SOC, V112, P907, DOI 10.1021/ja00158a082	48	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25733	25738		10.1074/jbc.270.43.25733	http://dx.doi.org/10.1074/jbc.270.43.25733			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592754	hybrid			2022-12-25	WOS:A1995TB46600071
J	YEH, CH; ZONG, WX; SHATKIN, AJ				YEH, CH; ZONG, WX; SHATKIN, AJ			THE SER(36)-SER(37) PAIR IN HELA NUCLEAR-PROTEIN P21/SIIR MEDIATES SER/THR PHOSPHORYLATION AND IS ESSENTIAL FOR ROUS-SARCOMA VIRUS LONG TERMINAL REPEAT REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION	Phosphorylation of HeLa SII (or TFIIS)-related nuclear protein p21/SIIR was demonstrated in transfected COS-1 cells. To test for a possible functional link between phosphorylation and the previously described Rous sarcoma virus (RSV) long terminal repeat (LTR) repression (Yeh, C, H., and Shatkin, A. J. (1994) Proc. Natl. Acad. Sci. U.S. A. 91, 11002-11006), p21/SIIR mutants were constructed and assayed for phosphorylation level and effect on RSV LTD-driven chloramphenicol acetyltransferase (CAT) reporter expression. A major phosphorylation target in p21/SIIR was localized to the Arg/Ser-rich region between amino acids 12 and 49. Deletion of this region impaired the ability of pB1/SIIR to down-regulate RSV LTR promoter function. Four serine pairs, all displaying the Arg/Lys-Ser-Ser motif typical of phosphorylation sites, are present in p21/SIIR between positions 31 and 48. Conversion of these individual serine pairs to alanine resulted in decreased phosphorylation in each case. Mutation of the Ser(36)-Ser(37) pair also diminished by severalfold the repression activity of p21/SIIR. The single tyrosine (Tyr(155)) in pS1/SIIR was not detectably phosphorylated in transfected COS-1 cells, suggesting that the Ser(36)-Ser(37) pair mediates Ser/Thr phosphorylation of p21/SIIR and is critical for LTR repression function.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick								CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; YEH CH, 1995, J BIOL CHEM, V270, P15815, DOI 10.1074/jbc.270.26.15815; YEH CH, 1994, GENE, V143, P285; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002	16	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25313	25315		10.1074/jbc.270.43.25313	http://dx.doi.org/10.1074/jbc.270.43.25313			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592688	hybrid			2022-12-25	WOS:A1995TB46600004
J	FRITZ, G; KAINA, B; AKTORIES, K				FRITZ, G; KAINA, B; AKTORIES, K			THE RAS-RELATED SMALL GTP-BINDING PROTEIN RHOB IS IMMEDIATE-EARLY INDUCIBLE BY DNA-DAMAGING TREATMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; EPIDERMAL GROWTH-FACTOR; HAMSTER OVARY CELLS; C-FOS GENE; CLOSTRIDIUM-BOTULINUM; MAMMALIAN-CELLS; UV IRRADIATION; MESSENGER-RNA; KINASE-C; SIGNAL-TRANSDUCTION	The low molecular weight GTP-binding proteins RhoA, RhoB, and RhoC are characterized as specific substrates for the ADP-ribosyltransferase C3 from Clostridium botulinum and are supposed to be involved in the organization of the microfilamental network and transformation. rhoB is known to be immediate-early inducible by growth factors and protein-tyrosine kinases. Since increasing evidence indicates overlapping of growth factor- and UV-induced signal pathways, we studied the effect of UV light and other genotoxic agents on early rhoB transcription. Within 30 min after UV irradiation of NIH3T3 cells, the amount of rhoB mRNA increased 3-4-fold. Elevated rhoB mRNA was accompanied by an increase in RhoB protein, as detected by C3-mediated [P-32]ADP-ribosylation. The transcription inhibitor actinomycin D prevented the UV-induced increase in rhoB mRNA and proved rhoB mRNA to be unstable with a half life of similar to 20 min. Transcriptional activation of rhoB by UV light was confirmed by run-on analysis. The increase in rhoB mRNA after UV irradiation was prevented by inhibitors of protein kinase A (H9) and C (H7, Go18). The tyrosine kinase inhibitor genistein did not affect UV induction of rhoB. In addition to UV, N-methyl-N-nitrosourea and the cytostatic drug cisplatin evoked rhoB response. Cycloheximide was likewise effective in increasing the amount of rhoB mRNA, whereas Bt(2)cAMP, 12-O-tetradecanoylphorbol-13-acetate, and retinoic acid were without effect. Prior down-regulation of signaling by la 12-O-tetradecanoylphorbol-13-acetate and serum pretreatment reduced UV-stimulated rhoB expression. The data indicate that rhoB represents a novel DNA damage-inducible function involved in early steps of signal transduction upon genotoxic stress.	UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY	Saarland University	FRITZ, G (corresponding author), UNIV MAINZ,INST TOXICOL,ANGEW TOXIKOL ABT,OBERE ZAHLABACHER STR 67,D-55131 MAINZ,GERMANY.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1985, CANCER CELL, V3, P315; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSCHER M, 1988, ONCOGENE, V3, P301; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2727; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EGAN SE, 1983, NATURE, V363, P45; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HARRIS ELV, 1989, PROTEIN PURIFICATION, P29; HOLLANDER MC, 1989, CANCER RES, V49, P1687; JAHNER D, 1991, ONCOGENE, V6, P1259; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KAINA B, 1987, MOL CELL BIOL, V7, P2024, DOI 10.1128/MCB.7.5.2024; KAINA B, 1990, DNA REPAIR MECHANISM, P149; KASHANISABET M, 1990, J BIOL CHEM, V265, P11285; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KOURAZIDES T, 1989, NATURE, V340, P568; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MISKIN R, 1981, P NATL ACAD SCI-BIOL, V78, P6236, DOI 10.1073/pnas.78.10.6236; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCANLON KJ, 1994, P NATL ACAD SCI USA, V91, P11123, DOI 10.1073/pnas.91.23.11123; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	63	139	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25172	25177		10.1074/jbc.270.42.25172	http://dx.doi.org/10.1074/jbc.270.42.25172			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559652	hybrid			2022-12-25	WOS:A1995TB46500086
J	LI, K; WILLIAMS, RS				LI, K; WILLIAMS, RS			CLONING AND CHARACTERIZATION OF 3 NEW MURINE GENES ENCODING SHORT HOMOLOGS OF RNASE-P RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; ESCHERICHIA-COLI; HELA-CELLS; YEAST; COMPONENT; SUBUNIT; NUCLEAR; IDENTIFICATION; SEQUENCE; PROTEIN	Three novel genes encoding small RNAs homologous to human and mouse RNase P RNA have been isolated from a mouse genomic Library. As assessed by Northern blot analysis and nuclease protection assays, transcripts derived from one or more of these genes are expressed in murine cells and tissues. The RNA products of these RNase P RNA-homologous genes are smaller in size (238-248 nucleotides) than the 305-nucleotide transcript previously identified. These smaller transcripts are uniformly less abundant than the larger RNase P RNA, but their expression varies severalfold among different mouse tissues. Similar short homologues of RNase P RNA also are expressed in rat, rabbit, and human cells. We conclude that higher vertebrates express multiple isoforms of RNase P RNA.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; ALTMAN S, 1993, GENOMICS, V18, P418, DOI 10.1006/geno.1993.1488; ALTMAN S, 1989, ADV ENZYMOLOGY RELAT, P1; BAER M, 1985, SCIENCE, V228, P999, DOI 10.1126/science.2408335; BAER M, 1989, NUCLEIC ACIDS RES, V18, P97; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; DANG YL, 1993, J BIOL CHEM, V268, P19791; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DORIA M, 1991, NUCLEIC ACIDS RES, V9, P2315; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARDINER K, 1985, J BIOL CHEM, V255, P7507; GOLD HA, 1986, CELL, V44, P243, DOI 10.1016/0092-8674(86)90758-0; GREENE JM, 1992, CURRENT PROTOCOLS MO; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; HAAS ES, 1991, SCIENCE, V254, P853, DOI 10.1126/science.1719634; HANNON GJ, 1991, J BIOL CHEM, V266, P22796; KRUMP G, 1986, EMBO J, V5, P1697; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P21; MILLER DL, 1983, CELL, V34, P911, DOI 10.1016/0092-8674(83)90548-2; MORALES MJ, 1992, P NATL ACAD SCI USA, V89, P9875, DOI 10.1073/pnas.89.20.9875; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; REILLY RM, 1986, J BIOL CHEM, V261, P2928; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; Sambrook J, 1989, MOL CLONING LABORATO; SHIRAISHI H, 1988, EMBO J, V7, P3817, DOI 10.1002/j.1460-2075.1988.tb03266.x; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TRANGUCH AJ, 1993, J BIOL CHEM, V268, P14045; WESTHOF E, 1994, P NATL ACAD SCI USA, V91, P5133, DOI 10.1073/pnas.91.11.5133; WISE CA, 1991, J BIOL CHEM, V266, P19154	35	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25281	25285		10.1074/jbc.270.42.25281	http://dx.doi.org/10.1074/jbc.270.42.25281			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559668	hybrid			2022-12-25	WOS:A1995TB46500102
J	DAVLETOV, BA; KRASNOPEROV, V; HATA, Y; PETRENKO, AG; SUDHOF, TC				DAVLETOV, BA; KRASNOPEROV, V; HATA, Y; PETRENKO, AG; SUDHOF, TC			HIGH-AFFINITY BINDING OF ALPHA-LATROTOXIN TO RECOMBINANT NEUREXIN I-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							WIDOW SPIDER VENOM; TRANSMITTER RELEASE; NEUROMUSCULAR-JUNCTIONS; BRAIN SYNAPTOSOMES; PLASMA-MEMBRANE; TOXIN BINDING; RECEPTOR; PURIFICATION; STIMULATION; PROTEIN	alpha-Latrotoxin is a potent neurotoxin from black widow spider venom that stimulates neurotransmitter release. alpha-Latrotoxin is thought to act by binding to a high affinity receptor on presynaptic nerve terminals. In previous studies, high affinity alpha-latrotoxin binding proteins were isolated and demonstrated to contain neurexin I alpha as a major component. Neurexin I alpha is a cell surface protein that exists in multiple differentially spliced isoforms and belongs to a large family of neuron-specific proteins. Using a series of neurexin I-IgG fusion proteins, we now show that recombinant neurexin I alpha binds alpha-latrotoxin directly with high affinity (K-d approximate to 4 nM). Binding of alpha-latrotoxin to recombinant neurexin I alpha is dependent on Ca2+ (EC(50) approximate to 30 mu M). Our data suggest that neurexin I alpha is a Ca2+-dependent high affinity receptor for alpha-latrotoxin.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; NYU,MED CTR,DEPT ENVIRONM MED,NEW YORK,NY 10016	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University			Davletov, Bazbek/ABA-8569-2021	Petrenko, Alexander/0000-0002-6689-6546; Davletov, Bazbek/0000-0003-4658-3275				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CECCARELLI B, 1979, J CELL BIOL, V81, P163, DOI 10.1083/jcb.81.1.163; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; MELDOLESI J, 1983, NEUROSCIENCE, V10, P997, DOI 10.1016/0306-4522(83)90238-5; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; NICHOLLS DG, 1982, P NATL ACAD SCI-BIOL, V79, P7924, DOI 10.1073/pnas.79.24.7924; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; ROBELLO M, 1987, J MEMBRANE BIOL, V95, P55, DOI 10.1007/BF01869630; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6	23	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23903	23905		10.1074/jbc.270.41.23903	http://dx.doi.org/10.1074/jbc.270.41.23903			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592578	hybrid			2022-12-25	WOS:A1995TA21700006
J	SCHULTZ, SJ; WHITING, SH; CHAMPOUX, JJ				SCHULTZ, SJ; WHITING, SH; CHAMPOUX, JJ			CLEAVAGE SPECIFICITIES OF MOLONEY MURINE LEUKEMIA-VIRUS RNASE-H IMPLICATED IN THE 2ND STRAND TRANSFER DURING REVERSE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; DEOXYRIBONUCLEIC-ACID POLYMERASE; LONG TERMINAL REPEAT; RIBONUCLEASE-H; RETROVIRAL DNA; INTEGRATION SITE; SEQUENCE; TYPE-1; PRIMER; MECHANISM	Reverse transcription of a retroviral RNA genome requires two template jumps to generate the linear double-stranded DNA required for integration. The RNase H activity of reverse transcriptase has several roles during this process. We have examined RNase H cleavages that define the maximal 3' and 5' ends of Moloney murine leukemia virus minus strand DNA prior to the second template jump. In both the endogenous reaction and on model substrates in vitro, RNase H cleaves the genomic RNA template between the second and third ribonucleotides 5' of the U5/PBS junction, but other minor cleavages between 1 and 10 nucleotides 5' of this junction are also observed. Similar experiments examining the specificity of RNase H for tRNA primer removal revealed that cleavage generally leaves a ribo A residue at the 5' end of minus strand DNA. These observations suggest that three bases are typically duplicated on the ends of the minus strands, leading to an intermediate following the second jump which contains unpaired nucleotides. Model substrates mimicking the structure of this intermediate demonstrate that reverse transcriptase has little difficulty in utilizing such a branched structure for the initiation of displacement synthesis.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCI NIH HHS [R37 CA51605, T32 CA09229] Funding Source: Medline; NIGMS NIH HHS [5T32GM07266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009229, R37CA051605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALTIMORE D, 1972, J BIOL CHEM, V247, P7282; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BLAIN SW, 1993, J BIOL CHEM, V268, P23585; BREWER LC, 1974, J VIROL, V14, P1494, DOI 10.1128/JVI.14.6.1494-1502.1974; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUISER RG, 1991, J BIOL CHEM, V266, P13103; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Coffin J. M., 1990, VIROLOGY, P1437; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1991, J BIOL CHEM, V262, P7423; ELLIS J, 1989, J VIROL, V63, P2844, DOI 10.1128/JVI.63.6.2844-2846.1989; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; GRANDGENETT DP, 1974, J BIOL CHEM, V249, P5148; HUANG L, 1994, J BIOL CHEM, V269, P25922; HUBER HE, 1990, J BIOL CHEM, V265, P10565; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; LOBEL LI, 1989, J VIROL, V63, P2629, DOI 10.1128/JVI.63.6.2629-2637.1989; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PAUZA CD, 1990, VIROLOGY, V179, P886; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SHOEMAKER C, 1980, P NATL ACAD SCI-BIOL, V77, P3932, DOI 10.1073/pnas.77.7.3932; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JS, 1992, J BIOL CHEM, V267, P15071; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; VARMUS H, 1989, MOBILE DNA, P53; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942	61	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24135	24145		10.1074/jbc.270.41.24135	http://dx.doi.org/10.1074/jbc.270.41.24135			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592616	hybrid			2022-12-25	WOS:A1995TA21700044
J	GENET, R; BENETTI, PH; HAMMADI, A; MENEZ, A				GENET, R; BENETTI, PH; HAMMADI, A; MENEZ, A			L-TRYPTOPHAN 2',3'-OXIDASE FROM CHROMOBACTERIUM-VIOLACEUM - SUBSTRATE-SPECIFICITY AND MECHANISTIC IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN OXIDASE	L-Tryptophan 2',3'-oxidase, an amino acid alpha,beta-dehydrogenase isolated from Chromobacterium violaceum, catalyzes the formation of a double bond between the C-alpha and C-beta carbons of various tryptophan derivatives provided that they possess: (i) a L-enantiomeric configuration, (ii) an alpha-carbonyl group, and (iii) an unsubstituted and unmodified indole nucleus. Kinetic parameters were evaluated for a series of tryptophan analogues, providing information on the contribution of each chemical group to substrate binding. The stereochemistry of the dehydro product was determined to be a Z-configuration from proton nuclear magnetic resonance assignments. No reaction can be observed in the presence of other aromatic beta-substituted alanyl residues which behave neither as substrates nor as inhibitors and therefore do not compete against this reaction. The enzymatic synthesis of alpha,beta-dehydrotryptophanyl peptides from 5 to 24 residues was successfully achieved without side product formation, irrespective of the position of the tryptophan residue in the amino acid sequence. A reactional mechanism involving a direct alpha,beta-dehydrogenation of the tryptophan side chain is proposed.			GENET, R (corresponding author), CEA SACLAY, DEPT INGN & ETUDES PROT, BAT 152, F-91191 GIF SUR YVETTE, FRANCE.							BREARLEY GM, 1994, APPL MICROBIOL BIOT, V41, P670; BROWN AG, 1969, J CHEM SOC CHEM COMM, P1489, DOI 10.1039/c29690001489; BRUNHUBER NMW, 1994, CRIT REV BIOCHEM MOL, V29, P415, DOI 10.3109/10409239409083486; BRUNHUBER NMW, 1994, J BIOL CHEM, V269, P16203; Chargaff E, 1943, J BIOL CHEM, V151, P273; Dakin HD, 1926, J BIOL CHEM, V67, P341; DAVIS PJ, 1975, BIOCHIM BIOPHYS ACTA, V385, P133, DOI 10.1016/0304-4165(75)90081-1; GENET R, 1994, J BIOL CHEM, V269, P18177; GHISLA S, 1984, BIOCHEMISTRY-US, V23, P3154, DOI 10.1021/bi00309a008; GUSTAFSON ME, 1977, J CHEM SOC CHEM COMM, P842, DOI 10.1039/c39770000842; HENGARTNER U, 1979, J ORG CHEM, V44, P3741, DOI 10.1021/jo01336a001; JOHNSON JK, 1992, BIOCHEMISTRY-US, V31, P10564, DOI 10.1021/bi00158a020; KUPKE T, 1994, J BIOL CHEM, V269, P5653; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; PREVIERO A, 1967, BIOCHIM BIOPHYS ACTA, V147, P453, DOI 10.1016/0005-2795(67)90005-0; TABORSKY G, 1955, YALE J BIOL MED, V127, P267; TAKAI K, 1987, METHOD ENZYMOL, V142, P195; ZAVALA F, 1983, J BIOL CHEM, V258, P344	18	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23540	23545		10.1074/jbc.270.40.23540	http://dx.doi.org/10.1074/jbc.270.40.23540			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559518	hybrid			2022-12-25	WOS:A1995RY90900047
J	HOHENADL, C; MANN, K; MAYER, U; TIMPL, R; PAULSSON, R; AESCHLIMANN, D				HOHENADL, C; MANN, K; MAYER, U; TIMPL, R; PAULSSON, R; AESCHLIMANN, D			2 ADJACENT N-TERMINAL GLUTAMINES OF BM-40 (OSTEONECTIN, SPARC) ACT AS AMINE ACCEPTOR SITES IN TRANSGLUTAMINASE(C)-CATALYZED MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; LAMININ-NIDOGEN COMPLEXES; CATALYZED CROSS-LINKING; CALCIUM-BINDING; FACTOR-XIIIA; TISSUE TRANSGLUTAMINASE; MOLECULAR ANALYSIS; HIGH-AFFINITY; COLLAGEN; BONE	The extracellular matrix protein BM-40 (osteonectin, SPARC) has recently been shown to be a major target for transglutaminase catalyzed cross-linking in differentiating cartilage. In the present study we demonstrate that recombinant human BM-40 can be modified with [H-3]putrescine in a 1:1 molar ratio by transglutaminase(C) (tissue transglutaminase). Residues Gln(3) and Gln(4) were identified as major amine acceptor sites, This was confirmed with several mutant proteins, including deletions in the N-terminal domain I of BM-40, site-directed mutagenesis of the reactive glutamines, and fusion of the seven-amino acid-long N-terminal sequence (APQQEAL) to an unrelated protein, The results showed that the N-terminal target site is sufficient for modification by transglutaminase but at a low level, For high efficiency amine incorporation an intact domain I is required, The conservation of at least one of the transglutaminase target glutamines in the known vertebrate BM-40 sequences and their absence in an invertebrate homologue point to an important, but yet unknown, role of this modification in vertebrates.	MAX PLANCK INST BIOCHEM,DEPT PROT CHEM,D-82152 MARTINSRIED,GERMANY; UNIV BERN,ME MULLER INST BIOMECH,CH-3010 BERN,SWITZERLAND; UNIV COLOGNE,FAC MED,INST BIOCHEM,D-50931 COLOGNE,GERMANY; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706	Max Planck Society; University of Bern; University of Cologne; University of Wisconsin System; University of Wisconsin Madison			Mann, Karlheinz/C-4254-2008	Aeschlimann, Daniel/0000-0003-0930-7706				AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BASSUK JA, 1993, EUR J BIOCHEM, V218, P117, DOI 10.1111/j.1432-1033.1993.tb18358.x; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BOLANDER ME, 1988, P NATL ACAD SCI USA, V85, P2919, DOI 10.1073/pnas.85.9.2919; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CLEZARDIN P, 1988, EUR J BIOCHEM, V175, P275, DOI 10.1111/j.1432-1033.1988.tb14194.x; CONNELLAN JM, 1971, J BIOL CHEM, V246, P1093; DAMJANOVSKI S, 1992, BIOCHEM J, V281, P513, DOI 10.1042/bj2810513; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; FESUS L, 1991, EUR J CELL BIOL, V56, P170; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1991, FASEB J, V5, P3072; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; KELM RJ, 1991, J BIOL CHEM, V266, P9632; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MAURER P, 1992, EUR J BIOCHEM, V205, P233, DOI 10.1111/j.1432-1033.1992.tb16773.x; MAYER U, 1991, EUR J BIOCHEM, V198, P141, DOI 10.1111/j.1432-1033.1991.tb15996.x; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHWARZBAUER JE, 1993, MOL BIOL CELL, V4, P941, DOI 10.1091/mbc.4.9.941; SIMON M, 1988, J BIOL CHEM, V263, P18093; STENNER DD, 1986, P NATL ACAD SCI USA, V83, P6892, DOI 10.1073/pnas.83.18.6892; TERMINE JD, 1981, J BIOL CHEM, V256, P403; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; THOMAZY V, 1989, CELL TISSUE RES, V255, P216; TIMPL R, 1993, MOL CELLULAR ASPECTS, P211	42	50	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23415	23420		10.1074/jbc.270.40.23415	http://dx.doi.org/10.1074/jbc.270.40.23415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559501	hybrid			2022-12-25	WOS:A1995RY90900030
J	STRANDBERG, L; MADISON, EL				STRANDBERG, L; MADISON, EL			VARIANTS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR WITH SUBSTANTIALLY ENHANCED RESPONSE AND SELECTIVITY TOWARD FIBRIN COFACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CHAIN; BOVINE TRYPSINOGEN; CRYSTAL-STRUCTURE; PROTEOLYTIC-ENZYMES; AMIDOLYTIC ACTIVITY; ALPHA-CHYMOTRYPSIN; RESOLUTION; STREPTOKINASE; MECHANISM; CLEAVAGE	Unlike most proteases, tissue-type plasminogen activator (t-PA) is not synthesized as an inactive precursor or zymogen, Instead, the single-chain ''proenzyme'' form of t-PA possesses very significant catalytic activity, Recent investigations of the molecular basis of the unusually high enzymatic activity of single-chain t-PA have focused attention upon Asp-194, a residue that is invariant among chymotrypsin-like enzymes, The critical role of this residue in securing the active conformation of mature chymotrypsin-like enzymes has been discussed extensively. Subsequent work, however, has indicated that this conserved residue can also form interactions that dramatically influence the catalytic activity of serine protease zymogens, While Asp-194 forms interactions that suppress the activity of the zymogen chymotrypsinogen, it may, by contrast, directly promote the catalytically active conformation of single chain t-PA. To test the hypothesis that Asp-194 promotes the activity of both single- and two-chain t-PA and therefore plays opposing roles in single-chain t-PA and chymotrypsinogen, and also to examine whether this invariant residue plays an essential role in the stimulation of t-PA by fibrin, we used site directed mutagenesis to construct the following variants of t-PA: t-PA/D194E, t-PA/D194N, t-PA/R15E,D194E, and t-PA/R15E,D194N. In the absence of fibrin, the activity of enzymes carrying a mutation at position 194 was reduced by factors of 1000-2000 compared to wild type t-PA, Similar reductions of activity were observed for both single- and two chain variants, suggesting an important role for Asp-194 in both forms of the enzyme. The mutated enzymes, however, displayed a dramatically enhanced response to fibrin monomers. While the activity of wild type t-PA was stimulated by fibrin monomers by a factor of 960, the corresponding stimulation factor for the mutated enzymes varied from 498,000-1,050,000.	Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; COLLEN D, 1993, J BIOL CHEM, V268, P8284; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; HARLOW E, 1988, ANTIBODIES LABORATOR; HECKEL A, 1988, J COMPUT AID MOL DES, V2, P7, DOI 10.1007/BF01532049; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; HIGGINS DL, 1990, THROMB RES, V57, P527, DOI 10.1016/0049-3848(90)90070-S; HIGH K, 1995, MOL BASIS THROMBOSIS; HOLYAERTS K, 1982, J BIOL CHEM, V257, P2912; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P33, DOI 10.1016/0268-9499(92)90045-J; LIJNEN HR, 1993, METHOD ENZYMOL, V223, P197; LOSKUTOFF DJ, 1988, SEMIN THROMB HEMOST, V14, P100, DOI 10.1055/s-2007-1002762; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MADISON EL, 1994, FIBRINOLYSIS, V88, P221; MANN K, 1993, METHOD ENZYMOL, V223, P145; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NIENABER VL, 1992, BIOCHEMISTRY-US, V31, P3852, DOI 10.1021/bi00130a017; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; PETERSEN LC, 1990, BIOCHEMISTRY-US, V29, P3451, DOI 10.1021/bi00466a005; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SAMBROOK J, 1989, MOL CLONIGN LABORATO; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SIGLER PB, 1968, J MOL BIOL, V35, P143, DOI 10.1016/S0022-2836(68)80043-9; SUMMARIA L, 1969, P SOC EXP BIOL MED, V130, P737; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; URANO T, 1989, ARCH BIOCHEM BIOPHYS, V270, P356, DOI 10.1016/0003-9861(89)90038-6; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; WALLEN P, 1982, BIOCHIM BIOPHYS ACTA, V719, P318, DOI 10.1016/0304-4165(82)90105-2; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9	49	13	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23444	23449		10.1074/jbc.270.40.23444	http://dx.doi.org/10.1074/jbc.270.40.23444			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559505	hybrid			2022-12-25	WOS:A1995RY90900034
J	KUIPERS, OP; BEERTHUYZEN, MM; DERUYTER, PGGA; LUESINK, EJ; DEVOS, WM				KUIPERS, OP; BEERTHUYZEN, MM; DERUYTER, PGGA; LUESINK, EJ; DEVOS, WM			AUTOREGULATION OF NISIN BIOSYNTHESIS IN LACTOCOCCUS-LACTIS BY SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE ANTIBIOTIC NISIN; LANTIBIOTIC SUBTILIN; BACILLUS-SUBTILIS; GENE; PROTEIN; CLONING; EXPRESSION; PRECURSOR; ORGANIZATION; PURIFICATION	The post-translationally modified, antimicrobial peptide nisin is secreted by strains of Lactococcus lactis that contain the chromosomally located nisin biosynthetic gene cluster nisABTCIPRKFEG. When a 4-base pair deletion is introduced into the structural nisA gene (Delta nisA), transcription of Delta nisA is abolished. Transcription of the Delta nisA gene is restored by adding subinhibitory amounts of nisin, nisin mutants, or nisin analogs to the culture medium, but not by the unmodified precursor peptide or by several other antimicrobial peptides, Upon disruption of the nisK gene, which encodes a putative sensor protein that belongs to the class of two-component regulators, transcription of Delta nisA was no longer inducible by nisin, Fusion of a nisA promoter fragment to the promoterless reporter gene gusA resulted in expression of gusA in L, lactis NZ9800 (Delta nisA) only upon induction with nisin species, The expression level of gusA was directly related to the amount of inducer that was added extracellularly, These results provide insight into a new mechanism of autoregulation through signal transduction in prokaryotes and demonstrate that antimicrobial peptides can exert a second function as signaling molecules.			KUIPERS, OP (corresponding author), NETHERLANDS INST DAIRY RES, DEPT BIOPHYS CHEM, POB 20, 6710 BA EDE, NETHERLANDS.		Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; DEVOS WM, 1993, APPL ENVIRON MICROB, V59, P213, DOI 10.1128/AEM.59.1.213-218.1993; DeVos WM, 1995, DEV BIOLOGICALS, V85, P617; ENGELKE G, 1994, APPL ENVIRON MICROB, V60, P814, DOI 10.1128/AEM.60.3.814-825.1994; ENGELKE G, 1992, APPL ENVIRON MICROB, V58, P3730, DOI 10.1128/AEM.58.11.3730-3743.1992; FUKASE K, 1992, B CHEM SOC JPN, V65, P2227, DOI 10.1246/bcsj.65.2227; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GAO FH, 1991, APPL ENVIRON MICROB, V57, P2164, DOI 10.1128/AEM.57.8.2164-2170.1991; GASSON MJ, 1983, J BACTERIOL, V154, P1; Goodman M, 1991, NISIN NOVEL LANTIBIO, P59; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P799; GUTOWSKIECKEL Z, 1994, APPL ENVIRON MICROB, V60, P1; HOLO H, 1991, J BACTERIOL, V173, P3879, DOI 10.1128/JB.173.12.3879-3887.1991; HORINOUCHI S, 1982, J BACTERIOL, V150, P804, DOI 10.1128/JB.150.2.804-814.1982; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; KLEIN C, 1993, APPL ENVIRON MICROB, V59, P296, DOI 10.1128/AEM.59.1.296-303.1993; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Mattick ATR, 1944, NATURE, V154, P551, DOI 10.1038/154551a0; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PESCHEL A, 1993, MOL MICROBIOL, V9, P31, DOI 10.1111/j.1365-2958.1993.tb01666.x; PIARD JC, 1992, APPL ENVIRON MICROB, V58, P279, DOI 10.1128/AEM.58.1.279-284.1992; PIARD JC, 1993, J BIOL CHEM, V268, P16361; PLATTEEUW C, 1994, APPL ENVIRON MICROB, V60, P587, DOI 10.1128/AEM.60.2.587-593.1994; RAUCH PJG, 1992, J BACTERIOL, V174, P1280, DOI 10.1128/jb.174.4.1280-1287.1992; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; SAHL HG, 1981, J GEN MICROBIOL, V127, P377; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SIEGERS K, 1995, APPL ENVIRON MICROB, V61, P1082, DOI 10.1128/AEM.61.3.1082-1089.1995; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TANAKA T, 1988, J BACTERIOL, V170, P3593, DOI 10.1128/jb.170.8.3593-3600.1988; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; WAKAMIYA T, 1985, TETRAHEDRON LETT, V26, P665, DOI 10.1016/S0040-4039(00)89174-1; WAKAMIYA T, 1991, NISIN NOVEL LANTIBIO, P189; WAKAMIYA T, 1990, PEPTIDES CHEM STRUCT, P60; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	397	424	5	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27299	27304		10.1074/jbc.270.45.27299	http://dx.doi.org/10.1074/jbc.270.45.27299			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592991	Green Published, hybrid			2022-12-25	WOS:A1995TE58300091
J	SANFORD, JC; YU, JM; PAN, JY; WESSLINGRESNICK, M				SANFORD, JC; YU, JM; PAN, JY; WESSLINGRESNICK, M			GDP DISSOCIATION INHIBITOR SERVES AS A CYTOSOLIC ACCEPTOR FOR NEWLY SYNTHESIZED AND PRENYLATED RAB5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; GERANYLGERANYL TRANSFERASE; SMG P25A; VESICULAR TRANSPORT; FUSION INVITRO; COMPONENT-A; COMPARTMENTS; MEMBRANES; CYS	In vitro synthesis and post-translational prenylation of Rab5 is accomplished using reticulocyte lysate supplemented with prenyl precursors (Sanford, J. C., Pan, Y., and Wessling-Resnick, M. (1993) J. Biol. Chem, 268, 23773-23776), When Rab5 is translated in the presence of biotin-lysine-tRNA, it incorporates biotin-lysine into its peptide backbone and is efficiently prenylated; since this modification is dependent on guanine nucleotide binding, biotin-Rab5's functional integrity must be maintained, Prenylated biotin-Rab5 associates with a 45-kDa reticulocyte GDP dissociation inhibitor (GDI), sedimenting as a similar to 70-kDa particle on 5-20% sucrose density gradients, The GDI-Rab5 complex can be captured using streptavidin-linked agarose beads, Only Rab5 peptides that are substrates for prenylation are found to cosediment with the lysate GDI on sucrose gradients, Post-translational association of Rab5 and GDI is a novel finding, since previous reports suggested Rab5 remains associated with Rab escort protein (REP) after prenylation (Alexandrov, K., Horiuchi, H., Steele-Mortimer, O., Seabra, M. C., and Zerial, M. (1994) EMBO J. 13, 5262-5273), Since post-translational prenylation is catalytically mediated by REP, our study suggests that a complex between Rab5 and this factor is transient in nature, Thus, newly synthesized and prenylated Rab5 is most likely escorted to its target membrane by a GDI acceptor molecule. Biotin-Rab5 provides a novel tool for future efforts to capture and characterize additional accessory factors required for Rab protein function in vesicle transport.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health								ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HOFFENBERG S, 1995, J BIOL CHEM, V270, P5048, DOI 10.1074/jbc.270.10.5048; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURZCHALIA TV, 1992, J BIOL CHEM, V267, P18419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI GP, 1993, J BIOL CHEM, V268, P24475; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SANFORD JC, 1995, ANAL BIOCHEM, V224, P547, DOI 10.1006/abio.1995.1086; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; YANG CZ, 1994, J BIOL CHEM, V269, P31891	41	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26904	26909		10.1074/jbc.270.45.26904	http://dx.doi.org/10.1074/jbc.270.45.26904			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592935	hybrid			2022-12-25	WOS:A1995TE58300035
J	BOLHUIS, H; POELARENDS, G; VANVEEN, HW; POOLMAN, B; DRIESSEN, AJM; KONINGS, WN				BOLHUIS, H; POELARENDS, G; VANVEEN, HW; POOLMAN, B; DRIESSEN, AJM; KONINGS, WN			THE LACTOCOCCAL LMRP GENE ENCODES A PROTON MOTIVE FORCE-DEPENDENT DRUG TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; MULTIDRUG-RESISTANCE; ANTISEPTIC RESISTANCE; LACTIC STREPTOCOCCI; BACILLUS-SUBTILIS; EFFLUX; SYSTEM; SEQUENCE; PROTEINS	To genetically dissect the drug extrusion systems of Lactococcus lactis, a chromosomal. DNA library was made in Escherichia coli and recombinant strains were selected for resistance to high concentrations of ethidium bromide. Recombinant strains were found to be resistant not only to ethidium bromide but also to daunomycin and tetraphenylphosphonium. The drug resistance is conferred by the lmrP gene, which encodes a hydrophobic polypeptide of 408 amino acid residues with 12 putative membrane-spanning segments, Some sequence elements in this novel membrane protein share similarity to regions in the transposon Tn10-encoded tetracycline resistance determinant TetA, the multidrug transporter Bmr from Bacillus subtilis, and the bicyclomycin resistance determinant Bcr from E. coli. Drug resistance associated with ImrP expression correlated with energy-dependent extrusion of the molecules. Drug extrusion was inhibited by ionophores that dissipate the proton motive force but not by the ATPase inhibitor ortho-vanadate. These observations are indicative for a drug-proton antiport system. A ImrP deletion mutant was constructed via homologous recombination using DNA fragments of the flanking region of the gene. The L. lactis (Delta lmrP) strain exhibited residual ethidium extrusion activity, which in contrast to the parent strain was inhibited by ortho-vanadate. The results indicate that in the absence of the functional drug-proton antiporter LmrP, L. lactis is able to overexpress another, ATP-dependent, drug extrusion system. These findings substantiate earlier studies on the isolation and characterization of drug-resistant mutants oft. lactis (Bolhuis, H., Molenaar, D., Poelarends, G., van Veen, H. W., Poolman, B., Driessen, A. J. M., and Konings, W. N. (1994) J. Bacteriol. 176, 6957-6964).	UNIV GRONINGEN, GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS	University of Groningen			Konings, Wilhelmus N./C-7063-2013; Bolhuis, Henk/A-4308-2008; Bolhuis, Henk/H-8535-2014; Driessen, Arnold J.M./D-1876-2012; Bolhuis, Henk/S-2986-2019; van Veen, Hendrik W./A-4162-2008; Bolhuis, Henk/M-6677-2019	Bolhuis, Henk/0000-0002-4772-1898; Bolhuis, Henk/0000-0002-4772-1898; van Veen, Hendrik W./0000-0002-9658-8077; Driessen, Arnold J.M./0000-0001-9258-9104; Poelarends, Gerrit/0000-0002-6917-6368				AHMED M, 1994, J BIOL CHEM, V269, P28506; BENTLEY J, 1993, GENE, V127, P117, DOI 10.1016/0378-1119(93)90625-D; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; CULLITON BJ, 1992, NATURE, V356, P473, DOI 10.1038/356473a0; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FRANCOIS V, 1987, GENE, V56, P99, DOI 10.1016/0378-1119(87)90162-4; GASSON MJ, 1983, J BACTERIOL, V154, P1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; HACHLER H, 1991, J BACTERIOL, V173, P5532; HAGTING A, 1994, J BIOL CHEM, V269, P11391; HENDERSON PJF, 1991, BIOSCIENCE REP, V11, P477, DOI 10.1007/BF01130216; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HILLGINS CF, 1992, ANN REV CELL BIOL, V8, P67; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leenhouts K, 1993, PLASMIDS PRACTICAL A, P65; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MIDGLEY M, 1987, MICROBIOL SCI, V4, P125; MIDGLEY M, 1986, J GEN MICROBIOL, V132, P3187; MIYAUCHI S, 1992, BIOCHIM BIOPHYS ACTA, V1110, P144, DOI 10.1016/0005-2736(92)90351-L; MOLENAAR D, 1992, J BACTERIOL, V174, P3118, DOI 10.1128/jb.174.10.3118-3124.1992; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RM, 1987, ATLAS PROTEIN SEQUEN, V5, P353; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	40	101	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26092	26098		10.1074/jbc.270.44.26092	http://dx.doi.org/10.1074/jbc.270.44.26092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592810	hybrid			2022-12-25	WOS:A1995TC97800017
J	NEILSON, KM; FRIESEL, RE				NEILSON, KM; FRIESEL, RE			CONSTITUTIVE ACTIVATION OF FIBROBLAST GROWTH-FACTOR RECEPTOR-2 BY A POINT MUTATION ASSOCIATED WITH CROUZON SYNDROME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEVELOPMENTAL EXPRESSION; XENOPUS DEVELOPMENT; MESODERM INDUCTION; LIGAND-BINDING; FGF; SPECIFICITY; FAMILY; MUTANT	The fibroblast growth factor receptors (FGFRs) are a family of ligand-activated, membrane-spanning tyrosine kinases. Mutations in several human FGFR genes have been identified as playing a role in certain disorders of bone growth and development. One of these, Crouzon syndrome, an autosomal dominant disorder causing craniosynostosis, has been associated with mutations in the human FGFR-2 gene. We report here that microinjection of Xenopus embryos with RNA encoding an FGFR-2 protein bearing a Cys(332) --> Tyr mutation (FGFR-2CS) found in Crouzon syndrome results in fibroblast growth factor (FGF) independent induction of mesoderm in animal pole explants. Wild-type FGFR-2 did not induce mesoderm when injected at similar doses. The effects of the mutant receptor were blocked by co-expression of dominant negative mutants of either Raf or Ras. Analysis of the mutant receptor protein expressed in Xenopus oocytes indicates that it forms covalent homodimers, does not bind radiolabeled FGF, and has increased tyrosine phosphorylation. These results indicate that FGFR-2CS forms an intermolecular disulfide bond resulting in receptor dimerization and ligand-independent activation that may play a role in the etiology of Crouzon syndrome.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [T32-HL-07698] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007698] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HOU JZ, 1992, J BIOL CHEM, V267, P17804; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moon R. T., 1989, TECHNIQUE, V1, P76; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PENG HB, 1991, XENOPUS LAEVIS PRACT; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; UENO H, 1992, J BIOL CHEM, V267, P1470; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WILKIE AOM, 1995, CURR BIOL, V5, P500; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	42	127	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26037	26040		10.1074/jbc.270.44.26037	http://dx.doi.org/10.1074/jbc.270.44.26037			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592798	hybrid			2022-12-25	WOS:A1995TC97800005
J	ADAMS, ME; DWYER, TM; DOWLER, LL; WHITE, RA; FROEHNER, SC				ADAMS, ME; DWYER, TM; DOWLER, LL; WHITE, RA; FROEHNER, SC			MOUSE ALPHA-1-SYNTROPHIN AND BETA-2-SYNTROPHIN GENE STRUCTURE, CHROMOSOME LOCALIZATION, AND HOMOLOGY WITH A DISCS LARGE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY LOCUS; NONMUSCLE TISSUES; MEMBRANE-PROTEIN; MAJOR PRODUCT; TRANSCRIPT; SEQUENCE; TORPEDO; MUSCLE; CELLS; BRAIN	The syntrophin family of dystrophin-associated proteins consists of three isoforms, alpha 1, beta 1, and beta 2, each encoded by a distinct gene. We have cloned and characterized the mouse alpha 1- and beta 2-syntrophin genes. The mouse alpha 1-syntrophin gene (>24 kilobases) is comprised of eight exons. The mouse beta 2-syntrophin gene (>33 kilobases) contains seven exons, all of which have homologues at the corresponding position in the alpha 1-syntrophin gene. Primer extension analysis reveals two transcription initiation sites in the alpha 1-syntrophin gene and a single site in the beta 2-syntrophin gene. The sequence immediately 5' of the transcription start sites of both genes lacks a TATA box but is GC-rich and has multiple putative SP1 binding sites. The alpha 1-syntrophin gene is located on human chromosome 20 and mouse chromosome 2, while the beta 2-syntrophin gene is on human chromosome 16 and mouse chromosome 8. Analysis of the amino acid sequence of the syntrophins reveals the presence of four conserved domains. The carboxyl-terminal 56 amino acids are highly conserved and constitute a syntrophin unique domain. Two pleckstrin homology domains are Located at the amino-terminal end of the protein. The first pleckstrin homology domain is interrupted by a domain homologous to repeated sequences originally found in the Drosophila discs-large protein.	UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599; UNIV MISSOURI,CHILDRENS MERCY HOSP,KANSAS CITY SCH MED,GENET SECT,KANSAS CITY,MO 64108	University of North Carolina; University of North Carolina Chapel Hill; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014871] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 14871] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; AHN AH, 1995, IN PRESS J BIOL CHEM; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CARTAUD A, 1993, J BIOL CHEM, V268, P13019; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DSOUZA VN, 1995, HUM MOL GENET, V4, P837, DOI 10.1093/hmg/4.5.837; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FROEHNER SC, 1984, J CELL BIOL, V99, P88, DOI 10.1083/jcb.99.1.88; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LANE PW, 1976, J HERED, V67, P135, DOI 10.1093/oxfordjournals.jhered.a108687; LEDERFEIN D, 1993, HUM MOL GENET, V2, P1883, DOI 10.1093/hmg/2.11.1883; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MALTAIS LJ, 1993, GBASE; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; TINSLEY JM, 1993, HUM MOL GENET, V2, P521, DOI 10.1093/hmg/2.5.521; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; WOODS DF, 1991, DEV BIOL, V134, P222; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	54	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25859	25865		10.1074/jbc.270.43.25859	http://dx.doi.org/10.1074/jbc.270.43.25859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592771	hybrid			2022-12-25	WOS:A1995TB46600088
J	LEECH, AP; JAMES, R; COGGINS, JR; KLEANTHOUS, C				LEECH, AP; JAMES, R; COGGINS, JR; KLEANTHOUS, C			MUTAGENESIS OF ACTIVE-SITE RESIDUES IN TYPE-I DEHYDROQUINASE FROM ESCHERICHIA-COLI - STALLED CATALYSIS IN A HISTIDINE TO ALANINE MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIKIMATE PATHWAY ENZYME; STEREOCHEMICAL COURSES; BRONSTED ANALYSIS; SALMONELLA-TYPHI; 3-DEHYDROQUINASE; PURIFICATION; IDENTIFICATION; INTERMEDIATE; BINDING; PROTEIN	Chemical modification experiments have previously implicated four amino acid residues in the mechanism of type I dehydroquinase from Escherichia coli. To further test their importance, these residues were mutated, and the resulting mutants were expressed, purified, and characterized. When the highly conserved, Schiff base-forming lysine residue was mutated (K170A) the resulting enzyme showed a similar to 10(6)-fold reduction in catalytic activity, but was still able to bind both substrate and product, as shown by a novel fluorescence-based ligand-binding assay. This is consistent with Lys-170 playing a central role in catalysis and shows that, although forming a covalent bond with the substrate, it is not essential for ground state binding of substrate or product. Conversely, substituting leucine for the conserved, iodoacetate-reactive methionine residue (M205L) had little effect on k(cat) or K-m. Diethylpyrocarbonate experiments had previously implicated either His-143 or His-146 as the putative active site general base. Substituting alanine for each shows that H146A retains full catalytic activity while H143A shows a 10(6)-fold loss of activity. As with the K170A mutant, H143A can bind Ligand, and in addition to the predicted role of this residue as the proton-abstracting general base, our data suggest that it is also involved in the formation and breakdown of Schiff base intermediates. Isoelectric focusing, electrospray ionization mass spectrometry, and fluorescence spectroscopy show that the H143A mutant preferentially stabilizes the formation of the product Schiff base, and that this results in burst kinetics reminiscent of p-nitrophenyl acetate hydrolysis by chymotrypsin. The most striking illustration of this stabilization is the fact that the H143A mutant is isolated from overexpressing cells with a significant proportion of the enzyme monomers covalently bound to the product, 3-dehydroshikimate, via a Schiffbase linkage. Our data suggest that the H143A mutant is able to slowly transform substrate to product but that the hydrolytic release of the product is stalled. The proposed dual role of His-143 in the mechanism of type I dehydroquinase may explain why the elimination reaction catalyzed by this enzyme proceeds with syn stereochemistry.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; UNIV GLASGOW, DEPT BIOCHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of East Anglia; University of Glasgow			James, Richard/B-2252-2009	James, Richard/0000-0002-5086-788X				BENNER SA, 1981, J AM CHEM SOC, V103, P993, DOI 10.1021/ja00394a071; BONNER CA, 1994, BIOCHEM J, V302, P11, DOI 10.1042/bj3020011; BOYS CWG, 1992, J MOL BIOL, V227, P352, DOI 10.1016/0022-2836(92)90704-N; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG TDH, 1989, THESIS CAMBRIDGE U U; BUTLER JR, 1974, J AM CHEM SOC, V96, P1617, DOI 10.1021/ja00812a069; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; CHAUDHURI S, 1986, BIOCHEM J, V239, P699, DOI 10.1042/bj2390699; CURTIS MD, 1991, MOL MICROBIOL, V5, P2727, DOI 10.1111/j.1365-2958.1991.tb01981.x; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DEKA RK, 1992, J BIOL CHEM, V267, P22237; DUNCAN K, 1986, BIOCHEM J, V238, P475, DOI 10.1042/bj2380475; EUVERINK GJW, 1992, J GEN MICROBIOL, V138, P2449, DOI 10.1099/00221287-138-11-2449; GARBE T, 1991, MOL GEN GENET, V228, P385, DOI 10.1007/BF00260631; GILES NH, 1967, P NATL ACAD SCI USA, V58, P1930, DOI 10.1073/pnas.58.5.1930; GOURLEY DG, 1994, J MOL BIOL, V241, P488, DOI 10.1006/jmbi.1994.1524; GREWE R, 1968, BIOCH PREP, V12, P21; HANSON KR, 1963, P NATL ACAD SCI USA, V50, P981, DOI 10.1073/pnas.50.5.981; HARRIS J, 1993, J CHEM SOC CHEM COMM, P1080, DOI 10.1039/c39930001080; HARTLEY BS, 1954, BIOCHEM J, V56, P288, DOI 10.1042/bj0560288; Haslam E., 1974, SHIKIMATE PATHWAY; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10929; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10935; KLEANTHOUS C, 1992, BIOCHEM J, V282, P687, DOI 10.1042/bj2820687; KLEANTHOUS C, 1991, J BIOL CHEM, V266, P10893; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; MITSUHASHI S, 1954, BIOCHIM BIOPHYS ACTA, V15, P54; MOORE JD, 1993, BIOCHEM J, V295, P277, DOI 10.1042/bj2950277; PITTARD J, 1966, J BACTERIOL, V91, P1494, DOI 10.1128/JB.91.4.1494-1508.1966; REILLY A, 1994, J BIOL CHEM, V269, P5523; REILLY A, 1993, BIOORG MED CHEM LETT, V3, P1429, DOI 10.1016/S0960-894X(01)80424-8; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SHNEIER A, 1991, J AM CHEM SOC, V113, P9416, DOI 10.1021/ja00024a085; SHNEIER A, 1993, BIOORG MED CHEM LETT, V3, P1399, DOI 10.1016/S0960-894X(01)80419-4; TONEY MD, 1992, PROTEIN SCI, V1, P107; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VAZ ADN, 1979, THESIS TULANE U NEW; WHITE PJ, 1990, BIOCHEM J, V265, P735, DOI 10.1042/bj2650735	39	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25827	25836		10.1074/jbc.270.43.25827	http://dx.doi.org/10.1074/jbc.270.43.25827			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592767	hybrid			2022-12-25	WOS:A1995TB46600084
J	YU, L; DENG, KP; YU, CA				YU, L; DENG, KP; YU, CA			CLONING, GENE SEQUENCING, AND EXPRESSION OF THE SMALL MOLECULAR-MASS UBIQUINONE-BINDING PROTEIN OF MITOCHONDRIAL UBIQUINOL-CYTOCHROME-C REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART UBIQUINOL; AMINO-ACID SEQUENCE; BC1 COMPLEX; RECOMBINANT PROTEINS; INCLUSION-BODIES; ESCHERICHIA-COLI; KDA; CRYSTALLIZATION; SUBUNITS	The cDNA encoding QPc-9.5 kDa (subunit VII) of bovine heart mitochondrial ubiquinol-cytochrome c reductase was cloned and sequenced. This cDNA is 665 base pairs long with an open reading frame of 246 base pairs that encodes an 81-amino acid mature QPc-9.5 kDa, The insert contains 395 base pairs of a 3'-noncoding sequence with a poly(A) tail. The amino acid sequence of QPc-9.5 kDa deduced from this nucleotide sequence is the same as that obtained by protein sequencing except that residue 61 is tryptophan instead of cysteine, The QPc-9.5 kDa was overexpressed in Escherichia coli JM109 cells as a glutathione S-transferase fusion protein (GST-QPc) using the expression vector, pGEX/QPc, The yield of soluble active recombinant GST-QPc fusion protein depends on the induction growth time, temperature, and medium. Maximum yield of recombinant fusion protein was obtained hom cells harvested 3 h postinduction of growth at 27 degrees C on LB medium containing betaine and sorbitol, QPc-9.5 kDa was released from the fusion protein by proteolytic cleavage with thrombin. Isolated recombinant QPc-9.5 kDa showed one protein band in SDS-polyacrylamide gel electrophroesis corresponding to subunit VII of mitochondrial ubiquinol-cytochrome c reductase. Although the isolated recombinant QPc-9.5 kDa is soluble in aqueous solution, it is in a highly aggregated form, with an apparent molecular mass of over 1 million, Addition of detergent deaggreates the isolated protein to the monomeric state, suggesting that the recombinant protein exists as a hydrophobic aggregation in aqueous solution, The recombinant QPc-9.5 kDa binds ubiquinone and shows a spectral blue shift. Upon titration of the recombinant protein with ubiquinone, a saturation behavior is observed, suggesting that the binding is specific and that the recombinant protein may be in the functionally active state.			YU, L (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,STILLWATER,OK 74078, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SL, 1981, J MOL BIOL, V156, P683; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BARR PJ, 1966, BIOTECHNIQUES, V4, P428; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BERRY EA, 1985, COENZYME Q, P365; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BORCHART U, 1986, FEBS LETT, V200, P81, DOI 10.1016/0014-5793(86)80515-4; BORCHART U, 1985, FEBS LETT, V191, P125, DOI 10.1016/0014-5793(85)81007-3; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; DARBY NJ, 1990, NATURE, V334, P715; HART RA, 1992, BIOTECHNOL BIOENG, V39, P1112, DOI 10.1002/bit.260391106; HARTLEY DL, 1988, BIOCHEM SOC T, V16, P101, DOI 10.1042/bst0160101; HARTMAN J, 1992, BIOTECHNOL BIOENG, V39, P828, DOI 10.1002/bit.260390805; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HE DY, 1994, J BIOL CHEM, V269, P2292; HOESS A, 1988, BIO-TECHNOL, V6, P1214, DOI 10.1038/nbt1088-1214; HOSOKAWA Y, 1989, J BIOL CHEM, V264, P13483; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; SAMBROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; USUI S, 1990, BIOCHEMISTRY-US, V29, P4618, DOI 10.1021/bi00471a017; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WAKABAYASHI S, 1982, J BIOL CHEM, V257, P9335; YU CA, 1972, J BIOL CHEM, V247, P1012; YU L, 1985, J BIOL CHEM, V260, P963; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002; ALTERED SITESTM IN V	37	24	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25634	25638		10.1074/jbc.270.43.25634	http://dx.doi.org/10.1074/jbc.270.43.25634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592738	hybrid			2022-12-25	WOS:A1995TB46600055
J	FAN, F; MAYO, KH				FAN, F; MAYO, KH			EFFECT OF PH ON THE CONFORMATION AND BACKBONE DYNAMICS OF A 27-RESIDUE PEPTIDE IN TRIFLUOROETHANOL - AN NMR AND CD STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLDING INITIATION SITES; MAGNETIC-RESONANCE RELAXATION; PROTEIN SECONDARY STRUCTURE; FIBRINOGEN GAMMA-CHAIN; HELIX-COIL TRANSITION; MODEL-FREE APPROACH; CIRCULAR-DICHROISM; ALIPHATIC-ALCOHOLS; WATER SOLUTION; SPECTROSCOPY	The C terminal fragment, residues 385-411, from human fibrinogen gamma-chain, i.e. KIIPFNRLTIGEGQQHHLG-GAKQAGDV, shows multiple turn conformations in aqueous solution (Mayo, K, H., Burke, C., Lindon, J, N., and Kloczewiak, M. (1990) Biochemistry 29, 3277-3286). The present study investigates the effect of pH and trifluoroethanol on the conformation and backbone dynamics of this 27-residue peptide. Both circular dichroism (CD) and H-1-NMR data indicate the normally observed increased helical conformations as a function of increasing trifluoroethanol. H-1-NMR structural studies done in the presence of 40% trifluoroethanol, pH 5.3, yield a network of nuclear Overhauser effects consistent with significant populations of helix like conformation. Distance geometry calculations based on nuclear Overhauser effect-derived distance constraints yield a family of structures with relatively well defined N- and C-terminal conformations and an ill defined mid-peptide region from Gly(397) to Gly(403). Similar conformational populations are observed at pH 2.5. CD studies, however, indicate an increase in average alpha-helix content on decreasing the pH from 6 to 2. This apparent conflict between CD and NMR results may be explained by a transition from multiple beta-turn character at pH 5.3 to increased alpha-helix structure at pH 2.5. C-13(alpha) NMR relaxation data analyzed with the Lipari-Szabo model-free approach provide order parameters that demonstrate little if any influence of pH on backbone motional restrictions within the more flexible mid-peptide domain. At low pH, however, motions become less restricted within N-terminal residues Lys(385)-Phe(389) and more restricted within C-terminal residues Ala(405)-Val(411).	UNIV MINNESOTA,CTR BIOMED ENGN,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								AUE WP, 1975, J CHEM PHYS, V64, P2229; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BLUMENSTEIN M, 1992, BIOCHEMISTRY-US, V31, P10692, DOI 10.1021/bi00159a008; BROWN JE, 1971, BIOCHEMISTRY-US, V10, P470, DOI 10.1021/bi00779a019; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1978, ADV ENZYMOL RELAT AR, V48, P45; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CONIO G, 1970, J BIOL CHEM, V245, P3335; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; ILYINA E, 1994, BIOCHEMISTRY-US, V33, P13436, DOI 10.1021/bi00249a032; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kuwajima Kunihiro, 1992, Current Opinion in Biotechnology, V3, P462, DOI 10.1016/0958-1669(92)90072-Q; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LEIST T, 1984, BIOCHEMISTRY-US, V23, P2541, DOI 10.1021/bi00307a001; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LLINAS M, 1975, J AM CHEM SOC, V97, P4731, DOI 10.1021/ja00849a040; LU ZX, 1984, J BIOL CHEM, V259, P7367; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MAYO KH, 1990, BIOCHEMISTRY-US, V29, P3277, DOI 10.1021/bi00465a019; MORODER L, 1975, BIOPOLYMERS, V14, P2075, DOI 10.1002/bip.1975.360141008; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NIRMALA NR, 1988, J AM CHEM SOC, V110, P7557, DOI 10.1021/ja00230a057; PALMER AG, 1991, J AM CHEM SOC, V13, P4371; PARODI RM, 1973, J BIOL CHEM, V248, P4047; PENA MC, 1989, BIOCHIM BIOPHYS ACTA, V957, P380; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SANZ JM, 1994, BIOCHEMISTRY-US, V33, P11189, DOI 10.1021/bi00203a015; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SHAKA AJ, 1983, J MAGN RESON, V51, P161; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6348, DOI 10.1021/bi00076a007; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Stewart JM, 1984, SOLID PHASE PEPTIDE; VANMIERLO CPM, 1993, J MOL BIOL, V229, P1125, DOI 10.1006/jmbi.1993.1108; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG YQ, 1993, J BIOL CHEM, V268, P9223	50	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24693	24701		10.1074/jbc.270.42.24693	http://dx.doi.org/10.1074/jbc.270.42.24693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559584	hybrid			2022-12-25	WOS:A1995TB46500018
J	LI, YY; HU, ZX; JORDAN, F; INOUYE, M				LI, YY; HU, ZX; JORDAN, F; INOUYE, M			FUNCTIONAL-ANALYSIS OF THE PROPEPTIDE OF SUBTILISIN-E AS AN INTRAMOLECULAR CHAPERONE FOR PROTEIN-FOLDING - REFOLDING AND INHIBITORY ABILITIES OF PROPEPTIDE MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PRO-PEPTIDE; DENATURED SUBTILISIN; REGION; POLYMERASE; EXPRESSION; BEHAVIOR; SEQUENCE; INVITRO; ENZYME	The amino-terminal propeptide, consisting of 77 amino acid residues, is known to be required as an in tramolecular chaperone to guide the folding of mature subtilisin E, a serine protease, into active mature enzyme. Many mutations within the pro-sequence have been shown to abolish the production of active subtilisin E (Kobayashi, T., and Inouye, M. (1992) J. Mol. Biol. 226, 931-933). Here we report characterization, refolding, and inhibitory abilities of six single amino acid substitution mutations (Ile(-67) --> Val, Ile(-48) --> Thr, Gly(-44) -->) Asp, Lys(-36) --> Glu, Ala(-30) --> Thr, and Pro(-15) --> Leu) and a nonsense mutation (N59-mer) at the codon for Lys(-18). These mutant propeptides were expressed in Escherichia coli using a T7 expression system and were purified to homogeneity. Surprisingly, Lys(-36) --> Glu, Ala(-30) --> Thr and Pro(-15) --> Leu were found to still function as a chaperone for in vitro refolding of denatured subtilisin BPN' with 60, 80, and 54% efficiency compared to the wild-type propeptide, respectively. The K-i values against subtilisin BPN' were 1.6 x 10(-9) M, 1.2 x 10(-9) M, and 2.1 x 10(-9) M, respectively, almost identical to the K-i value exhibited by the wild-type propeptide (1.4 x 10(-9) M). In contrast, Ile(-67) --> Val and Gly(-44) --> Asp were able to refold denatured subtilisin BPN' with only 18 and 13% efficiencies and had K-i values of 10 and 11 x 10(-9) M, respectively. The Ile(-48) --> Thr mutant propeptide was unable to refold denatured subtilisin BPN' and gave a 100-fold higher K-i (118 x 10(-9) M) than the wild-type propeptide. The N59-mer propeptide extending from Leu(-19) to Met(-78) was unable to function as a chaperone. Like the wild-type propeptide, none of the mutant propeptides had secondary structures as judged by their circular dichroism spectra. The present results demonstrate that the ability of the propeptide as a chaperone to refold the denatured protein is well correlated with its ability as a competitive inhibitor for the active enzyme. This supports the notion that the secondary and tertiary structures of the propeptide are identical or highly homologous between the renatured propeptide-subtilisin complex and the inhibitory complex formed between the propeptide and the active enzyme.	RUTGERS STATE UNIV, DEPT CHEM, NEWARK, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	LI, YY (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.							BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; HAYASHI T, 1993, CHEM PHARM BULL, V41, P2063; HU Z, 1994, ROLE PROPEPTIDE REFO; HU ZX, 1994, BIOCHEMISTRY-US, V33, P562, DOI 10.1021/bi00168a022; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LI YY, 1994, J BIOL CHEM, V269, P4169; Maniatis T., 1982, MOL CLONING; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; OHTA Y, 1990, MOL MICROBIOL, V4, P295, DOI 10.1111/j.1365-2958.1990.tb00596.x; RAMOS C, 1994, J BIOL CHEM, V269, P7006; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; ZHU X, 1992, BIOCH LIFE SCI ADV, V11, P35; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	28	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25127	25132		10.1074/jbc.270.42.25127	http://dx.doi.org/10.1074/jbc.270.42.25127			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559646	hybrid			2022-12-25	WOS:A1995TB46500080
J	SCHWEITZ, H; BRUHN, T; GUILLEMARE, E; MOINIER, D; LANCELIN, JM; BERESS, L; LAZDUNSKI, M				SCHWEITZ, H; BRUHN, T; GUILLEMARE, E; MOINIER, D; LANCELIN, JM; BERESS, L; LAZDUNSKI, M			KALICLUDINES AND KALISEPTINE - 2 DIFFERENT CLASSES OF SEA-ANEMONE TOXINS FOR VOLTAGE-SENSITIVE K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DEPENDENT POTASSIUM CHANNELS; CELL DEGRANULATING PEPTIDE; AMINO-ACID-SEQUENCE; GREEN MAMBA VENOM; DENDROTOXIN-I; SODIUM-CHANNEL; PHARMACOLOGICAL PROPERTIES; RECEPTOR-SITES; MCD PEPTIDE	New peptides have been isolated from the sea anemone Anemonia sulcata which inhibit competitively the binding of I-125-dendrotoxin I (a classical ligand for K+ channel) to rat brain membranes and behave as blockers of voltage-sensitive K+ channels. Sea anemone kali-cludines are 58-59-amino acid peptides cross-linked with three disulfide bridges. They are structurally homologous both to dendrotoxins which are snake venom toxins and to the basic pancreatic trypsin inhibitor (Kunitz inhibitor) and have the unique property of expressing both the function of dendrotoxins in blocking voltage-sensitive K+ channels and the function of the Kunitz inhibitor in inhibiting trypsin. Kaliseptine is another structural class of peptide comprising 36 amino acids with no sequence homology with kalicludines or with dendrotoxins. In spite of this structural difference, it binds to the same receptor site as dendrotoxin and kalicludines and is as efficient as a K+ channel inhibitor as the most potent kalicludine.	CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE; CHRISTIAN ALBRECHTS UNIV KIEL KLINIKUM, TOXIKOL ABT, W-2300 KIEL, GERMANY; CNRS, CEA, INST BIOL STRUCT JEAN PIERRE EBEL, F-38027 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); University of Kiel; Schleswig Holstein University Hospital; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Lancelin, Jean-marc/AAC-5686-2019					ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J; AWAN KA, 1991, NEUROSCIENCE, V40, P29, DOI 10.1016/0306-4522(91)90172-K; BARHANIN J, 1981, J BIOL CHEM, V256, P5764; BENISHIN CG, 1988, MOL PHARMACOL, V34, P152; BERESS L, 1975, FEBS LETT, V50, P311, DOI 10.1016/0014-5793(75)80517-5; BERESS L, 1978, DRUGS FOOD SEA MYTH, P59; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BIDARD JN, 1987, BIOCHEM BIOPH RES CO, V143, P383, DOI 10.1016/0006-291X(87)90677-2; BIDARD JN, 1989, BRAIN RES, V495, P45, DOI 10.1016/0006-8993(89)91216-X; CHERUBINI E, 1987, NATURE, V328, P70, DOI 10.1038/328070a0; DREYER F, 1990, REV PHYSIOL BIOCH P, V115, P93; FRELIN C, 1984, MOL PHARMACOL, V26, P70; FRITZ H, 1972, H-S Z PHYSIOL CHEM, V353, P19, DOI 10.1515/bchm2.1972.353.1.19; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; Harvey A.L., 1991, P131; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KATO I, 1979, FED PROC, V38, P832; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCELIN JM, 1994, NAT STRUCT BIOL, V1, P246, DOI 10.1038/nsb0494-246; LAZDUNSKI M, 1986, ANN NY ACAD SCI, V479, P204, DOI 10.1111/j.1749-6632.1986.tb15571.x; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MARSHALL DL, 1992, BIOL CHEM H-S, V373, P707, DOI 10.1515/bchm3.1992.373.2.707; MEVES H, 1992, HDB EXPT PHARM, V102, P739; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; POSSANI LD, 1982, CARLSBERG RES COMMUN, V47, P285, DOI 10.1007/BF02907789; REHM H, 1988, BIOCHEMISTRY-US, V27, P1827, DOI 10.1021/bi00406a005; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1988, BIOCHEM BIOPH RES CO, V153, P231, DOI 10.1016/S0006-291X(88)81213-0; REHM H, 1991, EUR J BIOCHEM, V202, P701, DOI 10.1111/j.1432-1033.1991.tb16425.x; ROGOWSKI RS, 1994, P NATL ACAD SCI USA, V91, P1475, DOI 10.1073/pnas.91.4.1475; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; SCHMIDT RR, 1988, BIOCHEMISTRY-US, V27, P963, DOI 10.1021/bi00403a019; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; SCHWEITZ H, 1989, BIOCHEMISTRY-US, V28, P9708, DOI 10.1021/bi00451a025; SCHWEITZ H, 1985, BIOCHEMISTRY-US, V24, P3554, DOI 10.1021/bi00335a025; SCHWEITZ H, 1989, FEBS LETT, V250, P519, DOI 10.1016/0014-5793(89)80788-4; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; TARR GE, 1983, P NATL ACAD SCI-BIOL, V80, P6552, DOI 10.1073/pnas.80.21.6552; VINCENT JP, 1980, P NATL ACAD SCI-BIOL, V77, P1646, DOI 10.1073/pnas.77.3.1646; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; VINCENT JP, 1974, EUR J BIOCHEM, V42, P505, DOI 10.1111/j.1432-1033.1974.tb03365.x; WACHTER E, 1987, RECEPTORS ION CHANNE, P313; WLODAWER A, 1987, J MOL BIOL, V193, P145, DOI 10.1016/0022-2836(87)90633-4	53	180	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25121	25126		10.1074/jbc.270.42.25121	http://dx.doi.org/10.1074/jbc.270.42.25121			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559645	hybrid			2022-12-25	WOS:A1995TB46500079
J	WANG, CN; HOBMAN, TC; BRINDLEY, DN				WANG, CN; HOBMAN, TC; BRINDLEY, DN			DEGRADATION OF APOLIPOPROTEIN-B IN CULTURED RAT HEPATOCYTES OCCURS IN A POST-ENDOPLASMIC RETICULUM COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HEP G2 CELLS; ALPHA-MANNOSIDASE-II; VERY-LOW-DENSITY; GOLGI-APPARATUS; INTRACELLULAR DEGRADATION; MESSENGER-RNA; SECRETORY PROTEINS; HEPATOMA-CELLS; PAUSE TRANSFER	The site of apolipoprotein B (apoB) degradation was investigated in cultured rat hepatocytes. Brefeldin A plus nocodazole completely blocked apoB degradation suggesting the involvement of a post-endoplasmic reticulum (ER) compartment. Monensin inhibited apoB degradation by 40% implying that a post-Golgi compartment could be involved in degradation of apoB. Ammonium chloride or chloroquine inhibited partially the degradation of apoB100 and apoB48, indicating some degradation in lysosomes, or in an acidic compartment such as trans-Golgi or endosomes. The degradations of apoB100 and apoB48 were blocked completely by (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (EST) during a chase of 90 min demonstrating that a cysteine protease was responsible for apoB degradation. Chymostatin, leupeptin, pepstatin, phenylmethylsulfonyl fluoride, and aprotinin had no significant effect on the degradation of apoB48. However, leupeptin and pepstatin decreased the degradation of apoB100 by 20-30%. Degradation of apoB100 and apoB48 occurred in isolated Golgi fractions with little degradation in heavy or light ER. Degradation of apoB in Golgi fractions was inhibited by EST and by preincubating hepatocytes with 10 nM dexamethasone. Immunofluorescent microscopy revealed that apoB accumulated in the Golgi region after EST treatment. it is concluded that a major part of apoB degradation in rat hepatocytes occurs in a post-ER compartment via the action of a cysteine protease that is regulated by glucocorticoids.	UNIV ALBERTA,DEPT BIOCHEM,SIGNAL TRANSDUCT LABS,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta; University of Alberta								ADELI K, 1994, J BIOL CHEM, V269, P9166; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ARION WJ, 1976, J BIOL CHEM, V251, P4901; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BERGERON JJ, 1973, J CELL BIOL, V59, P73, DOI 10.1083/jcb.59.1.73; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIANETTO R, 1955, BIOCHEM J, V59, P433, DOI 10.1042/bj0590433; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GRIFFITHS G, 1983, J CELL BIOL, V98, P835; GRINDE B, 1980, BIOCHIM BIOPHYS ACTA, V632, P73, DOI 10.1016/0304-4165(80)90250-0; HAMILTON RL, 1991, J LIPID RES, V32, P529; HAMILTON RL, 1989, BIOCHEM BIOPH RES CO, V160, P162, DOI 10.1016/0006-291X(89)91635-5; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HO WC, 1989, EUR J CELL BIOL, V48, P250; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P901; JANERO DR, 1983, J BIOL CHEM, V258, P4496; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLER HR, 1955, METHOD ENZYMOL, V2, P553; MARTINSANZ P, 1990, BIOCHEM J, V271, P575, DOI 10.1042/bj2710575; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Sambrook J., 1989, MOL CLONING LAB MANU; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, ARTERIOSCL THROM VAS, V15, P1481, DOI 10.1161/01.ATV.15.9.1481; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WANG HX, 1994, J BIOL CHEM, V269, P18514; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILKINSON J, 1992, BIOCHEM J, V288, P413, DOI 10.1042/bj2880413; WILKINSON J, 1993, J LIPID RES, V34, P815; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1989, J BIOL CHEM, V264, P11373	72	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24924	24931		10.1074/jbc.270.42.24924	http://dx.doi.org/10.1074/jbc.270.42.24924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559618	hybrid			2022-12-25	WOS:A1995TB46500052
J	HUANG, LX; ROHLFS, RJ; HILLE, R				HUANG, LX; ROHLFS, RJ; HILLE, R			THE REACTION OF TRIMETHYLAMINE DEHYDROGENASE WITH ELECTRON TRANSFERRING FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; IDENTIFICATION; SUBSTRATE; BINDING; W3A1	The kinetics of electron transfer between trimethylamine dehydrogenase (TMADH) and its physiological acceptor, electron transferring flavoprotein (ETF), has been studied by static and stopped-flow absorbance measurements. The results demonstrate that reducing equivalents are transferred from TMADH to ETF solely through the 4Fe/4S center of the former. The intrinsic limiting rate constant (k(lim)) and dissociation constant (K-d) for electron transfer from the reduced 4Fe/4S center of TMADH to ETF are about 172 s(-1) and 10 mu M, respectively. The reoxidation of fully reduced TMADH with an excess of ETF is markedly biphasic, indicating that partial oxidation of the iron-sulfur center in 1-electron reduced enzyme significantly reduces the rate of electron transfer out of the enzyme in these forms. The interaction of the two unpaired electron spins of flavin semiquinone and reduced 4Fe/4S center in 2-electron reduced TMADH, on the other hand, does not significantly slow down the electron transfer from the 4Fe/4S center to ETF. From a comparison of the limiting rate constants for the oxidative and reductive half-reactions, we conclude that electron transfer from TMADH to ETF is not rate-limiting during steady-state turnover. The overall kinetics of the oxidative half-reaction are not significantly affected by high salt concentrations, indicating that electrostatic forces are not involved in the formation and decay of reduced TMADH-oxidized ETF complex.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Ohio State University								BEINERT H, 1993, ARCH BIOCHEM BIOPHYS, V222, P333; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P250; NAGY J, 1979, J BIOL CHEM, V254, P2684; PACE CP, 1991, ARCH BIOCHEM BIOPHYS, V287, P97, DOI 10.1016/0003-9861(91)90393-W; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	24	33	33	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23958	23965		10.1074/jbc.270.41.23958	http://dx.doi.org/10.1074/jbc.270.41.23958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592591	hybrid			2022-12-25	WOS:A1995TA21700019
J	PIKE, CJ; OVERMAN, MJ; COTMAN, CW				PIKE, CJ; OVERMAN, MJ; COTMAN, CW			AMINO-TERMINAL DELETIONS ENHANCE AGGREGATION OF BETA-AMYLOID PEPTIDES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLAQUE CORE PROTEIN; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; INVITRO; DEPOSITION; PATHOLOGY; FRAGMENTS; TOXICITY; FIBRILS	beta-Amyloid protein, which assembles into pathological aggregates deposited in Alzheimer's disease brain tissue, exhibits N-terminal heterogeneity both in vitro and in vivo. To investigate the effects of this N-terminal heterogeneity on the assembly characteristics and biophysical properties of beta-amyloid, we synthesized a series of peptides with progressively shortened N termini (initial residues at positions beta 1, beta 4, beta 8, beta 12, and beta 17) and C termini extending to residue beta 40 or beta 42, We report that peptides with N-terminal deletions exhibit enhanced peptide aggregation relative to full-length species, as quantitatively assessed by sedimentation analyses. Overall, sedimentation levels were greater for peptides terminating at residue beta 42 than for those terminating at residue beta 40. To determine if established biophysical features of the full-length protein were maintained in the truncated peptides, structural and bioactive properties of these peptides were examined and compared. Full-length and truncated peptides exhibiting aggregation showed circular dichroism spectra consistent with predominant beta-sheet conformation, fibrillar morphology under transmission electron microscopy, and significant toxicity in cultures of rat hippocampal neurons. These data demonstrate that N-terminal deletions enhance aggregation of beta-amyloid into neurotoxic, beta-sheet fibrils and suggest that such peptides may initiate and/or nucleate the pathological deposition of beta-amyloid.			PIKE, CJ (corresponding author), UNIV CALIF IRVINE,INST BRAIN AGING & DEV,DEPT PSYCHOBIOL,IRVINE,CA 92717, USA.		Pike, Christian J/D-4013-2018	Pike, Christian/0000-0003-4577-7668	NIA NIH HHS [AG12663] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012663] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GOWING E, 1994, J BIOL CHEM, V269, P10987; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; NASLUND J, 1994, BIOCHEM BIOPH RES CO, V204, P780, DOI 10.1006/bbrc.1994.2527; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; PIKE CJ, 1995, BRAIN RES, V671, P293, DOI 10.1016/0006-8993(94)01354-K; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; SARKAR PK, 1966, P NATL ACAD SCI USA, V55, P981, DOI 10.1073/pnas.55.4.981; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	46	280	296	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23895	23898		10.1074/jbc.270.41.23895	http://dx.doi.org/10.1074/jbc.270.41.23895			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592576	hybrid			2022-12-25	WOS:A1995TA21700004
J	LU, AL; TSAIWU, JJ; CILLO, J				LU, AL; TSAIWU, JJ; CILLO, J			DNA DETERMINANTS AND SUBSTRATE SPECIFICITIES OF ESCHERICHIA-COLI MUTY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR; BASE-PAIR; IONIZING-RADIATION; RNA-POLYMERASE; GENE-PRODUCT; DAMAGED BASE; GLYCOSYLASE; DUPLEX; SITE; 8-OXOGUANINE	Potential DNA contacts involved in the specific interaction between the Escherichia coli MutY protein and a 40-mer oligonucleotide containing an A/G mismatch have been examined by alkylation interference techniques. Ethylation interference patterns suggest that more than five phosphates are involved in electrostatic interactions between MutY and DNA, Interestingly, MutY has more contacts on the G-strand than on the A strand. Methylation at both the N-7 position of the mismatched G and the N-3 position of the mispaired A interfere with MutY binding, In addition to these mismatched bases, MutY also contacts purines on both sides of the mismatch. Binding and endonuclease activities of MutY were assayed with 20-mer oligonucleotides containing A/G, A/C, A/7,8-dihydro-8-oxo-guanine (A/GO), A/inosine (A/I), A/2-aminopurine (A/2AP), nebularine/G (N/G), inosine/G (I/G), 2AP/G, and 7-deaza-adenosine/G (Z/G) mispairs, The C-8 keto group of GO in A/GO contributes to a much tighter binding but weaker endonuclease activity than is seen with A/G. Because A/I is not specifically well recognized by MutY, the a-amino group of G in A/G is essential for recognition, The C-6 keto group present in A/G but absent in A/2AP is also important for recognition, The B-amino group of adenine appears not to be required for either binding or endonuclease activity because N/G is as good a substrate as A/G. The 2AP/G mispair is bound and cleaved weaker than is the A/G mispair, Binding and endonuclease activities are abolished when the N-7 group of A is replaced by C-7 as in the Z/G mispair, When a C-6 keto group is present as in the L/G pair, its binding by MutY is as good as for A/G, but no endonuclease activity is observed, Taken together, our data suggest that DNA sequences proximal to and specific functional groups of mismatched bases are necessary for recognition and catalysis by MutY protein.			LU, AL (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201, USA.		Cillo, Joseph/AAS-4294-2020		NIGMS NIH HHS [GM 35132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BROWN T, 1990, J MOL BIOL, V212, P437, DOI 10.1016/0022-2836(90)90320-L; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CARBONNAUX C, 1991, BIOCHEMISTRY-US, V30, P5449, DOI 10.1021/bi00236a018; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHENG KC, 1991, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; KAN LS, 1983, P NATL ACAD SCI-BIOL, V80, P4263, DOI 10.1073/pnas.80.14.4263; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1980, NUCLEIC ACIDS RES, V18, P3841; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PATEL DJ, 1984, BIOCHEMISTRY-US, V23, P3207, DOI 10.1021/bi00309a015; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; RADICELLA JP, 1993, J BACTERIOL, V175, P7732, DOI 10.1128/JB.175.23.7732-7736.1993; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SU SS, 1988, J BIOL CHEM, V263, P6829; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1994, J BIOL CHEM, V269, P1513; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	42	99	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23582	23588		10.1074/jbc.270.40.23582	http://dx.doi.org/10.1074/jbc.270.40.23582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559523	hybrid			2022-12-25	WOS:A1995RY90900052
J	RIBONI, L; PRINETTI, A; BASSI, R; CAMINITI, A; TETTAMANTI, G				RIBONI, L; PRINETTI, A; BASSI, R; CAMINITI, A; TETTAMANTI, G			A MEDIATOR ROLE OF CERAMIDE IN THE REGULATION OF NEUROBLASTOMA NEURO2A CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; BLASTOMA CELLS; SPHINGOLIPID SYNTHESIS; EXOGENOUS GANGLIOSIDE; PLASMA-MEMBRANE; RETINOIC ACID; SPHINGOSINE; INHIBITION; SPHINGOMYELIN; CULTURE	Current studies indicate that ceramide is involved in the regulation of important cell functions, namely cell growth, differentiation, and apoptosis, In the present study, the possible role of ceramide in the differentiation of neuroblastoma Neuro2a cells was investigated, The following results were obtained, (a) Ceramide content of Neuro2a cells, induced to differentiate by retinoic acid (RA) treatment rapidly increased after addition of RA, was maintained at high levels in RA differentiated cells and returned to the starting levels with removal of RA and reversal of differentiation; under the same conditions, the sphingosine content remained unchanged, (b) After a short pulse with [H-3]sphingomyelin or [H-3]sphingosine or L-[H-3]serine, the metabolic formation of ceramide was markedly higher and more rapid in RA-differentiated than undifferentiated cells, (c) Inhibitors of ceramide biosynthesis (Fumonisin B1, beta-chloroalanine and L-cycloserine) diminished the extent of the differentiating effect of RA and concomitantly Cer content decreased, (d) The activity of neutral sphingomyelinase increased after addition of RA, maintained high levels in RA-differentiated cells, and returned to the initial levels with removal of RA, (e) Experimental conditions that cause an elevation of ceramide content (treatment with sphingosine or ceramide or C-2-ceramide or bacterial sphingomyelinase) inhibited cell proliferation and stimulated neurite outgrowth; dihydro analogues of sphingosine, ceramide, and C-2-ceramide had no effect on differentiation. (f) treatment with Fumonisin B1 completely inhibited sphingosine-induced differentiation. These data suggest a specific bioregulatory function of ceramide in the control of Neuro2a cell growth and differentiation and pose the general hypothesis of a mediator role of ceramide in the differentiation of cells of neural origin.	UNIV MILAN,DEPT MED CHEM & BIOCHEM,STUDY CTR FUNCT BIOCHEM BRAIN LIPIDS,I-20133 MILAN,ITALY	University of Milan			Prinetti, Alessandro/R-4206-2017; Riboni, Laura/R-4281-2017; Sonnino, Sandro/R-4154-2017	Prinetti, Alessandro/0000-0003-0252-2593; Riboni, Laura/0000-0002-4149-8226; Sonnino, Sandro/0000-0001-8180-5908; BASSI, ROSARIA/0000-0001-7409-4730				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, V1, P152; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DODGE JT, 1967, J LIPID RES, V8, P667; GATT S, 1976, BIOCHEM BIOPH RES CO, V68, P235, DOI 10.1016/0006-291X(76)90034-6; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAREL R, 1993, J BIOL CHEM, V268, P14476; HARRIS G, 1954, CHEM IND, V39, P249; IWAMORI M, 1975, J LIPID RES, V16, P332; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; KADOWAKI H, 1990, J NEUROCHEM, V54, P2125, DOI 10.1111/j.1471-4159.1990.tb04919.x; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK R, 1994, MOL CHEM NEUROPATHOL, V21, P287, DOI 10.1007/BF02815356; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1994, CURR TOP MEMBR, V40, P361, DOI 10.1016/S0070-2161(08)60988-0; MOOIBROEK MJ, 1985, J NEUROCHEM, V44, P1551, DOI 10.1111/j.1471-4159.1985.tb08794.x; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PARTRIDGE SM, 1948, BIOCHEM J, V42, P238, DOI 10.1042/bj0420238; PREISS J, 1986, J BIOL CHEM, V261, P8597; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; RIBONI L, 1994, FEBS LETT, V352, P323, DOI 10.1016/0014-5793(94)00984-8; RIBONI L, 1991, J NEUROCHEM, V57, P1931, DOI 10.1111/j.1471-4159.1991.tb06406.x; RIBONI L, 1995, J NEUROCHEM, V64, P451; RIBONI L, 1990, NEUROCHEM RES, V15, P1176; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; SPENCE MW, 1978, J NEUROCHEM, V30, P917, DOI 10.1111/j.1471-4159.1978.tb10804.x; SPENCE MW, 1982, BIOCHIM BIOPHYS ACTA, V719, P162, DOI 10.1016/0304-4165(82)90321-X; SUGIYAMA E, 1993, J BIOCHEM-TOKYO, V113, P467, DOI 10.1093/oxfordjournals.jbchem.a124068; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKETOMI T, 1970, J BIOCHEM-TOKYO, V68, P475, DOI 10.1093/oxfordjournals.jbchem.a129378; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; TSUJI S, 1988, J NEUROCHEM, V50, P414, DOI 10.1111/j.1471-4159.1988.tb02928.x; UEMURA K, 1993, J BIOCHEM-TOKYO, V114, P610, DOI 10.1093/oxfordjournals.jbchem.a124225; VANCE DE, 1967, J LIPID RES, V8, P621	50	158	158	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26868	26875		10.1074/jbc.270.45.26868	http://dx.doi.org/10.1074/jbc.270.45.26868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592930	hybrid			2022-12-25	WOS:A1995TE58300030
J	SCRIPTURE, JB; HUBER, PW				SCRIPTURE, JB; HUBER, PW			ANALYSIS OF THE BINDING OF XENOPUS RIBOSOMAL-PROTEIN L5 TO OOCYTE 5-S-RIBOSOMAL-RNA - THE MAJOR DETERMINANTS OF RECOGNITION ARE LOCATED IN HELIX-III-LOOP-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; ESCHERICHIA-COLI; LAEVIS OOCYTES; RIBONUCLEIC-ACID; FINGER PROTEIN; ALPHA-SARCIN; RNA GENE; COMPLEX; DNA; TFIIIA	Xenopus ribosomal protein L5 was expressed in Escherichia:coli and exhibits high affinity (K-d = 2 nM) and specificity for oocyte 5 S rRNA. The pH dependence of the association constant for the complex reveals an ionization with a pK(a) value of 10.1, indicating that tyrosine and/or lysine residues are important for specific binding of L5 to the RNA. Formation of the L5 5 S rRNA complex is remarkably insensitive to ionic strength, providing evidence that nonelectrostatic interactions make significant contributions to binding, Together, these results suggest that one or more tyrosine residues may form critical contacts through stacking interactions with bases in the RNA, In order to locate recognition elements within 5 S rRNA, we measured binding of L5 to a collection of site-specific mutants, Mutations in the RNA that affected the interaction are confined to the hairpin structure comprised of helix III and loop C, Earlier experiments with a rhodium structural probe had shown that the two nucleotide bulge in helix III and the intrinsic structure of loop C create sites in the major groove that are opened and accessible to stacking interactions with the metal complex, In the present studies, we detect a correlation between the intercalative binding of the rhodium complex to mutants in the hairpin and binding of L5, supporting the proposal that binding of the protein is mediated, in some part, by stacking interactions. Furthermore, the results from mutagenesis establish;that, despite overlapping binding sites on 5 S rRNA, L5 and transcription factor IIIA utilize distinct structural elements for recognition.	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556	University of Notre Dame					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1991, DEV BIOL, V144, P129, DOI 10.1016/0012-1606(91)90485-L; ALLISON LA, 1995, DEV BIOL, V168, P284, DOI 10.1006/dbio.1995.1080; AOYAMA K, 1984, J BIOCHEM-TOKYO, V95, P1179, DOI 10.1093/oxfordjournals.jbchem.a134707; BAUDIN F, 1991, J MOL BIOL, V218, P679; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROW DA, 1987, J BIOL CHEM, V262, P13959; BRUNEL C, 1990, J MOL BIOL, V215, P103, DOI 10.1016/S0022-2836(05)80099-3; CHAN YL, 1987, J BIOL CHEM, V262, P12879; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P3534, DOI 10.1021/bi00128a030; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P972, DOI 10.1021/bi00119a005; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DARSILLO P, 1991, J BIOL CHEM, V266, P21075; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; GABBAY EJ, 1973, BIOCHEMISTRY-US, V12, P4021, DOI 10.1021/bi00745a001; GROSS B, 1985, NUCLEIC ACIDS RES, V13, P2325, DOI 10.1093/nar/13.7.2325; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUBER PW, 1984, P NATL ACAD SCI-BIOL, V81, P322, DOI 10.1073/pnas.81.2.322; HUBER PW, 1991, J BIOL CHEM, V266, P3278; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; LI SJ, 1987, BIOCHEMISTRY-US, V26, P1578, DOI 10.1021/bi00380a014; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NAZAR RN, 1979, J BIOL CHEM, V254, P7724; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PICARD B, 1980, EUR J BIOCHEM, V109, P359, DOI 10.1111/j.1432-1033.1980.tb04802.x; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; ROMBY P, 1990, BIOCHIMIE, V72, P437, DOI 10.1016/0300-9084(90)90068-R; SCHULTE C, 1974, BIOCHEMISTRY-US, V13, P1032, DOI 10.1021/bi00702a031; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; TERAO K, 1982, BIOCHIM BIOPHYS ACTA, V697, P20, DOI 10.1016/0167-4781(82)90040-9; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; YEH LCC, 1988, J BIOL CHEM, V263, P17412; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028; ZANG WQ, 1995, J MOL BIOL, V245, P549, DOI 10.1006/jmbi.1994.0045	45	34	37	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27358	27365		10.1074/jbc.270.45.27358	http://dx.doi.org/10.1074/jbc.270.45.27358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592999	hybrid			2022-12-25	WOS:A1995TE58300099
J	VANSEUNINGEN, I; OSTROWSKI, J; BUSTELO, XR; SLEATH, PR; BOMSZTYK, K				VANSEUNINGEN, I; OSTROWSKI, J; BUSTELO, XR; SLEATH, PR; BOMSZTYK, K			THE K-PROTEIN DOMAIN THAT RECRUITS THE INTERLEUKIN 1-RESPONSIVE K-PROTEIN-KINASE LIES ADJACENT TO A CLUSTER OF C-SRC AND VAV SH3-BINDING SITES - IMPLICATIONS THAT K-PROTEIN ACTS AS A DOCKING PLATFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; T-CELLS; BINDING; RNA; DNA; EXPRESSION; IDENTIFICATION; PURIFICATION; ACTIVATION; AFFINITY	The heterogeneous ribonucleoprotein particle (hnRNP) K protein interacts with multiple molecular partners including DNA, RNA, serine/threonine, and tyrosine kinases and the product of the proto-oncogene, Vav. The K protein is phosphorylated in vivo and in vitro on serine/threonine residues by an interleukin 1 (IL-1)-responsive kinase with which it forms a complex. In this study we set out to map the K protein domains that bind kinases. We demonstrate that the K protein contains a cluster of at least three SH3-binding sites (P1, PPGRGGRPMPPSRR, amino acids 265-278; P2, PRRGPPPPPPGRG, 285-297; and P3, RARNLPLPPPPPPRGG, 303-318) and that each one of these sites is capable of selectively engaging c-Src and Vav SH3 domains but not SH3 domains of Abl, p85 phosphatidylinositol 3-kinase, Grb-2, and Csk. We demonstrate that the K protein domain that recruits and is phosphorylated in an RNA-dependent manner by the IL-1-responsive kinase, designated KPK for K protein kinase, is contained within the 338-425-amino acid stretch and thus is contiguous but does not include the cluster of the SH3-binding sites. K protein and KPK co-immunoprecipitate from cell extracts with either c-Src or Vav, suggesting that K protein-KPK-c-Src and K protein-KPK-Vav complexes exist in vivo. Furthermore, in the context of K protein, c-Src can reactivate KPK in vitro. The succession of kinase-binding sites contained within the K protein that allow it to form multienzyme complexes and facilitate kinase cross-talk suggest that K protein may serve as a docking platform that promotes molecular interactions occurring during signal transduction.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA; CTR CANC, MED CTR POSTGRAD EDUC, DEPT GASTROENTEROL, PL-02781 WARSAW, POLAND	University of Washington; University of Washington Seattle; Bristol-Myers Squibb; Centre of Postgraduate Medical Education - Poland			Bustelo, Xose R./A-9526-2010; VAN SEUNINGEN, Isabelle/N-6176-2016	Bustelo, Xose R./0000-0001-9398-6072; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Ostrowski, Jerzy/0000-0003-1363-3766	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508, R01GM045134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42508, GM45134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHOI KY, 1994, CELL, V78, P499; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLO KA, 1994, J BIOL CHEM, V269, P15092; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOBERT O, 1994, J BIOL CHEM, V269, P20225; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU Q, 1995, MOL CELL BIOL, V15, P2800; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; OSTROWSKI J, 1993, NUCLEIC ACIDS RES, V21, P1045, DOI 10.1093/nar/21.4.1045; RACHIE NA, 1993, J BIOL CHEM, V268, P22143; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SEGEL IH, 1993, ENZYME KINETICS, P106; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	46	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26976	26985		10.1074/jbc.270.45.26976	http://dx.doi.org/10.1074/jbc.270.45.26976			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592945	hybrid			2022-12-25	WOS:A1995TE58300045
J	MCGEADY, P; KURODA, S; SHIMIZU, K; TAKAI, Y; GELB, MH				MCGEADY, P; KURODA, S; SHIMIZU, K; TAKAI, Y; GELB, MH			THE FARNESYL GROUP OF H-RAS FACILITATES THE ACTIVATION OF A SOLUBLE UPSTREAM ACTIVATOR OF MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; ESCHERICHIA-COLI; OOCYTES; PURIFICATION; STIMULATION; TRANSFERASE; CONTAINS; RAS-P21; CYCLASE; EGGS	To study the function of the farnesyl modification of Pas, the farnesyl group and a variety of its structural analogs, which lack one or more double bonds and/or the methyl groups, were enzymatically incorporated into recombinant H Ras in vitro. These proteins were used in a cell and membrane-free, Ras-dependent mitogen-activated protein kinase (MAP kinase) activation system derived from Xenopus laevis eggs to examine the contribution of the farnesyl group toward the activation of the kinase, Whereas non-farnesylated H-Ras is unable to activate MAP kinase, farnesylation of H-Ras alone, in the absence of further processing, is sufficient to cause the activation of MAP kinase in this system, All of the analogs of the farnesyl group, when incorporated into H-Ras, support the activation of the kinase to variable extents, These results suggest a direct but fairly nonspecific interaction of the farnesyl moiety of H-Ras with a soluble upstream activator of MAP kinase.	OSAKA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, OSAKA 565, JAPAN; UNIV WASHINGTON, DEPT CHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Osaka University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016158] Funding Source: NIH RePORTER; NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562, GM16158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1993, MOL CELL BIOCHEM, V128, P201, DOI 10.1007/BF01076771; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CORNFORTH RH, 1969, METHOD ENZYMOL, V15, P359; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; EIDEM A, 1975, ACTA CHEM SCAND B, V29, P1015, DOI 10.3891/acta.chem.scand.29b-1015; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; KAWAHARA FK, 1968, ANAL CHEM, V40, P2073, DOI 10.1021/ac60269a044; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAI Y, 1993, CIBA F S, V170, P128; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	41	51	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26347	26351		10.1074/jbc.270.44.26347	http://dx.doi.org/10.1074/jbc.270.44.26347			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592846	hybrid, Green Published			2022-12-25	WOS:A1995TC97800053
J	SHAPIRO, DB; ESQUERRA, RM; GOLDBECK, RA; BALLAS, SK; MOHANDAS, N; KLIGER, DS				SHAPIRO, DB; ESQUERRA, RM; GOLDBECK, RA; BALLAS, SK; MOHANDAS, N; KLIGER, DS			CARBON-MONOXIDE RELIGATION KINETICS TO HEMOGLOBIN-S POLYMERS FOLLOWING LIGAND PHOTOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; SINGULAR VALUE DECOMPOSITION; POLYMERIZATION; GELATION; BINDING; NUCLEATION; MECHANISM; MYOGLOBIN	The re-equilibration rate of carbon monoxide binding to hemoglobin S polymers is determined by time-resolved measurements of linear dichroism spectra. Linear dichroism is used to detect religation to hemoglobin in the polymer in the presence of rebinding to free hemoglobin S tetramers. Measurement of the linear dichroism resulting from photolysis of the small percentage of ligand bound to the polymer is accomplished through the use of an ultrasensitive, ellipsometric linear dichroism technique developed for this purpose. The major finding is that the return of the polymer phase to its equilibrium ligation state is much slower than that of the solution phase hemoglobin tetramers. Assuming all hemes in the polymer are equally likely to participate in rebinding, the re-equilibration rate for carbon monoxide religation to hemoglobin S polymers is found to be 0.14 +/- 0.07 (s(-1) m(-1)), about 1000 times slower than the rebinding rate of carbon monoxide to T-state monomer hemoglobin. Several interpretations of this result are discussed. An understanding of the ligand binding kinetics to hemoglobin S polymers could have pathophysiological significance in its relevance to polymer formation and melting during red blood cell circulation.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; JEFFERSON MED COLL,DEPT MED,CALDEZA FDN,PHILADELPHIA,PA 19107	University of California System; University of California Santa Cruz; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632, R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035158] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31579, HL38632] Funding Source: Medline; NIGMS NIH HHS [GM35158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN D W, 1954, Rev Hematol, V9, P155; ALTMAN PA, 1971, RESP CIRC, P417; BERTINI I, 1994, BIORGANIC CHEM, P186; BOOKCHIN RM, 1994, J MOL BIOL, V244, P100, DOI 10.1006/jmbi.1994.1707; BRIEHL RW, 1992, J MOL BIOL, V245, P710; BRODERSEN S, 1990, J MOL SPECTROSC, V142, P122, DOI 10.1016/0022-2852(90)90296-3; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHE DP, 1994, CHEM PHYS LETT, V224, P145, DOI 10.1016/0009-2614(94)00530-3; CHEN E, 1993, METHOD ENZYMOL, V226, P119, DOI 10.1016/0076-6879(93)26008-W; CHUNG LL, 1978, ARCH BIOCHEM BIOPHYS, V189, P535, DOI 10.1016/0003-9861(78)90244-8; DEYOUNG A, 1982, METHOD ENZYMOL, V76, P792; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EATON WA, 1967, J CHEM PHYS, V46, P2533, DOI 10.1063/1.1841081; EATON WA, 1968, J CHEM PHYS, V49, P985, DOI 10.1063/1.1670263; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; FERRONE FA, 1985, J MOL BIOL, V183, P591, DOI 10.1016/0022-2836(85)90174-3; FERRONE FA, 1978, FRONT BIOL ENERGET, V2, P1085; GERACI G, 1969, J BIOL CHEM, V244, P4664; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GILL SJ, 1979, J MOL BIOL, V130, P175, DOI 10.1016/0022-2836(79)90425-X; GOLDBECK RA, 1993, METHOD ENZYMOL, V226, P147, DOI 10.1016/0076-6879(93)26009-X; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; GROSS CT, 1991, BIOCHIM BIOPHYS ACTA, V1079, P152, DOI 10.1016/0167-4838(91)90120-O; HARRINGTON JP, 1977, P NATL ACAD SCI USA, V74, P203, DOI 10.1073/pnas.74.1.203; HASINOFF BB, 1981, BIOPHYS CHEM, V13, P173, DOI 10.1016/0301-4622(81)80016-6; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HOFRICHTER J, 1973, P NATL ACAD SCI USA, V70, P3604, DOI 10.1073/pnas.70.12.3604; HOFRICHTER J, 1979, J MOL BIOL, V128, P335, DOI 10.1016/0022-2836(79)90092-5; HOFRICHTER J, 1994, METHOD ENZYMOL, V232, P387; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; KLIGER DS, 1987, REV CHEM INTERMED, V8, P367, DOI 10.1007/BF03055509; MATHEWS AJ, 1994, METHOD ENZYMOL, V232, P363; MESSER MJ, 1976, DHEW NIH761007 PUBL, P225; MIZUKAMI H, 1977, P SOC EXP BIOL MED, V154, P304, DOI 10.3181/00379727-154-39659; MOFFAT K, 1974, BIOCHEM BIOPH RES CO, V61, P237, DOI 10.1016/0006-291X(74)90558-0; MOZARELLI A, 1988, SCIENCE, V237, P500; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; PENNELLY RR, 1978, BIOCH CLIN ASPECTS H, P401; POILLON WN, 1993, P NATL ACAD SCI USA, V90, P5039, DOI 10.1073/pnas.90.11.5039; RUCKNAGEL DL, 1975, SICKLE CELL ANEMIA O, P1; SAMUEL RE, 1990, NATURE, V345, P833, DOI 10.1038/345833a0; SEAKINS M, 1973, J CLIN INVEST, V52, P422, DOI 10.1172/JCI107199; SHAPIRO DB, 1994, BIOCHEM BIOPH RES CO, V205, P154, DOI 10.1006/bbrc.1994.2643; SHAPIRO DB, 1995, BIOPHYS J, V68, P326, DOI 10.1016/S0006-3495(95)80191-8; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; SUNSHINE HR, 1982, J MOL BIOL, V158, P251, DOI 10.1016/0022-2836(82)90432-6; WINSLOW RM, 1978, BIOCH CLIN ASPECTS H, P369	48	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26078	26085		10.1074/jbc.270.44.26078	http://dx.doi.org/10.1074/jbc.270.44.26078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592808	hybrid			2022-12-25	WOS:A1995TC97800015
J	ALTMEYER, A; KLAMPFER, L; GOODMAN, AR; VILCEK, J				ALTMEYER, A; KLAMPFER, L; GOODMAN, AR; VILCEK, J			PROMOTER STRUCTURE AND TRANSCRIPTIONAL ACTIVATION OF THE MURINE TSG-14 GENE ENCODING A TUMOR-NECROSIS-FACTOR INTERLEUKIN-1-INDUCIBLE PENTRAXIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; AMYLOID-P-COMPONENT; ACUTE PHASE PROTEINS; NUCLEAR FACTOR; EXPRESSION NF-IL6; HUMAN FIBROBLASTS; DNA-SEQUENCE; C/EBP FAMILY; KAPPA-B; INTERLEUKIN-6	Human TNF-stimulated gene 14 (TSG-14) encodes a secreted 42-kDa glycoprotein that shows significant homology to proteins of the pentraxin family, which includes the acute phase reactants C-reactive protein and serum amyloid P component. Levels of TSG-14 protein (also termed PTX-3) become elevated in the serum of mice and humans after injection with bacterial Lipopolysaccharide, but in contrast to conventional acute phase proteins, the bulk of TSG-14 synthesis in the intact organism occurs outside the liver. In the present study we cloned and partially sequenced murine genomic TSG-14 DNA. Analysis of the coding region predicts a high degree of amino acid sequence homology between murine and human TSG-14 (88 and 75% identity in the first and second exons, respectively). The promoter of the TSG-14 gene lacks consensus sequences for either a TATA box or CCAAT box. Primer extension analysis and S1 nuclease protection assay revealed one major transcription start site, situated within a consensus sequence for an initiator element. Sequence analysis of a similar to 1.4-kilobase pair fragment of the 5'-flanking region of the TSG-14 gene revealed the presence of numerous potential enhancer binding elements, including six NF-IL6-like sites, four AP-1, one AP-2, one NF-kappa B, two Sp1, two interferon-gamma-activated sites (GAS), one Hox-1.3, and five binding sites for Ets family members. Transfection of BALB/c 3T3 cells with promoter DNA fragments linked to the luciferase reporter gene revealed that the 5'-flanking region of the TSG-14 gene comprises elements that can mediate a basal level of transcription and inducibility by TNF.	NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [R35-CA49731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALLES VV, 1994, BLOOD, V84, P3483; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DANOFF TM, 1994, J IMMUNOL, V152, P1182; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOWTON SB, 1991, BIOCHEMISTRY-US, V30, P9531, DOI 10.1021/bi00103a021; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; HU SI, 1986, BIOCHEMISTRY-US, V25, P7834, DOI 10.1021/bi00372a008; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; ITOH Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P261, DOI 10.1016/0167-4781(92)90024-T; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLAMPFER L, 1995, J BIOL CHEM, V270, P3677, DOI 10.1074/jbc.270.8.3677; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, MOL CELL BIOL, V15, P5995; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KU NO, 1993, BIOCHEM J, V295, P379, DOI 10.1042/bj2950379; LEE GW, 1994, J IMMUNOL, V153, P3700; LEE GW, 1993, J IMMUNOL, V150, P1804; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEI KJ, 1985, J BIOL CHEM, V260, P3377; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI SP, 1990, J BIOL CHEM, V265, P4136; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NISHIGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1366, DOI 10.1016/S0006-291X(88)81292-0; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; ODENWALD WF, 1987, GENE DEV, V1, P482, DOI 10.1101/gad.1.5.482; OHNISHI S, 1988, BIOCHEM BIOPH RES CO, V156, P814, DOI 10.1016/S0006-291X(88)80917-3; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; REID MS, 1994, J BIOL CHEM, V269, P32615; RUBIO N, 1993, J BIOCHEM-TOKYO, V113, P277, DOI 10.1093/oxfordjournals.jbchem.a124039; Sambrook J, 1989, MOL CLONING LABORATO; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SCIAVOLINO PJ, 1994, J BIOL CHEM, V269, P21627; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TONIATTI C, 1990, MOL BIOL MED, V7, P199; WHITEHEAD AS, 1990, ACUTE PHASE PROTEINS, P47; WOO P, 1985, J BIOL CHEM, V260, P3384; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	53	65	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25584	25590		10.1074/jbc.270.43.25584	http://dx.doi.org/10.1074/jbc.270.43.25584			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592730	hybrid			2022-12-25	WOS:A1995TB46600047
J	BRICKMAN, YG; FORD, MD; SMALL, DH; BARTLETT, PF; NURCOMBE, V				BRICKMAN, YG; FORD, MD; SMALL, DH; BARTLETT, PF; NURCOMBE, V			HEPARAN SULFATES MEDIATE THE BINDING OF BASIC FIBROBLAST GROWTH-FACTOR TO A SPECIFIC RECEPTOR ON NEURAL PRECURSOR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; HIGH-AFFINITY; FGF RECEPTOR; IMMUNOGLOBULIN DOMAIN; BIOLOGICAL-ACTIVITIES; LIGAND SPECIFICITY; MESSENGER-RNA; MOUSE-BRAIN; FAMILY; EXPRESSION	Heparan sulfate proteoglycans are thought to be obligatory for receptor binding and subsequent mitogenic activity of basic fibroblast growth factor (FGF-2). In a previous study (Nurcombe V., Ford, M. D., Wildschut, J., Bartlett, P. F. (1993) Science 260, 103-106) we have shown that primary cultures of mouse neuroepithelial cells and a cell line derived from them, 2.3D, secrete a heparan sulfate proteoglycan with a high affinity for EGF-2. In this study, a combination of affinity chromatography and gel chromatography was used to further isolate heparan sulfate side chains with high affinity for FGF-2. These active chains had an average molecular weight of 18,000-20,000. In order to determine whether heparan sulfate chains with specificity for FGF-2 also displayed selectivity for the different FGF receptors, peptides designed to the heparin-binding region of the receptors were used in competitive inhibition studies. The structure of the predicted heparin-binding domain of the FGF receptor 1 was modeled on the basis of its presumed secondary and tertiary structure homology with immunoglobulin loops. These results suggested that many of the basic residues within the second immunoglobulin loop of the FGF receptor 1 form a basic domain in the molecule and therefore form part of a heparin-binding site. Peptides homologous to this region of FGF receptor 1 were shown to inhibit mitogenesis in 2.3D cells, while those to FGF receptor types 2, 3, and 4 did not. A reverse transcriptase-polymerase chain reaction assay designed to detect expression of the four FGF receptors types demonstrated that FGF receptors 1 and 3 were present on the 2.3D cell line but that receptors 2 and 4 were not. These findings indicate that unique heparan sulfate domains interact with specific cell-surface receptors to direct cellular responses.	UNIV MELBOURNE, DEPT ANAT & CELL BIOL, MELBOURNE, VIC 3052, AUSTRALIA; UNIV MELBOURNE, DEPT PATHOL, MELBOURNE, VIC 3052, AUSTRALIA; UNIV MELBOURNE, ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA	University of Melbourne; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Walter & Eliza Hall Institute			Bartlett, Perry/F-3813-2012					AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ASAI T, 1993, MOL BRAIN RES, V17, P174, DOI 10.1016/0169-328X(93)90088-7; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HANLEY RM, 1989, NUCLEIC ACIDS RES, V17, P3992, DOI 10.1093/nar/17.10.3992; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LAFONT F, 1994, DEV BIOL, V165, P453, DOI 10.1006/dbio.1994.1267; Ledoux D, 1991, Growth Factors, V5, P221, DOI 10.3109/08977199109000286; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RICHARDSON JS, 1976, J MOL BIOL, V102, P221, DOI 10.1016/S0022-2836(76)80050-2; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SENSENBRENNER M, 1993, PROG NEUROBIOL, V41, P683, DOI 10.1016/0301-0082(93)90031-M; STARK KL, 1991, DEVELOPMENT, V113, P641; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WALKER A, 1994, J BIOL CHEM, V269, P931; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	48	82	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24941	24948		10.1074/jbc.270.42.24941	http://dx.doi.org/10.1074/jbc.270.42.24941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559620	hybrid			2022-12-25	WOS:A1995TB46500054
J	CERVINI, R; HOUHOU, L; PRADAT, PF; BEJANIN, S; MALLET, J; BERRARD, S				CERVINI, R; HOUHOU, L; PRADAT, PF; BEJANIN, S; MALLET, J; BERRARD, S			SPECIFIC VESICULAR ACETYLCHOLINE TRANSPORTER PROMOTERS LIE WITHIN THE FIRST INTRON OF THE RAT CHOLINE-ACETYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; REGION; EXPRESSION; BRAIN	The sequence encoding the vesicular acetylcholine transporter (VAChT) has recently been localized within the first intron of the choline acetyltransferase (ChAT) gene in various species. In rat, we previously identified a class of VAChT mRNAs that may originate from the same promoter region as two ChAT mRNAs. Here, we demonstrate by a detailed analysis of the 5'-noncoding region of the VAChT gene, that two specific VAChT promoters lie within the first intron of the ChAT gene. Two VAChT mRNAs are generated from these promoters. These results demonstrate that the promoter regions of these two genes are intermingled, which highlight the unique organization of the ChaT/VAChT gene locus.	GRP HOSP PITIE SALPETRIERE, GENET MOLEC NEUROTRANSMISS & PROC NEURODEGENERAT, BATIMENT CERVI, F-75651 PARIS 13, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite								ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BIGUET NF, 1986, EMBO J, V5, P287, DOI 10.1002/j.1460-2075.1986.tb04211.x; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CIVELLI O, 1982, J BIOL CHEM, V257, P6783; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; HARRISON SM, 1987, NUCLEIC ACIDS RES, V15, P10267, DOI 10.1093/nar/15.24.10267; IBANEZ CF, 1991, EUR J NEUROSCI, V3, P1309, DOI 10.1111/j.1460-9568.1991.tb00063.x; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MISAWA H, 1992, J BIOL CHEM, V267, P20392; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; WU DH, 1994, J NEUROCHEM, V62, P1653	17	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24654	24657		10.1074/jbc.270.42.24654	http://dx.doi.org/10.1074/jbc.270.42.24654			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559575	hybrid			2022-12-25	WOS:A1995TB46500009
J	CONRADT, M; STOFFEL, W				CONRADT, M; STOFFEL, W			FUNCTIONAL-ANALYSIS OF THE HIGH-AFFINITY, NA+-DEPENDENT GLUTAMATE TRANSPORTER GLAST-1 BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; ASPARTATE TRANSPORTER; GENE FAMILY; EXPRESSION; PROTEINS; CLONING; SEQUENCE; CARRIER	The reuptake of excitatory amino acids, such as glutamate, terminates excitatory signals and prevents the persistence of excitotoxic levels of glutamate in the synaptic cleft. The L-glutamate/L-aspartate transporter (GLAST-1) is the first member of the recently discovered glutamate transporter family, which includes GLT-1 and EAAC1. The neutral amino acid carrier ASCT1 is structurally closely related to this new family of membrane proteins. Transmembrane transport of neutral amino acids is expected to differ in its binding site from that of the acidic excitatory amino acids glutamate and aspartate. Three positively charged amino acid residues, Arg-122, Arg-280, Arg-479, and one polar Tyr-405 are conserved in all glutamate transporters. They are replaced by apolar amino acid residues in the ASCT1 sequence. We exchanged these residues in the GLAST-1-specific cDNA by site-directed mutagenesis. cRNAs of these mutants were expressed in the Xenopus oocyte system. The functional characterization of the mutants R122I and R280V and the double mutant R122I,R280V revealed that the mutations have no influence on the intrinsic properties and kinetics of glutamate transport but alter the K-m-values for L-aspartate and the competitive inhibitor D,L-threo-3-hydroxy aspartate. Substitutions of Tyr-405 by Phe (Y405F) and Arg-479 (R479T) by Thr completely inactivate the glutamate transporter. Immunoprecipitations of [S-35]methionine-labeled transporter molecules indicate similar expression levels of wild-type and mutant transporters. Immunostaining of oocyte sections clearly proves the correct targeting to and integration of the mutant GLAST-1 proteins in the plasma membrane. Our results suggest the pivotal function of the hydroxy group of the highly conserved Tyr-405 and the positively charged Arg-479 in the binding of the negatively charged acidic neurotransmitter glutamate.	UNIV COLOGNE, FAC MED, INST BIOCHEM, D-50931 COLOGNE, GERMANY	University of Cologne								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BENNETT JP, 1973, J NEUROCHEM, V21, P1533, DOI 10.1111/j.1471-4159.1973.tb06037.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; CONRADT M, 1995, EUR J BIOCHEM, V229, P682, DOI 10.1111/j.1432-1033.1995.tb20514.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; GORDON RD, 1983, J NEUROCHEM, V40, P1090, DOI 10.1111/j.1471-4159.1983.tb08097.x; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1994, FASEB J, V8, P1450; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KLOCKNER U, 1994, J NEUROSCI, V14, P5759; KUHAR MJ, 1973, LIFE SCI, V13, P1623, DOI 10.1016/0024-3205(73)90110-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORI H, 1994, J BIOL CHEM, V269, P11578; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADDING W, 1991, J THEOR BIOL, V150, P239, DOI 10.1016/S0022-5193(05)80335-2; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	30	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25207	25212		10.1074/jbc.270.42.25207	http://dx.doi.org/10.1074/jbc.270.42.25207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559657	hybrid			2022-12-25	WOS:A1995TB46500091
J	LAI, WS; THOMPSON, MJ; TAYLOR, GA; LIU, Y; BLACKSHEAR, PJ				LAI, WS; THOMPSON, MJ; TAYLOR, GA; LIU, Y; BLACKSHEAR, PJ			PROMOTER ANALYSIS OF ZFP-36, THE MITOGEN-INDUCIBLE GENE ENCODING THE ZINC-FINGER PROTEIN TRISTETRAPROLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; GROWTH-FACTOR; 3T3 CELLS; C-FOS; GLOBIN GENE; DNA-BINDING; ACTIN GENE; EXPRESSION; SEQUENCES; MOUSE	The gene encoding the putative zinc finger protein tristetraprolin (TTP), Zfp-36, is rapidly induced by a variety of mitogens and growth factors. We show here that 77 base pairs 5' of the transcription start site are sufficient for full serum inducibility of the mouse Zfp-36 promoter. This region of the promoter includes consensus sequences for the binding of the transcription factors EGR-1, AP2, and Sp1. In addition, we have identified a previously undescribed element, TTP promoter element 1 (TPE1); this 10-base pair sequence includes a palindrome and is identical in the human, bovine, and mouse genes. Each of the three binding elements, EGR-1, AP2, and TPE1, contribute to the serum induction of Zfp-36 and can confer serum-inducible expression on a heterologous minimal promoter. Gel mobility shift assays demonstrated the formation of complexes consisting of this region of the promoter and cellular nuclear proteins and demonstrated that the extent of complex formation could be altered by treatment of the cells with serum or insulin. These results suggest that the response of Zfp-36 to serum and other mitogens is mediated by a series of cis-acting elements acting in concert to confer full inducible transcription of this gene.	DUKE UNIV,MED CTR,DEPT MED,DIV METAB ENDOCRINOL & NUTR,DIABET & METAB SECT H,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,SARAH W STEDMAN CTR NUTR STUDIES,DURHAM,NC 27710; DUKE UNIV,DEPT MICROBIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [K11-DK02227-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002227] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; CAO XM, 1993, J BIOL CHEM, V268, P16949; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; HUMPHRIES RK, 1982, CELL, V30, P173; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JUVEN T, 1993, ONCOGENE, V8, P3411; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KERRIGAN LA, 1992, NUCLEIC ACIDS RES, V20, P6673, DOI 10.1093/nar/20.24.6673; LAI WS, 1990, J BIOL CHEM, V265, P16556; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; LIM RW, 1987, ONCOGENE, V1, P263; LOPEZRODAS G, 1993, FEBS LETT, V317, P175, DOI 10.1016/0014-5793(93)81271-Z; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSCHONAS N, 1981, NUCLEIC ACIDS RES, V9, P4391, DOI 10.1093/nar/9.17.4391; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Sambrook J, 1989, MOL CLONING LABORATO; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xie W.Q., 1991, BIOTECHNIQUES, V11, P326	39	61	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25266	25272		10.1074/jbc.270.42.25266	http://dx.doi.org/10.1074/jbc.270.42.25266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559666	hybrid			2022-12-25	WOS:A1995TB46500100
J	LEUNG, HT; BRADSHAW, J; CLEAVELAND, JS; LINSLEY, PS				LEUNG, HT; BRADSHAW, J; CLEAVELAND, JS; LINSLEY, PS			CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED MOLECULE-4, A HIGH AVIDITY RECEPTOR FOR CD80 AND CD86, CONTAINS AN INTRACELLULAR-LOCALIZATION MOTIF IN ITS CYTOPLASMIC TAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ACTIVATION; EXPRESSION; CTLA-4; CD28; GENE; BINDING; PROTEIN; COSTIMULATION; 3-KINASE; PATHWAY	CD28 and CTLA-4, T cell receptors for B7-1 (CD80) and B7-2 (CD86) molecules on antigen-presenting cells, transmit costimulatory signals important for optimal T cell activation. Despite sharing sequence homology and common ligands, these receptors have distinct binding properties and patterns of expression. The function of CTLA-4 during T cell activation is not well understood, although an important role is suggested by complete amino acid sequence conservation of its cytoplasmic tail in all species studied to date. We report here a role of the cytoplasmic tail of CTLA-4 in regulating its subcellular localization and cell surface expression. In activated human peripheral blood T cells, or in several transfected or transduced cell types, CTLA-4 is not primarily a cell surface protein, but rather is localized intracellularly in a region which overlaps the Golgi apparatus. Transfer of 11 cytoplasmic residues, (161)TTGVYVKMPPT, from the CTLA-4 cytoplasmic tail to the homologous position in CD28 was sufficient to confer intracellular localization. Mutation of the tyrosine residue (Tyr(165)) in this motif to phenylalanine resulted in increased sur face expression of CTLA-4. Thus, the subcellular localization of CTLA-4 is controlled by a tyrosine-containing motif within its cytoplasmic domain. Contained within this motif is a binding site for SH2 domains of the p85 subunit of phosphatidylinositol 3-kinase.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Bristol-Myers Squibb								ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AZUMA M, 1993, J EXP MED, V177, P845, DOI 10.1084/jem.177.3.845; BALZANO C, 1992, INT J CANCER, P28; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DAMLE NK, 1994, J IMMUNOL, V152, P2686; GUINAN EC, 1994, BLOOD, V84, P3261; HAFFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094, DOI 10.1073/pnas.90.23.11094; HARPER K, 1991, J IMMUNOL, V147, P1037; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUPFER A, 1991, P NATL ACAD SCI USA, V88, P775, DOI 10.1073/pnas.88.3.775; LINDSTEN T, 1993, J IMMUNOL, V151, P3489; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; MILLER AD, 1988, J VIROL, V62, P4337, DOI 10.1128/JVI.62.11.4337-4345.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SANSOM DM, 1993, EUR J IMMUNOL, V23, P295, DOI 10.1002/eji.1830230148; SCHNEIDER H, 1995, J EXP MED, V181, P351, DOI 10.1084/jem.181.1.351; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; STPIERRE Y, 1989, J IMMUNOL, V143, P808; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	132	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25107	25114		10.1074/jbc.270.42.25107	http://dx.doi.org/10.1074/jbc.270.42.25107			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559643	hybrid			2022-12-25	WOS:A1995TB46500077
J	SAMSON, SLA; PARAMCHUK, WJ; SHWORAK, NW; GEDAMU, L				SAMSON, SLA; PARAMCHUK, WJ; SHWORAK, NW; GEDAMU, L			FUNCTIONAL ANALYSES OF THE HUMAN METALLOTHIONEIN-IG GENE - IN-VITRO AND IN-VIVO STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL RESPONSE ELEMENT; DIFFERENTIAL EXPRESSION; DEPENDENT BINDING; CRYSTAL-STRUCTURE; PROMOTER; TRANSCRIPTION; LIVER; CELLS; ZINC; SEQUENCES	We have analyzed the human (h) metallothionein (MT)-IG proximal promoter region (-174 to +5) using a TATA box mutation (TATCA) and four trinucleotide mutants of the proximal MREa. Transient transfection of HepG2 cells was complemented by in vitro transcription with rat liver nuclear extracts. In both systems, mutations of the TATA box and conserved core of metal responsive element (MRE)a were detrimental to hMT-IG promoter activity suggesting that both elements make significant contributions to hMT-IG transcription. Although MRE binding factors were active in vitro, further metal activation of MT promoter activity was accomplished only by in vivo metal treatment rather than addition of zinc in vitro. Southwestern blotting identified nuclear proteins in rat liver and HepGa cells which physically interact with MREa in a zinc-dependent manner and could be responsible for MREa function in each system. In addition, the functional effects of the TATCA mutation correlate with altered physical interaction with TATA box-binding protein as observed using DNase I protection.	UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Calgary; Massachusetts Institute of Technology (MIT)			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BLALOCK TL, 1988, J NUTR, V118, P222, DOI 10.1093/jn/118.2.222; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; COUSINS RJ, 1986, AM J PHYSIOL, V251, pE688, DOI 10.1152/ajpendo.1986.251.6.E688; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DEWET JR, 1984, MOL CELL BIOL, V7, P725; FOSTER R, 1991, J BIOL CHEM, V266, P9866; GARG LC, 1989, J BIOL CHEM, V264, P2134; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; IMBERT J, 1990, ADV INORG BIOCHEM, V8, P138; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Maniatis T., 1982, MOL CLONING; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; REACH M, 1991, EMBO J, V10, P3439, DOI 10.1002/j.1460-2075.1991.tb04908.x; SAMSON SLA, 1995, J BIOL CHEM, V270, P6864, DOI 10.1074/jbc.270.12.6864; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT CJ, 1985, J BIOL CHEM, V260, P7731; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1990, NUCLEIC ACIDS RES, V18, P4683, DOI 10.1093/nar/18.16.4683; SHAPIRO SG, 1978, BIOCHEM J, V175, P833, DOI 10.1042/bj1750833; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SHWORAK NW, 1990, THESIS U CALGARY; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; SUZUKI KT, 1993, METALLOTHIONEIN, V3, P363; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	38	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25194	25199		10.1074/jbc.270.42.25194	http://dx.doi.org/10.1074/jbc.270.42.25194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559655	hybrid			2022-12-25	WOS:A1995TB46500089
J	TAHA, C; MITSUMOTO, Y; LIU, Z; SKOLNIK, EY; KLIP, A				TAHA, C; MITSUMOTO, Y; LIU, Z; SKOLNIK, EY; KLIP, A			THE INSULIN-DEPENDENT BIOSYNTHESIS OF GLUT1 AND GLUT3 GLUCOSE TRANSPORTERS IN L6 MUSCLE-CELLS IS MEDIATED BY DISTINCT PATHWAYS - ROLES OF P21(RAS) AND PP70 S6 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNALING PATHWAYS; EXPRESSION; RAS; RECEPTOR; PROTEINS; CULTURE; P21RAS	Insulin binding results in rapid phosphorylation of insulin receptor substrate-1 to activate p21(ras) and mitogen-activated protein kinase. Insulin also activates the ribosomal protein S6 kinase (pp70 S6 kinase) independently of the Ras pathway. Chronic (18 h) treatment of L6 muscle cells with insulin increases glucose transport activity severalfold due to biosynthetic elevation of the GLUT1 and GLUT3 but not the GLUT4 glucose transporters. Here we investigate the roles of p21(ras) and pp70 S6 kinase in the insulin-mediated increases in GLUT1 and GLUTS expression. L6 cells were transfected with the dominant negative Ras(S17N) under the control of a dexamethasone-inducible promoter. Induction of Ras(S17N) failed to block the insulin-mediated increase in GLUT1 glucose transporter protein and mRNA; however, it abrogated the insulin-mediated increase in GLUTS glucose transporter protein and mRNA, Inhibition of pp70 S6 kinase by rapamycin, on the other hand, eliminated the insulin-mediated increase in GLUT1 but had no effect on that of GLUT3 in both parental and Ras(S17N) transfected L6 cells. These results suggest that the biosynthetic regulation of glucose transporters is differentially determined, with pp70 S6 kinase and p21(ras) playing active roles in the insulin stimulated increases in GLUT1 and GLUT3, respectively.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; NYU,MED CTR,SKIRBALL INST BIOMOLEC MED,DEPT PHARMACOL,NEW YORK,NY 10024	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); New York University								BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; GUILLETDENIAU I, 1994, J CELL SCI, V107, P487; HAINQUE B, 1990, J BIOL CHEM, V265, P7982; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAYANO T, 1988, J BIOL CHEM, V263, P12245; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KHAN CR, 1988, J CLIN INVEST, V82, P1151; KLIP A, 1993, CELL SIGNAL, V5, P519, DOI 10.1016/0898-6568(93)90047-P; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; MAHER F, 1992, BIOCHEM BIOPH RES CO, V182, P703, DOI 10.1016/0006-291X(92)91789-S; MANCHESTER J, 1994, P NATL ACAD SCI USA, V91, P4644, DOI 10.1073/pnas.91.11.4644; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; Mitsumoto Y, 1993, ENDOCR J, V1, P307; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SARGEANT R, 1993, J ENDOCRINOL INVEST, V16, P147, DOI 10.1007/BF03347669; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIVITZ WI, 1995, BIOCHEM BIOPH RES CO, V206, P51, DOI 10.1006/bbrc.1995.1008; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	34	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24678	24681		10.1074/jbc.270.42.24678	http://dx.doi.org/10.1074/jbc.270.42.24678			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559581	hybrid			2022-12-25	WOS:A1995TB46500015
J	YANG, ZH; SWEENEY, HL				YANG, ZH; SWEENEY, HL			RESTORATION OF PHOSPHORYLATION-DEPENDENT REGULATION TO THE SKELETAL-MUSCLE MYOSIN REGULATORY LIGHT-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE; ASSAY	Regulation of the ATPase activity of smooth and nonmuscle myosin II involves reversible phosphorylation of the regulatory light chain (RLC). The RLC from skeletal muscle myosin (skRLC) is unable to confer regulation (myosin is locked in an inactive state) to smooth muscle myosin when substituted for the endogenous smooth RLC (smRLC). Studies of chimeric light chains comprised of the N or C-terminal half of each skRLC and smRLC suggest that the structural basis for the loss of this regulation is within the C-terminal half of the RLC (Trybus, K. M., and Chatman, T. A. (1993) J. Biol. Chem, 268, 4412-4419). The purpose of this study is to delineate the structural elements within the C-terminal half of the smRLC that are absent in the skRLC and are necessary for regulation. By sequence comparison, six residues, Arg-103, Arg-123, Met-129, Gly-130, Arg-143, and Arg-160, which are conserved in regulated myosin RLCs but missing in nonregulated myosin RLCs, were identified in smRLC. To test whether these amino acids provide the missing structural elements necessary for phosphorylation-mediated regulation, a skRLC was engineered that replaced the corresponding skRLC amino acids (positions 100, 120, 126, 127, 140, and 157, respectively) with their smRLC counterparts. Using a newly developed RLC exchange procedure, the purified mutant protein was evaluated for its ability to regulate chicken gizzard smooth muscle myosin. Substitution of the six conserved amino acids into the skRLC completely restored phosphorylation-mediated regulation. Thus, a subset of these amino acids, including four basic arginine residues located in the E, F, G, and H helices which are missing in skRLC, may be the structural coordinates for the phosphorylserine in the N terminus, Based on this result, the regulation of glycogen phosphorylase is discussed as a model for the regulation of smooth muscle myosin.	UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania			Sweeney, H Lee/F-1862-2010					CHACKO S, 1977, P NATL ACAD SCI USA, V74, P129, DOI 10.1073/pnas.74.1.129; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; COOK WJ, 1994, BIOCHEMISTRY-US, V33, P15259, DOI 10.1021/bi00255a006; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1991, J BIOL CHEM, V266, P21339; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVINE BA, 1988, BIOCHEM J, V254, P277, DOI 10.1042/bj2540277; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; VANDONSELAAR M, 1994, NAT STRUCT BIOL, V1, P795, DOI 10.1038/nsb1194-795; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	22	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24646	24649		10.1074/jbc.270.42.24646	http://dx.doi.org/10.1074/jbc.270.42.24646			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559573	hybrid			2022-12-25	WOS:A1995TB46500007
J	RICHARD, C; LIUZZO, JP; MOSCATELLI, D				RICHARD, C; LIUZZO, JP; MOSCATELLI, D			FIBROBLAST GROWTH FACTOR-II CAN MEDIATE CELL ATTACHMENT BY LINKING RECEPTORS AND HEPARAN-SULFATE PROTEOGLYCANS ON NEIGHBORING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; FACTOR FGF RECEPTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; LIGAND-BINDING; LEUKEMIA-CELLS; EXPRESSION; FAMILY	The myeloid 32D cell line, which grows in suspension and does not express FGF receptors or heparan sulfate proteoglycans, was transfected with the cDNA encoding FGF receptor-1 (32D-flg cells), When co cultured with glutaraldehyde-fixed Chinese hamster ovary (CHO) cells, the 32D-flg cells remained in suspension in the absence of FGF-2 but attached to the CHO monolayer in the presence of 10 ng/ml FGF-2. In contrast, 32D cells transfected with the vector alone did not attach to the CHO monolayer in the presence of FGF-2, FGF-2-dependent attachment of 32D-flg cells was prevented by inclusion of 10 mu g/ml heparin in the incubation medium and was diminished when CHO mutants in glycosaminoglycan synthesis or wild-type CHO cells treated with heparinase were used, indicating that the attachment occurred through FGF-2 interactions with heparan sulfates on the CHO cells. Attachment of 32D-flg cells to wild-type CHO cells was half-maximal at 0.4 ng/ml FGF-2 and was also observed with FGF-1 but not FGF-4, 32D-flg cells also attached to living CHO cells in a FGF-S-dependent manner, but attachment was transient at 37 degrees C. Induction of new proteins was not required for FGF-2-dependent attachment, since attachment occurred when the co cultures were incubated at 4 degrees C and when the 32D-flg cells were preincubated with cycloheximide. FGF-2-dependent attachment of 32D-flg cells was also observed with Balb/C 3T3, NIH 3T3, and bovine capillary endothelial cells. We conclude that attachment is due to FGF-2 binding simultaneously to receptors on the 32D-flg cells and heparan sulfates on the CHO monolayers; thus, the FGF-P acts as a bridge between receptor-expressing cells and heparan sulfate-bearing cells. In addition, induction of DNA synthesis in 32D-flg cells in response to FGF-2 was potentiated by the CHO-associated heparan sulfates to the same extent as by soluble heparin, indicating that this interaction has functional significance.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University				Moscatelli, David/0000-0002-4627-4213	NCI NIH HHS [CA42229, CA34289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; ARMSTRONG E, 1992, CANCER RES, V52, P2004; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BENTLEY SA, 1982, BRIT J HAEMATOL, V50, P1, DOI 10.1111/j.1365-2141.1982.tb01884.x; BERGONZONI L, 1992, EUR J BIOCHEM, V210, P823, DOI 10.1111/j.1432-1033.1992.tb17485.x; BIKFALVI A, 1992, BLOOD, V80, P1905; BRUNO E, 1993, BLOOD, V82, P430, DOI 10.1182/blood.V82.2.430.bloodjournal822430; BURGER PE, 1994, BLOOD, V83, P1808; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1993, BLOOD, V81, P909; GABRILOVE JL, 1994, BLOOD, V83, P907; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATOH O, 1992, BIOCHEM BIOPH RES CO, V183, P83, DOI 10.1016/0006-291X(92)91612-T; KAUFMAN SE, 1993, ANAL BIOCHEM, V211, P261, DOI 10.1006/abio.1993.1267; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KODAMA H, 1994, EXP HEMATOL, V22, P979; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LOWRY PA, 1992, BLOOD, V80, P663; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SMYTH SS, 1993, BLOOD, V81, P2827; UEMURA N, 1993, BLOOD, V82, P2634; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; WILSON EL, 1991, BLOOD, V77, P954; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	57	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24188	24196		10.1074/jbc.270.41.24188	http://dx.doi.org/10.1074/jbc.270.41.24188			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592623	hybrid			2022-12-25	WOS:A1995TA21700051
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			SPHINGOSYLPHOSPHORYLCHOLINE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE IN SWISS 3T3 CELLS REQUIRES PROTEIN-KINASE-C AND A PERTUSSIS-TOXIN-SENSITIVE G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; CELLULAR PROTEIN; PHORBOL ESTER; MAP KINASES; PATHWAYS; PHOSPHORYLATION; IDENTIFICATION; BOMBESIN; FIBROBLASTS	Sphingosylphosphorylcholine (SPC) is a potent mitogen for Swiss 3T3 cells, but the signaling mechanisms involved are poorly characterized, Here, we report that addition of SPC induces a rapid and transient activation of p42 mitogen-activated protein kinase (p42(MAPK)) in these cells, SPC induced p42(MAPK) activation peaked at 5 min and was undetectable after 30 min of incubation with SPC. The effect of SPC on p42(MAPK) activation was comparable to that induced by bombesin and platelet-derived growth factor. As SPC strongly induced phosphorylation of the major protein kinase C (PKC) substrate 80W/MARCKS in either intact or permeabilized cells, we examined whether PKC could be involved in SPC-induced p42(MAPK) activation. Here, we demonstrate that p42(MAPK) activation by SPC was dependent on PKC activity as shown by inhibition of PKC with the bisindolylmaleimide GF 109203X or down-regulation of PKC by prolonged treatment of Swiss 3T3 cells with phorbol esters, Activation of both PKC and p42(MAPK) by SPC was markedly inhibited by treatment with pertussis toxin, implicating a G protein(s) of the G(i)/G(o) subfamily in the action of SPC. SPC-induced rapid activation of a downstream target of p42(MAPK), p90 ribosomal S6 kinase (p90(rsh)), also required PKC and a pertussis toxin-sensitive G protein, In addition, SPC-induced mitogenesis was dependent on a G(i) protein in Swiss 3T3 cells, SPC also induced p42(MAPK) activation and DNA synthesis in secondary cultures of mouse embryo fibroblasts through a pertussis toxin-sensitive pathway, As G proteins link many cell surface receptors to effector proteins, we hypothesize, therefore, that SPC could bind to a receptor that mediates at least some of its biological effects in Swiss 3T3 cells and mouse embryo fibroblasts.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FUJINO Y, 1968, BIOCHEM J, V109, P310, DOI 10.1042/bj1090310; FUJINO Y, 1968, BIOCHIM BIOPHYS ACTA, V152, P428, DOI 10.1016/0005-2760(68)90058-1; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, P NATL ACAD SCI USA, V80, P7224; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEIJO L, 1994, LIPIDS, V29, P359, DOI 10.1007/BF02537190; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SOZERI O, 1992, ONCOGENE, V7, P2259; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; STRASBERG PM, 1987, LIPID STORAGE DISORD, P601; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YULE D, 1994, J BIOL CHEM, V268, P12353	52	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24334	24342		10.1074/jbc.270.41.24334	http://dx.doi.org/10.1074/jbc.270.41.24334			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592645	hybrid			2022-12-25	WOS:A1995TA21700073
J	YU, K; BAYONA, W; KALLEN, CB; HARDING, HP; RAVERA, CP; MCMAHON, G; BROWN, M; LAZAR, MA				YU, K; BAYONA, W; KALLEN, CB; HARDING, HP; RAVERA, CP; MCMAHON, G; BROWN, M; LAZAR, MA			DIFFERENTIAL ACTIVATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS BY EICOSANOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY LIGAND; 9-CIS RETINOIC ACID; FATTY-ACIDS; ADIPOCYTE DIFFERENTIATION; NUCLEAR RECEPTOR; RESPONSE ELEMENT; GENE-EXPRESSION; HORMONE; TRANSCRIPTION; CLONING	Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate gene transcription in response to peroxisome proliferators and fatty acids. PPARs also play an important role in the regulation of adipocyte differentiation. It is unclear, however, what naturally occurring compounds activate each of the PPAR subtypes. To address this issue, a screening assay was established using heterologous fusions of the bacterial tetracycline repressor to several members of the peroxisome proliferator-activated receptor (PPAR) family. This assay was employed to compare the activation of PPAR family members by known PPAR activators including peroxisome proliferators and fatty acids. Interestingly, the activation of PPARs by fatty acids was partially inhibited by the cyclooxygenase inhibitor indomethacin, which prevents prostaglandin synthesis. Indeed, prostaglandins PGA1 and 2, PGD1 and 2, and PGJ2-activated PPARs, while a number of other prostaglandins had no effect. We also screened a variety of hydroxyeicosatetraenoic acids (HETEs) for the ability to activate PPARs. 8(S)-HETE, but not other (S)-HETEs, was a strong activator of PPAR alpha. Remarkably, PPAR activation by 8(S)-HETE was stereoselective. In addition, 8(S)-HETE was able to induce differentiation of 3T3-L1 preadipocytes. These results indicate that PPARs are differentially activated by naturally occurring eicosanoids and related molecules.	UNIV PENN, SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED,DEPT GENET, PHILADELPHIA, PA 19104 USA; SANDOZ PHARMACEUT CORP, SANDOZ RES INST,PRECLIN RES,ONCOL RES PROGRAM, E HANOVER, NJ 07936 USA; DANA FARBER CANC INST, DIV NEOPLAST DIS MECHANISMS, BOSTON, MA 02115 USA	University of Pennsylvania; University of Pennsylvania; Novartis; Sandoz; Harvard University; Dana-Farber Cancer Institute			Lazar, Mitchell A/AAF-3738-2019	Kallen, Caleb/0000-0002-4156-6719; Harding, Heather P/0000-0002-7359-7974	NIDDK NIH HHS [DK45586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BRANDES R, 1987, LIFE SCI, V40, P935, DOI 10.1016/0024-3205(87)90312-2; BREGMAN MD, 1986, PROSTAGLANDINS, V26, P449; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALGUEYRET JP, 1988, BIOCHEM BIOPH RES CO, V156, P1083, DOI 10.1016/S0006-291X(88)80743-5; FUKUSHIMA M, 1982, BIOCHEM BIOPH RES CO, V105, P956, DOI 10.1016/0006-291X(82)91063-4; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIKUCHI Y, 1992, J CANCER RES CLIN, V118, P453, DOI 10.1007/BF01629429; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NATARAJAN R, 1994, HYPERTENSION, V23, pI142, DOI 10.1161/01.HYP.23.1_Suppl.I142; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; POWELL WS, 1992, J BIOL CHEM, V267, P19233; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SERHAN CN, 1991, J BIOENERG BIOMEMBR, V23, P105; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; TANG DG, 1994, ANN NY ACAD SCI, V744, P199, DOI 10.1111/j.1749-6632.1994.tb52738.x; THIERAUCH KH, 1994, J HYPERTENS, V12, P1; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	57	611	622	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23975	23983		10.1074/jbc.270.41.23975	http://dx.doi.org/10.1074/jbc.270.41.23975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592593	hybrid			2022-12-25	WOS:A1995TA21700021
J	DALY, C; REICH, NC				DALY, C; REICH, NC			CHARACTERIZATION OF SPECIFIC DNA-BINDING FACTORS ACTIVATED BY DOUBLE-STRANDED-RNA AS POSITIVE REGULATORS OF INTERFERON ALPHA/BETA-STIMULATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; HUMAN-CELLS; PROMOTER; 2-AMINOPURINE; VIRUS; INHIBITION; INDUCTION; ENHANCER; LOCUS	Viral infection results in transcriptional activation of the cellular interferon alpha/beta-stimulated genes (ISGs) independent of the autocrine action of interferon alpha/beta (IFN-alpha/beta). Induction of ISG expression by virus appears to be mediated through production of viral double-stranded RNA (dsRNA). Previously, we identified two novel dsRNA-activated factors (DRAFs) that bind to the interferon-stimulated response element (ISRE), the DNA sequence that mediates transcriptional activation by IFN-alpha/beta In this report we define sequences that flank the classical ISRE to be necessary for DRAF1 binding. More significantly, it is shown that the sequences required to bind DRAF1 correlate with the ability to mediate ISG induction by virus. These results strongly suggest that DRAF1 is a positive regulator of ISG transcription. DRAF1 is shown to bind selectively to the promoters of those ISGs which are strongly induced by viral infection, again suggesting the functional significance of this factor. UV cross-linking experiments indicate that DRAF1 and DRAF2 share a common DNA-binding subunit of approximately 70 kDa which is referred to as the DRAF binding component (DRAF(B)). DRAF(B) is shown to preexist in the cytoplasm of unstimulated cells. Consistent with this observation, both DRAF1 and DRAF2 are activated in the cytoplasm prior to nuclear translocation.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Daly, Christopher/0000-0003-3800-8174				BAZZIGHER L, 1992, VIROLOGY, V186, P154, DOI 10.1016/0042-6822(92)90069-2; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P591; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEMAEYER E, 1988, INTERFERONS OTHER RE, P1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FUSE A, 1984, JPN J CANCER RES, V75, P379; HUANG JT, 1990, P NATL ACAD SCI USA, V87, P7115, DOI 10.1073/pnas.87.18.7115; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x; WATHELET MG, 1988, EUR J BIOCHEM, V174, P323, DOI 10.1111/j.1432-1033.1988.tb14101.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU CQ, 1994, J INTERFERON RES, V14, P357, DOI 10.1089/jir.1994.14.357	26	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23739	23746		10.1074/jbc.270.40.23739	http://dx.doi.org/10.1074/jbc.270.40.23739			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559546	hybrid			2022-12-25	WOS:A1995RY90900075
J	LUO, ZJ; ZHANG, XF; RAPP, U; AVRUCH, J				LUO, ZJ; ZHANG, XF; RAPP, U; AVRUCH, J			IDENTIFICATION OF THE 14.3.3-ZETA DOMAINS IMPORTANT FOR SELF-ASSOCIATION AND RAF BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEINS; KINASE; PURIFICATION; EXPRESSION; P21(RAS); FAMILY	The 14.3.3 zeta protein is a ubiquitous and abundant arachidonate-selective acyltransferase and putative phospholipase A(2), which self assembles into dimers and binds to c-Raf-1 and other polypeptides in vitro and in intact cells. The 14.3.3 polypeptides endogenous to Sf9 cells associate in situ with both active and inactive recombinant Raf and copurify at a fairly reproducible molar ratio that is probably 1. Purified baculoviral recombinant Raf, despite its preassociated 14.3.3 polypeptide, binds additional recombinant 14.3.3 zeta polypeptide in vitro, in a saturable and specific reaction, forming a complex that is resistant to 1 M LiCl. A two-hybrid analysis indicates that 14.3.3 zeta binds primarily to Raf noncatalytic sequences distinct from those that bind Ras-GTP, and in vitro 14.3.3 zeta binds to Raf without inhibiting the Ras-Raf association or Raf catalyzed MEK phosphorylation. Deletion analysis of 14.3.3 zeta (1-245) indicates that the 14.3.3 domain responsible for binding to Raf extends over the carboxyl-terminal 100 amino acids, whereas 14.3.3 dimerization is mediated by amino-terminal sequences. As with Ras, the 14.3.3 zeta polypeptide does not activate purified Raf directly in vitro. Moreover, expression of recombinant 14.3.3 zeta in COS cells beyond the substantial level of endogenous 14.3.3 pro tein does not alter endogenous Raf kinase, as judged by the activity of a cotransfected Erk-1 reporter. Coexpression of recombinant 14.3.3 with recombinant Myc-tagged Raf in COS cells does increase substantially the Myc-Raf kinase activity achieved during transient expression, which is attributable primarily to an increased level of Myc-Raf polypeptide, without alteration of Myc-Raf specific activity or the activation that occurs in response to epidermal growth factor or 12-O-tetradecanoylphorbol-13-acetate. Nevertheless, evidence that 14.3.3 actively participates in Raf activation in situ is provided by the finding that although full-length 14.3.3 zeta binds active Raf in situ, truncated versions of 14.3.3, some of which bind Raf polypeptide in situ nearly as well as full-length 14.3.3 zeta, are recovered in association only with inactive Raf polypeptides. Thus, 14.3.3 polypeptides bind tightly to one or more sites on c-Raf. Overexpression of 14.3.3 zeta enhances the expression of recombinant Raf, perhaps by stabilizing the Raf polypeptide. In addition, Raf polypeptides bound to truncated 14.3.3 polypeptides are unable to undergo activation in situ, indicating that 14.3.3 participates in the process of Raf activation by mechanisms that remain to be elucidated.	MASSACHUSETTS GEN HOSP EAST, DIABET RES LABS, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP EAST, MED SERV, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; UNIV WURZBURG, INST MED STRAHLENKUNDE & ZELLFORSCH, D-97078 WURZBURG, GERMANY	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Wurzburg			Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289				AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	25	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23681	23687		10.1074/jbc.270.40.23681	http://dx.doi.org/10.1074/jbc.270.40.23681			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559537	hybrid			2022-12-25	WOS:A1995RY90900066
J	PINKO, C; MARGOSIAK, SA; VANDERPOOL, D; GUTOWSKI, JC; CONDON, B; KAN, CC				PINKO, C; MARGOSIAK, SA; VANDERPOOL, D; GUTOWSKI, JC; CONDON, B; KAN, CC			SINGLE-CHAIN RECOMBINANT HUMAN CYTOMEGALOVIRUS PROTEASE - ACTIVITY AGAINST ITS NATURAL PROTEIN SUBSTRATE AND FLUOROGENIC PEPTIDE SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ASSEMBLY PROTEIN; IDENTIFICATION; GENE; EXPRESSION; SEQUENCE; DOMAIN; DNA; POLYMERASE; CLEAVAGE	We report here the production of active recombinant single-chain human cytomegalovirus protease in Escherichia coli and development of a continuous assay for this protease. In order to produce the human cytomegalovirus (HCMV) protease for structural studies and accurate kinetic analysis, mutation of alanine 143 at an internal cleavage site was introduced to prevent autoproteolysis. The resulting soluble 29-kDa A143Q protease was purified to homogeneity as a stable single-chain protein by hydrophobic interaction and ionic-exchange chromatography. The in vivo protein substrate, assembly protein precursor, was also expressed and purified for activity studies. To develop a continuous protease assay, fluorescent synthetic peptide substrates similar to the cleavage sequence P5 to P5' of the maturation site containing anthranilic acid and nitrotyrosine as a resonance energy transfer donor-acceptor pair were designed. Purified HCMV A143Q protease cleaved the recombinant assembly protein precursor with K-m and k(cat) values of 3.0 +/- 1.0 mu M and 13.3 +/- 1.6 min(-1). The K-m for peptide substrates is at least 45-fold higher than for the natural protein substrate, but the k(cat) values are similar. A sensitive assay was developed using fluorescent peptide substrates, which can detect nM HCMV protease activity.	AGOURON PHARMACEUT INC, MOLEC BIOL BIOCHEM GRP, SAN DIEGO, CA 92121 USA; AGOURON PHARMACEUT INC, BIOPHYS GRP, SAN DIEGO, CA 92121 USA	Pfizer; Pfizer								BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GAO M, 1994, J VIROL, V68, P3702, DOI 10.1128/JVI.68.6.3702-3712.1994; GIBSON W, 1990, J VIROL, V64, P1241, DOI 10.1128/JVI.64.3.1241-1249.1990; GIBSON W, 1972, J VIROL, V10, P1044, DOI 10.1128/JVI.10.5.1044-1052.1972; GIBSON W, 1974, J VIROL, V13, P155, DOI 10.1128/JVI.13.1.155-165.1974; Gold E, 1982, VIRAL INFECT HUMANS, P167; GOODGAME RW, 1993, ANN INTERN MED, V119, P924, DOI 10.7326/0003-4819-119-9-199311010-00010; HOLSKIN BP, 1995, ANAL BIOCHEM, V227, P148, DOI 10.1006/abio.1995.1264; HOLWERDA BC, 1994, J BIOL CHEM, V269, P25911; KAN CC, 1992, J PROTEIN CHEM, V11, P467, DOI 10.1007/BF01025023; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OBOYLE DR, 1995, J BIOL CHEM, V270, P4753, DOI 10.1074/jbc.270.9.4753; PERDUE ML, 1974, VIROLOGY, V59, P201, DOI 10.1016/0042-6822(74)90216-5; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; ROBSON L, 1989, J VIROL, V63, P669, DOI 10.1128/JVI.63.2.669-676.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDANA VV, 1994, J BIOL CHEM, V269, P14337; SCHENK P, 1991, J VIROL, V65, P1525, DOI 10.1128/JVI.65.3.1525-1529.1991; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991	31	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23634	23640		10.1074/jbc.270.40.23634	http://dx.doi.org/10.1074/jbc.270.40.23634			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559530	hybrid			2022-12-25	WOS:A1995RY90900059
J	PANAGOPOULOS, I; MANDAHL, N; MITELMAN, F; AMAN, P				PANAGOPOULOS, I; MANDAHL, N; MITELMAN, F; AMAN, P			2 DISTINCT FUS BREAKPOINT CLUSTERS IN MYXOID LIPOSARCOMA AND ACUTE MYELOID-LEUKEMIA WITH THE TRANSLOCATIONS T(12-16) AND T(16-21)	ONCOGENE			English	Article						MYXOID LIPOSARCOMA; ACUTE MYELOID LEUKEMIA; T(12-16); T(16-21); BREAKPOINT MAPPING; FUS GENE	GENE; CHOP; LOCALIZATION; ERG	The PUS gene, which maps to 16p11, is fused to the CHOP gene in the t(12;16) (q13;p11) that characterizes myxoid liposarcomas (MLS) and to the ERG gene in acute myeloid leukemia (AML) with t(16;21) (p11;q22). In the present study we have mapped the breakpoints within FUS in 13 MLS with t(12;16) and in one AML with t(16;21). This region of PUS is about 3.9 kb and contains four exons. The breakpoints clustered to two zones (1 and 2). A strong association was found between the two known types of PUS/CHOP transcripts and the genomic localization of the breakpoints. In all cases expressing only type I or both type I and II PUS/CHOP transcript the genomic breakpoints mapped to zone 1. In all cases expressing only the type II transcript the breakpoints occurred in zone 2. The breakpoint in the AML case was in zone 1, suggesting that in-frame fusion transcripts are selected by similar mechanisms in both MLS and AML.			PANAGOPOULOS, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Aman, Pierre/0000-0002-1482-8875; Panagopoulos, Ioannis/0000-0003-2159-5341				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; ENEROTH M, 1990, CANCER GENET CYTOGEN, V48, P101, DOI 10.1016/0165-4608(90)90222-V; ICHIKAWA H, 1994, CANCER RES, V54, P2865; LADANYI M, 1994, CANCER RES, V54, P2837; MANDAHL N, 1994, INT J ONCOL, V4, P307; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PONCE MR, 1992, NUCLEIC ACIDS RES, V29, P623; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	18	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1133	1137						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566973				2022-12-25	WOS:A1995RX18000016
J	LEE, JW; ZHANG, YX; WEAVER, CD; SHOMER, NH; LOUIS, CF; ROBERTS, DM				LEE, JW; ZHANG, YX; WEAVER, CD; SHOMER, NH; LOUIS, CF; ROBERTS, DM			PHOSPHORYLATION OF NODULIN-26 ON SERINE-262 AFFECTS ITS VOLTAGE-SENSITIVE CHANNEL ACTIVITY IN PLANAR LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INTRINSIC PROTEIN; PERIBACTEROID MEMBRANE; JUNCTION PROTEIN; SOYBEAN NODULES; LENS; SEQUENCE; ACID; MP26; MIP	Nodulin 26 is an symbiosome membrane protein of soybean nodules that shows ion channel activity in planar lipid bilayers, Serine 262 of nodulin 26 is phosphorylated by calmodulin-like domain protein kinase. To study the effects of phosphorylation, nodulin 26 with Ser, Ala, or Asp at position 262 were expressed in Escherichia coli, The expressed protein possessed a histidine-rich leader sequence for purification by Ni(2+)chelate fast protein liquid chromatography, Upon reconstitution into planar lipid bilayers, the recombinant proteins showed a large single channel conductance (3.1 nanosiemens (nS) in cis(0.2 M)/trans(1.0) and 1.6 nS in cis(0.2 M)/trans(0.2 M KCl)) and weak anion selectivity, similar to native soybean nodulin 26. Nodulin 26 with Ser or Ala-262 occupied the maximal open conductance state greater than 97% of the time (3.1 nS in cis(0.2 M)/ trans(1.0 M KCl)) regardless of applied voltage. However, nodulin 26 with Asp-262 showed increased gating and preferential occupancy of lower subconductance states (1.8 and 0.6 nS in cis(0.2 M)/trans (1.0 M KCl)) at high applied voltages (e.g, 70 mV), In situ phosphorylation of Ser-262 of nodulin 26 by calmodulin-like domain protein kinase also resulted in increased voltage-dependent gating and preferential occupancy of lower subconductance states. These results suggest that phosphorylation of serine 262 of nodulin 26 modulates channel activity by conferring voltage sensitivity.	UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996; UNIV TENNESSEE,CTR LEGUME RES,KNOXVILLE,TN 37996; UNIV MINNESOTA,DEPT VET PATHOBIOL & BIOCHEM,ST PAUL,MN 55108	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Minnesota System; University of Minnesota Twin Cities			Lee, Jung Weon/AAC-1146-2020; Lee, Jung Weon/F-9149-2012	Lee, Jung Weon/0000-0003-2722-8200; Roberts, Daniel/0000-0002-0780-7056; Shomer, Nirah/0000-0003-2520-0108				BENZANILLA F, 1994, ANNU REV BIOPH BIOM, V23, P819; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chandy Grischa, 1995, Biophysical Journal, V68, pA353; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; DAY DA, 1993, SYMBIOSIS, V14, P175; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; EHRING GR, 1991, J MEMBRANE BIOL, V126, P75; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; JAN LY, 1994, SCIENCE, V371, P119; JOHNSON KD, 1992, PLANT PHYSIOL, V100, P1787, DOI 10.1104/pp.100.4.1787; JOHNSON KR, 1986, J CELL BIOL, V102, P1334, DOI 10.1083/jcb.102.4.1334; LABARCA P, 1992, METHOD ENZYMOL, V207, P447; LAMPE PD, 1986, EUR J BIOCHEM, V156, P351, DOI 10.1111/j.1432-1033.1986.tb09590.x; LAMPE PD, 1989, J MEMBRANE BIOL, V107, P145, DOI 10.1007/BF01871720; LAMPE PD, 1990, EUR J BIOCHEM, V194, P541, DOI 10.1111/j.1432-1033.1990.tb15650.x; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; Roth L.E., 1988, MOL GENETICS PLANT M, P220; SHEN L, 1991, J MEMBRANE BIOL, V124, P21, DOI 10.1007/BF01871361; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UDVARDI MK, 1989, PLANT PHYSIOL, V90, P982, DOI 10.1104/pp.90.3.982; VANDONGEN AMJ, 1992, BIOPHYS J, V61, pA256; VERBAVATZ JM, 1994, J CELL SCI, V107, P1083; WEAVER CD, 1991, PLANT PHYSIOL, V95, P222, DOI 10.1104/pp.95.1.222; WEAVER CD, 1994, J BIOL CHEM, V269, P17858; WEAVER CD, 1992, BIOCHEMISTRY-US, V31, P8954, DOI 10.1021/bi00152a035; YANG LJO, 1991, FEBS LETT, V293, P188; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHANG YX, 1995, MOL BIOL CELL, V6, P109, DOI 10.1091/mbc.6.1.109	35	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27051	27057		10.1074/jbc.270.45.27051	http://dx.doi.org/10.1074/jbc.270.45.27051			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592955	hybrid			2022-12-25	WOS:A1995TE58300055
J	WISHART, MJ; DENU, JM; WILLIAMS, JA; DIXON, JE				WISHART, MJ; DENU, JM; WILLIAMS, JA; DIXON, JE			A SINGLE MUTATION CONVERTS A NOVEL PHOSPHOTYROSINE BINDING DOMAIN INTO A DUAL-SPECIFICITY PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAP KINASE; PROTEIN	Dual-specificity protein-tyrosine phosphatases (dsPTPases) have been implicated in the inactivation of mitogen-activated protein kinases (MAPKs), We have identified a novel. phosphoserine/thhreonine/tyrosine-binding protein (STYX) that is related in amino acid sequence to dsPTPases, except for the substitution of Gly for Cys in the conserved dsPTPase catalytic loop (HCXYGXXR(S/T)), cDNA subcloning and Northern blot analysis in mouse shows poly(A(+)) hybridization bands of 4.6, 2.4, 1.5, and 1.2 kilobases, with highest abundance in skeletal muscle, testis, and heart, Polymerase chain reaction amplification of reverse-transcribed poly(A(+)) RNA revealed an alternatively spliced form of STYX containing a unique carboxyl terminus, Bacterially expressed STYX. is incapable of hydrolyzing Tyr(P)-containing substrates; however, mutation of Gly(120) to Cys (G120C), which structurally mimics the active site of dsPTPases, confers phosphatase activity to this molecule, STYX-G120C mutant hydrolyzes p-nitrophenyl phosphate and dephosphorylates both Tyr(P) and Thr(P) residues of peptide sequences of MAPK homologues. The kinetic parameters of dephosphorylation are similar to human dsPTPase, Vaccinia H1-related, including inhibition by vanadate, We believe this is the first example of a naturally occurring ''dominant negative'' phosphotyrosine/serine/threonine-binding protein which is structurally related to dsPTPases.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849, R01DK041122, R01DK018024, R37DK041122, R37DK018024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-18849, DK-41122, DK-18024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; AROCA P, 1995, J BIOL CHEM, V270, P14229, DOI 10.1074/jbc.270.23.14229; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; ISHIBASHI T, 1995, P NATL ACAD SCI USA, V89, P12170; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SCHUBERT HL, 1995, IN PRESS PROTEIN SCI; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	20	79	316	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26782	26785		10.1074/jbc.270.45.26782	http://dx.doi.org/10.1074/jbc.270.45.26782			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592916	hybrid			2022-12-25	WOS:A1995TE58300016
J	BONTEN, EJ; GALJART, NJ; WILLEMSEN, R; USMANY, M; VLAK, JM; DAZZO, A				BONTEN, EJ; GALJART, NJ; WILLEMSEN, R; USMANY, M; VLAK, JM; DAZZO, A			LYSOSOMAL PROTECTIVE PROTEIN CATHEPSIN-A - ROLE OF THE LINKER DOMAIN IN CATALYTIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPODOPTERA-FRUGIPERDA CELLS; BACULOVIRUS EXPRESSION VECTOR; BETA-GALACTOSIDASE; HUMAN-FIBROBLASTS; NEURAMINIDASE; GLYCOSYLATION; PURIFICATION; BIOSYNTHESIS; BARLEY; YEAST	Lysosomal protective protein/cathepsin A is a serine carboxypeptidase that forms a complex with beta-galactosidase and neuraminidase. The enzyme is synthesized as a 54-kDa precursor/zymogen and processed into a catalytically active 32- and 20-kDa two chain form, We have expressed in baculovirus-infected insect cells the human one chain precursor as well as the two separate subunits in order to establish the mode of catalytic activation of the zymogen and the assembly and activation of the two subunits. Infected insect cells synthesize large quantities of the exogenous proteins, which are glycosylated and secreted but not processed. Co-expression of the two subunits results in their assembly into a two-chain form of 34- and 20-kDa with negligible enzymatic activity. Limited proteolysis with trypsin of the 54-kDa precursor and the reconstituted 34- and 20-kDa form gives rise to a fully active 32- and 20-kDa product. These results enabled us to map the sites of proteolytic cleavage needed for full activation of the cathepsin A zymogen, They further indicate that the 34- and 20-kDa form is a transient processing intermediate that is converted into a mature and active enzyme by removal of a 2-kDa 'linker'' peptide from the COOH terminus of the 34-kDa subunit.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, 3000 DR ROTTERDAM, NETHERLANDS; AGR UNIV WAGENINGEN, DEPT VIROL, 6700 EM WAGENINGEN, NETHERLANDS	St Jude Children's Research Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Wageningen University & Research			Galjart, Niels/D-1146-2010	Galjart, Niels/0000-0003-1964-3607	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOSE JA, 1991, PROTEIN EXPRES PURIF, V2, P228; BOOSE JA, 1990, PROTEIN EXPRES PURIF, V741, P111; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; D'Azzo A, 1995, METABOLIC MOL BASES, V2, P2825; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DOAN NP, 1988, J BIOL CHEM, V263, P11106; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GRABOWSKI GA, 1989, ENZYME, V41, P131, DOI 10.1159/000469068; HANNA WL, 1994, J IMMUNOL, V153, P4663; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; INGLEY E, 1991, EUR J BIOCHEM, V196, P623, DOI 10.1111/j.1432-1033.1991.tb15858.x; ITOH K, 1990, BIOCHEM BIOPH RES CO, V167, P746, DOI 10.1016/0006-291X(90)92088-H; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; MARTIN BM, 1988, DNA-J MOLEC CELL BIO, V7, P99, DOI 10.1089/dna.1988.7.99; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Sambrook J, 1989, MOL CLONING LABORATO; SMITH GE, 1978, VIROLOGY, V89, P517, DOI 10.1016/0042-6822(78)90193-9; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SORENSEN SB, 1989, CARLSBERG RES COMMUN, V54, P193, DOI 10.1007/BF02904473; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDERWILK F, 1987, J GEN VIROL, V68, P2615, DOI 10.1099/0022-1317-68-10-2615; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VLAK JM, 1988, J GEN VIROL, V69, P765, DOI 10.1099/0022-1317-69-4-765; WILLEMSEN R, 1986, EUR J CELL BIOL, V40, P9; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	35	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26441	26445		10.1074/jbc.270.44.26441	http://dx.doi.org/10.1074/jbc.270.44.26441			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592859	hybrid			2022-12-25	WOS:A1995TC97800066
J	CAMANI, C; KRUITHOF, EKO				CAMANI, C; KRUITHOF, EKO			THE ROLE OF THE FINGER AND GROWTH-FACTOR DOMAINS IN THE CLEARANCE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROLONGED CLEARANCE; HEPATIC RECEPTOR; DELETION; BINDING	The relative contribution of the finger/growth factor domains of tissue-type plasminogen activator (t-PA) and of the other t-PA domains to the clearance of t-PA by hepatocytes was investigated. A recombinant finger/growth factor construct inhibited t-PA and t-PA/plasminogen activator inhibitor type-1 degradation with an IC50 of 1800 nM, whereas a t-PA mutant lacking the finger and growth factor domains inhibited degradation with an estimated IC50 of 1200 nM. In comparison the IC50 of t-PA was found to be approximately 10 nM. Clearance of t-PA by human or rat hepatoma cells was not inhibited by high concentrations of fucose (50 mM), which suggests that the fucose on Thr-61 is not involved in clearance by these cells. These results suggest that the binding of t-PA involves several low affinity binding sites located on distinct domains of the t-PA molecule.	UNIV HOSP GENEVA,DIV ANGIOL & HEMOSTASIS,CH-1211 GENEVA,SWITZERLAND; UNIV LAUSANNE HOSP,DIV HEMATOL,LAUSANNE,SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Kruithof, Egbert/AGR-4755-2022					BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BROWNE MJ, 1988, J BIOL CHEM, V263, P1599; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAMANI C, 1994, J BIOL CHEM, V269, P5770; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KRAUSE J, 1988, Fibrinolysis, V2, P133, DOI 10.1016/0268-9499(88)90026-4; LARSEN GR, 1989, BLOOD, V73, P1842, DOI 10.1182/blood.V73.7.1842.1842; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; NGUYEN G, 1992, BIOCHEM J, V287, P911, DOI 10.1042/bj2870911; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; ORTH K, 1994, J BIOL CHEM, V269, P21117; SMITH BO, 1994, BIOCHEMISTRY-US, V33, P2422, DOI 10.1021/bi00175a010; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	16	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26053	26056		10.1074/jbc.270.44.26053	http://dx.doi.org/10.1074/jbc.270.44.26053			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592802	hybrid			2022-12-25	WOS:A1995TC97800009
J	CANDI, E; MELINO, G; MEI, G; TARCSA, E; CHUNG, SI; MAREKOV, LN; STEINERT, PM				CANDI, E; MELINO, G; MEI, G; TARCSA, E; CHUNG, SI; MAREKOV, LN; STEINERT, PM			BIOCHEMICAL, STRUCTURAL, AND TRANSGLUTAMINASE SUBSTRATE PROPERTIES OF HUMAN LORICRIN, THE MAJOR EPIDERMAL CORNIFIED CELL-ENVELOPE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; EXPRESSION; DIFFERENTIATION; INVOLUCRIN; KERATIN	Loricrin is the major protein of the cornified cell envelope of terminally differentiated epidermal keratinocytes which functions as a physical barrier, In order to understand its properties and role in cornified cell envelope, we have expressed human loricrin from a full-length cDNA clone in bacteria and purified it to homogeneity. We have also isolated loricrin from newborn mouse epidermis. By circular dichroism and fluorescence spectroscopy, the in vivo mouse and bacterially expressed human loricrins possess no alpha or beta structure but have some organized structure in solution associated with their multiple tyrosines and can be reversibly denatured by either guanidine hydrochloride or temperature. The transglutaminase (TGase) 1, 2, and 3 enzymes expressed during epidermal differentiation utilized loricrin in vitro as a complete substrate, but the types of cross-linking were different. The TGase 3 reaction favored certain lysines and glutamines by forming mostly intrachain cross-links, whereas TGase 1 formed mostly large oligomeric complexes by interchain crosslinks involving different lysines and glutamines. Together, the glutamines and lysines used in vitro are almost identical to those seen in vivo. The data support a hypothesis for the essential and complementary roles of both TGase 1 and TGase 3 in cross-linking of loricrin in vivo. Failure to cross-link loricrin by TGase 1 may explain the phenotype of lamellar ichthyosis, a disease caused by mutations in the TGase 1 gene.	NIAMS,SKIN BIOL BRANCH,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; UNIV ROMA TOR VERGATA,IST DERMOPAT IMMACOLATA,DEPT EXPTL MED,BIOCHEM LABS,I-00167 ROME,ITALY; UNIV LAQUILA,DEPT BIOL,I-67100 LAQUILA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of L'Aquila								CHUNG SI, 1970, J BIOL CHEM, V245, P681; DALE BA, 1983, J CELL BIOL, V101, P1257; DESMIT MH, 1994, J MOL BIOL, V244, P144, DOI 10.1006/jmbi.1994.1714; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FRIC L, 1971, COLLECT CZECH CHEM C, V36, P2012; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; HIBINO Y, 1988, AGR BIOL CHEM TOKYO, V52, P329; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOHL D, 1993, ARCH DERMATOL, V129, P626; HUBER M, 1995, SCIENCE, V276, P525; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; LAVRIJSEN S, 1995, ARCH DERMATOL, V131, P363; MACK JW, 1988, BIOCHEMISTRY-US, V27, P5418, DOI 10.1021/bi00415a006; MATOLTSY A. GEDEON, 1965, P291; MATOLTSY AG, 1970, J CELL BIOL, V47, P593, DOI 10.1083/jcb.47.3.593; MEHREL T, 1990, CELL, V60, P1103; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MILHAUD PG, 1980, BIOCHIM BIOPHYS ACTA, V630, P476, DOI 10.1016/0304-4165(80)90002-1; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; PARRY DAD, 1995, INTERMEDIATE FILAMEN; Reichert Uwe, 1993, P107; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SHVETS YP, 1990, MOL BIOL, V24, P663; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; STEINERT PM, 1994, J INVEST DERMATOL S, V103, pA19; STEVEN AC, 1994, J CELL SCI, V107, P693; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; WALSH F, 1963, NATURE, V198, P188; WILLIAMS ML, 1985, ARCH DERMATOL, V121, P477, DOI 10.1001/archderm.121.4.477; YONEDA K, 1992, J BIOL CHEM, V267, P18060	42	143	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26382	26390		10.1074/jbc.270.44.26382	http://dx.doi.org/10.1074/jbc.270.44.26382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592852	hybrid			2022-12-25	WOS:A1995TC97800059
J	MCGEE, MP; TEUSCHLER, H; PARTHASARATHY, N; WAGNER, WD				MCGEE, MP; TEUSCHLER, H; PARTHASARATHY, N; WAGNER, WD			SPECIFIC REGULATION OF PROCOAGULANT ACTIVITY ON MONOCYTES - INTRINSIC PATHWAY INHIBITION BY CHONDROITIN 4,6-DISULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; FACTOR-X ACTIVATION; TISSUE FACTOR; SULFATE PROTEOGLYCAN; BLOOD-COAGULATION; MACROPHAGES; GLYCOSAMINOGLYCAN; DIFFERENTIATION; BIOSYNTHESIS; CANCER	Hypercoagulability of blood, monocytic infiltration, and changes in pericellular and extracellular matrix glycosaminoglycans (GAGs)(1) are observed in atherosclerosis, inflammation, and neoplasia, In the present studies, monocyte procoagulants and different GAGs including chondroitin sulfate (CS) A, CSB, CSC, CSD, CSE, and heparan sulfate, were tested either in clotting assays with whole plasma or in chromogenic assays with purified coagulation proteases, Procoagulant activity in plasma was inhibited by three of the seven GAGs, including heparan sulfate, CSE, and CSB, In contrast, activity of purified coagulation protease was inhibited only by CSE, and the inhibition was observed with intrinsic (factor VIIIa/IXa) but not extrinsic (tissue factor/factor VII) components, Reciprocal titration experiments with enzyme and substrate and Scatchard type analyses were consistent with concentration dependent inhibitory interactions between CSE and sites on both factor VIIIa and IXa. On purified phospholipids, CSE concentration resulting in half-maximal inhibition (K-i) was 5 ng/ml for interaction with factor IXa and > 500 ng/ml for interaction with factor VIIIa, The K-i values were lower for reactions on purified lipid than for reactions on monocyte surfaces and for reactions on resting than on endotoxin-stimulated monocytes, Experiments with CSE oligosaccharides of defined size indicated that the smallest CSE fragment capable of inhibitory activity was composed of 12-18 monosaccharide units, Collectively, these results indicate that factor X-activating reactions are inhibited by GAGs expressed on monocyte membranes, Inhibition is specific with respect to the structure of both the GAG and the activating protease, Lack of inhibition by added CSA, CSB, and CSC in contrast to CSE strongly suggests a direct role of 4,6-di-O-sulfated N-acetylgalactosamine GAG structures in the inhibition of intrinsic pathway protease, These findings also suggest potential pharmacologic use of CSE as specific anticoagulant in the management of prothrombotic states mediated by intrinsic pathway coagulation reactions.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	MCGEE, MP (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, RHEUMATOL SECT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042812, R01HL025161] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42812, HL-25161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P20012; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BARROW RT, 1994, J BIOL CHEM, V269, P26789; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BRIGG R, 1961, THROMB DIATH HAEMO, V6, P1; DIETRICH CP, 1993, LAB INVEST, V68, P439; DOUGLAS KT, 1984, CHEM ENZYME ACTION, P114; EDWARDS IJ, 1995, ATHERIOSCLEROSIS; GALLAGHER JT, 1992, ADV EXP MED BIOL, V313, P49; GALLAGHER JT, 1985, BIOCHEM J, V230, P663; KAWAI Y, 1966, J BIOCHEM-TOKYO, V60, P317, DOI 10.1093/oxfordjournals.jbchem.a128438; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALAR RA, 1982, BLOOD, V60, P1353; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MCGEE MP, 1994, J EXP MED, V179, P1847, DOI 10.1084/jem.179.6.1847; MCGEE MP, 1992, J BIOL CHEM, V267, P24333; MCGEE MP, 1978, J RETICULOENDOTH SOC, V24, P253; MCGEE MP, 1990, J EXP MED, V176, P27; MCQUILLAN DJ, 1989, J BIOL CHEM, V264, P13245; OWENS RT, 1992, J LEUKOCYTE BIOL, V51, P626, DOI 10.1002/jlb.51.6.626; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; RICKLES FR, 1988, SEMIN THROMB HEMOST, V14, P88, DOI 10.1055/s-2007-1002760; ROSS R, 1993, ATHEROSCLER REV, V25, P195; ROTHBERGER H, 1984, J CLIN INVEST, V73, P1524, DOI 10.1172/JCI111358; SCULLY MF, 1986, BIOCHEM BIOPH RES CO, V137, P15, DOI 10.1016/0006-291X(86)91169-1; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SMITH RL, 1973, J BIOL CHEM, V248, P2418; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1993, BLOOD, V82, P2880; WAGNER WD, 1978, LAB INVEST, V39, P322; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZIMMERMAN TS, 1988, SEMIN HEMATOL, V25, P25	39	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26109	26115		10.1074/jbc.270.44.26109	http://dx.doi.org/10.1074/jbc.270.44.26109			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592813	hybrid			2022-12-25	WOS:A1995TC97800020
J	KAKUMA, T; NISHIDA, J; TSUZUKI, T; SEKIGUCHI, M				KAKUMA, T; NISHIDA, J; TSUZUKI, T; SEKIGUCHI, M			MOUSE MTH1 PROTEIN WITH 8-OXO-7,8-DIHYDRO-2'-DEOXYGUANOSINE 5'-TRIPHOSPHATASE ACTIVITY THAT PREVENTS TRANSVERSION MUTATION - CDNA CLONING AND TISSUE DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-SYNTHESIS; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; MUTAGENIC SUBSTRATE; NUCLEOTIDE-SEQUENCE; HUMAN-CELLS; MUTT; REPAIR; ENZYME; HYDROLYZES	8-Oxo-7,8-dihydro-2'-deoxyguanosine 5'-triphosphate (8-oxo-dGTP) is formed in the nucleotide pool of a cell during normal cellular metabolism, and when it is incorporated into DNA causes mutation. Organisms possess 8-oxo-dGTPase, an enzyme that specifically degrades 8-oxo-dGTP to 8-oxo-dGMP. We isolated cDNA for mouse 8-oxo-dGTPase, using as a probe human MTH1 (Escherichia coli mutT homolog) cDNA. The nucleotide sequence of the cDNA revealed that the mouse MTH1 protein (molecular weight of 17,896) comprises 156 amino acid residues. When the cDNA for mouse 8-oxo-dGTPase was expressed in E. coli mutT(-) mutant cells devoid of their own 8-oxo-dGTPase activity, an 18-kDa protein, which is cross-reactive with an anti-human MTH1 antibody, was formed. In such cells, the level of spontaneous mutation frequency that was elevated reverted to normal. High levels of 8-oxo-dGTPase activity were found in liver, thymus, and large intestine, whereas all other organs examined contained smaller amounts of the enzyme. In embryonic stem cells, an exceedingly high level of the enzyme was present.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT BIOCHEM,FUKUOKA 81282,JAPAN	Kyushu University								AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P; BESSHO T, 1992, BIOCHEM BIOPH RES CO, V188, P372, DOI 10.1016/0006-291X(92)92395-E; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FINANCSEK I, 1982, GENE, V18, P115; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; LUEDERS KK, 1980, P NATL ACAD SCI-BIOL, V77, P3571, DOI 10.1073/pnas.77.6.3571; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; STURDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAJIRI T, 1994, MUTAT RES, V336, P245; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; VIDMAR JJ, 1993, CAN J MICROBIOL, V39, P892, DOI 10.1139/m93-133; WEBER DJ, 1993, BIOCHEMISTRY-US, V32, P13081, DOI 10.1021/bi00211a018; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YEH YC, 1991, J BIOL CHEM, V266, P6480	39	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25942	25948		10.1074/jbc.270.43.25942	http://dx.doi.org/10.1074/jbc.270.43.25942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592783	hybrid			2022-12-25	WOS:A1995TB46600100
J	BERGAD, PL; SHIH, HM; TOWLE, HC; SCHWARZENBERG, SJ; BERRY, SA				BERGAD, PL; SHIH, HM; TOWLE, HC; SCHWARZENBERG, SJ; BERRY, SA			GROWTH-HORMONE INDUCTION OF HEPATIC SERINE-PROTEASE INHIBITOR-2.1 TRANSCRIPTION IS MEDIATED BY A STAT5-RELATED FACTOR-BINDING SYNERGISTICALLY TO 2 GAMMA-ACTIVATED SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; GENE	A growth hormone (GH)-inducible nuclear factor (GHINF) from rat liver has been purified to near homogeneity. On SDS-polyacrylamide gel electrophoresis and UV-cross-linking, a major band of mass similar to 93 kDa and a minor band of similar to 70 kDa are detected in the purified fraction. DNase I footprinting using purified GHINF yields a protected region of -149/-115 on the rat serine protease inhibitor 2.1 (Spi 2.1) promoter encompassed within the growth hormone response element (GHRE). Mutational analysis demonstrated that GHINF binds synergistically to two gamma-interferon activated sites (GAS) within the GHRE, with the 3' element being the pivotal binding domain. Functional assays show that both GAS elements are necessary for full GH response. GHINF has no immunoreactivity with either a C-terminal Stat1 antibody or an N-terminal Stat3 antibody, while cross-reacting with a C-terminal Stat5 monoclonal antibody. GHINF will bind to two GAS elements from the Stat5 binding region of the beta-casein gene. These studies indicate that GHINF is a Stat5-related factor binding synergistically to two GAS elements to activate Spi 2.1 transcription.	UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Shih, Hsiu-Ming/S-7023-2018	Berry, Susan/0000-0001-7970-688X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AUSUBEL FM, 1994, CURRENT PROTOLS MOL; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BERRY SA, 1984, ENDOCRINOLOGY, V115, P1164, DOI 10.1210/endo-115-3-1164; BERRY SA, 1986, ENDOCRINOLOGY, V119, P2290, DOI 10.1210/endo-119-5-2290; BERRY SA, 1994, MOL ENDOCRINOL, V8, P1714, DOI 10.1210/me.8.12.1714; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; GADDYKURTEN D, 1991, MOL ENDOCRINOL, V5, P1280, DOI 10.1210/mend-5-9-1280; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KLEINBERG DL, 1990, ENDOCRINOLOGY, V126, P3274, DOI 10.1210/endo-126-6-3274; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NIIMI S, 1991, ENDOCRINOLOGY, V129, P2734, DOI 10.1210/endo-129-5-2734; PAGES G, 1990, GENE, V94, P273, DOI 10.1016/0378-1119(90)90398-B; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RAZ R, 1994, J BIOL CHEM, V269, P24391; SCHWARZENBERG SJ, 1992, AM J PHYSIOL, V265, pC1144; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SLIVA D, 1994, J BIOL CHEM, V269, P26208; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WARREN WC, 1993, MOL CELL ENDOCRINOL, V98, P27, DOI 10.1016/0303-7207(93)90232-9; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YOON JB, 1990, J BIOL CHEM, V265, P19947	36	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24903	24910		10.1074/jbc.270.42.24903	http://dx.doi.org/10.1074/jbc.270.42.24903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559615	hybrid			2022-12-25	WOS:A1995TB46500049
J	DAVIES, AA; FRIEDBERG, EC; TOMKINSON, AE; WOOD, RD; WEST, SC				DAVIES, AA; FRIEDBERG, EC; TOMKINSON, AE; WOOD, RD; WEST, SC			ROLE OF THE RAD1 AND RAD10 PROTEINS IN NUCLEOTIDE EXCISION-REPAIR AND RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							YEAST DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; GENETIC-CONTROL; RESOLUTION	In Saccharomyces cerevisiae, the RAD1 and RADIO genes are involved in DNA nucleotide excision repair (NER) and in a pathway of mitotic recombination that occurs between direct repeat DNA sequences. In this paper, we show that purified Rad1 and Rad10 interact with a synthetic bubble structure and incise the DNA at the 5'-side of the centrally unpaired region. When Rad1-Rad10 and purified XPG protein (the human homolog of yeast Rad2 protein) were co-incubated with the DNA substrate, we observed incisions at both ends of the bubble. This reaction mimics the dual incision step in nucleotide excision repair in vivo. In addition, the recent suggestion that Rad1 can act to resolve Holliday junctions (Habraken, Y., Sung, P., Prakash, L., and Prakash, S. (1994) Nature 371, 531-534), explaining the recombination defect observed in rad1 mutants, has been further investigated. However, using proteins purified in two different laboratories we were unable to show any interaction between Rad1 and synthetic Holliday junctions. The role that Rad1-Rad10 plays in recombination is likely to resemble its activity in NER by acting upon partially unpaired DNA intermediates such as those formed by recombination mechanisms involving single-strand DNA annealing.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio			Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892; West, Stephen/0000-0001-8848-9418				BAILIS AM, 1992, MOL CELL BIOL, V12, P4988, DOI 10.1128/MCB.12.11.4988; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; FRIEDBERG EC, 1995, DNA REPAIR; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KLEIN HL, 1988, GENETICS, V120, P367; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SAFFRAN WA, 1994, NUCLEIC ACIDS RES, V22, P2823, DOI 10.1093/nar/22.14.2823; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WEST SC, 1995, NATURE, V373, P27, DOI 10.1038/373027a0; ZEHFUS BR, 1990, GENETICS, V126, P41	30	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24638	24641		10.1074/jbc.270.42.24638	http://dx.doi.org/10.1074/jbc.270.42.24638			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559571	hybrid			2022-12-25	WOS:A1995TB46500005
J	FORNARO, M; ZHENG, DQ; LANGUINO, LR				FORNARO, M; ZHENG, DQ; LANGUINO, LR			THE NOVEL STRUCTURAL MOTIF GLN(795)-GLN(802) IN THE INTEGRIN BETA(1C) CYTOPLASMIC DOMAIN REGULATES CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADHESION; SUBUNIT; BETA-1; IDENTIFICATION; EXPRESSION; ANTIBODIES; RECEPTOR; FORM	Alternative splicing of the integrin beta(1) subunit mRNA generates a variant form, beta(1C), with a unique cytoplasmic domain that differs from beta(1) for a 48-amino acid COOH-terminal sequence. The potential role of this unique sequence in modulating cellular functions was investigated using Chinese hamster ovary (CHO)(1) cells transiently transfected with cDNAs coding for human integrin beta(1C) or beta(1) subunits or mutants containing truncated forms of the beta(1C) cytoplasmic domain. A differential effect of beta(1C) and beta(1) on cell proliferation was ob served. Expression of wild type beta(1) was associated with a 6-10-fold increase in cell proliferation in response to serum, as measured by [H-3]thymidine incorporation. In contrast, only a a fold increase in cell proliferation was observed in transfectants expressing comparable levels of beta(1C). Cells expressing the beta(1C) mutant truncated at Leu794 and lacking the last 31 amino acids of the cytoplasmic domain showed a 12-fold proliferation increase in response to serum. However, three beta(1C) deletion mutants, lacking the COOH-terminal 23, 13, and 8 amino acids, which all contained residues Gln(795)-Gln(802) of the variant cytoplasmic domain responded to serum stimulation with a 2-fold increase in [H-3]thymidine uptake. The effect of beta(1C) expression on cell proliferation was not associated with changes in exposure of integrin functional epitopes, as judged by the finding that CHO transfectants expressing beta(1C) full-length or deletion mutants, or beta(1) equally adhered to a functionally inhibitory monoclonal antibody against human beta(1) integrin. Expression of beta(1C) inversely correlated with the mitogenic potential of vascular cells. Absent on growing cultured endothe lial cells, surface expression of beta(1C) was induced in growth arrested, tumor necrosis factor-stimulated endothelial cells. These findings suggest that integrin alternative splicing may provide an accessory mechanism to modulate cell type-specific growth regulatory pathways during vascular cell injury in vivo.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA	Yale University				Languino, Lucia/0000-0001-9011-7031				AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMLER ME, 1995, INTEGRINS BIOL PROBL; HOLMES E, 1993, ANAL BIOCHEM, V214, P100, DOI 10.1006/abio.1993.1462; HOWLETT AR, 1995, J CELL SCI, V108, P1945; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MEREDITH J, 1995, IN PRESS SCIENCE; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; STOLPEN AH, 1986, AM J PATHOL, V123, P16; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	35	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24666	24669		10.1074/jbc.270.42.24666	http://dx.doi.org/10.1074/jbc.270.42.24666			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559578	hybrid			2022-12-25	WOS:A1995TB46500012
J	SONG, LX; FRICKER, LD				SONG, LX; FRICKER, LD			PURIFICATION AND CHARACTERIZATION OF CARBOXYPEPTIDASE-D, A NOVEL CARBOXYPEPTIDASE E-LIKE ENZYME, FROM BOVINE PITUITARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-SYNTHESIZING CARBOXYPEPTIDASE; MEMBRANE-BOUND CARBOXYPEPTIDASE; NEUROPEPTIDE-PROCESSING ENZYME; STRUCTURAL CHARACTERIZATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; HUMAN-PLASMA; CDNA; FURIN; PC2	Carboxypeptidase E (CPE) is involved in the biosynthesis of most neuropeptides and peptide hormones. Until recently, CPE was the only intracellular carboxypeptidase thought to be involved in neuroendocrine peptide processing. However, the finding that fat/fat mice, which have a mutation within the CPE gene that inactivates the enzyme, are capable of a reduced amount of insulin processing suggests that another carboxypeptidase is present within the secretory pathway. We have detected a CPE-like enzyme, designated CPD, which has many properties in common with those of CPE. Like CPE, CPD is a metallocarboxypeptidase that has a pH optimum of 5.5-6. The K-m and K-ent values for a series of short peptide substrates show only minor differences between CPD and CPE. Several active site-directed inhibitors also show generally similar potency toward the two enzymes, although guanidinoethylmercaptosuccinic acid is approximately 10-fold more potent, and hippuryl-Arg is approximately 100-fold more potent as an inhibitor of CPD than of CPE. A major difference between the two enzymes is the molecular masses; CPE is 50,000-56,000, whereas CPD is approximately 180,000. Also, CPD does not elute from a substrate affinity column when the pH is raised to 8, which elutes CPE, although CPD can subsequently be eluted by arginine. Both CPE and CPD are present in purified bovine anterior pituitary secretory vesicles, but the tissue distribution of CPD is more uniform than that of CPE. Antisera to the N- and C-terminal regions of CPE do not recognize CPD. The partial N-terminal amino acid sequence of bovine CPD shows 30-40% homology with an N-terminal region of bovine and rat CPE and 70% homology with a duck protein known as gp180, a hepatitis B virus particle binding protein that shows 47% homology to CPE. Taken together, these results suggest that CPD is a novel secretory pathway enzyme that may be the bovine homologue of gp180.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIDA NIH HHS [R01 DA-04494] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1995, METH NEUROSCI; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEVI L, 1991, J NEUROCHEM, V56, P320, DOI 10.1111/j.1471-4159.1991.tb02598.x; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EATON DL, 1991, J BIOL CHEM, V266, P21833; EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9; FOLK JE, 1960, J BIOL CHEM, V235, P2272; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; FRICKER LD, 1994, NEUROPROTOCOLS, V5, P151; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; GREENE D, 1992, BIOCHEM J, V285, P613, DOI 10.1042/bj2850613; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; JUNG YK, 1991, MOL ENDOCRINOL, V5, P1257, DOI 10.1210/mend-5-9-1257; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NARAHASHI Y, 1979, J BIOCHEM-TOKYO, V86, P683, DOI 10.1093/oxfordjournals.jbchem.a132572; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PLUMMER TH, 1981, METHOD ENZYMOL, V80, P442; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROTH WW, 1991, MOL CELL ENDOCRINOL, V78, P171, DOI 10.1016/0303-7207(91)90120-H; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHAFER MKH, 1994, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAN FL, 1989, J BIOL CHEM, V264, P13165; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; WEBB E C, 1986, European Journal of Biochemistry, V157, P1; ZHENG M, 1994, J NEUROSCI, V14, P4656	53	130	131	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25007	25013		10.1074/jbc.270.42.25007	http://dx.doi.org/10.1074/jbc.270.42.25007			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559630	hybrid			2022-12-25	WOS:A1995TB46500064
J	XU, J; YU, WF; JAN, YN; JAN, LY; LI, M				XU, J; YU, WF; JAN, YN; JAN, LY; LI, M			ASSEMBLY OF VOLTAGE-GATED POTASSIUM CHANNELS - CONSERVED HYDROPHILIC MOTIFS DETERMINE SUBFAMILY-SPECIFIC INTERACTIONS BETWEEN THE ALPHA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; RAT-BRAIN; XENOPUS-OOCYTES; A-CURRENT; EXPRESSION; CLONING; SHAKER; PROTEIN; INACTIVATION; CELLS	Voltage-gated potassium (K+) channels are assembled by four identical or homologous alpha-subunits to form a tetrameric complex with a central conduction pore for potassium ions. Most of the cloned genes for the alpha-subunits are classified into four subfamilies: Kv1 (Shaker), Kv2 (Shah), Kv3 (Shaw), and Kv4 (Shal). Subfamily-specific assembly of heteromeric K+ channel complexes has been observed in vitro and in vivo, which contributes to the diversity of K+ currents. However, the molecular codes that mediate the subfamily-specific association remain unknown. To understand the molecular basis of the subfamily-specific assembly, we tested the protein-protein interactions of different regions of alpha-subunits. We report here that the cytoplasmic NH2-terminal domains of Kv1, Kv2, Rv3, and Kv4 subfamilies each associate to form homomultimers. Using the yeast two-hybrid system and eight K+ channel genes, two genes (one isolated from rat and one from Drosophila) from each subfamily, we demonstrated that the associations to form heteromultimers by the NH2-terminal domains are strictly subfamily-specific. These subfamily-specific associations suggest a molecular basis for the selective formation of heteromultimeric channels in vivo.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Jan, Lily/0000-0003-3938-8498				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BUTLER A, 1990, NUCLEIC ACIDS RES, V18, P2173, DOI 10.1093/nar/18.8.2173; BYRNE JH, 1980, J NEUROPHYSIOL, V43, P651, DOI 10.1152/jn.1980.43.3.651; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DREWE JA, 1992, J NEUROSCI, V12, P538; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HILLE B, 1991, IONIC CHANNELS EXCIT, P58; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; LUNEAU C, 1991, FEBS LETT, V288, P163, DOI 10.1016/0014-5793(91)81026-5; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHAO B, 1994, NEURON, V13, P1205, DOI 10.1016/0896-6273(94)90058-2	52	162	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24761	24768		10.1074/jbc.270.42.24761	http://dx.doi.org/10.1074/jbc.270.42.24761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559593	hybrid			2022-12-25	WOS:A1995TB46500027
J	BARBATO, R; FRISO, G; PONTICOS, M; BARBER, J				BARBATO, R; FRISO, G; PONTICOS, M; BARBER, J			CHARACTERIZATION OF THE LIGHT-INDUCED CROSS-LINKING OF THE ALPHA-SUBUNIT OF CYTOCHROME B(559) AND THE D1 PROTEIN IN ISOLATED PHOTOSYSTEM-II REACTION CENTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; PISUM-SATIVUM; TRANSMEMBRANE ORIENTATION; RHODOPSEUDOMONAS-VIRIDIS; PHOTOINDUCED DEGRADATION; D1-PROTEIN DEGRADATION; 3A RESOLUTION; CHLOROPLAST; POLYPEPTIDE; MEMBRANE	Illumination of the isolated reaction center of photosystem II generates a protein of 41 kDa molecular mass, Using immunoblotting, it is confirmed that the protein is an adduct of the D1 protein and the a-subunit of cytochrome b(559). Its formation seems to be photochemically induced, being independent of temperature between 4 and 20 degrees C and unaffected by a mixture of protease inhibitors. The maximum levels are detected when the pH is in the region 6.5-8.5 and when illumination intensities are moderate. Although higher light intensities induce a higher rate of formation, the accumulation of elevated levels of the 41-kDa protein does not occur due to light-induced degradation. This degradation is also unaffected by the presence of protease inhibitors, Proteolytic mapping and N-terminal sequencing indicates that the cross-linking process involves the N-terminal serine of the alpha-subunit of cytochrome b(599) and D1 residues in the 239-244 FGQEEE motif close to the Q(B) binding site. In conclusion, the results indicate that the N terminus of the cu-subunit is exposed on the stromal side of photosystem II in such a way as to undergo light-induced cross-linking in the Q(B) region of the D1 protein. They also suggest that the 41-kDa adduct may be an intermediate before the light-induced cleavage of the D1 protein in the FGQEEE region.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,WOLFSON LABS,DEPT BIOCHEM,PHOTOSYNTH RES GRP,LONDON SW7 2AY,ENGLAND	Imperial College London				Ponticos, Markella/0000-0001-5957-5851				ANDERSSON B, 1992, MOL MECHANISMS BIOEN, P121; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; BARBATO R, 1991, FEBS LETT, V290, P162, DOI 10.1016/0014-5793(91)81250-C; BARBATO R, 1992, FEBS LETT, V309, P165, DOI 10.1016/0014-5793(92)81087-3; BARBATO R, 1991, BIOCHEMISTRY-US, V30, P10220, DOI 10.1021/bi00106a021; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BARBER J, 1993, P NATL ACAD SCI USA, V90, P10942, DOI 10.1073/pnas.90.23.10942; BARBER J, 1987, TRENDS BIOCHEM SCI, V12, P321, DOI 10.1016/0968-0004(87)90151-4; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; CHAPMAN DJ, 1989, PHOTOSYNTHETICA, V23, P411; CHAPMAN DJ, 1991, METHODS PLANT BIOCH, V5, P171; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; FRISO G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P265, DOI 10.1016/0005-2728(93)90110-2; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; HE WZ, 1991, BIOCHEMISTRY-US, V30, P4552, DOI 10.1021/bi00232a027; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MARDER JB, 1988, BIOCHIM BIOPHYS ACTA, V932, P362, DOI 10.1016/0005-2728(88)90172-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; RIVAS JD, 1992, FEBS LETT, V301, P246; RUFFLE SV, 1992, PHOTOSYNTH RES, V34, P287, DOI 10.1007/BF00033446; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; SHIPTON CA, 1990, Z NATURFORSCH C, V45, P765; TAE GS, 1988, BIOCHEMISTRY-US, V27, P9075, DOI 10.1021/bi00426a002; TELFER A, 1994, J BIOL CHEM, V269, P13244; TELFER A, 1994, BIOCHEMISTRY-US, V33, P14469, DOI 10.1021/bi00252a013; TREBST A, 1987, Z NATURFORSCH C, V42, P742; VALLON O, 1989, BIOCHIM BIOPHYS ACTA, V975, P132, DOI 10.1016/S0005-2728(89)80211-7; WEBBER AN, 1989, PLANT MOL BIOL, V12, P141, DOI 10.1007/BF00020499; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8; [No title captured]	41	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24032	24037		10.1074/jbc.270.41.24032	http://dx.doi.org/10.1074/jbc.270.41.24032			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592601	hybrid			2022-12-25	WOS:A1995TA21700029
J	CHUANG, JY; LIN, CT; WU, CW; LIN, YS				CHUANG, JY; LIN, CT; WU, CW; LIN, YS			A MOVABLE AND REGULABLE INACTIVATION FUNCTION WITHIN THE CENTRAL REGION OF A TEMPERATURE-SENSITIVE P53 MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							WILD-TYPE P53; TRANSCRIPTION ACTIVATION; GENE AMPLIFICATION; TRANSFORMATION; PROTEIN; BINDING; SUPPRESSOR; RECEPTOR	p53 is the most frequently mutated gene in human cancer. Naturally occurring mutations of p53 are mainly located within a region containing residues 100-300 and are predominantly of missense type, resulting in loss of the protein's DNA binding activity. Here we show that this type of mutation also represses the p53 N-terminal activation domain. The repression activity is localized in the central region of mutant p53 containing residues 101-318. Interestingly, the central region of a temperature-sensitive mutant p53N247I possesses a movable and regulable inactivation function. It represses other activities present on the same polypeptide chain without strict regard to the configuration of that polypeptide only at the nonpermissive temperature (37 degrees C) and not at the permissive temperature (30 degrees C). Furthermore, this mutant p53 region exhibits no other activity, and its function is independent of endogenous p53 status.	ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST PATHOL,TAIPEI 10010,TAIWAN	Academia Sinica - Taiwan; National Taiwan University								ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN JY, 1993, ONCOGENE, V8, P2159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; Hay R. K. M, 1994, ATLAS HUMAN TUMOR CE; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	27	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23899	23902		10.1074/jbc.270.41.23899	http://dx.doi.org/10.1074/jbc.270.41.23899			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592577	hybrid			2022-12-25	WOS:A1995TA21700005
J	MATHIEU, M; CHATELAIN, E; ORNITZ, D; BRESNICK, J; MASON, I; KIEFER, P; DICKSON, C				MATHIEU, M; CHATELAIN, E; ORNITZ, D; BRESNICK, J; MASON, I; KIEFER, P; DICKSON, C			RECEPTOR-BINDING AND MITOGENIC PROPERTIES OF MOUSE FIBROBLAST-GROWTH-FACTOR-3 - MODULATION OF RESPONSE BY HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; FACTOR FAMILY; SIGNAL TRANSDUCTION; CELL-TRANSFORMATION; ENDOTHELIAL-CELLS; INT-2; SPECIFICITY; EXPRESSION; AFFINITY; GENE	fgf3 has been implicated in the embryonic and fetal development of the mouse and as an oncogene in murine breast cancer. We describe a procedure to purify the product of the mouse fgf3 gene and show it to be a potent mitogen for some epithelial cell lines. Using a receptor binding competition assay, Fgf3 was shown to bind with high affinity to the IIIb isoforms of Fgf receptor (FgfR) 1 and FgfR2 (ID50 = similar to 0.8 nM) and with a lower affinity to the me variant of FgfR2 (ID50 = similar to 9 nM). NO competition for the binding of I-125-Fgf1 was observed for FgfR1 (IIIc), FgfR3 (IIIb and IIIc), or FgfR4. Mitogenicity assays using BaF3 cells containing individual Fgf receptors showed a pattern of response in agreement with the receptor binding results. A comparison of two mammary epithelial cell lines showed a marked difference of potency and dependence upon heparin in their response to mouse Fgf3, suggesting a complex interaction between the ligand and its low and high affinity receptors.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050; Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P753; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; DELL KR, 1992, J BIOL CHEM, V267, P21225; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1991, FIBROBLAST GROWTH FA, P8; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; GOLDFARB M, 1991, ONCOGENE, V6, P65; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN M, 1991, METHOD ENZYMOL C, V198, P158; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MATHIEU M, 1995, J BIOL CHEM, V270, P6779, DOI 10.1074/jbc.270.12.6779; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PETERS G, 1991, SEMIN VIROL, V2, P319; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	50	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24197	24203		10.1074/jbc.270.41.24197	http://dx.doi.org/10.1074/jbc.270.41.24197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592624	hybrid			2022-12-25	WOS:A1995TA21700052
J	LOMAS, DA; STONE, SR; LLEWELLYNJONES, C; KEOGAN, MT; WANG, ZM; RUBIN, H; CARRELL, RW; STOCKLEY, RA				LOMAS, DA; STONE, SR; LLEWELLYNJONES, C; KEOGAN, MT; WANG, ZM; RUBIN, H; CARRELL, RW; STOCKLEY, RA			THE CONTROL OF NEUTROPHIL CHEMOTAXIS BY INHIBITORS OF CATHEPSIN-G AND CHYMOTRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; HUMAN ALPHA-1-PROTEINASE INHIBITOR; PEPTIDE CHLOROMETHYL KETONES; OBSTRUCTIVE LUNG-DISEASE; SUBSTRATE BINDING-SITE; POLYMORPHONUCLEAR LEUKOCYTES; PROTEOLYTIC INACTIVATION; PROTEASE INHIBITORS; NONINFECTED SPUTUM; ALPHA-1-ANTITRYPSIN	Neutrophil chemotaxis plays an important role in the inflammatory response and when excessive or persistent may augment tissue damage, The effects of inhibitors indicated the involvement of one or more serine proteinases in human neutrophil migration and shape change in response to a chemoattractant. Monospecific antibodies, chloromethylketone inhibitors, and reactive-site mutants of alpha(1)-antitrypsin and alpha(1)-antichymotrypsin were used to probe the specificity of the proteinases involved in chemotaxis, Antibodies specific for cathepsin G inhibited chemotaxis, Moreover, rapid inhibitors of cathepsin G and alpha-chymotrypsin suppressed neutrophil chemotaxis to the chemoattractants N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) and zymosan-activated serum in multiple blind well assays and to fMLP in migration assays under agarose, The concentrations of antichymotrypsin mutants that reduced chemotaxis by 50% would inactivate free cathepsin G with a half-life of 1.5-3 s, whereas the concentrations of chloromethylketones required to produce a similar inhibition of chemotaxis would inactivate cathepsin G with a half life of 345 s. These data suggest different modes of action for these two classes of inhibitors, Indeed the chloromethylketone inhibitors of cathepsin G (Z-Gly-Leu-Phe-CMK) and to a lesser extent of chymotrypsin (Cbz-Gly-Gly-Phe-CMK) mediated their effect by preventing a shape change in the purified neutrophils exposed to fMLP, Antichymotrypsin did not affect shape change in response to fMLP even at concentrations that were able to reduce neutrophil chemotaxis by 50%, These results support the involvement of cell surface proteinases in the control of cell migration and show that antichymotrypsin and chloromethylketones have differing modes of action, This opens the possibility for the rational design of anti-inflammatory agents targeted at neutrophil membrane enzymes.	UNIV CAMBRIDGE, CTR MRC, DEPT MED, CAMBRIDGE CB2 2QH, ENGLAND; GEN HOSP, LUNG IMMUNOBIOCHEM RES LAB, BIRMINGHAM B4 6NM, W MIDLANDS, ENGLAND; PAPWORTH HOSP, DEPT IMMUNOL, CAMBRIDGE CB3 8RE, ENGLAND; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA	University of Cambridge; Papworth Hospital; University of Pennsylvania	LOMAS, DA (corresponding author), UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND.			Keogan, Mary/0000-0002-2596-0660	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AVRON A, 1991, FEBS LETT, V280, P41, DOI 10.1016/0014-5793(91)80199-D; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BECKER EL, 1969, J EXP MED, V129, P569, DOI 10.1084/jem.129.3.569; BECKER EL, 1967, J EXP MED, V125, P1021, DOI 10.1084/jem.125.6.1021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETT D, 1987, LANCET, V2, P1043; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CHAPMAN HA, 1984, J CLIN INVEST, V74, P1693, DOI 10.1172/JCI111586; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DUQUE RE, 1983, J BIOL CHEM, V258, P8123; DWENGER A, 1986, J CLIN CHEM CLIN BIO, V24, P299; ERIKSSON S, 1978, ACTA MED SCAND, V203, P449; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GOETZL EJ, 1975, IMMUNOLOGY, V29, P163; HASLETT C, 1985, AM J PATHOL, V119, P101; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; HORNEBECK W, 1987, CELL BIOCHEM FUNCT, V5, P113, DOI 10.1002/cbf.290050206; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IP M, 1990, BRIT J RHEUMATOL, V29, P363; JEPSEN LV, 1982, SCAND J CLIN LAB INV, V42, P235; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KING CH, 1987, J CLIN INVEST, V79, P1091, DOI 10.1172/JCI112923; KITAGAWA S, 1980, J CLIN INVEST, V65, P74, DOI 10.1172/JCI109662; KITZ R, 1962, J BIOL CHEM, V237, P3245; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1993, J BIOL CHEM, V268, P516; MANTOVANI B, 1975, J IMMUNOL, V115, P15; MCGUIRE WW, 1982, J CLIN INVEST, V69, P543, DOI 10.1172/JCI110480; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NELSON RD, 1988, METHOD ENZYMOL, V162, P50; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHUSTER MG, 1992, J BIOL CHEM, V267, P5056; SEGAL DM, 1971, BIOCHEMISTRY-US, V10, P3728; SHAW E, 1970, PHYSIOL REV, V50, P244, DOI 10.1152/physrev.1970.50.2.244; SPEAR GT, 1984, J IMMUNOL METHODS, V73, P321, DOI 10.1016/0022-1759(84)90407-1; STOCKLEY RA, 1990, AM J RESP CELL MOL, V2, P163, DOI 10.1165/ajrcmb/2.2.163; STOCKLEY RA, 1979, AM REV RESPIR DIS, V120, P1081; STOCKLEY RA, 1980, AM REV RESPIR DIS, V122, P81; STOCKLEY RA, 1983, CLIN SCI, V64, P119, DOI 10.1042/cs0640119; TRAVIS J, 1985, J BIOL CHEM, V260, P4384; TRINCHIERI G, 1976, J IMMUNOL, V116, P885; VENGE P, 1979, J IMMUNOL, V122, P1180; WARD PA, 1967, J EXP MED, V125, P1001, DOI 10.1084/jem.125.6.1001; WARD PA, 1970, J IMMUNOL, V105, P1057; WATOREK W, 1993, BIOL CHEM H-S, V374, P385, DOI 10.1515/bchm3.1993.374.1-6.385; WEEKE B, 1973, SCAND J IMMUNOL, V2, P37, DOI 10.1111/j.1365-3083.1973.tb03777.x	51	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23437	23443		10.1074/jbc.270.40.23437	http://dx.doi.org/10.1074/jbc.270.40.23437			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559504	hybrid			2022-12-25	WOS:A1995RY90900033
J	UENO, T; SHIRASAKA, T; MITSUYA, H				UENO, T; SHIRASAKA, T; MITSUYA, H			ENZYMATIC CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE RESISTANT TO MULTIPLE 2,3-DIDEOXYNUCLEOSIDE 5-TRIPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; HIGH-LEVEL RESISTANCE; RIBONUCLEASE-H; HTLV-III; HIV-1; ZIDOVUDINE; SENSITIVITY; INHIBITOR; FIDELITY; INVITRO	A set of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the polymerase domain of reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1), which confers on the virus a reduced sensitivity to multiple therapeutic dideoxynucleosides (ddNs), has been identified, In this study, we defined the biochemical properties of RT with such mutations by using site-directed mutagenesis, overproduction of recombinant RTs, and steady-state kinetic analyses, A single mutation, Q151M, which developed first among the five mutations in patients receiving therapy, most profoundly reduced the sensitivity of RT to multiple ddN 5'-triphosphates (ddNTPs). Addition of other mutations to Q151M further reduced the sensitivity of RT to ddNTPs. RT with the five mutations proved to be resistant by 65-fold to 3'-azido-2',3'-dideoxythymidine 5'-triphosphate (AZTTP), 12-fold to ddCTP, 8.8-fold to ddATP, and 3.3-fold to 2',3'-dideoxyguanosine 5'-triphosphate (ddGTP), compared with wild-type RT (RT(wt)). Steady-state kinetic studies revealed comparable catalytic efficiency (k(cat)/K-m) of RTs carrying combined mutations as compared with that of RT(wt) (<3-fold), although a marked difference was noted in inhibition constants (K-i) (e.g. K-i of a mutant RT carrying the five mutations was 62-fold higher for AZTTP than that of RT(wt)). Thus, we conclude that the alteration of RT's substrate recognition, caused by these mutations, accounts for the observed multi-ddN resistance of HIV-1. The features of multi-ddNTP-resistant RTs should provide insights into the molecular mechanism of RT discriminating ddNTPs from natural substrates.	NCI,DIV CANC TREATMENT,MED BRANCH,EXPTL RETROVIROL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Ueno, Takamasa/F-5788-2013; Ueno, Takamasa/AAW-9491-2020	Ueno, Takamasa/0000-0003-4852-4236; Ueno, Takamasa/0000-0003-4852-4236				BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0; ERON JJ, 1993, ANTIMICROB AGENTS CH, V37, P1480, DOI 10.1128/AAC.37.7.1480; FIERS W, 1976, NATURE, V260, P500, DOI 10.1038/260500a0; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; IM GJ, 1993, BIOCHEM PHARMACOL, V46, P2307, DOI 10.1016/0006-2952(93)90622-4; IVERSEN AKN, 1995, IN PRESS J VIROL; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LACEY SF, 1994, ANTIMICROB AGENTS CH, V38, P1428, DOI 10.1128/AAC.38.6.1428; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1994, TXB AIDS MED, P721; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; NAJERA I, 1995, J VIROL, V69, P23; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1991, J BIOL CHEM, V266, P14128; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	47	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23605	23611		10.1074/jbc.270.40.23605	http://dx.doi.org/10.1074/jbc.270.40.23605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559526	hybrid			2022-12-25	WOS:A1995RY90900055
J	ALTOMARE, DA; GUO, K; CHENG, JQ; SONODA, G; WALSH, K; TESTA, JR				ALTOMARE, DA; GUO, K; CHENG, JQ; SONODA, G; WALSH, K; TESTA, JR			CLONING, CHROMOSOMAL LOCALIZATION AND EXPRESSION ANALYSIS OF THE MOUSE AKT2 ONCOGENE	ONCOGENE			English	Article						ONCOGENE; GENE MAPPING; DIFFERENTIATION; MUSCLE	FLUORESCENCE INSITU HYBRIDIZATION; MOLECULAR-CLONING; PROTEIN-KINASE; GENE; SUBFAMILY; HOMOLOGY; REGION	We isolated mouse cDNA clones containing the entire coding region of the putative oncogene Akt2, Sequence analysis revealed that, like its human homolog, Akt2 encodes a protein-serine/threonine kinase containing a pleckstrin homology domain at its amino terminus, Fluorescence in situ hybridization of the mouse cDNA to rodent metaphase spreads demonstrated that the Akt2 gene maps to mouse chromosome band 7B1 and rat chromosome 1q22. Expression levels of mouse Akt2 mRNA and Akt2 protein varied among tissues, with the highest levels in skeletal muscle, Akt2 expression was low in a multipotent fibroblast cell line, but it was upregulated when these cells were transformed with Myod and induced to differentiate into myocytes. These data demonstrate that Akt2 expression is activated during cellular differentiation and suggest that it functions in the signaling pathways of some adult tissues.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT CARDIOVASC RES,BOSTON,MA 02135	Fox Chase Cancer Center; St. Elizabeth's Medical Center; Tufts University					NCI NIH HHS [P30 CA006927, R01 CA077429, CA 09035, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER PJ, 1991, EUR J BIOCHEM, V210, P475; DATTA K, 1995, MOL CELL BIOL, V15, P2304; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FRANKE TF, 1994, ONCOGENE, V9, P141; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASLAM RJ, 1993, NATURE, V36, P309; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; Maltais L. J., 1994, Mouse Genome, V92, P62; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROPERS HH, 1991, CYTOGENET CELL GENET, V58, P751, DOI 10.1159/000133179; Sambrook J, 1989, MOL CLONING LABORATO; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	79	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1055	1060						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566964				2022-12-25	WOS:A1995RX18000007
J	BALER, R; KLEIN, DC				BALER, R; KLEIN, DC			CIRCADIAN EXPRESSION OF TRANSCRIPTION FACTOR FRA-2 IN THE RAT PINEAL-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSLATIONAL MODIFICATION; IMMEDIATE-EARLY GENE; C-FOS; FACTOR AP-1; CROSS-TALK; PROTEINS; JUN; ACTIVATION; IMMUNOREACTIVITY; INDUCTION	Physiological changes in Fos-like immunoreactivity in the rat pineal gland are shown here to be due primarily to changes in a 42/46-kDa Fos-related antigen (Era). Studies are presented that indicate this 42/46-kDa Fra is Fra-2, a poorly understood member of the Fos family of transcription factors. Both Fra-2 mRNA and protein are absent during the day and increase robustly at night on a circadian basis; organ culture studies indicate that regulation is mediated by an adrenergic --> cyclic AMP mechanism. AP-1 binding activity changes in parallel to changes in the level of Fra a protein.	NICHHD,DEV NEUROBIOL LAB,NEUROENDOCRINOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Klein, David/0000-0002-1792-5806				BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CARTER DA, 1992, MOL BRAIN RES, V16, P111, DOI 10.1016/0169-328X(92)90200-U; CARTER DA, 1990, BIOCHEM BIOPH RES CO, V166, P589, DOI 10.1016/0006-291X(90)90849-I; CARTER DA, 1995, NEUROSCIENCE, V62, P1267; CHATTON B, 1994, ONCOGENE, V9, P375; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; Curran T, 1988, ONCOGENE HDB, P307; EHRET M, 1991, J NEUROCHEM, V57, P1516, DOI 10.1111/j.1471-4159.1991.tb06346.x; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GRUDA MC, 1994, ONCOGENE, V9, P2537; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; KLEIN DC, 1985, CIBA F SYMP, V117, P38; KLEIN DC, 1992, P SOC BIOCH, V8, P61; KOISTINAHO J, 1990, HISTOCHEMISTRY, V95, P73, DOI 10.1007/BF00737230; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUI M, 1990, ONCOGENE, V5, P249; MURAKAMI M, 1989, P SOC EXP BIOL MED, V190, P190; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; PENNYPACKER KR, 1992, J BIOL CHEM, V267, P20148; QUINN JP, 1989, J VIROL, V63, P1737, DOI 10.1128/JVI.63.4.1737-1742.1989; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROSEBOOM PH, 1995, MOL PHARMACOL, V47, P439; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; SUGDEN AL, 1987, J BIOL CHEM, V262, P741; Sugden D., 1983, METHODS BIOGENIC AMI, P567; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TUULIVAARA A, 1991, HISTOCHEMISTRY, V96, P401, DOI 10.1007/BF00315997; VANECEK J, 1985, ENDOCRINOLOGY, V116, P2167, DOI 10.1210/endo-116-6-2167; VOISIN P, 1990, BRAIN RES, V517, P25, DOI 10.1016/0006-8993(90)91003-Y; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	47	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27319	27325		10.1074/jbc.270.45.27319	http://dx.doi.org/10.1074/jbc.270.45.27319			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592994	hybrid			2022-12-25	WOS:A1995TE58300094
J	BELLOSTA, S; NATHAN, BP; ORTH, M; DONG, LM; MAHLEY, RW; PITAS, RE				BELLOSTA, S; NATHAN, BP; ORTH, M; DONG, LM; MAHLEY, RW; PITAS, RE			STABLE EXPRESSION AND SECRETION OF APOLIPOPROTEINS E3 AND E4 IN MOUSE NEUROBLASTOMA-CELLS PRODUCES DIFFERENTIAL-EFFECTS ON NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SPORADIC ALZHEIMERS-DISEASE; RECEPTOR-RELATED PROTEIN; CENTRAL NERVOUS-SYSTEM; CULTURED-CELLS; CEREBROSPINAL-FLUID; TRANSGENIC MICE; E POLYMORPHISM; TYPE-4 ALLELE; E APOPROTEIN	Previously, we demonstrated in cultured dorsal root ganglion neurons that, in the presence of beta-migrating very low density lipoproteins (beta-VLDL), apolipoprotein (apo) E4, but not apoE3, suppresses neurite outgrowth, In the current studies, murine neuroblastoma cells (Neuro-2a) were stably transfected with human apoE3 or apoE4 eDNA, and the effect on neurite outgrowth was examined, The stably transfected cells secreted nano gram quantities of apoE (44-89 ng/mg of cell protein in 48 h), In the absence of lipoproteins, neurite outgrowth was similar in the apoE3- and apoE4-secreting cells, The apoE4-secreting cells, when incubated with beta-VLDL, VLDL, cerebrospinal fluid lipoproteins (d < 1.21 g/ml), or with triglyceride/phospholipid (2.7:1 (w/w)) emulsions, showed a reduction in the number of neurites/cell, a decrease in neurite branching, and an inhibition of neurite extension, whereas in the apoE3-secreting cells in the presence of a lipid source, neurite extension was increased, Uptake of beta-VLDL occurred to a similar extent in both the apoE3- and apoE4-secreting cells. With low density lipoproteins or with dimyristoylphosphatidylcholine emulsions, either alone or complexed with cholesterol, no differential effect on neurite outgrowth was observed, A slight differential effect was observed with apoE-containing high density lipoproteins. The differential effect of apoE3 and apoE4 in the presence of beta-VLDL was blocked by incubation of the cells with heparinase and chlorate, with lactoferrin, or with receptor-assocciated protein, all of which prevent the uptake of lipoproteins by the low density lipoprotein receptor-related protein (LRP). The data suggest that the secreted and/or cell surface-bound apoE interact with the lipoproteins and facilitate their internalization via the heparan sulfate proteoglycan-LRP pathway, The mechanism by which apoE3 and apoE4 exert differential effects on neurite outgrowth remains speculative, However, the data suggest that apoE4, which has been shown to be associated with late onset familial and sporadic Alzheimer's disease, may inhibit neuronal remodeling and contribute to the progression of the disease.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Orth, Matthias/AAF-7094-2019; Orth, Matthias/B-8519-2013; Bellosta, Stefano/B-4473-2010	Orth, Matthias/0000-0003-2881-8384; Orth, Matthias/0000-0003-2881-8384; Bellosta, Stefano/0000-0001-5344-7824	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013619] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG13619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOTTENSTEIN JE, 1980, EXP CELL RES, V129, P361, DOI 10.1016/0014-4827(80)90504-2; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DONG LM, 1994, J BIOL CHEM, V269, P22358; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Goedert M, 1991, Curr Opin Neurobiol, V1, P441, DOI 10.1016/0959-4388(91)90067-H; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; HUANG DY, 1994, NEUROSCI LETT, V182, P55, DOI 10.1016/0304-3940(94)90204-6; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1977, AM J PATHOL, V87, P205; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PEACOCK ML, 1994, NEUROLOGY, V44, P339, DOI 10.1212/WNL.44.2.339; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; REBECK GW, 1993, NEURON, V11, P575; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SPOONER PJR, 1988, J BIOL CHEM, V263, P1444; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; TSAI MS, 1994, AM J HUM GENET, V54, P643; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YU CE, 1994, AM J HUM GENET, V54, P631	57	275	280	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27063	27071		10.1074/jbc.270.45.27063	http://dx.doi.org/10.1074/jbc.270.45.27063			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592957	Green Published, hybrid			2022-12-25	WOS:A1995TE58300057
J	BRAUN, C; BRAYER, GD; WITHERS, SG				BRAUN, C; BRAYER, GD; WITHERS, SG			MECHANISM-BASED INHIBITION OF YEAST ALPHA-GLUCOSIDASE AND HUMAN PANCREATIC ALPHA-AMYLASE BY A NEW CLASS OF INHIBITORS - 2-DEOXY-2,2-DIFLUORO-ALPHA-GLYCOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-GLUCOSIDASES; IRREVERSIBLE INHIBITORS; GLYCOSIDASE INHIBITORS; CYCLOPHELLITOL	2-Deoxy-2,2-difluoroglycosides are a new class of mechanism-based inhibitors of alpha-glycosidases, which function via the accumulation of a stable difluoroglycosyl-enzyme intermediate. Two members of this new class of inhibitor have been synthesized and kinetic studies performed with their target glycosidases. Thus 2,4,6-trinitrophenyl 2-deoxy-2,2-difluoro-alpha-glucoside is shown to inactivate yeast a-glucosidase with a second order rate constant of k(i)/K-i = 0.25 min(-1) mM(-1). The equivalent difluoromaltoside inactivates human pancreatic cu-amylase with k(i)/K-i = 0.0073 min(-1) mM(-1). Competitive inhibitors protect the enzyme against inactivation in each case, showing reaction to occur at the active site. A burst of release of one equivalent of trinitrophenolate observed upon inactivation of human pancreatic a-amylase proves the required 1:1 stoichiometry. These are the first mechanism-based inhibitors of this class to be described, and the first mechanism-based inhibitors of any sort for the medically important alpha-amylase. In addition to having potential as therapeutics, compounds of this class should prove useful in subsequent structural and mechanistic studies of these enzymes.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHIM,VANCOUVER,BC V6T 1Z1,CANADA	University of British Columbia; University of British Columbia								ATSUMI S, 1990, J ANTIBIOT, V43, P1579, DOI 10.7164/antibiotics.43.1579; BRIGGS JC, 1992, J CHEM SOC CHEM COMM, P1039, DOI 10.1039/c39920001039; BURK D, 1993, J MOL BIOL, V230, P1084, DOI 10.1006/jmbi.1993.1221; CLAUSEN TP, 1990, TETRAHEDRON LETT, V31, P4537, DOI 10.1016/S0040-4039(00)97668-8; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KONSTANTINIDIS A, 1991, BIOCHEM J, V279, P587, DOI 10.1042/bj2790587; LEATHERBARROW RG, 1990, GRAFIT VERSION 2 0; LEGLER G, 1970, H-S Z PHYSIOL CHEM, V351, P25, DOI 10.1515/bchm2.1970.351.1.25; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LEGLER G, 1968, Z. Physiol. Chem., V349, P767; MARSHALL PJ, 1970, J CHEM SOC P1, P366; MCCARTER JD, 1993, CARBOHYD RES, V249, P77, DOI 10.1016/0008-6215(93)84061-A; MCCARTER JD, 1994, BIOCHEM J, V301, P343, DOI 10.1042/bj3010343; MOOSER G, 1991, J BIOL CHEM, V266, P8916; Mooser G., 1992, ENZYMES, P187; PRASAD SS, 1987, BIOCHEM BIOPH RES CO, V148, P206; Sinnott M. L., 1987, ENZYME MECHANISMS, P259; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SINNOTT ML, 1976, J CHEM SOC CHEM COMM, P223, DOI 10.1039/c39760000223; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; TRUSCHEIT E, 1981, ANGEW CHEM INT EDIT, V20, P744, DOI 10.1002/anie.198107441; WITHERS SG, 1991, BIOCHEM BIOPH RES CO, V177, P532, DOI 10.1016/0006-291X(91)92016-D; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WITHERS SG, 1995, PROTEIN SCI, V4, P361; WITHERS SG, 1995, IN PRESS PURE APPL C; WITHERS SG, 1987, J AM CHEM SOC, V109, P7630	29	114	119	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26778	26781		10.1074/jbc.270.45.26778	http://dx.doi.org/10.1074/jbc.270.45.26778			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592915	hybrid			2022-12-25	WOS:A1995TE58300015
J	LAIRD, AD; TAYLOR, SJ; OBERST, M; SHALLOWAY, D				LAIRD, AD; TAYLOR, SJ; OBERST, M; SHALLOWAY, D			RAF-1 IS ACTIVATED DURING MITOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; CELL-CYCLE; MAP KINASE; PHOSPHORYLATION; TRANSFORMATION; MATURATION; ARREST; ONCOPROTEIN; REQUIREMENT; RESIDUES	The Raf-1 serine/threonine kinase transmits proliferative and developmental signals to downstream effecters in the mitogen-activated protein kinase cascade, Studies to date have concentrated on its role in growth factor-mediated activation of the cell cycle. We show here that Raf-l kinase activity is also highly stimulated during mitosis, with an attendant distinctive electrophoretic mobility shift due to hyperphosphorylation. These results suggest that Raf-1 may play a role in traversal of at least two distinct phases of the cell cycle.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NCI NIH HHS [CA 32317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1995, ONCOGENE, V10, P2095; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SHALLOWAY D, 1991, ADV CANCER RES, V57, P185; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEWART N, 1995, ONCOGENE, V10, P109; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	35	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26742	26745		10.1074/jbc.270.45.26742	http://dx.doi.org/10.1074/jbc.270.45.26742			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592906	hybrid			2022-12-25	WOS:A1995TE58300006
J	LERNER, EC; QIAN, YM; BLASKOVICH, MA; FOSSUM, RD; VOGT, A; SUN, JZ; COX, AD; DER, CJ; HAMILTON, AD; SEBTI, SM				LERNER, EC; QIAN, YM; BLASKOVICH, MA; FOSSUM, RD; VOGT, A; SUN, JZ; COX, AD; DER, CJ; HAMILTON, AD; SEBTI, SM			RAS CAAX PEPTIDOMIMETIC FTI-277 SELECTIVELY BLOCKS ONCOGENIC RAS SIGNALING BY INDUCING CYTOPLASMIC ACCUMULATION OF INACTIVE RAS-RAF COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ASSOCIATION; PROTEIN; P21RAS; FARNESYLTRANSFERASE; TRANSFORMATION; INHIBITION; FARNESYL; TERMINUS	Ras-induced malignant transformation requires Ras farnesylation, a lipid posttranslational modification catalyzed by farnesyltransferase (FTase). Inhibitors of this enzyme have been shown to block Ras-dependent transformation, but the mechanism by which this occurs remains largely unknown. We have designed FTI-276, a peptide mimetic of the COOH-terminal Cys-Val-Ile-Met of K-Ras4B that inhibited potently FTase in vitro (IC50 = 500 pM) and was highly selective for FTase over geranylgeranyltransferase I (GGTase I) (IC50 = 50 nM). FTI-277, the methyl ester derivative of FTI-276, was extremely potent (IC50 = 100 nM) at inhibiting H-Ras, but not the geranylgeranylated Rap1A processing in whole cells. Treatment of H-Ras oncogene-transformed NIH 3T3 cells with FTI-277 blocked recruitment to the plasma membrane and subsequent activation of the serine/threonine kinase c-Raf-1 in cells transformed by farnesylated Ras (H-RasF), but not geranylgeranylated, Ras (H-RasGG), FTI-277 induced accumulation of cytoplasmic non-farnesylated H-Ras that was able to bind Raf and form cytoplasmic Ras/Raf complexes in which Raf kinase was not activated, Furthermore, FTI-277 blocked constitutive activation of mitogen-activated protein kinase (MAPK) in H-RasF, but not H-RasGG, or Raf-transformed cells, FTI-277 also inhibited oncogenic K-Ras4B processing and constitutive activation of MAPK, but the concentrations required were 100-fold higher than those needed for H-Ras inhibition. The results demonstrate that FTI-277 blocks Ras oncogenic signaling by accumulating inactive Ras/Raf complexes in the cytoplasm, hence preventing constitutive activation of the MAPK cascade.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,FAC ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT RADIAT ONCOL,CHAPEL HILL,NC 27599	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [U19-CA6777, CA-61951, CA-55823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA061951, R01CA055823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbacid M, 1986, Important Adv Oncol, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JAMES GL, 1993, SCIENCE, V260, P193; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NIGAM M, 1993, J BIOL CHEM, V268, P20695; QIAN YM, 1994, BIOORG MED CHEM LETT, V4, P2579, DOI 10.1016/S0960-894X(01)80287-0; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SUN JZ, 1995, CANCER RES, V55, P4243; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	39	336	348	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26802	26806		10.1074/jbc.270.45.26802	http://dx.doi.org/10.1074/jbc.270.45.26802			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592920	Green Published, hybrid			2022-12-25	WOS:A1995TE58300020
J	MOTTA, A; BREMNES, B; MORELLI, MAC; FRANK, RW; SAVIANO, G; BAKKE, O				MOTTA, A; BREMNES, B; MORELLI, MAC; FRANK, RW; SAVIANO, G; BAKKE, O			STRUCTURE-ACTIVITY RELATIONSHIP OF THE LEUCINE-BASED SORTING MOTIFS IN THE CYTOSOLIC TAIL OF THE MAJOR HISTOCOMPATIBILITY COMPLEX-ASSOCIATED INVARIANT CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; IMMUNOGENIC PEPTIDE-FRAGMENTS; HELIX-FORMING TENDENCIES; SECONDARY STRUCTURE; AMINO-ACIDS; INTERNALIZATION SIGNAL; PROTEIN STRUCTURES; CYTOPLASMIC TAIL; WATER SOLUTION; IDENTIFICATION	The cytosolic tail of the major histocompatibility complex-associated invariant chain protein contains two Leu-based motifs that both mediate efficient sorting to the endocytic pathway, Nuclear magnetic resonance data on a peptide of 27 residues corresponding to the cytosolic tail of human invariant chain indicate that in water at pH 7.4 the membrane distal motif Leu(7)-Ile(8) lies within a nascent helix, while the membrane proximal motif Met(16)-Leu(17) is part of a turn. The presence of a small amount of methanol stabilizes an alpha helix from Gln(4) to Leu(17) with a kink on pro(15), Point mutations of the cytosolic tail of the protein suggest that amino-terminal residues located in spatial proximity to the Leu motifs contribute to efficient internalization and targeting to endosomes in transfected COS cells, Residues on the spatially opposite side of the Leu motifs were, on the other hand, mutated with no measurable effect on targeting, Structural and biological data thus suggest that the signals are not continuous but consist of ''signal patches'' formed by the three-dimensional structure of the cytosolic tail of invariant chain.	UNIV OSLO,DEPT BIOL,DIV MOLEC CELL BIOL,N-0316 OSLO,NORWAY; UNIV BASILICATA,DIPARTIMENTO CHIM,I-85100 POTENZA,ITALY; UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69052 HEIDELBERG,GERMANY	University of Oslo; University of Basilicata; Ruprecht Karls University Heidelberg	MOTTA, A (corresponding author), CNR,IST CHIM MOLEC INTERESSE BIOL,I-80072 NAPLES,ITALY.		Saviano, Gabriella/AAZ-5650-2021	Castiglione Morelli, Maria Antonietta/0000-0003-3967-3117; Motta, Andrea/0000-0002-8643-658X; Saviano, Gabriella/0000-0002-1112-2041; Bakke, Oddmund/0000-0003-4843-7626				ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BREMNES B, 1994, J CELL SCI, V107, P2021; BROOKS CL, 1993, J AM CHEM SOC, V115, P11034, DOI 10.1021/ja00076a089; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DROBNY G, 1979, FARADAY DIV CHEM SOC, V13, P49; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; Frank R., 1988, MODERN METHODS PROTE, V3, P41; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUNTERT P, 1989, J AM CHEM SOC, V111, P3997; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; NEUHAUS D, 1985, EUR J BIOCHEM, V151, P257, DOI 10.1111/j.1432-1033.1985.tb09096.x; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OGATA S, 1994, J BIOL CHEM, V269, P5210; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIELA L, 1987, BIOPOLYMERS, V26, P1587, DOI 10.1002/bip.360260910; PIETERS J, 1993, J CELL SCI, V106, P831; POLINSKY A, 1992, BIOPOLYMERS, V32, P399, DOI 10.1002/bip.360320416; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROCHE PA, 1993, P NATL ACAD SCI USA, V84, P2688; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA, P1; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VANROMPUY L, 1982, J MOL BIOL, V161, P1, DOI 10.1016/0022-2836(82)90274-1; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WAGNER G, 1986, J MOL BIOL, V187, P131, DOI 10.1016/0022-2836(86)90413-4; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WILDE A, 1994, J BIOL CHEM, V269, P7131; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	59	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27165	27171		10.1074/jbc.270.45.27165	http://dx.doi.org/10.1074/jbc.270.45.27165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592972	hybrid, Green Published			2022-12-25	WOS:A1995TE58300072
J	REGNOUF, F; SAGOT, I; DELOUCHE, B; DEVILLIERS, G; CARTAUD, J; HENRY, JP; PRADEL, LA				REGNOUF, F; SAGOT, I; DELOUCHE, B; DEVILLIERS, G; CARTAUD, J; HENRY, JP; PRADEL, LA			IN-VITRO PHOSPHORYLATION OF ANNEXIN-2 HETEROTETRAMER BY PROTEIN-KINASE-C - COMPARATIVE PROPERTIES OF THE UNPHOSPHORYLATED AND PHOSPHORYLATED ANNEXIN-2 ON THE AGGREGATION AND FUSION OF CHROMAFFIN GRANULE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALPACTIN-I; BRAIN SPECTRIN; SUBSTRATE; CALCIUM; BINDING; EXOCYTOSIS; CELLS; FORMS	Heterotetrameric annexin 2 phosphorylated ''in vitro'' by rat brain protein kinase C is purified and obtained devoid of unphosphorylated protein; it contains 2 mol of phosphate/mol of heterotetramer. The aggregative and binding properties of the phosphorylated annexin 2 toward purified chromaffin granules are compared with those of the unphosphorylated annexin 2, Annexin 2 binds to chromaffin granules with high affinity, Phosphorylation of annexin 2 decreases the affinity of this binding without affecting the maximum binding capacity, The binding curves are strongly cooperative, It is suggested that a surface oligomerization of the proteins may take place upon binding. Besides, phosphorylation of annexin 2 is followed by a dissociation of the light chains from the heavy chains in the heterotetramer. Whereas annexin 2 induces the aggregation of chromaffin granules at mu M calcium concentration, the phosphorylated annexin 2 does not induce aggregation at any concentration of calcium either at pH 6 or 7, The phosphorylation of annexin 2 by protein kinase C, MgATP, and 12-O-tetradecanoylphorbol-13-acetate on chromaffin fin granules induces a fusion of chromaffin granules membranes observed in electron microscopy. The fusion requires the activation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate. Given these results and since annexin 2 is phosphorylated by protein kinase C under stimulation of chromaffin cells, it is suggested that phosphorylated annexin 2 may be implicated in the fusion step during exocytosis of chromaffin granules.	UNIV PARIS 07, INST BIOL PHYS CHIM, CTR NATL RECH SCI, UNITE 1112 NEUROBIOL PHYS CHIM, F-75005 PARIS, FRANCE; UNIV PARIS 07, INST JACQUES MONOD, DEPT BIOL SUPRAMOLEC & CELLULAIRE BIOL CELLULAIRE, UMR 9922, F-75005 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite								BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BLASCHKO H, 1967, BIOCHEM J, V104, P545, DOI 10.1042/bj1040545; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTY SE, 1980, ANAL BIOCHEM, V106, P438, DOI 10.1016/0003-2697(80)90545-X; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; DAMER CK, 1994, J BIOL CHEM, V269, P31115; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRAPPIER T, 1987, EUR J BIOCHEM, V169, P651, DOI 10.1111/j.1432-1033.1987.tb13657.x; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; JOHNSSON N, 1986, EMBO J, V5, P3455, DOI 10.1002/j.1460-2075.1986.tb04669.x; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; Kitano T, 1986, Methods Enzymol, V124, P349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; PEPINSKY RB, 1989, BIOCHEM J, V263, P97, DOI 10.1042/bj2630097; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PRADEL LA, 1993, FEBS LETT, V327, P41, DOI 10.1016/0014-5793(93)81035-X; REGNOUF F, 1985, EUR J BIOCHEM, V153, P313, DOI 10.1111/j.1432-1033.1985.tb09303.x; REGNOUF F, 1991, J NEUROCHEM, V56, P1985, DOI 10.1111/j.1471-4159.1991.tb03457.x; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; WEI W, 1992, BIOCHEMISTRY-US, V31, P9934, DOI 10.1021/bi00156a011; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4	30	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27143	27150		10.1074/jbc.270.45.27143	http://dx.doi.org/10.1074/jbc.270.45.27143			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592969	hybrid			2022-12-25	WOS:A1995TE58300069
J	SETIADI, H; DISDIER, M; GREEN, SA; CANFIELD, WM; MCEVER, RP				SETIADI, H; DISDIER, M; GREEN, SA; CANFIELD, WM; MCEVER, RP			RESIDUES THROUGHOUT THE CYTOPLASMIC DOMAIN AFFECT THE INTERNALIZATION EFFICIENCY OF P-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; DENSITY-LIPOPROTEIN RECEPTOR; FACTOR-II RECEPTOR; POLYMERIC IMMUNOGLOBULIN RECEPTOR; REGULATED SECRETORY PATHWAY; BASOLATERAL SORTING SIGNAL; LYSOSOMAL ACID-PHOSPHATASE; WEIBEL-PALADE BODIES; COATED PIT FORMATION; PLASMA-MEMBRANE	The cytoplasmic domains of many membrane proteins have short sequences, usually including a tyrosine or a di-leucine, that function as sorting signals, P-selectin is an adhesion receptor for leukocytes that is expressed on activated platelets and endothelial cells, Its 35 residue cytoplasmic domain contains signals for sorting into regulated secretory granules, for endocytosis, and for movement from endosomes to lysosomes, The domain has a membrane-distal sequence, YGVFTNAAF, that resembles some tyrosine-based signals, We studied the effects of deletions and mutations in the cytoplasmic tail of human P-selectin on its internalization in clathrin-coated pits of transfected Chinese hamster ovary cells. Mutations and deletions in the putative tyrosine-based motif did not clearly implicate these residues as critical components of a short internalization signal, Indeed, a construct containing a truncated 18-residue cytoplasmic domain with a single substitution (K761A/H773Stop) was internalized nearly three times as fast as wild-type P-selectin; this construct contained no di-leucine, tyrosine, or other known sorting motif, Substitution of residues throughout the cytoplasmic domain affected the internalization rate of P-selectin, Furthermore, the cytoplasmic domain of P-selectin mediated faster internalization when attached to the extracellular and transmembrane domains of the low density lipoprotein receptor than when attached to the corresponding domains of P-selectin. Thus, we were unable to identify a short internalization signal in the cytoplasmic tail of P-selectin, Residues throughout the cytoplasmic domain, and perhaps the transmembrane sequence to which the domain is attached, affect the efficiency of internalization.	UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV VIRGINIA,SCH MED,DEPT CELL BIOL,CHARLOTTESVILLE,VA 22908; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Virginia; University of Oklahoma System; University of Oklahoma Health Sciences Center			Setiadi, Hendra/ACQ-9386-2022	Setiadi, Hendra/0000-0002-0570-1354	NHLBI NIH HHS [HL 34363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034363, R01HL034363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AUCHAMPACH JA, 1994, GENE, V145, P251, DOI 10.1016/0378-1119(94)90015-9; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BONFANTI R, 1989, BLOOD, V73, P1109; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FUJIMOTO T, 1993, BLOOD, V82, P1758; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HAMBURGER SA, 1990, BLOOD, V75, P550; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LOW SH, 1991, J BIOL CHEM, V266, P13391; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NI F, 1994, ACCOUNTS CHEM RES, V27, P257, DOI 10.1021/ar00045a001; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTH MG, 1993, ADV CELL MOL BIOL M, V1, P19; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANDERS WE, 1992, BLOOD, V80, P795; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SOSA MA, 1993, J BIOL CHEM, V268, P12537; SRINIVASAN J, 1994, BIOCHEMISTRY-US, V33, P13553, DOI 10.1021/bi00250a007; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STRUBEL NA, 1993, BIOCHEM BIOPH RES CO, V192, P338, DOI 10.1006/bbrc.1993.1420; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; WILDE A, 1994, J BIOL CHEM, V269, P7131; WONG SH, 1993, J BIOL CHEM, V268, P22853	72	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26818	26826		10.1074/jbc.270.45.26818	http://dx.doi.org/10.1074/jbc.270.45.26818			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592923	hybrid			2022-12-25	WOS:A1995TE58300023
J	SPARKS, DL; DAVIDSON, WS; LUNDKATZ, S; PHILLIPS, MC				SPARKS, DL; DAVIDSON, WS; LUNDKATZ, S; PHILLIPS, MC			EFFECTS OF THE NEUTRAL LIPID-CONTENT OF HIGH-DENSITY-LIPOPROTEIN ON APOLIPOPROTEIN-A-I STRUCTURE AND PARTICLE STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; TRANSFER PROTEIN; SERUM-LIPOPROTEINS; PHASE-BEHAVIOR; HUMAN PLASMA; CONFORMATION; QUANTITATION; METABOLISM; EMULSIONS; TRIOLEIN	Alterations in high density lipoprotein (HDL) composition that occur in dyslipidemic states may modulate a number of events involved in cholesterol homeostasis. To elucidate the details of how HDL-core composition can affect the molecular structure of different kinds of HDL particles, the conformation and stability of apoA-I have been investigated in homogeneous recombinant HDL particles (LpA-I) containing palmitoyloleoyl phosphatidylcholine (POPC), triolein (TG), and/or cholesteryl linoleate (CE). In a discoidal particle containing two molecules of apoA-I and 85 molecules of POPC, apoA-I exhibits an alpha-helix content of 70% and a free energy of stability of its alpha-helical segments (Delta G(D)(0)) of 2.2 kcal/mol. Inclusion of eight molecules of TG into the complex significantly reduces the alpha-helix content and stability of apoA-I, whereas inclusion of four molecules of CE into the complex has an opposite effect in that the alpha-helix content is significantly reduced and the stability of the remaining alpha-helical structure of apoA-I is increased, Neutral lipids have a different effect on apoA-I conformation in spherical LpA-I particles. In a sonicated-spherical LpA-I particle containing two molecules of apoA-I and 70 molecules of POPC, apoA-I exhibits an alpha-helix content of about 60% and a Delta G(D)(0) of 1.2 kcal/mol apoA-I. Inclusion of either 10 molecules of TG or six molecules of CE into such a particle increases both the alpha-helix content and stability of apoA-I. Increasing the CE/TG ratio in LpA-I particles that contain both neutral lipids enhances the stability of the Alpha-helical segments. ApoA-I molecules tend to dissociate and cause particle instability when Delta G(D)(0) for the lipid-bound alpha-helices is less than that for helices in the lipid-free state. The stabilities of both discoidal and spherical LpA-I particles are relatively low when the only neutral lipid present is TG but the particle stability is enhanced by the presence of CE molecules, Such dissociation of apoA-I molecules from LpA-I particles that have a low CE/TG ratio would be promoted in the hypertriglyceridemic state in vivo.	MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129; HAHNEMANN UNIV,PHILADELPHIA,PA 19129	Drexel University; Drexel University	SPARKS, DL (corresponding author), UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.			Davidson, William/0000-0003-2756-2989; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443, P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443, HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CLAY MA, 1991, ARTERIOSCLER THROMB, V11, P415, DOI 10.1161/01.ATV.11.2.415; COLLET X, 1991, J BIOL CHEM, V266, P9145; DOBIASOVA M, 1991, ARTERIOSCLER THROMB, V11, P64, DOI 10.1161/01.ATV.11.1.64; DUVERGER N, 1993, BIOCHEMISTRY-US, V32, P12372, DOI 10.1021/bi00097a014; EISENBERG S, 1984, J LIPID RES, V25, P1017; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GLOMSET JA, 1970, AM J CLIN NUTR, V23, P1129; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIRZ R, 1970, BIOCHIM BIOPHYS ACTA, V207, P364, DOI 10.1016/0005-2795(70)90029-2; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; ISHIDA BY, 1987, J LIPID RES, V28, P778; JANIAK MJ, 1974, J MOL BIOL, V86, P325, DOI 10.1016/0022-2836(74)90022-9; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1993, J BIOL CHEM, V268, P1596; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KRUSKI AW, 1974, CHEM PHYS LIPIDS, V13, P27, DOI 10.1016/0009-3084(74)90040-1; LUNDKATZ S, 1990, J BIOL CHEM, V265, P12217; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCALL MR, 1993, J LIPID RES, V34, P37; MILLER KW, 1982, J COLLOID INTERF SCI, V89, P466, DOI 10.1016/0021-9797(82)90197-7; MILLER KW, 1983, BIOCHEMISTRY-US, V22, P443, DOI 10.1021/bi00271a030; MORTON RE, 1990, EXPERIENTIA, V46, P552, DOI 10.1007/BF01939693; MORTON RE, 1988, J BIOL CHEM, V263, P12235; NEARY RH, 1987, CLIN CHEM, V33, P1163; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS D, 1991, AM HEART J, V122, P601, DOI 10.1016/0002-8703(91)91031-H; SPARKS DL, 1989, ATHEROSCLEROSIS, V77, P183, DOI 10.1016/0021-9150(89)90080-4; SPARKS DL, 1995, J BIOL CHEM, V270, P5151, DOI 10.1074/jbc.270.10.5151; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1989, J LIPID RES, V30, P1491; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SPARKS DL, 1989, BIOCHEM CELL BIOL, V67, P358, DOI 10.1139/o89-056; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TERPSTRA AHM, 1981, ANAL BIOCHEM, V111, P149, DOI 10.1016/0003-2697(81)90243-8; TU AY, 1993, J BIOL CHEM, V268, P23098; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	47	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26910	26917		10.1074/jbc.270.45.26910	http://dx.doi.org/10.1074/jbc.270.45.26910			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592936	hybrid			2022-12-25	WOS:A1995TE58300036
J	DONG, LQ; CHAPLINE, C; MOUSSEAU, B; FOWLER, L; RAMSAY, K; STEVENS, JL; JAKEN, S				DONG, LQ; CHAPLINE, C; MOUSSEAU, B; FOWLER, L; RAMSAY, K; STEVENS, JL; JAKEN, S			35H, A SEQUENCE ISOLATED AS A PROTEIN-KINASE-C BINDING-PROTEIN, IS A NOVEL MEMBER OF THE ADDUCIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ADDUCIN; BETA-ADDUCIN; ASSOCIATION; CALMODULIN; PHOSPHORYLATION; REDISTRIBUTION; STAUROSPORINE; FIBROBLASTS; ACTIVATION; MEMBRANES	We recently cloned a partial cDNA (35H) for a protein kinase C (PKC) binding protein from a rat kidney cDNA library and demonstrated that it is a PKC substrate in vitro (Chapline, C., Ramsay, K., Klauck, T., and Jaken, S. (1993) J. Biol. Chem. 268, 6858-6861). Additional library screening and 5' rapid amplification of cDNA ends were used to obtain the complete open reading frame. Amino acid sequence analysis, DNA sequence analysis, and Northern analysis indicate that 35H is a unique cDNA related to alpha- and beta-adducins. Antisera prepared to the 35H bacterial fusion protein recognized two polypeptides of 80 and 90 kDa on immunoblots of kidney homogenates and cultured renal proximal tubule epithelial cell extracts. The 35H-related proteins were similar to alpha- and beta-adducins in that they were preferentially recovered in the Triton X-100-insoluble (cytoskeletal, CSK) fraction of cell extracts and were predominantly localized to cell borders. Phorbol esters stimulated phosphorylation of CSK 35H proteins, thus emphasizing that sequences isolated according to PKC binding activity in vitro are also PKC substrates in vivo. The phosphorylated forms of the 35H proteins were preferentially recovered in the soluble fraction, thus demonstrating that phosphorylation regulates their CSK association and, thereby, their function in regulating cytoskeletal assemblies, We have isolated another PKC binding protein partial cDNA (clone 45) from a rat fibroblast library with substantial homology to alpha-adducin. Antisera raised against this expressed sequence recognized a protein of 120 kDa, the reported size of alpha-adducin, on immunoblots of renal proximal tubule epithelial cell extracts. A 120-kDa protein that cross-reacts with the clone 45 (alpha-adducin) antisera coprecipitated with 35H immunecomplexes, indicating that alpha-adducin associates with 35H proteins in vivo. Taken together, these results indicate that 35H is a new, widely expressed form of adducin capable of forming heterodimers with alpha-adducin. We propose naming this adducin homologue gamma-adducin.	W ALTON JONES CELL SCI CTR INC,LAKE PLACID,NY 12946						NATIONAL CANCER INSTITUTE [R01CA053841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050152] Funding Source: NIH RePORTER; NCI NIH HHS [CA53841] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline; NIGMS NIH HHS [GM50152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BIANCHI G, 1994, P NATL ACAD SCI USA, V91, P3999, DOI 10.1073/pnas.91.9.3999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRAVARTHY BR, 1994, BIOCHEM J, V304, P809, DOI 10.1042/bj3040809; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DIAZGUERRA MJM, 1990, BIOCHEM J, V269, P163, DOI 10.1042/bj2690163; DONG LQ, 1994, CELL GROWTH DIFFER, V5, P881; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GRABAREK J, 1993, J BIOL CHEM, V268, P5543; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KILEY SC, 1992, CARCINOGENESIS, V13, P1997, DOI 10.1093/carcin/13.11.1997; KIM JY, 1994, J BIOL CHEM, V269, P28214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; OSBORN M, 1982, METHOD CELL BIOL, V24, P97; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; TRIPODI G, 1991, BIOCHEM BIOPH RES CO, V177, P939, DOI 10.1016/0006-291X(91)90629-L; WALLIN A, 1992, LAB INVEST, V66, P474; WASEEM A, 1990, J CELL SCI, V96, P93; WOLF M, 1988, BIOCHEM BIOPH RES CO, V154, P1273, DOI 10.1016/0006-291X(88)90277-X; ZHANG GH, 1991, J CELL PHYSIOL, V148, P295, DOI 10.1002/jcp.1041480216	31	102	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25534	25540		10.1074/jbc.270.43.25534	http://dx.doi.org/10.1074/jbc.270.43.25534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592723	hybrid			2022-12-25	WOS:A1995TB46600040
J	FAVERO, TG; ZABLE, AC; ABRAMSON, JJ				FAVERO, TG; ZABLE, AC; ABRAMSON, JJ			HYDROGEN-PEROXIDE STIMULATES THE CA2+ RELEASE CHANNEL FROM SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID CALCIUM RELEASE; REACTIVE OXYGEN; DYSFUNCTION; SENSITIVITY; INHIBITION; MECHANISMS; RYANODINE; OXIDATION	Hydrogen peroxide (H2O2) at millimolar concentrations induces Ca2+ release from actively loaded sarcoplasmic reticulum vesicles and induces biphasic [H-3]ryanodine binding behavior. High affinity [H-3]ryanodine binding is enhanced at concentrations hom 100 mu M to 10 mM (3-4-fold). At H2O2 concentrations greater than 10 mM, equilibrium binding is inhibited. H2O2 decreased the k(d) for [H-3]ryanodine binding by increasing its association rate, while having no effect on the rate of dissociation of [H-3]ryanodine from its receptor. H2O2 (1 mM) also reduced the EC(50) for Ca2+ activation hom 632 nM to 335 nM. These effects were completely abolished in the presence of catalase, ruthenium red, and/or Mg2+ (mM) H2O2-stimulated [H-3]ryanodine binding is not further enhanced by either doxorubicin or caffeine. The direct interaction between H2O2 and the Ca2+ release mechanism was further demonstrated in single-channel reconstitution experiments. Peroxide, at submillimolar concentrations, activated the Ca2+ release channel following fusion of a sarcoplasmic reticulum vesicle to a bilayer lipid membrane. At millimolar concentrations of peroxide, Ca2+ channel activity was inhibited. Peroxide stimulation of Ca2+ channel activity was reversed by the thiol reducing agent dithiothreitol. Paralleling peroxide induced activation of ryanodine binding, Ca2+ transport, and single Ca2+ channel activity, it was observed that the ryanodine receptor formed large disulfide-linked protein complexes that dissociated upon addition of dithiothreitol.	PORTLAND STATE UNIV,DEPT PHYS,PORTLAND,OR 97207	Portland State University	FAVERO, TG (corresponding author), UNIV PORTLAND,DEPT BIOL,5000 N WILLIAMETTE BLVD,PORTLAND,OR 97203, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM044337] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08388] Funding Source: Medline; NIGMS NIH HHS [1R15GM44337-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON JJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P245, DOI 10.1016/0003-9861(88)90633-9; ALLEN DG, 1983, J PHYSIOL-LONDON, V339, P107, DOI 10.1113/jphysiol.1983.sp014706; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; DAVISON A, 1988, MOL CELL BIOCHEM, V84, P199, DOI 10.1007/BF00421055; ELEY DW, 1989, CAN J PHYSL PHARM, V69, P1677; FREEMAN BA, 1982, LAB INVEST, V47, P412; HARRIS RN, 1985, BIOCHEM BIOPH RES CO, V130, P739, DOI 10.1016/0006-291X(85)90478-4; HEARSE DJ, 1987, FREE RADICALS OXIDAN, P13; KALCKAR HM, 1947, J BIOL CHEM, V196, P461; KAMINISHI T, 1989, BASIC RES CARDIOL, V84, P282, DOI 10.1007/BF01907975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; LU XY, 1994, J BIOL CHEM, V269, P6511; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; OKABE E, 1991, J PHARMACOL EXP THER, V256, P868; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; SCHERER NM, 1986, ARCH BIOCHEM BIOPHYS, V246, P589, DOI 10.1016/0003-9861(86)90314-0; SMITH JK, 1989, AM J PHYSIOL, V256, pH789, DOI 10.1152/ajpheart.1989.256.3.H789; STUART J, 1992, ARCH BIOCHEM BIOPHYS, V292, P512, DOI 10.1016/0003-9861(92)90024-Q; SUZUKI YJ, 1992, AM J PHYSIOL, V262, pH114, DOI 10.1152/ajpheart.1992.262.1.H114; SUZUKI YJ, 1991, AM J PHYSIOL, V261, pH568, DOI 10.1152/ajpheart.1991.261.2.H568; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; XIONG H, 1992, ARCH BIOCHEM BIOPHYS, V292, P522, DOI 10.1016/0003-9861(92)90025-R; YANAGISHITA T, 1989, BIOCHEM INT, V18, P1111	26	233	235	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25557	25563		10.1074/jbc.270.43.25557	http://dx.doi.org/10.1074/jbc.270.43.25557			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592726	hybrid			2022-12-25	WOS:A1995TB46600043
J	MOSIOR, M; NEWTON, AC				MOSIOR, M; NEWTON, AC			MECHANISM OF INTERACTION OF PROTEIN-KINASE-C WITH PHORBOL ESTERS - REVERSIBILITY AND NATURE OF MEMBRANE ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; PLASMA-MEMBRANE; MODEL MEMBRANES; HUMAN-PLATELETS; LIPID VESICLES; ACTIVATION; CALCIUM; PHOSPHATIDYLSERINE; DIACYLGLYCEROLS; FLUORESCENCE	A variety of approaches have been employed to demonstrate that the interaction of protein kinase C beta II with phorbol ester-containing membranes is reversible, is not accompanied by significant insertion of the protein into the hydrophobic core of the membrane, and is qualitatively similar to the interaction with diacylglycerol (DG), First, we show that under conditions when protein kinase C is bound with equal affinity to membranes containing either DG or phorbol myristate acetate (PMA), increasing ionic strength causes a similar reduction in membrane binding, The similar sensitivity to ionic strength indicates that the forces mediating the binding of protein kinase C to PMA are not significantly different from those mediating the binding to DG. At sufficiently high concentrations of PMA and relatively low concentrations of phosphatidylserine, the binding of protein kinase C to membranes became markedly less sensitive to ionic strength, suggesting that under these conditions direct non-electrostatic interactions with PMA dominate over electrostatic interactions with the lipid headgroups, Importantly, regardless of the strength of the interaction with PMA, protein kinase C exchanges between vesicle surfaces: protein kinase C bound first to phorbol ester-containing multilamellar vesicles exchanged to large unilamellar vesicles upon addition of an excess surface area of the latter, Lastly, the enzyme's intrinsic tryptophan fluorescence was not quenched by bromines located at various positions in the hydrophobic core of the membrane. In contrast, the enzyme's tryptophan fluorescence was significantly quenched by probes positioned at the membrane surface, In summary, our results are consistent with protein kinase C binding reversibly to PMA- or DG-containing membranes primarily via interactions at the membrane interface.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BELL RM, 1991, J BIOL CHEM, V266, P4661; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLUME A, 1983, BIOCHEMISTRY-US, V22, P5436, DOI 10.1021/bi00292a027; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; FLORINE KI, 1987, BIOCHEMISTRY-US, V26, P2978, DOI 10.1021/bi00385a004; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LADOKHIN AS, 1991, BIOCHEMISTRY-US, V30, P10200, DOI 10.1021/bi00106a018; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LETO TL, 1980, BIOCHEMISTRY-US, V19, P1911, DOI 10.1021/bi00550a028; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1994, BIOPHYS J, V66, pA30; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; QUEST AFG, 1994, PROTEIN KINASE C, P64; RASMUSSEN H, 1992, PROTEIN KINASE C CUR, P216; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SNOEK GT, 1986, BIOCHIM BIOPHYS ACTA, V860, P336, DOI 10.1016/0005-2736(86)90530-4; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TANFORD C, 1980, HYDROPHOBIC EFFECT; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	49	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25526	25533		10.1074/jbc.270.43.25526	http://dx.doi.org/10.1074/jbc.270.43.25526			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592722	hybrid			2022-12-25	WOS:A1995TB46600039
J	AUGUR, C; STIEFEL, V; DARVILL, A; ALBERSHEIM, P; PUIGDOMENECH, P				AUGUR, C; STIEFEL, V; DARVILL, A; ALBERSHEIM, P; PUIGDOMENECH, P			MOLECULAR-CLONING AND PATTERN OF EXPRESSION OF AN ALPHA-L-FUCOSIDASE GENE FROM PEA-SEEDLINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUXIN-STIMULATED GROWTH; XYLOGLUCAN OLIGOSACCHARIDES; STEM SEGMENTS; CDNA; SEQUENCE; NONASACCHARIDE; INHIBITION; SEEDS; RNA	alpha-L-Fucosidase is a cell wall protein purified from pea (Pisum sativum) epicotyls. The alpha-L-fucosidase hydrolyzes terminal fucosyl residues from oligosaccharides of plant cell wall xyloglucan. alpha-L-Fucosidase may be an important factor in plant growth regulation, as it inactivates fucose-containing xyloglucan oligosaccharides that inhibit growth of pea stem segments. The amino acid sequences of the NH2-terminal region and one internal peptide were used to design redundant oligonucleotides that were utilized as primers in a polymerase chain reaction (PCR) with cDNA, generated from pea mRNA, as the template. A specific PCR amplification product containing 357 base pairs was isolated, cloned, and sequenced. The deduced amino acid sequence included the two peptides used to design the primers for PCR plus two other peptides obtained by proteinase digestion of alpha-L-fucosidase. No sequence ho homology to other alpha-L-fucosidases was apparent, although the NH2-terminal region is strongly homologous to Kunitz-type trypsin inhibitors, cDNA and genomic copies were isolated and sequenced. In pea, the gene is present in two or three copies. Its mRNA is present in roots, leaves, and elongating shoots. The spatial pattern of expression of the alpha-L-fucosidase was determined by in situ hybridization.	CSIC,CID,MOLEC GENET LAB,E-08034 BARCELONA,SPAIN; UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; UNIV GEORGIA,DEPT BIOCHEM & MOLEC BIOL,ATHENS,GA 30602; ORSTOM,MEXICO CITY 11530,DF,MEXICO	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Institut de Recherche pour le Developpement (IRD)								AUGUR C, 1992, PLANT PHYSIOL, V99, P180, DOI 10.1104/pp.99.1.180; AUGUR C, 1993, PLANT J, V3, P415, DOI 10.1046/j.1365-313X.1993.t01-20-00999.x; BURR B, 1981, GENETICS, V98, P143; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; CHEN ZX, 1991, INFECT IMMUN, V59, P2846, DOI 10.1128/IAI.59.8.2846-2850.1991; EMMERLING M, 1990, PLANTA, V182, P174, DOI 10.1007/BF00197107; FISHER KJ, 1989, BIOCHEM J, V264, P695, DOI 10.1042/bj2640695; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; FUKUSHIMA H, 1985, P NATL ACAD SCI USA, V82, P1262, DOI 10.1073/pnas.82.4.1262; GARDINER M, 1975, PLANT PHYSIOL, V55, P536, DOI 10.1104/pp.55.3.536; HATTORI T, 1989, PLANT MOL BIOL, V13, P563, DOI 10.1007/BF00027316; HAYASHI T, 1984, PLANT PHYSIOL, V75, P596, DOI 10.1104/pp.75.3.596; Langdale Jane A., 1994, P165; MAESHIMA M, 1985, PHYTOCHEMISTRY, V24, P1899, DOI 10.1016/S0031-9422(00)83088-5; Maniatis T., 1982, MOL CLONING; MCDOUGALL GJ, 1990, PLANT PHYSIOL, V93, P1042, DOI 10.1104/pp.93.3.1042; MCDOUGALL GJ, 1988, PLANTA, V175, P412, DOI 10.1007/BF00396348; MOHNEN D, 1985, EMBO J, V4, P1631, DOI 10.1002/j.1460-2075.1985.tb03830.x; OCCHIODORO T, 1989, BIOCHEM BIOPH RES CO, V164, P439, DOI 10.1016/0006-291X(89)91739-7; RICHARDSON M, 1986, BIOCHIM BIOPHYS ACTA, V872, P134, DOI 10.1016/0167-4838(86)90156-1; Richardson MJ., 1991, METHODS PLANT BIOCH, P259; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; YAMAMOTO M, 1983, J BIOCHEM, V94, P849, DOI 10.1093/oxfordjournals.jbchem.a134427; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295	26	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24839	24843		10.1074/jbc.270.42.24839	http://dx.doi.org/10.1074/jbc.270.42.24839			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559605	hybrid			2022-12-25	WOS:A1995TB46500039
J	CHRISTOFFELS, VM; VANDENHOFF, MJB; MOORMAN, AFM; LAMERS, WH				CHRISTOFFELS, VM; VANDENHOFF, MJB; MOORMAN, AFM; LAMERS, WH			THE FAR-UPSTREAM ENHANCER OF THE CARBAMOYL-PHOSPHATE SYNTHETASE-I GENE IS RESPONSIBLE FOR THE TISSUE-SPECIFICITY AND HORMONE INDUCIBILITY OF ITS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-LIVER; CYCLIC-AMP; MESSENGER-RNAS; REPORTER GENE; CELL LINES; PROMOTER; PHOSPHORYLATION; TRANSCRIPTION; HEPATOCYTES	The role of the proximal promoter and the far-upstream enhancer in the hepatocyte-specific and hormonal regulation of the carbamoyl-phosphate synthetase I (CPS) gene was investigated in transient transfection assays using primary rat hepatocytes, hepatoma cells, and fibroblasts. These experiments revealed that the activity of the promoter is comparable in all cells tested and is, therefore, not responsible for tissue-specific expression, The 5'-untranslated region of the mRNA is a major, non-tissue specific stimulator of expression in FTO-2B hepatoma cells, acting at the post-transcriptional level. A 469-base pair DNA fragment, 6 kilobase pairs upstream of the transcription start-site in the CPS gene, confers strong hormone-dependent tissue specific expression, both in combination with the CPS promoter and a minimized viral thymidine kinase promoter. Sequences similar to a;cyclic AMP-responsive element and a glucocorticosteroid-responsive element were found in the isolated enhancer. Substitutional mutations in these sites strongly affected hormone-induced expression. Analysis of the interaction between the enhancer and parts of the CPS promoter revealed that, in addition to the TATA box, the GAG box, a motif similar to the GC box near the TATA motif, is instrumental in conferring the enhancer activity.	UNIV AMSTERDAM,DEPT ANAT & EMBRYOL,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam			Lamers, Wouter H./D-2965-2012	van den Hoff, Maurice/0000-0002-3837-8055				ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BLOMMAART PJE, 1993, J BIOL CHEM, V268, P1610; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTTREZ F, 1994, NUCLEIC ACIDS RES, V22, P2712, DOI 10.1093/nar/22.13.2712; DEGROOT CJ, 1986, BIOCHIM BIOPHYS ACTA, V866, P61, DOI 10.1016/0167-4781(86)90101-6; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HARAGUCHI Y, 1991, GENE, V107, P335; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; JANZEN JWG, 1988, J HISTOCHEM CYTOCHEM, V36, P1223, DOI 10.1177/36.10.2458406; JANZEN JWG, 1985, J HISTOCHEM CYTOCHEM, V339, P1205; KILLARY AM, 1976, CELL, V9, P269; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAGACE M, 1987, J BIOL CHEM, V262, P10415; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LAMERS WH, 1987, DIFFERENTIATION, V35, P228, DOI 10.1111/j.1432-0436.1987.tb00173.x; LAMERS WH, 1984, DEV BIOL, V105, P500, DOI 10.1016/0012-1606(84)90307-5; MAJUMDER S, 1993, EMBO J, V12, P1131, DOI 10.1002/j.1460-2075.1993.tb05754.x; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOORMAN AFM, 1990, HISTOCHEM J, V22, P457, DOI 10.1007/BF01007229; MOORMAN AFM, 1990, FEBS LETT, V276, P9, DOI 10.1016/0014-5793(90)80494-4; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PINTO M, 1983, BIOL CELL, V47, P323; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANDEHOFF MJB, 1995, METHODS MOL BIOL; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; VANROON MA, 1989, DIFFERENTIATION, V41, P139, DOI 10.1111/j.1432-0436.1989.tb00741.x; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	55	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24932	24940		10.1074/jbc.270.42.24932	http://dx.doi.org/10.1074/jbc.270.42.24932			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559619	hybrid			2022-12-25	WOS:A1995TB46500053
J	HOMER, MJ; DEAN, DR; ROBERTS, GP				HOMER, MJ; DEAN, DR; ROBERTS, GP			CHARACTERIZATION OF THE GAMMA-PROTEIN AND ITS INVOLVEMENT IN THE METALLOCLUSTER ASSEMBLY AND MATURATION OF DINITROGENASE FROM AZOTOBACTER-VINELANDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE; TRANSACTIVATOR MELC1; FEMO-COFACTOR; MOFE PROTEIN; NITROGENASE; APODINITROGENASE; ACTIVATION; GENE; APOTYROSINASE	Dinitrogenase, the enzyme capable of catalyzing the reduction of N2, is a heterotetramer (alpha 2 beta 2) and contains the iron-molybdenum cofactor (FeMo-co) at the active site of the enzyme. Mutant strains unable to synthesize FeMo-co accumulate an apo form of dinitrogenase, which is enzymatically inactive but can be activated in vitro by the addition of purified FeMo-co. Apodinitroge nase from certain mutant strains of Azotobacter vinelandii has a subunit composition of alpha(2) beta(2) gamma(2). The gamma subunit has been implicated as necessary for the efficient activation of apodinitrogenase in vitro. Characterization of gamma protein in crude extracts and partially pure fractions has suggested that it is a chaperone-insertase required by apodinitrogenase for the insertion of FeMo-co. There are three major forms of gamma protein detectable by Western analysis of native gels. An apodinitrogenase-associated form is found in extracts of nifB or nifNE strains and dissociates from the apocomplex upon addition of purified FeMo-co. A second form of gamma protein is unassociated with other proteins and exists as a homodimer. Both of these forms of gamma protein can be converted to a third form by the addition of purified FeMo-co. This conversion requires the addition of active FeMo-co and correlates with the incorporation of iron into gamma protein. Crude extracts that contain this form of gamma protein are capable of donating FeMo-co to apodinitrogenase, thereby activating the apodinitrogenase. These data support a model in which gamma protein is able to interact with both FeMo-co and apodinitrogenase, facilitate FeMo-co insertion into apodinitrogenase, and then dissociate from the activated dinitrogenase complex.	UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA; UNIV WISCONSIN, CTR STUDY NITROGEN FIXAT, MADISON, WI 53706 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Virginia Polytechnic Institute & State University					NIGMS NIH HHS [T32GM07215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOLIN JT, 1993, ACS SYM SER, V535, P186; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BUSH JA, 1959, NATURE, V184, P381, DOI 10.1038/184381a0; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CHEN LY, 1993, J BIOL CHEM, V268, P18710; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM J, 1992, SCIENCE, V360, P553; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAL S, 1991, J BIOL CHEM, V266, P10654; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WHITE TC, 1992, J BIOL CHEM, V267, P24007	30	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24745	24752		10.1074/jbc.270.42.24745	http://dx.doi.org/10.1074/jbc.270.42.24745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559591	hybrid			2022-12-25	WOS:A1995TB46500025
J	LINK, TA; VONJAGOW, G				LINK, TA; VONJAGOW, G			ZINC IONS INHIBIT THE Q(P) CENTER OF BOVINE HEART MITOCHONDRIAL BC(1) COMPLEX BY BLOCKING A PROTONATABLE GROUP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; IRON-SULFUR PROTEIN; BC1 COMPLEX; ELECTRON-TRANSPORT; BEEF-HEART; ZN2+ IONS; UBIQUINOL; BINDING; RECONSTITUTION; CLUSTER	Bovine heart bc(1) complex is reversibly inhibited by zinc ions with an inhibition constant K-I of 10(-7) M at pH greater than or equal to 7.0. Binding of zinc is at least a factor of 10 tighter than binding of any other metal ion tested. Essentially complete inhibition of ubihydroquinonecytochrome c oxidoreductase activity is observed at concentrations of [Zn2+] > 5 mu M. Zinc does not affect the K-m for the substrates, ubihydroquinone or cytochrome c, but zinc inhibits reduction of the cytochromes by ubihydroquinone through the Q(P) center. A radioactive binding assay using Zn-65 revealed one high affinity binding site per bc(1) complex with K-D less than or equal to 10(-7) M at pH = 7.0 and 3-4 additional low affinity binding sites (K-D > 2 x 10(-6) M). Zinc binding does not depend on the redox state of the high potential chain (iron sulfur protein and cytochrome c(1)). Zinc binds 3 times tighter to Fe-S-depleted bc(1) complex indicating that the zinc binding site is not on the ''Rieske'' iron-sulfur protein in contrast to a recent report by Lorusso et al, (Lorusso, M,, Cocco, T., Sardanella, A. M., Minuto, M., Bonomi, F., and Papa, S. (1991) Eur. J. Biochem. 197, 555-561). Zinc binds to a site which has the same affinity for zinc as for protons. We conclude that the zinc binding site is close to a protonatable group of the bc(1) complex with pK(a) = 7.2 which has not been identified previously. We propose that this group is part of the proton channel at the hydroquinone oxidation center of the bc(1) complex.			LINK, TA (corresponding author), UNIV FRANKFURT KLINIKUM,ZBC,THEODOR STERN KAI 7,HAUS 25B,D-60590 FRANKFURT,GERMANY.							BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; KLEINER D, 1974, ARCH BIOCHEM BIOPHYS, V165, P121, DOI 10.1016/0003-9861(74)90148-9; KLEINER D, 1972, FEBS LETT, V20, P229, DOI 10.1016/0014-5793(72)80802-0; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; LORUSSO M, 1991, EUR J BIOCHEM, V197, P555, DOI 10.1111/j.1432-1033.1991.tb15944.x; MARET W, 1993, METHOD ENZYMOL, V226, P52; NICHOLLS P, 1968, BIOCHEMISTRY-US, V7, P305, DOI 10.1021/bi00841a038; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; RICH PR, 1982, FARADAY DISCUSS, V74, P349, DOI 10.1039/dc9827400349; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SKULACHE.VP, 1967, BIOCHEM BIOPH RES CO, V26, P1, DOI 10.1016/0006-291X(67)90242-2; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; TRUMPOWER BL, 1980, J BIOL CHEM, V255, P7487; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P224; WESTER PO, 1965, BIOCHIM BIOPHYS ACTA, V109, P268, DOI 10.1016/0926-6585(65)90111-1	26	148	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25001	25006		10.1074/jbc.270.42.25001	http://dx.doi.org/10.1074/jbc.270.42.25001			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559629	hybrid			2022-12-25	WOS:A1995TB46500063
J	LIU, Y; NESHEIM, JC; LEE, SK; LIPSCOMB, JD				LIU, Y; NESHEIM, JC; LEE, SK; LIPSCOMB, JD			GATING EFFECTS OF COMPONENT-B ON OXYGEN ACTIVATION BY THE METHANE MONOOXYGENASE HYDROXYLASE COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							METHYLOCOCCUS-CAPSULATUS BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; CATALYTIC CYCLE; PROTEIN-B; REDUCTASE; EPR; MOSSBAUER; IDENTIFICATION; HYDROCARBONS; OXIDATION	Component B (MMOB) of the soluble methane mono oxygenase (MMO) system accelerates the initial velocity of methane oxidation by up to 150-fold by an unknown mechanism. The active site of MMO contains a diferric, hydroxo-bridged diiron cluster located on the hydroxylase component (MMOH). This cluster is reduced by the NAD(P)H-coupled reductase component to the diferrous state, which then reacts with O-2 to yield two reaction cycle intermediates sequentially termed compounds P and Q. The rate of compound P formation is shown here to be independent of O-2 concentration, suggesting that an MMOH-O-2 complex (compound O) is (similar to irreversibly) formed before compound P. Compound Q is capable of reacting with hydrocarbons to yield the MMOH-product complex, compound T. It is shown here that MMOB accelerates catalysis by increasing similar to 1000-fold the rate of O-2 association and reaction with diferrous MMOH leading to compound P. Modeling of the single turnover reaction in the presence of substoichiometric MMOB suggests that MMOB also accelerates the compound P to Q conversion by similar to 40-fold. Due to this O-2-gating effect of MMOB, either compound Q or T becomes the dominant species during turnover, depending upon the substrate concentration and type. Because these are the species that either react with substrate (Q) or release product (T), their buildup maximizes the turnover rate. This is the first direct role in catalysis to be recognized for MMOB and represents a novel method for oxygenase regulation.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Lipscomb, John/0000-0002-8158-5594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008277, R01GM040466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40466, GM08277, R01 GM040466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1991, NEW J CHEM, V15, P411; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GREEN J, 1985, J BIOL CHEM, V260, P5795; GREEN J, 1989, BIOCHEM J, V259, P167, DOI 10.1042/bj2590167; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HIGGINS IJ, 1980, NATURE, V286, P561, DOI 10.1038/286561a0; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LIU KE, 1991, J BIOL CHEM, V266, P12836; LIU KE, 1994, J AM CHEM SOC, V116, P7465, DOI 10.1021/ja00095a083; LIU KE, 1995, J AM CHEM SOC, V117, P4997, DOI 10.1021/ja00122a032; LIU KE, 1991, J BIOL CHEM, V266, P24859; LUND J, 1985, EUR J BIOCHEM, V147, P291, DOI 10.1111/j.1432-1033.1985.tb08749.x; LUND J, 1985, EUR J BIOCHEM, V147, P297, DOI 10.1111/j.1432-1033.1985.tb08750.x; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; PAULSEN KE, 1994, BIOCHEMISTRY-US, V33, P713, DOI 10.1021/bi00169a013; PULVER S, 1993, J AM CHEM SOC, V115, P12409, DOI 10.1021/ja00079a024; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068	31	139	140	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24662	24665		10.1074/jbc.270.42.24662	http://dx.doi.org/10.1074/jbc.270.42.24662			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559577	hybrid			2022-12-25	WOS:A1995TB46500011
J	LUPISELLA, JA; DRISCOLL, JE; METZLER, WJ; RECZEK, PR				LUPISELLA, JA; DRISCOLL, JE; METZLER, WJ; RECZEK, PR			THE LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR-GAMMA IS PREDOMINANTLY ALPHA-HELICAL WITH A TRP RESIDUE IN THE LIGAND-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ESCHERICHIA-COLI; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; SECONDARY STRUCTURE; RESPONSIVE ELEMENT; CIRCULAR-DICHROISM; ESTROGEN-RECEPTOR; X RECEPTOR; BETA-GENE	Retinoic acid exerts its many biological effects by interaction with a nuclear protein, the retinoic acid receptor (RAR). The details of this interaction are unknown due mainly to the lack of sufficient quantities of pure functional receptor protein for biochemical and structural studies. We have recently subcloned the D and E domains of human RAR gamma for expression in Escherichia coli. Using nickel-chelation affinity chromatography with a polyhistidine amino terminal tail, purification of the DE peptide with a pI of 5.18 was accomplished to greater than 98% purity. Scatchard analysis and fluorescence quenching techniques using the purified protein indicate a very high percentage of functional molecules (>95%) with a K-d for retinoic acid (t-RA) of 0.6 +/- 0.1 nM. Circular dichroism spectra of the purified domains predict a predominantly alpha-helical structure (similar to 56%) with little beta sheet present. No significant changes in these structural characteristics were observed upon binding of t-RA. Inspection of the amino acid sequence within these domains identified a single tryptophan residue at position 227. Modeling the amino acid sequence in this region as an alpha-helical structure indicates that this tryptophan is adjacent to alanine 234, which corresponds to alanine 225 in RAR beta that has previously been linked to the ligand binding site. Fluorescence of this tryptophan was quenched in a dose-dependent manner on the addition of t-RA, confirming that Trp-227 is within the ligand binding site. Tryptophan flourescence quenching analysis also demonstrates that a single retinoic acid molecule is bound per receptor and suggests that receptor-ligand interactions occur within the amino-terminal portion of the predominantly alpha-helical ligand binding domain.	BRISTOL MYERS SQUIBB CO,RES INST,DEPT MOLEC BIOL,BUFFALO,NY 14213; SQUIBB INST MED RES,PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb				Lupisella, John/0000-0003-1343-6412				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1991, RETINOIDS : 10 YEARS ON, P110; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOURGUET W, 1992, BIOCHEM BIOPH RES CO, V187, P711, DOI 10.1016/0006-291X(92)91253-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clark Alfred Joseph., 1933, MODE ACTION DRUGS CE; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAWSON MI, 1993, RETINOIDS PROGR RES, P205; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOKOH S, 1981, ANAL BIOCHEM, V116, P211, DOI 10.1016/0003-2697(81)90346-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GODOVACZIMMERMA.J, 1988, TRENDS BIOCHEM SCI, V13, P64; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KEIDEL S, 1992, EUR J BIOCHEM, V204, P1141, DOI 10.1111/j.1432-1033.1992.tb16739.x; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Lotan R, 1988, Prog Clin Biol Res, V259, P261; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAKSYMOWYCH AB, 1992, RECEPTOR, V2, P225; MANAVALAN P, 1985, J BIOSCIENCE, V8, P141, DOI 10.1007/BF02703972; NAPOLI JL, 1990, CHEM BIOL SYNTHETIC, P229; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; REDDY AP, 1992, BIOCHEM J, V287, P833, DOI 10.1042/bj2870833; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VNAHOLDE KE, 1985, PHYSICAL BIOCH, P58; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	49	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24884	24890		10.1074/jbc.270.42.24884	http://dx.doi.org/10.1074/jbc.270.42.24884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559612	hybrid			2022-12-25	WOS:A1995TB46500046
J	MAXWELL, MM; NEARING, J; AZIZ, N				MAXWELL, MM; NEARING, J; AZIZ, N			KE-6-GENE - SEQUENCE AND ORGANIZATION AND ABERRANT REGULATION IN MURINE POLYCYSTIC KIDNEY-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE; MODEL; DEHYDROGENASE; LOCALIZATION; REGION; H-2K; MHC	Ke 6 gene is a newly identified gene located in the major histocompatibility complex and is a candidate steroid dehydrogenase gene because of structural homology and regulatory similarities with mammalian steroid dehydrogenases. We report here the complete nucleotide sequence and intron-exon organization of the Ke 6 gene and cloning of the alternatively spliced Ke 6b transcript. We find that Ke 6 gene expression is downregulated in pcy mice which is a murine model of polycystic kidney disease (PKD). Thus far, Ke 6 gene expression is down-regulated in all murine models of PKD we have examined. Abnormal steroid metabolism as a possible cause of PKD is discussed.	CHILDRENS HOSP,DEPT MED,DIV NEPHROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 48098] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048098] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE K, 1988, EMBO J, V7, P3441, DOI 10.1002/j.1460-2075.1988.tb03218.x; [Anonymous], 1994, CELL, V77, P881; ARTZT K, 1988, IMMUNOGENETICS, V28, P30, DOI 10.1007/BF00372526; ATALA A, 1993, KIDNEY INT, V43, P1081, DOI 10.1038/ki.1993.151; AVNER ED, 1984, EXPERIENTIA, V40, P489, DOI 10.1007/BF01952400; AZIZ N, 1993, MOL CELL BIOL, V13, P1847, DOI 10.1128/MCB.13.3.1847; AZIZ N, 1994, AM J PHYSIOL-RENAL, V267, pF791, DOI 10.1152/ajprenal.1994.267.5.F791; AZIZ N, 1994, J AM SOC NEPHROL, V5, P617; AZIZ N, 1994, IN PRESS J AM SOC NE; AZIZ N, 1995, BIOESSAYS, V17, P1; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; CROCKER JFS, 1976, AM J PATHOL, V82, P373; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILMER RB, 1973, AM J PATHOL, V72, P461; FRY JL, 1985, J UROLOGY, V134, P828, DOI 10.1016/S0022-5347(17)47448-9; GRIDLEY T, 1991, GENOMICS, V11, P501, DOI 10.1016/0888-7543(91)90056-K; HANSON IM, 1991, IMMUNOGENETICS, V34, P5, DOI 10.1007/BF00212306; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; LORENCE MC, 1990, MOL ENDOCRINOL, V4, P1850, DOI 10.1210/mend-4-12-1850; MCDONALD ATJ, 1990, KIDNEY INT, V37, P901, DOI 10.1038/ki.1990.64; OJEDA JL, 1986, NEPHRON, V42, P240, DOI 10.1159/000183674; PATEL PI, 1986, MOL CELL BIOL, V6, P393, DOI 10.1128/MCB.6.2.393; PEREY DYE, 1967, SCIENCE, V158, P494, DOI 10.1126/science.158.3800.494; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; Sambrook J, 1989, MOL CLONING LABORATO; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; STJACQUES B, 1990, MOL CELL BIOL, V10, P138, DOI 10.1128/MCB.10.1.138; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; TAKAHASHI H, 1986, J UROLOGY, V135, P1280, DOI 10.1016/S0022-5347(17)46074-5; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; VAN LT, 1990, MOL ENDOCRINOL, V4, P268; WELLING L, 1991, KIDNEY, V2, P1657; WHITEHOUSE RW, 1980, EXPERIENTIA, V36, P244, DOI 10.1007/BF01953758; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429	34	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25213	25219		10.1074/jbc.270.42.25213	http://dx.doi.org/10.1074/jbc.270.42.25213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559658	hybrid			2022-12-25	WOS:A1995TB46500092
J	MORRIS, BJ				MORRIS, BJ			STIMULATION OF IMMEDIATE-EARLY GENE-EXPRESSION IN STRIATAL NEURONS BY NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS ADP-RIBOSYLATION; DEPENDENT PROTEIN-KINASE; RAT-BRAIN; NADPH-DIAPHORASE; NERVOUS-SYSTEM; MESSENGER-RNAS; C-FOS; CALCIUM; GMP; ACTIVATION	Exposure of primary cultures of embryonic rat striatal neurons to agents releasing nitric oxide (NO), including sin-1 molsidomine, S-nitroso-n-acetyl-penicillamine (SNAP), and S-nitrosoglutathione, resulted in an increase in the levels of expression of the immediate early genes c-fos and zif/268 in the cultured neurons. The membrane permeable cGMP analogue, 8-bromo-cGMP, did not significantly affect c-fos and zif/268 mRNA levels, and the highly selective inhibitor of cGMP dependent protein kinase, KT5823, was unable to inhibit the elevation in c-fos and zif/268 mRNA levels induced by SNAP. The induction of c-fos by the calcium ionophore A23187 was reduced by treatment with SNAP or 8-bromo-cGMP. Inhibitors of ADP-ribosyltransferases attenuated the stimulation of c-fos expression by SNAP. These results demonstrate for the first time that NO can induce immediate early gene expression in neurons, suggesting that NO may act as a mediator of neuronal plasticity via alterations in the expression of downstream genes. In addition, the results suggest that NO may exert these effects through a pathway that does not involve guanylate cyclase and cGMP-dependent protein kinase.			MORRIS, BJ (corresponding author), UNIV GLASGOW, INST BIOMED & LIFE SCI, PHARMACOL LABS, W MED BLDG, GLASGOW G12 8QQ, LANARK, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BANNON MJ, 1986, J BIOL CHEM, V261, P6640; BRUNE B, 1989, J BIOL CHEM, V264, P8455; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DRAGUNOW M, 1990, NEUROSCIENCE, V37, P287, DOI 10.1016/0306-4522(90)90399-O; DUMAN RS, 1991, J NEUROCHEM, V57, P2124, DOI 10.1111/j.1471-4159.1991.tb06431.x; EHRETHILBERER S, 1992, FEBS LETT, V309, P394, DOI 10.1016/0014-5793(92)80814-W; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GARG UC, 1991, J BIOL CHEM, V266, P9; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GRAYBIEL AM, 1986, NEUROPEPTIDES NEUROL, P135; HABY C, 1994, J NEUROCHEM, V62, P496; HOPE BT, 1989, J HISTOCHEM CYTOCHEM, V37, P653, DOI 10.1177/37.5.2703701; Ito M, 1990, Neuroreport, V1, P129; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P40, DOI 10.1016/0005-2736(92)90160-N; JOHNSTON HM, 1994, NEUROSCIENCE, V61, P435, DOI 10.1016/0306-4522(94)90423-5; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; KENDALL DA, 1984, J NEUROCHEM, V42, P1388, DOI 10.1111/j.1471-4159.1984.tb02799.x; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MERCHANT KM, 1989, BRAIN RES, V500, P21, DOI 10.1016/0006-8993(89)90295-3; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS BJ, 1989, J COMP NEUROL, V290, P358, DOI 10.1002/cne.902900305; MORRIS BJ, 1988, NEUROSCIENCE, V25, P525, DOI 10.1016/0306-4522(88)90256-4; OLIVA AM, 1995, NEUROREPORT, V6, P565, DOI 10.1097/00001756-199502000-00039; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POZDNYAKOV N, 1993, BIOCHEM BIOPH RES CO, V192, P610, DOI 10.1006/bbrc.1993.1459; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; ROBERTSON HA, 1989, BRAIN RES, V503, P346, DOI 10.1016/0006-8993(89)91689-2; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIMPSON CS, 1994, TISSUE CELL, V26, P929, DOI 10.1016/0040-8166(94)90042-6; SIMPSON CS, 1994, J NEUROCHEM, V63, P1955; SIMPSON CS, 1994, NEUROSCI LETT, V170, P281, DOI 10.1016/0304-3940(94)90338-7; SIMPSON CS, 1995, NEUROSCIENCE, V68, P97, DOI 10.1016/0306-4522(95)00122-Y; SMITH SS, 1993, MOL PHARMACOL, V43, P1; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SURMEIER DJ, 1988, DEV BRAIN RES, V42, P265, DOI 10.1016/0165-3806(88)90245-3; VACCARINO FM, 1992, MOL BRAIN RES, V12, P233, DOI 10.1016/0169-328X(92)90089-T; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; WILLIAMS MB, 1992, BRAIN RES, V592, P49, DOI 10.1016/0006-8993(92)91657-Z; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	47	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24740	24744						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559590				2022-12-25	WOS:A1995TB46500024
J	WILSON, LK; BENTON, BM; ZHOU, S; THORNER, J; MARTIN, GS				WILSON, LK; BENTON, BM; ZHOU, S; THORNER, J; MARTIN, GS			THE YEAST IMMUNOPHILIN FPR3 IS A PHYSIOLOGICAL SUBSTRATE OF THE TYROSINE-SPECIFIC PHOSPHOPROTEIN PHOSPHATASE PTP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; FK506-BINDING PROTEIN; FACTOR RECEPTOR; ALPHA-FACTOR; V-SRC; KINASE; THREONINE; SERINE; GENE	The tyrosine-specific phosphoprotein phosphatase encoded by the Saccharomyces cerevisiae PTP1 gene dephosphorylates artificial substrates in vitro, but little is known about its functions and substrates in vivo. The presence of Ptp1 resulted in dephosphorylation of multiple tyrosine-phosphorylated proteins in yeast expressing a heterologous tyrosine-specific protein kinase, indicating that Ptp1 can dephosphorylate a broad range of substrates in vivo. Correspondingly, several proteins phosphorylated at tyrosine by endogenous protein kinases exhibited a marked increase in tyrosine phosphorylation in ptp1 mutant cells. One of these phosphotyrosyl proteins (p70) was also dephosphorylated in vitro when incubated with recombinant Ptp1. p70 was purified to homogeneity; analysis of four tryptic peptides revealed that p70 is identical to the recently described FPR3 gene product, a nucleolarly localized proline rotamase of the FK506- and rapamycin-binding family. The identity of p70 with Fpr3 was confirmed in the demonstration that the abundance of tyrosine-phosphorylated p70 in ptp1 mutants was strictly correlated with the level of FPR3 expression; immobilized phosphotyrosyl Fpr3 was directly dephosphorylated by recombinant Ptp1. Site-directed mutagenesis demonstrated that the site of tyrosine phosphorylation is Tyr-184, which resides within the nucleolin-like amino-terminal domain of Fpr3. Protein kinase activities from yeast cell extracts can bind to and phosphorylate the immobilized aminoterminal domain of Fpr3 on serine, threonine, and tyrosine. Fpr3 represents the first phosphotyrosyl protein identified in S. cerevisiae that is not itself a protein kinase and is as yet the only known physiological substrate of Ptp1.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44143, GM21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOSCHELLI F, 1993, J CELL SCI, V105, P519; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Delidow B C, 1993, Methods Mol Biol, V15, P1, DOI 10.1385/0-89603-244-2:1; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLORIO M, 1994, MOL BIOL CELL, V5, P283, DOI 10.1091/mbc.5.3.283; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANNIG G, 1993, YEAST, V9, P1039, DOI 10.1002/yea.320091002; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; JAMES P, 1992, GENE, V122, P101, DOI 10.1016/0378-1119(92)90037-P; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIM MY, 1993, J BIOL CHEM, V268, P21155; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANNINGKRIEG UC, 1994, FEBS LETT, V352, P98, DOI 10.1016/0014-5793(94)00927-9; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NIELSEN JB, 1992, P NATL ACAD SCI USA, V89, P7471, DOI 10.1073/pnas.89.16.7471; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WAN J, 1992, J BIOL CHEM, V267, P11274; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029	52	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25185	25193		10.1074/jbc.270.42.25185	http://dx.doi.org/10.1074/jbc.270.42.25185			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559654	hybrid			2022-12-25	WOS:A1995TB46500088
J	BLACKBURN, MR; WAKAMIYA, M; CASKEY, CT; KELLEMS, RE				BLACKBURN, MR; WAKAMIYA, M; CASKEY, CT; KELLEMS, RE			TISSUE-SPECIFIC RESCUE SUGGESTS THAT PLACENTAL ADENOSINE-DEAMINASE IS IMPORTANT FOR FETAL DEVELOPMENT IN MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEOXYADENOSINE METABOLISM; S-ADENOSYLHOMOCYSTEINE; MOUSE; EXPRESSION; DEFICIENCY	Adenosine deaminase (ADA, EC 3.5.4.4) is an essential enzyme of purine metabolism that is expressed at very high levels in the murine placenta where it accounts for over 95% of the ADA present at the fetal gestation site. We have recently shown that ADA-deficient fetuses, which also lack ADA in their adjoining placentas, die during late fetal development in association with profound purine metabolic disturbances and hepatocellular impairment. We have now investigated the potential importance of placental ADA by genetically restoring the enzyme to placentas of ADA-deficient fetuses. This genetic engineering strategy corrected most of the purine metabolic disturbances, prevented serious fetal liver damage, and rescued the fetuses from perinatal lethality. Our findings suggest that placental ADA is important for murine fetal development and illustrate a general strategy for the tissue specific correction of phenotypes associated with null mutations in mice.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Blackburn, Michael/0000-0002-1394-9966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042436] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30302] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM42436] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARSON DA, 1980, J IMMUNOL, V124, P8; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; FINKELSTEIN JD, 1973, ARCH BIOCHEM BIOPHYS, V159, P160, DOI 10.1016/0003-9861(73)90440-2; GAO X, 1993, TERATOLOGY, V49, P1; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; Hogan B, 1994, MANIPULATING MOUSE E; JOHNSTON JM, 1979, J IMMUNOL, V123, P97; KASH SF, 1994, MOL CELL BIOL, V14, P6198, DOI 10.1128/MCB.14.9.6198; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; Naeye RL, 1992, DISORDERS PLACENTA F; STILES GL, 1992, J BIOL CHEM, V267, P6451; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; YEUNG CY, 1985, J BIOL CHEM, V260, P299	25	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23891	23894		10.1074/jbc.270.41.23891	http://dx.doi.org/10.1074/jbc.270.41.23891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592575	hybrid			2022-12-25	WOS:A1995TA21700003
J	WASSLER, M; ESNARD, F; FRIES, E				WASSLER, M; ESNARD, F; FRIES, E			POSTTRANSLATIONAL FOLDING OF ALPHA(1)-INHIBITOR-3 - EVIDENCE FOR A COMPACTION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; MACROGLOBULIN RAT ALPHA-1-INHIBITOR-3; ENDOPLASMIC-RETICULUM; HUMAN ALPHA-2-MACROGLOBULIN; LIMITED PROTEOLYSIS; ALPHA-MACROGLOBULINS; SECRETORY PROTEINS; BOND FORMATION; IN-VITRO; BIOSYNTHESIS	alpha(1)-Inhibitor 3 (alpha(1)I(3)) is a rodent-specific proteinase inhibitor of about 190 kDa belonging to the alpha(2)-macroglobulin family. It consists of five globular domains, three of which are connected by disulfide bridges, and contains an intramolecular thiol ester which can react with attaching proteinases. To explore the folding of newly synthesized alpha(1)I(3), We have used rat hepatocytes and pulse-chase experiments. In one of the analyses, the radiolabeled protein was isolated from cell lysates by immunoprecipitation and its Asp-Pro bonds cleaved by treatment with formic acid. The size of the major fragment, as assessed by electrophoresis under nonreducing conditions, was found to increase from 100 to 150 kDa upon the chasing. This result, together with knowledge of the positions of the cleavage sites and the disulfide arrangement, indicates that one of the interdomain disulfide bonds is formed after the synthesis of the polypeptide. Analysis of the same material by limited proteolysis and by velocity centrifugation showed that the folded regions became larger and that the protein became more compact; the thiol ester was found to be formed after these conformational changes. These results suggest that the domains of alpha(1)I(3) are only partially developed directly after the synthesis of the polypeptide and that they acquire their final structure as the protein condenses and the domains interact with one another.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; UNIV TOURS,BIOCHEM LAB,F-37032 TOURS,FRANCE	Uppsala University; Universite de Tours								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ESNARD F, 1980, BIOCHIM BIOPHYS ACTA, V614, P553, DOI 10.1016/0005-2744(80)90244-2; ESNARD F, 1985, FEBS LETT, V182, P125, DOI 10.1016/0014-5793(85)81168-6; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GEIGER T, 1987, BIOCHEM J, V245, P493, DOI 10.1042/bj2450493; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARPEL PC, 1979, J BIOL CHEM, V254, P8669; HOWARD JB, 1980, J BIOL CHEM, V255, P3820; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IKAI A, 1990, FEBS LETT, V260, P291, DOI 10.1016/0014-5793(90)80126-4; ISAAC L, 1992, J BIOL CHEM, V267, P10062; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KARP DR, 1983, J BIOL CHEM, V258, P4490; Landon, 1977, Methods Enzymol, V47, P145; LAW SKA, 1990, BIOCHEM SOC T, V18, P1155; LILIE H, 1994, J BIOL CHEM, V269, P14290; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LORIMER GH, 1992, CURR OPIN STRUC BIOL, V2, P26; MARQUARDT T, 1993, J BIOL CHEM, V268, P19619; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PETERS T, 1982, J BIOL CHEM, V257, P8847; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; RUBENSTEIN DS, 1991, J BIOL CHEM, V266, P11252; RUCHEL R, 1974, H-S Z PHYSIOL CHEM, V355, P997, DOI 10.1515/bchm2.1974.355.2.997; SAITO A, 1985, J BIOCHEM-TOKYO, V98, P501, DOI 10.1093/oxfordjournals.jbchem.a135305; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SJOBERG M, 1991, EUR J BIOCHEM, V197, P61, DOI 10.1111/j.1432-1033.1991.tb15882.x; SONDEREGGER P, 1982, ANAL BIOCHEM, V122, P298, DOI 10.1016/0003-2697(82)90285-8; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STELLWAGEN E, 1962, BIOCHEMISTRY-US, V1, P1056, DOI 10.1021/bi00912a016; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; WASSLER M, 1987, BIOCHEM J, V247, P407, DOI 10.1042/bj2470407	42	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24598	24603		10.1074/jbc.270.41.24598	http://dx.doi.org/10.1074/jbc.270.41.24598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592680	hybrid			2022-12-25	WOS:A1995TA21700108
J	BARNIER, JV; PAPIN, C; EYCHENE, A; LECOQ, O; CALOTHY, G				BARNIER, JV; PAPIN, C; EYCHENE, A; LECOQ, O; CALOTHY, G			THE MOUSE B-RAF GENE ENCODES MULTIPLE PROTEIN ISOFORMS WITH TISSUE-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE CODING SEQUENCE; SERINE THREONINE KINASE; GROWTH-FACTOR; C-MIL; ONCOGENE; IDENTIFICATION; PROTOONCOGENE; FAMILY; CELLS; ORGANIZATION	The c-Rmil/B raf proto-oncogene is a member of the mil/raf family encoding serine/threonine protein kinases shown to be involved in signal transduction from the membrane to the nucleus. We isolated from a mouse brain library B-raf cDNAs containing a previously unidentified 36-base pair alternatively spliced exon located between exons 8 and 9 and, therefore, designated exon 8b. Human and mouse B raf mRNAs also contain the 120-base pair alternatively spliced exon 10 previously described in the avian c-Rmil gene. Independent splicing of these two exons, located between the conserved region 2 (CR2) and the catalytic domain (CR3) gives rise to mRNAs potentially encoding four distinct proteins. By using specific sera generated against different portions of B-Raf, we identified at least 10 protein isoforms in adult mouse tissues. Some isoforms, in the range of 69-72 kDa, are not recognized by antisera directed against peptides encoded by exons 1 and 2, indicating the existence of B-Raf proteins with two different NH2 extremities. The other isoforms, in the range of 79-99 kDa, contain the amino acids encoded by exons 1 and 2, by either or both of the alternatively spliced exons, and, possibly, by another unidentified exon. Analysis of B-raf mRNA expression by reverse transcriptase polymerase chain reaction and immunocharacterization of B-Raf proteins in different tissues of the adult mouse showed a tissue-specific pattern of B-Raf isoforms expression. Interestingly, isoforms containing amino acids encoded by exon 10 are specifically expressed in neural tissues. Taken together, these results suggest that distinct B-Raf proteins could be involved, in a tissue-specific manner, in signal transduction pathways.			BARNIER, JV (corresponding author), CTR UNIV ORSAY,INST CURIE BIOL,LAB 110,CNRS,UNITE MIXTE RECH 146,F-91405 ORSAY,FRANCE.		Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225; Barnier, Jean-Vianney/0000-0002-2182-0900				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; DOZIER C, 1991, ONCOGENE, V6, P1307; EYCHENE A, 1992, ONCOGENE, V7, P1657; EYCHENE A, 1995, ONCOGENE, V10, P1159; EYCHENE A, 1992, ONCOGENE, V7, P1315; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HARLOW E, 1988, ANTIBODIES LABORATOR; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MIHALY A, 1993, BRAIN RES, V627, P225, DOI 10.1016/0006-8993(93)90325-H; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAPIN C, 1995, ONCOGENE, V10, P1647; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RAPP UR, 1991, ONCOGENE, V6, P495; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; Sambrook J, 1989, MOL CLONING LABORATO; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	132	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23381	23389		10.1074/jbc.270.40.23381	http://dx.doi.org/10.1074/jbc.270.40.23381			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559496	Green Published, hybrid			2022-12-25	WOS:A1995RY90900025
J	LIESSEM, B; GLOMBITZA, GJ; KNOLL, F; LEHMANN, J; KELLERMANN, J; LOTTSPEICH, F; SANDHOFF, K				LIESSEM, B; GLOMBITZA, GJ; KNOLL, F; LEHMANN, J; KELLERMANN, J; LOTTSPEICH, F; SANDHOFF, K			PHOTOAFFINITY-LABELING OF HUMAN LYSOSOMAL BETA-HEXOSAMINIDASE-B - IDENTIFICATION OF GLU-355 AT THE SUBSTRATE BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-FIBROBLASTS; ESCHERICHIA-COLI; ACTIVE-SITE; D-GALACTOSIDASE; ALPHA-SUBUNITS; PRO-ALPHA; ENZYME; GM2; PURIFICATION; PROTEINS	The carbene precursor 3-azi-1-[([6-H-3]-2-acetamido-2-adeoxy-1- beta-D-galactopyranosyl)thio]-butane (also designated [H-3]-1-ATB-GalNAc) has been used as a photoaffinity label for human lysosomal beta-hexosaminidase B (Hex B, EC 3.2.1.52) purified to apparent homogeneity from postmortal liver, [H-3]-1-ATB-GalNAc behaved as an active site-directed inhibitor, which bound covalently to Hex B upon photolysis at 350 nm and resulted in 15% inactivation of enzyme activity. Up to 75% of the inactivation of Hex B was prevented by including the competitive inhibitor 2-acetamido-2-deoxy-D-glucono-1,5-lactone in the photoaffinity experiment. Incubation of [H-3]-1-ATB-GalNAc with the enzyme followed by irradiation and subsequent separation of the three polypeptides composing the beta-subunit led mainly to labeling of the beta(a)-polypeptide. Subsequent proteolysis of beta(a) with trypsin and separation of the resulting peptides by high pressure liquid chromatography yielded one prominently labeled peptide fraction. Edman degradation resulted in the sequence E(339)ISEVFPDQFIHLGGDEVEFK(359). However, no modified amino acid was detected, indicating that the photoaffinity label was presumably bound to the peptide by a labile ester linkage. This was proven when the radiolabel was almost completely released from the peptide by treatment with aqueous ammonium hydroxide. Simultaneously, Glu-355 was converted into Gln-355, which is located within a region of Hex B that shows considerable homology with the alpha-subunit of human hexosaminidase A and other hexosaminidases from various species.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; UNIV FREIBURG,INST ORGAN CHEM & BIOCHEM,D-79104 FREIBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Bonn; University of Freiburg; Max Planck Society								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CA, 1991, J BIOL CHEM, V266, P15855; BURG J, 1983, H-S Z PHYSIOL CHEM, V364, P821, DOI 10.1515/bchm2.1983.364.2.821; CHURCH WB, 1992, J MOL BIOL, V227, P557; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GEIGER B, 1977, AM J HUM GENET, V29, P508; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; HILLENKAMP F, 1988, ANAL CHEM, V60, P2299; HUBBES M, 1989, FEBS LETT, V249, P316, DOI 10.1016/0014-5793(89)80649-0; KUHN CS, 1987, CARBOHYD RES, V160, pC6, DOI 10.1016/0008-6215(87)80332-4; KUHN CS, 1992, CARBOHYD RES, V232, P227, DOI 10.1016/0008-6215(92)80056-7; KUHN CS, 1992, BIOCONJUGATE CHEM, V3, P230, DOI 10.1021/bc00015a005; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LAI ECK, 1994, BIOCHEMISTRY-US, V33, P14743, DOI 10.1021/bi00253a012; LEGLER G, 1991, BIOCHIM BIOPHYS ACTA, V1080, P89, DOI 10.1016/0167-4838(91)90133-K; LEHMANN J, 1993, CARBOHYD RES, V239, P133, DOI 10.1016/0008-6215(93)84209-O; LIESSEM B, 1993, CARBOHYD RES, V250, P19, DOI 10.1016/0008-6215(93)84151-U; LITTLE LE, 1988, J BIOL CHEM, V263, P4288; MAHURAN D, 1980, CAN J BIOCHEM CELL B, V58, P287, DOI 10.1139/o80-038; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; POKORNY M, 1974, CARBOHYD RES, V37, P321, DOI 10.1016/S0008-6215(00)82921-3; PROIA RL, 1984, J BIOL CHEM, V259, P3350; QUON DVK, 1989, J BIOL CHEM, V264, P3380; SAGHERIAN C, 1993, BIOCHEM CELL BIOL, V71, P340, DOI 10.1139/o93-051; SANDHOFF K, 1979, HUM GENET, V50, P107, DOI 10.1007/BF00390234; SANDHOFF K, 1977, H-S Z PHYSIOL CHEM, V358, P779, DOI 10.1515/bchm2.1977.358.2.779; SANDHOFF K, 1971, J NEUROCHEM, V18, P2469, DOI 10.1111/j.1471-4159.1971.tb00204.x; SANDHOFF K, 1971, HOPPESEYLERS Z PHYSL, V358, P1119; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERWE M, 1993, EUR J BIOCHEM, V211, P341, DOI 10.1111/j.1432-1033.1993.tb19903.x; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SOMERVILLE CC, 1993, P NATL ACAD SCI USA, V90, P6751, DOI 10.1073/pnas.90.14.6751; SONDERFELDFRESK.S, 1988, J BIOL CHEM, V263, P13463; SUZUKI K, 1991, DEV NEUROSCI-BASEL, V13, P288, DOI 10.1159/000112175; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; WITHERS SG, 1995, PROTEIN SCI, V4, P361	38	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23693	23699		10.1074/jbc.270.40.23693	http://dx.doi.org/10.1074/jbc.270.40.23693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559539	hybrid			2022-12-25	WOS:A1995RY90900068
J	OLSON, AL; PESSIN, JE				OLSON, AL; PESSIN, JE			TRANSCRIPTIONAL REGULATION OF THE HUMAN GLUT4 GENE PROMOTER IN DIABETIC TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; INSULIN-SENSITIVE TISSUES; RAT ADIPOSE CELL; SKELETAL-MUSCLE; MESSENGER-RNA; DIFFERENTIAL REGULATION; PLASMA-MEMBRANE; WHITE MUSCLE; EXPRESSION; TRANSLOCATION	We previously reported that 2400 base pairs (bp) of 5'-flanking DNA is sufficient for tissue-specific and hormonal/metabolic regulation of the human GLUT4 gene in transgenic mice (Liu, M.-L., Olson, A, L., Moye-Rowley, W. S., Buse, J. B., Bell, G. I., and Pessin, J. E. (1992) J. Biol, Chem, 267, 11673-11676), To further define the DNA sequences required for GLUT4 expression, we generated transgenic mice carrying 1975, 1639, 1154, 730, and 412 bp of the GLUT4 5'-flank (hG4) fused to the chloramphenicol acetyltransferase (CAT) reporter gene, The 1975-hG4-CAT, 1639-hG4-CAT, and 1154-hG4-CAT constructs were expressed in a tissue specific manner identical to the endogenous murine GLUT4 mRNA. Regulation of these reporter gene constructs in insulin-deficient diabetes also paralleled the endogenous gene, In contrast, 730-hG4-CAT was expressed at high levels only in skeletal muscle and at low levels in all of the other tissues examined, Additionally, expression of 412-hG4-CAT was completely unrestricted, Neither the 730-hG4-CAT nor the 412-hG4-CAT reporter genes displayed any insulin-dependent regulation, These data demonstrate that a skeletal muscle-specific DNA element is located within 730 bp of the GLUT4 5'-flanking DNA but that 1154 bp is necessary to direct the full extent of tissue-specific and insulin-dependent regulation of the human GLUT4 gene in transgenic mice.			OLSON, AL (corresponding author), UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242, USA.				NIDDK NIH HHS [DK47894, DK49012, DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R01DK047894, R55DK047894, R01DK049012] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1993, J BIOL CHEM, V268, P19161; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GARVEY WT, 1991, J CLIN INVEST, V87, P172; GERRITS PM, 1993, J BIOL CHEM, V268, P640; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KORANYI LI, 1991, DIABETOLOGIA, V34, P763, DOI 10.1007/BF00401526; LAWRENCE JC, 1992, P NATL ACAD SCI USA, V89, P3493, DOI 10.1073/pnas.89.8.3493; LEMARCHANDBRUST.Y, 1990, ENDOCRINOLOGY, V127, P2687; LIU ML, 1994, J BIOL CHEM, V269, P28514; LIU ML, 1992, J BIOL CHEM, V267, P11673; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OLSON AL, 1990, PEDIATR RES, V28, P183, DOI 10.1203/00006450-199009000-00001; OLSON AL, 1993, J BIOL CHEM, V268, P9839; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REN JM, 1993, J BIOL CHEM, V268, P16113; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SIVITZ WI, 1990, MOL ENDOCRINOL, V4, P583, DOI 10.1210/mend-4-4-583; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	40	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23491	23495		10.1074/jbc.270.40.23491	http://dx.doi.org/10.1074/jbc.270.40.23491			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559512	hybrid			2022-12-25	WOS:A1995RY90900041
J	VERA, JC; RIVAS, CI; VELASQUEZ, FV; ZHANG, RH; CONCHA, II; GOLDE, DW				VERA, JC; RIVAS, CI; VELASQUEZ, FV; ZHANG, RH; CONCHA, II; GOLDE, DW			RESOLUTION OF THE FACILITATED TRANSPORT OF DEHYDROASCORBIC ACID FROM ITS INTRACELLULAR ACCUMULATION AS ASCORBIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; VITAMIN-C UPTAKE; MEMBRANE-VESICLES; HUMAN-NEUTROPHILS; EPITHELIAL-CELLS; 3T6 FIBROBLASTS; SMALL-INTESTINE; CYTOCHALASIN-B; GLUCOSE; REDUCTASE	We performed a detailed kinetic analysis of the uptake of dehydroascorbic acid by HL-60 cells under experimental conditions that enabled the differentiation of dehydroascorbic acid transport from the intracellular reduction/accumulation of ascorbic acid. Immunoblotting and immunolocalization experiments identified GLUT1 as the main glucose transporter expressed in the HL-60 cells. Kinetic analysis allowed the identification of a single functional activity involved in the transport of dehydroascorbic acid in the HL-60 cells. Transport was inhibited in a competitive manner by both 3-O-methyl-D-glucose and 2-deoxy-D-glucose. In turn, dehydroascorbic acid competitively inhibited the transport of both sugars. A second functional component identified in experiments measuring the accumulation of ascorbic acid appears to be associated with the intracellular reduction of dehydroascorbic acid to ascorbic acid and is not directly involved in the transport of dehydroascorbic acid via GLUT1. Transport of dehydroascorbic acid by HL-60 ells was independent of the presence of external Na+, whereas the intracellular accumulation of ascorbic acid was found to be a Na+-sensitive process. Thus, the transport of dehydroascorbic acid via glucose transporters is a Na+-independent process which is kinetically and biologically separable from the reduction of dehydroascorbic acid to ascorbic acid and its subsequent intracellular accumulation.	UNIV AUSTRAL CHILE, INST BIOCHIM, VALDIVIA, CHILE	Universidad Austral de Chile	VERA, JC (corresponding author), MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA030388, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748, R01 CA30388] Funding Source: Medline; NHLBI NIH HHS [R01 HL42107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON R, 1983, CANCER RES, V43, P4696; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BIANCHI J, 1986, P SOC EXP BIOL MED, V181, P333; BIANCHI J, 1985, BIOCHIM BIOPHYS ACTA, V820, P265, DOI 10.1016/0005-2736(85)90120-8; BIGLEY R, 1981, BIOCHIM BIOPHYS ACTA, V659, P15, DOI 10.1016/0005-2744(81)90266-7; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; BODE AM, 1990, CLIN CHEM, V36, P1807; BODE AM, 1993, CURR EYE RES, V12, P593, DOI 10.3109/02713689309001838; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CHOI JL, 1989, AM J PHYSIOL, V257, pC110, DOI 10.1152/ajpcell.1989.257.1.C110; DILIBERTO EJ, 1983, J BIOL CHEM, V258, P2886; DIMATTIO J, 1989, EXP EYE RES, V49, P873, DOI 10.1016/S0014-4835(89)80046-6; DYER DL, 1994, AM J PHYSIOL, V267, pC301, DOI 10.1152/ajpcell.1994.267.1.C301; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; FAY MJ, 1990, LIFE SCI, V46, P619, DOI 10.1016/0024-3205(90)90130-J; FINN FM, 1980, ENDOCRINOLOGY, V106, P811, DOI 10.1210/endo-106-3-811; HELBIG H, 1989, AM J PHYSIOL, V256, pC44, DOI 10.1152/ajpcell.1989.256.1.C44; HODGES RE, 1969, AM J CLIN NUTR, V22, P535; INGERMANN RL, 1986, AM J PHYSIOL, V250, pC637, DOI 10.1152/ajpcell.1986.250.4.C637; KAPEGHIAN JC, 1984, LIFE SCI, V34, P577, DOI 10.1016/0024-3205(84)90491-0; KHATAMI M, 1986, INVEST OPHTH VIS SCI, V27, P1665; LAM KW, 1993, OPHTHALMIC RES, V25, P100, DOI 10.1159/000267272; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; MARTENSSON J, 1993, P NATL ACAD SCI USA, V90, P317, DOI 10.1073/pnas.90.1.317; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MOORADIAN AD, 1987, DIABETES, V36, P1001, DOI 10.2337/diabetes.36.9.1001; MRTENSSON J, 1991, P NATL ACAD SCI USA, V88, P4656, DOI 10.1073/pnas.88.11.4656; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; OKAMURA M, 1979, J NUTR SCI VITAMINOL, V25, P269, DOI 10.3177/jnsv.25.269; PADH H, 1990, BIOCHEM CELL BIOL, V68, P1166, DOI 10.1139/o90-173; PADH H, 1987, BIOCHIM BIOPHYS ACTA, V901, P283, DOI 10.1016/0005-2736(87)90125-8; PADH H, 1985, CELL BIOL INT REP, V9, P531, DOI 10.1016/0309-1651(85)90017-7; PADH H, 1989, J BIOL CHEM, V264, P6065; PATTERSON LT, 1982, LIFE SCI, V31, P2783, DOI 10.1016/0024-3205(82)90725-1; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; SILBER R, 1992, BLOOD, V80, P2038; SILIPRANDI L, 1979, BIOCHIM BIOPHYS ACTA, V552, P129, DOI 10.1016/0005-2736(79)90252-9; STAHL RL, 1985, CANCER RES, V45, P6507; STAHL RL, 1985, BIOCHIM BIOPHYS ACTA, V839, P119, DOI 10.1016/0304-4165(85)90189-8; STANKOVA L, 1991, GEN PHARMACOL, V22, P903, DOI 10.1016/0306-3623(91)90228-X; TIRRELL JG, 1979, NEUROSCIENCE, V4, P181, DOI 10.1016/0306-4522(79)90227-6; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WILSON JX, 1989, J MEMBRANE BIOL, V111, P83, DOI 10.1007/BF01869211; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5; WINKLER BS, 1992, BIOCHIM BIOPHYS ACTA, V1117, P287, DOI 10.1016/0304-4165(92)90026-Q; WRIGHT EM, 1992, ACTA PHYSIOL SCAND, V146, P201; ZHOU A, 1991, BIOCHEM J, V274, P739, DOI 10.1042/bj2740739	54	152	152	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23706	23712		10.1074/jbc.270.40.23706	http://dx.doi.org/10.1074/jbc.270.40.23706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559541	hybrid			2022-12-25	WOS:A1995RY90900070
J	WAITE, LL; COX, MM				WAITE, LL; COX, MM			A PROTEIN DISSOCIATION STEP LIMITS TURNOVER IN FLP RECOMBINASE-MEDIATED SITE-SPECIFIC RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								When two ongoing FLP-mediated recombination reactions are mixed, formation of cross-products is subject to a lag of several minutes, and the subsequent rate of cross-product formation is greatly reduced relative to normal reaction progress curves. The lag reflects the formation of a stable complex containing multiple FLP monomers and two FLP recombination target-containing DNA recombination products, a process completed within 5-10 min after addition of FLP recombinase to a reaction mixture. The reaction products are sequestered within this complex for an extended period of time, unavailable for further reaction. The length of the lag increases with increasing FLP protein concentration and is not affected by the introduction of unreacted (non FLP-bound) substrate. The results provide evidence that disassembly of FLP complexes from products occurs in a minimum of two steps. At least one FLP protein monomer is released from reaction complexes in a discrete step that leaves the reaction products sequestered. The recombination products are released in a form free to react with other FLP recombination target-containing DNA molecules only after at least one additional disassembly step. One or both of these disassembly steps are rate limiting for reaction turnover under conditions often used to monitor FLP-mediated recombination in vitro.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM37835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEATTY LG, 1908, J BIOL CHEM, V204, P283; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COX MM, 1988, GENETIC RECOMBINATIO, V1, P429; CRAIG NL, 1988, ANNU REV GENET, V22, P77; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GATES CA, 1988, P NATL ACAD SCI USA, V85, P4628, DOI 10.1073/pnas.85.13.4628; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; IYPE LE, 1995, THESIS WISCONSIN MAD; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; PAN G, 1991, MOL CELL BIOL, V13, P3167; QIAN XH, 1990, J BIOL CHEM, V265, P21779; SADOWSKI P, 1989, J BACTERIOL, V165, P341; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ CJ, 1989, J MOL BIOL, V205, P6547; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380	21	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23409	23414		10.1074/jbc.270.40.23409	http://dx.doi.org/10.1074/jbc.270.40.23409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559500	hybrid			2022-12-25	WOS:A1995RY90900029
J	KATZAV, S; PACKHAM, G; SUTHERLAND, M; AROCA, P; SANTOS, E; CLEVELAND, JL				KATZAV, S; PACKHAM, G; SUTHERLAND, M; AROCA, P; SANTOS, E; CLEVELAND, JL			VAV AND RAS INDUCE FIBROBLAST TRANSFORMATION BY OVERLAPPING SIGNALING PATHWAYS, WHICH REQUIRE C-MYC FUNCTION	ONCOGENE			English	Article						VAV; VAS; C-MYC; SH2	TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; ORNITHINE DECARBOXYLASE; HEMATOPOIETIC-CELLS; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; SH2 DOMAIN; PROTEIN; EXPRESSION; KINASE	Recent evidence has suggested that the Vav oncoprotein may function as a hematopoietic-specific GTP exchange factor for the Ras superfamily of proteins, However, transformation of NIH3T3 fibroblast cells by Vav is morphologically distinct from that induced by activated Ras oncogenes, suggesting that the two oncoproteins induce separate signal transduction pathways which promote transformation, To address this issue, the effects of dominant negative mutants of H-ras and proto-Vav (proto-VavR695L, a mutation in the VavSH2 domain) were tested on Vav- and Ras-induced transformation, These mutants partially inhibited both Vav- and Ras-induced transformation, suggesting that they may induce a common downstream signaling pathway which potentiates transformation, As an independent measure of Vav function we also tested the ability of the purified protein encoded by VavSH2 to influence Germinal Vesicle Breakdown (GVBD) during Xenopus oocyte maturation, Microinjection of the VavSH2 protein alone, but not mutant VavR695L SH2 protein, was sufficient to induce GVBD and accelerated maturation induced by normal Ras, suggesting that in this system as well Vav and Ras signals overlap through a common effector, A key target of multiple signalling pathways is c-Myc. Dominant negative versions of c-Myc totally abolished morphologic transformation of NIH3T3 cells by both Vav and Ras oncogenes, These results suggest that distinct, but overlapping, signalling pathways are induced by Vav and Ras and that fibroblast cell transformation by either oncogene requires c-Myc functions.	MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	McGill University; McGill University; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tennessee System; University of Tennessee Health Science Center	KATZAV, S (corresponding author), MCGILL UNIV, JEWISH GEN HOSP, LADY DAVIS INST MED RES, TERRY FOX MOLEC ONCOL GRP, MONTREAL, PQ H3T 1E2, CANADA.			Aroca, Pilar/0000-0002-7557-6931	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTINO M, 1991, SCIENCE, V253, P565; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BUSTELO XR, 1992, NATURE, V356, P69; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P2095, DOI 10.1021/bi00007a002; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MIN SY, 1994, CELL GROWTH DIFFER, V5, P563; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MURKHERJEE B, 1992, GENE DEV, V6, P1480; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; NEBREDA AR, 1993, ONCOGENE, V8, P467; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRENDERGAST GC, 1991, CELL, V65, P186; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAVIGIAN SV, 1994, MOL CELL BIOL WAGNJ, V5, P375; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629	84	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1079	1088						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566967				2022-12-25	WOS:A1995RX18000010
J	NATOLI, G; IANNI, A; COSTANZO, A; DEPETRILLO, G; ILARI, I; CHIRILLO, P; BALSANO, C; LEVRERO, M				NATOLI, G; IANNI, A; COSTANZO, A; DEPETRILLO, G; ILARI, I; CHIRILLO, P; BALSANO, C; LEVRERO, M			RESISTANCE TO FAS-MEDIATED APOPTOSIS IN HUMAN HEPATOMA-CELLS	ONCOGENE			English	Article						FAS; SOLUBLE FAS; ALTERNATIVE SPLICING; APOPTOSIS; PROTEIN SYNTHESIS INHIBITORS	TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; PROTEIN; DNA; EXPRESSION; INDUCTION; MEMBER	CTLs- and lymphokine-induced apoptosis of infected hepatocytes during the course of chronic viral hepatitis is thought to be important for both disease termination and prevention of hepatocellular transformation, We therefore studied apoptosis induced by Pas (APO-1 or CD95) - a widely expressed cell surface receptor whose ligand is involved in lymphocyte cytotoxicity - in a set of human hepatoma cell lines. As normal hepatocytes, all of the human hepatoma cell lines tested do express detectable amounts of Fas on their surface. Nevertheless, only PLC/PRF/5 cells undergo apoptosis following treatment with anti-Fas. Systematic cloning and sequence analysis of the Pas cDNA did not show mutations in the Pas gene in any of the cells lines tested, However, due to alternative splicing, 5 to 10% of the Fas cDNAs are deleted of 63 internal nucleotides corresponding to the transmembrane domain, thus encoding for a soluble and secreted form of Fas (Fas Delta TM), potentially able to neutralize anti-Fas or Fas-Ligand. Although we could not demonstrate a direct correlation between resistance of different hepatoma cell lines to Pas mediated death and endogenous expression of this transcript, we show that PLC/PRF 5 stable transfectants overexpressing Fas Delta TM are less sensitive to anti-Pas than control cells, Tn three different cell lines, resistance to anti-Pas was overcome by treatment with the protein synthesis inhibitor cyclohexymide, Although this could suggest the existence of short-lived repressors of the Fas-activated apoptotic signalling pathway(s), we show that translational inhibition is not required for the synergistic effect of cycloheximide to take place, and that resistant hepatoma cells can be sensitized to anti-Pas by subinhibitory concentrations of this protein synthesis inhibitor. Since cycloheximide is able to activate intracellular signalling independently on its effects on protein sysnthesis, we suggest that it might provide a costimulatory signal that cooperates with Fas in the induction of cell death and that, at least in the cells we tested, resistance to Fas is not an active process involving gene transciption and translation but only the consequence of an inadequate apoptotic stimulation.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,IST CLIN MED 1,I-00161 ROME,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,LAQUILA,ITALY; UNIV CAGLIARI,IST MED INTERNA,CAGLIARI,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of Cagliari	NATOLI, G (corresponding author), UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Costanzo, Antonio/D-3896-2012; Natoli, gioacchino/J-2100-2018; Costanzo, Antonio/GZG-2433-2022; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Levrero, Massimo/0000-0002-4978-0875				ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CRISPE IN, 1994, IMMUNITY, V1, P347; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1979, LANCET, V2, P827; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; MORIMOTO H, 1993, CANCER RES, V53, P2591; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OSAWA H, 1986, EUR J IMMUNOL, V16, P467, DOI 10.1002/eji.1830160426; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Popper H., 1988, LIVER BIOL PATHOBIOL, P1087; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHALL TJ, 1990, CELL, V61, P361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALLACH D, 1984, J IMMUNOL, V132, P2464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	38	147	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1157	1164						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566976				2022-12-25	WOS:A1995RX18000019
J	OUCHIDA, M; OHNO, T; FUJIMURA, Y; RAO, VN; REDDY, ESP				OUCHIDA, M; OHNO, T; FUJIMURA, Y; RAO, VN; REDDY, ESP			LOSS OF TUMORIGENICITY OF EWINGS-SARCOMA CELLS EXPRESSING ANTISENSE RNA TO EWS-FUSION TRANSCRIPTS	ONCOGENE			English	Article						EWINGS SARCOMA; THERAPY; RNA BINDING; ETS; EWS	ETS-RELATED GENE; CHROMOSOMAL TRANSLOCATIONS; DNA-BINDING; FLI-1; ERG; PROTEIN; ACTIVATION; FAMILY; LIPOSARCOMA; LEUKEMIA	Cytogenetic analysis of Ewing's sarcoma, primitive neuroectodermal tumors and Askin tumors revealed characteristic translocations t(11;22) or t(21;22). Molecular analysis of these translocations revealed S-region of EWS gene (from band 22q12) is fused to the 3'-region of either Fli-1 gene (from band 11q24) or erg gene (from band 21q22). Functional characterization of the EWS-Fli-1 and EWS-erg chimeric proteins suggested that they function as transcriptional activators. In order to develop therapeutic agents, it is essential to know whether expression of the EWS-fusion gene products is coupled to tumorigenicity of Ewing's sarcoma cells and if targeting the EWS-fusion products results in loss of tumorigenicity of Ewing's sarcoma cells. For this reason, we have made stable Ewing's sarcomas expressing antisense EWS-Fli-1 or EWS-erg transcripts by transfecting the antisense EWS-Fli-1 or EWS-erg expression plasmids. Expression of antisense EWS fusion transcripts resulted in a significant loss of endogenous EWS-Fli-1 and EWS-erg proteins in Ewing's sarcoma cells. These cells expressing antisense EWS fusion transcripts showed loss of anchorage independent growth and tumorigenicity in nude mice unlike the parental Ewing's sarcoma cells. These results demonstrate the necessity of a certain threshold level of expression of EWS-fusion products in the clonogenicity and tumorigenicity of Ewing's sarcoma cells and therefore emphasizes the importance of targeting the EWS-fusion products as a therapy for Ewing family of tumors.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057157, P01CA051083] Funding Source: NIH RePORTER; NCI NIH HHS [CA58642, CA51083, CA57157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOYD JA, 1994, MOL IMMUNOLOGIC APPR; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V369, P162; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LADANYI M, 1994, CANCER RES, V54, P2837; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	122	135	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1049	1054						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566963				2022-12-25	WOS:A1995RX18000006
J	SCHERER, PE; WILLIAMS, S; FOGLIANO, M; BALDINI, G; LODISH, HF				SCHERER, PE; WILLIAMS, S; FOGLIANO, M; BALDINI, G; LODISH, HF			A NOVEL SERUM-PROTEIN SIMILAR TO C1Q, PRODUCED EXCLUSIVELY IN ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUCOSE-TRANSPORT PROTEIN; PLASMA-MEMBRANE; CELL-LINE; INSULIN; RECEPTORS; REDISTRIBUTION; IDENTIFICATION; EXPRESSION; SEQUENCES; TISSUES	We describe a novel 30-kDa secretory protein, Acrp30 (adipocyte complement-related protein of <(30)under bar> kDa), that is made exclusively in adipocytes and whose mRNA is induced over 100-fold during adipocyte differentiation. Acrp30 is structurally similar to complement factor Clq and to a hibernation-specific protein isolated from the plasma of Siberian chipmunks; it forms large homo-oligomers that undergo a series of post-translational modifications, Like adipsin, secretion of Acrp30 is enhanced by insulin, and Acrp30 is an abundant serum protein. Acrp30 may be a factor that participates in the delicately balanced system of energy homeostasis involving food intake and carbohydrate and lipid catabolism. Our experiments also further corroborate the existence of an insulin regulated secretory pathway in adipocytes.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; PFIZER INC,CENT RES,GROTON,CT 06340; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Pfizer; Massachusetts Institute of Technology (MIT)			Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NIDDK NIH HHS [DK 47618] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618, R01DK047618] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; CORVERA S, 1989, J BIOL CHEM, V264, P10133; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FLOROS J, 1986, J BIOL CHEM, V261, P9029; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; GEPPERT M, 1994, NATURE, V369, P498; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P88; KONDO N, 1992, J BIOL CHEM, V267, P473; MOORE HPH, 1988, NATURE, V302, P434; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; RESNICK D, 1993, J BIOL CHEM, V268, P3538; SAMBANIS A, 1990, BIOTECHNOL BIOENG, V35, P771, DOI 10.1002/bit.260350804; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	2483	2730	3	98	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26746	26749		10.1074/jbc.270.45.26746	http://dx.doi.org/10.1074/jbc.270.45.26746			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592907	hybrid			2022-12-25	WOS:A1995TE58300007
J	SILENCE, K; HARTMANN, M; GUHRS, KH; GASE, A; SCHLOTT, B; COLLEN, D; LIJNEN, HR				SILENCE, K; HARTMANN, M; GUHRS, KH; GASE, A; SCHLOTT, B; COLLEN, D; LIJNEN, HR			STRUCTURE-FUNCTION-RELATIONSHIPS IN STAPHYLOKINASE AS REVEALED BY CLUSTERED CHARGE TO ALANINE MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT STAPHYLOKINASE; HUMAN PLASMINOGEN; THROMBOLYTIC PROPERTIES; ACTIVATION; ALPHA-2-ANTIPLASMIN; MECHANISM; FIBRIN; STREPTOKINASE; PURIFICATION; EXPRESSION	Eighteen mutants of recombinant staphylokinase (SakSTAR) in which clusters of two or three charged residues were converted to alanine (''clustered charge-to-alanine scan'') were characterized, Fifteen of these mutants had specific plasminogen-activating activities of >20% of that of wild-type SakSTAR, whereas three mutants, SakSTAR K11A D13A D14A (SakSTAR13), SakSTAR E46A K50A (SakSTAR48), and SakSTAR E65A D69A (SakSTARB67) had specific activities of 3%. SakSTAR13 had an intact affinity for plasminogen and a normal: rate of active site exposure in equimolar mixtures with plasminogen. The plasmin-SakSTAR13 complex had a 14-fold reduced catalytic efficiency for plasminogen activation but was 5-fold more efficient for conversion of plasminogen-SakSTAR13 to plasmin-SakSTAR13, SakSTAR48 and SakSTAR67 had a 10-20-fold reduced affinity for plasminogen and a markedly re reduced active site exposure; their complexes with plasmin had a more than 20-fold reduced catalytic efficiency toward plasminogen. Thus, plasminogen activation by catalytic amounts of SakSTAR is dependent on complex formation between plasmin(ogen) and SakSTAR, which is deficient with SakSTAR48 and SakSTAR67, but also on the induction of a functional active site configuration in the plasmin-SakSTAR complex, which is deficient with all three mutants, These findings support a mechanism for the activation of plasminogen by SakSTAR involving formation of an equimolar complex of SakSTAR with traces of plasmin, which converts plasminogen to plasmin and, more rapidly, inactive plasminogen-SakSTAR to plasmin-SakSTAR.	UNIV LOUVAIN,CTR MOLEC & VASC BIOL,B-3000 LOUVAIN,BELGIUM; INST MOLEC BIOTECHNOL,O-6980 JENA,GERMANY				Lijnen, Roger/AAA-4085-2020					BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COLLEN D, 1993, CIRCULATION, V87, P996, DOI 10.1161/01.CIR.87.3.996; COLLEN D, 1993, CIRCULATION, V87, P1850, DOI 10.1161/01.CIR.87.6.1850; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1993, J BIOL CHEM, V268, P8284; CUNNINGHAM BC, 1989, SCIENCE, V244, P1801; DAMASCHUN G, 1993, BIOCHIM BIOPHYS ACTA, V1161, P244, DOI 10.1016/0167-4838(93)90220-L; DECLERCK PJ, 1994, THROMB HAEMOSTASIS, V12, P185; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LEWIS JH, 1951, AM J PHYSIOL, V166, P594, DOI 10.1152/ajplegacy.1951.166.3.594; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1992, BIOCHIM BIOPHYS ACTA, V1118, P144, DOI 10.1016/0167-4838(92)90142-Z; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P143, DOI 10.1111/j.1432-1033.1994.tb20005.x; MATSUO O, 1990, BLOOD, V76, P925; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NELLES L, 1978, EUR J BIOCHEM, V87, P143; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; Sambrook J, 1989, MOL CLONING LABORATO; SCHLOTT B, 1994, BIO-TECHNOL, V12, P185, DOI 10.1038/nbt0294-185; SILENCE K, 1993, J BIOL CHEM, V268, P9811; SILENCE K, 1993, BLOOD, V82, P1175, DOI 10.1182/blood.V82.4.1175.bloodjournal8241175; SOTTRUPJENSEN L, 1977, PROGR CHEM FIBRINOLY, V3, P191; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; UESHIMA S, 1994, THROMB HAEMOSTASIS, V71, P134; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	31	37	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27192	27198		10.1074/jbc.270.45.27192	http://dx.doi.org/10.1074/jbc.270.45.27192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592976	hybrid			2022-12-25	WOS:A1995TE58300076
J	YAN, CYI; FERRARI, G; GREENE, LA				YAN, CYI; FERRARI, G; GREENE, LA			N-ACETYLCYSTEINE-PROMOTED SURVIVAL OF PC12 CELLS IS GLUTATHIONE-INDEPENDENT BUT TRANSCRIPTIONAL-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SYMPATHETIC NEURONS; FACTOR DEPRIVATION; KAPPA-B; PHEOCHROMOCYTOMA CELLS; STIMULATED HUMAN; BINDING-ACTIVITY; DEATH; 2-MERCAPTOETHANOL; APOPTOSIS	Our prior work established that comparable concentrations of N-acetylcysteine (NAG) both block the proliferation of PC12 cells and prevent death of trophic factor-deprived sympathetic neurons and PC12 cells. The present work addresses several aspects of the mechanisms of these actions, NAC increases intracellular levels of glutathione (GSH) by approximately 10-fold in PC12 cells, However, blockade of this increase by treatment with buthionine sulfoximine did not affect either promotion of survival or inhibition of DNA synthesis. Thus, these actions of NAC are independent of its effects on intracellular GSH, NAC's actions in our system do not appear to be dependent on its anti-oxidant/radical scavenger properties, but may be due to its activity as a reductant, Consistent with this, several other reducing agents, the most effective of which was 2,3-dimercaptopropanol, mimicked NAC in blocking DNA synthesis and suppressing death of PC12 cells and sympathetic neurons, Finally, we observed that in striking contrast to nerve growth factor and a number of other trophic agents, the survival-promoting effects of NAC on PC12 cells are blocked by actinomycin D. This suggests that NAC may act by inducing specific gene expression.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	YAN, CYI (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA.		Yan, Chao Yun Irene/B-4700-2011	Yan, Chao Yun Irene/0000-0003-0527-5719				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERRARI G, 1993, J NEUROSCI, V13, P1879; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1990, J NEUROSCI, V10, P1479; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; GRILL RJ, 1993, BRAIN RES, V613, P168, DOI 10.1016/0006-8993(93)90470-8; HEFTI F, 1994, NEUROBIOL AGING, V15, pS193; ISHII K, 1993, NEUROSCI LETT, V163, P159, DOI 10.1016/0304-3940(93)90371-Q; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; LEE VM, 1980, NEUROSCIENCE, V5, P2239, DOI 10.1016/0306-4522(80)90140-2; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MESSINA JP, 1992, INT J IMMUNOPHARMACO, V14, P1221, DOI 10.1016/0192-0561(92)90058-S; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MITOMO K, 1994, GENE, V145, P197; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; OISHI T, 1993, J NEURAL TRANSM-PARK, V6, P45, DOI 10.1007/BF02252622; OLSON L, 1994, J NEUROL, V242, pS12, DOI 10.1007/BF00939233; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RATAN RR, 1994, J NEUROSCI, V14, P4385; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; THOR H, 1979, ARCH BIOCHEM BIOPHYS, V192, P405, DOI 10.1016/0003-9861(79)90109-7; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; WEI S, 1992, TOXICOL APPL PHARM, V112, P32, DOI 10.1016/0041-008X(92)90276-X	44	121	124	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26827	26832		10.1074/jbc.270.45.26827	http://dx.doi.org/10.1074/jbc.270.45.26827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592924	hybrid			2022-12-25	WOS:A1995TE58300024
J	ARGRAVES, KM; BATTEY, FD; MACCALMAN, CD; MCCRAE, KR; GAFVELS, M; KOZARSKY, KF; CHAPPELL, DA; STRAUSS, JF; STRICKLAND, DK				ARGRAVES, KM; BATTEY, FD; MACCALMAN, CD; MCCRAE, KR; GAFVELS, M; KOZARSKY, KF; CHAPPELL, DA; STRAUSS, JF; STRICKLAND, DK			THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR MEDIATES THE CELLULAR CATABOLISM OF LIPOPROTEIN-LIPASE AND UROKINASE-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-I COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; LDL-RECEPTOR; ENDOTHELIAL-CELLS; BOVINE-MILK; SURFACE; BINDING; GLYCOPROTEIN-330; EXPRESSION; IDENTIFICATION; PROTEOGLYCANS	The very low density Lipoprotein (VLDL) receptor binds apolipoprotein E-rich lipoproteins as well as the 39-kDa receptor-associated protein (RAP). Ligand blotting experiments using RAP and immunoblotting experiments using an anti-VLDL receptor IgG detected the VLDL receptor in detergent extracts of human aortic endothelial cells, human umbilical vein endothelial cells, and human aortic smooth muscle cells. To gain insight into the role of the VLDL receptor in the vascular endothelium, its ligand binding properties were further characterized. In vitro binding experiments documented that lipoprotein lipase (LpL), a key enzyme in lipoprotein catabolism, binds with high affinity to purified VLDL receptor. In addition, urokinase complexed with plasminogen activator-inhibitor type I (uPA . PAI-1) also bound to the purified VLDL receptor with high affinity. To assess the capacity of the VLDL receptor to mediate the cellular internalization of ligands, an adenoviral vector was used to introduce the VLDL receptor gene into a murine embryonic fibroblast cell line deficient in the VLDL receptor and the LDL receptor-related protein, another endocytic receptor known to bind LpL and uPA . PAI-1 complexes. Infected fibroblasts that express the VLDL receptor mediate the cellular internalization of I-125-labeled LpL and uPA . PAI-1 complexes, leading to their degradation. Non-infected fibroblasts or fibroblasts infected with the lacZ gene did not internalize these ligands. These studies confirm that the VLDL receptor binds to and mediates the catabolism of LpL and uPA . PAI-1 complexes. Thus, the VLDL receptor may play a unique role on the vascular endothelium in lipoprotein catabolism by regulating levels of LpL and in the regulation of fibrinolysis by facilitating the removal of urokinase complexed with its inhibitor.	AMER RED CROSS,DEPT BIOCHEM,HOLLAND LAB,ROCKVILLE,MD 20855; UNIV PENN,SCH MED,DEPT OBSTET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GYNECOL,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH MED,THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; KAROLINSKA INST,DEPT INTERNAL MED,METAB UNIT,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT INTERNAL MED,MOLEC NUTR UNIT,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,DEPT INTERNAL MED,S-14186 HUDDINGE,SWEDEN; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV PENN,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	American Red Cross; University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Iowa; University of Pennsylvania; University of Pennsylvania; The Wistar Institute					NHLBI NIH HHS [HL50787, HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CISAR LA, 1989, J BIOL CHEM, V264, P1767; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; HADDOCK RC, 1991, J BIOL CHEM, V266, P21466; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MULTHAUPT HAB, 1994, CIRCULATION, V90, P1; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; PLOUG M, 1991, J BIOL CHEM, V266, P1926; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHLEEF RR, 1988, HAEMOSTASIS, V18, P328; STINS MF, 1993, J LIPID RES, V34, P1853; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEBB JC, 1992, J LIPID RES, V33, P689; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WITTMAACK FM, 1995, ENDOCRINOLOGY, V136, P340, DOI 10.1210/en.136.1.340; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	54	148	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26550	26557		10.1074/jbc.270.44.26550	http://dx.doi.org/10.1074/jbc.270.44.26550			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592875	hybrid			2022-12-25	WOS:A1995TC97800082
J	CALDENHOVEN, E; VANDIJK, T; RAAIJMAKERS, JAM; LAMMERS, JWJ; KOENDERMAN, L; DEGROOT, RP				CALDENHOVEN, E; VANDIJK, T; RAAIJMAKERS, JAM; LAMMERS, JWJ; KOENDERMAN, L; DEGROOT, RP			ACTIVATION OF THE STAT3 ACUTE-PHASE RESPONSE FACTOR TRANSCRIPTION FACTOR BY INTERLEUKIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION; GM-CSF; HUMAN EOSINOPHILS; INTERFERON-ALPHA; CELL LINES; RECEPTOR; GENE	The receptor for interleukin-5 (IL-5R) is composed of a unique alpha chain (IL-5R alpha) expressed on eosinophils and basophils, associated with a beta c subunit, which is shared by the receptors for IL-S and granulocyte macrophage-colony stimulating factor. One of the molecular events activated via the IL-BR is the JAK/STAT signaling pathway. Recent reports have shown that IL-5 induces tyrosine phosphorylation of JAK2 followed by the subsequent cell type-specific activation of either STAT1 alpha or STAT5. To identify additional STAT proteins activated by IL-5, we co-transfected the IL-5R with STAT cDNAs in COS cells. We found that IL-5 induces binding of STAT3 to the intercellular adhesion molecule-1 pIRE, and activates STAT3-dependent transcription. Moreover, endogenous STAT3 was tyrosine phosphorylated and activated in human IL-5-stimulated BaF3 cells ectopically expressing the human IL-5R (BaF3/IL5R). These data imply that multiple STAT proteins are involved in gene regulation by IL-S in a cell type-specific manner. We further demonstrate using C-terminal truncations of the alpha and beta c subunits of the IL-5R that the membrane-proximal regions of both subunits are required for STAT activation. Interestingly, a beta c receptor mutant lacking intracellular tyrosine residues is able to mediate STAT3 activation, suggesting that tyrosine phosphorylation of the beta c receptor is not essential for STAT3 activation.	UNIV UTRECHT HOSP,DEPT PULM DIS,3584 CX UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center				Koenderman, Leo/0000-0002-5636-6453				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFER P, 1995, ONCOGENE, V10, P985; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; INGLEY E, 1991, BLOOD, V78, P339; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KITAMURA T, 1992, BLOOD, V80, P84; KRESS C, 1990, DEVELOPMENT, V109, P775; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1994, P SOC EXP BIOL MED, V206, P284; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OGAWA M, 1993, BLOOD, V81, P2844; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TIAN SS, 1994, BLOOD, V84, P1760; TORIGOE T, 1992, BLOOD, V80, P617; VANDERBRUGGEN T, 1994, J IMMUNOL, V153, P2729; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZANDERS ED, 1994, EUR CYTOKINE NETW, V5, P35; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25778	25784		10.1074/jbc.270.43.25778	http://dx.doi.org/10.1074/jbc.270.43.25778			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592760	Green Published, hybrid			2022-12-25	WOS:A1995TB46600077
J	HANNA, DE; RETHINASWAMY, A; GLOVER, CVC				HANNA, DE; RETHINASWAMY, A; GLOVER, CVC			CASEIN KINASE-II IS REQUIRED FOR CELL-CYCLE PROGRESSION DURING G(1) AND G(2)/M IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; PROTEIN-KINASE; CONSERVED FEATURES; DIVISION CYCLE; BUDDING YEAST; BETA-SUBUNIT; PHOSPHORYLATION; MITOSIS; IDENTIFICATION; TRANSCRIPTION	The catalytic subunit of Saccharomyces cerevisiae casein kinase II (Sc CKII) is encoded by the CKA1 and CKA2 genes, which together are essential for viability. Five independent temperature-sensitive alleles of the CKA2 gene were isolated and used to analyze the function of CHII during the cell cycle. Following a shift to the nonpermissive temperature, cka2(ts) strains arrested within a single cell cycle and exhibited a dual arrest phenotype consisting of 50% unbudded and 50% large-budded cells. The unbudded half of the arrested population contained a single nucleus and a single focus of microtubule staining, consistent with arrest in G(1). Most of the large-budded fraction contained segregated chromatin and an extended spindle, indicative of arrest in anaphase, though a fraction contained an undivided nucleus with a short thick intranuclear spindle, indicative of arrest in G(2) and/or metaphase. Flow cytometry of pheromone-synchronized cells confirmed that CKII is required in G(1), at a point which must lie at or beyond Start but prior to DNA synthesis. Similar analysis of hydroxyurea-synchronized cells indicated that CKII is not required for completion of previously initiated DNA replication but confirmed that the enzyme is again required for cell cycle progression in G(2) and/or mitosis. These results establish a role for CKII in regulation and/or execution of the eukaryotic cell cycle.	UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia					NIGMS NIH HHS [GM33237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARROLL D, 1989, J BIOL CHEM, V264, P7345; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; ELLIOTT SG, 1978, P NATL ACAD SCI USA, V75, P4384, DOI 10.1073/pnas.75.9.4384; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; GLOVER CVC, 1994, CELL MOL BIOL RES, V40, P481; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARTWELL LH, 1973, GENETICS, V74, P267; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; Rose MD., 1990, METHODS YEAST GENETI; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SIKORSKI RS, 1989, GENETICS, V122, P19; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	46	187	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25905	25914		10.1074/jbc.270.43.25905	http://dx.doi.org/10.1074/jbc.270.43.25905			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592778	hybrid			2022-12-25	WOS:A1995TB46600095
J	LI, ML; LYON, MK; GARCEA, RL				LI, ML; LYON, MK; GARCEA, RL			IN-VITRO PHOSPHORYLATION OF THE POLYOMAVIRUS MAJOR CAPSID PROTEIN VP1 ON SERINE-66 BY CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LARGE T-ANTIGEN; SIMIAN VIRUS-40; MOUSE KIDNEY; CELL-GROWTH; HOST RANGE; INSULIN; GENE; PHOSPHATASE-2A; ONCOPROTEINS	Phosphorylation of the polyomavirus major capsid protein VP1 plays a role in virus assembly and may function in virus-cell recognition. Previous mapping of the in vivo phosphorylation sites on VP1 identified phosphorylation of threonine residues Thr-63 and Thr-156 (Li, M., and Garcea, R. L. (1994) J. Virol. 68, 320-327). Phosphoserine was detected in a tryptic phosphopeptide encompassing residues 58-78. Because of consensus casein kinase II (CK II) sites in this peptide, we examined the in vitro phosphorylation of the purified recombinant VP1 protein by CK II. CK II phosphorylated VP1 on serine, and the resulting tryptic phosphopeptide eluted in a 30-31 min high performance liquid chromatography fraction corresponding to residues 58-78. The VP1 tryptic phosphopeptide also co-migrated in two-dimensional peptide analysis with one of the tryptic peptides obtained from VP1 isolated after in vivo P-32 labeling of virus-infected cells. A site-directed mutant VP1 protein, Ser-66 to Ala, was phosphorylated poorly by CK II in vitro. As determined by electron microscopy, all of the mutant proteins were isolated in pentameric form similar to the mild-type protein, although the Ala-66 pentamers had a tendency to self-assemble in vitro into tubular as well as capsid-like structures. These findings identify Ser-66 as a site of VP1 phosphorylation in vitro, and suggest that VP1 may serve as a substrate for CK II in vivo.	UNIV COLORADO, HLTH SCI CTR,SCH MED,DEPT PEDIAT, PEDIAT HEMATOL ONCOL SECT, DENVER, CO 80262 USA; UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver					NATIONAL CANCER INSTITUTE [R01CA037667] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA037667, CA37667] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AEBERSOLD R, 1989, PRACTICAL GUIDE PEPT, P73; ANDERS DG, 1983, J VIROL, V48, P206, DOI 10.1128/JVI.48.1.206-217.1983; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BOLEN JB, 1981, J VIROL, V37, P80, DOI 10.1128/JVI.37.1.80-91.1981; BOLEN JB, 1979, J VIROL, V32, P679, DOI 10.1128/JVI.32.2.679-683.1979; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GARCEA RL, 1985, J VIROL, V54, P311, DOI 10.1128/JVI.54.2.311-316.1985; GARCEA RL, 1983, P NATL ACAD SCI-BIOL, V80, P3613, DOI 10.1073/pnas.80.12.3613; GARCEA RL, 1987, NATURE, V329, P86, DOI 10.1038/329086a0; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GRESSER FA, 1988, VIROLOGY, V165, P13; GRIFFIN JD, 1979, P NATL ACAD SCI USA, V76, P2610, DOI 10.1073/pnas.76.6.2610; GROSE C, 1989, J VIROL, V63, P3912, DOI 10.1128/JVI.63.9.3912-3918.1989; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; LEAVITT AD, 1985, J BIOL CHEM, V260, P2803; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P51; LI ML, 1994, J VIROL, V68, P320, DOI 10.1128/JVI.68.1.320-327.1994; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LUDLOW JW, 1987, J VIROL, V61, P509, DOI 10.1128/JVI.61.2.509-515.1987; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MANAK JR, 1993, ONCOGENE, V8, P703; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991; MORELAND RB, 1991, J VIROL, V65, P1168, DOI 10.1128/JVI.65.3.1168-1176.1991; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TJIAN R, 1979, COLD SPRING HARB SYM, V44, P103; Tooze J, 1980, DNA TUMOR VIRUSES; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WITTERS LA, 1983, J BIOL CHEM, V258, P5643; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	49	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					26006	26011		10.1074/jbc.270.43.26006	http://dx.doi.org/10.1074/jbc.270.43.26006			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592792	hybrid			2022-12-25	WOS:A1995TB46600109
J	INOUE, H; YOKOYAMA, C; HARA, S; TONE, Y; TANABE, T				INOUE, H; YOKOYAMA, C; HARA, S; TONE, Y; TANABE, T			TRANSCRIPTIONAL REGULATION OF HUMAN PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2 GENE BY LIPOPOLYSACCHARIDE AND PHORBOL ESTER IN VASCULAR ENDOTHELIAL-CELLS - INVOLVEMENT OF BOTH NUCLEAR FACTOR FOR INTERLEUKIN-6 EXPRESSION SITE AND CAMP RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GRANULOSA-CELLS; MAMMALIAN-CELLS; CDNA CLONING; C/EBP FAMILY; H SYNTHASE; PROMOTER; CYCLOOXYGENASE; NF-IL6; IDENTIFICATION	There exist two distinct isozymes of prostaglandin-endoperoxide synthase (PES). PES-2 mRNA is synergistically induced by lipopolysaccharide (LPS) and 12-O-tetradecanoylphorbol-13-acetate (TPA) in bovine arterial endothelial cells. On the other hand, PES-1 mRNA is constitutively expressed under these conditions. Therefore, the promoter activities of the human genes for PES-1 and -2 in bovine arterial endothelial cells were examined. The 5'-flanking region of the human PES-2 gene (nucleotides -327 to +59) showed promoter activity inducible by LPS and TPA using transient transfection analysis, whereas that of the PES-1 gene (nucleotides -1010 to +69) showed constitutive promoter activity. Destruction of both consensus sequences for the nuclear factor responsible for the interleukin-6 expression (NF-IL6) site (nucleotides -132 to -124) and the cyclic AMP response element (CRE) (nucleotides -59 to -53) of the human PES-2 gene markedly reduced the promoter activity (25%) of the PES-2 gene after combined treatment with LPS and TPA, although single destruction of the NF-IL6 site or the CRE slightly reduced the promoter activity (60 or 90%, respectively). Moreover, cotransfection experiments showed that a trans-acting factor, CCAAT enhancer binding protein delta (C/EBP delta), which binds to both the NP-IL6 site and the CRE, increased the promoter activity of the PES-2 gene mainly through the CRE. C/EBP delta mRNA was rapidly induced by LPS. Collectively, these results suggest that transcription of the PES-2 gene in vascular endothelial cells is regulated through combination of the NF-IL6 site and the CRE and that C/EBP delta functions as one of the trans-acting factors.	NATL CARDIOVASC CTR,RES INST,DEPT PHARMACOL,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CAO Z, 1991, GENE DEV, V5, P1553; Chomczynski P, 1987, ANAL BIOCHEM, V132, P6; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1993, MOL BRAIN RES, V20, P299, DOI 10.1016/0169-328X(93)90056-U; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES DA, 1992, J BIOL CHEM, V268, P9049; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LALLI E, 1994, J BIOL CHEM, V269, P17359; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN AH, 1989, J BIOL CHEM, V264, P17379; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1990, BIOCHIM BIOPHYS ACTA, V1083, P1; TANABE T, 1993, J LIPID MEDIATOR, V6, P139; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; YAMAMOTO S, 1988, PROSTAGLANDINS BIOL, P37; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	36	458	460	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24965	24971		10.1074/jbc.270.42.24965	http://dx.doi.org/10.1074/jbc.270.42.24965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559624	hybrid			2022-12-25	WOS:A1995TB46500058
J	ENGLARO, W; REZZONICO, R; DURANDCLEMENT, M; LALLEMAND, D; ORTONNE, JP; BALLOTTI, R				ENGLARO, W; REZZONICO, R; DURANDCLEMENT, M; LALLEMAND, D; ORTONNE, JP; BALLOTTI, R			MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND AP-1 ARE ACTIVATED DURING CAMP-INDUCED MELANOGENESIS IN B-16 MELANOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING HORMONE; SIGNAL-TRANSDUCTION; HUMAN MELANOCYTES; MAP KINASES; MAMMALIAN TYROSINASE; S6 KINASE; PHOSPHORYLATION; BIOSYNTHESIS; DIACYLGLYCEROL; PROLIFERATION	In mammalian melanocytes, melanin synthesis is controlled by tyrosinase, the critical enzyme in the melanogenic pathway. We and others showed that the stimulation of melanogenesis by cAMP is due to an increased tyrosinase expression at protein and mRNA levels, However, the molecular events connecting the rise of intracellular cAMP and the increase in tyrosinase activity remain to be elucidated, In this study, using B16 melanoma cells, we showed that cAMP-elevating agents stimulated mitogen-activated protein (MAP) kinase, p44(mapk). This effect was mediated by the activation of MAP kinase kinase, cAMP-elevating agents induced a translocation of p44(mapk) to the nucleus and an activation of the transcription factor AP-1, cAMP-induced AP-1 contained FOS-related antigen-2 in association with JunD, while after phorbol ester stimulation AP-1 complexes consist mainly of JunD/c-Fos heterodimers. In an attempt to connect these molecular events to the control of tyrosinase expression that appears to be the pivotal point of melanogenesis regulation, we hypothesized that following its activation by cAMP, p44(mapk) activates AP-1, Then AP-1 could stimulate tyrosinase expression through the interaction with specific DNA sequences present in the mouse tyrosinase promoter.	FAC MED NICE,INSERM,U385,F-06107 NICE 02,FRANCE; FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,ONCOGEN VIRUSES UNIT,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			BALLOTTI, Robert/F-8825-2013; lallemand, dominique/O-7445-2017; REZZONICO, Roger/N-9626-2016	lallemand, dominique/0000-0002-0212-7342; REZZONICO, Roger/0000-0002-8460-1641; BALLOTTI, Robert/0000-0002-7322-4908				AGIN PP, 1991, PHOTODERMATOL PHOTO, V8, P51; AROCA P, 1993, J BIOL CHEM, V268, P25650; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARSBERG CJ, 1994, J CELL SCI, V107, P2591; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P56; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FULLER BB, 1987, J BIOL CHEM, V262, P4024; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Halaban R., 1981, BIOCHIM BIOPHYS ACTA, V230, P383; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HIBI M, 1993, GENE DEV, V7, P1031; HUNT G, 1994, J CELL SCI, V107, P205; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMOKAWA G, 1986, J INVEST DERMATOL, V87, P319, DOI 10.1111/1523-1747.ep12524388; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KORNER A, 1977, NATURE, V267, P444, DOI 10.1038/267444a0; KUZUMAKI T, 1993, EXP CELL RES, V207, P33, DOI 10.1006/excr.1993.1159; LACOUR JP, 1992, J CELL PHYSL, V15, P287; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MCNEIL S, 1992, PIGM CELL RES, V2, P154; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OIKAWA A, 1972, ARCH BIOCHEM BIOPHYS, V148, P548, DOI 10.1016/0003-9861(72)90173-7; OKUMURA N, 1994, J BIOCHEM-TOKYO, V115, P304, DOI 10.1093/oxfordjournals.jbchem.a124333; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SETH A, 1992, J BIOL CHEM, V267, P24796; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STORM SM, 1990, ONCOGENE, V5, P345; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMIR A, 1994, J IMMUNOL, V152, P3391; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	49	190	193	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24315	24320		10.1074/jbc.270.41.24315	http://dx.doi.org/10.1074/jbc.270.41.24315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592642	hybrid			2022-12-25	WOS:A1995TA21700070
J	GALLEGO, MI; LAZO, PA				GALLEGO, MI; LAZO, PA			DELETION IN HUMAN-CHROMOSOME REGION 12Q13-15 BY INTEGRATION OF HUMAN PAPILLOMAVIRUS DNA IN A CERVICAL-CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELA-CELLS; HUMAN SARCOMAS; GENES; TRANSLOCATION; AMPLIFICATION; FUSION; SITES; PROTOONCOGENES; TRANSCRIPTION; LIPOSARCOMA	In human cervical carcinomas papillomavirus DNA is frequently integrated in the cell genome, We have cloned the integration site of human papillomavirus-18 DNA in human chromosome region 12q13-15 present in the SW756 cervical carcinoma cell line. Viral DNA is broken from nucleotides 2643 to 3418 in the El and E2 open reading frames, resulting in a deletion of 775 bases of viral DNA, Cloning and sequence analysis of the rearranged and germline alleles shows that there is no homology between the target cellular and viral DNA, suggesting it is a nonhomologous recombination. The target cellular region is called papillomavirus associated locus 2 (PAL2). The 5'- and 3'-flanking probes derived from the hybrid viral-cellular clone detect completely different germline restriction fragments in DNA from cells with normal chromosome 12. There is no overlap between the restriction maps of the target germline clones obtained with 5'- and 3'-flanking probes. Probes from these germline clones beyond the breakpoint position do not detect any DNA rearrangement in SW756 cells DNA. These data prove that there is a deletion of cellular DNA as consequence of the integration, with an estimated minimum size of 14 kilobases, Both cellular flanking probes are outside the amplicon of this chromosome region identified in the OSA and RMS13 sarcoma cell lines, comprising SAS-CHOP-CDK4-MDM2 genes and where translocation breakpoints are located in liposarcomas. The integration at 12q13-15 might have been selected by its contribution to the tumor phenotype.	INST SALUD CARLOS III,CTR NACL BIOL CELULAR,CSIC,GENET MOLEC UNIDAD,E-28220 MAJADAHONDA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III			Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025; Gallego, Marta I./0000-0003-0143-2553				AMAN P, 1993, GENE CHROMOSOME CANC, V5, P278; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BERUBE NG, 1994, CANCER RES, V54, P3077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; GALLEGO MI, 1994, GENE CHROMOSOME CANC, V9, P28, DOI 10.1002/gcc.2870090106; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAUSEN HZ, 1991, ORIGINS OF HUMAN CANCER, P685; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; HOTTA H, 1988, CANCER RES, V48, P2955; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; KAHN T, 1994, CANCER RES, V54, P1305; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kucherlapati R, 1994, Cytogenet Cell Genet, V67, P245, DOI 10.1159/000133868; LAZO PA, 1989, CANCER RES, V49, P4305; LAZO PA, 1992, FEBS LETT, V300, P109, DOI 10.1016/0014-5793(92)80175-G; LAZO PA, 1987, EUR J BIOCHEM, V165, P393, DOI 10.1111/j.1432-1033.1987.tb11452.x; LAZO PA, 1988, J BIOL CHEM, V263, P360; LAZO PA, 1988, BIOESSAYS, V9, P157; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; MITELMAN F, 1991, CATALOG HUMAN CHROMO; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; PEDEUTOUR F, 1994, GENOMICS, V22, P512, DOI 10.1006/geno.1994.1424; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; POPESCU NC, 1990, HUM GENET, V84, P383; POPESCU NC, 1987, J VIROL, V61, P1682, DOI 10.1128/JVI.61.5.1682-1685.1987; POPESCU NC, 1990, CANCER GENET CYTOGEN, V42, P157; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; ROSSL F, 1989, MOL CARCINOGEN, V2, P72; Roth D., 1988, GENETIC RECOMBINATIO, P621; Sambrook J, 1989, MOL CLONING LABORATO; SASTREGARAU X, 1995, CR ACAD SCI III-VIE, V318, P475; SASTREGARAU X, 1990, CANCER GENET CYTOGEN, V44, P243, DOI 10.1016/0165-4608(90)90053-D; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; SEYGER MMB, 1995, CANCER GENET CYTOGEN, V80, P23, DOI 10.1016/0165-4608(94)00157-7; SHAH KV, 1990, VIROLOGY, P1651; SHOENMAKERS EFP, 1994, GENOMICS, V20, P210; THOMAS M, 1995, ONCOGENE, V10, P261; TSICHLIS PN, 1991, CURR TOP MICROBIOL I, V171, P97; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	61	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24321	24326		10.1074/jbc.270.41.24321	http://dx.doi.org/10.1074/jbc.270.41.24321			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592643	Green Published, hybrid			2022-12-25	WOS:A1995TA21700071
J	LEE, KI; REDDY, EP; REDDY, CD				LEE, KI; REDDY, EP; REDDY, CD			CELLULAR FACTORS BINDING TO A NOVEL CIS-ACTING ELEMENT MEDIATE STEROID-HORMONE RESPONSIVENESS OF MOUSE MAMMARY-TUMOR VIRUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; FUNCTIONAL INTERFERENCE; REGULATORY ELEMENTS; PROVIRAL ACTIVATION; DNA; REGION; EXPRESSION; INDUCTION	Steroid hormone receptors regulate mouse mammary tumor virus (MMTV) gene expression by binding to hormone response DNA elements present in the long terminal repeat. Tissue-specific expression of MMTV is unlikely to be regulated by steroid hormone-receptor complex alone, and mammary cell-specific factors might play a role in the hormone-induced transcriptional activation. In this report we have investigated the function of a novel cis-acting element designated Kil (-204 to -188) which is located adjacent to the distal glucocorticoid response element, in steroid hormone-induced transcription of MMTV. Electrophoretic mobility shift assays indicate that cellular factors bind to the Kil element, and dexamethasone stimulation results in alterations in the binding pattern of proteins in this region. By transient transfection assays using wild type and deletion mutants of the Kil element, we show that this novel cis acting element is necessary for hormone-induced transcription of MMTV and functions in mammary tumor cells but not in NIH/3T3 cells. Mutagenesis of the Kil sequence suggests that the entire Kil element functioning as one unit is necessary for hormone-induced transcription of MMTV. When placed in the context of heterologous promoters, neither Kil element nor glucocorticoid response element is able to induce significant hormone-induced transcription of MMTV. The presence of both the DNA elements in tandem results in optimal induction of transcription in the presence of steroid hormones. Our results also indicate that the Kil element functions in human breast carcinoma cell lines such as T47D and MCF-7. These results suggest that Kil element in combination with distal glucocorticoid response element functions as a mammary cell-specific enhancer to regulate MMTV transcription.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; ESPANAS ML, 1994, MOL CELL BIOL, V14, P4116; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOECK W, 1989, J BIOL CHEM, V264, P14396; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORWITZ KB, 1978, J BIOL CHEM, V253, P8185; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; KWON BS, 1984, J VIROL, V52, P1000, DOI 10.1128/JVI.52.3.1000-1004.1984; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MELLENTINMICHEL.J, 1994, J BIOL CHEM, V269, P31893; MEULIA T, 1990, J MOL BIOL, V216, P850; MICHALIDES R, 1985, MOL CELL BIOL, V5, P823, DOI 10.1128/MCB.5.4.823; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; ONDEK B, 1988, NATURE, V33, P40; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEIDEREIT C, 1983, NATURE, V340, P749; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; THEUNISSEN HJM, 1989, J VIROL, V63, P3466, DOI 10.1128/JVI.63.8.3466-3471.1989; WELLINGER RJ, 1986, J VIROL, V60, P1; WESTLEY B, 1980, CELL, V20, P353, DOI 10.1016/0092-8674(80)90621-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	47	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24502	24508		10.1074/jbc.270.41.24502	http://dx.doi.org/10.1074/jbc.270.41.24502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592667	hybrid			2022-12-25	WOS:A1995TA21700095
J	BENHAR, I; PASTAN, I				BENHAR, I; PASTAN, I			IDENTIFICATION OF RESIDUES THAT STABILIZE THE SINGLE-CHAIN FV OF MONOCLONAL-ANTIBODIES B3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; POLYMERASE; GENES; IMMUNOTOXIN; EXPRESSION; CLONING; PRIMERS	B3(Fv)-PE38 is a recombinant single-chain immunotoxin in which the Fv portion of the B3 antibody in a single-chain form, which serves as the targeting moiety, is fused to PE38, a truncated form of Pseudomonas exotoxin A, which serves as the cytotoxic moiety, B3(FV)-PE38 is specifically cytotoxic to many human cancer cell lines and is currently evaluated in a clinical trial. Monoclonal antibodies B3 (IgG1k) and B5 (IgMk) recognize related carbohydrate epitopes on human carcinoma cells. The Fv regions of these antibodies were previously cloned and expressed as the single chain Fv-immunotoxins B3(Fv) PE38 and B5(Fv)-PE38, respectively. The B3(Fv)-PE38 immunotoxin binds to antigen positive cancer cells with a higher affinity than B5(Fv)-PE38 and is a more potent cytotoxic agent than B5(Fv)-PE38. However, it is less stable and rapidly aggregates upon incubation at 37 degrees C. The V-L domains of the two Fvs are very similar, differing by only three residues, the fourth and seventh Fr1 residues and the fifth CDR1 residue. The V-H domains of the two Fvs vary considerably. To investigate whether any of the different V-L residues may influence the stability of the B3(Fv), we constructed a chimeric immunotoxin containing the B3V(H) and the B5V(L). This chimera had an improved stability and a higher apparent antigen binding affinity and cytotoxic activity when compared with B3(Fv)-PE38. Site-specific mutagenesis was used to show that the V-L M4L mutation has an important role in stabilizing B3(Fv), although residues V-L Ser-7 and V-L Ile-28 also play a role in the increased stability. When tested in an in vivo model system, the chimera containing the B3V(H) and the B5V(L) had an improved antitumor activity in a human xenograft mouse model. These studies indicate that the common use of degenerate (''family-specific'') primers to clone Fv fragments may introduce destabilizing mutations.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Benhar, Itai/0000-0002-0824-7177				BENHAR I, 1994, PROTEIN ENG, V7, P1509, DOI 10.1093/protein/7.12.1509; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CHAUDHARY V, 1990, P NATL ACAD SCI USA, V89, P1066; CREAMER P, 1992, P NATL ACAD SCI USA, V89, P5973; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARRICK JW, 1989, BIOCHEM BIOPH RES CO, V160, P1250, DOI 10.1016/S0006-291X(89)80138-X; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PAI LH, 1991, CANCER RES, V51, P2808; PASTAN I, 1991, CANCER RES, V51, P3781; PASTAN IH, 1995, ANN NY ACAD SCI, V758, P345, DOI 10.1111/j.1749-6632.1995.tb24840.x; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; REITER Y, 1994, CANCER RES, V54, P2714; REITER Y, 1994, BIOCHEMISTRY-US, V33, P5451, DOI 10.1021/bi00184a014; SCHMID FX, 1990, PROTEIN STRUCTURE PR, P281; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; YASUI H, 1994, FEBS LETT, V353, P143, DOI 10.1016/0014-5793(94)01027-7	22	33	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23373	23380		10.1074/jbc.270.40.23373	http://dx.doi.org/10.1074/jbc.270.40.23373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559495	hybrid			2022-12-25	WOS:A1995RY90900024
J	OKAN, I; WANG, YS; CHEN, F; HU, LF; IMREH, S; KLEIN, G; WIMAN, KG				OKAN, I; WANG, YS; CHEN, F; HU, LF; IMREH, S; KLEIN, G; WIMAN, KG			THE EBV-ENCODED LMP1 PROTEIN INHIBITS P53-TRIGGERED APOPTOSIS BUT NOT GROWTH ARREST	ONCOGENE			English	Article						LMP1; P53; APOPTOSIS	WILD-TYPE P53; PROGRAMMED CELL-DEATH; CHROMOSOMAL BREAKPOINT; LYMPHOMA LINE; CYCLE CONTROL; EXPRESSION; BCL-2; SUPPRESSION; P53-PROTEIN; INDUCTION	We have previously shown that exogenous wild type p53 induces apoptosis in the Burkitt lymphoma line BL41 that carries endogenous mutant p53, using a temperature sensitive p53 construct expressed as mutant p53 at 37 degrees C and wild type p53 at 32 degrees C (Ramqvist et al., Oncogene, 8, 1495-1500, 1993). We also found that wild type p53-induced apoptosis is blocked by bcl-2 in a mouse T lymphoma line (Wang et al., Oncogene, 8, 3427-3431, 1993) The Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) can protect Burkitt lymphoma cells from apoptosis induced by low serum, In order to test if LMP1 can block p53-triggered apoptosis, we infected BL41 cells expressing the ts p53 construct with an LMP1-carrying retrovirus, The LMP1-expressing BL41-ts p53 cells were arrested in G1 upon induction of wild type p53 expression at 32 degrees C, but did not enter apoptosis as shown by the absence of positive TUNEL staining, WAF1/p21 mRNA was induced at 32 degrees C in both the ts p53-expressing and ts p53/LMP1-expressing BL41 cells, Thus, LMP1 prevents p53-induced apoptosis but does not interfere induction of WAF1/p21, The LMP1-infected expressed elevated bcl-2 protein levels, Therefore, our data suggest that LMP1 blocks p53-triggered apoptosis but not G1 arrest by upregulating bcl-2 expression.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DELDEIRY WS, 1994, CANCER, V54, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAVRIELI Y, 1993, J CELL BIOL, V119, P493; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAMQVIST T, 1993, ONCOGENE, V8, P1495; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TOWBIN H, 1979, P NATL ACAD SCI USA, V88, P4350; TRIVEDI P, 1991, INT J CANCER, V48, P794, DOI 10.1002/ijc.2910480527; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WILLIAMS C A, 1989, Methods in Molecular and Cellular Biology, V1, P35; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	35	81	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1027	1031						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566960				2022-12-25	WOS:A1995RX18000003
J	RICHARDSON, PM; ZON, LI				RICHARDSON, PM; ZON, LI			MOLECULAR-CLONING OF A CDNA WITH A NOVEL DOMAIN PRESENT IN THE TRE-2 ONCOGENE AND THE YEAST-CELL CYCLE REGULATORS BUB2 AND CDC16	ONCOGENE			English	Article						HEMATOPORESIS; MAST CELLS; CELL CYCLE; CDNA; GERM CELLS	BINDING TRANSCRIPTION FACTORS; MAST-CELLS; CARBOXYPEPTIDASE-A; PROTEIN CDNA; GENE; IDENTIFICATION; SEQUENCES; CYTOKINESIS; ENCODES; MITOSIS	Tn an effort to identify genes that are differentially regulated during mast cell development, subtracted cDNA prepared from wild-type murine P815 mastocytoma cells and a P815 subline that exhibits properties of mast cell differentiation was used to screen mast cell cDNA libraries. Several known mast cell-specific cDNAs were isolated including mast cell carboxypeptidase A (MC-CPA), murine mast cell protease-5 (MMCP-5), and gp49. A novel cDNA, designated Tbc1, was identified that showed differential expression in the two mast cell lines. The amino acid sequence predicted from the cDNA contains a 200 amino acid domain that is homologous to regions in the tre-2 oncogene and the yeast regulators of mitosis, BUB2 and cdc16. The N-terminal region contains a number of cysteine and histidine residues, potentially encoding a zinc finger domain. Tbc1 is a nuclear protein and is expressed in highest levels in hematopoietic cells, testis and kidney. Within these tissues, expression of Tbc1 is cell- and stage-specific. Based on sequence similarity, pattern of expression and subcellular localization, Tbc1 may play a role in the cell cycle and differentiation of various tissues.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute					NHLBI NIH HHS [P10 HL32262, R01 HL46668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, R01HL046668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARM JP, 1991, J BIOL CHEM, V266, P15966; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; CHANG F, 1993, TRENDS GENET, V9, P333, DOI 10.1016/0168-9525(93)90022-A; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GURISH MF, 1991, J IMMUNOL, V146, P1527; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUANG RY, 1991, EUR J IMMUNOL, V21, P39; HUEBNER K, 1988, ONCOGENE, V3, P449; ITO E, 1993, NATURE, V3623, P466; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1990, DNA CELL BIOL, V9, P697, DOI 10.1089/dna.1990.9.697; ONNO M, 1993, DNA CELL BIOL, V12, P107, DOI 10.1089/dna.1993.12.107; ONNO M, 1992, ONCOGENE, V7, P2519; ORKIN SH, 1992, BLOOD, V80, P575; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PEVNY L, DEVELOPMENT, V121, P163; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, J CELL BIOL, V110, P1033; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; STEPHENSON DA, 1994, MAMM GENOME, V5, P342, DOI 10.1007/BF00356552; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TRANSY C, 1987, J EXP MED, V166, P341, DOI 10.1084/jem.166.2.341; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; ZON LI, 1991, J BIOL CHEM, V266, P22948	33	60	66	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1139	1148						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566974				2022-12-25	WOS:A1995RX18000017
J	DE FRUTOS, PG; HARDIG, Y; DAHLBACK, B				DE FRUTOS, PG; HARDIG, Y; DAHLBACK, B			SERUM AMYLOID-P COMPONENT BINDING TO C4B-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT PROTEIN; C-REACTIVE PROTEIN; HUMAN-COMPLEMENT; S-BINDING; ALPHA-CHAIN; LIGAND; SITE; ASSOCIATION; GALACTOSE; COMPLEXES	Human C4b-binding protein (C4BP), which is a regulator of the classical complement pathway C3 convertase, forms high affinity complexes with anticoagulant protein S and with the pentraxin serum amyloid P component (SAP), SAP is a plasma protein present in all amyloid deposits. Recently, SAP was shown to inhibit the complement regulatory functions of C4BP. In this investigation, we have studied the structural requirements for the C4BP-SAP interaction. C4BP was subjected to chymotrypsin digestion, which yielded two major fragments corresponding to the central core (160 kDa) and to the cleaved-off tentacles (48 kDa). SAP-Sepharose specifically bound the 160-kDa fragment, suggesting that the central core of C4BP contains the binding site for SAP. In a quantitative affinity chromatography assay, the dissociation constants for binding of intact C4BP and of the 160-kDa central core fragment to SAP were found,to be 30 and 70 nM, respectively. Recombinant C4BP composed of only alpha-chains bound SAP with similar affinity (K-d = 22 nM), whereas nonglycosylated recombinant ru-chain C4BP (synthesized in the presence of tunicamycin) bound SAP with lower affinity (K-d = 126 nM). This suggests that the carbohydrate moiety of the central core of C4BP is important for binding of C4BP to SAP in contrast to the C4BP beta-chain, which is not required. EDTA, heparin, and phosphorylethanolamine as well as a peptide comprising amino acids 27-39 of SAP were found to completely displace C4BP from the SAP matrix. Moreover, the immobilized SAP peptide bound C4BP in a reaction that, in contrast to the C4BP-SAP interaction, was not dependent on calcium.	LUND UNIV, MALMO GEN HOSP, DEPT CLIN CHEM, WALLENBERG LAB, S-20502 MALMO, SWEDEN	Lund University			de Frutos, Pablo García/B-8594-2011	de Frutos, Pablo García/0000-0003-1547-1190; Dahlback, Bjorn/0000-0003-1546-0328				BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BREATHNACH SM, 1989, J EXP MED, V170, P1433, DOI 10.1084/jem.170.4.1433; BROWN MR, 1993, J IMMUNOL, V151, P2087; CHRISTNER RB, 1994, ARCH BIOCHEM BIOPHYS, V314, P337, DOI 10.1006/abbi.1994.1451; CHRISTNER RB, 1994, J BIOL CHEM, V269, P9760; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DE FRUTOS PG, 1994, BLOOD, V84, P815; DE FRUTOS PG, 1995, BBA-GENE STRUCT EXPR, V1261, P285, DOI 10.1016/0167-4781(95)00019-D; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DHAWAN S, 1990, BIOCHEM BIOPH RES CO, V171, P1284, DOI 10.1016/0006-291X(90)90825-8; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HAMAZAKI H, 1989, BIOCHIM BIOPHYS ACTA, V998, P231, DOI 10.1016/0167-4838(89)90279-3; HARDIG Y, 1995, BIOCHEM J, V308, P795; HESSING M, 1993, FEBS LETT, V317, P228, DOI 10.1016/0014-5793(93)81281-4; HICKS PS, 1992, J IMMUNOL, V149, P3689; HILLARP A, 1987, J BIOL CHEM, V262, P11300; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; HILLARP A, 1994, J IMMUNOL, V153, P4190; HOGG PJ, 1987, ANAL BIOCHEM, V163, P331, DOI 10.1016/0003-2697(87)90232-6; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; LANDSMANN P, 1994, EUR J BIOCHEM, V223, P805, DOI 10.1111/j.1432-1033.1994.tb19056.x; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; NAGASAWA S, 1982, J BIOCHEM-TOKYO, V125, P578; OGATA RT, 1993, J IMMUNOL, V150, P2273; PAINTER RH, 1982, ANN NY ACAD SCI, V389, P199, DOI 10.1111/j.1749-6632.1982.tb22138.x; PEPYS MB, 1982, ANN NY ACAD SCI, V389, P286, DOI 10.1111/j.1749-6632.1982.tb22144.x; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; PERSSON E, 1993, J BIOL CHEM, V268, P22531; ROBEY FA, 1981, J BIOL CHEM, V256, P969; RUBIO N, 1993, J BIOCHEM-TOKYO, V113, P277, DOI 10.1093/oxfordjournals.jbchem.a124039; SCHWALBE RA, 1992, BIOCHEMISTRY-US, V31, P4907, DOI 10.1021/bi00135a023; SCHWALBE RA, 1991, J BIOL CHEM, V266, P12896; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SIRIPONT J, 1988, CELL IMMUNOL, V117, P239, DOI 10.1016/0008-8749(88)90115-3; STENFLO J, 1976, J BIOL CHEM, V251, P355	44	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26950	26955		10.1074/jbc.270.45.26950	http://dx.doi.org/10.1074/jbc.270.45.26950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592941	hybrid			2022-12-25	WOS:A1995TE58300041
J	JUNG, D; YANG, B; MEYER, J; CHAMBERLAIN, JS; CAMPBELL, KP				JUNG, D; YANG, B; MEYER, J; CHAMBERLAIN, JS; CAMPBELL, KP			IDENTIFICATION AND CHARACTERIZATION OF THE DYSTROPHIN ANCHORING SITE ON BETA-DYSTROGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; CYSTEINE-RICH DOMAIN; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; PROTEINS; ORGANIZATION; DEFICIENCY; SARCOLEMMA; LAMININ	Dystrophin, the product of the Duchenne muscular dystrophy gene, is tightly associated with the sarcolemmal membrane to a large glycoprotein complex. One function of the dystrophin-glycoprotein complex is to Link the cytoskeleton to the extracellular matrix in skeletal muscle. However, the molecular interactions of dystrophin with the membrane components of the dystrophin-glycoprotein complex are still elusive, Here, we demonstrate and characterize a specific interaction between beta-dystroglycan and dystrophin. We show that skeletal muscle and brain dystrophin as well as brain dystrophin isoforms specifically bind to beta-dystroglycan, To localize and characterize the dystrophin and beta-dystroglycan interaction domains, we reconstituted the interaction in vitro using dystrophin fusion proteins and in vitro translated beta-dystroglycan. We demonstrated that the 15 C-terminal amino acids of beta-dystroglycan constituted a unique binding site for the second half of the hinge 4 and the cysteine-rich domain of dystrophin (amino acids 3054-3271), This dystrophin binding site is located in a proline-rich environment of beta-dystroglycan within amino acids 880-895, The identification of the interaction sites in dystrophin and beta-dystroglycan provides further insight into the structure and the molecular organization of the dystrophin glycoprotein complex at the sarcolemma membrane and will be helpful for studying the pathogenesis of Duchenne muscular dystrophy.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR HUMAN GENOME,ANN ARBOR,MI 48109	University of Iowa; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JUNG, D (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,400 ECKSTEIN MED RES BLDG,IOWA CITY,IA 52242, USA.			Campbell, Kevin/0000-0003-2066-5889; Chamberlain, Jeffrey/0000-0001-5299-0059				AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; BIES RD, 1992, J CLIN INVEST, V90, P666, DOI 10.1172/JCI115909; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CORRADO K, 1994, FEBS LETT, V334, P255; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DSOUZA VN, 1995, HUM MOL GENET, V4, P837, DOI 10.1093/hmg/4.5.837; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABRIZIO E, 1994, BIOCHEM J, V299, P359; GEE SH, 1993, J BIOL CHEM, V268, P14972; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; IBRAGHIMOVBESKR.O, 1993, HUM MOL GENET, V2, P1641; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1993, NEUROMUSCULAR DISORD, V3, P515, DOI 10.1016/0960-8966(93)90107-U; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; YOSHIOKA K, 1992, J NEUROL SCI, V108, P214, DOI 10.1016/0022-510X(92)90054-O; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	36	271	280	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27305	27310		10.1074/jbc.270.45.27305	http://dx.doi.org/10.1074/jbc.270.45.27305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592992	hybrid			2022-12-25	WOS:A1995TE58300092
J	RIMON, A; GERCHMAN, Y; OLAMI, Y; SCHULDINER, S; PADAN, E				RIMON, A; GERCHMAN, Y; OLAMI, Y; SCHULDINER, S; PADAN, E			REPLACEMENTS OF HISTIDINE-226 OF NHAA-NA+/H+ ANTIPORTER OF ESCHERICHIA-COLI - CYSTEINE (H226C) OR SERINE (H226S) RETAIN BOTH NORMAL ACTIVITY AND PH SENSITIVITY, ASPARTATE (H226D) SHIFTS THE PH PROFILE TOWARD BASIC PH, AND ALANINE (H226A) INACTIVATES THE CARRIER AT ALL PH VALUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC-PROPERTIES; MEMBRANE-VESICLES; GENE; ANT; EXPRESSION; PROTEINS; GRADIENT	We have previously shown that replacement of His-226 in the NhaA Na+/H+ antiporter of Escherichia coli to Arg (H226R) shifts the pH profile of the antiporter toward acidic pH and as a result a Delta nha Delta nhaB strain bearing this mutation is Na+ sensitive at alkaline pH (Gerchman, Y., Olami, Y., Rimon, A., Taglicht, D., Schuldiner, S. and Padan, E. (1993) Proc. Natl. Acad. Sci, U.S.A. 90, 1212-1216). In the present work the role of His-226 in the response of NhaA to pH has been studied in detail. The Na+ sensitivity of the Delta nhaA Delta nhaB mutant bearing the H226R NhaA plasmid at alkaline pH provided a very powerful tool to isolate revertants and suppressants of H226R growing on high Na+ at alkaline pH, With this approach cysteine (H226C) and serine (H226S) replacements were found to efficiently replace His-226 and yield an antiporter, which like the wild-type protein, is activated by pH between pH 7 and 8. These results imply that polarity and/or hydrogen bonding, the common properties shared by these amino acid residues, are essential at position 226 for pH regulation of NhaA. This suggestion was substantiated by site-directed mutagenesis of His-226 either to alanine (H226A) or aspartate (H226D), Whereas H226A-NhaA shows very low activity which is not activated by pH, H226D-NhaA is active and regulated by pH. The pH profile of H226D is shifted by half a pH unit toward alkaline pH, as opposed to the previously isolated mutant H226R which has a pH profile shift, to the same extent, but toward acidic pH, It is suggested that charge modifies the pH profile but is not essential for the pH regulation of NhaA.	HEBREW UNIV JERUSALEM, INST LIFE SCI, DIV MICROBIAL & MOLEC ECOL, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012; Gerchman, Yoram/F-5226-2015; Gerchman, Yoram/H-4698-2019	Schuldiner, Shimon/0000-0002-4874-6237; Gerchman, Yoram/0000-0002-8637-9589; 				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budowsky E I, 1976, Prog Nucleic Acid Res Mol Biol, V16, P125; CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; MILLER JH, 1992, LABORATORY MANUAL HD; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; OLSNES S, 1987, BIOCHEMISTRY-US, V26, P2778, DOI 10.1021/bi00384a019; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; PINNER E, 1994, J BIOL CHEM, V269, P26274; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P135; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382	33	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26813	26817		10.1074/jbc.270.45.26813	http://dx.doi.org/10.1074/jbc.270.45.26813			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592922	hybrid			2022-12-25	WOS:A1995TE58300022
J	PIERRES, A; BENOLIEL, AM; BONGRAND, P				PIERRES, A; BENOLIEL, AM; BONGRAND, P			MEASURING THE LIFETIME OF BONDS MADE BETWEEN SURFACE-LINKED MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMINAR SHEAR-FLOW; INTERACTION FORCES; CELL-ADHESION; RECEPTOR; MODEL; DETACHMENT; ANTIBODY	It is not well known how the kinetic constants of association between soluble receptors and ligands may be used to predict the behavior of these molecules when they are bound to cell surfaces. Spherical beads were coated with varying densities of anti-rabbit immuno globulin monoclonal antibodies and driven along glass surfaces derivatized with rabbit anti-dinitrophenol. Particle motion was analyzed The velocity, attachment frequency, and duration of binding events were determined on individual particles, It was found that i) beads exhibited frequent arrests lasting between a few tenths of a second and more than one minute; ii) when antibodies were diluted, the median arrest duration remained fairly constant (approximate to 1 s) whereas binding frequency varied as the first power of the antibody concentration, suggesting that most particle arrests were due to the formation of a single bond; iii) when the shear rate was increased 7-fold, the duration of transient binding events remained constant. The disruptive force exerted on attachment points was estimated to range between about 6 and 37 piconewtons; and iv) the distribution of arrest durations suggested that binding was not a monophasic reaction but involved at least one intermediate step. Therefore, transient binding events reflected the formation of unstable associations that are not detected with standard techniques.	HOP ST MARGUERITE,INSERM,U387,IMMUNOL LAB,F-13274 MARSEILLE 09,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Bongrand, Pierre/C-4456-2013; PIERRES, anne/F-6695-2013	Bongrand, Pierre/0000-0001-6185-6572; 				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ANDRE P, 1990, J CELL SCI, V200, P618; BEESON C, 1994, P NATL ACAD SCI USA, V91, P8842, DOI 10.1073/pnas.91.19.8842; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bongrand P., 1994, STUDYING CELL ADHESI; CAPO C, 1982, J CELL SCI, V56, P21; Cochran W.G, 1957, STAT METHODS, V6th ed; COZENSROBERTS C, 1990, BIOPHYS J, V58, P841, DOI 10.1016/S0006-3495(90)82430-9; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; Fersht A., 1985, ENZYME STRUCTURE MEC; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; HAMMER DA, 1987, BIOPHYS J, V52, P475, DOI 10.1016/S0006-3495(87)83236-8; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; KUO SC, 1993, BIOPHYS J, V65, P2191, DOI 10.1016/S0006-3495(93)81277-3; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; MEGE JL, 1990, BIORHEOLOGY, V27, P433; MICHL J, 1979, J EXP MED, V150, P607, DOI 10.1084/jem.150.3.607; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; PIERRES A, 1994, CELL MECHANICS AND CELLULAR ENGINEERING, P145; PIERRES A, 1994, J CELL BIOL, V125, P945, DOI 10.1083/jcb.125.4.945; SCHMIDSCHOENBEI.GW, 1975, CIRC RES, V36, P173; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEES DFJ, 1993, BIOPHYS J, V65, P1318, DOI 10.1016/S0006-3495(93)81180-9; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; THA SP, 1986, BIOPHYS J, V50, P1117, DOI 10.1016/S0006-3495(86)83556-1; TISSOT O, 1992, BIOPHYS J, V61, P204, DOI 10.1016/S0006-3495(92)81827-1; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; WATTENBARGER MR, 1990, BIOPHYS J, V57, P765, DOI 10.1016/S0006-3495(90)82597-2; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; WONG CW, 1991, INTRO MATH PHYSICS, P102; ZAFFRAN Y, 1993, BLOOD CELLS, V19, P115	35	70	73	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26586	26592		10.1074/jbc.270.44.26586	http://dx.doi.org/10.1074/jbc.270.44.26586			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592881	hybrid			2022-12-25	WOS:A1995TC97800088
J	KLEFF, S; ANDRULIS, ED; ANDERSON, CW; STERNGLANZ, R				KLEFF, S; ANDRULIS, ED; ANDERSON, CW; STERNGLANZ, R			IDENTIFICATION OF A GENE ENCODING A YEAST HISTONE H4 ACETYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; EXTENSIVE PURIFICATION; ACETYLATION; MUTANTS; NUCLEOSOMES; CHROMATIN; VECTORS; NUCLEI; CELLS; DNA	A collection of yeast temperature-sensitive mutants was screened by an enzymatic assay to find a mutant defective in the acetylation of histone H4. The assay used a fractionated cell extract and measured acetylation of a peptide corresponding to amino acids 1-28 of H4. There are at least two activities in this fraction that acetylate the peptide. A mutation, hat1-1, that eliminates one of the activities was identified and mapped to a locus near the centromere of chromosome XVI. The HAT1 gene was cloned and found to encode a protein of 374 amino acids. Analysis of the peptide used in the assay demonstrated that the HAT1 enzyme acetylates lysine 12 of histone H4. hat1 mutants have no obvious growth defects or phenotypes other than the enzyme defect itself. The HAT1 protein expressed in Escherichia coli gave histone acetyltransferase activity in vitro, demonstrating that HAT1 is the structural gene for the enzyme.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory					NCRR NIH HHS [RR02-427] Funding Source: Medline; NIGMS NIH HHS [GM28220] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALLFREY VG, 1977, CHROMATIN CHROMOSOME; ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; ATTISANO L, 1990, J BIOL CHEM, V265, P3949; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; CHRISTENSEN ME, 1982, DEV BIOL, V93, P404, DOI 10.1016/0012-1606(82)90127-0; ERICKSON JR, 1993, GENETICS, V134, P151; GARCEA RL, 1980, J BIOL CHEM, V255, P1454; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; KLYCE HR, 1973, EXP CELL RES, V82, P47, DOI 10.1016/0014-4827(73)90243-7; KULKARNI MS, 1994, J BIOL CHEM, V269, P13141; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PERRY M, 1982, J BIOL CHEM, V257, P7336; RILES L, 1993, GENETICS, V134, P81; Rose MD., 1990, METHODS YEAST GENETI; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TRAVIS GH, 1984, J BIOL CHEM, V259, P4406	24	279	301	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24674	24677		10.1074/jbc.270.42.24674	http://dx.doi.org/10.1074/jbc.270.42.24674			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559580	hybrid			2022-12-25	WOS:A1995TB46500014
J	LIU, Y; LIGGITT, D; ZHONG, W; TU, GH; GAENSLER, K; DEBS, R				LIU, Y; LIGGITT, D; ZHONG, W; TU, GH; GAENSLER, K; DEBS, R			CATIONIC LIPOSOME-MEDIATED INTRAVENOUS GENE DELIVERY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MAMMALIAN-CELLS; TRANSGENIC MICE; ADULT MICE; EXPRESSION; INVIVO; ACTIVATION; EFFICIENCY; INTRON; VIRUS	Systemic gene transfer provides new opportunities for the analysis of gene function and gene regulation in vivo, as well as for human gene therapy. We used the chloramphenicol acetyltransferase reporter gene to examine several parameters important for the development of efficient, cationic liposome-mediated, intravenous (IV) gene transfer in mice. We then demonstrated that this approach can produce high level expression of biologically important genes. Specifically, we assessed the relationship of expression vector design to the level of systemic gene expression produced, and compared transfection levels produced by intravenously injecting DNA alone versus DNA liposome complexes. We found that both the position of the heterologous intron, and the promoter element used in the expression plasmid, significantly affected the level of systemic gene expression produced. Although intravenous injection of plasmid DNA alone transfected every tissue analyzed, liposome-mediated delivery was much more efficient. We also established that repeated IV injection of DNA liposome complexes produced high level systemic transfection. The second injection of DNA liposome complexes produced levels of gene expression at least as high as those following a single IV injection. Thus, unlike some viral vectors, a neutralizing host-immune response does not limit re-expression, following reinjection of DNA liposome complexes. Finally, we showed that the expression vectors which produced the highest levels of chloramphenicol acetyltransferase reporter gene expression could also produce high level expression of two colony stimulating factor genes in mice. Specifically, IV injection of liposomes complexed to expression vectors into which we had inserted either the murine granulocyte-macrophage-colony stimulating factor cDNA or the human granulocyte-CSF cDNA, produced circulating levels of the corresponding colony stimulating factor gene product comparable to levels which have been shown previously to be both biologically and therapeutically significant.	CALIF PACIFIC MED RES INST,SAN FRANCISCO,CA 94115; UNIV WASHINGTON,DEPT COMPARAT MED,SEATTLE,WA 98195; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco					NCI NIH HHS [R01-CA 58914] Funding Source: Medline; NHLBI NIH HHS [R01-HL 53762] Funding Source: Medline; NIDDK NIH HHS [R01-DK45917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGHAM KL, 1993, AM J RESP CELL MOL, V8, P209, DOI 10.1165/ajrcmb/8.2.209; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CHENG L, 1993, P NATL ACAD SCI USA, V90, P4455, DOI 10.1073/pnas.90.10.4455; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEBS R, 1992, AM J RESPIR CELL MOL, P406; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; HAAS R, 1993, EXP HEMATOL, V21, P109; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; ICHIKAWA T, 1995, EXP HEMATOL, V23, P192; KAWAKAMI M, 1990, BLOOD, V76, P1962; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LESOONWOOD LA, 1995, HUM GENE THER, V6, P365; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; PAUKSEN K, 1994, BRIT J HAEMATOL, V88, P256, DOI 10.1111/j.1365-2141.1994.tb05015.x; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PETROS WP, 1992, PHARMACOTHERAPY, V12, pS32; PHILIP R, 1993, J BIOL CHEM, V268, P16087; ROSENTHAL FM, 1994, BLOOD, V84, P2960; Sambrook J, 1989, MOL CLONING LABORATO; STINSKI MF, 1985, J VIROL, V55, P431, DOI 10.1128/JVI.55.2.431-441.1985; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; WANG C, 1995, J CLIN INVEST, V95, P1710, DOI 10.1172/JCI117847; WU GY, 1991, J BIOL CHEM, V266, P14338; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073; ZHU N, 1993, Patent No. 24640	33	204	278	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24864	24870		10.1074/jbc.270.42.24864	http://dx.doi.org/10.1074/jbc.270.42.24864			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559609	hybrid			2022-12-25	WOS:A1995TB46500043
J	LORD, ST; ROONEY, MM; HOPFNER, KP; DICERA, E				LORD, ST; ROONEY, MM; HOPFNER, KP; DICERA, E			BINDING OF FIBRINOGEN A-ALPHA-1-50-BETA-GALACTOSIDASE FUSION PROTEIN TO THROMBIN STABILIZES THE SLOW FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTION	The interaction of fibrinogen A alpha 1-50-beta-galactosidase fusion protein with the slow and fast forms of thrombin was studied and compared to thrombin-fibrinogen interaction under identical solution conditions. At equilibrium, the affinity of the fusion protein for the slow form of thrombin is 3 times higher than its affinity for the fast form. The fusion protein and fibrinogen have the same affinity for the fast form. On the other hand, the affinity of the fusion protein for the slow form of thrombin is 40 times tighter than that of fibrinogen. In the transition state, binding of the fusion protein has the same properties as fibrinogen, with the fast form showing higher specificity. The N-terminal fragment of the fibrinogen A alpha chain thus contains residues that are responsible for the preferential binding of the fusion protein to the slow form at equilibrium and to the fast form in the transition state. If this fragment binds to thrombin in a similar way for fibrinogen and the fusion protein, then the N-terminal domains of the B beta and gamma chains of fibrinogen, that are not present in the fusion protein, must play a key role in the binding of fibrinogen to thrombin at equilibrium. These chains may destabilize binding to the slow form by nearly 2.4 kcal/mol, thereby favoring binding of fibrinogen to the fast form. We propose that the three chains of fibrinogen play different roles in the thrombin-fibrinogen interaction, with the A alpha chain containing residues for preferential binding to the fast form in the transition state and the B beta and gamma chains containing residues that destabilize binding to the slow form at equilibrium.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Hopfner, Karl-Peter/B-6864-2014	Hopfner, Karl-Peter/0000-0002-4528-8357	NHLBI NIH HHS [HL49413, HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, P01HL045100, R01HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BINNIE CG, 1993, BLOOD, V81, P3186; BODE W, 1992, PROTEIN SCI, V1, P421; DANG QD, 1994, J PROTEIN CHEM, V13, P367, DOI 10.1007/BF01901692; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; HOPFNER KP, 1992, BIOCHEMISTRY-US, V31, P11567, DOI 10.1021/bi00161a040; KACZMAREK E, 1988, J BIOL CHEM, V263, P13896; KOOPMAN J, 1992, J CLIN INVEST, V90, P238, DOI 10.1172/JCI115841; LIU CY, 1985, J BIOL CHEM, V260, P4390; LORD ST, 1989, BLOOD, V73, P166; LORD ST, 1990, J BIOL CHEM, V265, P838; MATHUR A, 1993, BIOCHEMISTRY-US, V32, P7568, DOI 10.1021/bi00080a031; NG AS, 1993, METHOD ENZYMOL, V222, P341; NIWA K, 1993, BLOOD, V82, P3658; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SIEBENLIST KR, 1990, J BIOL CHEM, V265, P18650; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TULINSKY A, 1991, THROMB HAEMOSTASIS, V66, P16; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775	20	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24790	24793		10.1074/jbc.270.42.24790	http://dx.doi.org/10.1074/jbc.270.42.24790			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559597	hybrid			2022-12-25	WOS:A1995TB46500031
J	SEWELL, AK; YOKOYA, F; YU, W; MIYAGAWA, T; MURAYAMA, T; WINGE, DR				SEWELL, AK; YOKOYA, F; YU, W; MIYAGAWA, T; MURAYAMA, T; WINGE, DR			MUTATED YEAST HEAT-SHOCK TRANSCRIPTION FACTOR EXHIBITS ELEVATED BASAL TRANSCRIPTIONAL ACTIVATION AND CONFERS METAL RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; HSP 70 GENE; SACCHAROMYCES-CEREVISIAE; METALLOTHIONEIN GENE; EXPRESSION; ELEMENT; DOMAIN; STRAIN; CELLS; ACE1	Cadmium-resistant Saccharomyces cerevisiae strain 301N exhibits high basal as well as cadmium-induced expression of the CUP1 metallothionein gene. Since regulation of CUP1 is usually restricted to copper ions, our goal was to identify the factor responsible for the high metallothionein levels in strain 301N. The gene responsible for the observed phenotype is a spontaneously mutated heat shock transcription factor gene (HSF1). A double, semidominant HSF1 mutant with substitutions at codons 206 and 256 within the DNA-binding domain of the heat shock factor (HSF) confers two phenotypes. The first phenotype is elevated transcriptional activity of the HSF mutant (HSF301), which results in constitutive thermotolerance. A second HSF301 phenotype is enhanced binding affinity for the heat shock element (HSE) within the CUP1 5'-sequences, resulting in high basal transcription of metallothionein. The CUP1 HSE is a minimal heat shock element containing only two perfectly spaced inverted repeats of the basic nGAAn block. Cells containing HSF301 are resistant to cadmium salts. The single R206S mutation is responsible for the high affinity binding to the CUP1 HSE. In addition, the R206S HSF substitution exhibits constitutive transcriptional activation from a consensus HSE (HSE2). The F256Y substitution in HSF attenuates the effects of R206S on the consensus HSE2, but not on the CUP1 HSE.	UNIV UTAH, HLTH SCI CTR, DEPT MED, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA; EHIME UNIV, FAC SCI, DEPT BIOL, MATSUYAMA, EHIME 790, JAPAN	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Ehime University			Sewell, Andrew/GPT-4220-2022	Sewell, Andrew/0000-0003-3194-3135	NATIONAL CANCER INSTITUTE [R01CA061286] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; FLICK KE, 1994, J BIOL CHEM, V269, P12475; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOJ A, 1994, EMBO J, V13, P2617; INOUHE M, 1989, BIOCHIM BIOPHYS ACTA, V993, P51, DOI 10.1016/0304-4165(89)90142-6; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1993, J BIOL CHEM, V268, P12512; TOHOYAMA H, 1977, AGR BIOL CHEM TOKYO, V41, P1523, DOI 10.1080/00021369.1977.10862708; TOHOYAMA H, 1992, FEMS MICROBIOL LETT, V95, P81, DOI 10.1111/j.1574-6968.1992.tb05346.x; TOHOYAMA H, 1992, CURR GENET, V21, P275, DOI 10.1007/BF00351682; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676	45	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25079	25086		10.1074/jbc.270.42.25079	http://dx.doi.org/10.1074/jbc.270.42.25079			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559639	hybrid			2022-12-25	WOS:A1995TB46500073
J	TYTGAT, J; DEBONT, T; CARMELIET, E; DAENENS, P				TYTGAT, J; DEBONT, T; CARMELIET, E; DAENENS, P			THE ALPHA-DENDROTOXIN FOOTPRINT ON A MAMMALIAN POTASSIUM CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDROASPIS-POLYLEPIS-POLYLEPIS; PROTEASE INHIBITOR HOMOLOGS; GREEN MAMBA VENOM; ACETYLCHOLINE-RELEASE; SUBUNIT STOICHIOMETRY; TRYPSIN-INHIBITOR; SNAKE-VENOMS; ANGUSTICEPS; TOXINS; BINDING	alpha-Dendrotoxin, a 59-amino acid basic peptide from the venom of Dendroaspis angusticeps (green mamba snake), potently blocks some but not all voltage-dependent potassium channels. Here we have investigated the relative contribution of the individual alpha-subunits constituting functional Kv1.1 potassium channels to alpha-dendrotoxin binding. Three residues critical for alpha-dendrotoxin binding and located in the loop between domains S5 and S6 were mutated (A352P, E353S, and Y379H), and multimeric cDNAs were constructed encoding homo- and heterotetrameric channels composed of all possible ratios of wild-type and mutant alpha-subunits. Complete mutant channels were about 200-fold less sensitive for the alpha-dendrotoxin block than complete wild-type channels, which is attributable to a smaller association rate. Analysis of the bimolecular reaction between alpha-dendrotoxin and the different homo- and heteromeric channel constructs revealed that the association rate depends on the number of wild-type alpha-subunits in the functional channel. Furthermore, we observed a linear relationship between the number of wild-type alpha-subunits in functional channels and the free energy for alpha-dendrotoxin binding, providing evidence that all four alpha-subunits must interact with alpha-dendrotoxin to produce a high affinity binding site.	UNIV LOUVAIN, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM		TYTGAT, J (corresponding author), UNIV LOUVAIN, TOXICOL LAB, VAN EVENST 4, B-3000 LOUVAIN, BELGIUM.		Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				Adams P R, 1986, Adv Neurol, V44, P137; ANDERSON AJ, 1985, TOXICON, V23, P947, DOI 10.1016/0041-0101(85)90387-3; BARRETT JC, 1979, BRIT J PHARMACOL, V67, P199, DOI 10.1111/j.1476-5381.1979.tb08667.x; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BENISHIN CG, 1988, MOL PHARMACOL, V34, P152; BENOIT E, 1986, BRAIN RES, V377, P374, DOI 10.1016/0006-8993(86)90884-X; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; DREYER F, 1990, REV PHYSIOL BIOCH P, V115, P93; DREYER F, 1987, J PHYSL, V318, P455; GARCIACALVO M, 1994, P NATL ACAD SCI USA, V91, P4718, DOI 10.1073/pnas.91.11.4718; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; HARVEY AL, 1982, BRIT J PHARMACOL, V77, P153, DOI 10.1111/j.1476-5381.1982.tb09281.x; HARVEY AL, 1980, N-S ARCH PHARMACOL, V312, P1, DOI 10.1007/BF00502565; HARVEY AL, 1981, TOXICON, V19, P373, DOI 10.1016/0041-0101(81)90042-8; HARVEY AL, 1985, PHARMACOL THERAPEUT, V31, P33, DOI 10.1016/0163-7258(85)90036-1; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; HUBER R, 1970, NATURWISSENSCHAFTEN, V57, P389, DOI 10.1007/BF00599976; HURST RS, 1991, MOL PHARMACOL, V40, P572; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P661, DOI 10.1515/bchm2.1980.361.1.661; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PENNER R, 1986, PFLUG ARCH EUR J PHY, V407, P365, DOI 10.1007/BF00652619; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; RUSSELL SN, 1994, AM J PHYSIOL-CELL PH, V267, pC1729, DOI 10.1152/ajpcell.1994.267.6.C1729; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; STRYDOM DJ, 1976, EUR J BIOCHEM, V69, P169, DOI 10.1111/j.1432-1033.1976.tb10870.x; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471	34	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24776	24781		10.1074/jbc.270.42.24776	http://dx.doi.org/10.1074/jbc.270.42.24776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559595	hybrid			2022-12-25	WOS:A1995TB46500029
J	DAS, T; GUPTA, AK; SIMS, PW; GELFAND, CA; JENTOFT, JE; BANERJEE, AK				DAS, T; GUPTA, AK; SIMS, PW; GELFAND, CA; JENTOFT, JE; BANERJEE, AK			ROLE OF CELLULAR CASEIN KINASE-II IN THE FUNCTION OF THE PHOSPHOPROTEIN-(P) SUBUNIT OF RNA-POLYMERASE OF VESICULAR STOMATITIS-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES TRANSCRIPTION INVITRO; NS PROTEIN; PHOSPHORYLATION; DOMAIN; EXPRESSION; RESIDUES; CELLS; GENE; SITE; ACID	The phosphorylation of the P protein of vesicular stomatitis virus by cellular casein kinase II (CKII) is essential for its activity in viral transcription, Recent in vitro studies have demonstrated that CKII converts the inactive unphosphorylated form of P (P0) to an active phosphorylated form P1, after phosphorylation at two serine residues, Ser-59 and Ser-61. To gain insight into the role of CKII-mediated phosphorylation in the structure and function of the P protein, we have carried out circular dichroism (CD) and biochemical analyses of both PO and P1. The results of CD analyses reveal that phosphorylation of P0 to P1 significantly increases the predicted alpha-helical structure of the P1 protein from 27 to 48%. The phosphorylation defective double serine mutant (P59/61), which is transcriptionally inactive, possesses a secondary structure similar to that of P0, P1, at a protein concentration of 50 mu g/ml, elutes from a gel filtration column apparently as a dimer, whereas both P0 and the double serine mutant elute as a monomer at the same concentration. Interestingly, unlike wild-type P1 protein, the P mutants in which either Ser-59 or Ser-61 is altered to alanine required a high concentration of CKII for optimal phosphorylation. We demonstrate here that phosphorylation of either Ser-59 or Ser-61 is necessary and sufficient to transactivate L polymerase although alteration of one serine residue significantly decreases its affinity for CKII. We have also shown that P1 binds to the N-RNA template more efficiently than P0 and the formation of P1 is a prerequisite for the subsequent phosphorylation by L protein-associated kinase. In addition, mutant P59/61 acts as a transdominant negative mutant when used in a transcription reconstitution assay in the presence of wild-type P protein.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NIAID NIH HHS [AI-26585] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026585] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1974, VIROLOGY, V61, P547, DOI 10.1016/0042-6822(74)90289-X; BANERJEE AK, 1992, VIROLOGY, V188, P417, DOI 10.1016/0042-6822(92)90495-B; BANERJEE AK, 1987, MICROBIOL REV, V51, P66, DOI 10.1128/MMBR.51.1.66-87.1987; BANERJEE AK, 1987, CELL, V48, P363, DOI 10.1016/0092-8674(87)90184-X; BARIK S, 1991, J VIROL, V65, P1719, DOI 10.1128/JVI.65.4.1719-1726.1991; BARIK S, 1992, J VIROL, V66, P1109, DOI 10.1128/JVI.66.2.1109-1118.1992; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P320; BELL JC, 1985, J VIROL, V54, P697, DOI 10.1128/JVI.54.3.697-702.1985; CHATTOPADHYAY D, 1987, CELL, V49, P407, DOI 10.1016/0092-8674(87)90293-5; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; DE BP, 1984, J VIROL, V51, P628, DOI 10.1128/JVI.51.3.628-634.1984; DE BP, 1985, BIOCHEM BIOPH RES CO, V26, P40; EMERSON SU, 1987, RHABDOVIRUSES, P167; GILL DS, 1986, P NATL ACAD SCI USA, V83, P8873, DOI 10.1073/pnas.83.23.8873; GILL DS, 1985, J VIROL, V55, P60, DOI 10.1128/JVI.55.1.60-66.1985; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HSU CH, 1982, J VIROL, V43, P104, DOI 10.1128/JVI.43.1.104-112.1982; HSU CH, 1985, J BIOL CHEM, V260, P8990; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KINGSFORD L, 1980, J VIROL, V33, P1097, DOI 10.1128/JVI.33.3.1097-1105.1980; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MASTERS PS, 1986, VIROLOGY, V154, P259, DOI 10.1016/0042-6822(86)90452-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAUL PR, 1988, VIROLOGY, V166, P350, DOI 10.1016/0042-6822(88)90505-3; SLEAT DE, 1993, J VIROL, V67, P1334, DOI 10.1128/JVI.67.3.1334-1339.1993; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; TAKACS AM, 1992, J VIROL, V66, P5842, DOI 10.1128/JVI.66.10.5842-5848.1992	29	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24100	24107		10.1074/jbc.270.41.24100	http://dx.doi.org/10.1074/jbc.270.41.24100			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592611	hybrid			2022-12-25	WOS:A1995TA21700039
J	AKIYAMA, Y; YOSHIHISA, T; ITO, K				AKIYAMA, Y; YOSHIHISA, T; ITO, K			FTSH, A MEMBRANE-BOUND ATPASE, FORMS A COMPLEX IN THE CYTOPLASMIC MEMBRANE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; OSMOREGULATION; LOCALIZATION; TOPOLOGY; DOMAIN; MUTANT; GENE; ENVZ	The FtsH (HflB) protein of Escherichia coli is inte grated into the membrane with two N-terminally located transmembrane segments, while its large cytoplasmic domain is homologous to the AAA family of ATPases, The previous studies on dominant negative ftsH mutants raised a possibility that FtsH functions in multimeric states, We found that FtsH was eluted at fractions corresponding to a larger molecular weight than expected from monomeric structure in size-exclusion chromatography, Moreover, treatment of membranes or their detergent extracts with a cross-linker, dithiobis(succinimidyl propionate), yielded cross linked products of FtsH, To dissect possible FtsH complex, we constructed an FtsH derivative with c-Myc epitope at its C terminus (FtsH-His(6)-Myc). When membranes prepared from cells in which FtsH-His(6)-Myc was overproduced together with the normal FtsH were treated with the cross-linker, intact FtsH and in vitro degradation products of FtsH-His(6)-Myc without the tag were cross linked with the tagged FtsH protein, Co-immunoprecipitation experiments confirmed the interaction between the FtsH molecules, To identify regions of FtsH required or sufficient for this interaction, we constructed chimeric proteins between FtsH and EnvZ, a protein with a similar topological arrangement, by exchanging their corresponding domains, We found that only the FtsH-EnvZ hybrid protein with an FtsH-derived membrane anchoring domain and an EnvZ-derived cytoplasmic domain caused a dominant ftsH phenotype and was cross-linked with FtsH, We suggest that the N-terminal transmembrane region of FtsH mediates directly the interaction between the FtsH subunits.			AKIYAMA, Y (corresponding author), KYOTO UNIV, INST VIRUS RES, DEPT CELL BIOL, KYOTO 60601, JAPAN.		Yoshihisa, Tomoki/AFA-7466-2022					AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BEGG KJ, 1992, J BACTERIOL, V174, P2416, DOI 10.1128/JB.174.7.2416-2417.1992; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Davis R., 1980, ADV BACTERIAL GENETI; DRIESSEN AJM, 1991, METHOD CELL BIOL, V34, P147; FORST S, 1987, J BIOL CHEM, V262, P16433; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; PAIC A, 1994, FEBS LETT, V353, P301; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; Silhavy T.J., 1984, EXPT GENE FUSIONS; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; TOKISHITA S, 1990, J BIOCHEM-TOKYO, V108, P488, DOI 10.1093/oxfordjournals.jbchem.a123226; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITLEY P, 1993, BIOCHEMISTRY-US, V32, P8534, DOI 10.1021/bi00084a020; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	34	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23485	23490		10.1074/jbc.270.40.23485	http://dx.doi.org/10.1074/jbc.270.40.23485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559511	hybrid			2022-12-25	WOS:A1995RY90900040
J	NORRIS, ML; MILLHORN, DE				NORRIS, ML; MILLHORN, DE			HYPOXIA-INDUCED PROTEIN-BINDING TO O-2-RESPONSIVE SEQUENCES ON THE TYROSINE-HYDROXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEINS; C-FOS TRANSCRIPTION; MEMBRANE DEPOLARIZATION; CYCLIC-AMP; JUN; ELEMENT; HETERODIMERS; EXPRESSION; INDUCTION; INTERACTS	We reported recently that the gene that encodes tyrosine hydroxylase (TH), the rate-limiting enzyme in the biosynthesis of catecholamines, is regulated by hypoxia in the dopaminergic cells of the mammalian carotid body (Czyzyk-Krzeska, M. F., Bayliss, D. A., Lawson, E. E. & Millhorn, D. E. (1992) J. Neurochem, 58, 1538-1546) and in pheochromocytoma (PC12) cells (Czyzyk-Krzeska, M. F., Furnari, B. A., Lawson, E. E. & Millhorn, D. E. (1994) J. Biol. Chem. 269, 760-764). Regulation of this gene during low O-2 conditions occurs at both the level of transcription and RNA stability. Increased transcription during hypoxia is regulated by a region of the proximal promoter that extends from -284 to +27 bases, relative to transcription start site. The present study was undertaken to further characterize the sequences that confer O-2 responsiveness of the TH gene and to identify hypoxia-induced protein interactions with these sequences. Results from chloramphenicol acetyltransferase assays identified a region between bases -284 and -150 that contains the essential sequences for O-2 regulation. This region contains a number of regulatory elements including AP1, AP2, and HIF-1. Gel shift assays revealed enhanced protein interactions at the AP1 and HIF-1 elements of the native gene. Further investigations using supershift and shift-Western analysis showed that c-Fos and JunB bind to the AP1 element during hypoxia and that these protein levels are stimulated by hypoxia. Mutation of the AP1 sequence prevented stimulation of transcription of the TH-chloramphenicol acetyltransferase reporter gene by hypoxia.	UNIV CINCINNATI,COLL MED,DEPT MOLEC & CELLULAR PHYSIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028948] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL033831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33831] Funding Source: Medline; NICHD NIH HHS [HD-28948] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; DEMECZUK S, 1993, P NATL ACAD SCI USA, V90, P2574; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GONZALEZ C, 1979, J NEUROCHEM, V33, P713, DOI 10.1111/j.1471-4159.1979.tb05216.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAYASHI Y, 1990, J NEUROCHEM, V54, P1115, DOI 10.1111/j.1471-4159.1990.tb01937.x; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; KOONG AC, 1994, CANCER RES, V54, P1425; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MECHTA F, 1989, New Biologist, V1, P297; MINER LL, 1992, J NEUROSCI RES, V33, P10, DOI 10.1002/jnr.490330103; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	33	192	198	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23774	23779		10.1074/jbc.270.40.23774	http://dx.doi.org/10.1074/jbc.270.40.23774			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559551	hybrid			2022-12-25	WOS:A1995RY90900080
J	VINAY, DS; RAJE, M; VERMA, RK; MISHRA, GC				VINAY, DS; RAJE, M; VERMA, RK; MISHRA, GC			CHARACTERIZATION OF NOVEL COSTIMULATORY MOLECULES - A PROTEIN 38-42 KDA FROM B-CELL SURFACE IS CONCERNED WITH T-CELL ACTIVATION AND DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODY; COUNTER-RECEPTOR; LYMPHOCYTES-T; ANTIGEN; INDUCTION; CTLA-4; INVITRO; GROWTH; SIGNAL	Optimal activation of T cells often requires signals delivered by the ligation of T cell receptor (TcR) and those resulting from costimulatory interaction between certain T cell surface accessory molecules and their respective counter receptors on antigen presenting cells. The molecular events underlying the co-stimulatory activity are still not understood fully. Here we describe a 38-42-kDa (B3) protein, present on the surface of lipopolysaccharide-activated B cells, which can provide costimulation to resting T cells leading to a predominant release of interleukin (IL)-4 and IL-5 and negligible amounts of IL-2 and interferon-gamma. Binding assay and electron microscopic autoradiography data suggest that this molecule binds T cells, and the same can be competed by unlabeled B3. Characterization experiments point out that B3 shows up as a single prominent peak on reverse phase-high performance liquid chromatography, runs as a single spot in reducing two dimensional gel electrophoresis, and is a phosphoglycoprotein. The Western analysis indicate that it does not cross-react with antibodies directed against murine ICAM-1, LFA-1 alpha, VCAM-1, HSA, and B7 suggesting the novelty of the protein. The internal amino acid sequence of this molecule suggests that it does not belong to a known category of murine B cell surface molecules.	INST MICROBIAL TECHNOL,CHANDIGARH 160014,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)								AGREWALA JN, 1994, EUR J IMMUNOL, V24, P2092, DOI 10.1002/eji.1830240924; AMES BN, 1960, J BIOL CHEM, V235, P769; AMORY A, 1980, J BIOL CHEM, V255, P9353; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; BOUSSIOTIS VA, 1993, P NATL ACAD SCI USA, V90, P11059, DOI 10.1073/pnas.90.23.11059; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P573, DOI 10.1021/bi00376a032; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; CROFT M, 1994, J IMMUNOL, V152, P2675; FERNANDEZBOTRAN R, 1986, J EXP MED, V164, P580, DOI 10.1084/jem.164.2.580; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FRY DW, 1987, ANAL BICOH, V90, P809; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HERNANDEZCASELL.T, 1993, EUR J IMMUNOL, V23, P2799; HOFFMANN MK, 1980, J IMMUNOL, V125, P2076; IMAMURA K, 1992, METHOD ENZYMOL, V90, P150; JENKINS MK, 1992, IMMUNOL TODAY, V13, P69, DOI 10.1016/0167-5699(92)90137-V; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; JOHNSON JG, 1994, J IMMUNOL, V152, P429; KAKIUCHI T, 1983, J IMMUNOL, V131, P109; KATO K, 1993, EUR J IMMUNOL, V23, P1412, DOI 10.1002/eji.1830230638; KAWAKAMI K, 1969, J IMMUNOL, V142, P1818; KAY R, 1990, J IMMUNOL, V145, P1952; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTMAN AH, 1988, P NATL ACAD SCI USA, V85, P9699, DOI 10.1073/pnas.85.24.9699; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; PENIN F, 1984, BIOCHIM BIOPHYS ACTA, V775, P239, DOI 10.1016/0005-2736(84)90175-5; POWRIE F, 1988, IMMUNOL TODAY, V9, P274, DOI 10.1016/0167-5699(88)91309-6; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWAIN SL, 1985, J IMMUNOL, V134, P3934; TAKEI F, 1985, J IMMUNOL, V134, P1403; TERRY RW, 1993, P NATL ACAD SCI USA, V90, P5919, DOI 10.1073/pnas.90.13.5919; TOWBIN H, 1909, P NATL ACAD SCI USA, V76, P4350; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; WAITE JG, 1979, ANAL BIOCHEM, V70, P279; WHITE BA, 1982, J BIOL CHEM, V257, P8569	52	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23429	23436		10.1074/jbc.270.40.23429	http://dx.doi.org/10.1074/jbc.270.40.23429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559503	hybrid			2022-12-25	WOS:A1995RY90900032
J	HERRMANN, JM; KOLL, H; COOK, RA; NEUPERT, W; STUART, RA				HERRMANN, JM; KOLL, H; COOK, RA; NEUPERT, W; STUART, RA			TOPOGENESIS OF CYTOCHROME-OXIDASE SUBUNIT II - MECHANISMS OF PROTEIN EXPORT FROM THE MITOCHONDRIAL MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST NUCLEAR GENE; POSITIVELY CHARGED RESIDUES; C-OXIDASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; INTERMEMBRANE SPACE; TRANSLATION; EXPRESSION; COMPLEX; PRODUCT	Cytochrome c oxidase subunit II (COXII) in yeast mitochondria is synthesized as a precursor (preCOXII) and is sorted across the inner membrane, whereby both N and C termini become exposed to the intermembrane space. We describe here how this process can be experimentally dissected into a number of distinct stages. Our results demonstrate that the translation of COXII is not obligatorily coupled to translocation, Insertion into the inner membrane and export of the N and C-terminal domains require an energized inner membrane. The export of COXII is independent of both maturation by the Imp1p protease and assembly into the cytochrome c oxidase complex. When linked to a mitochondrial matrix-targeting sequence, the N terminal portion of preCOXII (fused to mouse dihydrofolate reductase) can be imported into the mitochondrial matrix. Following accumulation in the matrix, this chimeric protein can become exported across the inner membrane, delivering the N terminus into the intermembrane space where it undergoes processing by the Imp1p protease. This export process displays a number of similarities to bacterial protein export and supports the view that the principles of sorting are conserved from prokaryotes to eukaryotic organelles.			HERRMANN, JM (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY.							ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ANDRE J., 1965, ARCH BIOL, V76, P277; BARANOWSKA H, 1983, CURR GENET, V7, P225, DOI 10.1007/BF00434894; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BISSON R, 1982, J BIOL CHEM, V257, P6716; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BORST P, 1978, CELL, V15, P705, DOI 10.1016/0092-8674(78)90257-X; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CHOMYN A, 1981, NUCLEIC ACIDS RES, V9, P867, DOI 10.1093/nar/9.4.867; CLARKSON GHD, 1989, J BIOL CHEM, V264, P10114; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; COVELLO PS, 1992, EMBO J, V11, P3815, DOI 10.1002/j.1460-2075.1992.tb05473.x; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACINO G, 1983, J BIOL CHEM, V258, P3230; MASON TL, 1973, J BIOL CHEM, V248, P1355; MCKEE EE, 1984, J BIOL CHEM, V259, P9320; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; Poyton Robert O., 1992, Trends in Cell Biology, V2, P369, DOI 10.1016/0962-8924(92)90049-S; PRATJE E, 1983, EMBO J, V2, P1049, DOI 10.1002/j.1460-2075.1983.tb01544.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SEVERINO KA, 1980, P NATL ACAD SCI USA, V77, P142; STEFFENS GCM, 1979, H-S Z PHYSIOL CHEM, V360, P1633, DOI 10.1515/bchm2.1979.360.2.1633; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; VIGNAIS PV, 1969, FEBS LETT, V3, P177, DOI 10.1016/0014-5793(69)80128-6; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WATSON K, 1972, J CELL BIOL, V55, P721, DOI 10.1083/jcb.55.3.721; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x	47	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27079	27086		10.1074/jbc.270.45.27079	http://dx.doi.org/10.1074/jbc.270.45.27079			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592959	hybrid			2022-12-25	WOS:A1995TE58300059
J	BUREAU, MH; LASCHET, JJ				BUREAU, MH; LASCHET, JJ			ENDOGENOUS PHOSPHORYLATION OF DISTINCT GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR POLYPEPTIDES BY SER/THR AND TYR KINASE-ACTIVITIES ASSOCIATED WITH THE PURIFIED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT MESSENGER-RNAS; A RECEPTOR; RAT-BRAIN; BENZODIAZEPINE RECEPTORS; GABA(A) RECEPTOR; MAMMALIAN BRAIN; 2 FORMS; CAMP; BINDING	We have investigated the phosphorylation of gamma-aminobutyric acid type A (GABA(A)) receptor purified from bovine cerebral cortex in the absence of added kinases. Incubation of the affinity-purified receptor with [gamma-P-32]ATP and 500 mu M MnCl2 yielded incorporation of 0.45 mel of P-32/mol of muscimol binding sites within 2 h at 30 degrees C. Mn2+ was much more effective than Mg2+ as activator. Phosphorylation of the receptor was observed on at least three different polypeptides of 51, 53, and 55 kDa. It was predominant on 51- and 53-kDa polypeptides that co-migrate with the [H-3]flunitrazepam photoaffinity-labeled bands, suggesting that P-32 incorporation mainly occurs on alpha-subunits. A monoclonal antibody specific for alpha-subunits adsorbed the endogenously phosphorylated GABA(A) receptor with a stoichiometry close to 1 mol of phosphate/mol of muscimol. The phosphorylation of the 51-kDa polypeptide, corresponding to alpha(1)-subunit, exhibited a micromolar affinity for ATP and sigmoid kinetics (n(H) = 2). Major incorporation of phosphate occurred on serine and threonine residues in roughly equimolar ratio. By enzyme-linked immunosorbent assay and immunoblotting studies we also detected a minor incorporation on tyrosine residues; this was specific for a 55-kDa polypeptide. Comparison with molecular data suggests that at least alpha(1)- and alpha(2)-subunits (Ser and Thr residues) and possibly gamma(2)-subunits (Tyr residue) are endogenously phosphorylated by multiple kinases, with a clear preference for alpha(1)-subunit. The beta-subunits were not phosphorylated in our experimental conditions. The corresponding kinase activities are closely associated to the receptor protein, indicating a new complexity in the regulation of the GABA(A) receptor.	UNIV LIEGE,NEUROCHEM LAB,B-4020 LIEGE,BELGIUM; INSERM,CJF 9012,F-35033 RENNES,FRANCE	University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm)								BENKE D, 1991, J BIOL CHEM, V266, P4478; BROWNING MD, 1993, NEUROCHEM RES, V18, P95, DOI 10.1007/BF00966927; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BUREAU M, 1990, MOL PHARMACOL, V37, P497; BUREAU M, 1992, ARCH INT PHYSL BIOCH, V100, P1; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; BYLUND DB, 1976, ANAL BIOCHEM, V73, P477, DOI 10.1016/0003-2697(76)90197-4; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GYENES M, 1988, MOL PHARMACOL, V34, P719; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; KHAN ZU, 1994, J NEUROCHEM, V63, P371; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LIN YF, 1994, NEURON, V13, P1421, DOI 10.1016/0896-6273(94)90427-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; OLSEN RW, 1991, NEUROCHEM RES, V16, P317, DOI 10.1007/BF00966095; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHRODER H, 1993, J NEUROCHEM, V60, P1007, DOI 10.1111/j.1471-4159.1993.tb03248.x; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WISDEN W, 1992, J NEUROSCI, V12, P1040	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26482	26487		10.1074/jbc.270.44.26482	http://dx.doi.org/10.1074/jbc.270.44.26482			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592865	hybrid			2022-12-25	WOS:A1995TC97800072
J	DU, XP; SAIDO, TC; TSUBUKI, S; INDIG, FE; WILLIAMS, MJ; GINSBERG, MH				DU, XP; SAIDO, TC; TSUBUKI, S; INDIG, FE; WILLIAMS, MJ; GINSBERG, MH			CALPAIN CLEAVAGE OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN BETA(3) SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; PLATELET-AGGREGATION; PLASMA-MEMBRANE; GPIIB-IIIA; RECEPTOR; PROTEIN; PROTEOLYSIS; LIGAND; ALPHA-IIB-BETA-3	The cytoplasmic domains of integrin beta subunits are involved in bidirectional transmembrane signaling. We report that the cytoplasmic domain of the integrin beta(3) subunit undergoes limited proteolysis by calpain, an intracellular calcium-dependent protease, Calpain cleavage occurs during platelet aggregation induced by agonists such as thrombin. Five cleavage sites have been identified. Four of these sites (C-terminal to Thr(741), Tyr(747), Phe(754) and Tyr(759)) are utilized in intact platelets and flank two NXXY motifs (Asn(744)-Pro-Leu-Tyr(747) and Asn(756)-Ile-Thr-Tyr(759)). The fifth site (Ala(735)) is accessible to calpain after EDTA treatment of the alpha(IIb)beta(3) heterodimer, The NXXY motifis critical to the bidirectional signaling functions of beta(3) integrins and their association with the cytoskeleton. Thus, calpain cleavage of the beta(3) cytoplasmic domain may provide a means to regulate integrin signaling functions.	TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Metropolitan Institute of Medical Science	DU, XP (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903	NHLBI NIH HHS [HL48728, HL52547, HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R29HL052547, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; NIEWIAROWSKI S, 1989, BIOCHIM BIOPHYS ACTA, V983, P91, DOI 10.1016/0005-2736(89)90384-2; ODA A, 1993, J BIOL CHEM, V268, P12603; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; RABB H, 1993, J IMMUNOL, V151, P990; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P173, DOI 10.1093/oxfordjournals.jbchem.a135457; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SHATTIL SJ, 1985, BLOOD, V66, P92; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAPLEY P, 1989, ONCOGENE, V4, P325; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	45	153	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26146	26151		10.1074/jbc.270.44.26146	http://dx.doi.org/10.1074/jbc.270.44.26146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592818	hybrid			2022-12-25	WOS:A1995TC97800025
J	FRANCO, R; MOURA, JJG; MOURA, I; LLOYD, SG; HUYNH, BH; FORBES, WS; FERREIRA, GC				FRANCO, R; MOURA, JJG; MOURA, I; LLOYD, SG; HUYNH, BH; FORBES, WS; FERREIRA, GC			CHARACTERIZATION OF THE IRON-BINDING SITE IN MAMMALIAN FERROCHELATASE BY KINETIC AND MOSSBAUER METHODS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LIVER FERROCHELATASE; MOLECULAR-CLONING; GENE; ENZYMES; PROTOPORPHYRIA; PURIFICATION; EXPRESSION; SEQUENCE; PROTEIN	All organisms utilize ferrochelatase (protoheme ferrolyase, EC 4.99.1.1) to catalyze the terminal step of the heme biosynthetic pathway, which involves the insertion of ferrous ion into protoporphyrin IX. Kinetic methods and Mossbauer spectroscopy have been used in an effort to characterize the ferrous ion-binding active site of recombinant murine ferrochelatase. The kinetic studies indicate that dithiothreitol, a reducing agent commonly used in ferrochelatase activity assays, interferes with the enzymatic production of heme. Ferrochelatase specific activity values determined under strictly anaerobic conditions are much greater than those obtained for the same enzyme under aerobic conditions and in the presence of dithiothreitol. Mossbauer spectroscopy conclusively demonstrates that, under the commonly used assay conditions, dithiothreitol chelates ferrous ion and hence competes with the enzyme for binding the ferrous substrate. Mossbauer spectroscopy of ferrous ion incubated with ferrochelatase in the absence of dithiothreitol shows a somewhat broad quadrupole doublet. Spectral analysis indicates that when 0.1 mM Fe(II) is added to 1.75 mM ferrochelatase, the overwhelming majority of the added ferrous ion is bound to the protein. The spectroscopic parameters for this bound species are delta = 1.36 +/- 0.03 mm/s and Delta E(Q) = 3.04 +/- 0.06 mm/s, distinct from the larger Delta E(Q) of a control sample of Fe(II) in buffer only. The parameters for the bound species are consistent with an active site composed of nitrogenous/oxygenous Ligands and inconsistent with the presence of sulfur ligands. This finding is in accord with the absence of conserved cysteines among the known ferrochelatase sequences. The implications these results have with regard to the mechanism of ferrochelatase activity are discussed.	EMORY UNIV, DEPT PHYS, ATLANTA, GA 30322 USA; UNIV NOVA LISBOA, FAC CIENCIAS & TECNOL, CTR QUIM FINA & BIOTECNOL, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV S FLORIDA, COLL MED, H LEE MOFFIT CANC CTR & RES INST, INST BIOMOLEC SCI, TAMPA, FL 33612 USA	Emory University; Universidade Nova de Lisboa; State University System of Florida; University of South Florida			Ferreira, Gloria C/A-4709-2012; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013	Ferreira, Gloria C/0000-0001-9279-2217; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Franco, Ricardo/0000-0002-5139-2871	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CAMADRO JM, 1984, J BIOL CHEM, V259, P5678; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DAILEY HA, 1987, ANN NY ACAD SCI, V514, P81, DOI 10.1111/j.1749-6632.1987.tb48763.x; DAILEY HA, 1994, J BIOL CHEM, V33, P403; DEBRUNNER PG, 1990, IRON PORPHYRINS 3, P139; FERREIRA GC, 1987, J BIOL CHEM, V262, P4407; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FERREIRA GC, 1994, J BIOL CHEM, V269, P4396; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P221, DOI 10.1007/BF02110037; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; HANSSON M, 1994, EUR J BIOCHEM, V220, P201, DOI 10.1111/j.1432-1033.1994.tb18615.x; Huynh B H, 1984, Adv Inorg Biochem, V6, P163; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; JORDAN PM, 1991, BIOSYNTHESIS TETRAPY, P257; KOHNO H, 1994, BBA-PROTEIN STRUCT M, V1209, P95, DOI 10.1016/0167-4838(94)90142-2; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MIYAMOTO K, 1994, PLANT PHYSIOL, V105, P769, DOI 10.1104/pp.105.2.769; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; PORRA RJ, 1963, BIOCHEM J, V87, P186, DOI 10.1042/bj0870186; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; PORRA RJ, 1967, BIOCHEM J, V104, P321, DOI 10.1042/bj1040321; PUNEKAR NS, 1991, BIOTECHNOL APPL BIOC, V14, P21; RAVI N, 1994, J AM CHEM SOC, V116, P8007, DOI 10.1021/ja00097a007; SAMS JR, 1979, PORPHYRINS, V4, P425; Schulz C., 1976, J PHYS C SOLID STATE, V37, DOI DOI 10.1051/JPHYSCOL:1976633; SMITH AG, 1994, J BIOL CHEM, V269, P13405; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; WHITCOMBE DM, 1991, GENOMICS, V11, P1152, DOI 10.1016/0888-7543(91)90044-F; White WI., 1978, PORPHYRINS, P303, DOI [10.1016/B978-0-12-220105-9.50014-X, DOI 10.1016/B978-0-12-220105-9.50014-X]	42	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26352	26357		10.1074/jbc.270.44.26352	http://dx.doi.org/10.1074/jbc.270.44.26352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592847	hybrid			2022-12-25	WOS:A1995TC97800054
J	HECKERT, LL; SCHULTZ, K; NILSON, JH				HECKERT, LL; SCHULTZ, K; NILSON, JH			DIFFERENT COMPOSITE REGULATORY ELEMENTS DIRECT EXPRESSION OF THE HUMAN ALPHA-SUBUNIT GENE TO PITUITARY AND PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PROTEIN-BINDING DOMAINS; CAMP RESPONSE ELEMENTS; GLYCOPROTEIN HORMONES; C-FOS; TRANSCRIPTION; ENHANCER; INTERACT; PROMOTER; PEA3	To identify elements of the human alpha subunit gene necessary for cell-specific expression, we generated an array of block mutations spanning approximately 400 base pairs (bp) of promoter proximal region and examined them using transient transfection analysis in pituitary (alpha T3) and placental (BeWo) cell lines, Comparison of promoter activity in the two cell types revealed both common and unique elements required for transcription in pituitary and placenta, Two strong elements, the cyclic AMP response element (CRE) and the upstream regulatory element (URE), regulate expression of the a subunit gene in BeWo cells, In contrast, promoter activity in alpha T3 cells requires an array of weaker elements, These include the CREs, the URE, as well as two previously described elements, pituitary glycoprotein hormore basal element (PGBE) and gonadotrope-specific element (GSE), and two new elements we designated as the a basal elements 1 and 2 (alpha BE1 and alpha BE2). These new elements reside between -316 and -302 bp (alpha BE1) and -296 and -285 bp (alpha BE2) of the human a subunit promoter and bind distinct proteins designated alpha BP1 and alpha BP2, respectively, Southwestern blot analysis revealed that alpha BE1 specifically binds 54- and 56-kDa proteins, Additional studies disclosed several potential interactions between proteins that bind the CRE and proteins that occupy PGBE, alpha BE1, and alpha BE2, suggesting that gonadotrope-specific expression occurs through a unique composite regulatory element that includes components of the placenta-specific enhancer.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028559, F32DK008975] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08975-02, DK 28559] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABMAYR SM, 1994, CURRENT PROTOCOLS MO; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; Bousfield George R., 1994, P1749; CHIN WW, 1984, PITUITARY GLAND, P103; CHODOSH LA, 1994, CURRENT PROTOCOLS MO; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JAMESON JL, 1987, MOL CELL BIOL, V7, P3032, DOI 10.1128/MCB.7.9.3032; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KAY TWH, 1992, MOL ENDOCRINOL, V6, P1767, DOI 10.1210/me.6.11.1767; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; MOORE WT, 1980, CHORIONIC GONADOTROP, P89; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	35	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26497	26504		10.1074/jbc.270.44.26497	http://dx.doi.org/10.1074/jbc.270.44.26497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592867	hybrid			2022-12-25	WOS:A1995TC97800074
J	BECERRA, SP; SAGASTI, A; SPINELLA, P; NOTARIO, V				BECERRA, SP; SAGASTI, A; SPINELLA, P; NOTARIO, V			PIGMENT EPITHELIUM-DERIVED FACTOR BEHAVES LIKE A NONINHIBITORY SERPIN - NEUROTROPHIC ACTIVITY DOES NOT REQUIRE THE SERPIN REACTIVE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; CONFORMATIONAL CHANGE; ALPHA-1-PROTEINASE INHIBITOR; OVALBUMIN; BINDING; ALPHA-1-ANTITRYPSIN; ANGIOTENSINOGEN; ANTITHROMBIN; FAMILY; IDENTIFICATION	Pigment epithelium-derived factor (PEDF), a neurite-promoting factor, has an amino acid primary structure that is related to members of the serine protease inhibitor (serpin) family. Controlled proteolysis of native PEDF (50 kDa) with either trypsin, chymotrypsin, elastase, or subtilisin yields in each case one major limited product of 46 kDa as analyzed by SDS-polyacrylamide gel electrophoresis. N-terminal sequence analysis of the isolated 46-kDa products indicates a favored cleavage region located toward the C-terminal end of PEDF. A proteolyzed PEDF protein reaction mixture reveals two overlapping sequences: that of the N terminus of intact PEDF and that of an internal region, consistent with cleavage of PEDF about position 382. These data indicate that PEDF protein has a globular conformation with one protease-sensitive exposed loop that contains the homologous serpin-reactive site. Cleavage within the reactive-site loop of PEDF does not cause a conformational change in the molecules (the stressed (S) --> relaxed (R) transition) and results in heat denaturation identical to its native counterpart. This lack of conformational change is also seen upon cleavage within the reactive-site loop of the noninhibitory serpin ovalbumin. Furthermore, the PEDF neurite-promoting function is not lost with cleavage of the exposed loop, Recombinant PEDF polypeptide fragments with larger truncations from the C-terminal end show neurotrophic activity. Our results clearly indicate that integrity of the PEDF homologous serpin reactive center is dispensable for neurotrophic activity. Thus, the PEDF induction of neurites must be mediated by a mechanism other than serine protease inhibition. Altogether our data indicate that PEDF belongs to the subgroup of noninhibitory serpins and that its N-terminal region confers a neurite-promoting activity to the protein. The neurotrophic active site of PEDF is separated from the serpin reactive-site loop, not only in the primary structure, but also in the folded protein structure.	NIH,OFF INTRAMURAL RES,PROT EXPRESS LAB,BETHESDA,MD 20892; GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; Georgetown University	BECERRA, SP (corresponding author), NEI,RETINAL CELL & MOLEC BIOL LAB,6 CTR DR,MSC 2740,BLDG 6,RM 308,BETHESDA,MD 20892, USA.		/AAB-6461-2022; /AFP-0764-2022; Spinella, Philip/GNW-3633-2022					BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; BOCK SC, 1990, PROTEIN ENG, V4, P107, DOI 10.1093/protein/4.2.107; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; EVANS DL, 1991, J BIOL CHEM, V266, P22307; GETTINS P, 1989, J BIOL CHEM, V264, P3781; GLOOR S, 1986, CELL, V47, P687; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HOUENOU LJ, 1995, P NATL ACAD SCI USA, V92, P895, DOI 10.1073/pnas.92.3.895; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MONARD D, 1990, PROG BRAIN RES, V2, P167; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PEMBERTON PA, 1995, J BIOL CHEM, V270, P18832; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TANAWAKI T, 1995, J NEUROCHEM, V64, P2509; TANIWAKI T, 1994, 24 ANN M SOC NEUR MI, V20, P1691; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060	32	203	216	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25992	25999		10.1074/jbc.270.43.25992	http://dx.doi.org/10.1074/jbc.270.43.25992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592790	hybrid			2022-12-25	WOS:A1995TB46600107
J	BACHHAWAT, N; OUYANG, QA; HENRY, SA				BACHHAWAT, N; OUYANG, QA; HENRY, SA			FUNCTIONAL-CHARACTERIZATION OF AN INOSITOL-SENSITIVE UPSTREAM ACTIVATION SEQUENCE IN YEAST - A CIS-REGULATORY ELEMENT RESPONSIBLE FOR INOSITOL-CHOLINE MEDIATED REGULATION OF PHOSPHOLIPID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; SACCHAROMYCES-CEREVISIAE; INO1 PROMOTER; DNA-SEQUENCE; BINDING-SITE; GENE; ENCODES; COMPLEXES; SYNTHASE	A repeated element, the inositol-sensitive upstream activation sequence (UAS(INO)), having the consensus sequence, 5'-CATGTGAAAT-3', is present in the promoters of genes encoding enzymes of phospholipid biosynthesis that are regulated in response to the phospholipid precursors, inositol and choline. None of the naturally occurring variants of the UAS(INO) element exactly recapitulates the consensus (for review, see Carman, G. M., and Henry, S. A. (1989) Annu. Rev. Biochem. 58, 635-669 and Paltauf, F., Kolwhein, S., and Henry, S. A. (1992) in Molecular Biology of the Yeast Saccharomyces cerevisiae (Broach, J., Jones, E., and Pringle, J., eds) Vol. 2, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). The first six bases of the UAS(INO) element are homologous with canonical binding motif for proteins of the basic helix-loop helix (bHLH) family. Two bHLH regulatory proteins, Ino2p and Ino4p from yeast, were previously shown to bind to promoter fragments containing this element. In the present study, an extensive analysis of UAS(INO) function has been conducted. We report that any base substitution within the putative bHLH binding site resulted either in a dramatic reduction or in a complete obliteration of UAS(INO) function as tested in an expression assay in vivo. Base substitutions in the 5' region that flanks the 10-base pair repeat, as well as sequences within the repeat itself at its 3' end outside the bHLH core, were also assessed. The two bases immediately flanking the 5' end of the element proved to be very important to its function as a UAS element as did the two bases immediately 3' of the bHLH core motif. Substitutions of the final two bases of the original ten base pair consensus (i.e. 5'-CATGTGAAAT-3') had less dramatic effects. We also tested a subset of the altered elements for their ability to serve as competitors in an assay of Ino2p . Ino4p binding. The strength of any given sequence as a UAS(INO) element, as assayed in vivo, was strongly correlated with its strength as a competitor for Ino2p . Ino4p binding. We also tested a subset of the modified UAS(INO) elements for their effects on expression in vivo in a strain carrying an opi1 mutation. The opi1 mutation renders the coregulated enzymes of phospholipid synthesis constitutive in the presence of phospholipid precursors. All elements that retained some residual UAS(INO) activity when tested in the wild-type strain were constitutively expressed at a level comparable with the wild-type derepressed level when tested in the opi1 mutant. Thus, UAS(INO) appears to be responsible for OPI1 mediated repression, as well as Ino2p . Ino4p binding. Furthermore, each of the identified functions of the UAS(INO) element appears to have the same sequence specificity, and all require the presence of the intact bHLH motif, suggesting that transcriptional activation, repression, and Ino2p . Ino4p binding are all components of a single regulatory mechanism.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University			Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; GREENBERG ML, 1996, IN PRESS MICROBIOL R; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Sambrook J, 1989, MOL CLONING LABORATO; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SLEKAR KH, 1995, NUCLEIC ACIDS RES, V23, P1964, DOI 10.1093/nar/23.11.1964; WHITE MJ, 1991, J BIOL CHEM, V266, P863	26	100	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25087	25095		10.1074/jbc.270.42.25087	http://dx.doi.org/10.1074/jbc.270.42.25087			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559640	hybrid			2022-12-25	WOS:A1995TB46500074
J	JARS, MU; OSBORN, S; FORSTROM, J; MACKAY, VL				JARS, MU; OSBORN, S; FORSTROM, J; MACKAY, VL			N-GLYCOSYLATION AND O-GLYCOSYLATION AND PHOSPHORYLATION OF THE BAR SECRETION LEADER DERIVED FROM THE BARRIER PROTEASE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; COLLISION-INDUCED DISSOCIATION; LIQUID-CHROMATOGRAPHY; LINKED OLIGOSACCHARIDES; POLYACRYLAMIDE GELS; PROTEINS; YEAST; GLYCOPROTEIN; SITES; GENE	A secretion leader derived from a domain of the extracellular Barrier protease of the yeast Saccharomyces cerevisiae has been expressed in wild-type and in mnn1, mnn9, and mnn1 mnn9 glycosylation mutant strains of S. cerevisiae. Structural comparison of the extracellular leader by mass spectrometry, peptide mapping, and elementary analysis proved that all strains produced a heterogeneous, heavily glycosylated polypeptide of 161 amino acids with both N- and O-glycosylation and phosphorylation. All three potential Asn N linked sites were glycosylated to some extent with the expected structures. Neither the different growth media used nor the glycosylation mutations had significant effect on O-glycosylation with respect to both site selectivity and size of the carbohydrate structures. All 33 Ser and 21 Thr residues in the polypeptide were glycosylated at least partially, with an average of more than 2 mannoses/site, Although the mnn1 mutation blocks addition of alpha 1,3-linked mannose, the bar secretion domain expressed in the mnn1 and mnn1 mnng transformants unexpectedly contained some O-linked structures with at least 4 mannoses/chain. These O-linked structures were as large as when the leader was expressed in the mnn9 and wild-type strains. The bar secretion domain also had a previously undocumented phosphorylated O-linked structure.	ZYMOGENET INC, SEATTLE, WA 98102 USA	Zymogenet Inc.								BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BORYS MC, 1993, BIO-TECHNOL, V11, P720, DOI 10.1038/nbt0693-720; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; CARR SA, 1993, PROTEIN SCI, V2, P183; CONBOY JJ, 1992, J AM SOC MASS SPECTR, V3, P804, DOI 10.1016/1044-0305(92)80003-4; COVEY TR, 1991, ANAL CHEM, V63, P1193, DOI 10.1021/ac00013a003; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Franzusoff A, 1992, Semin Cell Biol, V3, P309, DOI 10.1016/1043-4682(92)90018-Q; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GELLERFORS P, 1989, J BIOL CHEM, V264, P11444; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; GRAHAM TR, 1992, YEAST S, V8, P458; GUZZETTA AW, 1993, ANAL CHEM, V65, P2953, DOI 10.1021/ac00069a004; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JIANG SJ, 1988, SPECTROCHIM ACTA B, V43, P405, DOI 10.1016/0584-8547(88)80068-5; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; KONIG W, 1970, CHEM BER-RECL, V103, P788, DOI 10.1002/cber.19701030319; KRISHNA PG, 1993, METHODS PROTEIN SEQU, P167; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRIBA G, 1993, YEAST, V9, P441, DOI 10.1002/yea.320090502; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; MACKAY VL, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P25; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MACKAY VL, 1991, P ASPARTIC PROTEINAS, P161; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; SETTINERI CA, 1990, BIOMED ENVIRON MASS, V19, P665, DOI 10.1002/bms.1200191106; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; THIM L, 1993, FEBS LETT, V318, P345, DOI 10.1016/0014-5793(93)80543-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRUEHEART J, 1989, P NATL ACAD SCI USA, V86, P9916, DOI 10.1073/pnas.86.24.9916; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YAMADA T, 1994, BIOCHEMISTRY-US, V33, P3885, DOI 10.1021/bi00179a013; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	51	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24810	24817		10.1074/jbc.270.42.24810	http://dx.doi.org/10.1074/jbc.270.42.24810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559601	hybrid			2022-12-25	WOS:A1995TB46500035
J	JOHNSON, WJ; FISCHER, RT; PHILLIPS, MC; ROTHBLAT, GH				JOHNSON, WJ; FISCHER, RT; PHILLIPS, MC; ROTHBLAT, GH			EFFLUX OF NEWLY SYNTHESIZED CHOLESTEROL AND BIOSYNTHETIC STEROL INTERMEDIATES FROM CELLS - DEPENDENCE ON ACCEPTOR TYPE AND ON ENRICHMENT OF CELLS WITH CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; PLASMA-MEMBRANE; INTRACELLULAR MEMBRANES; ENDOPLASMIC-RETICULUM; HUMAN FIBROBLASTS; COENZYME-A; PROTEIN; REDUCTASE; TRANSPORT	Previous studies suggest that during sterol synthesis in cells, cholesterol and precusor sterols are transported to the plasma membrane and that this transport is stimulated by the binding of high density lipoprotein (HDL) to its putative cell surface receptor, leading to enhanced sterol efflux. Little is known about the identities of synthesized sterols subject to efflux or whether efflux of cholesterol and precursor sterols are stimulated equally by HDL. To address these issues, cells were incubated with [H-3]acetate or [H-3]mevalonate and sterol accepters, and then the labeled sterols in cells and efflux media were analyzed by high pressure liquid chromatography methods that resolved cholesterol and precursor sterols. In non-hepatic cells (Chinese hamster ovary (CHO), fibroblasts, and smooth muscle), cholesterol and multiple precursor sterols accumulated. In CHO cells, the major products were cholesterol and des-mosterol, which together constituted 50% of labeled nonsaponifiable lipids. When media contained human HDL(3) (1 mg of protein/ml), the molar efflux of synthesized desmosterol was four times that of cholesterol, and the 8-h efflux of those sterols, each normalized to its own production, averaged 48 and 16%, respectively. When media contained egg phosphatidylcholine vesicles (1 mg/ml), the efflux of these sterols averaged 18 and 2.4%, respectively. Thus, with both accepters, desmosterol was the major synthesized sterol released from cells, and its efflux was substantially greater than that of synthesized cholesterol. High relative efflux of desmosterol (or a desmosterol-like sterol) occurred in all cell types and in both cholesterol-enriched and unenriched cells. These results demonstrated qualitatively similar efflux of synthesized sterols in the presence of HDL(3) and phospholipid vesicles, arguing against an absolute requirement for accepters that interact with the HDL receptor. To probe for possible quantitative differences in the capabilities of these two accepters, the ratios of (efflux to HDL(3))/(efflux to phosphatidylcholine vesicles) were calculated for synthesized cholesterol and desmosterol, plasma membrane cholesterol, and lysosomal cholesterol. In comparison to plasma membrane cholesterol, there was little or no HDL selectivity for lysosomal cholesterol or synthesized desmosterol, whereas there was a 2-3-fold selectivity for synthesized cholesterol, suggesting that the ability of HDL to enhance the efflux of synthesized sterols is a modest quantitative effect and confined to cholesterol.	HAHNEMANN UNIV,PHILADELPHIA,PA 19129; DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880	Drexel University; DuPont	JOHNSON, WJ (corresponding author), MED COLL PENN,DEPT BIOCHEM,2900 QUEEN LANE,PHILADELPHIA,PA 19129, USA.			Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; AVIRAM M, 1989, J LIPID RES, V30, P65; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BJORKHEM I, 1987, J LIPID RES, V28, P1137; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURKI E, 1987, J LIPID RES, V28, P1199; CAPRIOTTI AM, 1987, J TISSUE CULTURE MET, V10, P219; CLEJAN S, 1984, J BIOL CHEM, V259, P441; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FAUST J, 1987, J BIOL CHEM, V262, P1996; FISCHER RT, 1989, J LIPID RES, V30, P1621; HANSBURY E, 1980, J LIPID RES, V21, P921; HASLAM RM, 1953, BIOCHEM J, V55, P340, DOI 10.1042/bj0550340; Hatch F T, 1968, Adv Lipid Res, V6, P1; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; ISSODORIDES CH, 1962, J ORG CHEM, V27, P4693; JOHNSON WJ, 1994, J LIPID RES, V35, P563; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1987, J BIOL CHEM, V262, P4433; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MENDEZ AJ, 1985, J BIOL CHEM, V270, P5891; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; SPERRY WM, 1950, J BIOL CHEM, V187, P97; TABACIK C, 1991, ATHEROSCLEROSIS, V86, P123, DOI 10.1016/0021-9150(91)90208-K; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANHANEN HT, 1993, J LIPID RES, V34, P1535	38	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25037	25046		10.1074/jbc.270.42.25037	http://dx.doi.org/10.1074/jbc.270.42.25037			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559634	hybrid			2022-12-25	WOS:A1995TB46500068
J	LIN, WH; HUANG, LH; YEH, JY; HOHEISEL, J; LEHRACH, H; SUN, YH; TSAI, SF				LIN, WH; HUANG, LH; YEH, JY; HOHEISEL, J; LEHRACH, H; SUN, YH; TSAI, SF			EXPRESSION OF A DROSOPHILA GATA TRANSCRIPTION FACTOR IN MULTIPLE TISSUES IN THE DEVELOPING EMBRYOS - IDENTIFICATION OF HOMOZYGOUS LETHAL MUTANTS WITH P-ELEMENT INSERTION AT THE PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; NITROGEN REGULATORY GENE; SEQUENCE-ANALYSIS; ENDOTHELIAL-CELLS; FAMILY; ENHANCER; DOMAIN; ZINC; LOCALIZATION; POLYMERASE	GATA transcription factors are DNA-binding proteins that recognize the core consensus sequence, WGATAR. Previous studies indicated that GATA factors play an important role in the development of tissue-specific functions in vertebrates, Here we report the identification of a new Drosophila melanogaster GATA factor, dGATAc, which displays a distinct expression pattern in embryos. The local concentration of dGATAc transcripts varies at different stages, being most prominent in the procephalic region at stages 6-10 and in the posterior spiracles, the gut, and the central nervous system at stages 11-13. On the basis of its predicted sequence, DNA-binding assays were performed to confirm that the dGATAc gene encodes a zinc finger protein that can bind the GATA consensus motif with predicted specificity. Two independent mutants carrying a P-element insertion at the dGATAc gene promoter region were identified that are homozygous lethal at the embryonic stage. Using a genetic scheme, it was demonstrated that the lack of dGATAc function can block normal embryonic development. Our results suggest that the dGATAc protein is a tissue-specific transcription factor that is vital to the development of multiple organ systems in D. melanogaster.	NATL YANG MING UNIV, INST GENET, TAIPEI 112, TAIWAN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Cancer Research UK			Sun, Y. Henry/AAZ-7966-2021; Tsai, Shih-Feng/E-3997-2010; Lin, Wen-Hsing/K-8580-2013; Sun, Y. Henry/ABC-4614-2021	Lin, Wen-Hsing/0000-0001-5023-310X; Sun, Y. Henry/0000-0001-8279-5270				ABEL T, 1993, DEVELOPMENT, V119, P623; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KARPEN GH, 1992, GENETICS, V132, P737; KELLEY C, 1993, DEVELOPMENT, V118, P817; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KULDA B, 1990, EMBO J, V9, P1355; LEE ME, 1991, J BIOL CHEM, V266, P16188; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WINICK J, 1993, DEVELOPMENT, V119, P1055; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	55	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25150	25158		10.1074/jbc.270.42.25150	http://dx.doi.org/10.1074/jbc.270.42.25150			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559649	hybrid			2022-12-25	WOS:A1995TB46500083
J	MILEV, P; MEYERPUTTLITZ, B; MARGOLIS, RK; MARGOLIS, RU				MILEV, P; MEYERPUTTLITZ, B; MARGOLIS, RK; MARGOLIS, RU			COMPLEX-TYPE ASPARAGINE-LINKED OLIGOSACCHARIDES ON PHOSPHACAN AND PROTEIN-TYROSINE PHOSPHATASE-ZETA/BETA MEDIATE THEIR BINDING TO NEURAL CELL-ADHESION MOLECULES AND TENASCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SODIUM DODECYL-SULFATE; CHONDROITIN SULFATE; N-GLYCOSYLATION; BRAIN; DEGLYCOSYLATION; RECOGNITION; GLYCANS; CLONING; DOMAIN	Phosphacan, a soluble nervous tissue-specific chondroitin sulfate proteoglycan, is an alternative splicing product representing the entire extracellular domain of a transmembrane receptor-type protein-tyrosine phosphatase (RPTP zeta/beta) that also occurs as a chondroitin sul fate proteoglycan in brain. We have previously demonstrated that phosphacan binds with high affinity to neural cell adhesion molecules (Ng-CAM/L1 and N-CAM) and to the extracellular matrix protein tenascin and that it is a potent inhibitor of cell adhesion and neurite outgrowth. Tryptic digests of I-125-labeled phosphacan contain two glycopeptides that bind to Ng-CAM/L1, N-CAM, and tenascin. The larger of these (17 kDa) begins at Gln-209 near the end of the carbonic anhydrase-like domain of phosphacan/RPTP zeta/beta, whereas a 13-kDa glycopeptide begins at His-361 located in the middle of the fibronectin type III-like domain. Treatment of phosphacan with peptide N-glycosidase under nondenaturing conditions reduced its binding to the neural cell adhesion molecules and tenascin by 65-75%, whereas endo-beta-N-acetylglucosaminidase H had no effect, and peptide N-glycosidase treatment both decreased the molecular sizes of the tryptic peptides to similar to 11 kDa and abolished their binding. Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex type oligosaccharides. Our results therefore indicate that the interactions of phosphacan/RPTP zeta/beta with neural cell adhesion molecules and tenascin are mediated by asparagine-linked oligosaccharides present in their carbonic anhydrase- and fibronectin type III-like domains.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009348, R01NS013876] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-09348, NS-13876] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allendoerfer K. L., 1995, Society for Neuroscience Abstracts, V21, P276; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEACH BS, 1980, BIOCHEMISTRY-US, V19, P5734, DOI 10.1021/bi00566a011; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MAUREL P, 1995, DNA SEQUENCE, V5, P323, DOI 10.3109/10425179509030989; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; NUCK R, 1990, GLYCOCONJUGATE J, V7, P279, DOI 10.1007/BF01073372; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHITARA K, 1994, J BIOL CHEM, V269, P20189; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WEITZHANDLER M, 1993, J BIOL CHEM, V268, P5121	25	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24650	24653		10.1074/jbc.270.42.24650	http://dx.doi.org/10.1074/jbc.270.42.24650			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559574	hybrid			2022-12-25	WOS:A1995TB46500008
J	CHAPMAN, ER; HANSON, PI; AN, S; JAHN, R				CHAPMAN, ER; HANSON, PI; AN, S; JAHN, R			CA2+ REGULATES THE INTERACTION BETWEEN SYNAPTOTAGMIN AND SYNTAXIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; CHROMAFFIN CELLS; EXOCYTOSIS; SECRETION; SYNAPTOBREVIN; INHIBITION; DOCKING; BINDING; TETANUS; FUSION	While there is compelling evidence that the synaptic vesicle protein synaptotagmin serves as the major Ca2+ sensor for regulated exocytosis, it is not known how Ca2+ binding initiates membrane fusion. Here we report that Ca2+ increases the affinity, by approximately 2 orders of magnitude, between synaptotagmin and syntaxin 1, a component of the synaptic fusion apparatus. This effect is specific for divalent cations which can stimulate exocytosis of synaptic vesicles (Ca2+ > Ba2+, Sr2+ >> Mg2+). The Ca2+- dependence of the interaction was composed of two components with EC(50) values of 0.7 and 180 mu M Ca2+. The interaction is mediated by the carboxyl-terminal region of syntaxin 1 (residues 194-288) and is regulated by a novel Ca2+-binding site(s) which does not require phospholipids and is not disrupted by mutations that abolish Ca2+-dependent phospholipid binding to synaptotagmin. We propose that this interaction constitutes an essential step in excitation-secretion coupling.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University; Yale University	CHAPMAN, ER (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510, USA.		Hanson, Phyllis/E-9420-2012	Chapman, Edwin/0000-0001-9787-8140; Jahn, Reinhard/0000-0003-1542-3498				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHAPMAN ER, 1994, SEMIN NEUROSCI, V6, P159; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; JAHN R, 1994, NATURE, V370, P191; Katz B., 1969, 10 SHERR LECT SPRING; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; PERIN M, 1990, NATURE, V343, P260; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; YOSHIDA A, 1992, J BIOL CHEM, V276, P24925; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	43	314	319	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23667	23671		10.1074/jbc.270.40.23667	http://dx.doi.org/10.1074/jbc.270.40.23667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559535	hybrid			2022-12-25	WOS:A1995RY90900064
J	CHEN, J; BERNSTEIN, HS; CHEN, M; WANG, L; ISHII, M; TURCK, CW; COUGHLIN, SR				CHEN, J; BERNSTEIN, HS; CHEN, M; WANG, L; ISHII, M; TURCK, CW; COUGHLIN, SR			TETHERED LIGAND LIBRARY FOR DISCOVERY OF PEPTIDE AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-RECEPTOR; MOLECULAR-CLONING; STRUCTURAL REQUIREMENTS; SIGNAL-TRANSDUCTION; CDNA; CHEMOATTRACTANTS; ACTIVATION; EXPRESSION; NEUTROPHILS; MECHANISM	We exploited the mechanism underlying thrombin receptor activation to develop a novel screening method to identify peptide agonists, The thrombin receptor is activated by limited proteolysis of its amino-terminal exodomain. Thrombin cleaves this domain to unmask a new amino terminus, which then functions as a tethered peptide agonist, binding intramolecularly to the body of the receptor to trigger signaling. The thrombin receptor's amino-terminal exodomain can also donate the tethered agonist intermolecularly to activate nearby thrombin receptors. We utilized this ability by co expressing a ''tethered ligand library,'' which displayed the thrombin receptor's amino-terminal exodomain bearing random pentapeptides in place of the native tethered ligand together with target receptors in Xenopus oocytes. Clones that conferred thrombin-dependent signaling by intermolecular ligation of the target receptor were isolated by sib selection, Agonists for the thrombin receptor itself (GFIYF) and for the formyl peptide receptor (MMWLL) were identified. Surprisingly, the latter agonist was quite active at the formyl peptide receptor even without N-formylation, and its formylated form, fMMWLL, was more potent than the classical formyl peptide receptor agonist fMLF. In addition to identifying novel peptide agonists for targets of pharmacological interest, this method might be used to discover agonists for orphan receptors. It also suggests a possible evolutionary path from peptide to protease-activated receptors.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHEN J, 1994, J BIOL CHEM, V269, P16041; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; FREER RJ, 1982, BIOCHEMISTRY-US, V21, P257, DOI 10.1021/bi00531a009; FREER RJ, 1980, BIOCHEMISTRY-US, V19, P2404, DOI 10.1021/bi00552a019; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; ISHII K, 1993, J BIOL CHEM, V268, P9780; ISHII K, 1995, J BIOL CHEM, P16435; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PEREZ HD, 1992, GENE, V118, P303, DOI 10.1016/0378-1119(92)90208-7; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROSS PC, 1990, P NATL ACAD SCI USA, V87, P3052, DOI 10.1073/pnas.87.8.3052; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	27	24	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23398	23401		10.1074/jbc.270.40.23398	http://dx.doi.org/10.1074/jbc.270.40.23398			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559498	hybrid			2022-12-25	WOS:A1995RY90900027
J	GUIJARRO, JI; GONZALEZPASTOR, JE; BALEUX, F; MILLAN, JLS; CASTILLA, MA; RICO, M; MORENO, F; DELEPIERRE, M				GUIJARRO, JI; GONZALEZPASTOR, JE; BALEUX, F; MILLAN, JLS; CASTILLA, MA; RICO, M; MORENO, F; DELEPIERRE, M			CHEMICAL-STRUCTURE AND TRANSLATION INHIBITION STUDIES OF THE ANTIBIOTIC MICROCIN C7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ACTIVATING ENZYME; GENETIC-DETERMINANTS; HYDROGEN-EXCHANGE; ESCHERICHIA-COLI; C-13 ASSIGNMENTS; NMR; SEQUENCE; SPECTROSCOPY; MECHANISM; CLONING	Escherichia coli microcin C7 (MccC7) is an antibiotic that inhibits protein synthesis in vivo. It is a heptapeptide containing unknown modifications at the N and C termini (Garcia-Bustos, J. F., Pezzi, N., and Mendez, E. (1985) Antimicrob. Agents Chemoth. 27, 791-797), The chemical structure of MccC7 has been characterized by use of H-1 homonuclear and heteronuclear (C-13, N-15, P-31) nuclear magnetic resonance spectroscopy as well as mass spectrometry (1177 +/- 1 Dal. The heptapeptide Met-Arg-Thr-Gly-Asn-Ala-Asp is substituted at the N terminus by a N formyl group, The C-terminal substituent consists of the phosphodiester of 5'-adenylic acid and n-aminopropanol (AMPap), which is linked via the phosphorus atom to an amide group, thus forming a phosphoramide, The main chain carbonyl of the C-terminal aspartic acid residue is connected via this amide bond to the modified nucleotide unit, MccC7: and the peptide unit inhibit protein translation in vitro while a synthetic analog of the AMPap substituent is not active, Neither the peptide nor the AMPap molecule has an effect on the growth of MccC7-sensible cells, Our results strongly suggest that the peptide is responsible for MccC7 antibiotic activity while the C-terminal substituent is needed for MccC7 transport. Implications of the structure determined in this work for MccC7 synthesis and mode of action are discussed.	INST PASTEUR, CNRS, URA 1129, RESONANCE MAGNET NUCL LAB, F-75015 PARIS, FRANCE; INST PASTEUR, CNRS, URA 489, UNITE CHIM ORGAN, F-75015 PARIS, FRANCE; HOSP RAMON Y CAJAL, UNIDAD GENET MOLEC, E-28034 MADRID, SPAIN; CSIC, INST ESTRUCTURA MAT, E-28006 MADRID, SPAIN	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM)			González-Pastor, José/I-2118-2015; Guijarro, J. Inaki/E-6438-2019; San-Millán, José L./F-9944-2015	González-Pastor, José/0000-0002-7615-7042; Guijarro, J. Inaki/0000-0002-3826-5245; 				ASHCROFT J, 1989, J AM CHEM SOC, V111, P363, DOI 10.1021/ja00183a054; BACHMANN P, 1977, J MAGN RESON, V28, P29, DOI 10.1016/0022-2364(77)90253-0; BAQUERO F, 1984, FEMS MICROBIOL LETT, V23, P117; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BODENHAUSEN G, 1977, J MAGN RESON, V26, P133, DOI 10.1016/0022-2364(77)90243-8; BORTHAKUR D, 1990, MOL GEN GENET, V221, P227, DOI 10.1007/BF00261725; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DIAZGUERRA L, 1989, J BACTERIOL, V171, P2906, DOI 10.1128/jb.171.5.2906-2908.1989; GAMCSIK MP, 1993, J MED CHEM, V36, P3636, DOI 10.1021/jm00075a019; GARCIABUSTOS JF, 1984, BIOCHEM BIOPH RES CO, V119, P779, DOI 10.1016/S0006-291X(84)80318-6; GARCIABUSTOS JF, 1985, ANTIMICROB AGENTS CH, V27, P791, DOI 10.1128/AAC.27.5.791; GONZALEZPASTOR JE, 1994, NATURE, V369, P281, DOI 10.1038/369281a0; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GU ZP, 1994, P NATL ACAD SCI USA, V91, P5612, DOI 10.1073/pnas.91.12.5612; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; ISONO K, 1960, J ANTIBIOT, V13, P270; Kalinowsky H.O., 1988, CARBON 13 NMR SPECTR; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; KUREPINA NE, 1993, MOL GEN GENET, V241, P700, DOI 10.1007/BF00279914; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METLITSKAYA AZ, 1995, FEBS LETT, V357, P235, DOI 10.1016/0014-5793(94)01345-2; MORENO F, 1992, BACTERIAL PLASMID CO, P141; NOVOA MA, 1986, J BACTERIOL, V168, P1384, DOI 10.1128/jb.168.3.1384-1391.1986; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; SOBERT HA, 1968, HDB BICOH SELECTED D; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283; Wuthrich K., 1986, NMR PROTEINS NUCL AC	42	116	121	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23520	23532		10.1074/jbc.270.40.23520	http://dx.doi.org/10.1074/jbc.270.40.23520			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559516	hybrid			2022-12-25	WOS:A1995RY90900045
J	MCCANN, S; SULLIVAN, J; GUERRA, J; ARCINAS, M; BOXER, LM				MCCANN, S; SULLIVAN, J; GUERRA, J; ARCINAS, M; BOXER, LM			REPRESSION OF THE C-MYB GENE BY WT1 PROTEIN IN T-CELL AND B-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; WILMS-TUMOR LOCUS; MESSENGER-RNA; SUPPRESSOR WT1; EXPRESSION; BINDING; PRODUCT; HEMATOPOIESIS; SEQUENCE; INVITRO	The c-myb gene is primarily expressed in immature hematopoietic cells, and it is overexpressed in many leukemias. We have investigated the role of negative regulatory sites in the c-myb promoter in the Molt-4 T cell line and in the DHL-9 B cell line. A potential binding site for either the EGR-1 or WT1 protein was identified by in vivo footprinting in the 5'-flanking region of c-myb in a region of negative regulatory activity in T cells. We showed by electrophoretic mobility shift assay and electrophoretic mobility shift assay Western that WT1, EGR-1, and Sp1 bound to this site. A mutation of this site which prevented protein binding increased the activity of the c myb promoter by 2.5 fold. In the DHL-9 B cell line, this site was nonfunctional; however, we found a potential EGR-1/WT1 site located more 3' in a region of negative regulatory activity. We showed that WT1, EGR-1, and Sp1 bound to this site, and that mutation of this site increased the activity of the c-myb promoter by 3.2-fold. Cotransfection of a WT1 expression vector repressed the activity of the c-myb promoter in both cell lines, and this repression was relieved when the EGR-1/WT1 sites were removed. Cotransfection of either an EGR-1 or Sp1 expression vector had no significant effect on the activity of the c-myb promoter. We conclude that WT1 is a negative regulator of c-myb expression in both T and B cell lines.	STANFORD UNIV,SCH MED,DEPT MED,DIV HEMATOL,STANFORD,CA 94305; VET AFFAIRS MED CTR,CTR MOLEC BIOL MED,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [5T32 CA09302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARCINAS M, 1994, ONCOGENE, V9, P2699; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GUERRA J, 1995, IN PRESS BLOOD; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JACOBS SM, 1994, ONCOGENE, V9, P227; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maxam A M, 1980, Methods Enzymol, V65, P499; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOUNTZ JD, 1993, MOL IMMUNOL, V30, P787, DOI 10.1016/0161-5890(93)90001-R; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY C, 1989, P NATL ACAD SCI USA, V86, P7626; SEKIYA M, 1994, BLOOD, V83, P1876; WATSON R, 1988, ONCOGENE, V8, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WERNER H, 1994, J BIOL CHEM, V269, P12577	38	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23785	23789		10.1074/jbc.270.40.23785	http://dx.doi.org/10.1074/jbc.270.40.23785			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559553	hybrid			2022-12-25	WOS:A1995RY90900082
J	SHAW, LM; TURNER, CE; MERCURIO, AM				SHAW, LM; TURNER, CE; MERCURIO, AM			THE ALPHA-6A-BETA-1-INTEGRIN AND ALPHA-6B-BETA-1-INTEGRIN VARIANTS SIGNAL DIFFERENCES IN THE TYROSINE PHOSPHORYLATION OF PAXILLIN AND OTHER PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAINS; CELL-ADHESION; 3T3 CELLS; TRANSDUCTION; FIBROBLASTS; EXPRESSION; CONTACTS; SUBUNIT; LAMININ	Integrin receptors can mediate transmembrane signaling in response to ligand binding. To further examine the role of the integrin alpha subunit in these signaling functions, we assessed the contribution of the alpha 6 cytoplasmic domain variants to the signaling properties of the alpha 6 beta 1 integrin using P388D1 cells that had been transfected with either the alpha 6A or the alpha 6B cDNA. The alpha 6A beta 1 and alpha 6B beta 1 receptors induced marked quantitative differences in the tyrosine phosphorylation of several proteins after binding to laminin. Specifically, the alpha 6A cytoplasmic domain was more effective than the alpha 6B cytoplasmic domain in inducing the tyrosine phosphorylation of three major proteins (molecular mass, 120, 110, and 76 kDa). In addition to these proteins, we also observed that the tyrosine phosphorylation of the cytoskeletal protein paxillin was increased significantly more by alpha 6A beta 1 integrin-mediated adhesion to laminin than by that of alpha 6B beta 1. This differential pattern of tyrosine phosphorylation induction does not appear to be a secondary event initiated by cell shape changes. Also, differences in tyrosine phosphorylation in the alpha 6 transfectants were not evident in response to attachment to other substrates. These findings provide biochemical evidence for functional differences between alpha subunit cytoplasmic domain variants of the same integrin.	SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	SHAW, LM (corresponding author), HARVARD UNIV,DEACONESS HOSP,SCH MED,CANC BIOL LAB,50 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA44704, CA42276] Funding Source: Medline; NIGMS NIH HHS [GM47607, R01 GM047607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042276, P01CA044704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; DECURTIS I, 1994, J CELL SCI, V107, P3165; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; RANKIN S, 1994, J BIOL CHEM, V269, P704; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHWARTZ MA, 1993, TRENDS CELL BIOL, V2, P304; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TAWIL N, 1993, J CELL BIOL, V120, P261, DOI 10.1083/jcb.120.1.261; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	32	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23648	23652		10.1074/jbc.270.40.23648	http://dx.doi.org/10.1074/jbc.270.40.23648			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559532	hybrid			2022-12-25	WOS:A1995RY90900061
J	DAUCH, P; VINCENT, JP; CHECLER, F				DAUCH, P; VINCENT, JP; CHECLER, F			MOLECULAR-CLONING AND EXPRESSION OF RAT-BRAIN ENDOPEPTIDASE-3.4.24.16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; NEUROTENSIN-DEGRADING METALLOENDOPEPTIDASE; MITOCHONDRIAL INTERMEDIATE PEPTIDASE; AMINO-ACID SEQUENCE; SOLUBLE METALLOENDOPEPTIDASE; MICROSOMAL ENDOPEPTIDASE; PROCESSING PROPROTEINS; SUBSTRATE-SPECIFICITY; SYNAPTIC-MEMBRANES; PURIFICATION	We have isolated by immunological screening of a lambda ZAPII cDNA library constructed from rat brain mRNAs a cDNA clone encoding endopeptidase 3.4.24.16. The longest open reading frame encodes a 704-amino acid protein with a theoretical molecular mass of 80,202 daltons and bears the consensus sequence of the zinc metalloprotease family, The sequence exhibits a 60.2% homology with those of another zinc metallopeptidase, endopeptidase 3.4.24.15, Northern blot analysis reveals two mRNA species of about 3 and 5 kilobases in rat brain, ileum, kidney, and testis, We have transiently transfected COS-7 cells with pcDNA(3) containing the cloned cDNA and established the overexpression of a 70-75-kDa immunoreactive protein. This protein hydrolyzes QFS, a quenched fluorimetric substrate of endopeptidase 3.4.24.16, and cleaves neurotensin at a single peptide bond, leading to the formation of neurotensin (1-10) and neurotensin (11-13), QFS and neurotensin hydrolysis are potently inhibited by the selective endopeptidase 3.4.24.16 dipeptide blocker pro-lie and by dithiothreitol, while the enzymatic activity remains unaffected by phosphoramidon and captopril, the specific inhibitors of endopeptidase 3.4.24.11 and angiotensin-converting enzyme, respectively, Altogether, these physicochemical, biochemical, and immunological properties unambiguously identify endopeptidase 3.4.24.16 as the protein encoded by the isolated cDNA clone.	INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Checler, Frederic/C-1241-2009	Checler, Frederic/0000-0003-2098-1750				BARELLI H, 1993, EUR J BIOCHEM, V211, P79, DOI 10.1111/j.1432-1033.1993.tb19872.x; BARELLI H, 1988, EUR J BIOCHEM, V175, P481, DOI 10.1111/j.1432-1033.1988.tb14220.x; BARELLI H, 1994, BRIT J PHARMACOL, V112, P127, DOI 10.1111/j.1476-5381.1994.tb13041.x; BARELLI H, 1991, NEUROCHEM LIFE SCI A, V10, P115; BERNSTEIN KE, 1988, J BIOL CHEM, V263, P11021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHLER M, 1994, EUR J BIOCHEM, V219, P627, DOI 10.1111/j.1432-1033.1994.tb19978.x; CHABRY J, 1990, J NEUROSCI, V10, P3916, DOI 10.1523/JNEUROSCI.10-12-03916.1990; CHECLER F, 1986, J BIOL CHEM, V261, P1274; CHECLER F, 1995, METHOD ENZYMOL, V248, P593; CHECLER F, 1983, J NEUROCHEM, V41, P375, DOI 10.1111/j.1471-4159.1983.tb04753.x; CHECLER F, 1989, BIOCHEM J, V257, P549, DOI 10.1042/bj2570549; CHECLER F, 1988, BIOCHIMIE, V70, P75, DOI 10.1016/0300-9084(88)90161-7; CHECLER F, 1995, METH NEUROSCI, V23, P363; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; DAUCH P, 1991, EUR J BIOCHEM, V202, P269, DOI 10.1111/j.1432-1033.1991.tb16372.x; DAUCH P, 1991, BIOCHEM J, V280, P421, DOI 10.1042/bj2800421; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; HENRICH B, 1993, J BACTERIOL, V175, P7290, DOI 10.1128/JB.175.22.7290-7300.1993; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HRYCYNA CA, 1993, BIOCHEMISTRY-US, V32, P11293, DOI 10.1021/bi00093a005; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MILLICAN PE, 1991, BIOCHEM J, V276, P583, DOI 10.1042/bj2760583; MITRA A, 1994, J BIOL CHEM, V269, P19876; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; ROY P, 1993, J BIOL CHEM, V268, P2699; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; SUDA H, 1973, J ANTIBIOT TOKYO, V10, P621; VINCENT B, 1995, BRIT J PHARMACOL, V115, P1053, DOI 10.1111/j.1476-5381.1995.tb15918.x; WOULFE J, 1992, EUR J NEUROSCI, V4, P1309, DOI 10.1111/j.1460-9568.1992.tb00156.x	44	65	69	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27266	27271		10.1074/jbc.270.45.27266	http://dx.doi.org/10.1074/jbc.270.45.27266			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592986	hybrid			2022-12-25	WOS:A1995TE58300086
J	GRAY, AJ; PARK, PW; BROEKELMANN, TJ; LAURENT, GJ; REEVES, JT; STENMARK, KR; MECHAM, RP				GRAY, AJ; PARK, PW; BROEKELMANN, TJ; LAURENT, GJ; REEVES, JT; STENMARK, KR; MECHAM, RP			THE MITOGENIC EFFECTS OF THE B-BETA CHAIN OF FIBRINOGEN ARE MEDIATED THROUGH CELL-SURFACE CALRETICULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MOLECULAR-CLONING; HUMAN FIBROBLASTS; GROWTH-FACTORS; EXPRESSION; RETICULUM; SEQUENCE; ALPHA	We have previously shown that soluble partially degraded fibrin(ogen) remains in solution after fibrin clot formation and is a potent fibroblast mitogen (Gray, A, J,, Bishop, J, E,, Beeves, J, T,, Mecham, R.P,, and Laurent, G.J. (1995) Am, J. Cell Mot Biol. 12, 684-690), Mitogenic sites within the fibrin(ogen) molecule are located on the Aa! and B beta chains of the protein (Gray, A. J,, Bishop, J, E,, Reeves, J, T,, and Laurent, G. J, (1993) J. Cell Sci. 104, 409-413), However, receptor pathways through which mitogenic effects are mediated are unknown, The present study sought to determine the nature of fibrin (ogen) receptors expressed on human fibroblasts which interact with the fibrinogen B beta chain, Receptor complexes were isolated from I-125-surface-labeled fibroblasts and purified on a fibrinogen B beta chain affinity column. Subsequent high performance liquid chromatography and SDS-polyacrylamide gel electrophoresis analysis indicated fibrinogen B beta chain bound specifically to a 60-kDa surface protein. Sequence analysis of the amino terminus of this protein indicated 100% homology to human calreticulin. Immunoprecipitation experiments employing a polyclonal anti-calreticulin antibody provided further evidence that the 60-kDa protein isolated in this study was calreticulin. Further, polyclonal antibodies to human calreticulin significantly inhibited the mitogenic activity of fibrinogen B beta chain on human fibroblasts. The present study has shown that cell surface calreticulin binds to the B beta chain of fibrinogen mediating its mitogenic activity.	WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DIV CRIT CARE & DEV LUNG BIOL,DENVER,CO 80262	Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GRAY, AJ (corresponding author), UNIV LONDON UNIV COLL,SCH MED,RAYNE INST,DIV CARDIOPULM BIOCHEM,5 UNIV ST,LONDON WC1E 6JJ,ENGLAND.		stenmark, kurt/AAH-3124-2022; stenmark, kurt/AFI-6776-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN LF, 1989, AM REV RESPIR DIS, V140, P1104, DOI 10.1164/ajrccm/140.4.1104; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GRAY AJ, 1990, J CELL SCI, V96, P271; GRAY AJ, 1995, AM J RESP CELL MOL, V12, P684, DOI 10.1165/ajrcmb.12.6.7766431; GRAY AJ, 1993, J CELL SCI, V104, P409; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; MACLENNAN DH, 1972, COLD SPRING HARB SYM, V37, P469; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; Malhotra R, 1993, Behring Inst Mitt, P254; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; OLIVER MH, 1989, J CELL SCI, V92, P513; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770	19	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26602	26606		10.1074/jbc.270.44.26602	http://dx.doi.org/10.1074/jbc.270.44.26602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592883	hybrid			2022-12-25	WOS:A1995TC97800090
J	WEI, JY; HENDERSHOT, LM				WEI, JY; HENDERSHOT, LM			CHARACTERIZATION OF THE NUCLEOTIDE-BINDING PROPERTIES AND ATPASE ACTIVITY OF RECOMBINANT HAMSTER BIP PURIFIED FROM BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; SHOCK COGNATE PROTEIN; ESCHERICHIA-COLI DNAJ; UNCOATING ATPASE; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; MUTATIONAL ANALYSIS; UNFOLDED PROTEINS; CLATHRIN COATS; HOMOLOG	HSP70 family proteins bind ATP and hydrolyze it, but the precise role of these activities in their in vivo chaperoning function has not been determined. In this report, we characterized wild-type hamster BiP isolated hom bacteria in terms of its ATP binding and ATPase activities. Recombinant BiP behaved essentially the same as endogenous BiP in terms of oligomeric status, protease digestion patterns, and ATPase properties. By engineering a Factor Xa cleavable site following the His tag which was used for affinity purification, we demonstrated that the six histidines had no effect on either the structural or ATPase properties of recombinant BiP. We also found that bacteria-synthesized BiP had a tightly bound ADP that was resistant to dialysis. Removal of the bound nucleotide allowed us to directly measure the binding affinity of ATP and ADP to BiP (K-d of 0.2 mu M for ATP and 0.29 mu M for ADP) by equilibrium dialysis. Careful characterization of wild-type BiP will allow us to use this system to characterize BiP ATP binding site mutants that can be used to probe the role of ATP binding and ATPase activity in BiP functions.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 43576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENAROUD JN, 1994, EUR J BIOCHEM, V221, P121; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SEALS JR, 1978, ANAL BIOCHEM, V90, P785, DOI 10.1016/0003-2697(78)90169-0; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677	43	76	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26670	26676		10.1074/jbc.270.44.26670	http://dx.doi.org/10.1074/jbc.270.44.26670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592893	hybrid			2022-12-25	WOS:A1995TC97800100
J	SONG, RD; IKEGUCHI, M; ZHOU, G; KUO, MT				SONG, RD; IKEGUCHI, M; ZHOU, G; KUO, MT			IDENTIFICATION AND CHARACTERIZATION OF A HEPATOMA CELL-SPECIFIC ENHANCER IN THE MOUSE MULTIDRUG-RESISTANCE MDR1B PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN GENE; BACTERIAL TRANSPORT PROTEINS; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; BINDING-SITE; RAT-LIVER; EXPRESSION; SEQUENCE; FAMILY	The expression of multidrug resistance/P-glycoprotein genes mdr1b(mdr1) and mdr1a(mdr3) is elevated during hepatocarcinogenesis. To investigate the regulation of mdr1b gene expression, we used transient transfection expression assays of reporter constructs containing various 5'-mdr1b flanking sequences in hepatoma and non-hepatoma cells. We found that nucleotides -233 to -116 preferentially enhanced the expression of reporter gene in mouse hepatoma cell Lines in an orientation- and promoter context-independent manner. DNase I footprinting using nuclear extracts prepared from hepatoma and non-hepatoma cells identified four protein binding sites at nucleotides -205 to -186 (site A), -181 to -164 (site B), -153 to -135 (site C), and -128 to -120 (site D). Further analyses revealed that, while site B alone played a major part for the enhancer function, sites A and B combined conferred full enhancer activity, Site-directed mutagenesis results also supported these results. Gel retardation experiments using oligonucleotide competitors revealed that the site B contains a dominant binding protein. This is the first report demonstrating a cell type-specific enhancer in the mdr locus. The role of this enhancer in the activation of mdr1b gene during hepatocarcinogenesis is discussed.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA55813, CA56846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056846, R01CA055813] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1987, MOL CELL BIOL, V7, P3089; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRADLEY G, 1991, CANCER RES, V52, P5154; Chan H S, 1993, Adv Pharmacol, V24, P157, DOI 10.1016/S1054-3589(08)60937-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN D, 1991, J BIOL CHEM, V266, P2239; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING ZM, 1995, J BIOL CHEM, V270, P3667, DOI 10.1074/jbc.270.8.3667; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FARDEL O, 1990, EUR J BIOCHEM, V205, P847; GANT WT, 1991, NUCLEIC ACIDS RES, V20, P2841; GERMANN UA, 1994, GENE CHROMOSOME CANC, V10, P267, DOI 10.1002/gcc.2870100408; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HANKINSON O, 1979, P NATL ACAD SCI USA, V96, P373; HSU SIH, 1989, J BIOL CHEM, V264, P12053; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIMURA O, 1994, HUM GENE THER, V5, P845, DOI 10.1089/hum.1994.5.7-845; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KUO MT, 1990, CELL GROWTH DIFFER, V3, P531; LEE CH, 1993, J CELL PHYSIOL, V157, P392, DOI 10.1002/jcp.1041570223; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; MANDEL DB, 1991, SCIENCE, V254, P1762; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NAKATSUKASA H, 1992, MOL CARCINOGEN, V6, P190, DOI 10.1002/mc.2940060304; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P717; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHUETZ JD, 1993, CELL GROWTH DIFFER, V4, P31; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; TEETER LD, 1990, MOL CELL BIOL, V11, P5728; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1987, J BIOL CHEM, V262, P17432; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WANG YB, 1994, J BIOL CHEM, V269, P9137; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395; YU LJ, 1993, J BIOL CHEM, V268, P7520; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	64	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25468	25474		10.1074/jbc.270.43.25468	http://dx.doi.org/10.1074/jbc.270.43.25468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592715	hybrid			2022-12-25	WOS:A1995TB46600031
J	ETO, A; AKITA, Y; SAIDO, TC; SUZUKI, K; KAWASHIMA, S				ETO, A; AKITA, Y; SAIDO, TC; SUZUKI, K; KAWASHIMA, S			THE ROLE OF THE CALPAIN-CALPASTATIN SYSTEM IN THYROTROPIN-RELEASING HORMONE-INDUCED SELECTIVE DOWN-REGULATION OF A PROTEIN-KINASE-C ISOZYME, NPKC-EPSILON, IN RAT PITUITARY GH(4)C(1) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; PROTEOLYTIC ACTIVATION; BINDING; HETEROGENEITY; PURIFICATION; DEGRADATION; INHIBITION; SEQUENCES; MEMBRANE; DOMAINS	We have examined the mechanism for the selective down-regulation of protein kinase C epsilon (nPKC epsilon) in rat pituitary GH(4)C(1) cells responding to thyrotropin-releasing hormone (TRH) stimulation. Among various low molecular weight protease inhibitors examined, only a cysteine protease inhibitor (calpain inhibitor I, N-acetyl-Leu-Leu-norleucinal) blocked the down-regulation of nPKC epsilon. Furthermore, the introduction of a synthetic calpastatin peptide, an exclusively specific inhibitor of calpain, into the cells also reduced the down-regulation, suggesting the involvement of calpain among all the intracellular cysteine proteases in this process. In accordance, we observed TRH-induced translocation of m-calpain from the cytosol to the membrane and the concomitant up regulation of calpastatin isoforms; presumably, the former represents activation of the protease initiating the kinase degradation, while the latter constitutes a negative feedback system protecting the cells from activated calpain. These results suggest that in GH(4)C(1) cells, TRH mobilizes both protease (m-calpain) and inhibitor (calpastatin) as a strictly regulating system for the nPKC epsilon pathway mediating TRH signals.	TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Metropolitan Institute of Medical Science; University of Tokyo			Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				ADACHI Y, 1990, BIOMED RES-TOKYO, V11, P313, DOI 10.2220/biomedres.11.313; ADACHI Y, 1991, J BIOL CHEM, V266, P3968; AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; AKITA Y, 1994, J BIOL CHEM, V269, P4653; AL ZW, 1993, BIOCHEM J, V296, P675, DOI 10.1042/bj2960675; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ARIYOSHI H, 1992, BIOCHEM INT, V27, P335; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; CHIDA K, 1986, J BIOL CHEM, V261, P3013; Crawford C., 1990, INTRACELLULAR CALCIU, P75; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Goll DE, 1990, INTRACELLULAR CALCIU, P3; HASHIMOTO E, 1989, J BIOCHEM-TOKYO, V106, P1041, DOI 10.1093/oxfordjournals.jbchem.a122961; HATA A, 1992, FEBS LETT, V304, P241, DOI 10.1016/0014-5793(92)80628-T; ISHIDA S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P436; ISHIURA S, 1978, J BIOCHEM, V84, P225, DOI 10.1093/oxfordjournals.jbchem.a132111; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; KILEY S, 1990, J BIOL CHEM, V265, P15704; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LEE WJ, 1992, J BIOL CHEM, V267, P8437; MAKI M, 1989, J BIOL CHEM, V264, P18866; MELLONI E, 1986, J BIOL CHEM, V261, P4101; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; NAKAMURA M, 1992, EXP CELL RES, V200, P513, DOI 10.1016/0014-4827(92)90203-K; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1994, J BIOL CHEM, V269, P17495; ORWIG KE, 1994, ENDOCRINOLOGY, V134, P78, DOI 10.1210/en.134.1.78; OSHIMA M, 1989, J BIOL CHEM, V264, P20811; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SAITO Y, 1994, FEBS LETT, V353, P327, DOI 10.1016/0014-5793(94)01075-7; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHEA TB, 1994, FEBS LETT, V350, P223, DOI 10.1016/0014-5793(94)00769-1; SHENOY AM, 1991, CELL IMMUNOL, V138, P24, DOI 10.1016/0008-8749(91)90129-Y; SHOJIKASAI Y, 1988, P NATL ACAD SCI USA, V85, P146, DOI 10.1073/pnas.85.1.146; YAJIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P571, DOI 10.1016/S0006-291X(05)80073-7; YAJIMA Y, 1988, MOL PHARMACOL, V33, P592; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	45	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25115	25120		10.1074/jbc.270.42.25115	http://dx.doi.org/10.1074/jbc.270.42.25115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559644	hybrid			2022-12-25	WOS:A1995TB46500078
J	LAIN, B; IRIARTE, A; MATTINGLY, JR; MORENO, JI; MARTINEZCARRION, M				LAIN, B; IRIARTE, A; MATTINGLY, JR; MORENO, JI; MARTINEZCARRION, M			STRUCTURAL FEATURES OF THE PRECURSOR TO MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE RESPONSIBLE FOR BINDING TO HSP70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; STRESS PROTEINS; IMPORT; TRANSLOCATION; CELL; POLYPEPTIDES; TRANSAMINASE; MEMBRANE; CLEAVAGE	The precursor (pmAspAT) and mature (mAspAT) forms of mitochondrial aspartate aminotransferase interact with hsp70 very early during translation when synthesized in either rabbit reticulocyte lysate or wheat germ extract (Lain, B., Iriarte, A., and Martinez-Carrion, (1994) J, Biol, Chem, 269, 15588-15596). The nature of the structural elements responsible for recognition and binding of this protein to hsp70 has been studied by examining the folding and potential association with the chaperone of several engineered forms of this enzyme, Whereas pmAspAT and mAspAT bind hsp70 very early during translation, the cytosolic form of this enzyme (cAspAT) does not interact with hsp70. A fusion protein consisting of the mitochondrial presequence peptide attached to the amino terminus of cAspAT associates with hsp70 only after the protein has acquired its native-like conformation, apparently through binding to the presequence exposed on the surface of the folded protein. Deletion of the amino-terminal segment of mAspAT or its replacement with the corresponding domain from the cytosolic isozyme eliminates the cotranslational binding of hsp70 to the mitochondrial protein, We conclude that both the presequence and NH2-terminal region of pmAspAT represent recognition signals for binding of hsp79 to the newly synthesized mitochondrial precursor. Results from competition studies with synthetic peptides support this conclusion. The ability of hsp70 to discriminate between these two highly homologous proteins probably involves the recognition of specific sequence elements in the NH2-terminal portion of the mitochondrial protein and may relate to their separate localization in the cell. A slower folding rate and higher affinity for cytosolic chaperones may represent evolutionary adaptations of translocated mitochondrial proteins to ensure their efficient importation into the organelle.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City			López-Moreno, Juan Ignacio/K-2114-2014	López-Moreno, Juan Ignacio/0000-0002-7270-9313; Moreno, J. Ignacio/0000-0002-5133-7573	NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Freedman Robert B., 1992, P455; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; IRARTE A, 1994, BIOCH VITAMIN B6 PQQ, P75; IRIARTE A, 1984, J BIOL CHEM, V259, P723; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P107; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P269; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; MARTINEZCARRION M, 1967, BIOCHEMISTRY-US, V6, P1715, DOI 10.1021/bi00858a021; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1995, J BIOL CHEM, V270, P1138, DOI 10.1074/jbc.270.3.1138; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229	42	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24732	24739		10.1074/jbc.270.42.24732	http://dx.doi.org/10.1074/jbc.270.42.24732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559589	hybrid			2022-12-25	WOS:A1995TB46500023
J	SHEN, BQ; WIDDICOMBE, JH; MRSNY, RJ				SHEN, BQ; WIDDICOMBE, JH; MRSNY, RJ			EFFECTS OF LOVASTATIN ON TRAFFICKING OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN HUMAN TRACHEAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-METHYLATION; CHLORIDE SECRETION; TRANSPORT; CELLS; CFTR; INHIBITION; MUTATIONS; PROTEINS; CHANNEL	Genetic defects in the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel, cause cystic fibrosis. Most defective forms of CFTR show improper intracellular trafficking. Because isoprenylated, small GTP-binding proteins are involved in the vesicular trafficking of other integral membrane proteins, we have investigated the role of isoprenylation in the trafficking of CFTR to the apical membranes of primary cultures of human airway epithelium and of Calu-3 cells, a human lung carcinoma cell line, CFTR function was measured as short circuit current, I-125 efflux, and conductance of cell sheets with permeabilized basolateral membranes. Lovastatin, an inhibitor of isoprenyl lipid biosynthesis, markedly inhibited all measures of CFTR function, The lovastatin-induced declines in CFTR function were corrected by the simultaneous addition of mevalonate or the isoprenyl Lipids geranylgeranyl and farnesyl but not cholesterol. Lovastatin reduced total cellular CFTR as assessed by immunoprecipitation. Mevalonate or isoprenyl lipids protected CFTR levels from the actions of lovastatin. Together, these results suggest a role for isoprenyl lipids, presumably through the actions of small GTP-binding proteins, in the trafficking of CFTR to the apical membrane of human airway epithelium.	GENENTECH INC, DEPT PHARMACEUT RES & DEV, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; CHILDRENS HOSP, OAKLAND RES INST, OAKLAND, CA 94609 USA	Roche Holding; Genentech; University of California System; University of California San Francisco; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42368] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CHENG SH, 1993, CYSTIC FIBROSIS CURR, V1, P175; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; ECAY TW, 1993, AM J PHYSIOL, V265, pC422, DOI 10.1152/ajpcell.1993.265.2.C422; FULLER CM, 1994, AM J PHYSIOL, V266, pC661, DOI 10.1152/ajpcell.1994.266.3.C661; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANRAHAN JW, 1993, CYSTIC FIBROSIS CURR, V1, P93; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OHRUI T, 1995, J APPL PHYSIOL, V78, P1197, DOI 10.1152/jappl.1995.78.3.1197; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIND S, 1994, J BIOL CHEM, V269, P12784; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SHEN BQ, 1993, J BIOL CHEM, V268, P19070; SHEN BQ, 1995, IN PRESS AM J PHYSL; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WARD CL, 1994, J BIOL CHEM, V269, P25710; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WIDDICOMBE JH, 1983, AM J PHYSIOL, V245, pC388, DOI 10.1152/ajpcell.1983.245.5.C388; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Yang Yiping, 1994, American Journal of Respiratory Cell and Molecular Biology, V11, P7; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	41	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25102	25106		10.1074/jbc.270.42.25102	http://dx.doi.org/10.1074/jbc.270.42.25102			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559642	hybrid			2022-12-25	WOS:A1995TB46500076
J	ARREAZA, G; BROWN, DA				ARREAZA, G; BROWN, DA			SORTING AND INTRACELLULAR TRAFFICKING OF A GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN AND 2 HYBRID TRANSMEMBRANE PROTEINS WITH THE SAME ECTODOMAIN IN MADIN-DARBY CANINE KIDNEY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; POLYMERIC IMMUNOGLOBULIN RECEPTOR; PLACENTAL ALKALINE-PHOSPHATASE; CYTOPLASMIC DOMAIN ALTERS; MDCK CELLS; BREFELDIN-A; PHOSPHATIDYLINOSITOL-GLYCAN; MEMBRANE-GLYCOPROTEINS; SELECTIVE-INHIBITION; BASOLATERAL SURFACE	We compared the trafficking of the glycosylphosphatidylinositol (GPI)-anchored placental alkaline phosphatase (FLAP) and two chimeric transmembrane proteins containing the FLAP ectodomain in stably transfected Madin-Darby canine kidney epithelial cells to determine whether different mechanisms might be used in apical sorting of GPI-anchored and transmembrane proteins. PLAP-G, which contained the transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein, was delivered directly to the basolateral surface. FLAP-HA contained the transmembrane and cytoplasmic domains of influenza hemagglutinin. Both FLAP and FLAP-HA were delivered directly to the apical membrane. FLAP becomes insoluble in Triton X-100 during biosynthetic transport, as it associates with detergent-resistant membranes. Neither hybrid protein was detergent insoluble, though the small amount of FLAP that was missorted to the basolateral surface was insoluble. We examined the effects of three drugs known to interfere with membrane trafficking on sorting and delivery of FLAP and the hybrid proteins. Monensin had no effect on sorting or surface expression of any of the proteins. Nocodazole affected the sorting of both FLAP and FLAP-HA but not of PLAP-G. Brefeldin A appeared to disrupt the sorting of FLAP and FLAP-HA but not of PLAP-G. This conclusion was tempered by the observation that this drug affected the distribution of proteins at the cell surface. Thus, sorting and transport of GPI-anchored and apical transmembrane proteins are similar in a number of respects.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM47897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; ALONSO FV, 1981, J CELL BIOL, V89, P700, DOI 10.1083/jcb.89.3.700; ALONSOCAPLEN FV, 1983, J CELL BIOL, V97, P659, DOI 10.1083/jcb.97.3.659; AMBESIIMPIOMBAT.FS, 1979, INT REV CYTOL S, V10, P163; APODACA G, 1993, J BIOL CHEM, V268, P20380; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BERGER J, 1989, P NATL ACAD SCI USA, V86, P1457, DOI 10.1073/pnas.86.5.1457; BRANDLI AWU, 1992, J CELL BIOL, V111, P2909; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BREWER CB, 1993, MOL MECHANISMS MEMBR, P297; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; ESFAHANI M, 1993, BIOCHIM BIOPHYS ACTA, V1149, P217, DOI 10.1016/0005-2736(93)90204-D; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANNAN LA, 1993, MOL BIOL CELL S, V4, P313; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFONT F, 1994, NATURE, V372, P801; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCQUEEN NL, 1987, J BIOL CHEM, V262, P16233; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MIESS HK, 1982, MOL CELL BIOL, V2, P1287; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; QUARONI A, 1979, BIOCHEM J, V182, P213, DOI 10.1042/bj1820213; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; WALTER EI, 1990, J IMMUNOL, V144, P1030; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	64	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23641	23647		10.1074/jbc.270.40.23641	http://dx.doi.org/10.1074/jbc.270.40.23641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559531	hybrid			2022-12-25	WOS:A1995RY90900060
J	AVANTAGGIATO, V; TORINO, A; WONG, WT; DIFIORE, PP; SIMEONE, A				AVANTAGGIATO, V; TORINO, A; WONG, WT; DIFIORE, PP; SIMEONE, A			EXPRESSION OF THE RECEPTOR TYROSINE KINASE SUBSTRATE GENES EPS8 AND EPS15 DURING MOUSE DEVELOPMENT	ONCOGENE			English	Article						EPS8; EPS15; DEVELOPMENT; EXPRESSION	GROWTH-FACTOR RECEPTOR; DROSOPHILA-TRITHORAX; INT-1 PROTOONCOGENE; SIGNAL TRANSDUCTION; ACUTE LEUKEMIAS; ONCOGENE INT-1; EGF RECEPTOR; CELLS; DOMAINS; WNT-1	Receptor tyrosine kinases (RTKs) control proliferation and differentiation through their ability to bind and/or phosphorylate intracellular substrates, The repertoire of substrates recruited by different RTK is largely overlapping, It is not clear, therefore, how a cell distinguishes among signals originating from different RTKs. One possibility is that selective availability of substrates participates in the regulation of this process, To gain insight into this issue, we studied the expression pattern, embryogenesis, of the eps8 and eps15 encode two recently identified RTK substrates, Both genes are expressed from E 10 in a restricted fashion, eps8 is first expressed in frontonasal neural crest-derived cells, in the mesenchyme of branchial arches and in the liver primordium. At E 12.5-E 14, eps8 is additionally expressed in the central nervous system (CNS) in a regional restricted pattern at the met-mesencephalic transition area and in the developing submandibular salivary glands, eps15 is expressed at E 10 in the liver primordium, in the spinal ganglia and in the encephalic ganglia derived from the hindbrain neural crest, In addition, at E 12.5-E 14, eps15 is expressed, along all the CNS, in the ventricular zone where undifferentiated neuroblasts are located. The regional pattern of developmental expression of these two substrates sharply contrasts with their ubiquitous expression in adults, raising the possibility that their expression during embryogenesis is linked to selective proliferative and/or differentiative responses of specific neuroectodermal regions and body organs.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; EUROPEAN INST ONCOL,IEO,I-20132 MILAN,ITALY; UNIV BARI,IST MICROBIOL,I-70100 BARI,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro			Simeone, Antonio/ABG-5269-2020; Di Fiore, Pier Paolo/K-2130-2012	Simeone, Antonio/0000-0003-2693-9836; Di Fiore, Pier Paolo/0000-0002-2252-0950				BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BERNARD OA, 1994, ONCOGENE, V9, P1039; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; MATOSKOVA B, 1995, IN PRESS MOL CELL BI; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SCHUMACHER C, 1995, IN PRESS J BIOL CHEM; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG WT, 1994, ONCOGENE, V9, P3057; WONG WT, 1994, ONCOGENE, V9, P1591; ZERLIN M, 1993, ONCOGENE, V8, P2731	31	11	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1191	1198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566980				2022-12-25	WOS:A1995RX18000023
J	KISTLER, B; PFISTERER, P; WIRTH, T				KISTLER, B; PFISTERER, P; WIRTH, T			LYMPHOID-AND MYELOID-SPECIFIC ACTIVITY OF THE PU.1 PROMOTER IS DETERMINED BY THE COMBINATORIAL ACTION OF OCTAMER AND ETS TRANSCRIPTION FACTORS	ONCOGENE			English	Article						GENE REGULATION; CELL-TYPE-SPECIFIC TRANSCRIPTION; ETS-TRANSCRIPTION FACTORS; POU-DOMAIN PROTEINS	PUTATIVE ONCOGENE SPI-1; CHAIN GENE ENHANCER; DNA-BINDING MOTIF; REGULATES EXPRESSION; CD11B PROMOTER; DOMAIN; ACTIVATION; ERYTHROLEUKEMIAS; COMPONENT; PROTEINS	The putative oncogene PU.1/Spi-1 is a member of the ets-family of transcription factors normally expressed in a subset of hematopoietic cell types. Here we have characterized the role of the PU.1 promoter region for the eel-type specific expression. The proximal 120 bp are sufficient to mediate a high level of activity specifically in B cells and macrophages. Three important motifs could be identified within this region. Two of them, an ets binding site (EBS) and a variant octamer motif were most important for cell-type-specific promoter activity in B cells and macrophages, An additional Spl motif stimulates basal activity of this promoter element. The relative contribution to overall activity of octamer motif and EBS differs in B cells and macrophages. In B cells, both octamer motif and EBS combine to mediate high level activity, whereas in macrophages the EBS predominantly confers promoter activity. Both the Oct1 and Oct2 transcription factors, presumably in combination with a B-cell-restricted coactivator, are responsible for the activity of the variant octamer motif in B cells. Interestingly, the PU.1 transcription factor can functionally interact with the EBS in its own promoter, suggesting a positive feedback regulation.	UNIV HEIDELBERG,ZMBH,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; JOANNSEN E, 1995, J VIROL, V69, P253; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LU Y, 1972, CELL, V71, P231; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PFISTERER P, 1995, UNPUB; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WIRTH T, 1995, IN PRESS IMMUNOBIOLO; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X	43	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1095	1106						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566969				2022-12-25	WOS:A1995RX18000012
J	HO, MY; CARTER, DA; ANG, HL; MURPHY, D				HO, MY; CARTER, DA; ANG, HL; MURPHY, D			BOVINE OXYTOCIN TRANSGENES IN MICE - HYPOTHALAMIC EXPRESSION, PHYSIOLOGICAL REGULATION, AND INTERACTIONS WITH THE VASOPRESSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RAT; STIMULATION; RESPONSES; PROMOTER; NEURONS; NEUROPHYSIN; SEQUENCE; ELEMENT; SYSTEM	To gain insights into the molecular mechanisms that restrict the expression of the oxytocin gene to anatomically defined groups of neurons in the hypothalamus, we generated transgenic mice bearing bovine oxytocin genomic fragments, Appropriate neuron specific and physiological regulation was observed in mice bearing transgene bOT3.5, which consists of the oxytocin structural gene flanked by 0.6 kilobase pair (kbp) of upstream and 1.9 kbp of downstream sequences, bOT3.5 is expressed in oxytocin magnocellular neurons in the mouse supraoptic nucleus and paraventricular nucleus, but transgene RNAs are excluded from vasopressin neurons, Replacement of the drinking diet of the transgenic mice with 2% (w/v) NaCl for 7 days significantly increased the abundance of bovine oxytocin transcripts in the supraoptic nucleus, but not in the paraventricular nucleus, in parallel with the endogenous mouse oxytocin RNA. Surprisingly, mimicry of the endogenous oxytocin gene expression pattern was lost with larger transgenes, Addition of 0.7 kbp of contiguous downstream sequences (transgene bOT) or linkage to the bovine vasopressin gene (transgene VP-B/bOT3.5) repressed hypothalamic expression, No mice were derived bearing transgene bOT6.4, which consists of the oxytocin structural gene flanked by 3 kbp of upstream and 2.6 kbp of downstream sequences, suggesting that the presence of this DNA is detrimental to normal embryonic development, These data suggest that while bOT3.5 contains sufficient cis-acting sequences to mediate expression to particular subsets of hypothalamic neurons, the overall regulation of the oxytocin gene is governed by multiple interacting enhancers and repressors.	INST MOLEC & CELL BIOL,NEUROPEPTIDE LAB,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)			Carter, David/A-4479-2010; Murphy, David/C-3967-2012	Carter, David/0000-0002-8419-3975; Murphy, David/0000-0003-2946-0353				ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ADAN RAH, 1992, J BIOL CHEM, V267, P3771; ANG HL, 1993, EMBO J, V12, P2397, DOI 10.1002/j.1460-2075.1993.tb05894.x; ANG HL, 1994, J ENDOCRINOL, V140, P53, DOI 10.1677/joe.0.1400053; ANG HL, 1991, ENDOCRINOLOGY, V128, P2110, DOI 10.1210/endo-128-4-2110; AXELSON JF, 1990, J NEUROENDOCRINOL, V2, P209, DOI 10.1111/j.1365-2826.1990.tb00852.x; BELENKY M, 1992, BRAIN RES, V583, P279, DOI 10.1016/S0006-8993(10)80034-4; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; BURBACH JPH, 1984, NEUROENDOCRINOLOGY, V39, P582; BURBACH JPH, 1990, J NEUROENDOCRINOL, V2, P633; DALE HH, 1906, J PHYSIOL-LONDON, V34, P165; Gainer Harold, 1994, P1099; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; HERMAN JP, 1991, MOL ENDOCRINOL, V5, P1447, DOI 10.1210/mend-5-10-1447; IVELL R, 1991, J NEUROENDOCRINOL, V3, P583, DOI 10.1111/j.1365-2826.1991.tb00321.x; IVELL R, 1986, EMBO J, V5, P971, DOI 10.1002/j.1460-2075.1986.tb04311.x; KIYAMA H, 1990, J NEUROENDOCRINOL, V2, P257, DOI 10.1111/j.1365-2826.1990.tb00401.x; LEFEBVRE DL, 1994, ENDOCRINOLOGY, V134, P2556, DOI 10.1210/en.134.6.2556; LEFEBVRE DL, 1992, SCIENCE, V256, P1553, DOI 10.1126/science.1598587; LEFEBVRE DL, 1994, ENDOCRINOLOGY, V134, P2562, DOI 10.1210/en.134.6.2562; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; MAZEY E, 1991, ENDOCRINOLOGY, V129, P1814; MOHR E, 1988, FEBS LETT, V242, P144, DOI 10.1016/0014-5793(88)81003-2; MURPHY D, 1990, MOL ENDOCRINOL, V4, P1051, DOI 10.1210/mend-4-7-1051; MURPHY D, 1993, ANN NY ACAD SCI, V689, P91, DOI 10.1111/j.1749-6632.1993.tb55540.x; MURPHY D, 1992, Current Opinion in Cell Biology, V4, P274, DOI 10.1016/0955-0674(92)90043-C; MURPHY D, 1993, TRANSGENIC TECHNIQUE; OTT L, 1911, P SOC EXP BIOL MED, V8, P48; RENAUD LP, 1991, PROG NEUROBIOL, V36, P131, DOI 10.1016/0301-0082(91)90020-2; RICHARD S, 1991, J BIOL CHEM, V266, P21428; RICHARD S, 1990, J BIOL CHEM, V265, P6098; RICHARD S, 1991, Molecular and Cellular Neuroscience, V2, P501; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SCHMITZ E, 1991, DNA CELL BIOL, V10, P81, DOI 10.1089/dna.1991.10.81; SHERMAN TG, 1988, J NEUROSCI, V8, P3785; VANTOL HHM, 1987, ENDOCRINOLOGY, V120, P71, DOI 10.1210/endo-120-1-71; VANTOL HHM, 1988, ENDOCRINOLOGY, V122, P945, DOI 10.1210/endo-122-3-945; YOUNG WS, 1990, J NEUROENDOCRINOL, V2, P917, DOI 10.1111/j.1365-2826.1990.tb00660.x; ZENG Q, 1994, J NEUROENDOCRINOL, V6, P469, DOI 10.1111/j.1365-2826.1994.tb00610.x; ZINGG HH, 1986, J BIOL CHEM, V261, P2956	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27199	27205		10.1074/jbc.270.45.27199	http://dx.doi.org/10.1074/jbc.270.45.27199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592977	hybrid			2022-12-25	WOS:A1995TE58300077
J	LIU, PS; ANDERSON, RGW				LIU, PS; ANDERSON, RGW			COMPARTMENTALIZED PRODUCTION OF CERAMIDE AT THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; MA104 CELLS; RECEPTOR; CAVEOLAE; PROTEIN; FOLATE; CHOLESTEROL; BINDING; INTERNALIZATION; FIBROBLASTS	Ceramide produced by the hydrolysis of sphingomyelin is an important cellular intermediate in hormone action. Here, we present evidence that interleukin 1 beta (IL-1 beta) binding to normal human fibroblasts initiates a lipid messenger cascade that takes place in a sphingomyelin-rich plasma membrane domain with the characteristics of caveolae. Hormone binding first stimulated the appearance of diacylglycerol (DAG) in a caveolea-rich membrane fraction isolated from whole cells, This was immediately followed by the loss of a resident population of sphingomyelin from the fraction and the concomitant appearance of ceramide. The ceramide produced in response to IL-1 beta blocked platelet-derived growth factor-stimulated DNA synthesis, IL-1 beta stimulated the appearance of DAG in other fractions from the same cell, but this DAG was not coupled to ceramide production. This indicates that ceramide production is highly compartmentalized at the cell surface. Since caveolae are known to be involved in membrane internalization, they may be essential for the delivery of ceramide to a site of action within the cell.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Liu, Pingsheng/B-7124-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MONTESANO R, 1979, NATURE, V280, P328, DOI 10.1038/280328a0; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PRASAD PD, 1994, BBA-MOL CELL RES, V1222, P309, DOI 10.1016/0167-4889(94)90184-8; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1983, J CELL BIOL, V97, P1592, DOI 10.1083/jcb.97.5.1592; SIMIONESCU N, 1983, PHYSIOL REV, V63, P1536, DOI 10.1152/physrev.1983.63.4.1536; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SMART EJ, 1995, IN PRESS J CELL BIOL; SMART EJ, 1995, IN PRESS P NATL ACAD; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; SUCKLING KE, 1985, J LIPID RES, V26, P647; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	50	278	284	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27179	27185		10.1074/jbc.270.45.27179	http://dx.doi.org/10.1074/jbc.270.45.27179			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592974	hybrid			2022-12-25	WOS:A1995TE58300074
J	KAROOR, V; BALTENSPERGER, K; PAUL, H; CZECH, MP; MALBON, CC				KAROOR, V; BALTENSPERGER, K; PAUL, H; CZECH, MP; MALBON, CC			PHOSPHORYLATION OF TYROSYL RESIDUES-350/354 OF THE BETA-ADRENERGIC-RECEPTOR IS OBLIGATORY FOR COUNTERREGULATORY EFFECTS OF INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-MEDIATED PATHWAYS; BETA-2-ADRENERGIC RECEPTOR; CROSS-REGULATION; KINASE-ACTIVITY; EXPRESSION; BINDING; SIGNAL	Insulin stimulates a loss of function and increased phosphotyrosine content of the beta(2)-adrenergic receptor in intact cells, raising the possibility that the beta(2)-receptor itself is a substrate for the insulin receptor tyrosine kinase. Phosphorylation of synthetic peptides corresponding to cytoplasmic domains of the beta(2)-adrenergic receptor by the insulin receptor in vitro and peptide mapping of the beta(2)-adrenergic receptor phosphorylated in vivo in cells stimulated by insulin reveal tyrosyl residues 350/354 and 364 in the cytoplasmic, C-terminal region of the beta(2)-adrenergic receptor as primary targets. Mutation of tyrosyl residues 350, 354 (double mutation) to phenylalanine abolishes the ability of insulin to counterregulate beta-agonist stimulation of cyclic AMP accumulation. Phenylalanine substitution of tyrosyl reside 364, in contrast, abolishes beta-adrenergic stimulation itself.	SUNY STONY BROOK, DEPT MOLEC PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			malbon, craig/ABF-3604-2020					BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CZECH MP, 1980, J CLIN INVEST, V66, P574, DOI 10.1172/JCI109889; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO, P239; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; PORT JD, 1992, J BIOL CHEM, V267, P8468; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUMMERS MD, 1987, AGR EXP STN B, V1555, P16; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALIQUETTE M, 1993, BIOCHEMISTRY-US, V32, P4979, DOI 10.1021/bi00070a002; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	19	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25305	25308		10.1074/jbc.270.43.25305	http://dx.doi.org/10.1074/jbc.270.43.25305			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592686	hybrid			2022-12-25	WOS:A1995TB46600002
J	ADHIKARI, P; KIRBY, SD; NOWALK, AJ; VERALDI, KL; SCHRYVERS, AB; MIETZNER, TA				ADHIKARI, P; KIRBY, SD; NOWALK, AJ; VERALDI, KL; SCHRYVERS, AB; MIETZNER, TA			BIOCHEMICAL-CHARACTERIZATION OF A HAEMOPHILUS-INFLUENZAE PERIPLASMIC IRON TRANSPORT OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOFERRIN-BINDING-PROTEINS; BACTERIAL OUTER-MEMBRANE; NEISSERIA-MENINGITIDIS; SERRATIA-MARCESCENS; REGULATED PROTEIN; HUMAN TRANSFERRIN; ESCHERICHIA-COLI; HEMOPHILUS-INFLUENZAE; IDENTIFICATION; GONORRHOEAE	Bacterial iron transport is critical for growth of pathogens in the host environment, where iron is limited as a form of nonspecific immunity. For Gram-negative bacteria such as Haemophilus influenzae, iron first must be transported across the outer membrane and into the periplasmic space, then from the periplasm to the cytosol. H. influenzae express a periplasmic iron-binding protein encoded by the hitA gene. This gene is organized as the first of a three-gene operon purported to encode a classic high affinity iron acquisition system that includes hitA, a cytoplasmic permease (hitB), and a nucleotide binding protein (hitC). In this study we describe the cloning, overexpression, and purification of the H. influenzae hitA gene product. The function of this protein is unambiguously assigned by demonstrating its ability to compete for iron bound to the chemical iron chelator 2,2'-dipyridyl, both in vitro and within the periplasmic space of a siderophore-deficient strain of Escherichia coli. Finally, the importance of a functional hitABC operon for iron acquisition is demonstrated by complementation of this siderophore-deficient E. coli to growth on dipyridyl-containing medium. These studies represent a detailed genetic, biochemical, and physiologic description of an active transport system that has evolved to efficiently transport iron and consequently is widely distributed among Gram-negative pathogenic bacteria.	UNIV CALGARY, DEPT MICROBIOL & INFECT DIS, CALGARY, AB T2N 4N1, CANADA	University of Calgary	ADHIKARI, P (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA.		Schryvers, Anthony B./AAF-3417-2020	Veraldi, Kristen/0000-0002-5580-4810	NIAID NIH HHS [1R29AI32226-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032226] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON PW, 1990, NEW GENERATION VACCI, P349; ANGERER A, 1990, J BACTERIOL, V172, P572, DOI 10.1128/jb.172.2.572-578.1990; ANGERER A, 1992, J BACTERIOL, V174, P1378, DOI 10.1128/jb.174.4.1378-1387.1992; BERISH SA, 1990, J EXP MED, V171, P1535, DOI 10.1084/jem.171.5.1535; BERISH SA, 1992, MOL MICROBIOL, V6, P2607, DOI 10.1111/j.1365-2958.1992.tb01438.x; BERISH SB, 1994, 9TH P INT PATH NEISS, P196; Bullen J J, 1978, Curr Top Microbiol Immunol, V80, P1; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; CORNELISSEN CN, 1993, J BACTERIOL, V175, P2448, DOI 10.1128/JB.175.8.2448-2450.1993; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; CROSA JH, 1984, ANNU REV MICROBIOL, V38, P69, DOI 10.1146/annurev.mi.38.100184.000441; CROSA JH, 1989, MICROBIOL REV, V53, P517, DOI 10.1128/MMBR.53.4.517-530.1989; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FROST GE, 1975, J BACTERIOL, V124, P704, DOI 10.1128/JB.124.2.704-712.1975; GRAYOWEN SD, 1995, INFECT IMMUN, V63, P1201, DOI 10.1128/IAI.63.4.1201-1210.1995; HARKNESS RE, 1992, J BACTERIOL, V174, P2425, DOI 10.1128/jb.174.8.2425-2430.1992; HERRINGTON DA, 1985, INFECT IMMUN, V48, P248, DOI 10.1128/IAI.48.1.248-251.1985; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; MICKELSEN PA, 1981, INFECT IMMUN, V33, P555, DOI 10.1128/IAI.33.2.555-564.1981; MICKELSEN PA, 1982, INFECT IMMUN, V35, P915, DOI 10.1128/IAI.35.3.915-920.1982; MIETZNER TA, 1994, ANNU REV NUTR, V14, P471, DOI 10.1146/annurev.nu.14.070194.002351; MIETZNER TA, 1984, INFECT IMMUN, V45, P410, DOI 10.1128/IAI.45.2.410-416.1984; MIETZNER TA, 1986, INFECT IMMUN, V51, P60, DOI 10.1128/IAI.51.1.60-68.1986; MIETZNER TA, 1987, J EXP MED, V165, P1041, DOI 10.1084/jem.165.4.1041; MIETZNER TA, 1985, PATHOGENIC NEISSERIA, P406; Neilands J.B., 1987, IRON TRANSPORT MICRO, P3; NEILANDS JB, 1982, ANNU REV MICROBIOL, V36, P285, DOI 10.1146/annurev.mi.36.100182.001441; NEILANDS JB, 1980, IRON BIOCH MED, P529; Nikaido H, 1993, Trends Microbiol, V1, P5, DOI 10.1016/0966-842X(93)90016-K; NIKAIDO H, 1990, ADV MICROBIAL PHYSL, P163; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; PITTARD J, 1966, J BACTERIOL, V91, P1494, DOI 10.1128/JB.91.4.1494-1508.1966; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; SANDERS JD, 1994, INFECT IMMUN, V62, P4515, DOI 10.1128/IAI.62.10.4515-4525.1994; SCHRYVERS AB, 1992, J INFECT DIS, V165, pS103, DOI 10.1093/infdis/165-Supplement_1-S103; SCHRYVERS AB, 1989, CAN J MICROBIOL, V35, P409, DOI 10.1139/m89-063; SCHRYVERS AB, 1989, J MED MICROBIOL, V29, P121, DOI 10.1099/00222615-29-2-121; SCHRYVERS AB, 1988, MOL MICROBIOL, V2, P281, DOI 10.1111/j.1365-2958.1988.tb00029.x; SCHRYVERS AB, 1988, INFECT IMMUN, V56, P1144, DOI 10.1128/IAI.56.5.1144-1149.1988; SHEA CM, 1991, MOL MICROBIOL, V5, P1415, DOI 10.1111/j.1365-2958.1991.tb00788.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WILLIAMS P, 1992, MED MICROBIOL IMMUN, V181, P301; ZIMMERMANN L, 1989, J BACTERIOL, V171, P238, DOI 10.1128/jb.171.1.238-243.1989	47	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25142	25149		10.1074/jbc.270.42.25142	http://dx.doi.org/10.1074/jbc.270.42.25142			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559648	hybrid			2022-12-25	WOS:A1995TB46500082
J	FUHRER, DK; FENG, GS; YANG, YC				FUHRER, DK; FENG, GS; YANG, YC			SYP ASSOCIATES WITH GP130 AND JANUS KINASE-2 IN RESPONSE TO INTERLEUKIN-11 IN 3T3-L1 MOUSE PREADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; IL-6 SIGNAL TRANSDUCER; FACTOR RECEPTOR-BETA; BCR-ABL ONCOGENE; PHOSPHORYLATION; JAK2; IDENTIFICATION; CELLS; ACTIVATION	Protein tyrosine phosphorylation and thus dephosphorylation are part of the interleukin (IL)-11 response in mouse 3T3-L1 cells. We report here for the first time the involvement and interactions of the SH2-containing protein tyrosine phosphatase Syp in the IL-11 signal transduction pathway. Addition of IL-11 to 3T3-L1 cells resulted in an increase in the tyrosine phosphorylation of Syp. When cell lysates were precipitated with glutathione S transferase fusion products of Syp, the C-terminal SH2 domain of Syp was shown to precipitate several proteins of 70, 130, 150, and 200 kDa that were tyrosine phosphorylated in response to IL-11. Reciprocal immunoprecipitation experiments showed that Syp was inducibly associated with both gp130 and Janus kinase 2 (JAK2). A phosphopeptide containing the sequence for a potential Syp binding site (YXXV) was used to compete with the associations of Syp with gp130 and JAK2. The phosphopeptide reduced the Syp association with both gp130 and JAK2. To summarize, Syp has multiple interactions in IL-11 signal transduction. In addition to the IL-11-induced tyrosine phosphorylation of Syp, Syp coprecipitated with gp130, JAK2, and other tyrosine-phosphorylated proteins in response to IL-11, These findings may have extensive significance to IL-11 and related cytokine signal transduction, suggesting new pathways and mechanisms.	INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HARPUR AG, 1992, ONCOGENE, V7, P1347; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MALEK SN, 1994, J BIOL CHEM, V269, P33009; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; XIAO S, 1994, J BIOL CHEM, V269, P21244; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1992, J BIOL CHEM, V267, P8347; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467; ZAFRIRI D, 1993, P NATL ACAD SCI USA, V90, P477, DOI 10.1073/pnas.90.2.477; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24826	24830		10.1074/jbc.270.42.24826	http://dx.doi.org/10.1074/jbc.270.42.24826			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559603	hybrid			2022-12-25	WOS:A1995TB46500037
J	MARTIN, MB; GARCIAMORALES, P; STOICA, A; SOLOMON, HB; PIERCE, M; KATZ, D; ZHANG, SM; DANIELSEN, M; SACEDA, M				MARTIN, MB; GARCIAMORALES, P; STOICA, A; SOLOMON, HB; PIERCE, M; KATZ, D; ZHANG, SM; DANIELSEN, M; SACEDA, M			EFFECTS OF 12-O-TETRADECANOYLPHORBOL-13-ACETATE ON ESTROGEN-RECEPTOR ACTIVITY IN MCF-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CLINICAL BREAST-CANCER; RESPONSIVE ELEMENT; CARCINOMA-CELLS; MESSENGER-RNAS; PHORBOL ESTER; BINDING; PHOSPHORYLATION; ACTIVATION; TRANSCRIPTION	The effects of long term treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) on estrogen receptor (ER) expression in the human breast cancer cell line, MCF-7, were studied. This study demonstrates that treatment of cells with the phorbol ester blocked estrogen receptor activity. Treatment of cells with 100 nM TPA resulted in an 80% decrease in the level of ER protein and a parallel decrease in ER mRNA and binding capacity. Following removal of TPA from the medium, the level of ER protein and mRNA returned to control values; however, the receptor failed to bind estradiol. These cells also failed to induce progesterone receptor in response to estradiol, In addition, TPA treatment blocked transcription from an estrogen response element in transient transfection assays and inhibited ER binding to its response element in a DNA mobility shift assay. The estrogen receptor in treated cells was recognized by two monoclonal anti-ER antibodies and was not quantitatively different from ER in control cells. RNase protection analysis failed to detect any qualitative changes in the ER mRNA transcript. Mixing experiments suggest that TPA induces/activates a factor which interacts with the ER to block binding of estradiol. The effects of TPA on ER levels and binding capacity were concentration-dependent. Low concentrations of TPA inhibited estradiol binding without a decrease in the level of protein, whereas higher concentrations were required to decrease the level of ER protein. The effects of TPA appear to be mediated by activation of protein kinase C since the protein kinase C inhibitors, H-7 and bryostatin, block the effects of TPA on estradiol induction of progesterone receptor. TPA treatment had no effect on the level or binding capacity of the glucocorticoid receptor, indicating that the effects are not universal for steroid receptors. These data demonstrate that activation of the protein kinase C signal transduction pathway modulates the estrogen receptor pathway. The long term effect of protein kinase C activation is to inhibit estrogen receptor function through induction/activation of a factor which interacts with the receptor.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,DEPT MED ONCOL,WASHINGTON,DC 20007	Georgetown University	MARTIN, MB (corresponding author), GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,DEPT BIOCHEM & MOLEC BIOL,E411 RES BLDG,WASHINGTON,DC 20007, USA.		Danielsen, Mark/B-1606-2008; danielsen, mark/AAE-9813-2020; Garcia Morales, Pilar/ABD-4362-2021; Saceda, Miguel/A-1581-2008	Danielsen, Mark/0000-0002-0923-9945; danielsen, mark/0000-0002-0923-9945; Saceda, Miguel/0000-0002-1564-3602	NCI NIH HHS [UO1 CA51908] Funding Source: Medline; NIDDK NIH HHS [K04 DK02105, R01 DK42552] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042552, K04DK002105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allegra J C, 1980, Recent Results Cancer Res, V71, P20; AURICCHIO F, 1984, J STEROID BIOCHEM, V20, P31, DOI 10.1016/0022-4731(84)90185-7; AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BELL PA, 1973, BIOCHEM J, V136, P97, DOI 10.1042/bj1360097; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DESOMBRE ER, 1980, CANCER, V46, P2783, DOI 10.1002/1097-0142(19801215)46:12+<2783::AID-CNCR2820461408>3.0.CO;2-4; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FABBRO D, 1986, CANCER RES, V46, P2720; FUQUA SAW, 1991, CANCER RES, V51, P105; FUQUA SAW, 1992, CANCER RES, V52, P483; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GUILBAUD N, 1988, MOL CELL ENDOCRINOL, V56, P157, DOI 10.1016/0303-7207(88)90020-2; HASHIMOTO Y, 1991, JPN J CANCER RES, V82, P665, DOI 10.1111/j.1349-7006.1991.tb01902.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECLERCQ G, 1992, J STEROID BIOCHEM, V41, P545, DOI 10.1016/0960-0760(92)90381-R; LEE CSL, 1989, BIOCHEM BIOPH RES CO, V162, P415, DOI 10.1016/0006-291X(89)92013-5; Lippman M.E., 1985, TXB ENDOCRINOLOGY, P1309; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; MCGUIRE WL, 1992, J STEROID BIOCHEM, V43, P243, DOI 10.1016/0960-0760(92)90214-4; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MIGLIACCIO S, 1993, MOL ENDOCRINOL, V7, P1133, DOI 10.1210/me.7.9.1133; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; PARIDAENS R, 1980, CANCER-AM CANCER SOC, V46, P2889, DOI 10.1002/1097-0142(19801215)46:12+<2889::AID-CNCR2820461430>3.0.CO;2-4; PICCART D, 1990, NATURE, V348, P166; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; SACEDA M, 1991, J BIOL CHEM, V266, P17809; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLATER EP, 1991, MOL ENDOCRINOL, V5, P386, DOI 10.1210/mend-5-3-386; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; VALETTE A, 1987, CANCER RES, V47, P1615; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097	51	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25244	25251		10.1074/jbc.270.42.25244	http://dx.doi.org/10.1074/jbc.270.42.25244			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559663	hybrid			2022-12-25	WOS:A1995TB46500097
J	DYHRMIKKELSEN, H; KJEMS, J				DYHRMIKKELSEN, H; KJEMS, J			INEFFICIENT SPLICEOSOME ASSEMBLY AND ABNORMAL BRANCH SITE SELECTION IN SPLICING OF AN HIV-1 TRANSCRIPT IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRE-MESSENGER-RNA; REV PROTEIN; INTRONIC SEQUENCES; EXPRESSION; MUTATIONS; COMPLEX; INVITRO; IDENTIFICATION; TRANSLATION	Continuous replication of human immunodeficiency virus type I (HIV-1) requires balanced expression of spliced and nonspliced mRNAs in the cytoplasm. This process is regulated post-transcriptionally by the viral-encoded Rev protein. An important prerequisite for Rev responsiveness is the presence of weak splice sites in the viral mRNA, We have investigated the splicing of the second intron of the HIV-1 Tat/Rev transcript in vitro and show that the S'-splice site region is responsible for the inefficient splicing of the HIV-1 transcript. In contrast, the HIV-1 5'-splice site is highly functional in combination with a heterologous S' splice site. Incubation of the HIV-1 transcript in nuclear extract leads to a rapid accumulation of 50 S nonproductive pre-spliceosome complexes. These complexes contain mainly U1 and U2 small nuclear ribonucleoproteins and are formed independently of the presence of the downstream 3'-splice site. The HIV-1 transcripts, which do proceed through the first splicing step, utilize primarily a uridine as the branch acceptor nucleotide. Sequence comparison with other HIV-1 introns suggests that nucleotides other than adenosines are commonly used as branch points in these viruses.	AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS,DENMARK	Aarhus University			Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317				ADEMA GJ, 1988, NUCLEIC ACIDS RES, V16, P9513, DOI 10.1093/nar/16.20.9513; AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BERBERICH SL, 1991, J VIROL, V65, P2640, DOI 10.1128/JVI.65.5.2640-2646.1991; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; HAMMARSKJOLD ML, 1994, J VIROL, V68, P951; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KATZ RA, 1988, J VIROL, V62, P2686, DOI 10.1128/JVI.62.8.2686-2695.1988; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; MCNALLY MT, 1992, J VIROL, V66, P6, DOI 10.1128/JVI.66.1.6-11.1992; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276	45	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24060	24066		10.1074/jbc.270.41.24060	http://dx.doi.org/10.1074/jbc.270.41.24060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592605	hybrid			2022-12-25	WOS:A1995TA21700033
J	TORPHY, TJ; ZHOU, HL; FOLEY, JJ; SARAU, HM; MANNING, CD; BARNETTE, MS				TORPHY, TJ; ZHOU, HL; FOLEY, JJ; SARAU, HM; MANNING, CD; BARNETTE, MS			SALBUTAMOL UP-REGULATES PDE4 ACTIVITY AND INDUCES A HETEROLOGOUS DESENSITIZATION OF U937 CELLS TO PROSTAGLANDIN E(2) - IMPLICATIONS FOR THE THERAPEUTIC USE OF BETA-ADRENOCEPTOR AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP-PHOSPHODIESTERASE; NUCLEOTIDE PHOSPHODIESTERASE; BRONCHIAL-ASTHMA; CALCIUM MOBILIZATION; HORMONAL-REGULATION; PROTEIN-KINASE; MESSENGER-RNA; U-937 CELLS; INHIBITORS; CAMP	Previous studies with U937 cells, a human monocyte cell line, have shown that the activity of cyclic nucleotide phosphodiesterase 4 (PDE4) is increased by agents that elevate cyclic AMP content, The present experiments were conducted to determine 1) whether an increase in PDE4 steady-state message and/or protein accompanies the up-regulation of PDE4 activity and 2) whether the up regulation changes the functional responses of U937 cells to activators of adenylyl cyclase, To up regulate PDE4 activity, U937 cells were treated for 4 h with a combination of 1 mu M salbutamol, a beta-adrenoceptor agonist, and 30 mu M rolipram, a PDE4 inhibitor, Cells were washed extensively to remove drugs and used immediately in various experimental protocols, Reverse transcriptase-polymerase chain reactions conducted with primers specific for the four PDE4 subtypes suggested that pretreatment with salbutamol and rolipram increased steady-state mRNA levels of PDE4A and PDE4B, but not PDE4C or PDE4D. Immunoblot analyses using two rabbit polyclonal antibodies, one directed against human recombinant PDE4A and PDE4D and a second directed against human recombinant PDE4B, revealed bands of immunoreactivity corresponding to similar to 125 kDa (PDE4A) and similar to 70 MDa (PDE4B), respectively, that increased in intensity after cells were treated with salbutamol and rolipram, As demonstrated in both time course and concentration-response studies with prostaglandin E(2) (PGE(2)), an agent that activates adenylyl cyclase by a non-beta-adrenoceptor-mediated mechanism, cAMP accumulation was substantially decreased in cells in which PDE4 activity had been up regulated. The difference in PGE(2)-stimulated cAMP accumulation be tween control and PDE4 up-regulated cells was greatly reduced in the presence of rolipram, consistent with the notion that an increase in PDE4 activity was responsible for the heterologous desensitization. Functionally, upregulation of PDE4 markedly decreased the ability of PGE(2) to inhibit LTD(4)-induced Ca2+ mobilization in intact cells, A hypothetical implication of these results is that increasing PDE4 activity in vivo by administering beta-adrenoceptor agonists could exacerbate inflammatory processes by decreasing the activity of endogenous antiinflammatory agents such as PGE(2).			TORPHY, TJ (corresponding author), SMITHKLINE BEECHAM PHARMACEUT INC, DIV PHARMACOL SCI, UW2532, 709 SWEDELAND RD, KING OF PRUSSIA, PA 19406 USA.							BAECKER PA, 1994, GENE, V138, P253, DOI 10.1016/0378-1119(94)90818-4; BARNES PJ, 1992, TRENDS PHARMACOL SCI, V13, P20, DOI 10.1016/0165-6147(92)90011-T; BARNES PJ, 1986, J ALLERGY CLIN IMMUN, V77, P791, DOI 10.1016/0091-6749(86)90375-1; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BOURNE HR, 1973, SCIENCE, V181, P952, DOI 10.1126/science.181.4103.952; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHAN SC, 1982, J CYCLIC NUCL PROT, V8, P211; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; ENGELS P, 1994, FEBS LETT, V350, P291, DOI 10.1016/0014-5793(94)00788-8; GIEMBYCZ MA, 1992, CLIN EXP ALLERGY, V22, P337, DOI 10.1111/j.1365-2222.1992.tb03095.x; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669, DOI 10.1111/j.1365-2125.1986.tb02956.x; HOLDEN CA, 1987, AGENTS ACTIONS, V22, P36, DOI 10.1007/BF01968814; JOST JP, 1971, ANNU REV BIOCHEM, V40, P741, DOI 10.1146/annurev.bi.40.070171.003521; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KUEHL FA, 1987, AM REV RESPIR DIS, V136, P210, DOI 10.1164/ajrccm/136.1.210; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; NALLY JE, 1994, BRIT J PHARMACOL, V113, P1328, DOI 10.1111/j.1476-5381.1994.tb17143.x; NELSON HS, 1991, AM REV RESPIR DIS, V144, P249, DOI 10.1164/ajrccm/144.2.249; OBERNOLTE R, 1993, GENE, V129, P239, DOI 10.1016/0378-1119(93)90274-7; PAGE CP, 1991, LANCET, V337, P717, DOI 10.1016/0140-6736(91)90289-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAUSSY DL, 1989, J BIOL CHEM, V264, P19845; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1991, THORAX, V46, P512, DOI 10.1136/thx.46.7.512; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; WINKLER JD, 1990, CELL SIGNAL, V2, P427, DOI 10.1016/0898-6568(90)90039-D; WINKLER JD, 1988, J PHARMACOL EXP THER, V246, P204	42	81	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23598	23604		10.1074/jbc.270.40.23598	http://dx.doi.org/10.1074/jbc.270.40.23598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559525	hybrid			2022-12-25	WOS:A1995RY90900054
J	JIANG, HP; LIN, J; YOUNG, SM; GOLDSTEIN, NI; WAXMAN, S; DAVILA, V; CHELLAPPAN, SP; FISHER, PB				JIANG, HP; LIN, J; YOUNG, SM; GOLDSTEIN, NI; WAXMAN, S; DAVILA, V; CHELLAPPAN, SP; FISHER, PB			CELL-CYCLE GENE-EXPRESSION AND E2F TRANSCRIPTION FACTOR COMPLEXES IN HUMAN-MELANOMA CELLS INDUCED TO TERMINALLY DIFFERENTIATE	ONCOGENE			English	Review						TERMINAL CELL DIFFERENTIATION; REVERSIBLE DIFFERENTIATION; HUMAN MELANOMA; E2F GROWTH ARREST COMPLEX; E2F TERMINAL DIFFERENTIATION COMPLEX	DNA POLYMERASE-DELTA; WILD-TYPE P53; PROTEIN-KINASE-C; MESSENGER-RNA; AUXILIARY PROTEIN; NUCLEAR ANTIGEN; S-PHASE; RETINOBLASTOMA PROTEIN; DOWN-REGULATION; F9 CELLS	Defects in cellular differentiation are a common occurrence in human cancers, The combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) results in an irreversible loss of proliferative capacity and terminal cell differentiation in H0-1 human melanoma cells, In contrast, either agent alone induces reversible growth arrest and/or specific components of the differentiation process without inducing terminal differentiation, The current study investigates changes in cell cycle, cell cycle gene expression and E2F transcription factor complex formation during the processes of reversible and irreversible (terminal) differentiation, Induction of both terminal differentiation and reversible differentiation (MEZ treatment) results in a temporal decrease in DNA synthesis and the percentage of cells in S phase and a decrease in the expression of cell cycle and growth regulated genes, including cdc2, cyclin A, cyclin B, histone H1, histone H4, nm23-H1, p53 and c-myc, Persistent gene expression changes occur in terminally differentiated cells, but not in reversibly differentiated cells, H0-1 cells contain several E2F binding activities, including uncomplexed E2F, an E2F-p107-cyclin A-cdk2 kinase complex and an Rb-E2F complex, Induction of growth arrest by MEZ results in a slow migrating gel-shift band that contains E2F associated with the pRb2/p130 protein. There is also a loss of the Rb-E2F complex. Induction of terminal differentiation after treatment with IFN-beta+MEZ generates a second pRb2/p130-E2F complex that migrates considerably faster than the pRb2/p130-E2F complex resulting from growth arrest, The slower migrating complex may contribute to growth arrest, whereas the faster migrating complex may play a role in terminal differentiation. Our results demonstrate that terminal cell differentiation involves a co-ordinate and continuous suppression of a number of cell cycle and growth related genes and results in the development of a novel E2F transcription factor complex not apparent in growth arrested and reversibly differentiated human melanoma cells.	COLUMBIA UNIV, COLL PHYS & SURG,CTR COMPREHENS CANC, INST CANC RES,DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,CTR COMPREHENS CANC, INST CANC RES,DEPT UROL, NEW YORK, NY 10032 USA; IMCLONE SYST INC, DEPT IMMUNOL MONOCLONAL ANTIBODIES, NEW YORK, NY 10014 USA; MT SINAI MED CTR, DEPT MED, DIV MED ONCOL, NEW YORK, NY 10029 USA	Columbia University; Columbia University; Eli Lilly; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA063136, R01CA035675] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHURST RJ, 1989, DIFFERENTIATION, V40, P36, DOI 10.1111/j.1432-0436.1989.tb00811.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CAROZZI N, 1984, SCIENCE, V224, P1115, DOI 10.1126/science.6719136; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHELLAPPAN SP, 1994, MOL CELL DIFFER, V22, P201; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLLART DG, 1988, J BIOL CHEM, V263, P15860; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FISHER PB, 1991, SERONO SYM, V82, P201; FISHER PB, 1988, PHARM EFFECTS LIPIDS, V3, P69; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GUARINI L, 1992, PIGM CELL RES, P123; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; HAYES TE, 1991, NEW BIOL, V3, P259; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; JIANG HP, 1992, INT J ONCOL, V1, P227; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KEIM DR, 1993, CLIN EXP METASTAS, V11, P83, DOI 10.1007/BF00880069; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIYOKAWA H, 1992, CELL GROWTH DIFFER, V3, P377; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAYOL X, 1993, ONCOGENE, V8, P2561; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RICHON VM, 1989, ONCOGENE, V4, P165; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHEN DW, 1993, P NATL ACAD SCI USA, V80, P5919; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; WHITMAN MM, 1990, CANCER RES, V50, P3193; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHIRO S, 1994, ONCOGENE, V9, P2461; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	102	55	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1179	1189						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566979				2022-12-25	WOS:A1995RX18000022
J	POHLMANN, R; BOEKER, MWC; VONFIGURA, K				POHLMANN, R; BOEKER, MWC; VONFIGURA, K			THE 2 MANNOSE 6-PHOSPHATE RECEPTORS TRANSPORT DISTINCT COMPLEMENTS OF LYSOSOMAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; TRANSMEMBRANE PROTEIN; TARGETED DISRUPTION; ACID-PHOSPHATASE; BOVINE LIVER; ENZYMES; OLIGOSACCHARIDES; CELLS; PHOSPHORYLATION; PURIFICATION	Mammalian cells express two different mannose g-phosphate receptors (MPR 46 and MPR 300), which both mediate targeting of Man-6-P-containing lysosomal proteins to lysosomes, To assess the contribution of either and both MPRs to the transport of lysosomal proteins, fibroblasts were established from mouse embryos that were homozygous for disrupted alleles of either MPR 46 or MPR 300 or both MPRs, Fibroblasts missing both MPRs secreted most of the newly synthesized lysosomal proteins and were unable to maintain the catabolic function of lysosomes. The intracellular levels of lysosomal proteins decreased to <20%, and undigested material accumulated in the lysosomal compartment. Fibroblasts lacking either MPR exhibited only a partial missorting and maintained, in general, half normal to normal level of lysosomal proteins, The same species of lysosomal proteins were found in secretions of double MPR-deficient fibroblasts as in secretions of single MPR-deficient fibroblasts, but at different ratios, This clearly indicates that neither MPR has an exclusive affinity for one or several lysosomal proteins, Furthermore, neither MPR can substitute in vivo for the loss of the other. It is proposed that the heterogeneity of the Man B-P recognition marker within a lysosomal protein and among different lysosomal proteins has necessitated the evolution of two MPRs with complementary binding properties to ensure an efficient targeting of lysosomal proteins.			POHLMANN, R (corresponding author), UNIV GOTTINGEN,BIOCHEM ABT 2,GOSSLERSTR 12D,D-37073 GOTTINGEN,GERMANY.							BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; FILSON AJ, 1993, DEVELOPMENT, V118, P731; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GIESELMANN V, 1994, HOPPESEYLERS Z PHYSL, V365, P651; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HOGAN B, 1986, MANIPULATING MOUSE L; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSTER A, 1994, EUR J BIOCHEM, V224, P685, DOI 10.1111/j.1432-1033.1994.00685.x; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TONG PY, 1989, J BIOL CHEM, V264, P7970; ULLRICH K, 1978, BIOCHEM J, V170, P643, DOI 10.1042/bj1700643; VONFIGURA K, 1985, BIOCHEM J, V225, P543, DOI 10.1042/bj2250543; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WENK J, 1991, BIOCHEM INT, V23, P723	35	173	176	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27311	27318		10.1074/jbc.270.45.27311	http://dx.doi.org/10.1074/jbc.270.45.27311			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592993	hybrid			2022-12-25	WOS:A1995TE58300093
J	SCHLOSSMANN, J; NEUPERT, W				SCHLOSSMANN, J; NEUPERT, W			ASSEMBLY OF THE PREPROTEIN RECEPTOR MOM72/MAS70 INTO THE PROTEIN IMPORT COMPLEX OF THE OUTER-MEMBRANE OF MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; TRANSLOCATION; INSERTION; IDENTIFICATION; RECOGNITION; BINDING; MOM19; MOM22	Membrane integration and assembly of MOM72 from Neurospora crassa and its yeast homolog MAS70 was studied with isolated mitochondria. After synthesis in vitro, the precursors of MOM72/MAS70 are tightly folded and expose only their N-terminal amino acid residues comprising the targeting and the membrane anchor domain. Insertion of the protein into the mitochondrial outer membrane (MOM) occurs in a time- and temperature-dependent manner and is stimulated by ATP. MOM72/MAS70 is then assembled into the outer membrane MOM complex. Whereas membrane insertion occurred independently of the presence of protease-sensitive surface components, the assembly reaction depended on such components. In the MOM complex MOM72 and MAS70 were found in the neighborhood of different components in yeast and N. crassa mitochondria, MOM72 was found in association with MOM22 in N. crassa mitochondria, whereas MAS70 was in proximity to a 37-kDa component in yeast outer mitochondrial membrane. The interaction with the 37-kDa protein is important for integration of MAS70 into the MOM complex. Thus, the 37-kDa protein plays an important role in the biogenesis of MAS70.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich			Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HARKNESS TAA, 1994, GENETICS, V136, P107; HASHIYA N, 1994, EMBO J, V13, P5146; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KEIL P, 1993, J BIOL CHEM, V269, P19177; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MCBRIDE HM, 1992, J CELL BIOL, V19, P1451; MILLAR DG, 1994, J BIOL CHEM, V269, P12229; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; NAKAI M, 1993, J BIOL CHEM, V268, P24262; NAKAI M, 1995, FEBS LETT, V357, P202; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P7528; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WEISS H, 1970, EUR J BIOCHEM, V14, P75, DOI 10.1111/j.1432-1033.1970.tb00263.x; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	43	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27116	27121		10.1074/jbc.270.45.27116	http://dx.doi.org/10.1074/jbc.270.45.27116			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592965	hybrid			2022-12-25	WOS:A1995TE58300065
J	UFRETVINCENTY, CA; SHORT, AD; ALFONSO, A; GILL, DL				UFRETVINCENTY, CA; SHORT, AD; ALFONSO, A; GILL, DL			A NOVEL CA2+ ENTRY MECHANISM IS TURNED ON DURING GROWTH ARREST INDUCED BY CA2+ POOL DEPLETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; SARCOPLASMIC-RETICULUM; CAFFEINE ANALOGS; CELL-GROWTH; RELEASE; THAPSIGARGIN	Ca2+ pool depletion with Ca2+ pump blockers induces growth arrest of rapidly dividing DDT(1)MF-2 smooth muscle cells and causes cells to enter a stable, quiescent G(o)-like growth state (Short, A. D., Bian, J., Ghosh, T. K., Waldron, R. T., Rybak, S. L., and Gill, D. L. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 4986-4990). Here we reveal that induction of this quiescent growth state with the Ca2+ pump blocker, thapsigargin, is correlated with the appearance of a novel caffeine-activated Ca2+ influx mechanism. Ca2+ influx through this mechanism is clearly distinct from and additive with Ca2+ entry through store-operated channels (SOCs). Whereas SOC-mediated entry is activated seconds after Ca2+ pool release, caffeine-sensitive influx requires at least 30 min of pool emptying, Although activated in the 1-10 mM caffeine range, this mechanism has clearly distinct methylxanthine specificity from ryanodine receptors and is not modified by ryanodine. It is also unaffected by the Ca2+ channel blockers SKF96365 or verapamil and is independent of modifiers of cyclic nucleotide levels. Growth arrest by thapsigargin-induced Ca2+ pool depletion can be reversed by treatment with 20% serum (Waldron, R. T., Short, A. D., Meadows, J. J., Ghosh, T. K., and Gill, D. L. (1994) J. Biol. Chem. 269, 11927-11933). The serum-induced return of functional Ca2+ pools and reentry of cells into the cell cycle correlates exactly with the disappearance of the caffeine-sensitive Ca2+ influx mechanism. Therefore, appearance and function of this novel Ca2+ entry mechanism are closely tied to Ca2+ pool function and cell, growth state and may provide an important means for modifying exit from or entry into the cell cycle.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Alfonso, Amparo/GLN-2591-2022	Alfonso Rancano, Maria Amparo/0000-0003-1572-9016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15407] Funding Source: Medline; NINDS NIH HHS [NS19304] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; DALY JW, 1991, PHARMACOLOGY, V42, P309, DOI 10.1159/000138813; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FURUYA Y, 1994, CANCER RES, V54, P6167; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V261, P3440; GUERRERO A, 1994, J GEN PHYSIOL, V104, P395, DOI 10.1085/jgp.104.2.395; GUERRERO A, 1994, J GEN PHYSIOL, V104, P375, DOI 10.1085/jgp.104.2.375; HOTH M, 1992, J PHYSIOL-LONDON, V465, P359; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MULLER CE, 1993, BIOCHEM PHARMACOL, V46, P1825, DOI 10.1016/0006-2952(93)90589-O; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WALDRON RT, 1994, J BIOL CHEM, V269, P11927	24	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26790	26793		10.1074/jbc.270.45.26790	http://dx.doi.org/10.1074/jbc.270.45.26790			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592918	hybrid			2022-12-25	WOS:A1995TE58300018
J	BRANDSCH, M; BRANDSCH, C; PRASAD, PD; GANAPATHY, V; HOPFER, U; LEIBACH, FH				BRANDSCH, M; BRANDSCH, C; PRASAD, PD; GANAPATHY, V; HOPFER, U; LEIBACH, FH			IDENTIFICATION OF A RENAL-CELL LINE THAT CONSTITUTIVELY EXPRESSES THE KIDNEY-SPECIFIC HIGH-AFFINITY H+/PEPTIDE COTRANSPORTER	FASEB JOURNAL			English	Article						H+ PEPTIDE COTRANSPORTER; PEPT 1; PEPT 2; SKPT-0193 RENAL CELL LINE; RAT KIDNEY	BORDER MEMBRANE-VESICLES; GLYCYL-L-PROLINE; CARRIER-MEDIATED TRANSPORT; DIPEPTIDE TRANSPORT; PROXIMAL TUBULE; PH GRADIENT; RABBIT; GLYCYLSARCOSINE; PEPTIDES; REABSORPTION	In this study we describe for the first time the identification of a renal cell line that expresses the kidney-specific high-affinity H+/peptide cotransport system, The kidney cell line SKPT-0193 Cl.2 was obtained by SV40 transformation of rat proximal tubular cells, The transport of the dipeptide glycylsarcosine (Gly-Sar) was studied in this cell line grown as a confluent monolayer on impermeable plastic supports, Uptake of the dipeptide was rapid and was stimulated sixfold by an inwardly directed H+ gradient, with optimal uptake occurring at an extracellular pH of 6.0. The uptake was markedly reduced by the protonophore carbonyl cyanide 4(trifluoromethoxy) phenylhydrazone whether measured at pH 7.5 or 6.0. Intracellular acidification of the cells by NH4Cl prepulse also reduced the uptake of glycylsarcosine, The dipeptide uptake was found to be mediated by a high-affinity transport system with a Michaelis-Menten constant (K-t) of 67 +/- 2 mu M and a maximal transport velocity of 1.20 +/- 0.02 nmol . 10 min(-1). mg protein(-1). Studied over a concentration range of 5 mu M to 5 mM, there was no evidence for a second saturable transport component, Di- and tripeptides, but not glycine, were strong inhibitors of glycylsarcosine uptake, indicating that these peptides also interact with the transport system with high affinity, Northern blot analysis of poly(A)(+)RNA from these cells using cDNA probes specific for the human intestinal peptide transporter (PEPT 1) or the human kidney-specific peptide transporter (PEPT 2) revealed that the transport system expressed in these cells is PEPT 2, It is concluded that the SKPT-0193 Cl.2 cell line constitutively expresses the kidney-specific high-affinity H+/peptide cotransporter described in the proximal tubular epithelial cells of the normal kidney.	MED COLL GEORGIA, DEPT BIOCHEM & MOLEC BIOL, AUGUSTA, GA 30912 USA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	University System of Georgia; Augusta University; Case Western Reserve University			Hopfer, Ulrich/B-5463-2009	Hopfer, Ulrich/0000-0003-1357-0101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50173] Funding Source: Medline; NIDDK NIH HHS [DK-28389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1987, METABOLISM, V36, P1001, DOI 10.1016/0026-0495(87)90140-5; BARFUSS DW, 1988, AM J PHYSIOL, V255, pF177, DOI 10.1152/ajprenal.1988.255.1.F177; BARFUSS DW, 1981, AM J PHYSIOL, V241, pF322, DOI 10.1152/ajprenal.1981.241.3.F322; BRANDSCH M, 1995, AM J PHYSIOL-RENAL, V268, pF391, DOI 10.1152/ajprenal.1995.268.3.F391; BRANDSCH M, 1994, BIOCHEM J, V299, P253, DOI 10.1042/bj2990253; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIEL H, 1991, J BIOL CHEM, V266, P19917; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FURST P, 1990, P NUTR SOC, V49, P343, DOI 10.1079/PNS19900041; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GANAPATHY V, 1986, AM J PHYSIOL, V251, pF945, DOI 10.1152/ajprenal.1986.251.6.F945; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GANAPATHY V, 1987, ADV BIOSCI, V65, P91; Ganapathy Vadivel, 1994, P1773; GRIMBLE GK, 1994, ANNU REV NUTR, V14, P419, DOI 10.1146/annurev.nu.14.070194.002223; INUI KI, 1984, BIOCHIM BIOPHYS ACTA, V769, P449, DOI 10.1016/0005-2736(84)90329-8; KRAMER W, 1988, BIOCHIM BIOPHYS ACTA, V939, P167, DOI 10.1016/0005-2736(88)90059-4; KULANTHAIVEL P, 1991, BIOCHEM J, V277, P53, DOI 10.1042/bj2770053; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Matthews DM, 1991, PROTEIN ABSORPTION D; MIYAMOTO Y, 1985, BIOCHEM BIOPH RES CO, V132, P946, DOI 10.1016/0006-291X(85)91899-6; MIYAMOTO Y, 1988, BIOCHEM J, V249, P247, DOI 10.1042/bj2490247; RAMAMOORTHY S, 1991, BIOCHEM J, V280, P317, DOI 10.1042/bj2800317; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RAMAMOORTHY S, 1995, IN PRESS BIOCH BIOPH; ROMERO MF, 1992, KIDNEY INT, V42, P1130, DOI 10.1038/ki.1992.397; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SEAL CJ, 1991, COMP BIOCHEM PHYS B, V99, P679, DOI 10.1016/0305-0491(91)90354-G; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; SILBERNAGL S, 1987, AM J PHYSIOL, V253, pF448, DOI 10.1152/ajprenal.1987.253.3.F448; SKOPICKI HA, 1991, AM J PHYSIOL, V261, pF670, DOI 10.1152/ajprenal.1991.261.4.F670; TAKUWA N, 1985, BIOCHIM BIOPHYS ACTA, V814, P186, DOI 10.1016/0005-2736(85)90435-3; THWAITES DT, 1993, J BIOL CHEM, V268, P7640; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P2048; WOOST PG, 1994, FASEB J, V8, pA529	37	63	63	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1995	9	14					1489	1496		10.1096/fasebj.9.14.7589991	http://dx.doi.org/10.1096/fasebj.9.14.7589991			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589991				2022-12-25	WOS:A1995TF67800014
J	KELLER, P; ZECCA, L; BOUKAMEL, R; ZWICKER, E; GLOOR, S; SEMENZA, G				KELLER, P; ZECCA, L; BOUKAMEL, R; ZWICKER, E; GLOOR, S; SEMENZA, G			FURIN, PC1/3, AND/OR PC6A PROCESS RABBIT, BUT NOT HUMAN, PRO-LACTASE-PHLORHIZIN HYDROLASE TO THE 180-KDA INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PHLORHIZIN HYDROLASE; SUCRASE-ISOMALTASE; FUNCTIONAL EXPRESSION; PROPROTEIN CONVERTASE; ENDOPROTEASE FAMILY; RAT; IDENTIFICATION; BIOSYNTHESIS; KEX2	Small intestinal lactase-phlorizin hydrolase (LPH) is synthesized as a large precursor (prepro-LPH) of 1926 amino acids. In the endoplasmic reticulum, prepro-LPR is split by signal protease. The resulting pro-LPH is cut to mature LPH directly (human) or via a 180-kDa intermediate (rabbit), most likely in the trans-Golgi network or in a later compartment. Antibodies directed against different regions of rabbit pro-LPH locate the cleavage site resulting in the 180-kDa intermediate between amino acid residues 79 and 286. This stretch contains the two sequences -Arg-Cys-Tyr-Arg(114)similar to and -Arg-Ala-Ser-Arg(191)similar to, which are potential cleavage sites for subtilisin-like proprotein convertases. These sites are not conserved in human pro-LPH, By coexpression in COS 7 cells of rabbit prepro-LPH and proprotein convertases (PC1/3, PC2, PC6A, PC6B, furin), we show that furin, PC1/3, and PC6A generate a processing intermediate that is immunologically indistinguishable from the one observed in vivo. Furin, PC1/3, and PC6A are all expressed in the small intestine as shown by a polymerase chain reaction-based approach and, more specifically, in enterocytes, as shown by in situ hybridization. These results suggest that furin, PC1/3, and/or PC6A are responsible for the in vivo processing of rabbit pro-LPH to the 180-kDa intermediate.	ETH ZURICH,ETH ZENTRUM,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND	ETH Zurich								BANZIGER R, 1990, HERSTELLUNG CHARAKTE; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BOURDAIS J, 1991, J BIOL CHEM, V266, P23386; BRESHNAHAN PA, 1991, J CELL BIOL, V111, P2851; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DUDLEY MA, 1993, J BIOL CHEM, V268, P13609; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; HADDAD P, 1993, CYTOTOXIC CELLS RECO, P251; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; JIANG WP, 1992, J BIOL CHEM, V267, P9185; KELLER P, 1995, AM J PHYSIOL-GASTR L, V268, pG41, DOI 10.1152/ajpgi.1995.268.1.G41; KELLER P, 1992, FEBS LETT, V313, P265, DOI 10.1016/0014-5793(92)81206-2; KELLER P, 1995, FEBS LETT, V368, P563, DOI 10.1016/0014-5793(95)00679-4; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONTGOMERY RK, 1989, JOINT M AM SOC BIOCH; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1994, J BIOL CHEM, V269, P26933; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; RHOLAM M, 1995, EUR J BIOCHEM, V227, P707, DOI 10.1111/j.1432-1033.1995.tb20192.x; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROSSI M, 1993, FEBS LETT, V336, P299, DOI 10.1016/0014-5793(93)80824-E; ROSSI M, 1992, FEBS LETT, V313, P260, DOI 10.1016/0014-5793(92)81205-Z; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKOVBJERG H, 1984, BIOCHIM BIOPHYS ACTA, V798, P247, DOI 10.1016/0304-4165(84)90312-X; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V200, P943, DOI 10.1006/bbrc.1994.1541; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WACKER H, 1992, J BIOL CHEM, V267, P18744; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994; YEH KY, 1991, GASTROENTEROLOGY, V101, P312, DOI 10.1016/0016-5085(91)90005-6; ZAMOLODCHIKOVA TS, 1995, EUR J BIOCHEM, V227, P866, DOI 10.1111/j.1432-1033.1995.tb20212.x; ZWICKER E, 1993, THESIS ETH ZURICH	60	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25722	25728		10.1074/jbc.270.43.25722	http://dx.doi.org/10.1074/jbc.270.43.25722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592752	hybrid			2022-12-25	WOS:A1995TB46600069
J	KURIBARA, H; TAGO, K; YOKOZEKI, T; SASAKI, T; TAKAI, Y; MORII, N; NARUMIYA, S; KATADA, T; KANAHO, Y				KURIBARA, H; TAGO, K; YOKOZEKI, T; SASAKI, T; TAKAI, Y; MORII, N; NARUMIYA, S; KATADA, T; KANAHO, Y			SYNERGISTIC ACTIVATION OF RAT-BRAIN PHOSPHOLIPASE-D BY ADP-RIBOSYLATION FACTOR AND RHOA P21, AND ITS INHIBITION BY CLOSTRIDIUM-BOTULINUM C3 EXOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; GTP; CELLS	An activator of rat brain phospholipase D (PLD) that is distinct from the already identified PLD activator, ADP-ribosylation factor (ARF), was partially purified from bovine brain cytosol by a series of chromatographic steps. The partially purified preparation contained a 22-kDa substrate for Clostridium botulinum C3 exoenzyme ADP-ribosyltransferase, which strongly reacted with anti-rhoA p21 antibody, but not with anti-rac1 p21 or anti-cdc42Hs p21 antibody. Treatment of the partially purified PLD-activating factor with both C3 exoenzyme and NAD significantly inhibited the PLD-stimulating activity. These results suggest that rhoA p21 is, at least in part, responsible for the PLD-stimulating activity in the preparation. Recombinant isoprenylated rhoA p21 expressed in and purified from Sf9 cells activated rat brain PLD in a concentration- and GTP gamma S (guanosine 5'-O-(3-thiotriphosphate))-dependent manner. In contrast, recombinant non-isoprenylated rhoA pal (fused to glutathione S-transferase) expressed in Escherichia coli failed to activate the PLD. This difference cannot be explained by a lower affinity of non-isoprenylated rhoA p21 for GTP gamma S, as the rates of [S-35]GTP gamma S binding were very similar for both recombinant preparations and the GTP gamma S-bound form of non-isoprenylated rhoA p21 did not induce PLD activation. Interestingly, recombinant isoprenylated rhoA p21 and ARF synergistically activated rat brain PLD; a similar pattern was seen with the partially purified PLD-activating factor. The synergistic activation was inhibited by C3 exoenzyme-catalyzed ADP-ribosylation of recombinant isoprenylated rhoA p21 in a NAD-dependent manner. Inhibition correlated with the extent of ADP-ribosylation. These findings suggest that rhoA pal regulates rat brain PLD in concert with ARF, and that isoprenylation of rhoA p21 is essential for PLD regulation in vitro.	TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 226, JAPAN; OSAKA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, SUITA, OSAKA 565, JAPAN; KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHYSIOL SCI, TOKYO 113, JAPAN	Tokyo Institute of Technology; Osaka University; Kyoto University; University of Tokyo								BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HORI Y, 1991, ONCOGENE, V6, P515; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; MAEHAMA T, 1990, FEBS LETT, V263, P376, DOI 10.1016/0014-5793(90)81418-N; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1993, J BIOL CHEM, V268, P27160; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; YANG SF, 1967, J BIOL CHEM, V242, P477	23	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25667	25671		10.1074/jbc.270.43.25667	http://dx.doi.org/10.1074/jbc.270.43.25667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592744	hybrid			2022-12-25	WOS:A1995TB46600061
J	MCGUIRE, SL; BAJT, ML				MCGUIRE, SL; BAJT, ML			DISTINCT LIGAND-BINDING SITES IN THE I-DOMAIN OF INTEGRIN ALPHA(M)BETA(2) THAT DIFFERENTIALLY AFFECT A DIVALENT CATION-DEPENDENT CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; LEUKOCYTE ADHESION GLYCOPROTEIN; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; TRANSENDOTHELIAL MIGRATION; VONWILLEBRAND-FACTOR; BETA-SUBUNIT; IIB-IIIA; MAC-1	The I domains of the leukocyte beta(2) integrins have been shown to be essential for Ligand recognition, Amino acid substitutions of Asp(140) and Ser(142), which reside in a conserved cluster of oxygenated residues, abrogate divalent cation ligand binding function of alpha(M) beta(2). Presently, we evaluated the role of two I domain regions in alpha(M) beta(2) ligand recognition: 1) the conserved cluster of oxygenated residues (Asp(134), Asp(140), Ser(142), and Ser(144)) and 2) a 7-amino acid region (Phe(246)-Tyr(252)), conserved in alpha(M), and alpha(X) but absent in alpha(L) of the beta(2) integrins. Recombinant alpha(M) beta(2) was expressed on COS-7 cells, and function was assessed by iC3b recognition. Alanine substitution at position Asp(140), Asp(140)/Ser(142), Ser(142), or Ser(144) produced a complete loss in the capacity of alpha(M) beta(2) to recognize iC3b and attenuated the binding of a divalent cation-dependent epitope recognized by monoclonal antibody 24. Moreover, alanine substitution at Asp(248) or Tyr(252) or deletion of Phe(246)-Tyr(252) abolished iCSb ligand recognition as web as the binding of a blocking antibody. In contrast, these mutations did not affect the binding of the cation-dependent epitope. These data implicate a second region within the I domain important for alpha(M) beta(2) ligand binding function and suggest that this region does not affect a divalent cation-dependent conformation of alpha(M) beta(2).	UPJOHN CO,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001	Pfizer								ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; Anderson D.C., 1994, METABOLIC BASIS INHE, P3955; ANDERSON DC, 1990, BLOOD, V76, P2613; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V12, P3759; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HUANG X, 1994, MOL BIOL CELL, V4, P282; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RANDI AM, 1994, J BIOL CHEM, V269, P12395; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YONG K, 1990, BLOOD REV, V4, P211, DOI 10.1016/0268-960X(90)90001-9; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	44	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25866	25871		10.1074/jbc.270.43.25866	http://dx.doi.org/10.1074/jbc.270.43.25866			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592772	hybrid			2022-12-25	WOS:A1995TB46600089
J	MENAA, C; VRTOVSNIK, F; FRIEDLANDER, G; CORVOL, M; GARABEDIAN, M				MENAA, C; VRTOVSNIK, F; FRIEDLANDER, G; CORVOL, M; GARABEDIAN, M			INSULIN-LIKE GROWTH-FACTOR-I, A UNIQUE CALCIUM-DEPENDENT STIMULATOR OF 1,25-DIHYDROXYVITAMIN D-3 PRODUCTION - STUDIES IN CULTURED MOUSE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-THYROID CELLS; SOMATOMEDIN-C; VITAMIN-D; PROXIMAL TUBULES; PI TRANSPORT; IGF-I; METABOLISM; 25-HYDROXYVITAMIN-D3; PHOSPHORYLATION	Previous in vivo and in vitro studies suggest that insulin-like growth factor (IGF-I) could be a regulator of the renal production of 1,25-(OH)(2)D-3. In the present work, the local effect of low nanomolar concentrations of IGF-I on the 25-OH-D-3-1 alpha-hydroxylase activity and the mechanism of its action have been investigated. To do so, an in vitro model of mouse proximal tubular cells in primary culture has been developed. These cells bear specific high affinity IGF-I binding sites (apparent K-d = 1.95 +/- 0.46 nM) and express the ability to convert [H-3]25-(OH)D-3 into [H-3]1,25-(OH)(2)D-3 (K-m = 139 +/- 15.7 nM). Human recombinant IGF-I (10-100 ng/ml) stimulated both sodium-dependent phosphate uptake and 1,25-(OH)(2)D-3 synthesis by these cells, in a time- and dose-dependent manner. IGF-I did not alter the apparent Michaelis constant but increased the maximum velocity of the 25-OH-D-3-1 alpha-hydroxylase activity. This effect required protein synthesis. It was not affected by calphostin or GF109203X, two protein kinase C inhibitors, and was not mimicked by phorbol 12-myristate 13-acetate. In contrast, it was blocked by verapamil, a calcium channel blocker. Calcium depletion of the medium blunted the IGF-I effect but not that of human 1-34 parathyroid hormone 5 x 10(-8) M. IGF-I thus appears to be the first example of a physiological calcium-dependent regulator of the renal metabolism of vitamin D.	UNIV PARIS 05,HOP ST VINCENT DE PAUL,CNRS,URA 583,F-75014 PARIS,FRANCE; HOP XAVIER BICHAT,INSERM,U251,F-75870 PARIS 18,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U30,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Friedlander, Gerard/0000-0002-6854-4261; Vrtovsnik, Francois/0000-0003-1554-314X				BLANCHARD RK, 1991, VITAMIN D, P269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNERGATI L, 1988, J CLIN INVEST, V82, P1144, DOI 10.1172/JCI113672; CAMPBELL PI, 1992, AM J PHYSIOL, V262, pE389, DOI 10.1152/ajpendo.1992.262.4.E389; CAVERZASIO J, 1990, ENDOCRINOLOGY, V127, P453, DOI 10.1210/endo-127-1-453; CAVERZASIO J, 1992, ENDOCRINOLOGY, V130, P373, DOI 10.1210/en.130.1.373; CAVERZASIO J, 1989, AM J PHYSIOL, V257, pF712, DOI 10.1152/ajprenal.1989.257.5.F712; CEJKA JC, 1994, PFLUG ARCH EUR J PHY, V427, P33, DOI 10.1007/BF00585939; CONDAMINE L, 1994, J CLIN INVEST, V94, P1673, DOI 10.1172/JCI117512; CONSTANTINO CX, 1991, ENDOCRINOLOGY, V128, P1702, DOI 10.1210/endo-128-4-1702; DAI ZH, 1992, J BIOL CHEM, V267, P19565; FLYVBJERG A, 1993, AM J PHYSIOL, V265, pF624, DOI 10.1152/ajprenal.1993.265.5.F624; FRASER DR, 1980, PHYSIOL REV, V60, P551, DOI 10.1152/physrev.1980.60.2.551; FRIEDLANDER G, 1989, J BIOL CHEM, V264, P3935; GHAZARIAN JG, 1985, BIOCHEM BIOPH RES CO, V132, P1095, DOI 10.1016/0006-291X(85)91919-9; GRAY RW, 1987, ENDOCRINOLOGY, V121, P504, DOI 10.1210/endo-121-2-504; GRAY RW, 1985, ENDOCRINOLOGY, V116, P189, DOI 10.1210/endo-116-1-189; HALLORAN BP, 1988, ENDOCRINOLOGY, V123, P1225, DOI 10.1210/endo-123-3-1225; HAMMERMAN MR, 1989, AM J PHYSIOL, V257, pF503, DOI 10.1152/ajprenal.1989.257.4.F503; HENRY HL, 1989, ENDOCRINOLOGY, V124, P2228, DOI 10.1210/endo-124-5-2228; JACOBS S, 1983, J BIOL CHEM, V258, P9581; KOJIMA I, 1993, J BIOL CHEM, V268, P10003; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KORKOR B, 1987, J BONE MINER RES, V6, P517; KUMAR R, 1986, KIDNEY INT, V30, P793, DOI 10.1038/ki.1986.258; MAGOFFIN DA, 1990, MOL ENDOCRINOL, V4, P489, DOI 10.1210/mend-4-3-489; MANDEL ML, 1990, BIOCHIM BIOPHYS ACTA, V1034, P239, DOI 10.1016/0304-4165(90)90044-W; MANDEL ML, 1990, BIOCHEM J, V266, P385, DOI 10.1042/bj2660385; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MONTESSUIT C, 1994, AM J PHYSIOL, V267, pE24, DOI 10.1152/ajpendo.1994.267.1.E24; NASEERUDDIN SA, 1990, ENDOCRINOLOGY, V127, P1673, DOI 10.1210/endo-127-4-1673; NEMANI R, 1989, J BIOL CHEM, V264, P15361; NESBITT T, 1993, ENDOCRINOLOGY, V132, P133, DOI 10.1210/en.132.1.133; NESTLER JE, 1989, ENDOCRINOLOGY, V125, P2127, DOI 10.1210/endo-125-4-2127; OKABE T, 1985, BIOCHEM BIOPH RES CO, V127, P635, DOI 10.1016/S0006-291X(85)80208-4; PORTALE AA, 1989, J CLIN INVEST, V83, P1494, DOI 10.1172/JCI114043; RO HK, 1992, ENDOCRINOLOGY, V131, P1424, DOI 10.1210/en.131.3.1424; SHEPARD RM, 1979, BIOCHEM J, V182, P55, DOI 10.1042/bj1820055; SPENCER EM, 1981, ENDOCRINOLOGY, V108, P1064, DOI 10.1210/endo-108-3-1064; SPENCER EM, 1982, VITAMIN D MOL CELLUL, P507; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TANAKA Y, 1984, AM J PHYSIOL, V246, pE168, DOI 10.1152/ajpendo.1984.246.2.E168; THOMAS BR, 1993, J NUTR BIOCHEM, V4, P158, DOI 10.1016/0955-2863(93)90044-W; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRANQUE PA, 1992, ENDOCRINOLOGY, V131, P1948, DOI 10.1210/en.131.4.1948; TRECHSEL U, 1979, J CLIN INVEST, V64, P206, DOI 10.1172/JCI109441; TRIPPEL SB, 1983, ENDOCRINOLOGY, V112, P2128, DOI 10.1210/endo-112-6-2128; VELDHUIS JD, 1986, J BIOL CHEM, V261, P2499; VIETH R, 1979, J BIOL CHEM, V254, P2455; VRTOVSNIK F, 1994, J BIOL CHEM, V269, P8872; WEAVER VM, 1992, CELL SIGNAL, V4, P293, DOI 10.1016/0898-6568(92)90069-K	51	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25461	25467		10.1074/jbc.270.43.25461	http://dx.doi.org/10.1074/jbc.270.43.25461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592714	hybrid			2022-12-25	WOS:A1995TB46600030
J	CHEN, JQ; NIKOLOVAKARAKASHIAN, M; MERRILL, AH; MORGAN, ET				CHEN, JQ; NIKOLOVAKARAKASHIAN, M; MERRILL, AH; MORGAN, ET			REGULATION OF CYTOCHROME-P450 2C11 (CYP2C11) GENE-EXPRESSION BY INTERLEUKIN-1, SPHINGOMYELIN HYDROLYSIS, AND CERAMIDES IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACUTE PHASE RESPONSE; FACTOR-KAPPA-B; NEUTRAL SPHINGOMYELINASE; CELL-DIFFERENTIATION; PROTEIN-KINASE; HL-60 CELLS; SPHINGOSINE; DEXAMETHASONE; ACTIVATION	Interleukin-1 triggers the down-regulation of several hepatic cytochrome P450 gene products, but the cellular signaling pathways involved are not known. We have examined the role of sphingomyelin hydrolysis to ceramide in the suppression of CYP2C11, a major constitutive form of cytochrome P450, by interleukin-1. Treatment of rat hepatocytes cultured on matrigel with interleukin-1 beta caused a rapid turnover of sphingomye lin and an increase in cellular ceramide, with no change in cellular phosphatidylcholine. The ceramide was composed mainly of a D-erythro-sphingosine backbone, suggesting that it was derived from sphingolipid hydrolysis rather than from increased de novo synthesis. Treat ment of the cells with either N-acetyl-D-erythro-sphingosine (C-2-ceramide) or bacterial sphingomyelinase sup pressed the expression of CYP2C11 and induced the expression of the interleukin-1-responsive alpha(1)-acid glycoprotein mRNA. In contrast, the acute-phase gene beta fibrinogen, which is induced by interleukin-6 but not by interleukin-1, did not respond to C-2-ceramide. N-Acetyl-D-erythro-sphinganine mimicked the effect of C-2-ceramide on CYP2C11, but not on alpha(1)-acid glycoprotein expression. These results are consistent with a role for ceramide or a related sphingolipid in mediating the down-regulation of CYP2C11, the induction of alpha(1)-acid glycoprotein, and perhaps other cellular effects of interleukin-1 in hepatocytes.	EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University				Morgan, Edward/0000-0003-4273-2261; Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046897, R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46897, GM46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; CHEN JQ, 1995, MOL PHARMACOL, V47, P940; CHEN YL, 1992, BIOCHEM PHARMACOL, V44, P137, DOI 10.1016/0006-2952(92)90047-M; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; FERRARI L, 1993, BIOCHEM PHARMACOL, V45, P2269, DOI 10.1016/0006-2952(93)90198-6; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GORODISCHER R, 1976, Biochemical Pharmacology, V25, P351, DOI 10.1016/0006-2952(76)90226-4; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOSTETLER KY, 1979, J LIPID RES, V20, P456; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAEMER MJ, 1994, PEDIATRICS, V69, P476; KUNO K, 1994, J LEUKOCYTE BIOL, V56, P542, DOI 10.1002/jlb.56.5.542; KUROKOHCHI K, 1992, BIOCHEM PHARMACOL, V44, P1669; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MAHU JL, 1984, ENZYME, V31, P234, DOI 10.1159/000469532; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P337; MORGAN ET, 1989, MOL PHARMACOL, V36, P699; MORGAN ET, 1994, BBA-GENE STRUCT EXPR, V1219, P475, DOI 10.1016/0167-4781(94)90074-4; MORGAN ET, 1993, BIOCHEM PHARMACOL, V45, P415, DOI 10.1016/0006-2952(93)90078-B; NIKOLOVAKARAKAS.M, 1994, FASEB J, V8, P908; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PORTER T, 1991, J BIOL CHEM, V269, P13469; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; RAO BG, 1976, J LIPID RES, V17, P506; RENTON KW, 1986, CLIN BIOCHEM, V19, P72, DOI 10.1016/S0009-9120(86)80051-0; RICCA GA, 1981, J BIOL CHEM, V256, P1199; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WRIGHT K, 1991, MOL PHARMACOL, V39, P468; WRIGHT K, 1990, FEBS LETT, V271, P59, DOI 10.1016/0014-5793(90)80371-O; YANG ZH, 1993, J BIOL CHEM, V268, P20520	54	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25233	25238		10.1074/jbc.270.42.25233	http://dx.doi.org/10.1074/jbc.270.42.25233			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559661	hybrid			2022-12-25	WOS:A1995TB46500095
J	MCKENNEY, DW; ONODERA, H; GORMAN, L; MIMURA, T; ROTHSTEIN, DM				MCKENNEY, DW; ONODERA, H; GORMAN, L; MIMURA, T; ROTHSTEIN, DM			DISTINCT ISOFORMS OF THE CD45 PROTEIN-TYROSINE-PHOSPHATASE DIFFERENTIALLY REGULATE INTERLEUKIN-2 SECRETION AND ACTIVATION SIGNAL PATHWAYS INVOLVING VAV IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGENS; PHOSPHOTYROSINE PHOSPHATASE; PROTOONCOGENE PRODUCT; EXPRESSION; KINASE; PHOSPHORYLATION; RECEPTOR; SUBSETS; DOMAIN; TRANSMEMBRANE	The CD45 family of transmembrane protein-tyrosine phosphatases plays a crucial role in the regulation of lymphocyte activation by coupling activation signals from antigen receptors to the signal transduction apparatus. Multiple CD45 isoforms, generated through regulated alternative mRNA splicing, differ only in the length and glycosylation of their extracellular domains. Differential distribution of these isoforms defines subsets of T cells having distinct functions and activation requirements, While the requirement for the intracellular protein-tyrosine phosphatase domains has been documented, the physiological role of the extracellular domains remains elusive. Here we report the generation of CD45-antisense transfected Jurkat T cell clones that lack CD45 or have been reconstituted to uniquely express either the smallest, CD45(0), or the largest, CD45(ABC), isoform. These cells exhibited marked isoform-dependent differences in IL-2 production and tyrosine phosphorylation of cellular proteins, including Vav after anti-CD3 stimulation. These results demonstrate that the distinct CD45 extracellular domains differentially regulate T cell receptor-mediated signaling pathways. Furthermore, these findings suggest that alterations in CD45 isoform expression by individual T cells during thymic ontogeny and after antigen exposure in the periphery directly affects the signaling pathways utilized.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEPHROL SECT, NEW HAVEN, CT 06529 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	Yale University; University of Tokyo			Mimura, Toshihide/AAV-2844-2020		NIDDK NIH HHS [DK02011] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002011] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL LR, 1988, J IMMUNOL, V141, P2781; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROTHSTEIN DM, 1993, INT IMMUNOL, V5, P409, DOI 10.1093/intimm/5.4.409; ROTHSTEIN DM, 1990, CELL IMMUNOL, V129, P449, DOI 10.1016/0008-8749(90)90220-L; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; RUDD CE, 1987, J EXP MED, V166, P1758, DOI 10.1084/jem.166.6.1758; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SMITH SH, 1986, IMMUNOLOGY, V58, P63; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J IMMUNOL, V141, P3910; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TEDDER TF, 1985, J IMMUNOL, V134, P2983; TEDDER TF, 1985, J IMMUNOL, V134, P2989; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WENG WK, 1994, J BIOL CHEM, V269, P32514; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	49	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24949	24954		10.1074/jbc.270.42.24949	http://dx.doi.org/10.1074/jbc.270.42.24949			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559621	hybrid			2022-12-25	WOS:A1995TB46500055
J	PAO, CI; ZHU, JL; ROBERTSON, DG; LIN, KWM; FARMER, PK; BEGOVIC, S; WU, GJ; PHILLIPS, LS				PAO, CI; ZHU, JL; ROBERTSON, DG; LIN, KWM; FARMER, PK; BEGOVIC, S; WU, GJ; PHILLIPS, LS			TRANSCRIPTIONAL REGULATION OF THE RAT INSULIN-LIKE GROWTH-FACTOR-I GENE INVOLVES METABOLISM-DEPENDENT BINDING OF NUCLEAR PROTEINS TO A DOWNSTREAM REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; IGF-I; MOLECULAR REGULATION; LEADER EXONS; FUNCTIONAL-ANALYSIS; ADULT-RAT; EXPRESSION; PROMOTER; SOMATOMEDIN; HEPATOCYTES	Insulin-like growth factor-I (IGF I) gene transcription is mediated largely via exon 1. In an initial search for regulatory regions, rat hepatocytes were transfected with IGF-I constructs. Since omission of downstream sequences led to reduced expression, we then used in vitro transcription to evaluate potential metabolic regulation via downstream regions. With templates including 219 base pairs of downstream sequence, transcriptional activity was reduced 70-90% with hepatic nuclear extracts from diabetic versus normal rats. However, activity was comparable with templates lacking downstream sequences. The downstream region contained six DNase I footprints, and templates with deletion of either region III or V no longer provided reduced transcriptional activity with nuclear extracts from diabetic rats. Nuclear protein binding to regions III and V appeared to be metabolically regulated, as shown by reduced DNase I protection and activity in gel mobility shift assays with nuclear extracts from diabetic rats. Southwestern blotting probes corresponding to regions III and V recognized a similar to 65-kDa nuclear factor present at reduced levels in diabetic rats, These findings indicate that a downstream region in exon 1 may be important for both IGF-I expression and metabolic regulation, Altered concentration or activity of a transcription factor(s) binding to this region may contribute to reduced IGF-I gene transcription associated with diabetes mellitus.	EMORY UNIV, SCH MED, DEPT MED, DIV ENDOCRINOL & METAB, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, ATLANTA, GA 30322 USA	Emory University; Emory University					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037261] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7-RR05364] Funding Source: Medline; NIDDK NIH HHS [DK-01872] Funding Source: Medline; NIGMS NIH HHS [GM-37261] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GINOT F, 1989, EUR J BIOCHEM, V180, P289, DOI 10.1111/j.1432-1033.1989.tb14646.x; GOLDSTEIN S, 1991, J MOL ENDOCRINOL, V6, P33, DOI 10.1677/jme.0.0060033; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HARP JB, 1991, DIABETES, V40, P95, DOI 10.2337/diabetes.40.1.95; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JACQUEMIN P, 1993, BIOCHEM BIOPH RES CO, V196, P376, DOI 10.1006/bbrc.1993.2259; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; LOWE WL, 1994, 76TH END SOC ANN M, P330; LUND PK, 1991, MODERN CONCEPTS INSU, P111; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; PAO CI, 1993, MOL ENDOCRINOL, V7, P1561, DOI 10.1210/me.7.12.1561; PAO CI, 1992, MOL ENDOCRINOL, V6, P969, DOI 10.1210/me.6.6.969; PAO CI, 1994, GROWTH REGUL S1, V4, P126; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PELL JM, 1993, ENDOCRINOLOGY, V132, P1797, DOI 10.1210/en.132.4.1797; PHILLIPS LS, 1991, DIABETES, V40, P1525, DOI 10.2337/diabetes.40.11.1525; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; ROUSSEAU S, 1993, MOL CELL BIOL, V13, P4904, DOI 10.1128/MCB.13.8.4904; SCHWANDER JC, 1983, ENDOCRINOLOGY, V113, P297, DOI 10.1210/endo-113-1-297; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUSSENBACH JS, 1994, GROWTH REGUL S1, V4, P1136; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WANG X, 1994, 76TH END SOC ANN M; ZHANG ZX, 1990, J BIOL CHEM, V265, P4785	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24917	24923		10.1074/jbc.270.42.24917	http://dx.doi.org/10.1074/jbc.270.42.24917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559617	hybrid			2022-12-25	WOS:A1995TB46500051
J	RODRIGUEZ, CG; CUNDELL, DR; TUOMANEN, EI; KOLAKOWSKI, LF; GERARD, C; GERARD, NP				RODRIGUEZ, CG; CUNDELL, DR; TUOMANEN, EI; KOLAKOWSKI, LF; GERARD, C; GERARD, NP			THE ROLE OF N-GLYCOSYLATION FOR FUNCTIONAL EXPRESSION OF THE HUMAN PLATELET-ACTIVATING-FACTOR RECEPTOR - GLYCOSYLATION IS REQUIRED FOR EFFICIENT MEMBRANE TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ADRENERGIC-RECEPTOR; RABBIT PLATELET; HORMONE-BINDING; CLONING; PROTEIN; SITES; CELLS; LEUKOCYTES; ANTIGEN	Streptococcus pneumoniae has been shown to utilize the platelet activating factor receptor for binding and invasion of host cells (Cundell, D. R., Gerard, N. P., Gerard, C., Idanpaan-Heikkila, I., and Tuomanen, E. I. (1995) Nature, in press). Because bacterial binding is in part carbohydrate dependent, and the human platelet activating factor (PAF) receptor bears a single N-linked glycosylation sequence in the second extracellular loop, we undertook studies to determine the role of this epitope in PAF receptor function. Binding of pneumococci to COS cells transfected with the human PAF receptor is greatly reduced for a receptor mutant that bears no N-linked glycosylation site. Immunohistochemical and binding analyses show decreased expression of the non-glycosylated molecule on the cell membrane relative to the wild type receptor; however, metabolic labeling and immunopurification indicate it is synthesized intracellularly at a level similar to the native molecule. A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant. The binding affinity for PAF is not significantly effected by the presence or location of the carbohydrate, and variations in cell surface expression have little influence on signal transduction, as the nonglycosylated PAF receptor is equally effective for activation of phospholipase C as the native molecule. These data are supportive of pneumococcal binding on protein moiety(ies) of the PAF receptor and indicate that N-glycosylation facilitates expression of the protein on the cell membrane.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215; HARVARD UNIV,CHILDRENS HOSP,SCH MED,INA SUE PERLMUTTER LAB,BOSTON,MA 02215; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02215; HARVARD UNIV,WOMENS HOSP,SCH MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,THORNDIKE LAB,BOSTON,MA 02215; ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Rockefeller University			Tuomanen, Elaine I/N-3081-2018; Garcia, Carmen/L-9961-2017	Tuomanen, Elaine I/0000-0003-0349-8716; Garcia, Carmen/0000-0002-7205-4572; Cundell, Diana/0000-0003-3119-180X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162, R01HL041587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023459] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36162, HL41587] Funding Source: Medline; NIAID NIH HHS [AI23459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI H, 1994, J BIOL CHEM, V269, P24557; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BRATTON DL, 1992, J IMMUNOL, V148, P514; BREITFELD PP, 1984, J BIOL CHEM, V259, P10144; CABELLOS C, 1992, J CLIN INVEST, V90, P612, DOI 10.1172/JCI115900; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; CUNDELL DR, 1994, MICROB PATHOGENESIS, V17, P361, DOI 10.1006/mpat.1994.1082; CUNDELL DR, 1995, IN PRESS NATURE; DATTATREYAMURTY B, 1992, ENDOCRINOLOGY, V131, P2437, DOI 10.1210/en.131.5.2437; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GEELEN S, 1993, INFECT IMMUN, V61, P1538, DOI 10.1128/IAI.61.4.1538-1543.1993; GERARD NP, 1994, J IMMUNOL, V152, P793; HABECKER BA, 1993, LIFE SCI, V52, P429, DOI 10.1016/0024-3205(93)90298-H; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HENSON PM, 1970, J EXP MED, V131, P287, DOI 10.1084/jem.131.2.287; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1983, BIOCHEMISTRY-US, V22, P4756, DOI 10.1021/bi00289a022; HWANG SB, 1986, J BIOL CHEM, V261, P532; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAD PM, 1985, BIOCHEM BIOPH RES CO, V129, P632, DOI 10.1016/0006-291X(85)91938-2; LIU XB, 1993, J BIOL CHEM, V268, P1513; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V57, P209; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PERRET JJ, 1992, BIOCHEM J, V228, P911; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RANDS E, 1990, J BIOL CHEM, V265, P10759; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1987, PLATELET ACTIVATING, P1; TOMASZ A, 1989, Pediatric Infectious Disease Journal, V8, P902, DOI 10.1097/00006454-198912000-00034; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	39	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25178	25184		10.1074/jbc.270.42.25178	http://dx.doi.org/10.1074/jbc.270.42.25178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559653	hybrid			2022-12-25	WOS:A1995TB46500087
J	CALVERT, PD; KLENCHIN, VA; BOWNDS, MD				CALVERT, PD; KLENCHIN, VA; BOWNDS, MD			RHODOPSIN KINASE INHIBITION BY RECOVERIN - FUNCTION OF RECOVERIN MYRISTOYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENTS; TERMINUS	Recoverin is a Ca2+-binding protein that may play a role in vertebrate photoreceptor light adaptation by imparting Ca2+ sensitivity to rhodopsin kinase. It is heterogeneously acylated (mostly myristoylated) at its aminoterminal glycine. Recent studies have shown that recoverin myristoylation is necessary for its Ca2+-dependent membrane association and cooperative Ca2+ binding. We have addressed several issues concerning the role of recoverin myristoylation with respect to inhibition of rhodopsin kinase. We find that 1) myristoylation of recoverin is not necessary for inhibition of rhodopsin kinase, 2) myristoylation of recoverin induces a cooperative Ca2+-dependence for rhodopsin kinase inhibition, and 3) each Ca2+-binding site on the nonmyristoylated recoverin partially inhibits rhodopsin kinase. The available data suggest that the functions of recoverin myristoylation in the living rod are to induce a sharp Ca2+ dependence of rhodopsin kinase inhibition and to bring this dependence into the rod's physiological Ca2+ concentration range.	UNIV WISCONSIN,RM BOCK LABS,MADISON,WI 53706; UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NEI NIH HHS [EY-00463] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; CHEN CK, 1995, J BIOL CHEM, V270, P18061; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; MCCARTHY ST, 1994, BIOPHYS J, V67, P2076, DOI 10.1016/S0006-3495(94)80691-5; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; POLANS AS, 1993, METH NEUROSCI, V15, P248; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	16	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24127	24129		10.1074/jbc.270.41.24127	http://dx.doi.org/10.1074/jbc.270.41.24127			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592614	hybrid			2022-12-25	WOS:A1995TA21700042
J	KLARLUND, JK; CHERNIACK, AD; CZECH, MP				KLARLUND, JK; CHERNIACK, AD; CZECH, MP			DIVERGENT MECHANISMS FOR HOMOLOGOUS DESENSITIZATION OF P21(RAS) BY INSULIN AND GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE-ACTIVITY; LIGAND-INDUCED INTERNALIZATION; GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; EGF RECEPTOR; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; GUANINE-NUCLEOTIDES; DOWN-REGULATION	Previous work suggested that desensitization of p21(ras) in response to growth factors such as epidermal growth factor (EGF) results from receptor down-regulation, Here we show that p21(ras) is desensitized by insulin in 3T3-L1 adipocytes in the continued presence of activated insulin receptors, while loss of epidermal growth factor and platelet-derived growth factor (PDGF) receptors in response to their ligands correlates with p21(ras) desensitization. Furthermore, elevated amounts of Grb2/Shc complexes persisted throughout p21(ras) desensitization by insulin. However, immunoblotting of anti Son-of-sevenless (Sos) 1 and 2 immunoprecipitates with anti-Grb2 antisera revealed that p21(ras) desensitization in response to insulin and PDGF, but not EGF, is associated with a marked decrease in cellular complexes containing Sos and Grb2 proteins, Nonetheless, the desensitization of p21(ras) in response to these stimuli was homologous, in that each peptide could reactivate [P-32]GTP loading of p21(ras) after desensitization by any of the others, Taken together, these data indicate that insulin, EGF, and PDGF all cause disassembly of Sos proteins from signaling complexes during p21(ras) desensitization, but at least two mechanisms are involved, Insulin elicits dissociation of Sos from Grb2 SH3 domains, whereas EGF signaling is reversed by receptor down-regulation and She dephosphorylation, releasing Grb2 SH2 domains, PDGF action triggers both mechanisms of Grb2 disassembly, which probably operate in concert with GAP to attenuate p21(ras) signaling.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	KLARLUND, JK (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSENIS G, 1985, J BIOL CHEM, V260, P2202; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHANG CP, 1993, J BIOL CHEM, V268, P1912; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, CELL, V64, P925; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KNUTSON VP, 1992, J BIOL CHEM, V267, P931; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUND KA, 1990, J BIOL CHEM, V265, P20517; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MCCUNE BK, 1990, J BIOL CHEM, V265, P9715; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERALDI P, 1993, EUR J BIOCHEM, V218, P815, DOI 10.1111/j.1432-1033.1993.tb18436.x; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SIMPSON IA, 1993, BIOCHIM BIOPHYS ACTA, V763, P393; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOLER C, 1994, ONCOGENE, V9, P2207; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WARD Y, 1994, NATURE, V267, P651; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	72	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23421	23428		10.1074/jbc.270.40.23421	http://dx.doi.org/10.1074/jbc.270.40.23421			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559502	hybrid			2022-12-25	WOS:A1995RY90900031
J	BILLY, D; WILLEMS, GM; HEMKER, HC; LINDHOUT, T				BILLY, D; WILLEMS, GM; HEMKER, HC; LINDHOUT, T			PROTHROMBIN CONTRIBUTES TO THE ASSEMBLY OF THE FACTOR VA-FACTOR XA COMPLEX AT PHOSPHATIDYLSERINE-CONTAINING PHOSPHOLIPID-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; CATALYZED ACTIVATION; COAGULATION; MEIZOTHROMBIN; VESICLES; BINDING; PROTEIN	The activation of prothrombin is catalyzed by prothrombinase, a complex of factor Xa and factor Va assembled on a negatively charged phospholipid membrane, We used a tubular flow reactor to identify the relative contributions of factor Va, prothrombin, and the negatively charged phosphatidylserine to the assembly of prothrombinase. Perfusion of phospholipid-coated capillaries with a mixture of factor Xa, factor Va, and prothrombin resulted in a steady-state rate of thrombin production that increased with (i) the phosphatidylserine content of the phospholipid bilayer, (ii) the factor Va concentration, and, most interestingly, (iii) the prothrombin concentration of the perfusion solution, Incorporation of 20 mol % phosphatidylethanolamine, a phospholipid with poor ability to promote prothrombinase activity, into a 5 mol % phosphatidylserine membrane also increased the steady-state rate of thrombin production, Direct measurements of the amount of prothrombinase in the flow reactor demonstrated that increased catalytic activities were the result of an increased steady-state amount of membrane associated prothrombinase. Thus, similar turnover numbers of prothrombin activation (3100 min(-1)) were calculated, irrespective of the phosphatidylserine content of the membrane, We established for membranes with low phosphatidylserine content (<10 mol%) a linear relationship between the prothrombinase activity and the arithmetical product of the factor Va concentration in the perfusion solution and the prothrombin concentration near the catalytic surface, Our results indicate that, in addition to factor Va, prothrombin also is essential to the assembly of prothrombinase at macroscopic surfaces with low phosphatidylserine content. The data further suggest that the prothrombin concentration near the surface, controlled by the prothrombinase activity and mass transfer, is an important regulator of the prothrombinase surface density,	UNIV LIMBURG,CARDIOVASC RES INST MAASTRICHT,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Maastricht University				Hemker, Coen/0000-0003-1669-2358				BILLY D, 1995, J BIOL CHEM, V270, P1029, DOI 10.1074/jbc.270.3.1029; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; ESMON CT, 1974, J BIOL CHEM, V249, P7798; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GIESEN PLA, 1991, J BIOL CHEM, V266, P18720; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HEMKER HC, 1987, NATURE, V215, P248; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; JACKSON CM, 1974, THROMB DIATH HAEMO, V17, P273; Jesty J, 1988, Thromb Res, V50, P745, DOI 10.1016/0049-3848(88)90333-7; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KUNG C, 1994, J BIOL CHEM, V269, P25838; Levich VG, 1962, PHYSICOCHEMICAL HYDR, P112; LINDHOUT T, 1978, BIOCHIM BIOPHYS ACTA, V533, P327; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5495; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PAPAHADJOPOULOS D, 1964, BIOCHIM BIOPHYS ACTA, V90, P436, DOI 10.1016/0304-4165(64)90220-X; PEI G, 1993, J BIOL CHEM, V268, P3226; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHOEN P, 1990, THROMB HAEMOSTASIS, V64, P542; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; SMITH RL, 1973, J BIOL CHEM, V248, P2418; TANS G, 1991, J BIOL CHEM, V266, P21864; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALKER RK, 1994, J BIOL CHEM, V269, P27441; ZWAAL RFA, 1978, BIOCHIM BIOPHYS ACTA, V515, P163, DOI 10.1016/0304-4157(78)90003-5	38	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26883	26889		10.1074/jbc.270.45.26883	http://dx.doi.org/10.1074/jbc.270.45.26883			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592932	hybrid			2022-12-25	WOS:A1995TE58300032
J	BUDD, ME; CHOE, WC; CAMPBELL, JL				BUDD, ME; CHOE, WC; CAMPBELL, JL			DNA2 ENCODES A DNA HELICASE ESSENTIAL FOR REPLICATION OF EUKARYOTIC CHROMOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; REPAIR	Although a number of eukaryotic DNA helicases have been identified biochemically and still more have been inferred from the amino acid sequences of the products of cloned genes, none of the cellular helicases or putative helicases has to date been implicated in eukaryotic chromosomal DNA replication, By the same token, numerous eukaryotic replication proteins have been identified, but none of these is a helicase, We have recently identified and characterized a temperature-sensitive yeast mutant, dna2ts, defective in DNA replication, and have cloned the corresponding gene (Kuo, C.-L., Huang, C.-H., and Campbell, J. L. (1983) Proc. Natl. Acad. Sci. U.S.A. 30, 6465-6469; Budd, M. E., and Campbell, J. L. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 7642-7646). The DNA2 gene is essential and encodes a 172-kDa protein with DNA helicase motifs in its C-terminal half and an N-terminal half with no similarity to any previously described protein (Budd, M. E., and Campbell, J. L. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 7642-7646). Here we show that the helicase domain is required in vivo and that a 3' to 5' DNA helicase activity specific for forked substrates is intrinsic to the Dna2p. The N terminus is also essential for DNA replication, Thus, the structure of this new helicase is different from all previously characterized replicative helicases, which is consistent with the complex organization of eukaryotic replication forks, where the activities of not one but three essential DNA polymerases must be coordinated.	CALTECH,BRAUN LABS,PASADENA,CA 91125	California Institute of Technology								BUDD ME, 1989, MOL CELL BIOL, V9, P365, DOI 10.1128/MCB.9.2.365; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; KUO CL, 1983, P NATL ACAD SCI-BIOL, V80, P6465, DOI 10.1073/pnas.80.21.6465; NAUMOVSKI L, 1986, MOL CELL BIOL, V6, P1218, DOI 10.1128/MCB.6.4.1218; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0	12	143	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26766	26769		10.1074/jbc.270.45.26766	http://dx.doi.org/10.1074/jbc.270.45.26766			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592912	hybrid, Green Accepted			2022-12-25	WOS:A1995TE58300012
J	LERNER, EC; QIAN, YM; HAMILTON, AD; SEBTI, SM				LERNER, EC; QIAN, YM; HAMILTON, AD; SEBTI, SM			DISRUPTION OF ONCOGENIC K-RAS4B PROCESSING AND SIGNALING BY A POTENT GERANYLGERANYLTRANSFERASE-I INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN GERANYLGERANYLTRANSFERASE; RAS PROTEIN; FARNESYLTRANSFERASE; FARNESYL; PEPTIDOMIMETICS; TRANSFORMATION; TRANSFERASE; PRENYLATION; SPECIFICITY; SUBUNIT	Prenylation of the carboxyl-terminal CAAX (C, cysteine; A, aliphatic acid; and X, any amino acid) of Pas is required for its biological activity. We have designed a CAAX peptidomimetic, GGTI-287, which is 10 times more potent toward inhibiting geranylgeranyltransferase I (GGTase I) in vitro (IC50 = 5 nM) than our previously reported farnesyltransferase inhibitor, FTI-276. In whole cells, the methyl ester derivative of GGTI-287, GGTI-286, was 25-fold more potent (IC50 = 2 mu M) than the corresponding methyl ester of FTI-276, FTI-277, toward inhibiting the processing of the geranylgeranylated protein Rap1A. Furthermore, GGTI-286 is highly selective for geranylgeranylation over farnesylation since it inhibited the processing of farnesylated H-Pas only at much higher concentrations (IC50 > 30 mu M), While the processing of H-Pas was very sensitive to inhibition by FTI-277 (IC50 = 100 nM), that of K-Ras4B was highly resistant (IC50 = 10 mu M). In contrast, we found the processing of K-Ras4B to be much more sensitive to GGTI-286 (IC50 = 2 mu M). Furthermore, oncogenic K-Ras4B stim ulation of mitogen-activated protein (MAP) kinase was inhibited potently by GGTI-286 (IC50 = 1 mu M) but weakly by FTI-277 (IC50 = 30 mu M). Significant inhibition of oncogenic K-Ras4B stimulation of MAP kinase by GGTI-286 occurred at concentrations (1-3 mu M) that did not inhibit oncogenic H-Ras stimulation of MAP kinase, The data presented in this study provide the first demonstration of seledtive disruption of oncogenic K-Ras4B processing and signaling by a CAAX peptidomimetic, The higher sensitivity of K-Ras4B toward a GGTase I inhibitor has a tremendous impact on future research directions targeting Pas in anticancer therapy.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,FAC ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055823] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55823, U19-CA67701] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbacid M, 1986, Important Adv Oncol, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAUFFMANN RC, 1995, IN PRESS P NATL ACAD, V92; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; QIAN YM, 1994, BIOORG MED CHEM LETT, V4, P2579, DOI 10.1016/S0960-894X(01)80287-0; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SUN JZ, 1995, CANCER RES, V55, P4243; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	34	170	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26770	26773		10.1074/jbc.270.45.26770	http://dx.doi.org/10.1074/jbc.270.45.26770			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592913	hybrid			2022-12-25	WOS:A1995TE58300013
J	SAOUAF, SJ; KUT, SA; FARGNOLI, J; ROWLEY, RB; BOLEN, JB; MAHAJAN, S				SAOUAF, SJ; KUT, SA; FARGNOLI, J; ROWLEY, RB; BOLEN, JB; MAHAJAN, S			RECONSTITUTION OF THE B-CELL ANTIGEN RECEPTOR SIGNALING COMPONENTS IN COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTORS; MYRISTIC ACID; IG-ALPHA; ASSOCIATION; IMMUNOGLOBULIN; ACTIVATION; COMPLEX; P60SRC; BETA	To elucidate interactions occurring between B cell protein tyrosine kinases and the signaling components of the B cell antigen receptor, we have co transfected into COS cells individual tyrosine kinases together with chimeric cell surface receptors containing the cytoplasmic domains of Iga or Ig beta, Of the tyrosine kinases transfected (Lyn, Blk, Hck, Syk, Fyn), only Blk was able to phosphorylate and subsequently associate with cotransfected Ig alpha and Ig beta chimeras in vivo, Association between Blk and the Ig alpha and Ig beta cytoplasmic domains was shown by mutational analyses to be the result of an SH2-phosphotyrosine interaction, We identified the tyrosine residues of the Ig alpha and Ig beta cytoplasmic domains phosphorylated by Blk. The enzymatic activity and membrane association of Blk were required for the observed phosphorylation of the Ig alpha and Ig beta chimeras, Sequences within the amino-terminal unique domain of Blk are responsible for recognition and subsequent phosphorylation of the Ig alpha chimera since transfer of the unique region of Blk to Fyn results in the chimeric kinase's ability to phosphorylate the cytoplasmic domain of Ig alpha. These findings indicate that the unique domain of Src family kinases may direct recognition of certain substrates leading to their phosphorylation.			SAOUAF, SJ (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, H24-03, POB 4000, PRINCETON, NJ 08543 USA.							ALLAND L, 1994, J BIOL CHEM, V269, P16701; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KIM KM, 1993, IMMUNOL REV, V132, P125, DOI 10.1111/j.1600-065X.1993.tb00840.x; KINET JP, 1988, P NATL ACAD SCI USA, V85, P6483, DOI 10.1073/pnas.85.17.6483; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TADDIE JA, 1994, J BIOL CHEM, V269, P13529; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG-SHARP D, 1990, Technique (Philadelphia), V2, P155	46	22	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27072	27078		10.1074/jbc.270.45.27072	http://dx.doi.org/10.1074/jbc.270.45.27072			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592958	hybrid			2022-12-25	WOS:A1995TE58300058
J	WEI, XY; PAN, S; LANG, WH; KIM, HY; SCHNEIDER, T; PEREZREYES, E; BIRNBAUMER, L				WEI, XY; PAN, S; LANG, WH; KIM, HY; SCHNEIDER, T; PEREZREYES, E; BIRNBAUMER, L			MOLECULAR DETERMINANTS OF CARDIAC CA2+ CHANNEL PHARMACOLOGY - SUBUNIT REQUIREMENT FOR THE HIGH-AFFINITY AND ALLOSTERIC REGULATION OF DIHYDROPYRIDINE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; SKELETAL-MUSCLE; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; CA-2+ CHANNEL; GAMMA-SUBUNIT; CELL-LINE; RECEPTOR; ALPHA-1-SUBUNIT; BLOCKERS	Cardiac L-type Ca2+ channels are multisubunit complexes composed of alpha(1C), alpha(2) delta, and beta(2) subunits, We tested the roles of these subunits in forming a functional complex by characterizing the effects of subunit composition on dihydropyridine binding, its allosteric regulation, and the ability of dihydropyridines to inhibit channel activity, Transfection of COS.M6 cells with cardiac alpha(1C-a) (alpha(1)) led to the appearance of dihydropyridine ([H-3]PN200-110) binding which was increased by coexpression of cardiac beta(2a) (beta), alpha(2) delta(a) (alpha(2)), and the skeletal muscle gamma. Maximum binding was achieved when cells expressed alpha(1), beta, and alpha(2). Cells transfected with alpha(1) and beta had a binding affinity that was 5-10-fold lower than that observed in cardiac membranes. Coexpression of alpha(2) normalized this affinity, (-)-D600 and diltiazem both partially inhibited PN200-110 binding to cardiac microsomes, but stimulated binding in cells transfected with alpha(1) and beta. Again, coexpression of alpha(2) normalized this allosteric regulation. Therefore coexpression of alpha(1) beta and alpha(2) completely reconstituted high affinity dihydropyridine binding and its allosteric regulation as observed in cardiac membranes, Skeletal muscle gamma was not required for this reconstitution, Expression in Xenopus oocytes demonstrated that coexpression of alpha(2) with alpha(1) beta increased the potency and maximum extent of block of Ca2+ channel currents by nisoldipine, a dihydropyridine Ca2+ channel antagonist. Our results demonstrate that alpha(2) subunits are essential components of the cardiac L-type Ca2+ channel and predict a minimum subunit composition of alpha(1C)beta(2) alpha(2) delta for this channel.	MED COLL GEORGIA, INST MOLEC MED & GENET, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; UNIV COLOGNE, INST NEUROPHYSIOL, COLOGNE, GERMANY; LOYOLA UNIV, MED CTR, DEPT PHYSIOL, MAYWOOD, IL 60153 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT ANESTHESIOL, LOS ANGELES, CA 90024 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Baylor College of Medicine; University of Cologne; Loyola University Chicago; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIAMS NIH HHS [AR43411] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043411] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHANG FC, 1988, J BIOL CHEM, V263, P18929; COOPER CL, 1987, J BIOL CHEM, V262, P509; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1917; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; KUNIYASU A, 1992, J BIOCHEM, V112, P235, DOI 10.1093/oxfordjournals.jbchem.a123883; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PEREZREYES E, 1994, DRUG DEVELOP RES, V33, P295, DOI 10.1002/ddr.430330311; RAMPE D, 1990, BIOCHEM BIOPH RES CO, V169, P825, DOI 10.1016/0006-291X(90)91967-W; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHNEIDER T, 1988, EUR J BIOCHEM, V174, P369, DOI 10.1111/j.1432-1033.1988.tb14107.x; SCHNEIDER T, 1991, EUR J BIOCHEM, V200, P245, DOI 10.1111/j.1432-1033.1991.tb21073.x; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STAUDINGER R, 1991, J BIOL CHEM, V266, P10787; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TOKUMARU H, 1992, EUR J PHARM-MOLEC PH, V227, P363, DOI 10.1016/0922-4106(92)90152-L; WEI XY, 1989, MOL PHARMACOL, V35, P541; WEI XY, 1991, J BIOL CHEM, V266, P21943; WEI XY, 1994, BIOPHYS J, V66, pA128; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; WELLING A, 1995, PFLUG ARCH EUR J PHY, V429, P400, DOI 10.1007/BF00374156	41	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27106	27111		10.1074/jbc.270.45.27106	http://dx.doi.org/10.1074/jbc.270.45.27106			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592963	hybrid			2022-12-25	WOS:A1995TE58300063
J	LU, ZH; WANG, ZX; HORUK, R; HESSELGESSER, J; LOU, YC; HADLEY, TJ; PEIPER, SC				LU, ZH; WANG, ZX; HORUK, R; HESSELGESSER, J; LOU, YC; HADLEY, TJ; PEIPER, SC			THE PROMISCUOUS CHEMOKINE BINDING PROFILE OF THE DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES IS PRIMARILY LOCALIZED TO SEQUENCES IN THE AMINO-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; RED-BLOOD-CELLS; PLASMODIUM-VIVAX; FUNCTIONAL EXPRESSION; ENDOTHELIN RECEPTOR; PEPTIDE RECEPTOR; LIGAND-BINDING; CLONING; CDNA; IDENTIFICATION	The Duffy antigen (DARC) is a promiscuous chemokine receptor that also binds Plasmodium vivax. DARC belongs to a family of heptahelical chemokine receptors that includes specific (IL-8RA) and shared (IL-8RB) IL-8 receptors, Ligand binding specificity of IL-8 receptors was localized to the amino terminal extracellular (El) domain, To determine the basis for promiscuous chemokine binding by DARC, a chimeric receptor composed of the E1 domain of DARC and hydrophobic helices and loops from IL-8RB (DARC(e1)/IL-8RB) was constructed, Scatchard analysis of stable transfectants demonstrated that the DARC(e1)/IL-8RB chimeric receptor bound IL-8 and melanoma growth stimulating activity (MGSA) with K-D values almost identical to the native receptors, The hybrid receptor also bound RANTES, MCP-1, and MGSA E(6)A (which binds DARC, but not IL-8RB), but not MIP-1 alpha, similarly to DARC, Ligand binding to DARC transfectants was unaltered by anti-Fy3, but inhibited by Fy6, which binds an epitope in the El domain, The epitope recognized by Fy3 was localized to the third extracellular loop by analysis of insect cells expressing chimeric receptors composed of complementary portions of DARC and IL-8RB. These findings implicate the El domain of DARC in multispecific chemokine binding.	UNIV LOUISVILLE,HENRY VOGT CANC RES INST,DEPT PATHOL,LOUISVILLE,KY 40292; UNIV LOUISVILLE,HENRY VOGT CANC RES INST,DEPT MED,LOUISVILLE,KY 40292; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Louisville; University of Louisville								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JI IH, 1991, J BIOL CHEM, V266, P14953; KOSUGI S, 1992, MOL ENDOCRINOL, V6, P166; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1986, NEW ENGL J MED, V295, P302; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Perez H D, 1994, Curr Opin Hematol, V1, P40; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1994, CYTOKINE HDB, P419; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723	46	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26239	26245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592830				2022-12-25	WOS:A1995TC97800037
J	OKAMURA, H; RESH, MD				OKAMURA, H; RESH, MD			P80/85 CORTACTIN ASSOCIATES WITH THE SRC SH2 DOMAIN AND COLOCALIZES WITH V-SRC IN TRANSFORMED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODIES; PP60(SRC) SUBSTRATE; STABLE ASSOCIATION; FOCAL ADHESIONS; IDENTIFICATION; FIBROBLASTS; AFFINITY	Expression of oncogenic variants of pp60(src) leads to dramatic changes in cytoskeletal organization characteristic of transformation. Activated Src associates with the cytoskeletal matrix, resulting in tyrosine phosphorylation of specific cytoskeletal substrates. We have previously shown that stable association of Src with the cytoskeletal matrix is mediated by the Src SH2 domain in a phosphotyrosine-dependent interaction. In this report, we demonstrate that one of the cytoskeletal binding partners of Src is p80/85 cortactin. The association was observed in lysates of transformed cells but was not seen in normal fibroblasts. The interaction could be reconstituted in vitro using transformed cell extracts and a glutathione S transferase (GST) fusion protein containing the Src SH2 domain but not with GST-Src SH3 or with GST-Src SH2 containing a point mutation in the FLVRES sequence, Confocal microscopy revealed that cortactin redistributed and colocalized with v-Src and a Src SH3 deletion mutant in transformed cells. However, in cells expressing a Src SH2 deletion mutant, the redistribution of cortactin and colocalization with Src did not occur, Furthermore, biochemical fractionation of transformed cells indicated that a significant increase in cortactin distribution to the cytoskeletal fraction occurred, which correlated with a shift in the tyrosine-phosphorylated form of the protein, Cortactin fractionated from cells expressing kinase-defective or myristylation-defective Src mutants did not exhibit this shift. These data suggest a molecular mechanism by which tyrosine phosphorylation of cortactin and association with the Src SH2 domain influence the cytoskeletal reorganization induced in Src transformed cells.	MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Memorial Sloan Kettering Cancer Center; Princeton University				Resh, Marilyn/0000-0001-6118-9466	NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MAA MC, 1992, ONCOGENE, V7, P2429; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MIGLARESE MR, 1994, ONCOGENE, V9, P1989; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHUURING E, 1992, ONCOGENE, V7, P355; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26613	26618		10.1074/jbc.270.44.26613	http://dx.doi.org/10.1074/jbc.270.44.26613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592885	hybrid			2022-12-25	WOS:A1995TC97800092
J	BENGTSSON, E; NEAME, PJ; HEINEGARD, D; SOMMARIN, Y				BENGTSSON, E; NEAME, PJ; HEINEGARD, D; SOMMARIN, Y			THE PRIMARY STRUCTURE OF A BASIC LEUCINE-RICH REPEAT PROTEIN, PRELP, FOUND IN CONNECTIVE TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARTILAGE PROTEOGLYCAN; KERATAN SULFATE PROTEOGLYCAN; ARTICULAR-CARTILAGE; OSTEOINDUCTIVE FACTOR; TYROSINE SULFATION; MATRIX PROTEIN; CORE PROTEIN; SEQUENCE; CDNA; FIBROMODULIN	We have determined the primary structure of a connective tissue matrix protein from the nucleotide sequence of a clone isolated from a human articular chondrocyte cDNA Library. The major part of the amino acid sequence has also been determined by direct protein sequencing. The translated primary sequence corresponds to 382 amino acid residues, including a 20-residue signal peptide. The molecular mass of the mature protein is 41,646 Da. The main part of the protein consists of 10 leucine-rich repeats ranging in length from 20 to 26 residues, with asparagine at position 10 (B-type). The N-terminal part is unusual in that it is basic and rich in arginine and proline. There are four potential N-linked glycosylation sites present. In three of these sites, post-translational modifications are likely to be present since Asn was not found by direct protein sequencing. The amino- and carboxyl-terminal parts contain four and two cysteine residues, respectively, probably forming disulfide bonds by analogy with the other members of this family. The protein shows highest identity (36%) to fibromodulin and 33% to bovine lumican, two other leucine-rich repeat connective tissue proteins. Northern blot analysis showed the presence of an similar to 3.8-kilobase mRNA in different types of bovine cartilage and cultured osteoblasts, whereas RNAs isolated from bovine kidney, skin, spleen, thymus, and trabecular bone and rat calvaria were negative. Human articular chondrocyte and rat chondrosarcoma cell RNAs contained an additional mRNA of similar to 1.6 and 1.8 kilobases, respectively.	LUND UNIV,DEPT CELLULAR & MOLEC BIOL,EXTRACELLULAR MATRIX BIOL SECT,S-22100 LUND,SWEDEN; SHRINERS HOSP CRIPPLED CHILDREN,TAMPA,FL 33612	Lund University			Bengtsson, Eva/AAA-1968-2019	Bengtsson, Eva/0000-0001-7075-1772	NIAMS NIH HHS [AR35322] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035322] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Heinegard Dick, 1993, P189; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1992, METHOD ENZYMOL, V216, P69; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MELCHING LI, 1990, BIOCHIM BIOPHYS ACTA, V1036, P213, DOI 10.1016/0304-4165(90)90037-W; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	39	101	108	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25639	25644		10.1074/jbc.270.43.25639	http://dx.doi.org/10.1074/jbc.270.43.25639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592739	hybrid			2022-12-25	WOS:A1995TB46600056
J	LEGGETT, RW; ARMSTRONG, SA; BARRY, D; MUELLER, CR				LEGGETT, RW; ARMSTRONG, SA; BARRY, D; MUELLER, CR			SP1 IS PHOSPHORYLATED AND ITS DNA-BINDING ACTIVITY DOWN-REGULATED UPON TERMINAL DIFFERENTIATION OF THE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR SP1; ZINC-FINGER PROTEINS; PROMOTER ELEMENTS; ALBUMIN GENE; EXPRESSION; CELLS; REGENERATION; SPECIFICITY	Using nuclear extracts prepared hom rat liver it was demonstrated that binding of a transcription factor to site II of the D-site binding protein promoter could be induced by dephosphorylation of these extracts. Competition band shifts and supershift assays reveal this protein to be the general transcription factor Sp1. Phosphorylation of Sp1 appears to occur as a result of terminal differentiation of the liver. Proteins from both 1-day-old rat liver and adult liver undergoing regeneration have less of the phosphorylated form of Sp1 present with consequent increased DNA binding activity. Sp1 is similarly phosphorylated in brain, kidney, and spleen with phosphatase treatment of the extracts significantly increasing the level of DNA binding activity. Dephosphorylation of Sp1 results in a 10-fold increase in the affinity of Sp1 for its cognate site. Two-dimensional gel electrophoresis reveals that approximately 20% of the detectable protein appears to be in the phosphorylated form in adult liver extracts. Another protein with similar characteristics also appears to be present in the liver, Decreasing Sp1 DNA binding activity by phosphorylation may be an important mechanism for regulating gene expression, and possibly bringing about growth arrest during terminal differentiation.	QUEENS UNIV, CANC RES LABS, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada								BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN XR, 1992, ONCOGENE, V7, P1805; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEGGETT RW, 1994, DNA CELL BIOL, V13, P693, DOI 10.1089/dna.1994.13.693; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MUELLER CR, 1992, DNA CELL BIOL, V11, P559, DOI 10.1089/dna.1992.11.559; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NAKAMURA T, 1992, J VIROL, V66, P6436, DOI 10.1128/JVI.66.11.6436-6450.1992; PANDURO A, 1986, BIOCHEMISTRY-US, V25, P1414, DOI 10.1021/bi00354a034; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUZUKIYAGAWA Y, 1992, MOL CELL BIOL, V12, P4046, DOI 10.1128/MCB.12.9.4046; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; YEN A, 1992, P SOC EXP BIOL MED, V199, P291	44	175	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25879	25884		10.1074/jbc.270.43.25879	http://dx.doi.org/10.1074/jbc.270.43.25879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592774	hybrid			2022-12-25	WOS:A1995TB46600091
J	NARITA, M; BU, GJ; OLINS, GM; HIGUCHI, DA; HERZ, J; BROZE, GJ; SCHWARTZ, AL				NARITA, M; BU, GJ; OLINS, GM; HIGUCHI, DA; HERZ, J; BROZE, GJ; SCHWARTZ, AL			2 RECEPTOR SYSTEMS ARE INVOLVED IN THE PLASMA-CLEARANCE OF TISSUE FACTOR PATHWAY INHIBITOR IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION INHIBITOR; 39-KDA PROTEIN; HEPARIN; DOMAINS; BINDING; IDENTIFICATION; RABBITS; LIGANDS	Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of the blood coagulation factor VIIa-tissue factor complex, as well as a direct inhibitor of factor Xa. Intravenously administered TFPI is rapidly cleared from circulation predominantly via liver. We previously reported that the low density lipoprotein receptor related protein (LRP), a multifunctional endocytic receptor, mediates the uptake and degradation of TFPI in hepatoma cells. This process is inhibited by a 39-kDa receptor-associated protein which binds to LRP and regulates its ligand binding activity. However, a distinct, low affinity binding site (perhaps heparin sulfate proteoglycans, HSPGs) on the endothelium and liver is thought to be responsible for the majority of TFPI cell surface binding. In the current study, we investigated the role of LRP and this second binding site in the clearance of I-125-TFPI in, vivo using competitors and inhibitors of the receptors. Mice overexpressing the 39-kDa protein via adenoviral-mediated gene transfer displayed diminished plasma clearance of I-125-TFPI. Blockade of cell surface HSPGs sites by incubation with the positively charged molecule, protamine, inhibited I-125-TFPI binding to the hepatoma cells in vitro. In addition, preadministration of protamine in vivo prolonged the plasma clearance of I-125-TFPI in a dose-dependent manner. However, a dramatic increase of the plasma half-life of I-125-TFPI and virtual elimination of I-125-TFPI clearance was observed in mice overexpressing the 39-kDa protein and administered protamine. Taken together, our results suggest that two receptor mechanisms are involved in the clearance of TFPI in vivo.	WASHINGTON UNIV,JEWISH HOSP,SCH MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; GD SEARLE & CO,DEPT CARDIOVASC DIS & RES,ST LOUIS,MO 63167; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; WASHINGTON UNIV,SCH MED,DEPT BIOL MOLEC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Washington University (WUSTL)	NARITA, M (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,BOX 8116,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 52040, HL 34462, HL 53280] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053280, R01HL052040, R01HL034462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREGENGAARD C, 1993, THROMB HAEMOSTASIS, V70, P454; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BU GJ, 1992, J BIOL CHEM, V267, P15595; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DAY KC, 1990, BLOOD, V76, P1538; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HARENBERG J, 1993, THROMB HAEMOSTASIS, V70, P942; HASKEL EJ, 1991, CIRCULATION, V84, P821, DOI 10.1161/01.CIR.84.2.821; HERZ J, 1991, J BIOL CHEM, V266, P21232; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; NOVOTNY WF, 1991, BLOOD, V78, P394; PALMIER MO, 1992, THROMB HAEMOSTASIS, V68, P33; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SMITH PL, 1992, J BIOL CHEM, V267, P19140; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WUN TC, 1988, J BIOL CHEM, V263, P6001; WUN TC, 1992, BLOOD, V79, P430	22	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24800	24804		10.1074/jbc.270.42.24800	http://dx.doi.org/10.1074/jbc.270.42.24800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559599	hybrid			2022-12-25	WOS:A1995TB46500033
J	SASS, C; GIROUX, LM; LUSSIERCACAN, S; DAVIGNON, J; MINNICH, A				SASS, C; GIROUX, LM; LUSSIERCACAN, S; DAVIGNON, J; MINNICH, A			UNEXPECTED CONSEQUENCES OF DELETION OF THE FIRST 2 REPEATS OF THE LIGAND-BINDING DOMAIN FROM THE LOW-DENSITY-LIPOPROTEIN RECEPTOR - EVIDENCE FROM A HUMAN MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERCHOLESTEROLEMIA; LDL-RECEPTOR; ELECTROPHORETIC TRANSFER; GENE; CHOLESTEROL; PROTEINS; IDENTIFICATION; FIBROBLASTS; PLASMA; CELLS	Heterozygosity for a 5-kilobase (kb) deletion of the first two ligand-binding repeats (exons 2 and 3) of the low density lipoprotein (LDL) receptor (R) gene (LDL-R Delta 5kb) confers familial hypercholesterolemia (FH). The FH phenotype is unexpected based on previous site-directed mutagenesis showing that deletion of exons 2 and 3 resulted in little or no defect in LDL-R activity. In the present study, we took unique advantage of the ability to distinguish the LDL R Delta 5kb from the normal receptor on the basis of size, in order to resolve this apparent discrepancy. Fibroblasts from heterozygotes for the LDL-R Delta 5kb displayed 50% of normal capacity to bind LDL and beta-VLDL, apparently due to lower receptor number, Cellular mRNA for the Delta 5kb allele was at least as abundant as that for the normal allele. Immunoblotting and cell binding assays with anti-LDL-R antibody IgG-4A4 demonstrated normal synthesis and transport of the Delta 5kb receptor. Ligand blotting demonstrated that the Delta 5kb receptor displayed minimal or no ability to bind LDL or beta-VLDL. Thus, in contrast to transfected cell lines, in human fibroblasts, the first two cysteine-rich repeats of the LDL-R appear functionally necessary. These characteristics of the LDL-R Delta 5kb in human fibroblasts explain the in vivo phenotype of carriers.	UNIV MONTREAL,CLIN RES INST MONTREAL,DEPT MED,HYPERLIPIDEMIA & ATHEROSCLEROSIS RES GRP,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; BILHEIMER DW, 1985, AM J MED GENET, V22, P593, DOI 10.1002/ajmg.1320220318; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; ESSER V, 1988, J BIOL CHEM, V263, P13282; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUDNASON V, 1994, ARTERIOSCLER THROMB, V14, P1717, DOI 10.1161/01.ATV.14.11.1717; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HARLOW E, 1988, ANTIBODIES LAB MANUA, P245; HIMBER J, 1993, ELECTROPHORESIS, V14, P794, DOI 10.1002/elps.11501401124; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; ISHIDA BY, 1987, J LIPID RES, V28, P778; KAJINAMI K, 1988, ARTERIOSCLEROSIS, V8, P187, DOI 10.1161/01.ATV.8.2.187; KAJINAMI K, 1989, CIRICULATION, V80, P278; KIGAWA K, 1993, J BIOCHEM-TOKYO, V113, P372, DOI 10.1093/oxfordjournals.jbchem.a124053; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LEITERSDORF E, 1988, NUCLEIC ACIDS RES, V16, P7215, DOI 10.1093/nar/16.14.7215; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; MA YH, 1989, CLIN GENET, V36, P219; MABUCHI H, 1990, ANN NY ACAD SCI, V598, P393, DOI 10.1111/j.1749-6632.1990.tb42310.x; MINNICH A, 1995, J LIPID RES, V36, P117; MOORJANI S, 1993, LANCET, V341, P1303, DOI 10.1016/0140-6736(93)90815-X; NORA JJ, 1985, AM J MED GENET, V22, P585, DOI 10.1002/ajmg.1320220317; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; RHOGANI A, 1988, BIOCHEMISTRY-US, V27, P7428; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SASS C, 1995, HUM GENET, V96, P21, DOI 10.1007/BF00214181; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SOUTAR AK, 1990, BRIT MED BULL, V46, P891, DOI 10.1093/oxfordjournals.bmb.a072445; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299	37	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25166	25171		10.1074/jbc.270.42.25166	http://dx.doi.org/10.1074/jbc.270.42.25166			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559651	hybrid			2022-12-25	WOS:A1995TB46500085
J	XU, YP; WARE, A				XU, YP; WARE, A			SELECTIVE-INHIBITION OF THROMBIN RECEPTOR-MEDIATED CA2+ ENTRY BY PROTEIN-KINASE-C-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-PLATELETS; CELLS; HYDROLYSIS; ACTIVATION; CHANNELS	Thrombin initiates many physiological processes in platelets and other megakaryocyte-lineage cells by interacting with surface receptors and generating rises in cytoplasmic Ca2+; these rises result from both Ca2+ release from intracellular stores and receptor-mediated Ca2+ entry. Regulators that limit Ca2+ entry after its initiation by thrombin have not been identified, In this study, prevention of expression of a single protein kinase C isoenzyme (PKC beta) by antisense cDNA overexpressed in HEL cells, a human megakaryoblastic cell line that expresses thrombin receptors, promotes thrombin receptor-mediated Ca2+ entry without altering thrombin-induced intracellular release of Ca2+, The cytoplasmic Ca2+ rise initiated by endoperoxide analogs was not affected by inhibiting PKC beta. Overexpression of a cDNA encoding wild-type PKC beta mutated to prevent recognition by the antisense cDNA abolished the enhancement of Ca2+ influx following thrombin, Thus, PKC beta appears to be a specific negative regulator of thrombin receptor-mediated Ca2+ entry.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NHLBI NIH HHS [HL38820, HL47032, HL02271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047032, K04HL002271, R29HL038820, R01HL038820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; JOHNSON PC, 1989, METHOD ENZYMOL, V169, P386; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; Ware J.A., 1994, WILLIAMS HEMATOLOGY, P1161; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	21	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23887	23890		10.1074/jbc.270.41.23887	http://dx.doi.org/10.1074/jbc.270.41.23887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592574	hybrid			2022-12-25	WOS:A1995TA21700002
J	GOODMAN, OB; KEEN, JH				GOODMAN, OB; KEEN, JH			THE ALPHA-CHAIN OF THE AP-2 ADAPTER IS A CLATHRIN BINDING SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY PROTEIN AP-2; PLASMA-MEMBRANE; COATED VESICLES; INHIBITS ENDOCYTOSIS; COMPLEX AP-2; ACIDIFICATION; DOMAIN; IDENTIFICATION; POLYPEPTIDES; AUXILIN	We have utilized a rabbit reticulocyte lysate coupled transcription-translation system to express the large subunits of the clathrin associated protein-2 (AP-2) complex so that their individual functions may be studied separately. Appropriate folding of each subunit into N-terminal core and C-terminal appendage domains was confirmed by limited proteolysis. Translated beta 2 subunit bound to both assembled clathrin cages and immobilized clathrin trimers, confirming and extending earlier studies with preparations obtained by chemical denaturation-renaturation. Translated alpha(a) exhibited rapid, reversible and specific binding to clathrin cages. As with native AP-2, proteolysis of alpha(a) bound to clathrin cages released the appendages, while cores were retained. Further digestion revealed a approximate to 29 kDa alpha(a) clathrin-binding fragment that remained tightly cage-associated. Translated alpha(a) also bound to immobilized clathrin trimers, although with greater sensitivity to increasing pH than the translated beta 2 subunit. Clathrin binding by both the alpha and beta subunits is consistent with a bivalent cross-linking model for lattice assembly (Keen, J. H. (1987) Cell Biol, 105, 1989). It also raises the possibility that the alpha clathrin interaction may have other consequences, such as modulation of lattice stability or shape, or other alpha functions.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University				Goodman, Oscar/0000-0002-0882-3621	NCI NIH HHS [CA09662] Funding Source: Medline; NIGMS NIH HHS [GM-28526] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1989, J BIOL CHEM, V264, P20089; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; COSSON P, 1989, J CELL BIOL, V108, P377, DOI 10.1083/jcb.108.2.377; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LIU Q, 1994, J BIOL CHEM, V269, P31592; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; MYERS M, 1993, J BIOL CHEM, V268, P9184; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; PRASAD K, 1993, MOL BIOL CELL, V4, P214; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	32	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23768	23773		10.1074/jbc.270.40.23768	http://dx.doi.org/10.1074/jbc.270.40.23768			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559550	hybrid			2022-12-25	WOS:A1995RY90900079
J	GROETTRUP, M; RUPPERT, T; KUEHN, L; SEEGER, M; STANDERA, S; KOSZINOWSKI, U; KLOETZEL, PM				GROETTRUP, M; RUPPERT, T; KUEHN, L; SEEGER, M; STANDERA, S; KOSZINOWSKI, U; KLOETZEL, PM			THE INTERFERON-GAMMA-INDUCIBLE 11S-REGULATOR (PA28) AND THE LMP2/LMP7 SUBUNITS GOVERN THE PEPTIDE PRODUCTION BY THE 20S-PROTEASOME IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR-HISTOCOMPATIBILITY-COMPLEX; LINKED LMP GENE; CLASS-II REGION; MULTICATALYTIC PROTEINASE; ANTIGEN PRESENTATION; HUMAN MHC; PROTEOLYSIS; EXPRESSION; SEQUENCE; CDNA	Antigenic peptides presented on major histocompatibility complex (MHC) class I molecules to cytotoxic T cells are generated in the cytosol by the 20 S proteasome. Upon stimulation of antigen presenting cells with interferon-gamma, two constitutive subunits of the 20 S proteasome are replaced by the MHC-encoded subunits low molecular mass polypeptide (LMP) 2 and LMP 7. In addition the expression of the two subunits of the 11 S regulator of the 20 S proteasome (PA28) are increased. As the function of LMP2 and LMP7 in antigen presentation is still controversial, we tested whether these subunits might operate by modifying proteasome activation through the 11 S regulator. We strongly overexpressed the two LMP subunits separately or together by transfection in murine fibroblasts. Isolated 20 S proteasomes from LMP transfectants were applied in digests of a 25-mer peptide in the presence or absence of a purified preparation of 11 S regulator from rabbit erythrocytes. Analysis of the cleavage products by high performance liquid chromatography and electrospray mass spectroscopy revealed marked differences in the peptide product profile in dependence on the LMP2 and LMP7 content. While the 11 S regulator did not preferentially activate LMP2 or 7 containing proteasomes, the binding of the 11 S regulator to any of the proteasome preparations markedly changed both the quality and quantity of peptides produced. These results suggest that the 11 S regulator increases the spectrum of peptides which can be generated in antigen presenting cells.	HUMBOLDT UNIV BERLIN,FAC MED CHARITE,INST BIOCHEM,D-10115 BERLIN,GERMANY; UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; DIABET RES INST,D-40225 DUSSELDORF,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg			Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ANROLD D, 1993, NATURE, V360, P171; ARIZTI P, 1993, ENZYME PROTEIN, V47, P285, DOI 10.1159/000468686; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CHEN WS, 1994, J EXP MED, V180, P1471, DOI 10.1084/jem.180.4.1471; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; COX JH, 1995, J IMMUNOL, V154, P511; DAHLMANN B, 1989, BIOCHIM BIOPHYS ACTA, V991, P253, DOI 10.1016/0304-4165(89)90113-X; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; DICK LR, 1994, J IMMUNOL, V152, P3884; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FRENTZEL S, 1992, FEBS LETT, V302, P121, DOI 10.1016/0014-5793(92)80420-L; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRENTZEL S, 1993, EUR J BIOCHEM, V216, P119, DOI 10.1111/j.1432-1033.1993.tb18123.x; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HENGEL H, 1994, J VIROL, V68, P289, DOI 10.1128/JVI.68.1.289-297.1994; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; KEIL GM, 1987, J VIROL, V61, P1901, DOI 10.1128/JVI.61.6.1901-1908.1987; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KIRSTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785; KOSZINOWSKI UH, 1986, J VIROL, V58, P59, DOI 10.1128/JVI.58.1.59-66.1986; KUCKELKORN U, 1995, IN PRESS EUR J IMMUN; KUEHN L, 1989, BIOCHIM BIOPHYS ACTA, V991, P263, DOI 10.1016/0304-4165(89)90114-1; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MOMBURG F, 1993, NATURE, V360, P174; MOTT JD, 1994, J BIOL CHEM, V269, P31466; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; TANAKA K, 1992, NEW BIOL, V4, P173; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O; ZWICKL P, 1994, STRUCT BIOL, V1, P765	55	204	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23808	23815		10.1074/jbc.270.40.23808	http://dx.doi.org/10.1074/jbc.270.40.23808			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559557	hybrid			2022-12-25	WOS:A1995RY90900086
J	SAWAI, H; OKAZAKI, T; YAMAMOTO, H; OKANO, H; TAKEDA, Y; TASHIMA, M; SAWADA, H; OKUMA, M; ISHIKURA, H; UMEHARA, H; DOMAE, N				SAWAI, H; OKAZAKI, T; YAMAMOTO, H; OKANO, H; TAKEDA, Y; TASHIMA, M; SAWADA, H; OKUMA, M; ISHIKURA, H; UMEHARA, H; DOMAE, N			REQUIREMENT OF AP-1 FOR CERAMIDE-INDUCED APOPTOSIS IN HUMAN LEUKEMIA HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; C-JUN PROTOONCOGENE; TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; GENE-EXPRESSION; FREE SYSTEM; KAPPA-B; DIFFERENTIATION	Ceramide has emerged as a novel lipid mediator in cell proliferation, differentiation, and apoptosis. In this work, we demonstrate that the levels of c-jun mRNA, c-Jun protein, and DNA binding activity of a nuclear transcription factor AP-1 to 12-o-tetradecanoylphorbol 13-acetate responsive elements all increased following treatment with the cell-permeable ceramide, N-acetylsphingosine in human leukemia HL-60 cells, N-Acetylsphingosine (1-10 mu M) increased the levels of c-jun mRNA in a dose-dependent manner, and maximal expression was achieved 1 h after treatment. Increase of c-jun expression treated with 5 mu M N-acetyldihydrosphingosine, which could not induce apoptosis, was one third of that with 5 mu M N-acetylsphingosine. Ceramide-induced growth inhibition and DNA fragmentation were both prevented by treatment with curcumin, 1,7-bis[4-hydroxy-3-methoxy-phenyl]-1,6-heptadiene-3,5-dione (an:inhibitor of AP-1 activation), or antisense oligonucleotides for c-jun. These results suggest that the transcription factor AP-1 is critical for apoptosis in HL-60 cells and that an intracellular sphingolipid mediator, ceramide, modulates a signal transduction inducing apoptosis through AP-1 activation.	OSAKA DENT UNIV,DEPT MED,CYUO KU,OSAKA 540,JAPAN; OSAKA DENT UNIV,DEPT ORAL SURG,CYUO KU,OSAKA 540,JAPAN; KYOTO UNIV,FAC MED,DEPT INTERNAL MED,DIV 1,KYOTO 606,JAPAN	Kyoto University								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; BRACH MA, 1992, BLOOD, V79, P728; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CIFONE MG, 1994, J EXP MED, V177, P1547; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GAYNOR R, 1991, BLOOD, V77, P2618; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; KIM MY, 1991, J BIOL CHEM, V266, P484; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLLINEDO F, 1991, EUR J BIOCHEM, V200, P483, DOI 10.1111/j.1432-1033.1991.tb16208.x; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGAWA K, 1994, EXP HEMATOL, V22, P45; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OKAZAKI T, 1989, J BIOL CHEM, V264, P19067; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RUBIN E, 1992, CANCER RES, V52, P878; RUBIN E, 1991, MOL PHARMACOL, V39, P697; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH MJ, 1992, BLOOD, V79, P2107; SU Y, 1994, J BIOL CHEM, V269, P16512; UMEHARA H, 1994, INT IMMUNOL, V6, P1071, DOI 10.1093/intimm/6.7.1071; WU BY, 1989, J BIOL CHEM, V264, P9000; YANG Z, 1983, J BIOL CHEM, V268, P20520	55	183	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27326	27331		10.1074/jbc.270.45.27326	http://dx.doi.org/10.1074/jbc.270.45.27326			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592995	hybrid			2022-12-25	WOS:A1995TE58300095
J	MOULD, AP; AKIYAMA, SK; HUMPHRIES, MJ				MOULD, AP; AKIYAMA, SK; HUMPHRIES, MJ			REGULATION OF INTEGRIN ALPHA-5-BETA-1-FIBRONECTIN INTERACTIONS BY DIVALENT-CATIONS - EVIDENCE FOR DISTINCT CLASSES OF BINDING-SITES FOR MN2+, MG2+, AND CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; CELL-ADHESION; LIGAND-BINDING; VITRONECTIN RECEPTOR; LEUKOCYTE ADHESION; PLATELET INTEGRIN; ALPHA-SUBUNIT; BETA-SUBUNIT; DOMAIN; IDENTIFICATION	Integrin-ligand interactions are known to be dependent on divalent cations, although the precise role of cations in ligand binding is still unclear. Using the interaction between alpha 5 beta 1 and fibronectin as a model system, we have performed a comprehensive analysis of the effects of Mn2+, Mg2+, and Ca2+ on Ligand binding. Each cation had distinct effects on the ligand-binding capacity of alpha 5 beta 1:Mn2+ promoted high levels of Ligand binding, Mg2+ promoted low levels of binding, and Ca2+ failed to support binding Studies of the effects of different combinations of cations on Ligand binding indicated that the cation-binding sites within alpha 5 beta 1 are not all identical, or of broad specificity, but instead each site shows a distinct preference for one or more cations, Ca2+ strongly inhibited Mn2+-supported Ligand binding, but this inhibition was noncompetitive, suggesting that Ca2+ recognizes different cation-binding sites to Mn2+. In contrast, Ca2+ acted as a direct competitive inhibitor of Mg2+-supported Ligand binding, implying that Ca2+ can displace Mg2+ from the integrin. However, low concentrations of Ca2+ greatly increased the apparent affinity of Mg2+ for its binding site, suggesting the existence of a distinct high affinity Ca2+-binding site. Taken together, our results imply that the ligand-binding capacity of alpha 5 beta 1 can be regulated in a complex manner through separate classes of binding sites for Mn2+, Mg2+, and Ca2+.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	MOULD, AP (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,WELLCOME TRUST CTR CELL MATRIX RES,2 205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.			Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BANAI S, 1990, CIRC RES, V67, P645, DOI 10.1161/01.RES.67.3.645; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAVIS GE, 1993, J IMMUNOL, V151, P7138; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GULINO D, 1992, J BIOL CHEM, V267, P1001; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1994, CURR OPIN GENET DEV, V4, P569, DOI 10.1016/0959-437X(94)90074-D; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON AM, 1994, IMMUNOLOGY, V81, P120; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RUOSLAHTI E, 1994, KIDNEY INT S; SANCHEZAPARICIO P, 1993, J IMMUNOL, V150, P3506; SANK A, 1989, SURGERY, V106, P1141; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	52	250	258	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26270	26277		10.1074/jbc.270.44.26270	http://dx.doi.org/10.1074/jbc.270.44.26270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592835	hybrid			2022-12-25	WOS:A1995TC97800042
J	TOTA, MR; XU, L; SIROTINA, A; STRADER, CD; GRAZIANO, MP				TOTA, MR; XU, L; SIROTINA, A; STRADER, CD; GRAZIANO, MP			INTERACTION OF [FLUORESCEIN-TRP(25)]GLUCAGON WITH THE HUMAN GLUCAGON RECEPTOR EXPRESSED IN DROSOPHILA SCHNEIDER-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; CLONING	The human glucagon receptor was expressed at high density in Drosophila Schneider 2 (S2) cells. Following selection with G418 and induction with CuSO4, the cells expressed the receptor at a level of 250 pmol/mg of membrane protein. The glucagon receptor was functionally coupled to increases in cyclic AMP in S2 cells. Protein immunoblotting with anti-peptide antibodies revealed the expressed receptor to have an apparent molecular mass of 48 kDa, consistent with low levels of glycosylation in this insect cell system. Binding of [fluorescein-Trp(25)]glucagon to 52 cells expressing the glucagon receptor was monitored as an increase in fluorescence anisotropy along with an increase in fluorescence intensity. Anisotropy data suggest that the mobility of the fluorescein is restricted when the ligand is bound to the receptor, Kinetic analysis indicates that the binding of glucagon to its receptor proceeds via a bimolecular interaction, with a forward rate constant that is several orders of magnitude slower than diffusion-controlled. These data would be consistent with a conformational change upon the binding of agonist to the receptor. The combination of [fluorescein-Trp(25)]glucagon with the 52 cell expression system should be useful for analyzing glucagon receptor structure and function.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065	Merck & Company	TOTA, MR (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,BOX 2000,RAHWAY,NJ 07065, USA.							BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BRAUN W, 1983, J MOL BIOL, V169, P921, DOI 10.1016/S0022-2836(83)80143-0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CARRAWAY KL, 1993, BIOCHEMISTRY-US, V32, P12039, DOI 10.1021/bi00096a014; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GRAZIANO MP, 1993, BIOCHEM BIOPH RES CO, V196, P141, DOI 10.1006/bbrc.1993.2226; HEITHIER H, 1988, BIOCHIM BIOPHYS ACTA, V971, P298; HORWITZ EM, 1985, J BIOL CHEM, V16, P9307; IWANIJ V, 1985, P NATL ACAD SCI USA, V82, P325, DOI 10.1073/pnas.82.2.325; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P88; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; MORAN EC, 1977, BIOCHEM BIOPH RES CO, V77, P1300, DOI 10.1016/S0006-291X(77)80121-6; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; SASAKI K, 1975, NATURE, V257, P751, DOI 10.1038/257751a0; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SKLAR LA, 1990, BIOCHEMISTRY-US, V29, P313, DOI 10.1021/bi00454a002; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TOTA MR, 1994, BIOCHEMISTRY-US, V33, P13079, DOI 10.1021/bi00248a017; Vetterling W.T., 1988, NUMERICAL RECIPES C; WRIGHT DE, 1983, J BIOL CHEM, V255, P10884	27	30	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26466	26472		10.1074/jbc.270.44.26466	http://dx.doi.org/10.1074/jbc.270.44.26466			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592863	hybrid			2022-12-25	WOS:A1995TC97800070
J	MEISNER, H; CZECH, MP				MEISNER, H; CZECH, MP			COUPLING OF THE PROTOONCOGENE PRODUCT C-CBL TO THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; SH3 DOMAINS; TYROSINE KINASES; V-CBL; RAS; GRB2; TRANSFORMATION; ASSOCIATION; ACTIVATION; TRUNCATION	The proto oncogene product, Cbl, is a 120-kDa protein present in lymphocytes that contains numerous PXXP motifs in its COOH-terminal region and constitutively binds the SH3-containing adaptor protein Grb2. Crosslinking of CD3 and CD4 receptors in Jurkat T cells causes tyrosine phosphorylation of Cbl and its association with phosphatidylinositol 3'-kinase (Meisner, H., Conway, B., Hartley, D., and Czech, M. P. (1995) Mol Cell. Biol. 15, 3571-3578). Here we demonstrate that Cbl is also present in nonlymphoid cells, and that epidermal growth factor (EGF) elicits its rapid tyrosine phosphorylation in human embryonic 293 cells. Immunoprecipitates of Cbl from lysates of these cells contain Grb2 in the basal state, while EGF stimulation causes co-precipitation of tyrosine-phosphorylated EGF receptors. Similarly, EGF receptor immunoprecipitates from EGF-treated 293 cells contain Cbl and Grb2. Both Grb2 and EGF receptors are released from Chl in the presence of a proline-rich peptide that binds the NH2-terminal SH3 domain of Grb2, These results indicate that autophosphorylated EGF receptors associate with the SH2 domain of Grb2, which is complexed through its SH3 domain with proline-rich regions of Cbl. Such recruitment of Cbl to EGF receptors may reflect an important mechanism for its tyrosine phosphorylation and for assembling signaling components that mediate or modulate EGF actions.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	MEISNER, H (corresponding author), UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DONOVAN J, 1994, J BIOL CHEM, V169, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GUSTAFSON T, 1995, MOL CELL BIOL, V15, P25000; HARLOW E, 1988, ANTIBODIES LABORATOR; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI J, 1994, ONCOGENE, V8, P2489; MYERS M, 1994, TRENDS BIOCHEM SCI, V198, P289; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V7, P93; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHOELSON S, 1993, J BIOL CHEM, V268, P9478; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443	36	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25332	25335		10.1074/jbc.270.43.25332	http://dx.doi.org/10.1074/jbc.270.43.25332			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592693	hybrid			2022-12-25	WOS:A1995TB46600009
J	WIELES, B; VANNOORT, J; DRIJFHOUT, JW; OFFRINGA, R; HOLMGREN, A; OTTENHOFF, THM				WIELES, B; VANNOORT, J; DRIJFHOUT, JW; OFFRINGA, R; HOLMGREN, A; OTTENHOFF, THM			PURIFICATION AND FUNCTIONAL-ANALYSIS OF THE MYCOBACTERIUM-LEPRAE THIOREDOXIN THIOREDOXIN REDUCTASE HYBRID PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THIOREDOXIN REDUCTASE; SELECTION; PLASMID	In Mycobacterium leprae, thioredoxin and thioredoxin reductase are expressed from a single gene. This results in the expression of a hybrid protein with subunits attached to each other by a hydrophilic peptide linker. In all other organisms studied so far, thioredoxin (Trx) and thioredoxin reductase (TR) are expressed as two separate proteins. This raises the question of whether the hybrid protein is enzymatically active and, if so, whether TR reduces its own Trx partner or alternatively a heterologous Trx subunit. To address this question, the hybrid TR/Trx protein of M. leprae as well as the individual parts of the hybrid gene coding for either TR or Trx were overexpressed in Escherichia coli and purified. The purified proteins were tested for their ability to catalyze NADPH-dependent insulin disulfide reduction. Here we show that the M. leprae hybrid protein is indeed enzymatically active. Compared with the enzymatic activity of the separately expressed Trx and TR proteins, the hybrid protein is shown to be more efficient, particularly at low equimolar concentrations. This suggests that the hybrid protein of M. leprae is active by itself and that its activity involves intramolecular interactions between the TR and Trx domains. The activity of the hybrid protein increases when exogenous TR or Trx is added, indicating an additional role for intermolecular interactions.	LEIDEN UNIV HOSP,BLOOD BANK,2333 AA LEIDEN,NETHERLANDS; KAROLINSKA INST,MED NOBEL INST BIOCHEM,S-17177 STOCKHOLM,SWEDEN	Leiden University; Leiden University Medical Center (LUMC); Karolinska Institutet	WIELES, B (corresponding author), LEIDEN UNIV HOSP,DEPT IMMUNOHEMATOL,RIJNSBURGERWEG 10,BLDG 1 E3Q,2333 AA LEIDEN,NETHERLANDS.		Drijfhout, Jan Wouter/ABA-6318-2021	Drijfhout, Jan Wouter/0000-0003-4808-5296; Wieles, Brigitte/0000-0001-9631-3404				BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CLARKCURTISS JE, 1985, J BACTERIOL, V161, P1093, DOI 10.1128/JB.161.3.1093-1102.1985; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1985, BIOSCIENCE REP, V4, P917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Sambrook J, 1989, MOL CLONING LABORATO; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; WIELES B, 1995, MOL MICROBIOL, V16, P921, DOI 10.1111/j.1365-2958.1995.tb02318.x; YOUNG RA, 1985, NATURE, V316, P450, DOI 10.1038/316450a0	16	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25604	25606		10.1074/jbc.270.43.25604	http://dx.doi.org/10.1074/jbc.270.43.25604			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592733	hybrid			2022-12-25	WOS:A1995TB46600050
J	BUHL, AM; JOHNSON, NL; DHANASEKARAN, N; JOHNSON, GL				BUHL, AM; JOHNSON, NL; DHANASEKARAN, N; JOHNSON, GL			G-ALPHA(12) AND G-ALPHA(13) STIMULATE RHO-DEPENDENT STRESS FIBER FORMATION AND FOCAL ADHESION ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; SIGNALING PATHWAYS; MOLECULAR-CLONING; ADENYLYL CYCLASE; PERTUSSIS TOXIN; GROWTH-FACTORS; GENE-PRODUCT; RECEPTOR; RAS; FIBROBLASTS	Rho, a member of the Ras superfamily of GTP-binding proteins, regulates actin polymerization resulting in the formation of stress fibers and the assembly of focal adhesions. In Swiss 3T3 cells, heterotrimeric G protein-coupled receptors for lysophosphatidic acid and gastrin releasing peptide stimulate Rho-dependent stress fiber and focal adhesion formation. The specific heterotrimeric G protein subunits mediating Rho-dependent stress fiber and focal adhesion formation have not been defined previously. We have expressed GTPase-deficient, constitutively activated G protein alpha subunits and mixtures of beta and gamma subunits in Swiss 3T3 cells. Measurement of actin polymerization and focal adhesion formation indicated that GTPase-deficient alpha(12) and alpha(13), but not the activated forms of a(i2) or a(q) stimulated stress fiber and focal adhesion assembly, Combinations of beta and gamma subunits were unable to stimulate stress fiber or focal adhesion formation. G alpha(12)- and alpha(13)-mediated stress fiber and focal adhesion assembly was inhibited by botulinum C3 exoenzyme, which ADP-ribosylates and inactivates Rho, indicating that a(12) and alpha(13), but not other G protein alpha subunits or beta gamma complexes, regulate Rho-dependent responses. The results define the integration of G(12) and G(13) with the regulation of the actin cytoskeleton.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; AARHUS UNIV,DEPT CHEM,DIV BIOSTRUCT CHEM,DK-8000 AARHUS C,DENMARK; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; Aarhus University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUNG DT, 1992, J BIOL CHEM, V267, P20831; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SEKINE A, 1989, J BIOL CHEM, V264, P8602; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	35	407	413	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24631	24634		10.1074/jbc.270.42.24631	http://dx.doi.org/10.1074/jbc.270.42.24631			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559569	hybrid			2022-12-25	WOS:A1995TB46500003
J	CHANG, J; KIM, DH; LEE, SW; CHOI, KY; SUNG, YC				CHANG, J; KIM, DH; LEE, SW; CHOI, KY; SUNG, YC			TRANSACTIVATION ABILITY OF P53 TRANSCRIPTIONAL ACTIVATION DOMAIN IS DIRECTLY RELATED TO THE BINDING-AFFINITY TO TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LESS PROMOTER; TFIID COMPLEX; WILD-TYPE; VP16; SEQUENCE; DNA; COACTIVATORS; ASSOCIATION; MECHANISM; ELEMENTS	Tumor suppressor protein p53 is a potent transcriptional activator and regulates cell growth negatively. To characterize the transcriptional activation domain (TAD) of p53, various point mutants were constructed in the context of Ga14 DNA binding domain and tested for their transactivation ability. Our results demonstrated that the positionally conserved hydrophobic residues shared with herpes simplex virus VP16 and other transactivators are essential for transactivation. Also, the negatively charged residues and proline residues are necessary for full activity, but not essential for the activity of p53 TAD. Deletion analyses showed that p53 TAD can be divided into two subdomains, amino acids 1-40 and 43-73. An in vitro glutathione S-transferase pull-down assay establishes a linear correlation between p53 TAD mediated transactivation in vivo and the binding activity of p53 TAD to TATA-binding protein (TBP) in vitro. Mutations that diminish the transactivation ability of Ga14-p53 TAD also impair the binding activity to TBP severely, Our results suggest that at least TBP is a direct target for p53 TAD and that the binding strength of TAD to TBP (TFIID) is an important parameter controlling activity of p53 TAD. In addition, circular dichroism spectroscopy has shown that p53 TAD peptide lacks any regular secondary structure in solution and that there is no significant difference between the spectra of the wild type TAD and that of the transactivation-deficient mutant type.	POHANG UNIV SCI & TECHNOL,CTR BIOFUNCT MOLEC,POHANG 790784,SOUTH KOREA; POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)				CHANG, JUN/0000-0002-8423-5987; Kim, Do-Hyung/0000-0002-2924-4370				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADDISON C, 1990, ONCOGENE, V5, P423; BARGONETTI J, 1991, CELL, V65, P1063; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CATHERINE JT, 1995, SCIENCE, V267, P100; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CRESS A, 1991, GENE, V103, P235, DOI 10.1016/0378-1119(91)90278-J; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GAUN KL, 1991, ANAL BIOCHEM, V192, P262; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HIRIKOSHI M, 1988, CELL, V54, P1033; HIRIKOSHI M, 1988, CELL, V54, P665; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE CW, 1994, J VIROL, V68, P2708, DOI 10.1128/JVI.68.4.2708-2719.1994; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1988, SCIENCE, V245, P371; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	59	104	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25014	25019		10.1074/jbc.270.42.25014	http://dx.doi.org/10.1074/jbc.270.42.25014			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559631	hybrid			2022-12-25	WOS:A1995TB46500065
J	FERGUSON, SSG; MENARD, L; BARAK, LS; KOCH, WJ; COLAPIETRO, AM; CARON, MG				FERGUSON, SSG; MENARD, L; BARAK, LS; KOCH, WJ; COLAPIETRO, AM; CARON, MG			ROLE OF PHOSPHORYLATION IN AGONIST-PROMOTED BETA(2)-ADRENERGIC RECEPTOR SEQUESTRATION - RESCUE OF A SEQUESTRATION-DEFECTIVE MUTANT RECEPTOR BY BETA-ARK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; ARRESTIN; INTERNALIZATION; MEMBRANE; BINDING; SITES; DEPHOSPHORYLATION	The beta(2)-adrenergic receptor (beta(2)AR) belongs to the large family of G protein coupled receptors. Mutation of tyrosine residue 326 to an alanine resulted in a beta(2)AR mutant (beta(2)AR-Y326A) that was defective in its ability to sequester and was less well coupled to adenylyl cyclase than the wild-type beta(2)AR. However, this mutant receptor not only desensitized in response to agonist stimulation but down-regulated normally. In an attempt to understand the basis for the properties of this mutant, we have examined the ability of this regulation-defective mutant to undergo agonist-mediated phosphorylation. When expressed in 293 cells, the maximal response for phosphorylation of the beta(2)AR-Y326A mutant was impaired by 75%. Further characterization of this phosphorylation, using either forskolin stimulation or phosphorylation site-deficient beta(2)AR-Y326A mutants, demonstrated that the beta(2)AR-Y326A mutant can be phosphorylated by cAMP-dependent protein kinase (PKA) but does not serve as a substrate for the beta-adrenergic receptor kinase 1 (beta ARK1). However, overexpression of beta ARK1 led to the agonist-dependent phosphorylation of the beta(2)AR-Y326A mutant and rescue of its sequestration. beta ARK1-mediated rescue of beta(2)AR-Y326A sequestration could be prevented by mutating putative beta ARK phosphorylation sites, but not PKA phosphorylation sites. In addition, both sequestration and phosphorylation of the wild-type beta(2)AR could be attenuated by overexpressing a dominant-negative mutant of beta ARK1 (C-20 beta ARK1-K220M). These findings implicate a role for beta ARK1 mediated phosphorylation in facilitating wild-type beta(2)AR sequestration.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL & MED,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOX RJ, 1987, FEBS LETT, V214, P323, DOI 10.1016/0014-5793(87)80079-0; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1994, J BIOL CHEM, V268, P16879; GURREVICH VV, 1995, J BIOL CHEM, V270, P720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INGLESE J, 1993, NATURE, V359, P147; KONG GH, 1994, J BIOL CHEM, V269, P13084; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MORO O, 1993, J BIOL CHEM, V268, P6862; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POPPIG S, 1995, MOL PHARMACOL, V47, P666; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHWINN DA, 1992, HEART CARDIOVASCULAR, P1657; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1983, J BIOL CHEM, V258, P3900; YU SS, 1993, J BIOL CHEM, V268, P337; YUAN NY, 1994, J BIOL CHEM, V269, P23032	44	207	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24782	24789		10.1074/jbc.270.42.24782	http://dx.doi.org/10.1074/jbc.270.42.24782			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559596	hybrid			2022-12-25	WOS:A1995TB46500030
J	KANAMORI, K; ROSS, BD				KANAMORI, K; ROSS, BD			STEADY-STATE IN-VIVO GLUTAMATE-DEHYDROGENASE ACTIVITY IN RAT-BRAIN MEASURED BY N-15 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOHISTOCHEMICAL DEMONSTRATION; PORTACAVAL ANASTOMOSIS; HYPERAMMONEMIC RATS; CEREBRAL-CORTEX; METABOLISM; AMMONIA; TRANSMITTER; GLUCOSE; PURIFICATION; PRECURSORS	The in vivo activity of glutamate dehydrogenase (GDH) in the direction of reductive amination was measured in rat brain at steady-state concentrations of brain ammonia and glutamate after intravenous infusion of the substrate (NH4+)-N-15. The in vivo rate was determined from the steady-state fractional. N-15 enrichment of brain ammonia, measured by selective observation of (NH4+)-N-15 protons in brain extract by H-1 -N-15 heteronuclear multiple-quantum coherence transfer MMR, and the rate of increase of brain [N-15]glutamate and [2-N-15]glutamine measured by N-15 NMR. The in vivo GDH activity was 0.76-1.17 mu mol/h/g at a brain ammonia concentration of 0.87 +/- 0,18 mu mol/g, and 1.1-1.2 mu mol/h/g at 1.0 +/- 0.17 mu mol/g. Comparison of the observed in. vivo GDH activity with the in vive rates of glutamine synthesis and of phosphate-activated glutaminase suggests that, under mild hyperammonemia, GDH-catalyzed de novo synthesis can provide a minimum of 19% of the glutamate pool that is recycled from neurons to astrocytes through the glutamate-glutamine cycle.			KANAMORI, K (corresponding author), HUNTINGTON MED RES INST,MAGNET RESONANCE SPECT LAB,660 S FAIR OAKS AVE,PASADENA,CA 91105, USA.				NINDS NIH HHS [1RO1 NS29048] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029048] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALAZS R, 1965, BIOCHEM J, V94, P131, DOI 10.1042/bj0940131; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; BERL S, 1962, J BIOL CHEM, V237, P2562; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI [10.1016/B978-0-12-091304-6.50017-3, DOI 10.1016/B978-0-12-091304-6.50017-3]; BUTTERWORTH RF, 1988, J NEUROCHEM, V51, P486, DOI 10.1111/j.1471-4159.1988.tb01064.x; CHEE PY, 1979, J NEUROCHEM, V33, P53, DOI 10.1111/j.1471-4159.1979.tb11705.x; COLON AD, 1986, J NEUROCHEM, V46, P1811; COOPER AJL, 1979, J BIOL CHEM, V254, P4982; COOPER AJL, 1985, J NEUROCHEM, V44, P1716, DOI 10.1111/j.1471-4159.1985.tb07159.x; CREMER JE, 1964, J NEUROCHEM, V11, P165, DOI 10.1111/j.1471-4159.1964.tb06127.x; DEJONG CHC, 1992, J NEUROCHEM, V59, P1071, DOI 10.1111/j.1471-4159.1992.tb08349.x; DENNIS SC, 1977, BIOCHEM J, V168, P521, DOI 10.1042/bj1680521; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; FARROW NA, 1990, BIOCHEM J, V270, P473, DOI 10.1042/bj2700473; GAITONDE MK, 1965, BIOCHEM J, V94, P345, DOI 10.1042/bj0940345; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; KANAMORI K, 1995, BIOCHEM J, V305, P329, DOI 10.1042/bj3050329; KANAMORI K, 1993, NMR BIOMED, V6, P21, DOI 10.1002/nbm.1940060104; KANAMORI K, 1995, J MAGN RESON SER B, V107, P107, DOI 10.1006/jmrb.1995.1066; KANAMORI K, 1995, BIOCHEM J, V311, P681, DOI 10.1042/bj3110681; KANAMORI K, 1993, BIOCHEM J, V293, P461, DOI 10.1042/bj2930461; KANEKO T, 1987, NEUROSCI LETT, V77, P171, DOI 10.1016/0304-3940(87)90581-7; KUN E, 1974, METHOD ENZYMAT AN, P1802; LUND P, 1974, METHOD ENZYMAT AN, P1719; MANS AM, 1984, J NEUROCHEM, V43, P697, DOI 10.1111/j.1471-4159.1984.tb12789.x; MANS AM, 1994, J NEUROCHEM, V63, P1829; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; MILLER AL, 1973, J NEUROCHEM, V20, P1393, DOI 10.1111/j.1471-4159.1973.tb00251.x; ONEAL RM, 1966, J NEUROCHEM, V13, P835, DOI 10.1111/j.1471-4159.1966.tb05879.x; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; PENG L, 1993, DEV NEUROSCI-BASEL, V15, P367, DOI 10.1159/000111357; ROTHE F, 1994, NEUROSCIENCE, V62, P1133, DOI 10.1016/0306-4522(94)90349-2; ROTHE F, 1990, NEUROSCIENCE, V39, P419, DOI 10.1016/0306-4522(90)90278-C; ROTHE F, 1983, DEV BRAIN RES, V11, P67, DOI 10.1016/0165-3806(83)90202-X; SALGANICOFF L, 1965, J NEUROCHEM, V12, P287, DOI 10.1111/j.1471-4159.1965.tb06766.x; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1045, DOI 10.1016/0306-4522(86)90121-1; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; TOLEDANO A, 1979, CELL MOL BIOL, V24, P113; WARD HK, 1983, J NEUROCHEM, V40, P855, DOI 10.1111/j.1471-4159.1983.tb08058.x; YUDKOFF M, 1991, J NEUROCHEM, V57, P153, DOI 10.1111/j.1471-4159.1991.tb02110.x; YUDKOFF M, 1986, BIOCHEM J, V234, P185, DOI 10.1042/bj2340185	44	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24805	24809		10.1074/jbc.270.42.24805	http://dx.doi.org/10.1074/jbc.270.42.24805			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559600	hybrid			2022-12-25	WOS:A1995TB46500034
J	NADKARNI, AK; MCDONOUGH, VM; YANG, WL; STUKEY, JE; OZIERKALOGEROPOULOS, O; CARMAN, GM				NADKARNI, AK; MCDONOUGH, VM; YANG, WL; STUKEY, JE; OZIERKALOGEROPOULOS, O; CARMAN, GM			DIFFERENTIAL BIOCHEMICAL REGULATION OF THE URA7-ENCODED AND URA8-ENCODED CTP SYNTHETASES FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; PHOSPHATIDYLINOSITOL SYNTHASE; MUTATOR GENE; PROTEINS; MUTANTS; TUMORS; CELLS; RNA	The URA7- and URA8-encoded CTP synthetases (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) are functionally overlapping enzymes responsible for the bio synthesis of CTP in the yeast Saccharomyces cerevisiae. URA8-encoded CTP synthetase was purified to apparent homogeneity by ammonium sulfate fractionation of the cytosolic fraction followed by chromatography with Q-Sepharose, Affi-Gel Blue, Mono Q, and Superose 6. The subunit molecular mass (67 kDa) of purified URA8-encoded CTP synthetase was in good agreement with the predicted size of the URA8 gene product. Antibodies raised against a fusion protein constructed from the coding sequences of the URA8 gene and expressed in Escherichia coli reacted with purified URA8-encoded CTP synthetase. Native URA8-encoded CTP synthetase existed as a dimer which oligomerized to a tetramer in the presence of its substrates UTP and ATP. Maximum URA8-encoded CTP synthetase activity was dependent on Mg2+ ions (K-alpha = 2.4 mM) and 2-mercaptoethanol at the pH optimum of 7.5. The enzyme followed saturation kinetics toward UTP (K-m = 74 mu M), ATP (K-m = 22 mu M), and glutamine (K-m = 0.14 mM). GTP stimulated (K-alpha = 26 mu M) URA8-encoded CTP synthetase activity 12-fold. CTP potently inhibited (IC50 = 85 mu M) URA8-encoded CTP synthetase activity and, in addition, caused the dependence of activity toward UTP to become cooperative. The URA8-encoded CTP synthetase and the previously purified URA7-encoded CTP synthetase differed significantly with respect to several biochemical properties including turnover number, pH optimum, substrate dependences, and sensitivity to inhibition by CTP. The URA7-encoded CTP synthetase mRNA was 2-fold more abundant when compared with URA8-encoded CTP synthetase mRNA. Both CTP synthetase isoforms were maximally expressed in the exponential phase of growth.	RUTGERS STATE UNIV,COOK COLL,NEW JERSEY AGR EXPT STN,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903; UNIV PARIS 06,CTR GENET MOLEC,CNRS,F-91198 GIF SUR YVETTE,FRANCE	Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay					NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1984, J BIOL CHEM, V259, P9035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COEN DM, 1987, CURRENT PROTOCOLS MO; CULBERTSON MR, 1975, GENETICS, V80, P23; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LABORATOR, P1; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KIZAKI H, 1980, CANCER RES, V40, P3921; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; OZIERKALOGEROPO.O, 1991, MOL GEN GENET, V0231; OZIERKALOGEROPO.O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROBERTSON JG, 1993, BIOCHEMISTRY-US, V32, P3769, DOI 10.1021/bi00065a032; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SELDEN RF, 1987, CURRENT PROTOCOLS MO; TRAUT TW, 1988, CRC CR REV BIOCH MOL, V23, P121, DOI 10.3109/10409238809088318; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; VINCENT BRD, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; WEBER G, 1979, ADV ENZYME REGUL, V17, P1; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	34	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24982	24988		10.1074/jbc.270.42.24982	http://dx.doi.org/10.1074/jbc.270.42.24982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559626	hybrid			2022-12-25	WOS:A1995TB46500060
J	PERLMAN, JH; WANG, W; NUSSENZVEIG, DR; GERSHENGORN, MC				PERLMAN, JH; WANG, W; NUSSENZVEIG, DR; GERSHENGORN, MC			A DISULFIDE BOND BETWEEN CONSERVED EXTRACELLULAR CYSTEINES IN THE THYROTROPIN-RELEASING-HORMONE RECEPTOR IS CRITICAL FOR BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; RHODOPSIN; RESIDUES; DOMAIN	The assumption that a disulfide bond is present between two highly conserved cysteines in the extracellular loops of G protein coupled receptors and is critical for receptor function has been cast in doubt. We undertook to determine whether a disulfide bond important for binding or activation is present in the thyrotropin-releasing hormone (TRH) receptor (TRH-R). Studies were performed with cells expressing wild-type (WT) and mutant receptors in the absence or presence of the reducing agent dithiothreitol (DTT). The affinity of WT TRH-R was 16-22-fold lower in the presence of DTT than in the absence of DTT. Mutant receptors were constructed in which Ala was substituted for conserved Cys-98 and Cys-179 of extracellular loops 1 and 2, respectively, and for the nonconserved Cys-100. C98A and C179A TRH-Rs did not exhibit high affinity binding. These mutant receptors were capable of stimulating inositol phosphate second messenger formation to the same extent as WT TRH-Rs but with a markedly lower potency. The affinities of C98A and C179A TRH-Rs, estimated from their potencies, were 4400- and 640-fold lower, respectively, than WT TRH-R. The estimated affinities of neither C98A nor C179A TRH-R were decreased by DTT. In contrast, the estimated affinity of C100A TRH-R was not different from WT TRH-R and was DTT sensitive. Moreover, the effect of mutating both Cys-98 and Cys-179 was not additive with the effects of the individual mutations. These data provide strong evidence that Cys-98 and Cys-179 form a disulfide bond. This interaction is not involved in receptor activation but is critical for maintaining the high affinity conformation of TRH-R.			PERLMAN, JH (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,DIV MOLEC MED,1300 YORK AVE,NEW YORK,NY 10021, USA.							ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; GERSHENGORN MC, 1991, ENDOCRINOLOGY, V128, P1204, DOI 10.1210/endo-128-2-1204; GUSTAVSSON B, 1994, BIOCHEM BIOPH RES CO, V199, P612, DOI 10.1006/bbrc.1994.1272; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOSUGI S, 1992, BIOCHEM BIOPH RES CO, V189, P1754, DOI 10.1016/0006-291X(92)90281-O; KURTENBACH E, 1990, BIOCHEM SOC T, V18, P442, DOI 10.1042/bst0180442; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P1; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; NODA K, 1994, J BIOL CHEM, V269, P6743; OGAWA N, 1982, PEPTIDES, V3, P669, DOI 10.1016/0196-9781(82)90169-3; PERLMAN JH, 1995, MOL PHARMACOL, V47, P480; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SHARIF NA, 1984, J NEUROCHEM, V42, P209, DOI 10.1111/j.1471-4159.1984.tb09719.x; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	27	68	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24682	24685		10.1074/jbc.270.42.24682	http://dx.doi.org/10.1074/jbc.270.42.24682			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559582	hybrid			2022-12-25	WOS:A1995TB46500016
J	CALLOW, MJ; RUBIN, EM				CALLOW, MJ; RUBIN, EM			SITE-SPECIFIC MUTAGENESIS DEMONSTRATES THAT CYSTEINE-4326 OF APOLIPOPROTEIN-B IS REQUIRED FOR COVALENT LINKAGE WITH APOLIPOPROTEIN(A) IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSING HUMAN APOLIPOPROTEIN(A); PHENOTYPIC SELECTION; LIPOPROTEIN(A); DNA; PLASMA; IDENTIFICATION; SEQUENCE	In the formation of the lipoprotein(a) (Lp(a)) particle, apolipoprotein(a) (apo(a)) and apolipoprotein B (apoB) are covalently linked via a disulfide bond in both humans and human-apo(a)/apoB transgenic mice. Studies based upon fluorescent labeling of free cysteine residues have suggested that cysteine 3734 of the 4 carboxyl-terminal cysteines of apoB (Cys-3734, Cys-3890, Cys-4190, and Cys-4326) is the most likely candidate to form a disulfide bond with apo(a). However, other recent studies using truncated apoB molecules suggest that Cys-4326, the terminal cysteine of apoB, may be implicated in the binding to apo(a). In order to definitively show which of apoB's carboxyl-terminal cysteines is essential in interacting with apo(a) we have used RecA-assisted restriction enzyme digestion coupled with site-specific mutagenesis to convert Cys-3734 and Cys-4326 to serine within separate 90-kilobase pair apoB P1 phagemid clones. Transgenic mice containing the normal or mutated apoB transgenes were created, and the covalent association of mutated apoB with apo(a) was assessed in mice transgenic for both apoB and apo(a). Analysis by ultracentrifugation and immunoblotting revealed that Cys-4326, but not Cys-3734, was essential in the formation of the covalent bond between apo(a) and apoB in vivo.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CTR HUMAN GENOME,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CALLOW MJ, 1994, NUCLEIC ACIDS RES, V22, P4348, DOI 10.1093/nar/22.20.4348; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLEMAN RD, 1990, BIOCHIM BIOPHYS ACTA, V1037, P129, DOI 10.1016/0167-4838(90)90111-R; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FERRIN LJ, 1993, METH MOL G, V2, P57; FLESS GM, 1985, J LIPID RES, V26, P1224; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; GABEL B, 1994, FEBS LETT, V350, P77, DOI 10.1016/0014-5793(94)00737-3; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; Hogan B, 1986, MANIPULATING MOUSE E, P89; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; SANDHOLZER C, 1992, J CLIN INVEST, V90, P1958, DOI 10.1172/JCI116074; STEYRER E, 1994, J CLIN INVEST, V94, P2330, DOI 10.1172/JCI117598; YANG CY, 1994, CHEM PHYS LIPIDS, V67-8, P99, DOI 10.1016/0009-3084(94)90128-7	31	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23914	23917		10.1074/jbc.270.41.23914	http://dx.doi.org/10.1074/jbc.270.41.23914			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592581	hybrid			2022-12-25	WOS:A1995TA21700009
J	BERMAN, YL; JULIANO, L; DEVI, LA				BERMAN, YL; JULIANO, L; DEVI, LA			PURIFICATION AND CHARACTERIZATION OF A DYNORPHIN-PROCESSING ENDOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CONVERTING ENZYME; MONOBASIC SITES; MESSENGER-RNA; SPINAL-CORD; CELL-LINE; ENDOPROTEASE; CLEAVAGE; SPECIFICITY; PITUITARY	Dynorphin B (Dyn B-13, also known as rimorphin) is generated from Dyn B-29 (leumorphin) by the cleavage at a single Arg residue. An enzymatic activity capable of processing at this monobasic site has been previously reported in neurosecretory vesicles of the bovine pituitary and pituitary-derived cell lines. This enzyme termed ''the dynorphin-converting enzyme'' (DCE) has been purified to apparent homogeneity from the neurointermediate lobe of the bovine pituitary using hydrophobic chromatography on phenyl-Sepharose, preparative isoelectrofocusing in a granulated gel between pH 4 to 6.5, and non-denaturing electrophoresis on 5% polyacrylamide gel, DCE exhibits a pI of about 5.1 and a molecular mass of about 54 kDa under reducing conditions. DCE is a metallopeptidase and exhibits a neutral pH optimum. Specific Inhibitors of soluble metallopeptidases such as enkephalinase (EC 3.4.24.11) or enkephalin generating neutral endopeptidase (EC 3.4.24.15) do not inhibit DCE activity indicating that DCE is distinct from these two enzymes. Cleavage site determination with matrix-assisted laser desorption ionization time of flight (MALDITOF) mass spectrometry shows that DCE cleaves the Dyn B-29 N terminus to the Arg(14) generating Dyn B-13 and Dyn B-(14-29). Among other peptides derived from Dyn B-29, DCE cleaves only those peptides that fit the predicted ''consensus motif'' for monobasic processing. These data are consistent with a broader role for the dynorphin converting enzyme in the biosynthesis of many peptide hormones and neuropeptides by processing at monobasic sites.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; ESCOLA PAULISTA MED, BR-04044020 SAO PAULO, BRAZIL	New York University; Universidade Federal de Sao Paulo (UNIFESP)			Devi P, Lakshmi/GXM-5982-2022; Juliano, Luiz/D-7204-2012	Devi P, Lakshmi/0000-0001-9274-4776; Juliano, Luiz/0000-0002-5589-2822	NIDA NIH HHS [DA 7254] Funding Source: Medline; NINDS NIH HHS [NS K04 1788, NS 26880] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880, K04NS001788, R29NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007254] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BERMAN YL, 1994, BIOCHIMIE, V76, P245, DOI 10.1016/0300-9084(94)90153-8; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1991, J NEUROCHEM, V56, P320, DOI 10.1111/j.1471-4159.1991.tb02598.x; DEVI L, 1985, BIOCHEM BIOPH RES CO, V130, P1168, DOI 10.1016/0006-291X(85)91738-3; DEVI L, 1984, P NATL ACAD SCI-BIOL, V81, P1892, DOI 10.1073/pnas.81.6.1892; DEVI L, 1993, ENDOCRINOLOGY, V132, P1139, DOI 10.1210/en.132.3.1139; DEVI L, 1994, J NEUROCHEM, V62, P2387; DEVI L, 1992, ENDOCRINOLOGY, V131, P1930, DOI 10.1210/en.131.4.1930; DIRKSEN ML, 1972, SEPAR SCI, V7, P747, DOI 10.1080/00372367208057980; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; FRICKER LD, 1995, IN PRESS PHARM OPIOI; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GRECO L, 1992, NEUROENDOCRINOLOGY, V55, P351, DOI 10.1159/000126136; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JULIANO L, 1990, BIOCHEM BIOPH RES CO, V173, P647, DOI 10.1016/S0006-291X(05)80084-1; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LC, 1978, ANAL BIOCHEM, V86, P655, DOI 10.1016/0003-2697(78)90792-3; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PETANCESKA S, 1993, MOL CELL ENDOCRINOL, V94, P37, DOI 10.1016/0303-7207(93)90049-P; RELTON JM, 1983, BIOCHEM J, V215, P519, DOI 10.1042/bj2150519; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SERIZAWA A, 1995, J BIOL CHEM, V270, P2092, DOI 10.1074/jbc.270.5.2092; SILBERRING J, 1992, J BIOL CHEM, V267, P21324; SILBERRING J, 1989, J BIOL CHEM, V264, P11082; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TEZAPSIDIS N, 1989, FEBS LETT, V246, P44, DOI 10.1016/0014-5793(89)80250-9; TEZAPSIDIS N, 1994, BIOCHEM J, V301, P607, DOI 10.1042/bj3010607; VIERECK JC, 1992, J BIOL CHEM, V267, P19475; WYPIJ DM, 1988, J BIOL CHEM, V263, P7079; YI Z, 1993, J BIOL CHEM, V268, P5615; [No title captured]	45	18	18	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23845	23850		10.1074/jbc.270.40.23845	http://dx.doi.org/10.1074/jbc.270.40.23845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559562	hybrid			2022-12-25	WOS:A1995RY90900091
J	NAKAYAMA, K; KADOWAKI, T; OKAMOTO, K; YAMAMOTO, K				NAKAYAMA, K; KADOWAKI, T; OKAMOTO, K; YAMAMOTO, K			CONSTRUCTION AND CHARACTERIZATION OF ARGININE-SPECIFIC CYSTEINE PROTEINASE (ARG-GINGIPAIN)-DEFICIENT MUTANTS OF PORPHYROMONAS-GINGIVALIS - EVIDENCE FOR SIGNIFICANT CONTRIBUTION OF ARG-GINGIPAIN TO VIRULENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; EXTRACELLULAR MEMBRANE-VESICLES; TRYPSIN-LIKE-ENZYME; ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; PROTEASE; GENE; DEGRADATION; PURIFICATION; DNA	Arginine-specific cysteine proteinase (Arg-gingipain; formerly, argingipain) is one of the major extracellular proteinases produced by the oral anaerobic bacterium Porphyromonas gingivalis, To determine whether Arg-gingipain is important for periodontopathogenicity of the organism, Arg-gingipain-deficient mutants were constructed via gene disruption by use of suicide plasmid systems, First, Southern hybridization analyses suggested that two separate Arg-gingipain-encoding genes designated rgpA and rgpB existed on 12.5- and 7.8-kilobase pair HindIII chromosomal fragments of P. gingivalis ATCC33277, respectively, rgpA and rgpB single mutants were constructed by mobilization of a suicide plasmid, Then, an rgpA rgpB double mutant was isolated by electroporation with a second suicide plasmid, No proteolytic activity for Arg-gingipain was ob served in either the cell extract or the culture supernatant of the rgpA rgpB mutant, The chemiluminescence response of polymorphonuclear leukocytes, which is closely related to their bactericidal function, was not inhibited by the culture supernatant of the rgpA rgpB mutant, while the wild type parent showed a significant inhibition of the response, The result suggests that Arg-gingipain is responsible for disruption of the function of polymorphonuclear leukocytes, In addition, the rgpA rgpB double mutations caused a marked decrease in the hemagglutination of P. gingivalis, indicating that a major part of the hemagglutinin activity of the organism is associated with the two genes, These findings demonstrate that Arg-gingipain makes a significant contribution to the virulence of P. gingivalis.	KYUSHU UNIV,FAC DENT,DEPT PHARMACOL,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University	NAKAYAMA, K (corresponding author), KYUSHU UNIV,FAC DENT,DEPT MICROBIOL,HIGASHI KU,FUKUOKA 812,JAPAN.							ANDERSON RP, 1977, ANNU REV MICROBIOL, V31, P473, DOI 10.1146/annurev.mi.31.100177.002353; BOURGEAU G, 1992, INFECT IMMUN, V60, P3186, DOI 10.1128/IAI.60.8.3186-3192.1992; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; CHU L, 1991, INFECT IMMUN, V59, P1932, DOI 10.1128/IAI.59.6.1932-1940.1991; CIBOROWSKI P, 1994, J BACTERIOL, V176, P4549, DOI 10.1128/JB.176.15.4549-4557.1994; EDLUND T, 1979, MOL GEN GENET, V173, P115, DOI 10.1007/BF00330301; FELDHAUS MJ, 1991, J BACTERIOL, V173, P4540, DOI 10.1128/JB.173.14.4540-4543.1991; FLETCHER HM, 1994, INFECT IMMUN, V62, P4279, DOI 10.1128/IAI.62.10.4279-4286.1994; FUJIMURA S, 1990, ORAL MICROBIOL IMMUN, V5, P360, DOI 10.1111/j.1399-302X.1990.tb00441.x; GIBBONS RJ, 1960, J BACTERIOL, V80, P164, DOI 10.1128/JB.80.2.164-170.1960; GRENIER D, 1989, ORAL MICROBIOL IMMUN, V4, P12, DOI 10.1111/j.1399-302X.1989.tb00400.x; Grenier Daniel, 1993, P227; KADOWAKI T, 1994, J BIOL CHEM, V269, P21371; KATO T, 1992, J BACTERIOL, V174, P3889, DOI 10.1128/jb.174.12.3889-3895.1992; KILIAN M, 1981, INFECT IMMUN, V34, P757, DOI 10.1128/IAI.34.3.757-765.1981; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON DA, 1992, INFECT IMMUN, V60, P1524, DOI 10.1128/IAI.60.4.1524-1529.1992; LIPPKE JA, 1987, APPL ENVIRON MICROB, V53, P2588, DOI 10.1128/AEM.53.10.2588-2589.1987; MAYRAND D, 1988, MICROBIOL REV, V52, P134, DOI 10.1128/MMBR.52.1.134-152.1988; MEKALANOS JJ, 1983, CELL, V35, P253, DOI 10.1016/0092-8674(83)90228-3; MEYER RJ, 1980, J BACTERIOL, V143, P1362, DOI 10.1128/JB.143.3.1362-1373.1980; NAKAYAMA K, 1994, J BACTERIOL, V176, P1939, DOI 10.1128/jb.176.7.1939-1943.1994; NISHIKATA M, 1991, BIOCHEM BIOPH RES CO, V178, P336, DOI 10.1016/0006-291X(91)91819-X; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; Ono M, 1987, Oral Microbiol Immunol, V2, P77, DOI 10.1111/j.1399-302X.1987.tb00294.x; OTOGOTO JI, 1993, INFECT IMMUN, V61, P117, DOI 10.1128/IAI.61.1.117-123.1993; OTSUKA M, 1987, J PERIODONTAL RES, V22, P491, DOI 10.1111/j.1600-0765.1987.tb02060.x; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; PIKE R, 1994, J BIOL CHEM, V269, P406; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; SCHENKEIN HA, 1988, J PERIODONTAL RES, V23, P187, DOI 10.1111/j.1600-0765.1988.tb01356.x; SHAH HN, 1976, J APPL BACTERIOL, V41, P473, DOI 10.1111/j.1365-2672.1976.tb00660.x; SHAH HN, 1992, J MED MICROBIOL, V36, P239, DOI 10.1099/00222615-36-4-239; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; SHAH HN, 1979, BIOCHEM J, V180, P45, DOI 10.1042/bj1800045; SLOTS J, 1988, J CLIN PERIODONTOL, V13, P570; SMALLEY JW, 1988, ARCH ORAL BIOL, V33, P323, DOI 10.1016/0003-9969(88)90065-9; SMALLEY JW, 1987, J GEN MICROBIOL, V133, P2883; SORSA T, 1987, J PERIODONTAL RES, V22, P375, DOI 10.1111/j.1600-0765.1987.tb01602.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; SUNDQVIST G, 1988, ORAL MICROBIOL IMMUN, V3, P103, DOI 10.1111/j.1399-302X.1988.tb00093.x; TAKEDAEZAKI M, 1993, ARCH BIOCHEM BIOPHYS, V304, P352, DOI 10.1006/abbi.1993.1361; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANWINKELHOFF AJ, 1988, J CLIN PERIODONTOL, V15, P145; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YAMAMOTO K, 1985, J BIOCHEM-TOKYO, V97, P821, DOI 10.1093/oxfordjournals.jbchem.a135122; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YONEDA M, 1990, INFECT IMMUN, V58, P406, DOI 10.1128/IAI.58.2.406-411.1990; YOSHIMOTO H, 1993, ORAL MICROBIOL IMMUN, V8, P208, DOI 10.1111/j.1399-302X.1993.tb00561.x; ZAMBON JJ, 1994, MOLECULAR PATHOGENESIS OF PERIODONTAL DISEASE, P3	52	212	216	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23619	23626		10.1074/jbc.270.40.23619	http://dx.doi.org/10.1074/jbc.270.40.23619			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559528	hybrid			2022-12-25	WOS:A1995RY90900057
J	OLINS, PO; BAUER, SC; BRAFORDGOLDBERG, S; STERBENZ, K; POLAZZI, JO; CAPARON, MH; KLEIN, BK; EASTON, AM; PAIK, K; KLOVER, JA; THIELE, BR; MCKEARN, JP				OLINS, PO; BAUER, SC; BRAFORDGOLDBERG, S; STERBENZ, K; POLAZZI, JO; CAPARON, MH; KLEIN, BK; EASTON, AM; PAIK, K; KLOVER, JA; THIELE, BR; MCKEARN, JP			SATURATION MUTAGENESIS OF HUMAN INTERLEUKIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; HEMATOPOIETIC GROWTH-FACTORS; ESCHERICHIA-COLI; GM-CSF; RECEPTOR ACTIVATION; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; FOREIGN GENES; PROTEIN; BINDING	A deletion variant of human interleukin-3, hIL-3(15-125), was produced in the periplasmic space of Escherichia coli and had full activity in an AML193.1.3 cell proliferation assay. Libraries of random single-amino acid substitutions were constructed at each of 105 positions in the gene for hIL-3(15-125). Approximately eight single-site substitutions at each position were produced in osmotic shock fractions and screened for activity, 15 mutants were found with bioactivity of 5-26-fold greater than that of native hIL-3. The majority of amino acids in hIL-3(15-125) could be substituted without substantial loss of activity. Substitution of residues predicted to be in the hydrophobic core of the protein often resulted in reduced activity and/or low accumulation levels. Only five residues predicted to be on the surface of the protein were intolerant of substitution and hence are candidates for sites of interaction with the receptor. We therefore propose that the majority of residues in hIL-3 serve a structural role and permit the display of a few key residues in the correct configuration for recognition by the receptor.	MONSANTO CO, SEARLE RES & DEV, ST LOUIS, MO 63198 USA	Monsanto; Pfizer								BAGLEY CJ, 1994, J CELL BIOCHEM, P17; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BIESMA B, 1992, BLOOD, V80, P1141; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DORSSERS LCJ, 1991, J BIOL CHEM, V266, P21310; EASTON AM, 1991, GENE, V101, P291, DOI 10.1016/0378-1119(91)90426-C; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FENG YQ, 1995, BIOCHEMISTRY-US, V34, P6540, DOI 10.1021/bi00019a036; GIANNI AM, 1993, ANN ONCOL, V4, P759, DOI 10.1093/oxfordjournals.annonc.a058661; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GREENFIELD L, 1978, P NATL ACAD SCI USA, V75, P4724, DOI 10.1073/pnas.75.10.4724; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KAUSHANSKY K, 1993, BLOOD, V82, P3229; KAUSHANSKY K, 1992, PROTEINS, V12, P1, DOI 10.1002/prot.340120102; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLEIN BK, 1991, BIO-TECHNOL, V9, P869, DOI 10.1038/nbt0991-869; KRISHNAN IS, 1994, FEBS LETT, V353, P185, DOI 10.1016/0014-5793(94)01017-X; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LEE SC, 1992, J BIOL CHEM, V267, P2849; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J BIOL CHEM, V266, P10624; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; MANAVALAN P, 1992, J PROTEIN CHEM, V11, P321, DOI 10.1007/BF01024870; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; METCALF D, 1993, BLOOD, V82, P3515; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NEU HC, 1965, J BIOL CHEM, V240, P3685; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P5145, DOI 10.1021/bi00070a025; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHORTLE D, 1992, Q REV BIOPHYS, V25, P205, DOI 10.1017/S0033583500004674; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; WLODAWER A, 1993, PROTEIN SCI, V2, P1373, DOI 10.1002/pro.5560020902; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	60	37	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23754	23760		10.1074/jbc.270.40.23754	http://dx.doi.org/10.1074/jbc.270.40.23754			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559548	hybrid			2022-12-25	WOS:A1995RY90900077
J	HAWLEY, RG; FONG, AZC; NGAN, BY; HAWLEY, TS				HAWLEY, RG; FONG, AZC; NGAN, BY; HAWLEY, TS			HEMATOPOIETIC TRANSFORMING POTENTIAL OF ACTIVATED RAS IN CHIMERIC MICE	ONCOGENE			English	Article						RAS ONCOGENE; LEUKEMOGENESIS; MSCV RETROVIRAL VECTOR	ACUTE MYELOID-LEUKEMIA; MURINE SARCOMA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL ANTIGEN RECEPTOR; MODIFIED BONE-MARROW; V-HA-RAS; NUCLEOTIDE-SEQUENCE; GENE-TRANSFER; MYELOPROLIFERATIVE DISEASE	Although activating mutations in ras genes are the most common genetic abnormality in human hematologic malignancies, the role of ras mutations as an initiating event in leukemogenesis remains unclear, To assess the consequences of ectopic expression of an activated ras gene in normal hematopoietic cells in vivo, lethally irradiated mice were reconstituted with bone marrow cells infected with a mutant ras-containing retrovirus [murine stem cell virus (MSCV)-v-H-ras] based on the MSCV retroviral vector which efficiently transduces functional genes into hematopoietic stem/progenitor cells, Despite a marked myeloid leukocytosis detectable in the peripheral blood within 4 weeks of engraftment, none of 22 primary or secondary transplant recipients studied for longer periods of time presented with myeloid neoplasms, Instead, 18 of the MSCV-v-H-ras mice developed pre-T-celI thymic lymphomas and/or pre-B-cell lymphoblastic leukemia/lymphomas between 7 and 12 weeks post-transplantation. The pre-B and pre-T lymphoid tumors that arose in one animal were shown to harbor a; common MSCV-v-H-ras provirus, indicating that the target cell for transformation was a bipotential lymphoid precursor. To more precisely examine the effects of activated ras expression on the behavior of hematopoietic progenitors, infected bone marrow cells were assayed in methylcellulose cultures under conditions favorable for growth of multilineage myeloid colonies or were passaged as bulk suspension cultures in the presence of various hematopoietic growth factors, including interleukin (IL)-3, IL-4, IL-6 and IL-7. MSCV-directed expression of v-H-ras selectively promoted the formation of large dense colonies comprised of monocyte-macrophages in methylcellulose cultures. When transferred to liquid cultures, the vast majority of the cells underwent terminal macrophage differentiation, By comparison, tumorigenic B-lymphoid and mixed lymphoid/myeloid cell lines were routinely established from the bulk suspension cultures, with cell lines of predominantly myeloid phenotype emerging only in IL-6-supplemented cultures/ These results, considered together with previous findings, suggest that activating ras mutations could be an initiating genetic alteration in human acute lymphoblastic leukemia but are more Likely to be a postinitiation change in human acute myeloid leukemia.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT PATHOL, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	HAWLEY, RG (corresponding author), UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, 2075 BAYVIEW AVE, TORONTO, ON M4N 3M5, CANADA.			Hawley, Robert/0000-0003-3512-5818				ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; AHUJA HG, 1990, BLOOD, V75, P1684; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; ANTICA M, 1994, BLOOD, V84, P111; BASHEY A, 1992, BLOOD, V79, P981; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; COGSWELL PC, 1989, BLOOD, V74, P2629; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRANZ T, 1985, NATURE, V315, P149, DOI 10.1038/315149a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOODWIN RG, 1991, CYTOKINE HDB, P191; HAGAG N, 1990, ONCOGENE, V5, P1481; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HARRIS JF, 1992, J IMMUNOL METHODS, V148, P199, DOI 10.1016/0022-1759(92)90173-Q; HAUPT Y, 1992, ONCOGENE, V7, P981; HAWLEY RG, 1994, ONCOGENE, V9, P1; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1994, STEM CELLS, V12, P155; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Hawley RG, 1995, ANN NY ACAD SCI, V762, P294; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HAWLEY TS, 1991, CYTOKINE, V3, P60, DOI 10.1016/1043-4666(91)90011-2; HIBI S, 1993, BLOOD, V81, P1841; HIRSCHGINSBERG C, 1990, BLOOD, V76, P1214; HOANG T, 1988, BLOOD, V72, P823; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; IWAMOTO A, 1987, J EXP MED, V165, P591, DOI 10.1084/jem.165.3.591; JACOBSON DR, 1994, ONCOGENE, V9, P553; KALEKO M, 1990, BLOOD, V75, P1733; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAWAKAMI T, 1980, NUCLEIC ACIDS RES, V8, P3933, DOI 10.1093/nar/8.17.3933; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KISHNER MB, 1994, P NATL ACAD SCI USA, V76, P253; LEONARD EJ, 1990, BIOTECHNIQUES, V9, P684; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUBBERT M, 1992, ONCOGENE, V7, P263; LUBBERT M, 1990, BLOOD, V75, P1163; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; MAYER A, 1982, NATURE, V295, P253; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NAOE T, 1993, BLOOD, V82, P2260, DOI 10.1182/blood.V82.7.2260.bloodjournal8272260; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEUBAUER A, 1994, BLOOD, V83, P1603; OVERELL RW, 1989, ONCOGENE, V4, P1425; PAQUETTE RL, 1993, BLOOD, V82, P590, DOI 10.1182/blood.V82.2.590.bloodjournal822590; PATTENGALE PK, 1983, AM J PATHOL, V113, P235; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; PRICE CM, 1994, BRIT J HAEMATOL, V88, P338, DOI 10.1111/j.1365-2141.1994.tb05028.x; RADICH JP, 1990, BLOOD, V76, P801; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SIRINIAN MI, 1993, ONCOGENE, V8, P157; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; WILLIAMS DA, 1990, HUM GENE THER, V1, P229, DOI 10.1089/hum.1990.1.3-229; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617	78	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1113	1123						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566971				2022-12-25	WOS:A1995RX18000014
J	OBEYESEKERE, MN; HERBERT, JR; ZIMMERMAN, SO				OBEYESEKERE, MN; HERBERT, JR; ZIMMERMAN, SO			A MODEL OF THE G1 PHASE OF THE CELL-CYCLE INCORPORATING CYCLIN E/CDK2 COMPLEX AND RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article						CYCLIN E; CDK2; RB; G1; CELL CYCLE; MATHEMATICAL MODELS	SUSCEPTIBILITY GENE-PRODUCT; MAMMALIAN FIBROBLASTS; DNA-REPLICATION; DEPHOSPHORYLATION; PHOSPHORYLATION; BINDING; GROWTH; IDENTIFICATION; PROGRESSION; EXPRESSION	A mathematical model of cyclin E, cdk2 and retinoblastoma protein control of the G1 phase of the human cell cycle is proposed. The model includes retinoblastoma (Rb) protein phosphorylation by a cyclin E/cdk2 complex and its subsequent dephosphorylation at the end of the cell cycle. The numerical solutions to this model demonstrates the cyclic behavior of the cyclin E/cdk2 complex, with and without Rb function, cell cycle. This model suggests an inhibition of cyclin E/cdk2 complex formation (or its activation) by hypophosphorylated retinoblastoma protein. The experimental results of cell cycle arrest upon injection of transforming growth factor-beta, alpha-interferon or D-erythro-sphingosine during G1 phase are reproduced. Cell cycle behavior predicted by this model for increasing the concentration of hypophosphorylated retinoblastoma protein during the G1 phase is discussed. Additional results are obtained by numerical simulation.	UNIV TEXAS,SCH MED,HOUSTON,TX	University of Texas System	OBEYESEKERE, MN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH,BOX 237,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BYBEE A, 1993, CELL CYCLE 93 REGULA; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHAO R, 1992, J BIOL CHEM, V267, P23459; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, CELL CYCLE 93 REGULA; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521; OBEYESEKERE MN, 1994, CELL PROLIFERAT, V27, P105, DOI 10.1111/j.1365-2184.1994.tb01409.x; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REED SI, 1991, COLD SH Q B, V56, P61; REED SI, 1992, P AM ASSOC CANC RES, V33, pA574; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL CYCLE 93 REGULA; TYSON JJ, 1991, P NATL ACAD SCI USA, V88, P7328, DOI 10.1073/pnas.88.16.7328; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1199	1205						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566981				2022-12-25	WOS:A1995RX18000024
J	BOGOYEVITCH, MA; MARSHALL, CJ; SUGDEN, PH				BOGOYEVITCH, MA; MARSHALL, CJ; SUGDEN, PH			HYPERTROPHIC AGONISTS STIMULATE THE ACTIVITIES OF THE PROTEIN-KINASES C-RAF AND A-RAF IN CULTURED VENTRICULAR MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC GENE-EXPRESSION; MAP KINASE; SIGNAL-TRANSDUCTION; PARACRINE MECHANISM; CELL HYPERTROPHY; MYOCARDIAL-CELLS; PHORBOL ESTERS; ACTIVATION; PATHWAY; CAMP	We detected expression of two Raf isoforms, c-Raf and A Raf, in neonatal rat heart, Both isoforms phosphorylated, activated, and formed complexes with mitogen-activated protein kinase kinase 1 in vitro. However, these isoforms were differentially activated by hypertrophic stimuli such as peptide growth factors, endothelin-l (ET1), or 12-O-tetradecanoylphorbol-13-acetate (TPA) that activate the mitogen-activated protein kinase cascade, Exposure of cultured ventricular myocytes to acidic fibroblast growth factor activated c-Raf but not A-Raf, In contrast, TPA produced a sustained activation of A-Raf and only transiently activated c-Raf. ET1 transiently activated both isoforms. TPA and ET1 were the most potent activators of c-Raf and A-Raf. Both utilized protein kinase C dependent pathways, but stimulation by ET1 was also partially sensitive to pertussis toxin pretreatment. c-Raf was inhibited by activation of cAMP-dependent protein kinase although A-Raf was less affected. Fetal calf serum, phenylephrine, and carbachol were less potent activators of c-Raf and A-Raf. These results demonstrate that A-Raf and c-Raf are differentially regulated and that A-Raf may be an important mediator of mitogen activated protein kinase cas cade activation when cAMP is elevated.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND	Imperial College London	BOGOYEVITCH, MA (corresponding author), INST CANC RES, CHESTER BEATTY LABS, CRC, CTR CELL & MOLEC BIOL, 237 FULHAM RD, LONDON SW3 6JB, ENGLAND.			Bogoyevitch, Marie/0000-0001-9745-3716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOGOYEVITCH MA, 1993, AM J PHYSIOL, V265, pC1247, DOI 10.1152/ajpcell.1993.265.5.C1247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLERK A, 1994, J BIOL CHEM, V269, P32848; CLERK A, 1995, IN PRESS AM J PHYSL; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOMEZ N, 1992, FEBS LETT, V314, P461, DOI 10.1016/0014-5793(92)81527-S; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MARAIS R, 1945, MEBO J, V14, P3136; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STORM SM, 1990, ONCOGENE, V5, P345; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOTJEK AB, 1993, CELL, V74, P205; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	100	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26303	26310		10.1074/jbc.270.44.26303	http://dx.doi.org/10.1074/jbc.270.44.26303			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592840	hybrid			2022-12-25	WOS:A1995TC97800047
J	MONDINO, A; JENKINS, MK				MONDINO, A; JENKINS, MK			ACCUMULATION OF SEQUENCE-SPECIFIC RNA-BINDING PROTEINS IN THE CYTOSOL OF ACTIVATED T-CELLS UNDERGOING RNA DEGRADATION AND APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH SEQUENCES; MESSENGER-RNA; CYCLOSPORINE-A; LYMPHOCYTES-T; CYCLE BLOCK; DEATH; DNA; DEOXYRIBONUCLEASE; GLUCOCORTICOIDS	Engagement of the T cell antigen receptor (TCR) causes transformed T cell hybridomas to produce lymphokines and then die by an apoptotic mechanism, Here we show that these functional effects of TCR-mediated signaling are associated with the accumulation of several cytosolic mRNA binding proteins including the previously described AU-A, -B, and -C proteins as well as a novel 70-kDa protein. The results indicate that the 70-kDa protein derived from a 90-kDa precursor present in unactivated T cells and that both proteins bound to two independent sites at the 3'-end of the interleukin-a mRNA, one in the coding region and the other in an AU-rich segment of the S'-untranslated region. Glucocorticoids, TCR engagement by monoclonal antibodies, pharmocologic mimics of TCR signaling, or high concentrations of protein or RNA synthesis inhibitors all induced apoptosis, the cytosolic appearance of the RNA-binding proteins, and an increased rate of RNA turnover, Moreover, drugs that interfere with TCR-mediated signals, such as cyclosporin A and staurosporin, prevented both apoptosis and the appearance of the RNA-binding factors. The fact that the accumulation of these factors occurred in the presence of inhibitors of transcription and translation suggested that these proteins are present in an inactive form in unstimulated T cells and are activated when apoptosis is induced.			MONDINO, A (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455, USA.		Mondino, Anna/K-9434-2016; Jenkins, Marc K/G-1063-2012	Mondino, Anna/0000-0003-0833-6927; Jenkins, Marc K/0000-0001-8009-7655	NIAID NIH HHS [AI-27998] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027998, R01AI027998] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; ASHWELL JD, 1994, HDB B T LYMPHOCYTES, P63; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HECHT TT, 1983, J IMMUNOL, V131, P1049; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HOBERT O, 1994, J BIOL CHEM, V269, P20225; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSTEN T, 1989, SCIENCE, V144, P339; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARTIN SJ, 1993, IMMUNOL LETT, V35, P125, DOI 10.1016/0165-2478(93)90080-L; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MERCEP M, 1989, J IMMUNOL, V142, P4085; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PERANDONES CE, 1993, J IMMUNOL, V151, P3521; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHYU AB, 1991, GENE DEV, V3, P60; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; UCKER DS, 1989, J IMMUNOL, V143, P3461; UMLAF S, IMMUNOL REV, V133, P177; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3857	50	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26593	26601		10.1074/jbc.270.44.26593	http://dx.doi.org/10.1074/jbc.270.44.26593			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592882	hybrid			2022-12-25	WOS:A1995TC97800089
J	TUMA, PL; COLLINS, CA				TUMA, PL; COLLINS, CA			DYNAMIN FORMS POLYMERIC COMPLEXES IN THE PRESENCE OF LIPID VESICLES - CHARACTERIZATION OF CHEMICALLY CROSS-LINKED DYNAMIN MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; SEA-URCHIN EGGS; CYTOPLASMIC DYNEIN; GTPASE; PURIFICATION; ACTIVATION; DOMAINS	Dynamin is a GTP-binding protein that is involved in the release of coated endocytic vesicles from the plasma membrane, We have been characterizing the enzymatic properties of purified rat brain dynamin to better understand how GTP binding and hydrolysis relate to its proposed function, Previously, we have demonstrated that activation of dynamin GTPase results from positive cooperative associations between dynamin molecules as they are bound to a polymeric surface, Our present report has extended these studies and has examined the structural features of dynamin self association. After treatment with the zero length protein cross-linking reagent, 1-ethyl-3-[3-(dimethylamino)propyl]carbo ide, dynamin in solution was found cross linked into dimers, This homodimer likely reflects the native soluble state of the molecule, After binding to brain vesicles, dynamin was cross-linked into higher order oligomers of greater than 800 kDa, Dynamin, copurified on brain membranous organelles, also formed multimeric complexes when cross-linked suggesting dynamin exists in polymeric form in vivo. No cross linked species other than homo-oligomers were observed, providing no evidence for close interactions between dynamin and membrane proteins, From experiments examining the effects of GTP, GDP, guanosine 5'-3-O-(thio)triphosphate, and 5'-guanylyl-beta,gamma-imidodiphosphate on cross-linking, we have determined that both dynamin membrane binding and self-association occur independently from the nucleotide-bound state of the enzyme, An 80-kDa dynamin fragment that is lacking its carboxyl-terminal domain is not cross-linked into higher order oligomers, suggesting that this domain is required for binding of dynamin to membranes and the subsequent enhancement of oligomerization, However, the dynamin fragment was found to form dimers indicating that this domain is not required for dynamin dimerization, Cross linked dynamin was able to cooperatively bind microtubules, but did not exhibit GTPase activation, We propose that intramolecular cross links in the dynamin monomer impart structural constraints that prevent the enhancement of GTP hydrolysis, We describe a model of the dynamin activation process to be considered in further investigations of the role for dynamin in endocytic vesicle formation.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL 60611 USA	Northwestern University								Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; COLLINS CA, 1986, P NATL ACAD SCI USA, V83, P4799, DOI 10.1073/pnas.83.13.4799; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JP, 1994, J BIOL CHEM, V269, P21043; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHIMIZU T, 1989, BIOCHEMISTRY-US, V28, P7016, DOI 10.1021/bi00443a035; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; STACHNIAK MC, 1989, J CELL BIOL, V111, pA291; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	28	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26707	26714		10.1074/jbc.270.44.26707	http://dx.doi.org/10.1074/jbc.270.44.26707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592898	hybrid			2022-12-25	WOS:A1995TC97800105
J	WANG, YJ; MEHTA, PP; ROSE, B				WANG, YJ; MEHTA, PP; ROSE, B			INHIBITION OF GLYCOSYLATION INDUCES FORMATION OF OPEN CONNEXIN-43 CELL-TO-CELL CHANNELS AND PHOSPHORYLATION AND TRITON X-100 INSOLUBILITY OF CONNEXIN-43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; MEMBRANE CHANNEL; COMMUNICATION; LIVER; EXPRESSION; GROWTH; GENE	We transfected the cDNA for the cell-to-cell channel protein connexin 43 (Cx43) into Morris hepatoma H5123 cells, which express little Cx43 and lack gap junctional communication (open cell-to-cell channels). We found that cells overexpressing Cx43 nonetheless lacked open cell-to-cell channels, but that inhibition of glycosylation by tunicamycin induced open channels in these cells. Tunicamycin also induced biochemical changes in Cx43 protein; the level increased, and a considerable fraction became phosphorylated and Triton X-100 insoluble, in contrast to untreated cells where Cx43 was non-phosphorylated and Triton X-100 soluble. Although tunicamycin caused the formation of open channels, channels were not found aggregated into gap junctional plaques, as they are when they have been induced by elevation of intracellular cAMP. The results suggest that although Cx43 itself is not glycosylated, other glycosylated proteins influence Cx43 posttranslational modification and the formation of Cx43 cell-to cell channels.	UNIV MIAMI,SCH MED,DEPT PHYSIOL & BIOPHYS,MIAMI,FL 33101; UNIV MIAMI,SCH MED,SYLVESTER COMPREHENS CANC CTR,DEPT MED,MIAMI,FL 33101; VET ADM MED CTR,CTR CLIN,MIAMI,FL 33101	University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA 14464-21] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABNEY JR, 1987, BIOPHYS J, V52, P441, DOI 10.1016/S0006-3495(87)83233-2; AZARNIA R, 1981, J MEMBRANE BIOL, V63, P133, DOI 10.1007/BF01969454; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOREK C, 1969, J MEMBRANE BIOL, V1, P274, DOI 10.1007/BF01869786; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DERMIETZEL R, 1987, J HISTOCHEM CYTOCHEM, V35, P387, DOI 10.1177/35.3.3029214; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; GOODENOUGH DA, 1970, J CELL BIOL, V45, P272, DOI 10.1083/jcb.45.2.272; HERTZBERG EL, 1979, J BIOL CHEM, V254, P2138; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KREUTZIGER GO, 1968, 26TH P EL MICR SOC A, P234; Kumar N M, 1992, Semin Cell Biol, V3, P3; LEVINE E, 1991, AM J PHYSIOL, V261, pC1025; LIN SS, 1987, SCIENCE, V237, P648, DOI 10.1126/science.3603045; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MEHTA PP, 1992, MOL BIOL CELL, V3, P839, DOI 10.1091/mbc.3.8.839; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MICEVYCH PE, 1991, J COMP NEUROL, V305, P96, DOI 10.1002/cne.903050110; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; PERACCHIA C, 1985, ENZYMES BIOL MEMBR, V1, P81; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; REVEL J. P., 1967, J CELL BIOL, V33, P7; SCHWARZMANN G, 1981, SCIENCE, V213, P551, DOI 10.1126/science.7244653; WANG YJ, 1995, EUR J CELL BIOL, V67, P285; Warner A., 1992, Seminars in Cell Biology, V3, P81	32	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26581	26585		10.1074/jbc.270.44.26581	http://dx.doi.org/10.1074/jbc.270.44.26581			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592880	hybrid			2022-12-25	WOS:A1995TC97800087
J	ZANCHIN, NIT; MCCARTHY, JEG				ZANCHIN, NIT; MCCARTHY, JEG			CHARACTERIZATION OF THE IN-VIVO PHOSPHORYLATION SITES OF THE MESSENGER-RNA-CENTER-DOT-CAP-BINDING COMPLEX PROTEINS EUKARYOTIC INITIATION FACTOR-4E AND P20 IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; RNA 5' CAP; TRANSLATIONAL CONTROL; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; ESCHERICHIA-COLI; FACTOR EIF-4E; FACTOR 4E; YEAST; PURIFICATION	Eukaryotic translation is believed to be regulated via the phosphorylation of specific eukaryotic initiation factors (eIFs), including one of the cap-binding complex proteins, eIF-4E. We show that in the yeast Saccharomyces cerevisiae, both eIF-4E and another cap-binding complex protein, p20, are phosphoproteins. The major sites of phosphorylation of yeast eIF-4E are found to be located in the N-terminal region of its sequence (Ser(2) and Ser(15)) and are thus in a different part of the protein from the main phosphorylation sites (Ser(53) and Ser(209)) proposed previously for mammalian eIF-4E. The most likely sites of p20 phosphorylation are at Ser(91) and/or Ser(154). All of the major sites in the two yeast proteins are phosphorylated by casein kinase II in vitro. Casein kinase II phosphorylation of cap complex proteins should therefore be considered as potentially involved in the control of yeast protein synthesis. Mutagenesis experiments revealed that yeast eIF-4E activity is not dependent on the presence of Ser(2) or Ser(15). On the other hand, we observed variations in the amount of (phosphorylated) p20 associated with the cap binding complex as a function of cell growth conditions. Our results suggest that interactions of yeast eIF-4E with other phosphorylatable proteins, such as p20, could play a pivotal role in translational control.	NATL BIOTECHNOL RES CTR, DEPT GENE EXPRESS, D-38124 BRAUNSCHWEIG, GERMANY				Zanchin, Nilson Ivo Tonin/AAB-4907-2019	Zanchin, Nilson Ivo Tonin/0000-0002-1153-0694				ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P7520, DOI 10.1093/nar/17.18.7520; ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BELEV TN, 1991, PLASMID, V26, P147, DOI 10.1016/0147-619X(91)90056-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DOBSON MJ, 1983, NUCLEIC ACIDS RES, V11, P2287, DOI 10.1093/nar/11.8.2287; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FEIGENBLUM D, 1993, J VIROL, V67, P3027, DOI 10.1128/JVI.67.6.3027-3035.1993; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; JONES EW, 1977, GENETICS, V85, P23; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG V, 1994, J BIOL CHEM, V269, P6117; LANKER S, 1992, J BIOL CHEM, V267, P21167; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1986, LABORATORY COURSE MA; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; ZHANG Y, 1994, J VIROL, V68, P7040, DOI 10.1128/JVI.68.11.7040-7050.1994	55	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26505	26510		10.1074/jbc.270.44.26505	http://dx.doi.org/10.1074/jbc.270.44.26505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592868	hybrid			2022-12-25	WOS:A1995TC97800075
J	WANG, LL; MUKHERJEE, S; JIA, FG; NARAYAN, O; ZHAO, LJ				WANG, LL; MUKHERJEE, S; JIA, FG; NARAYAN, O; ZHAO, LJ			INTERACTION OF VIRION PROTEIN VPR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH CELLULAR TRANSCRIPTION FACTOR SP1 AND TRANSACTIVATION OF VIRAL LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; GENE; PROMOTER; BINDING; AIDS; REPLICATION; INFECTION; COMPLEX; CELLS; DNA	Acquired immunodeficiency syndrome (AIDS) is a result of replication of the human immunodeficiency virus type 1 (HIV-1) predominantly in CD4(+) T lymphocytes and macrophages. However, most of these cells in vivo are immunologically quiescent, a condition restricting HIV-1 replication. Vpr is an HIV-1 virion protein suspected to enhance HIV-1 replication in vivo. We demonstrate in this report that Vpr specifically activates HIV-1 long terminal repeat (LTR)-directed transcription. This effect is most pronounced on a minimal promoter from HIV-1 LTR containing the TATA box and binding motifs for the ubiquitous cellular transcription factor Sp1. Evidence is presented that Vpr interacts with Sp1 when Sp1 is bound to the Sp1 motifs within the HIV-1 LTR. Both Vpr-Sp1 interaction and Vpr trans-activation require a central Leu/Ile-rich domain in Vpr. Our findings suggest that Vpr trans-activation through Sp1 is most critical for the immediate early transcription of HIV-1 when other positive regulators, such as NF-kappa B, are Limited or inactive, a condition presumably present in vivo. By interacting with Sp1, Vpr also has the potential to influence cellular gene expression and cellular functions. Thus, therapeutic approaches directed toward blocking the Vpr trans-activation function could prove valuable in treating AIDS.	UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,VIRAL PATHOGENESIS LAB,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center								BALOTTA C, 1993, J VIROL, V67, P4409, DOI 10.1128/JVI.67.7.4409-4414.1993; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DEDERA D, 1989, J VIROL, V63, P3205, DOI 10.1128/JVI.63.7.3205-3208.1989; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GREENE WC, 1990, ANNU REV IMMUNOL, V8, P453, DOI 10.1146/annurev.iy.08.040190.002321; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LEVY JA, 1993, MICROBIOL REV, V57, P189; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VIRELIZIER JL, 1990, CURR OPIN IMMUNOL, V2, P409, DOI 10.1016/0952-7915(89)90151-9; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1994, J BIOL CHEM, V269, P15577	33	158	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25564	25569		10.1074/jbc.270.43.25564	http://dx.doi.org/10.1074/jbc.270.43.25564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592727	hybrid			2022-12-25	WOS:A1995TB46600044
J	PATTI, ME; SUN, XJ; BRUENING, JC; ARAKI, E; LIPES, MA; WHITE, MF; KAHN, CR				PATTI, ME; SUN, XJ; BRUENING, JC; ARAKI, E; LIPES, MA; WHITE, MF; KAHN, CR			4PS/INSULIN RECEPTOR SUBSTRATE (IRS)-2 IS THE ALTERNATIVE SUBSTRATE OF THE INSULIN-RECEPTOR IN IRS-1-DEFICIENT MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING COMPLEXES; INTACT-CELLS; PROTEIN; IRS-1; ASSOCIATION; RAT; PHOSPHORYLATION; 3'-KINASE; MUSCLE	Insulin receptor substrate-1 (IRS-1) is the major cytoplasmic substrate of the insulin and insulin-like growth factor (IGF)-1 receptors. Transgenic mice lacking IRS-1 are resistant to insulin and IGF-1, but exhibit significant residual insulin action which corresponds to the presence of an alternative high molecular weight substrate in liver and muscle. Recently, Sun et al. (Sun, X.-J, Wang, L. M., Zhang, Y., Yenush, L. P., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J, H., and White, M. F. (1995) Nature 377, 173-177) purified and cloned 4PS, the major substrate of the IL-4 receptor-associated tyrosine kinase in myeloid cells, which has significant structural similarity to IRS-1. To determine if 4PS is the alternative substrate of the insulin receptor in IRS-1-deficient mice, we performed immunoprecipitation, immunoblotting, and phosphatidylinositol (PI) 3-kinase assays using specific antibodies to 4PS. Following insulin stimulation, 4PS is rapidly phosphorylated in liver and muscle, binds to the p85 subunit of PI 3-kinase, and activates the enzyme. Insulin stimulation also results in the association of 4PS with Grb 2 in both liver and muscle. In IRS-1-deficient mice, both the phosphorylation of 4PS and associated PI 3-kinase activity are enhanced, without an increase in protein expression. Immunodepletion of 4PS from liver and muscle homogenates removes most of the phosphotyrosine-associated PI 3-kinase activity in IRS-1-deficient mice. Thus, 4PS is the primary alternative substrate, i.e. IRS-2, which plays a major role in physiologic insulin signal transduction via both PI 3-kinase activation and Grb 2/Sos association. In IRS-1-deficient mice, 4PS/IRS 2 provides signal transduction to these two major pathways of insulin signaling.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33201, DK43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; FOLLI F, 1992, J BIOL CHEM, V267, P22171; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HADARI YR, 1993, J BIOL CHEM, V268, P9156; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MYERS MG, 1994, J BIOL CHEM, V269, P28783; OKADA T, 1994, J BIOL CHEM, V269, P3568; PONS S, 1995, MOL CELL BIOL, V15, P4453; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V238, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	33	190	191	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24670	24673		10.1074/jbc.270.42.24670	http://dx.doi.org/10.1074/jbc.270.42.24670			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559579	hybrid			2022-12-25	WOS:A1995TB46500013
J	PENG, H; LEVER, JE				PENG, H; LEVER, JE			REGULATION OF NA+-COUPLED GLUCOSE-TRANSPORT IN LLC-PK1 CELLS - MESSAGE STABILIZATION INDUCED BY CYCLIC-AMP ELEVATION IS ACCOMPANIED BY BINDING OF A M(R)=48,000 PROTEIN TO A URIDINE-RICH DOMAIN IN THE 3'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; C-FOS; NA+/GLUCOSE COTRANSPORTER; KINASE; LINE; PHOSPHORYLATION; DIFFERENTIATION; SPECIFICITY; LYMPHOKINE	In an exploration of the molecular basis of cyclic AMP-induced stabilization of Na+/glucose cotransporter mRNA (SGLT1 isoform) accompanying cell differentiation in the pig kidney cell line LLC-PK1, we have identified a 48-kDa cytoplasmic protein factor, designated SG-URBP, which specifically binds a 120-nucleotide sequence within the 3'-untranslated region of the SGLT1 message. A 46-nucleotide uridine-rich element within this region appears necessary for specific binding, and the presence of the 3'-untranslated region is necessary for message stabilization by cyclic AMP. The binding activity of SG-URBP is up-regulated after cyclic AMP elevation and protein kinase A activation, whereas protein dephosphorylation either in vivo or in vitro is associated with loss of binding activity. The increase in SG-URBP binding activity correlates with an increase in the half-life of the SGLT1 message, suggesting a cause and effect relationship.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System					NIDDK NIH HHS [DK 27400] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027400, R01DK027400] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; AMSLER K, 1991, AM J PHYSIOL, V260, pC1290, DOI 10.1152/ajpcell.1991.260.6.C1290; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; ATKINS RE, 1992, BIOTECHNIQUES, V12, P496; Belasco J.G., 2012, CONTROL MESSENGER RN; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, IN PRESS TRENDS BIOC; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG LY, 1993, J BIOL CHEM, V268, P25769; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; LEVER JE, 1989, ENVIRON HEALTH PERSP, V80, P173, DOI 10.2307/3430742; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Maniatis T, 1989, DECONTAMINATION DILU; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PENG H, 1993, J CELL PHYSIOL, V154, P238, DOI 10.1002/jcp.1041540205; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WRIGHT EM, 1993, ANNU REV PHYSIOL, V55, P575, DOI 10.1146/annurev.ph.55.030193.003043; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315; YONEYAMA Y, 1984, J CELL PHYSIOL, V121, P64, DOI 10.1002/jcp.1041210109; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	40	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23996	24003		10.1074/jbc.270.41.23996	http://dx.doi.org/10.1074/jbc.270.41.23996			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592596	hybrid			2022-12-25	WOS:A1995TA21700024
J	OTOOLE, GA; ESCALANTESEMERENA, JC				OTOOLE, GA; ESCALANTESEMERENA, JC			PURIFICATION AND CHARACTERIZATION OF THE BIFUNCTIONAL COBU ENZYME OF SALMONELLA-TYPHIMURIUM LT2 - EVIDENCE FOR A COBU-SIMILAR-TO-GMP INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENESIS; POLYMERASE; GENES; DNA	The CobU protein of Salmonella typhimurium was overexpressed and purified to similar to 94% homogeneity. N-terminal sequencing of purified CobU confirmed the first 22 amino acids, In vitro assays showed that CobU has kinase and guanylyltransferase activities which catalyze the synthesis of adenosyl-cobinamide-GDP from adenosyl-cobinamide, via an adenosyl-cobinamide-phosphate intermediate. We present evidence that the transfer of the guanylyl moiety of GTP to adenosyl-cobinamide-phosphate proceeds via an phosphoramidate linked, enzyme guanylyl intermediate, In the presence of oxygen, kinase and guanylyltransferase activities of CobU were lost. Treatment of inactive CobU with dithiothreitol restored similar to 20% of the kinase and guanylyltransferase activities, indicating the involvement of sulfhydryl groups in enzyme activity. The sulfhydryl modifying agents 5,5'-dithiobis(2-nitro-benzoic acid) and N-ethylmaleimide abolished both CobU activities, Native CobU protein was a dimer (similar to 40 kDa) that functioned optimally at pH 8.8-9.0 and 37 degrees C, Substrates and kinetic parameters for both activities were determined, The preferred corrinoid substrate for this enzyme was adenosyl-cobinamide. In vitro experiments are consistent with previous genetic studies which had suggested that adenosyl-cobinamide was the preferred substrate of CobU, and that CobU functioned more efficiently in the absence of oxygen.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040313, R01GM040313] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040313, GM40313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOVITCH J, 1962, BIOCHEM BIOPH RES CO, V8, P416, DOI 10.1016/0006-291X(62)90288-7; BLANCHE F, 1991, J BACTERIOL, V473, P6052; BOLLAG DM, 1991, PROTEIN METHODS, P162; DEBUSSCHE L, 1991, J BACTERIOL, V173, P6300, DOI 10.1128/jb.173.19.6300-6302.1991; ESCALANTESEMERE.JC, 1990, J BACTERIOL, V172, P273; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; GILESGONZALEZ MA, 1991, NATURE, V350, P170; HABEEB AFS, 1992, MEHTODS ENZYMOL, V25, P457; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; KUNKEL T, 1987, CURRENT PROTOCOLS MO, V1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; OTOOLE GA, 1993, J BACTERIOL, V175, P317; RONZIO RA, 1967, BIOCHEMISTRY-US, V6, P2344, DOI 10.1021/bi00860a009; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO, V2; TRZEBIATOWSKI JR, 1994, J BACTERIOL, V176, P3568, DOI 10.1128/JB.176.12.3568-3575.1994; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VITOLS E, 1966, J BIOL CHEM, V241, P1455; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WONG LJ, 1977, BIOCHEMISTRY-US, V16, P1010, DOI 10.1021/bi00624a032	28	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23560	23569		10.1074/jbc.270.40.23560	http://dx.doi.org/10.1074/jbc.270.40.23560			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559521	hybrid			2022-12-25	WOS:A1995RY90900050
J	REZZONICO, R; LOUBAT, A; LALLEMAND, D; PFARR, CM; FAR, DF; PROUDFOOT, A; ROSSI, B; PONZIO, G				REZZONICO, R; LOUBAT, A; LALLEMAND, D; PFARR, CM; FAR, DF; PROUDFOOT, A; ROSSI, B; PONZIO, G			CYCLIC-AMP STIMULATES A JUND/FRA-2 AP-1 COMPLEX AND INHIBITS THE PROLIFERATION OF INTERLEUKIN-6-DEPENDENT CELL-LINES	ONCOGENE			English	Article						ANTIPROLIFERATIVE EFFECT; AP-1; CYCLIC AMP; FRA-2; JUN D; INTERLEUKIN-6	TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; C-JUN; MACROPHAGE DIFFERENTIATION; GENE-TRANSCRIPTION; ENHANCER ACTIVITY; GROWTH-HORMONE; NUCLEAR FACTOR; PHORBOL ESTER; FOS	Interleukin-6 (IL-6) is a proinflammatory cytokine which also acts as a growth factor for some murine hybridomas (7TD1) or human myelomas (U266). We demonstrate that elevation of cAMP cellular content inhibits IL-6-stimulated cell growth, by blocking cells mainly in G1 phase. This inhibition is associated with increased expression of the Fos family protein Fra-2. Treatment of cells with 8Br-cAMP results in increased DNA-binding activity of two distinct AP-1 complexes; JunD/Fra-2 and JunB/Fra-2, and also in elevated AP-1 transactivation. When 8Br-cAMP is withdrawn from the medium, cells enter S phase and Fra-2 protein levels and AP-1 DNA-binding activity decrease to their basal value indicating that a temporally correlation exists between the 8Br-cAMP-mediated induction of JunD/Fra-2 AP-1 complex and the 7TD1 and U266 cell growth inhibition.	FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,ONCOGEN VIRUSES UNIT,F-75724 PARIS 15,FRANCE; GLAXO INST MOLEC BIOL SA,GENEVA,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline			Ponzio, Gilles/Q-1256-2016; Pfarr, Curt/HHD-1410-2022; lallemand, dominique/O-7445-2017; REZZONICO, Roger/N-9626-2016	Ponzio, Gilles/0000-0003-2741-0248; lallemand, dominique/0000-0002-0212-7342; REZZONICO, Roger/0000-0002-8460-1641				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V129, P1072; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GRUDA MC, 1994, ONCOGENE, V9, P2537; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUMAR G, 1994, J IMMUNOL, V153, P4436; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUI M, 1990, ONCOGENE, V5, P249; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NATSUKA S, 1992, BLOOD, V79, P460; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHWAB G, 1991, BLOOD, V77, P587; STANKOVA J, 1992, BIOCHEM J, V282, P625; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAMIR A, 1994, J IMMUNOL, V152, P3391; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9676; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGENKA UM, 1994, MOL CELL BIOL, V14, P1386; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOLLBERG P, 1994, J BIOL CHEM, V269, P19719; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	70	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1069	1078						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566966				2022-12-25	WOS:A1995RX18000009
J	SALGIA, R; BRUNKHORST, B; PISICK, E; LI, JL; LO, SH; CHEN, LB; GRIFFIN, JD				SALGIA, R; BRUNKHORST, B; PISICK, E; LI, JL; LO, SH; CHEN, LB; GRIFFIN, JD			INCREASED TYROSINE PHOSPHORYLATION OF FOCAL ADHESION PROTEINS IN MYELOID CELL-LINES EXPRESSING P210(BCR/ABL)	ONCOGENE			English	Article						P210(BCR/AB1); ACTIN; TYROSINE PHOSPHORYLATION; CYTOSKELETAL PROTEINS	CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; KINASE; PAXILLIN; BINDING; ABL; BCR; TRANSFORMATION; FIBROBLASTS; FIBRONECTIN	The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and induces growth factor independence of hematopoietic cell lines in tissue culture. p210(BCR/ABL) is localized at least in part to the cytoskeleton, and has been shown to interact directly with actin filaments through an actin binding domain located in the C-terminus of ABL. CML cells have reduced adhesion to some extracellular matrix components but the mechanism of this phenomenon is unknown. In this study we examined tyrosine phosphorylation of focal adhesion proteins in cells expressing p210(BCR/ABL) An interleukin-3 (IL-3)-dependent cell line, 32Dc13, was transformed with a BCR/ABL cDNA, and the patterns of localization, expression, and tyrosine phosphorylation of focal adhesion proteins were compared among untransformed 32Dc13 cells with and without IL-3 stimulation and BCR/ABL-transformed 32Dc13 cells. Of the focal adhesion proteins examined, only paxillin exhibited tyrosine phosphorylation in response to IL-3; while in cells transformed by p210(BCR/ABL), paxillin, vinculin, p125(FAK), talin and tensin were constitutively tyrosine phosphorylated. IL-3 induced a transient association between paxillin and vinculin, while in BCR/ABL-transformed cells, several proteins coimmunoprecipitated with paxillin, including vinculin, p125(FAK), talin and tensin. Pseudopodia enriched in focal adhesion proteins were transiently detected in 32Dc13 cells in response to IL-3, but constitutively detected in cells expressing p210(BCR/ABL). P210(BCR/ABL) protein was also found concentrated in punctate structures adjacent to the cell membrane in myeloid cell lines, which often contained vinculin and paxillin. Since the focal adhesion is where the interaction between integrins and actin filaments is believed to occur, the observed effect of p210(BCR/ABL) on food adhesion protein interactions in myeloid cell lines could contribute to the adhesion defects in CML cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X; Lo, Su Hao/0000-0002-2675-9387				AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DRUKER B, 1992, BLOOD, V79, P2215; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	35	144	147	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1149	1155						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566975				2022-12-25	WOS:A1995RX18000018
J	ENGEL, K; SCHULTZ, H; MARTIN, F; KOTLYAROV, A; PLATH, K; HAHN, M; HEINEMANN, U; GAESTEL, M				ENGEL, K; SCHULTZ, H; MARTIN, F; KOTLYAROV, A; PLATH, K; HAHN, M; HEINEMANN, U; GAESTEL, M			CONSTITUTIVE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN-KINASE-2 BY MUTATION OF PHOSPHORYLATION SITES AND AN A-HELIX MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; HEAT-SHOCK; IDENTIFICATION; SUBUNIT; CELLS; RAF	A recently described downstream target of mitogen-activated protein kinases (MAPKs) is the MAPK-activated protein (MAPKAP) kinase 2 which has been shown to be responsible for small heat shock protein phosphorylation, We have analyzed the mechanism of MAPKAP kinase 2 activation by MAPK phosphorylation using a recombinant MAPKAP kinase 2-fusion protein, p44(MAPK) and p38/40(MAPK) in vitro and using an epitope-tagged MAPKAP kinase 2 in heat-shocked NIH 3T3 cells. It is demonstrated that, in addition to the known phosphorylation of the threonine residue carboxyl-terminal to the catalytic domain, Thr-317, activation of MAPKAP kinase 2 in vitro and in vivo is dependent on phosphorylation of a second threonine residue, Thr-205, which is located within the catalytic domain and which is highly conserved in several protein kinases. Constitutive activation of MAPKAP kinase 2 is obtained by replacement of both of these threonine residues by glutamic acid, A constitutively active form of MAPKAP kinase 2 is also obtained by deletion of a carboxyl-terminal region containing Thr-317 and the A-helix motif or by replacing the conserved residues of the A-helix, These data suggest a dual mechanism of MAPKAP kinase 2 activation by phosphorylation of Thr-205 inside the catalytic domain and by phosphorylation of Thr-317 outside the catalytic domain involving an autoinhibitory A-helix motif.	MAX DELBRUCK CENTRUM MOLEK MED, D-13122 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Heinemann, Udo/AAH-4766-2019; Heinemann, Udo/S-3379-2016; Gaestel, Matthias/A-6560-2013	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850; Gaestel, Matthias/0000-0002-4944-4652; Plath, Kathrin/0000-0001-7796-3372				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; ENGEL K, 1993, FEBS LETT, V336, P143, DOI 10.1016/0014-5793(93)81628-D; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1993, MOL CELL BIOCHEM, V128, P157, DOI 10.1007/BF01076767; PLATH K, 1994, BIOCHEM BIOPH RES CO, V203, P1188, DOI 10.1006/bbrc.1994.2308; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; VERON M, 1994, CELL MOL BIOL, V40, P587; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566; ZU YL, 1995, J BIOL CHEM, V270, P202, DOI 10.1074/jbc.270.1.202	47	91	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27213	27221		10.1074/jbc.270.45.27213	http://dx.doi.org/10.1074/jbc.270.45.27213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592979	hybrid			2022-12-25	WOS:A1995TE58300079
J	GORZOWSKI, JJ; ECKERLEY, CA; HALGREN, RG; MANGURTEN, AB; PHILLIPS, B				GORZOWSKI, JJ; ECKERLEY, CA; HALGREN, RG; MANGURTEN, AB; PHILLIPS, B			METHYLATION-ASSOCIATED TRANSCRIPTIONAL SILENCING OF THE MAJOR HISTOCOMPATIBILITY COMPLEX-LINKED HSP70 GENES IN MOUSE-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR; EMBRYONAL CARCINOMA-CELLS; DNA-BINDING; ERYTHROLEUKEMIA-CELLS; CHROMATIN STRUCTURE; CPG ISLANDS; ACTIVATION; EXPRESSION; PROMOTER; PROTEIN	The MHC-linked hsp70 locus consists of duplicated genes, hsp70.1 and hsp70.3, which in primary mouse embryo cells are highly heat shock-inducible. Several mouse cell lines in which hsp70 expression is not activated by heat shock have been described previously, but the basis for the deficiency has not been identified. In this study, genomic footprinting analysis has identified a common basis for the deficient response of the hsp70.1 gene to heat shock in four such cell lines, viz., the promoter is inaccessible to transcription factors, including heat shock transcription factor. Southern blot analyses reveal extensive CpG methylation of a 1.2-kilobase re region spanning the hsp70.1 transcription start site and hypermethylation of the adjacent hsp70.3 gene, which is presumably also inaccessible to regulatory factors. Of four additional, randomly chosen mouse cell lines, three show no or minimal hsp70.3 heat shock responsiveness and CpG methylation of both hsp70 genes, and two of the three lines exhibit a suboptimal hsp70.1 response to heat shock as well. In all three lines, the accessibility of the hsp70.1 promoter to transcription factors is detectable but clearly diminished (relative to that in primary mouse cells). Our results suggest that the tandem hsp70 genes are concomitantly methylated and transcriptionally repressed with high frequency in cultured mouse cells.	NORTHWESTERN UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611	Northwestern University; Northwestern University								ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; AUJAME L, 1985, MOL CELL BIOL, V5, P1780, DOI 10.1128/MCB.5.7.1780; AUJAME L, 1987, BIOCH CELL BIOL, V66, P691; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BECKER PB, 1988, GENETIC ENG PRINCIPL, P1; BONAL FJ, 1986, J IMMUNOGENET, V13, P179; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; DAVIDSON S, 1995, MOL CELL BIOL, V15, P1071; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LI BY, 1994, J BIOL CHEM, V269, P7756; LOWE DG, 1986, J BIOL CHEM, V261, P2102; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MATHUR SK, 1994, P NATL ACAD SCI USA, V91, P8695, DOI 10.1073/pnas.91.18.8695; MERUELO D, 1986, P NATL ACAD SCI USA, V83, P4504, DOI 10.1073/pnas.83.12.4504; MEZGER V, 1987, DEV BIOL, V124, P544, DOI 10.1016/0012-1606(87)90507-0; MILNER CM, 1990, IMMUNOGENETICS, V32, P242; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURPHY SP, 1988, P NATL ACAD SCI USA, V85, P5587, DOI 10.1073/pnas.85.15.5587; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; PEDERSON DS, 1994, MOL CELL BIOL, V14, P189, DOI 10.1128/MCB.14.1.189; PERRY MD, 1994, GENE, V146, P273, DOI 10.1016/0378-1119(94)90305-0; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PIRITY M, 1993, EUR J BIOCHEM, V210, P793; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SARGENT CA, 1989, P NATL ACAD SCI USA, V86, P1968, DOI 10.1073/pnas.86.6.1968; SARGENT CA, 1989, EMBO J, V8, P2305, DOI 10.1002/j.1460-2075.1989.tb08357.x; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SNOEK M, 1993, GENOMICS, V15, P350, DOI 10.1006/geno.1993.1067; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; TYKOCINSKI ML, 1984, NUCLEIC ACIDS RES, V12, P4385, DOI 10.1093/nar/12.10.4385; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	62	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26940	26949		10.1074/jbc.270.45.26940	http://dx.doi.org/10.1074/jbc.270.45.26940			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592940	hybrid			2022-12-25	WOS:A1995TE58300040
J	KAUPPINEN, S; CHRISTGAU, S; KOFOD, LV; HALKIER, T; DORREICH, K; DALBOGE, H				KAUPPINEN, S; CHRISTGAU, S; KOFOD, LV; HALKIER, T; DORREICH, K; DALBOGE, H			MOLECULAR-CLONING AND CHARACTERIZATION OF A RHAMNOGALACTURONAN ACETYLESTERASE FROM ASPERGILLUS-ACULEATUS - SYNERGISM BETWEEN RHAMNOGALACTURONAN DEGRADING ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY RAMIFIED REGIONS; LYASE GENE PELA; CELL-WALLS; NIGER; NIDULANS; PECTINS; EXPRESSION; ACID; POLYGALACTURONASES; TRANSFORMATION	A rhamnogalacturonan acetylesterase (RGAE) was purified to homogeneity from the filamentous fungus Aspergillus aculeatus, and the NH2-terminal amino acid sequence was determined, Full-length cDNAs encoding the enzyme were isolated from an A. aculeatus cDNA library using a polymerase chain reaction-generated product as a probe, The 936-base pair rha1 cDNA encodes a 25O-residue precursor protein of 26,350 Da, including a 17-amino acid signal peptide, The rha1 cDNA was overexpressed in Aspergillus oryzae, a filamentous fungus that does not possess RGAE activity, and the recombinant enzyme was purified and characterized, Mass spectrometry of the native and recombinant RGAE revealed that the enzymes are heterogeneously glycosylated, In addition, the observed differences in their molecular masses, lectin binding patterns, and monosaccharide compositions indicate that the glycan moieties on the two enzymes are structurally different, The RGAE was shown to act in synergy with rhamnogalacturonase A as well as rhamnogalacturonase B from A, aculeatus in the degradation of apple pectin rhamnogalacturonan. RNA gel blot analyses indicate that the expression of rhamnogalacturonan degrading enzymes by A, aculeatus is regulated at the level of transcription and is subjected to carbon catabolite repression by glucose.			KAUPPINEN, S (corresponding author), NOVO NORDISK AS,GENESEARCH,NOVO ALLE,BLDG 1B121,DK-2880 BAGSVAERD,DENMARK.							ANDERSON AJ, 1978, PHYTOPATHOLOGY, V68, P1585, DOI 10.1094/Phyto-68-1585; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENSHALOM N, 1986, J FOOD SCI, V51, P720, DOI 10.1111/j.1365-2621.1986.tb13919.x; BUSSINK HJD, 1991, CURR GENET, V19, P467, DOI 10.1007/BF00312738; BUSSINK HJD, 1992, APPL MICROBIOL BIOT, V37, P324, DOI 10.1007/BF00210987; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSEN T, 1988, BIO-TECHNOL, V6, P1419, DOI 10.1038/nbt1288-1419; CHRISTGAU S, 1994, BIOCHEM MOL BIOL INT, V33, P917; Cooper RM, 1984, PLANT DIS INFECT DAM, P13; DALBOGE H, 1994, MOL GEN GENET, V243, P253, DOI 10.1007/BF00301060; DEAN RA, 1989, PLANT CELL, V1, P265, DOI 10.1105/tpc.1.3.265; DEAN RA, 1989, PLANT CELL, V1, P275, DOI 10.1105/tpc.1.3.275; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HARMSEN JAM, 1990, CURR GENET, V18, P161, DOI 10.1007/BF00312604; KOFOD LV, 1994, J BIOL CHEM, V269, P29182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANKARIOS AT, 1980, PHYSIOL PLANT PATHOL, V17, P93, DOI 10.1016/0048-4059(80)90010-7; MAY GS, 1985, J CELL BIOL, V101, P712, DOI 10.1083/jcb.101.3.712; MUTTER M, 1994, PLANT PHYSIOL, V106, P241, DOI 10.1104/pp.106.1.241; Nirpjit S, 1996, J GEN MICROBIOL, V18, P1435; O'Neill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI DOI 10.1016/B978-0-12-461012-5.50018-5; PILNIK W, 1979, POLYSACCHARIDES FOOD, P109; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLS HA, 1994, CARBOHYD RES, V256, P97, DOI 10.1016/0008-6215(94)84230-2; SCHOLS HA, 1990, CARBOHYD RES, V206, P105, DOI 10.1016/0008-6215(90)84010-R; SCHOLS HA, 1990, CARBOHYD RES, V206, P117, DOI 10.1016/0008-6215(90)84011-I; SEARLEVANLEEUWE.MJ, 1992, APPL MICROBIOL BIOT, V38, P347; SIESSERE V, 1992, J GEN MICROBIOL, V138, P1801, DOI 10.1099/00221287-138-9-1801; SIGGAARDANDERSE.M, 1991, P NATL ACAD SCI USA, V88, P4114, DOI 10.1073/pnas.88.10.4114; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAHARA T, 1975, J FERMENT TECHNOL, V53, P409; THIBAULT JF, 1993, CARBOHYD RES, V238, P271, DOI 10.1016/0008-6215(93)87019-O; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470	40	56	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27172	27178		10.1074/jbc.270.45.27172	http://dx.doi.org/10.1074/jbc.270.45.27172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592973	hybrid			2022-12-25	WOS:A1995TE58300073
J	WONG, MH; OELKERS, P; DAWSON, PA				WONG, MH; OELKERS, P; DAWSON, PA			IDENTIFICATION OF A MUTATION IN THE ILEAL SODIUM-DEPENDENT BILE-ACID TRANSPORTER GENE THAT ABOLISHES TRANSPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE RESIDUES; MEMBRANE; PROTEINS; MALABSORPTION; EXPRESSION; CLONING; VESICLES; DIARRHEA; GLUCOSE; SYSTEM	The ileal Na+/bile acid cotransporter plays a critical role in the reabsorption of bile acids from the small intestine. In the course of cloning and characterizing the human ileal Na+/bile acid cotransporter cDNA, a dysfunctional isoform was identified in a patient diagnosed with Crohn's disease. Expression studies using hamster-human ileal Na+/bile acid cotransporter cDNA chimeras narrowed the location of the defect to the carboxyl-terminal 94 amino acids. Comparison of the sequence of the dysfunctional isoform to that of a wild-type human ileal Na+/bile acid cotransporter genomic clone revealed a single C to T transition resulting in a proline to serine substitution at amino acid position 290. The inheritance of this mutation in the proband's family was confirmed by single-stranded conformation polymorphism analysis and DNA sequencing. In transfected COS-l cells, the single amino acid change abolished taurocholate transport activity but did not alter the transporter's synthesis or subcellular distribution. This dysfunctional mutation represents the first known molecular defect in a human sodium-dependent bile acid transporter.			WONG, MH (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT INTERNAL MED, DIV GASTROENTEROL, WINSTON SALEM, NC 27157 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047987, R29DK047987, F31DK008718] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47987, R29 DK047987, DK08718] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; Dawson Paul A., 1995, Current Opinion in Lipidology, V6, P109, DOI 10.1097/00041433-199504000-00009; DONALDSON RM, 1989, GASTROINTESTINAL DIS, P127; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; HEUBI JE, 1982, GASTROENTEROLOGY, V83, P804; HOFMANN AF, 1993, GASTROINTESTINAL DIS, P127; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LANTZ LM, 1995, BIOTECHNIQUES, V18, P56; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Sambrook J, 1989, MOL CLONING LABORATO; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMALL DM, 1972, ARCH INTERN MED, V130, P552, DOI 10.1001/archinte.130.4.552; STRAUSS WM, 1994, CURRENT PROTOCOLS MO; THAYSEN EH, 1973, DAN MED BULL, V20, P174; THAYSEN EH, 1985, SCAND J GASTROENTERO, V20, P452, DOI 10.3109/00365528509089679; TURK E, 1994, J BIOL CHEM, V269, P15204; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; VANTILBURG AJP, 1992, SCAND J GASTROENTERO, V27, P66, DOI 10.3109/00365529209096030; VANTILBURG AJP, 1991, GUT, V32, P500, DOI 10.1136/gut.32.5.500; WEINBERG SL, 1986, J CLIN INVEST, V78, P44, DOI 10.1172/JCI112571; WILSON FA, 1991, HDB PHYSL GASTROINTE, V4, P389; WONG MH, 1994, J BIOL CHEM, V269, P1340; XU SY, 1986, GENE ANAL TECH, V3, P90	35	189	197	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27228	27234		10.1074/jbc.270.45.27228	http://dx.doi.org/10.1074/jbc.270.45.27228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592981	hybrid			2022-12-25	WOS:A1995TE58300081
J	WAN, B; MOREADITH, RW				WAN, B; MOREADITH, RW			STRUCTURAL CHARACTERIZATION AND REGULATORY ELEMENT ANALYSIS OF THE HEART ISOFORM OF CYTOCHROME-C-OXIDASE VIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ADP/ATP TRANSLOCATOR; TISSUE-SPECIFIC REGULATION; SUBUNIT-VIIA; PARACOCCUS-DENITRIFICANS; SKELETAL-MUSCLE; 2 ISOFORMS; NUCLEAR GENES; MITOCHONDRIAL MYOPATHIES; PROTON PUMP; EXPRESSION	In order to investigate the mechanism(s) governing the striated muscle-specific expression of cytochrome c oxidase VIaH we have characterized the murine gene and analyzed its transcriptional regulatory elements in skeletal myogenic cell lines. The gene is single copy, spans 689 base pairs (bp), and is comprised of three exons, The 5'-ends of transcripts from the gene are heterogeneous, but the most abundant transcript includes a 5'-untranslated region of 30 nucleotides. When fused to the luciferase reporter gene, the 3.5-kilobase 5'-flanking region of the gene directed the expression of the heterologous protein selectively in differentiated So18 cells and transgenic mice, recapitulating the pattern of expression of the endogenous gene. Deletion analysis identified a 300-bp fragment sufficient to direct the myotube-specific expression of luciferase in So18 cells. The region lacks an apparent TATA element, and sequence motifs predicted to bind NRF-1, NRF-2, ox-box, or PPAR factors known to regulate other nuclear genes encoding mito chondrial proteins are not evident. Mutational analysis, however, identified two cis-elements necessary for the high level expression of the reporter protein: a MEF2 consensus element at -90 to -81 bp and an E-box element at -147 to -142 bp. Additional E-box motifs at closely located positions were mutated without loss of transcriptional activity. The dependence of transcriptional activation of cytochrome c oxidase VIaH on cis-elements similar to those found in contractile protein genes suggests that the striated muscle-specific expression is coregulated by mechanisms that control the lineage-specific expression of several contractile and cytosolic proteins.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, MOLEC CARDIOL LABS, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [5T32-HL-07360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007360] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1990, J BIOL CHEM, V265, P16389; ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; ANTHONY G, 1990, FEBS LETT, V277, P97, DOI 10.1016/0014-5793(90)80817-3; ARNAUDO E, 1992, GENE, V119, P299, DOI 10.1016/0378-1119(92)90287-Y; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; CAPALDI RA, 1987, CURR TOP BIOENERG, V15, P91; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHOMYN A, 1987, CURR TOP BIOENERG, V15, P295; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; Cormack B., 1991, CURRENT PROTOCOLS MO, V1, P851; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EWART GD, 1991, FEBS LETT, V292, P79, DOI 10.1016/0014-5793(91)80839-U; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; FABRIZI GM, 1992, GENE, V119, P307, DOI 10.1016/0378-1119(92)90288-Z; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P5845; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HALTIA T, 1988, EUR J BIOCHEM, V172, P543, DOI 10.1111/j.1432-1033.1988.tb13923.x; HARAGUCHI Y, 1994, J BIOL CHEM, V269, P9330; HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; HOGAN B, 1986, MANIPULATING MOUSE E; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KADENBACH B, 1991, J BIOENERG BIOMEMBR, V23, P321, DOI 10.1007/BF00762225; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; KLEIN SC, 1991, J BIOL CHEM, V266, P18058; KNOX BE, 1984, J BIOL CHEM, V259, P4757; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LI K, 1990, J BIOL CHEM, V265, P20585; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MELL OC, 1994, GENE, V140, P179, DOI 10.1016/0378-1119(94)90542-8; MITCHELL P, 1979, EUR J BIOCHEM, V95, P1, DOI 10.1111/j.1432-1033.1979.tb12934.x; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; PARDHASARADHI K, 1991, BIOPHYS J, V60, P408, DOI 10.1016/S0006-3495(91)82066-5; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; RACKER E, 1974, J BIOL CHEM, V249, P662; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; ROHDICH F, 1993, BIOCHEMISTRY-US, V32, P8499, DOI 10.1021/bi00084a015; SAMBROOKJ, 1989, MOL CLONING LABORATO; SCHEJA K, 1992, BIOCHIM BIOPHYS ACTA, V1132, P91, DOI 10.1016/0167-4781(92)90059-9; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SMITH EO, 1993, BIOCHIM BIOPHYS ACTA, V1174, P63, DOI 10.1016/0167-4781(93)90092-R; SMITH EO, 1991, BIOCHIM BIOPHYS ACTA, V1089, P266, DOI 10.1016/0167-4781(91)90022-E; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAANMAN JW, 1994, BIOCHEMISTRY-US, V33, P11833, DOI 10.1021/bi00205a020; TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TAGER JM, 1983, FEBS LETT, V151, P1, DOI 10.1016/0014-5793(83)80330-5; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; VANKUILENBURG ABP, 1992, EUR J BIOCHEM, V203, P193; VANKUILENBURG ABP, 1988, FEBS LETT, V240, P127, DOI 10.1016/0014-5793(88)80353-3; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	85	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26433	26440		10.1074/jbc.270.44.26433	http://dx.doi.org/10.1074/jbc.270.44.26433			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592858	hybrid			2022-12-25	WOS:A1995TC97800065
J	MARTYS, JL; SHEVELL, T; MCGRAW, TE				MARTYS, JL; SHEVELL, T; MCGRAW, TE			STUDIES OF TRANSFERRIN RECYCLING RECONSTITUTED IN STREPTOLYSIN-O PERMEABILIZED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; TRANS-GOLGI NETWORK; ENDOPLASMIC-RETICULUM; ENDOSOME FUSION; BETA-COP; VESICULAR TRAFFICKING; BREFELDIN-A; MDCK CELLS	Efficient transferrin receptor recycling is reconstituted when donor cytosol and ATP are added to the streptolysin O permeabilized cells. The rate of reconstituted recycling is dependent on the concentration of donor cytosol. The cytosol provides a factor(s) required for the transport of transferrin from the pericentriolar recycling compartment to the plasma membrane. N-Ethylmaleimide treatment of permeabilized cells inhibits both the fusion of recycling vesicles with the plasma membrane as well as the formation of functional recycling vesicles from the pericentriolar recycling compartment. Guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) does not affect reconstituted recycling in the presence of an optimal cytosol concentration. Therefore, the rate-limiting step in recycling is not regulated by GTP-hydrolyzing proteins, and hydrolysis of GTP is not required for endocytic recycling. GTP gamma S stimulates recycling when suboptimal concentrations of cytosol are used. This stimulatory effect is not mediated by a brefeldin A-sensitive ADP-ribosylation factor protein. Addition of mild-type donor cytosol to permeabilized END2 Chinese hamster ovary cells, which recycle transferrin at half the rate of mild-type cells, reconstitutes recycling to the reduced rate of intact END2 cells but not to the mild-type recycling rate. These results indicate that the defect responsible for the slowed transferrin recycling in END2 mutants is membrane associated or that the defective protein is too large to diffuse out of the cells through the streptolysin O pores.	COLUMBIA UNIV, DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University					NATIONAL INSTITUTE ON AGING [T32AG000189] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG00189] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FITZGERALD LA, 1981, J CELL SCI, V52, P405; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JOHNSON LS, 1994, J CELL PHYSIOL, V158, P29, DOI 10.1002/jcp.1041580105; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCGRAW TE, 1991, HDB EXPT PHARM, V100, P11; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; RAUB TJ, 1990, J CELL PHYSIOL, V144, P52, DOI 10.1002/jcp.1041440108; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; SUDHOF TC, 1993, CELL, V75, P1; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WILSON RB, 1993, J BIOL CHEM, V268, P1; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	60	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25976	25984		10.1074/jbc.270.43.25976	http://dx.doi.org/10.1074/jbc.270.43.25976			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592788	hybrid			2022-12-25	WOS:A1995TB46600105
J	CRESPO, P; CACHERO, TG; XU, NZ; GUTKIND, JS				CRESPO, P; CACHERO, TG; XU, NZ; GUTKIND, JS			DUAL EFFECT OF BETA-ADRENERGIC RECEPTORS ON MITOGEN-ACTIVATED PROTEIN-KINASE - EVIDENCE FOR A BETA-GAMMA-DEPENDENT ACTIVATION AND A G-ALPHA(S)-CAMP-MEDIATED INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; ADENYLYL CYCLASE; SIGNAL TRANSDUCTION; COUPLED RECEPTORS; RAS; GENE; EXPRESSION; SUBUNITS; CAMP; PATHWAY	The enzymatic activity of mitogen-activated protein kinases (MAP kinases) increases in response to agents acting on a variety of cell surface receptors, including receptors linked to heterotrimeric G proteins of the G(i) and G(q) family. Recently, it has been shown that stimulation of beta-adrenergic receptors, which are typical of those that act through G(s) to activate adenylyl cyclases, potently activates MAP kinases in the heart, resulting in the hypertrophy of the cardiac muscle (Lazou, A., Bogoyevitch, M. A., Clerk, A., Fuller, S. J., Marshall, C. J., and Sudgen, P. H. (1994) Circ, Res, 75, 938-941). We have observed that exposure of COS-7 cells to a beta-adrenergic agonist, isoproterenol, raises intracellular levels of cAMP and effectively activates protein kinase A (PKA) and an epitope-tagged MAP kinase. However, MAP kinase stimulation by isoproterenol was neither mimicked by expression of an activated mutant of G alpha(s), nor by treatment with PKA-stimulating agents. Moreover, pretreatment of COS-7 with a permeable cAMP analog, 8-Br-cAMP, markedly decreased MAP kinase activation by either isoproterenol or epidermal growth factor. Thus, in COS-7 cells cAMP and PKA do not appear to mediate MAP kinase activation by beta-adrenergic receptors. Signaling from beta-adrenergic receptors to MAP kinase was inhibited by transfection of a chimeric molecule consisting of the CD8 receptor and the carboxyl terminus of the beta-adrenergic receptor kinase, which includes the beta gamma-binding domain. MAP kinase activation by isoproterenol was not affected by depletion of protein kinase C, but it was completely abolished by expression of Ras-inhibiting molecules. We conclude that signaling from beta-adrenergic receptors to MAP kinase involves an activating signal mediated by beta gamma subunits acting on a Ras-dependent pathway and a G alpha(s)-induced inhibitory signal mediated by cAMP and PKA. The balance between these two opposing mechanisms of regulation would be expected to control the MAP kinase response to beta-adrenergic agonists as well as to other biologically active agents known to act on G(s) coupled receptors, including a number of hormones, neurotransmitters, and lipid mediators.	NIDR,MOLEC SIGNALING UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HO AK, 1987, J BIOL CHEM, V262, P10059; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LAZOU A, 1994, CIRC RES, V75, P938; LEFCOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAY LB, 1987, P NATL ACAD SCI USA, V85, P1502; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEPHENS EV, 1993, ONCOGENE, V8, P19; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	49	203	205	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25259	25265		10.1074/jbc.270.42.25259	http://dx.doi.org/10.1074/jbc.270.42.25259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559665	hybrid			2022-12-25	WOS:A1995TB46500099
J	HODITS, RA; NIMPF, J; PFISTERMUELLER, DM; HIESBERGER, T; SCHNEIDER, WJ; VAUGHAN, TJ; JOHNSON, KS; HAUMER, M; KUECHLER, E; WINTER, G; BLAAS, D				HODITS, RA; NIMPF, J; PFISTERMUELLER, DM; HIESBERGER, T; SCHNEIDER, WJ; VAUGHAN, TJ; JOHNSON, KS; HAUMER, M; KUECHLER, E; WINTER, G; BLAAS, D			AN ANTIBODY FRAGMENT FROM A PHAGE DISPLAY LIBRARY COMPETES FOR LIGAND-BINDING TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR FAMILY AND INHIBITS RHINOVIRUS INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; CHICKEN OOCYTE RECEPTOR; BY-PASSING IMMUNIZATION; PLASMINOGEN-ACTIVATOR; HIGH-AFFINITY; FILAMENTOUS PHAGE; APOLIPOPROTEIN-E; MEDIATES UPTAKE	Recently antibodies with a wide range of binding specificities have been isolated from large repertoires of antibody fragments displayed on filamentous phage, including those that are difficult to raise by immunization, We have used this approach to isolate an antibody fragment against chicken very low density lipoprotein (VLDL) receptor. It binds to the receptor with good affinity (K-aff = 2 x 10(8) M(-1)) as measured by plasmon surface resonance, and competes for binding of natural ligands (vitellogenin, VLDL, and receptor-associated protein). The antibody also binds to other members of the low density lipoprotein (LDL) receptor family including rat LDL receptor and human and rat low density lipoprotein receptor-related protein (LRP/alpha(2)MR), and it competes for binding of receptor-associated protein to LRP/alpha(2)MR. Moreover, the antibody fragment inhibits infection of human fibroblasts deficient in LDL-R but expressing LRP/alpha MR by human rhinovirus. Binding of the antibody is abolished upon reduction of the receptors and is strictly Ca2+ dependent. The phage antibody thus recognizes the ligand binding site(s) of several members of the LDL receptor family, in contrast to antibodies produced by hybridoma technology.	UNIV VIENNA,INST BIOCHEM,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,INST MOLEC GENET,A-1030 VIENNA,AUSTRIA; CAMBRIDGE ANTIBODY TECHNOL LTD,MELBOURNE SG8 6EJ,CAMBS,ENGLAND; UNIV VIENNA,INST MED CHEM,A-1090 VIENNA,AUSTRIA; MRC,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	University of Vienna; University of Vienna; AstraZeneca; University of Vienna; University of Cambridge				Nimpf, Johannes/0000-0002-9273-3492				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BEISIEGEL U, 1989, NATURE, V34, P162; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; COLONNO RJ, 1986, J VIROL, V57, P7, DOI 10.1128/JVI.57.1.7-12.1986; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDSTEIN JL, 1979, ANNU REV GENET, V13, P259, DOI 10.1146/annurev.ge.13.120179.001355; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HAYDEN FG, 1988, ANTIVIR RES, V9, P233, DOI 10.1016/0166-3542(88)90055-1; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1992, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HOCHULI E, 1988, J CHROMATOGR, V444, P293, DOI 10.1016/S0021-9673(01)94032-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; HUBER C, 1993, EUR J IMMUNOL, V23, P2868, DOI 10.1002/eji.1830231121; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEUBAUER C, 1987, VIROLOGY, V158, P255, DOI 10.1016/0042-6822(87)90264-9; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NIMPF J, 1994, J BIOL CHEM, V269, P212; NIMPF J, 1994, ANN NY ACAD SCI, V737, P145, DOI 10.1111/j.1749-6632.1994.tb44308.x; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SKERN T, 1984, VIROLOGY, V136, P125, DOI 10.1016/0042-6822(84)90253-8; SPERBER SJ, 1989, ANTIVIR RES, V12, P231, DOI 10.1016/0166-3542(89)90051-X; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TOMASSINI JE, 1986, J VIROL, V58, P290, DOI 10.1128/JVI.58.2.290-295.1986; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	73	23	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24078	24085		10.1074/jbc.270.41.24078	http://dx.doi.org/10.1074/jbc.270.41.24078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592608	hybrid			2022-12-25	WOS:A1995TA21700036
J	KUTCHAN, TM; DITTRICH, H				KUTCHAN, TM; DITTRICH, H			CHARACTERIZATION AND MECHANISM OF THE BERBERINE BRIDGE ENZYME, A COVALENTLY FLAVINYLATED OXIDASE OF BENZOPHENANTHRIDINE ALKALOID BIOSYNTHESIS IN PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; ADENOSYL-L-METHIONINE; 6-HYDROXY-D-NICOTINE OXIDASE; ARTHROBACTER-OXIDANS; PURIFICATION; SANGUINARINE; ELICITATION; EXPRESSION; GENE	The berberine bridge enzyme ((S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming), EC 1.5.3.9) catalyzes the oxidative cyclization of the N-methyl moiety of (S)-reticuline into the berberine bridge carbon, C-8, of (S)-scoulerine. This is a reaction that has neither an equivalent in organic chemistry nor a parallel in nature. The uniqueness of this catalytic reaction prompted an in depth study that began with the isolation of the cDNA encoding the berberine bridge enzyme followed by the overexpression of this cDNA in insect cell culture. The heterologously expressed enzyme has herein been shown to contain covalently attached FAD in a molar ratio of cofactor to protein of 1:1.03. Site-directed mutagenesis and laser desorption time of-flight mass spectrometry suggest that the site of covalent attachment is at His-104. The holoenzyme exhibited absorbance maxima at 380 and 442 nm and a fluorescence emission maximum at 628 nm (310 nn excitation). Enzymic transformation of a series of (S)-reticuline derivatives modified with respect to the stereochemistry at C-1 or in the aromatic ring substitution suggests that ring closure proceeds in two steps: formation of the methylene iminium ion and subsequent ring closure via an ionic mechanism.			KUTCHAN, TM (corresponding author), UNIV MUNICH,MOLEC BIOL LAB,KARLSTR 29,D-80333 MUNICH,GERMANY.		Kutchan, Toni/L-4625-2013					AMANN M, 1986, PLANTA, V167, P310, DOI 10.1007/BF00391333; AMANN M, 1988, EUR J BIOCHEM, V175, P17, DOI 10.1111/j.1432-1033.1988.tb14160.x; AUGUST PR, 1994, J BACTERIOL, V176, P4448, DOI 10.1128/jb.176.14.4448-4454.1994; BARTON DHR, 1963, P CHEM SOC LONDON, P267; BATTERSBY AR, 1963, P CHEM SOC LONDON, P268; BJORKLUND JA, 1995, J AM CHEM SOC, V117, P1533, DOI 10.1021/ja00110a009; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1985, FEBS LETT, V192, P204, DOI 10.1016/0014-5793(85)80108-3; BRANDSCH R, 1987, EUR J BIOCHEM, V167, P315, DOI 10.1111/j.1432-1033.1987.tb13338.x; CLINE SD, 1988, PLANT PHYSIOL, V86, P161, DOI 10.1104/pp.86.1.161; DECKER KF, 1993, ANNU REV NUTR, V13, P17, DOI 10.1146/annurev.nu.13.070193.000313; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; DZINK JL, 1985, ANTIMICROB AGENTS CH, V27, P663, DOI 10.1128/AAC.27.4.663; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3491, DOI 10.1016/0031-9422(90)85263-F; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; HESSE M, 1975, ALKALOIDS PROGR MASS, V3; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KUTCHAN TM, 1994, PHYTOCHEMISTRY, V35, P353, DOI 10.1016/S0031-9422(00)94763-0; MUELLER MJ, 1993, LIEBIGS ANN CHEM, P557; RINK E, 1975, FEBS LETT, V49, P396, DOI 10.1016/0014-5793(75)80794-0; ROTHERA MA, 1985, J NAT PROD, V48, P802, DOI 10.1021/np50041a015; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER HM, 1987, PLANT CELL REP, V6, P410, DOI 10.1007/BF00272770; STEFFENS P, 1985, PHYTOCHEMISTRY, V24, P2577, DOI 10.1016/S0031-9422(00)80672-X; SUAU R, 1988, PHYTOCHEMISTRY, V27, P1920, DOI 10.1016/0031-9422(88)80486-2; WAT CK, 1986, Z NATURFORSCH C, V41, P126	27	104	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24475	24481		10.1074/jbc.270.41.24475	http://dx.doi.org/10.1074/jbc.270.41.24475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592663	hybrid			2022-12-25	WOS:A1995TA21700091
J	ZHAO, YY; CHAUVET, PJP; ALPER, SL; BALTZ, JM				ZHAO, YY; CHAUVET, PJP; ALPER, SL; BALTZ, JM			EXPRESSION AND FUNCTION OF BICARBONATE CHLORIDE EXCHANGERS IN THE PREIMPLANTATION MOUSE EMBRYO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CL-/HCO3 EXCHANGER; CELL-LINE; KIDNEY; BAND-3; CDNA; CLONING; ANTIPORT; PROTEIN; GENE	Bicarbonate/chloride (HCO3-/Cl-) exchangers regulate intracellular pH in the alkaline range. Previously, it has been shown that mouse embryos at the two cell stage exhibit this activity, but that the otherwise ubiquitous mechanisms for regulating intracellular pH in the acid-to-neutral range are undetectable. We have examined mouse embryos during preimplantation development (one-cell zygote through blastocyst) to determine whether HCO3-/Cl- exchange activity exists at all stages, whether it is necessary for preimplantation development, and whether messenger RNAs from the known HCO3-/Cl- exchanger genes are expressed. We have found that all stages of preimplantation embryo have detectable HCO3-/Cl- exchange activity. In addition, inhibition of this activity with the stilbene anion exchange inhibitor DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid) disrupts intracellular pH homeostasis and markedly inhibits embryo development from the two-cell stage to blastocysts in culture under conditions of moderately high external pH. Finally, mRNA encoding two members of the band 3 related AE anion exchanger gene family are expressed in preimplantation embryos.	OTTAWA CIVIC HOSP,LOEB MED RES INST,HORMONES GROWTH & DEV UNIT,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT OBSTET & GYNECOL,REPROD BIOL UNIT,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT PHYSIOL,OTTAWA,ON K1Y 4E9,CANADA; BETH ISRAEL HOSP,MOLEC MED UNIT,BOSTON,MA 02215; BETH ISRAEL HOSP,RENAL UNIT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Baltz, Jay/0000-0002-9749-2480	NICHD NIH HHS [R01 HD29533] Funding Source: Medline; NIDDK NIH HHS [R01 DK43495] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043495] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; ALPER SL, 1994, CELL PHYSIOL BIOCHEM, V4, P265, DOI 10.1159/000154730; Baltz J. M., 1994, Molecular Biology of the Cell, V5, p102A; BALTZ JM, 1991, J BIOL CHEM, V266, P17212; BALTZ JM, 1990, DEV BIOL, V138, P421, DOI 10.1016/0012-1606(90)90208-Z; BALTZ JM, 1991, J BIOL CHEM, V266, P6052; BALTZ JM, 1993, DEVELOPMENT, V118, P1353; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CASSEL D, 1988, J BIOL CHEM, V263, P6122; HOGAN B, 1986, MANIPULATING MOUSE E; House C. R., 1994, Zygote, V2, P37; HUMPHREYS BD, 1994, AM J PHYSIOL-CELL PH, V267, pC1295, DOI 10.1152/ajpcell.1994.267.5.C1295; HUMPHREYS BD, 1995, AM J PHYSIOL-CELL PH, V37, pC201; IRITANI A, 1971, J ANIM SCI, V33, P829; JIANG LW, 1994, AM J PHYSIOL, V267, pC845, DOI 10.1152/ajpcell.1994.267.3.C845; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; KURTZ I, 1987, J BIOL CHEM, V262, P4516; LAWITTS JA, 1993, METHOD ENZYMOL, V255, P153; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINN SC, 1992, J BIOL CHEM, V267, P7927; MAAS DHA, 1977, FERTIL STERIL, V28, P981; MORGANS CW, 1993, J CELL SCI, V106, P1275; NORD EP, 1988, J BIOL CHEM, V263, P5599; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; YANNOUKAKOS D, 1994, CIRC RES, V75, P603, DOI 10.1161/01.RES.75.4.603	30	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24428	24434		10.1074/jbc.270.41.24428	http://dx.doi.org/10.1074/jbc.270.41.24428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592657	hybrid			2022-12-25	WOS:A1995TA21700085
J	BILGE, A; WARNER, CV; PRESS, OW				BILGE, A; WARNER, CV; PRESS, OW			TRANSLOCATION OF RICIN A-CHAIN INTO PROTEOLIPOSOMES RECONSTITUTED FROM GOLGI AND ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBILIZED ROUGH MICROSOMES; PROTEIN TRANSLOCATION; GALACTOSE-BINDING; CONTAINING IMMUNOTOXINS; INTRACELLULAR FUNCTIONS; CELL-SURFACE; B-CELLS; MEMBRANE; CYTOTOXICITY; TRANSPORT	Translocation to the cytosol is an essential and rate-limiting step in the cytotoxicity of the potent plant toxin ricin. In an attempt to study the mechanism of ricin A-chain (RTA) translocation in a cell-free assay, we have partially purified Golgi and endoplasmic reticulum from Jurkat cells by discontinuous sucrose gradient fractionation. The membranes of the organelle fractions were solubilized by the addition of sodium cholate and reconstituted into proteoliposomes by dialyzing out the detergent. The resulting vesicles supported cell-free translocation of RTA (as assessed by an enzyme protection assay) at a rate which was linearly dependent on the concentration of the vesicle preparation. Ricin B-chain (RTB) neither translocated into the vesicles, nor increased the efficiency of RTA translocation. Liposomes prepared from purified phospholipids were not capable of supporting RTA translocation. Furthermore, protease treatment or concanavalin A adsorption of pro teins from lysates prior to vesicle reconstitution resulted in abrogation of the translocation process, suggesting that the protein components of organelle membranes are required for RTA translocation. Reconstitution of translocation-competent proteoliposomes from detergent-solubilized membranes of endoplasmic reticulum- and Golgi-enriched fractions provides a convenient cell-free system to study the mechanism of RTA translocation.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	BILGE, A (corresponding author), UNIV WASHINGTON, DEPT BIOL STRUCT, POB 357420, SEATTLE, WA 98195 USA.			Press, Oliver/0000-0002-3147-8037	NCI NIH HHS [R01-CA-55596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; Bilge A, 1994, Ther Immunol, V1, P197; CARRASCO L, 1975, EUR J BIOCHEM, V54, P499, DOI 10.1111/j.1432-1033.1975.tb04162.x; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; GEISSLER F, 1992, CANCER RES, V52, P2907; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; LORD JM, 1992, BIOCHEM SOC T, V20, P734, DOI 10.1042/bst0200734; MCINTOSH DP, 1983, FEBS LETT, V164, P17, DOI 10.1016/0014-5793(83)80009-X; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; NICCHITTA C, 1991, METHOD CELL BIOL, V34, P263; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PRESS OW, 1991, BIOTHERAPY, V3, P65, DOI 10.1007/BF02175100; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; THEUER C, 1994, BIOCHEMISTRY-US, V33, P5894, DOI 10.1021/bi00185a029; THEUER CP, 1993, P NATL ACAD SCI USA, V90, P7774, DOI 10.1073/pnas.90.16.7774; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1990, TRAFFICKING BACTERIA, P91; Vitetta E S, 1991, Semin Cell Biol, V2, P47; VITETTA ES, 1983, P NATL ACAD SCI-BIOL, V80, P6332, DOI 10.1073/pnas.80.20.6332; VITETTA ES, 1986, J IMMUNOL, V136, P1880; WALES R, 1993, J BIOL CHEM, V268, P23986; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WAWRZYNCZAK EJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P55, DOI 10.1016/0167-4889(88)90161-9; WIENHUES U, 1992, BIOESSAYS, V14, P17, DOI 10.1002/bies.950140105; YOULE RJ, 1982, J BIOL CHEM, V257, P1598	41	10	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23720	23725		10.1074/jbc.270.40.23720	http://dx.doi.org/10.1074/jbc.270.40.23720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559543	hybrid			2022-12-25	WOS:A1995RY90900072
J	GETMAN, DK; MUTERO, A; INOUE, K; TAYLOR, P				GETMAN, DK; MUTERO, A; INOUE, K; TAYLOR, P			TRANSCRIPTION FACTOR REPRESSION AND ACTIVATION OF THE HUMAN ACETYLCHOLINESTERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MOUSE ACETYLCHOLINESTERASE; INDUCIBLE ENHANCER; PROMOTER ELEMENTS; MOLECULAR-CLONING; PROLACTIN GENE; FACTOR AP-2; T-ANTIGEN; EXPRESSION; SV40	Acetylcholinesterase in man is encoded by a single gene, ACHE, located on chromosome 7q22. In this study, the transcription start sites and major DNA promoter elements controlling the expression of this gene have been characterized by structural and functional studies, Immediately upstream of the first untranslated exon of the gene are CC-rich sequences containing consensus binding sites for several transcription factors, including Sp1, EGR-1 and AP2. In vitro transcription studies and RNase protection analyses of mRNA isolated from human NT2/D1 teratocarcinoma cells reveal that two closely spaced transcription cap sites are located at a consensus initiator (Inr) element similar to that found in the terminal transferase gene, Transient transfection of mutant genes shows that removal of three bases of this initiator sequence reduces promoter activity by 98% in NT2/D1 cells, In vitro transcription studies and transient transfection of a series of 5' deletion mutants of the ACHE promoter linked to a luciferase reporter show an Sp1 site at -71 to be essential for promoter activity, Purified Sp1 protein protects this site from DNase cleavage during in vitro footprinting experiments, A conserved AP2 consensus binding site, located between the GC box elements and the Inr, is protected by recombinant AP2 protein in DNase footprinting experiments, induces a mobility shift with AP2 protein and AP2-containing cell extracts, and fosters inhibition of transcription by AP2 as measured by transient transfection in mouse and human cell lines and in in vitro transcription reactions, These results indicate that AP2 functions as a repressor of human ACHE and mouse Ache transcription.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EHRLICH G, 1992, GENOMICS, V13, P1192, DOI 10.1016/0888-7543(92)90037-S; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FOURNIER D, 1989, J MOL BIOL, V210, P15, DOI 10.1016/0022-2836(89)90287-8; GETMAN DK, 1992, AM J HUM GENET, V51, P170; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LI Y, 1993, J BIOL CHEM, V268, P3563; LI Y, 1991, J BIOL CHEM, V266, P23083; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUMULA PW, 1988, DIABETES, V37, P1982; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514	42	67	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23511	23519		10.1074/jbc.270.40.23511	http://dx.doi.org/10.1074/jbc.270.40.23511			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559515	hybrid			2022-12-25	WOS:A1995RY90900044
J	MOSHER, RH; CAMP, DJ; YANG, KQ; BROWN, MP; SHAW, WV; VINING, LC				MOSHER, RH; CAMP, DJ; YANG, KQ; BROWN, MP; SHAW, WV; VINING, LC			INACTIVATION OF CHLORAMPHENICOL BY O-PHOSPHORYLATION - A NOVEL RESISTANCE MECHANISM IN STREPTOMYCES-VENEZUELAE ISP5230, A CHLORAMPHENICOL PRODUCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING PROTEINS; TRIPHOSPHATE CONFORMATION; TETRACYCLINE RESISTANCE; NUCLEOTIDE-SEQUENCE; CONFERS RESISTANCE; STRUCTURAL MODEL; GENE-EXPRESSION; CODON USAGE; ATP-BINDING	Plasmid pJV4, containing a 2.4-kilobase pair insert of genomic DNA from the chloramphenicol (Cm) producer Streptomyces venezuelae ISP5230, confers resistance when introduced by transformation into the Cm-sensitive host Streptomyces lividans M252 (Mosher, R. H. Ranade, N. P., Schrempf, H., and Vining, L. C. (1990) J. Gen. Microbiol. 136, 293-301), Transformants rapidly metabolized Cm to one major product, which was isolated and purified by reversed phase chromatography, The metabolite was identified by nuclear magnetic resonance spectroscopy and mass spectrometry as 3'-O-phospho-Cm, and was shown to have negligible inhibitory activity against Cm sensitive Micrococcus luteus, The nucleotide sequence of the S. venezuelae DNA insert in pJV4 contains an open reading frame (ORF) that encodes a polypeptide (19 kDa) with a consensus motif at its NH, terminus corresponding to a nucleotide-binding amino acid sequence (motif A or P-loop; Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) EMBO J. 1, 945-951). When a recombinant vector containing this ORF as a 1.6-kilobase pair SmaI-SmaI fragment was used to transform S. lividans M252, uniformly Cm-resistant transformants were obtained, A strain of S. lividans transformed by a vector in which the ORF had been disrupted by an internal deletion yielded clones that were unable to phosphorylate Cm, and exhibited normal susceptibility to the antibiotic. The results implicate the product of the ORF from S. venezuelae as an enzymic effector of Cm resistance in the producing organism by 3'-O-phosphorylation. We suggest the trivial name chloramphenicol 3'-O-phosphotransferase for the enzyme.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND; DALHOUSIE UNIV, DEPT BIOL, HALIFAX, NS B3H 4J1, CANADA	University of Leicester; Dalhousie University								ALEXEEV D, 1994, STRUCTURE, V2, P1061, DOI 10.1016/S0969-2126(94)00109-X; BIBB MJ, 1982, MOL GEN GENET, V187, P265, DOI 10.1007/BF00331128; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; CUNDLIFFE E, 1992, CIBA F SYMP, V171, P199; DESOMER J, 1992, MOL MICROBIOL, V6, P2377, DOI 10.1111/j.1365-2958.1992.tb01412.x; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DITTRICH W, 1991, MOL MICROBIOL, V5, P2789, DOI 10.1111/j.1365-2958.1991.tb01987.x; DORAN JL, 1990, J IND MICROBIOL, V5, P197, DOI 10.1007/BF01569677; Hopwood D. A., 1985, GENETIC MANIPULATION; HUANG WJ, 1994, STRUCTURE, V2, P407, DOI 10.1016/S0969-2126(00)00042-3; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; LARSON JL, 1986, PLASMID, V15, P199, DOI 10.1016/0147-619X(86)90038-7; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; MALIK VS, 1972, CAN J MICROBIOL, V18, P137, DOI 10.1139/m72-023; MALIK VS, 1970, CAN J MICROBIOL, V16, P173, DOI 10.1139/m70-030; MCMURRY LM, 1987, ANTIMICROB AGENTS CH, V31, P1648, DOI 10.1128/AAC.31.10.1648; MILNERWHITE EJ, 1991, J MOL BIOL, V221, P751; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOSHER RH, 1990, J GEN MICROBIOL, V136, P293, DOI 10.1099/00221287-136-2-293; MOSHER RH, 1993, THESIS DALHOUSIE U C; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; MURAKAMI T, 1989, J BACTERIOL, V171, P1459, DOI 10.1128/jb.171.3.1459-1466.1989; NAKANO H, 1977, J ANTIBIOT, V30, P76, DOI 10.7164/antibiotics.30.76; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONGS O, 1979, ANTIBIOTICS MECH ACT, P26; REEDER T, 1991, J BACTERIOL, V173, P7765, DOI 10.1128/jb.173.24.7765-7771.1991; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHAW WV, 1983, CRC CR REV BIOCH MOL, V14, P1, DOI 10.3109/10409238309102789; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SHAW WV, 1976, J GEN MICROBIOL, V94, P159, DOI 10.1099/00221287-94-1-159; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; STURROCK SS, 1993, BIOCOMPUTING UNIT; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; UCHIYAMA H, 1985, GENE, V38, P103, DOI 10.1016/0378-1119(85)90208-2; Vining LC, 1984, BIOTECHNOLOGY IND AN, P387; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; WU LJ, 1991, J BACTERIOL, V173, P4877, DOI 10.1128/jb.173.15.4877-4888.1991; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	49	45	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27000	27006		10.1074/jbc.270.45.27000	http://dx.doi.org/10.1074/jbc.270.45.27000			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592948	hybrid			2022-12-25	WOS:A1995TE58300048
J	HARADA, S; SMITH, RM; SMITH, JA; SHAH, N; HU, DQ; JARETT, L				HARADA, S; SMITH, RM; SMITH, JA; SHAH, N; HU, DQ; JARETT, L			INSULIN-INDUCED EGR-1 EXPRESSION IN CHINESE-HAMSTER OVARY CELLS IS INSULIN-RECEPTOR AND INSULIN-RECEPTOR SUBSTRATE-1 PHOSPHORYLATION-INDEPENDENT - EVIDENCE OF AN ALTERNATIVE SIGNAL-TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; IMMEDIATE-EARLY GENES; RAT HEPATOMA-CELLS; HYBRID RECEPTORS; NUCLEI; ACCUMULATION; STIMULATION; INTERNALIZATION; LIVER; RNA	Insulin's effects primarily are initiated by insulin binding to its plasma membrane receptor and the sequential tyrosine phosphorylation of the insulin receptor and intracellular substrates, such as insulin receptor substrate-1 (IRS-1), However, studies suggest some insulin effects, including those at the nucleus, may not be regulated by this pathway, The present study compared the levels of insulin binding, insulin receptor and IRS-1 tyrosine phosphorylation, and phosphatidylinositol 3'-kinase activity to immediate early gene c-fos and egr-1 mRNA expression in Chinese hamster ovary (CHO) cells expressing only neomycin-resistant plasmid (CHONEO), overexpressing wild type human insulin receptor (CHOHIRc) or ATP binding site-mutated insulin receptors (CHOA1018K). Insulin binding in CHONEO cells was markedly lower than that in other cell types, 10 nM insulin significantly increased tyrosine phosphorylation of insulin receptor and IRS-1 in CHOHIRc cells, Phosphorylation of insulin receptor and IRS-I in CHONEO and CHOA1018K cells was not detected in the presence or absence of insulin, Similarly, insulin increased phosphatidylinositol S-kinase activity only in CHOHIRc cells, As determined by Northern blot, nuclear run-on analysis, and in situ hybridization, insulin induced c-fos mRNA expression, through transcription, in CHOHIRc cells but not in CHONEO and CHOA1018K cells, consistent with previous reports, In contrast, all three cell types showed a similar insulin dose-dependent increase of egr-1 mRNA expression through transcription. These data indicated that insulin-induced egr-1 mRNA expression did not correlate with the levels of insulin binding to insulin receptor or phosphorylation of insulin receptor and IRS-1. These results suggest that different mechanisms are involved in induction of c-fos and egr-1 mRNA expression by insulin, the former by the more classic insulin receptor tyrosine kinase pathway and the latter by a yet to be determined alternative signal transduction pathway.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania					NIDDK NIH HHS [DK19525, DK28144, DK28143] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK028144, R01DK028143] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABLER A, 1992, J BIOL CHEM, V267, P3946; ANDO A, 1992, J BIOL CHEM, V267, P12788; ANDROLEWICZ MJ, 1989, BIOCHEMISTRY-US, V28, P9750, DOI 10.1021/bi00451a031; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BLAZERYOST BL, 1992, BIOCHEM INT, V28, P143; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; CONWAY BR, 1995, DIABETES, V44, pA50; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; FRATTALI AL, 1992, J CELL BIOCHEM, V48, P43, DOI 10.1002/jcb.240480108; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; HARADA S, 1992, J CELL PHYSIOL, V153, P607, DOI 10.1002/jcp.1041530323; HARADA S, 1994, DNA CELL BIOL, V13, P487, DOI 10.1089/dna.1994.13.487; HAWKER JR, 1992, AM J PHYSIOL, V262, pH1525, DOI 10.1152/ajpheart.1992.262.5.H1525; HEYNER S, 1989, DEV BIOL, V134, P48, DOI 10.1016/0012-1606(89)90077-8; HOPKINS CR, 1994, BIOCHEM PHARMACOL, V47, P151, DOI 10.1016/0006-2952(94)90449-9; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JUHN BH, 1995, BIOCHEMISTRY-US, V34, P7996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI NX, 1994, ONCOGENE, V9, P3457; LIN YZJ, 1992, P NATL ACAD SCI USA, V89, P9691, DOI 10.1073/pnas.89.20.9691; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; LOTEN EG, 1993, INT J BIOCHEM, V5, P653; MAGGI D, 1994, BIOCHEM BIOPH RES CO, V205, P693, DOI 10.1006/bbrc.1994.2721; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V155, P562; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOREL G, 1994, BIOCHEM PHARMACOL, V47, P63, DOI 10.1016/0006-2952(94)90438-3; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; Prystowsky M B, 1994, Immunomethods, V5, P49, DOI 10.1006/immu.1994.1037; PURRELLO F, 1983, P NATL ACAD SCI-BIOL, V80, P1189, DOI 10.1073/pnas.80.5.1189; PURRELLO F, 1982, SCIENCE, V215, P1005; RAPER SE, 1987, GASTROENTEROLOGY, V92, P1243, DOI 10.1016/S0016-5085(87)91084-5; SCHUMM DE, 1983, J CELL BIOCHEM, V23, P223, DOI 10.1002/jcb.240230119; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SMITH RM, 1987, P NATL ACAD SCI USA, V84, P459, DOI 10.1073/pnas.84.2.459; SMITH RM, 1990, DIABETES, V39, P683, DOI 10.2337/diabetes.39.6.683; SOLER AP, 1990, ENDOCRINOLOGY, V127, P595; SOLER AP, 1992, DIABETES, V41, P194, DOI 10.2337/diabetes.41.2.194; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAUB R, 1987, J BIOL CHEM, V262, P10893; VETTEMONY L, 1994, MOL ENDOCRINOL, V31, P623; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; WEITZMANN MN, 1992, BIOCHEM BIOPH RES CO, V187, P1166, DOI 10.1016/0006-291X(92)91319-L; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WONG EHA, 1995, ENDOCRINOLOGY, V136, P1459, DOI 10.1210/en.136.4.1459; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1995, DIABETES, V44, pA50; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	57	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26632	26638		10.1074/jbc.270.44.26632	http://dx.doi.org/10.1074/jbc.270.44.26632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592888	hybrid			2022-12-25	WOS:A1995TC97800095
J	IM, WB; PREGENZER, JF; BINDER, JA; DILLON, GH; ALBERTS, GL				IM, WB; PREGENZER, JF; BINDER, JA; DILLON, GH; ALBERTS, GL			CHLORIDE CHANNEL EXPRESSION WITH THE TANDEM CONSTRUCT OF ALPHA-6-BETA-2 GABA(A) RECEPTOR SUBUNIT REQUIRES A MONOMERIC SUBUNIT OF ALPHA-6 OR GAMMA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINOBUTYRIC ACIDA-RECEPTOR; A RECEPTORS; BENZODIAZEPINE SITE; BINDING-SITES; BETA-SUBUNIT; SUBTYPES; CURRENTS; ALPHA-1-BETA-2-GAMMA-2; HETEROGENEITY; PURIFICATION	Despite the presence of the multiple subunits (alpha, beta, gamma, and delta) and their isoforms for gamma-aminobutyric acid, type A (GABA(A)) receptors in mammalian brains, the alpha x beta 2 gamma 2 subtypes appear to be the prototype GABA(A) receptors sharing many properties with native neuronal receptors, In order to gain insight into their subunit stoichiometry and orientation, we prepared a tandem construct of the alpha 6 and beta 2 subunit cDNAs where the carboxyl-terminal of alpha 6 is linked to the amino terminal of beta 2 via a linker encoding 10 glutamine residues. Transfection of human embryonic kidney 293 cells with the tandem construct alone failed to induce GABA-dependent Cl- currents, but its cotransfection with the cDNA for alpha 6 or gamma 2, but not beta 2, led to the appearance of GABA currents which were picrotoxin-sensitive and, in the case of gamma 2 containing receptors, responded to a benzodiazepine agonist, U-92330. The high affinity GABA site, however, was detected with [H-3]muscimol binding in all combinations of the receptor subunits, including the tandem construct alone or with the beta 2. No appreciable differences were found in their K-d (2.5 nM) and B-max values (1.4 pmol/mg of protein), These data are consistent with the view that the polypeptides arising from the tandem construct were expressed with the high affinity GABA site, but unable to form GABA channels, The requirement of a specific monomeric subunit (alpha 6 or gamma 2) for the tandem construct to express Cl- currents supports a pentameric structure of GABA(A) receptors consisting of two alpha 6, two beta 2, and one gamma 2 for the alpha 6 beta 2 gamma 2 and three alpha 6 and two beta 2 for the alpha 6 beta 2 subtype.			IM, WB (corresponding author), UPJOHN CO,CNS DIS RES 7251209114,KALAMAZOO,MI 49001, USA.							AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BARNARD EC, 1993, ANN NY ACAD SCI, V707, P117; BATESON AN, 1991, J NEUROCHEM, V56, P1437, DOI 10.1111/j.1471-4159.1991.tb11443.x; CARTER DB, 1992, BIO-TECHNOL, V10, P679, DOI 10.1038/nbt0692-679; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; DILLON GH, 1993, MOL PHARMACOL, V44, P860; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARVEY RJ, 1993, FEBS LETT, V331, P211, DOI 10.1016/0014-5793(93)80339-V; HURST RS, 1992, J BIOL CHEM, V267, P23742; IM HK, 1993, MOL PHARMACOL, V44, P866; IM WB, 1994, BRIT J PHARMACOL, V112, P1025, DOI 10.1111/j.1476-5381.1994.tb13185.x; IM WB, 1993, BRIT J PHARMACOL, V110, P677, DOI 10.1111/j.1476-5381.1993.tb13864.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LUDDENS H, 1991, J RECEPTOR RES, V11, P535, DOI 10.3109/10799899109066426; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PREGENZER JF, 1993, MOL PHARMACOL, V43, P801; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1991, MOL PHARMACOL, V39, P691; Sambrook J, 1989, MOL CLONING LABORATO; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WANG G, 1992, MOL PHARMACOL, V42, P996; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y	30	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26063	26066		10.1074/jbc.270.44.26063	http://dx.doi.org/10.1074/jbc.270.44.26063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592805	hybrid			2022-12-25	WOS:A1995TC97800012
J	LEPPERT, D; HAUSER, SL; KISHIYAMA, JL; AN, SZ; ZENG, L; GOETZL, EJ				LEPPERT, D; HAUSER, SL; KISHIYAMA, JL; AN, SZ; ZENG, L; GOETZL, EJ			STIMULATION OF MATRIX METALLOPROTEINASE-DEPENDENT MIGRATION OF T-CELLS BY EICOSANOIDS	FASEB JOURNAL			English	Article						ARACHIDONIC ACID; PROTEASE; CONNECTIVE TISSUE; IMMUNITY	ARACHIDONIC-ACID; LYMPHOCYTE MIGRATION; PROSTAGLANDIN-E2; EXPRESSION; RECEPTORS; 5-LIPOXYGENASE; LEUKOTRIENES; METABOLISM; ACTIVATION; INHIBITION	Prostaglandin E(2) (PGE(2)) and leukotriene B4 (LTB4), at nanomolar to micromolar concentrations, elicited migration of human blood T cells and cultured T lymphoblastoma cells of the Tsup-1 line through a layer of Matrigel basement membrane matrix, The density of Tsup-1 cell high-affinity receptors was low for PGE(2) and high for LTB4, resulting in respectively predominant chemokinetic and chemotactic: stimulation of migration, Migration-enhancing concentrations of PGE(2) and LTB4 also increased Tsup-1 cell content and secretion of matrix metalloproteinases (MMPs) 2, 3, and 9, which were quantified by Western blots and zymography, and augmented Tsup-1 cell-surface expression of the MMPs, as shown by flow cytometry, That a specific MMP inhibitor suppressed migration of blood T cells and Tsup-1 cells through Matrigel, but did not affect PGE(2)- and LTB4-initiated T cell migration through micropore filters without Matrigel, suggests dual requirements for MMP expression and enhanced motility in T cell passage through basement membranes.	UNIV CALIF SAN FRANCISCO,MED CTR,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT IMMUNOL & MED MICROBIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; BALTER MS, 1989, J IMMUNOL, V142, P602; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BETZ M, 1991, J IMMUNOL, V146, P108; COETZL EJ, 1988, ANN NY ACAD SCI, V524, P345; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; FARRAR WL, 1985, J IMMUNOL, V135, P1153; FONTEH AN, 1993, J IMMUNOL, V150, P563; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FREITAS AA, 1979, IMMUNOLOGY, V36, P247; FUJIMOTO N, 1993, CLIN CHIM ACTA, V221, P91, DOI 10.1016/0009-8981(93)90024-X; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; GOETZL EJ, 1981, MED CLIN N AM, V65, P809, DOI 10.1016/S0025-7125(16)31499-7; GOETZL EJ, 1995, IN PRESS FASEB J; GOETZL EJ, 1994, CELLULAR GENERATION; GOLDMAN DW, 1991, J IMMUNOL, V146, P2671; HOPKINS J, 1981, IMMUNOLOGY, V42, P225; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; LEPPERT D, 1995, J IMMUNOL, V154, P4379; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MCCARTY J, 1979, CELL IMMUNOL, V43, P103, DOI 10.1016/0008-8749(79)90154-0; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; NAMBA T, 1994, J BIOL CHEM, V269, P9986; OPPENHEIMERMARKS N, 1994, J IMMUNOL, V152, P5703; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; ROLAPLESZCZYNSK.M, 1987, J IMMUNOL, V139, P513; ROLAPLESZCZYNSK.M, 1982, BIOCHEM BIOPH RES CO, V108, P1531; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; VANEPPS DE, 1981, INFLAMMATION, V5, P81, DOI 10.1007/BF00910782; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	40	90	97	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1995	9	14					1473	1481		10.1096/fasebj.9.14.7589989	http://dx.doi.org/10.1096/fasebj.9.14.7589989			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589989				2022-12-25	WOS:A1995TF67800012
J	REZAIE, AR; COOPER, ST; CHURCH, FC; ESMON, CT				REZAIE, AR; COOPER, ST; CHURCH, FC; ESMON, CT			PROTEIN-C INHIBITOR IS A POTENT INHIBITOR OF THE THROMBIN-THROMBOMODULIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT THROMBOMODULIN; BLOOD-COAGULATION; GLYCOSAMINOGLYCAN COMPONENT; PLASMINOGEN-ACTIVATOR; HEPARIN-BINDING; PLASMA; COFACTOR; ANTITHROMBIN; SPECIFICITY; INVITRO	Protein C inhibitor (PCI), a plasma serine protease inhibitor, inhibits several proteases including the anticoagulant enzyme, activated protein C (APC), and the coagulation enzymes, thrombin and factor Xa. Previous studies have shown that thrombin and APC are inhibited at similar rates by PCI and that heparin accelerates PCI inhibition of both enzymes more than 20-fold, We now demonstrate that the thrombin-binding proteoglycan, rabbit thrombomodulin, accelerates inhibition of thrombin by PCI approximate to 140-fold (k(2) = 2.4 x 10(6) in the presence of TM compared to 1.7 x 10(4) M(-1) s(-1) in the absence of TM). Most of this effect is mediated by protein-protein interactions since the active fragment of TM composed of epidermal growth factor-like domains 4-6 (TM 4-6) accelerates inhibition by PCI approximate to 59-fold (k(2) = 1.0 x 10(6) M(-1) s(-1)). The mechanism by which TM alters reactivity with PCI appears to reside in part in an alteration of the 52 specificity pocket. Replacing Phe(353) with Pro at the P2 position in the reactive loop of PCI yields a mutant that inhibits thrombin better in the absence of TM (k(2) = 6.3 x 10(5) M(-1) s(-1)), but TM 4-6 enhances inhibition by this mutant approximate to 9-fold (k(2) = 5.8 x 10(6) M(-1) s(-1)) indicating that TM alleviates the inhibitory effect of the less favored Phe residue. These results indicate that PCI is a potent inhibitor of the protein C anticoagulant pathway at the levels of both zymogen activation and enzyme inhibition.	UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	REZAIE, AR (corresponding author), OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NHLBI NIH HHS [R37 HL30340, R01 HL29807, P01 HL54804-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804, R01HL029807, R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; COOPER ST, 1995, BBA-PROTEIN STRUCT M, V1246, P29, DOI 10.1016/0167-4838(94)00185-J; DEMUNK GAW, 1993, BIOCHEM J, V290, P655, DOI 10.1042/bj2900655; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESPANA F, 1991, BLOOD, V77, P1754; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; HEEB MJ, 1991, J BIOL CHEM, V266, P17606; HEEB MJ, 1989, BLOOD, V73, P446; HEEB MJ, 1988, J BIOL CHEM, V263, P11613; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LIN JH, 1994, J BIOL CHEM, V269, P25021; MAILLARD C, 1993, ENDOCRINOLOGY, V133, P668, DOI 10.1210/en.133.2.668; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MOLINARI A, 1992, THROMB HAEMOSTASIS, V67, P226; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1992, J BIOL CHEM, V267, P8789; RADTKE KP, 1994, J CLIN INVEST, V94, P2117, DOI 10.1172/JCI117566; RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; STONE SR, 1985, BIOCHEM J, V230, P497, DOI 10.1042/bj2300497; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; TAKANO S, 1990, BLOOD, V76, P2024; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1994, J BIOL CHEM, V269, P17965	38	159	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25336	25339		10.1074/jbc.270.43.25336	http://dx.doi.org/10.1074/jbc.270.43.25336			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592694	hybrid, Green Published			2022-12-25	WOS:A1995TB46600010
J	SHI, XY; BAI, S; FORD, AC; BURK, RD; JACQUEMIN, E; HAGENBUCH, B; MEIER, PJ; WOLKOFF, AW				SHI, XY; BAI, S; FORD, AC; BURK, RD; JACQUEMIN, E; HAGENBUCH, B; MEIER, PJ; WOLKOFF, AW			STABLE INDUCIBLE EXPRESSION OF A FUNCTIONAL-RAT LIVER ORGANIC ANION TRANSPORT PROTEIN IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; PLASMA-MEMBRANE; BINDING-PROTEIN; SERUM-ALBUMIN; BILIRUBIN; SULFOBROMOPHTHALEIN; CHLORIDE	Recently we expression cloned a rat liver organic anion transport protein in Xenopus laevis oocytes (Jacquemin, E., Hagenbuch, B., Stieger, B., Wolkoff, A. W., and Meier, P. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 133-137). In the present study, we have stably transfected the cDNA encoding this protein into HeLa cells by using a vector containing a zinc-inducible promoter. The parent cells have virtually no baseline transport of [S-35]sulfobromophthalein, whereas the induced transfected cells express a novel 74-kDa protein and avidly transport this ligand. Transport by these cells is saturable (K-m = 3.3 mu M, V-max = 257 pmol/min/mg protein), bidirectional, and highly temperature-dependent. In the presence of albumin, uptake of [S-35]sulfobromophthalein requires the presence of extracellular Cl-, whereas in the absence of albumin, this Cl- dependence is not seen. These studies indicate that cellular uptake of sulfobromophthalein does not result hom direct interaction with the plasma membrane lipid bilayer but rather requires the presence of a specific plasma membrane transporter.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; UNITE RECH,F-94275 LE KREMLIN BICETR,FRANCE; UNIV ZURICH HOSP,DIV CLIN PHARMACOL,CH-8091 ZURICH,SWITZERLAND	Yeshiva University; Albert Einstein College of Medicine; University of Zurich; University Zurich Hospital			Hagenbuch, Bruno/M-5294-2016; jacquemin, emmanuel/J-8673-2013	Hagenbuch, Bruno/0000-0002-2938-8630; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK023026, P30DK041296] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-23026, DK-41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERK PD, 1987, HEPATOLOGY, V7, P165, DOI 10.1002/hep.1840070131; BLAUER G, 1972, BIOCHIM BIOPHYS ACTA, V278, P89, DOI 10.1016/0005-2795(72)90109-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; GOESER T, 1990, J CLIN INVEST, V86, P220, DOI 10.1172/JCI114687; GUPTA SL, 1994, INFECT IMMUN, V62, P2277, DOI 10.1128/IAI.62.6.2277-2284.1994; HAO XY, 1994, BIOCHEM J, V297, P59, DOI 10.1042/bj2970059; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JACQUEMIN E, 1991, J CLIN INVEST, V88, P2146, DOI 10.1172/JCI115546; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCNEALL J, 1989, GENE, V76, P81, DOI 10.1016/0378-1119(89)90010-3; MIN AD, 1991, HEPATOLOGY, V14, P1217, DOI 10.1002/hep.1840140642; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; NOY N, 1992, BIOPHYS CHEM, V42, P177, DOI 10.1016/0301-4622(92)85007-Q; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SHNEIDER BL, 1993, J BIOL CHEM, V268, P6985; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; TIRIBELLI C, 1990, BIOCHIM BIOPHYS ACTA, V1031, P261, DOI 10.1016/0304-4157(90)90012-2; Wolkoff Allan W., 1994, P179; WOLKOFF AW, 1979, AM J PHYSIOL, V236, pE638, DOI 10.1152/ajpendo.1979.236.6.E638; WOLKOFF AW, 1985, J CLIN INVEST, V76, P454, DOI 10.1172/JCI111993; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946	25	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25591	25595		10.1074/jbc.270.43.25591	http://dx.doi.org/10.1074/jbc.270.43.25591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592731	hybrid			2022-12-25	WOS:A1995TB46600048
J	SINGH, S; AGGARWAL, BB				SINGH, S; AGGARWAL, BB			ACTIVATION OF TRANSCRIPTION FACTOR NF-KAPPA-B IS SUPPRESSED BY CURCUMIN (DIFERULOLYLMETHANE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR-ALPHA; PROTEIN-KINASE; INTACT-CELLS; MOUSE SKIN; BINDING; EXPRESSION; PROMOTION; DNA	When activated, NF-kappa B, a ubiquitous transcription factor, binds DNA as a heterodimeric complex composed of members of the Rel/NF-kappa B family of polypeptides. Because of its intimate involvement in host defense against disease, this transcription factor is an important target for therapeutic intervention, In the present report we demonstrate that curcumin (diferuloylmethane), a known anti-inflammatory and anticarcinogenic agent, is a potent inhibitor of NF-kappa B activation. Treatment of human myeloid ML-1a cells with tumor necrosis factor (TNF) rapidly activated NF-kappa B, which consists of p50 and p65 subunits, and this activation was inhibited by curcumin, AP-1 binding factors were also found to be down-modulated by curcumin, whereas the Sp1 binding factor was unaffected. Besides TNF, curcumin also blocked phorbol ester-and hydrogen peroxide-mediated activation of NF-kappa B. The TNF-dependent phosphorylation and degradation of I kappa B alpha was not observed in curcumin-treated cells; the translocation of p65 subunit to the nucleus was inhibited at the same time, The mechanism of action of curcumin was found to be different from that of protein tyrosine phosphatase inhibitors, Our results indicate that curcumin inhibits NF-kappa B activation pathway at a step before I kappa B alpha phosphorylation but after the convergence of various stimuli.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC ONCOL, CYTOKINE RES LAB, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AMMON HPT, 1993, J ETHNOPHARMACOL, V38, P113, DOI 10.1016/0378-8741(93)90005-P; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; AZUINE MA, 1992, NUTR CANCER, V17, P77, DOI 10.1080/01635589209514174; AZUINE MA, 1992, INT J CANCER, V51, P412, DOI 10.1002/ijc.2910510313; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CONNEY AH, 1991, ADV ENZYME REGUL, V31, P385, DOI 10.1016/0065-2571(91)90025-H; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EICHER DM, 1994, J IMMUNOL, V152, P2710; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GENG Y, 1993, J IMMUNOL, V151, P6692; GRILLI M, 1993, INT REV CYTOL, V143, P1; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HUANG MT, 1992, CARCINOGENESIS, V13, P2183, DOI 10.1093/carcin/13.11.2183; HUANG MT, 1988, CANCER RES, V48, P5941; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; KIM HK, 1995, J IMMUNOL, V154, P4741; KOONG AC, 1994, CANCER RES, V54, P1425; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; MAHON TM, 1995, BIOCHEM SOC T, V23, pS111, DOI 10.1042/bst023111s; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGABHUSHAN M, 1992, J AM COLL NUTR, V11, P192; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; REDDY S, 1994, FEBS LETT, V341, P19, DOI 10.1016/0014-5793(94)80232-7; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SATOSKAR RR, 1986, INT J CLIN PHARM TH, V24, P651; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHANNON AG, 1980, FIBONACCI QUART, V18, P73; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SINGH H, 1995, CELL, V270, P10631; TAKADA T, 1994, CANCER RES, V54, P4653; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; YANG ZH, 1993, J BIOL CHEM, V268, P20520	50	1175	1220	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24995	25000		10.1074/jbc.270.42.24995	http://dx.doi.org/10.1074/jbc.270.42.24995			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559628	hybrid			2022-12-25	WOS:A1995TB46500062
J	XUI, ZJ; MOFFETT, DB; PETERS, TR; SMITH, LD; PERRY, BP; WHITMER, J; STOKKE, SA; TEINTZE, M				XUI, ZJ; MOFFETT, DB; PETERS, TR; SMITH, LD; PERRY, BP; WHITMER, J; STOKKE, SA; TEINTZE, M			THE ROLE OF THE LEADER SEQUENCE CODING REGION IN EXPRESSION AND ASSEMBLY OF BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; BACTERIO-OPSIN GENE; HALOBACTERIUM-HALOBIUM; HALORHODOPSIN; VESICLES; ARCHAEBACTERIUM; RECONSTITUTION; ASSOCIATION; INSERTION; BILAYERS	Bacterio-opsin is made as a precursor in Halobacterium halobium, which has 13 additional residues at the amino terminus. The codons for these residues have been proposed to form a hairpin structure in the mRNA and play a role in ribosome binding; the leader peptide sequence also has been proposed to have a role in membrane insertion of bacteriorhodopsin (BR). We have made mutations in the bop gene region coding for the leader sequence and expressed the mutant genes in an H. halobium mutant lacking wild-type BR. The leader sequence coding region was found to be important for the stability of the mRNA and for its efficient translation. Single base substitutions in this region that did not affect the amino acid sequence caused significant reductions in protein expression. Deletion of the leader region resulted in unstable mRNA and almost no BR production. Introduction of a new ribosome-binding sequence within the coding region of the mature protein restored mRNA stability and some protein expression, Protein made without the leader peptide was properly assembled in the membrane.	MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA	Montana State University System; Montana State University Bozeman					NIGMS NIH HHS [GM38142] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038142] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUER U, 1992, BIOCHEM BIOPH RES CO, V187, P1480, DOI 10.1016/0006-291X(92)90469-2; BETLACH M, 1984, NUCLEIC ACIDS RES, V12, P7949, DOI 10.1093/nar/12.20.7949; BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; CLINE SW, 1989, CAN J MICROBIOL, V35, P148, DOI 10.1139/m89-022; DASSARMA S, 1983, P NATL ACAD SCI-BIOL, V80, P2201, DOI 10.1073/pnas.80.8.2201; DENCHER NA, 1986, BIOCHEMISTRY-US, V25, P1195, DOI 10.1021/bi00353a038; DUNN R, 1981, P NATL ACAD SCI-BIOL, V78, P6744, DOI 10.1073/pnas.78.11.6744; GROPP R, 1992, P NATL ACAD SCI USA, V89, P1204, DOI 10.1073/pnas.89.4.1204; HEYMANN JAW, 1993, MOL MICROBIOL, V7, P623, DOI 10.1111/j.1365-2958.1993.tb01153.x; LAM WL, 1989, P NATL ACAD SCI USA, V86, P5478, DOI 10.1073/pnas.86.14.5478; NI B, 1990, GENE, V90, P169, DOI 10.1016/0378-1119(90)90456-2; Oesterhelt D, 1974, Methods Enzymol, V31, P667; Sambrook J, 1989, MOL CLONING LABORATO; SCOTTO AW, 1990, BIOCHEMISTRY-US, V29, P7244, DOI 10.1021/bi00483a012; SCOTTO AW, 1988, J BIOL CHEM, V263, P18500; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; SEEHRA JS, 1984, J BIOL CHEM, V259, P4187; SPUDICH EN, 1993, J BIOL CHEM, V268, P16095; STEINER M, 1983, EMBO J, V2, P1379, DOI 10.1002/j.1460-2075.1983.tb01595.x; VONHEIJNE G, 1987, FEBS LETT, V213, P238, DOI 10.1016/0014-5793(87)81497-7; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAKIM D, 1989, METHOD ENZYMOL, V171, P253	24	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24858	24863		10.1074/jbc.270.42.24858	http://dx.doi.org/10.1074/jbc.270.42.24858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559608	hybrid			2022-12-25	WOS:A1995TB46500042
J	DAVIDSON, VL; JONES, LH				DAVIDSON, VL; JONES, LH			COMPLEX-FORMATION WITH METHYLAMINE DEHYDROGENASE AFFECTS THE PATHWAY OF ELECTRON-TRANSFER FROM AMICYANIN TO CYTOCHROME C-551I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-TYPE CYTOCHROMES; PARACOCCUS-DENITRIFICANS; CRYSTAL-STRUCTURE; PROTEIN; CONSTANTS; OXIDATION; COPPER; ENZYME	Methylamine dehydrogenase (MADH), amicyanin, and cytochrome c-551i are soluble redox proteins that form a complex in solution (Chen, L., Durley, R., Mathews, F. S., and Davidson, V. L. (1994) Science 264, 86-90), which is required for the physiologic electron transfer from the tryptophan tryptophylquinone cofactor of MADH to heme via the copper center of amicyanin. The reduction of cytochrome by amicyanin within the complex in solution has been demonstrated using rapid scanning stopped-flow spectroscopy. Electron transfer from free, uncomplexed, amicyanin to cytochrome c-551i occurs much more rapidly but only to a very small extent because the reaction is thermodynamically much less favorable when amicyanin is not associated with MADH (Gray, K. A., Davidson, V. L., and Knaff, D. B. (1988) J. Biol. Chem. 263, 13987-13990). These kinetic data suggest that amicyanin binding to cytochrome c-551i occurs at different sites when amicyanin is free and when it is in complex with MADH. A model for the interactions of these proteins is presented.			DAVIDSON, VL (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,2500 N STATE ST,JACKSON,MS 39216, USA.			Davidson, Victor/0000-0002-1966-7302	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41574] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; DAVIDSON VL, 1993, BIOCHIM BIOPHYS ACTA, V1144, P39, DOI 10.1016/0005-2728(93)90028-E; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; DAVIDSON VL, 1991, ANAL CHIM ACTA, V249, P235, DOI 10.1016/0003-2670(91)87028-6; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; GRAY KA, 1986, FEBS LETT, V207, P239, DOI 10.1016/0014-5793(86)81496-X; GRAY KA, 1988, J BIOL CHEM, V263, P13987; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4	17	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23941	23943		10.1074/jbc.270.41.23941	http://dx.doi.org/10.1074/jbc.270.41.23941			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592588	hybrid			2022-12-25	WOS:A1995TA21700016
J	DEBERNARD, M; PAPINI, E; DEFILIPPIS, V; GOTTARDI, E; TELFORD, J; MANETTI, R; FONTANA, A; RAPPUOLI, R; MONTECUCCO, C				DEBERNARD, M; PAPINI, E; DEFILIPPIS, V; GOTTARDI, E; TELFORD, J; MANETTI, R; FONTANA, A; RAPPUOLI, R; MONTECUCCO, C			LOW PH ACTIVATES THE VACUOLATING TOXIN OF HELICOBACTER-PYLORI, WHICH BECOMES ACID AND PEPSIN RESISTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHRONIC GASTRITIS; CAMPYLOBACTER; MUCUS	The protein toxin VacA, produced by cytotoxic strains of Helicobacter pylori, causes a vacuolar degeneration of cells, which eventually die. VacA is strongly activated by a short exposure to acidic solutions in the pH 1.5-5.5 range, followed by neutralization. Activated VacA has different CD and fluorescence spectra and a limited proteolysis fragmentation pattern from VacA kept at neutral pH. Moreover, activated VacA is resistant to pH 1.5 and to pepsin. The relevance of these findings to pathogenesis of H. pylori-induced gastrointestinal ulcers is discussed.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,PADUA,ITALY; UNIV PADUA,CRIBI,PADUA,ITALY; UNIV SIENA,IST RIC IMMUNOBIOL SIENNA,I-53100 SIENA,ITALY	University of Padua; University of Padua; University of Siena	DEBERNARD, M (corresponding author), UNIV PADUA,CNR,CTR BIOMEMBRANE,VIA TRIESTE 75,PADUA,ITALY.		Telford, John Laird/ABG-8144-2020; Papini, Emanuele/AAE-6961-2022	Papini, Emanuele/0000-0001-6033-4473; de Bernard, Marina/0000-0002-0091-4502				ALLEN A, 1980, GUT, V21, P249, DOI 10.1136/gut.21.3.249; BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0; Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1994, J BIOL CHEM, V269, P10566; COVER TL, 1992, J BIOL CHEM, V287, P10570; DEFILIPPIS V, 1995, EUR J BIOCHEM, V229, P61; DEFILIPPIS V, 1995, BIOCHEMISTRY-US, V35, P9552; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FIOCCA R, 1992, VIRCHOWS ARCH A, V420, P489, DOI 10.1007/BF01600253; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRIERI G, 1995, DIGESTION, V56, P107, DOI 10.1159/000201229; Guyton AC, 1991, TXB MED PHYSL; LAKOWICZ JR, 1986, PRINCIPLES FLUORESCE, P341; MARCHETTI M, 1995, SCIENCE, V1267, P1655; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MENESTRINA G, 1994, MOL ASPECTS MED, V15, P79, DOI 10.1016/0098-2997(94)90043-4; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; VANDENBERG L, 1959, ARCH BIOCHEM BIOPHYS, V81, P319, DOI 10.1016/0003-9861(59)90209-7; VUILLEUMIER S, 1992, BIOCHEMISTRY-US, V32, P10303; WARREN JR, 1983, LANCET, V1, P1273; WILLIAMS SE, 1981, GUT, V22, P94, DOI 10.1136/gut.22.2.94; YANG JT, 1986, METHOD ENZYMOL, V130, P208; 1993, LANCET, V341, P1359	31	171	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23937	23940		10.1074/jbc.270.41.23937	http://dx.doi.org/10.1074/jbc.270.41.23937			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592587	hybrid, Green Published			2022-12-25	WOS:A1995TA21700015
J	MURASAWA, S; MATSUBARA, H; MORI, Y; KIJIMA, K; MARUYAMA, K; INADA, M				MURASAWA, S; MATSUBARA, H; MORI, Y; KIJIMA, K; MARUYAMA, K; INADA, M			IDENTIFICATION OF A NEGATIVE CIS-REGULATORY ELEMENT AND TRANS-ACTING PROTEIN THAT INHIBIT TRANSCRIPTION OF THE ANGIOTENSIN-II TYPE 1A RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; RAT; SUBTYPE; ENHANCER; CLONING; CELLS	The rat angiotensin II type la receptor (AT1a-R) gene is expressed in a cell-specific manner. We demonstrated that the negative regulatory element (NRE) between -489 and -331 is active in PC12 cells (Murasawa, S., Matsubara, H., Urakami, M., and Inada, M. (1993) J. Biol. Chem. 268, 26996-27003). Gel retardation assays confirmed that PC12 cells have a trans-acting factor bound to the NRE. By means of a DNase I footprint assay we identified the core of the NRE as an (A + T)-rich sequence (TAATCTTTTATTTTA) located at nucleotides -456 to -442. Oligonucleotides corresponding to the NRE core sequence bound to nuclear protein. Site-directed mutagenesis at nucleotides -451 to -448 eliminated the specific protein/DNA binding and restored expression of the AT1a-R in transient transfection assays (2.7-fold increase). The NRE did not negatively affect the thymidine kinase promoter. No homology was found with known NREs, suggesting that this is a novel NRE. Southwestern blotting revealed a 53-kDa, specific binding protein in PC12 cells and the rat brain, but not in the liver, spleen, adrenal gland, and kidney. These findings demonstrate that the NRE of the rat AT1a-R is an (A + T) rich sequence located at nucleotides -456 to -442 and the 53-kDa protein is a specific binding protein, and suggest that this protein may be a trans acting factor which determines the neuron-specific down-regulation of the AT1a-R gene.	KANSAI MED UNIV,DEPT INTERNAL MED 2,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University								AUSUBEL FM, 1983, CURRENT PROTOCOL MOL; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUO DF, 1994, BBA-GENE STRUCT EXPR, V1218, P91, DOI 10.1016/0167-4781(94)90105-8; GUO DF, 1994, BIOCHEM BIOPH RES CO, V200, P313, DOI 10.1006/bbrc.1994.1450; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SUMMERS C, 1991, P NATL ACAD SCI USA, V88, P7567; SUZUKI J, 1993, CIRC RES, V73, P439, DOI 10.1161/01.RES.73.3.439; TAKAYANAGI R, 1994, BIOCHEM BIOPH RES CO, V200, P1264, DOI 10.1006/bbrc.1994.1587; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; ZHANG ZX, 1990, J BIOL CHEM, V265, P4785	29	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24282	24286		10.1074/jbc.270.41.24282	http://dx.doi.org/10.1074/jbc.270.41.24282			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592637	hybrid			2022-12-25	WOS:A1995TA21700065
J	PREVARSKAYA, NB; SKRYMA, RN; VACHER, P; DANIEL, N; DJIANE, J; DUFY, B				PREVARSKAYA, NB; SKRYMA, RN; VACHER, P; DANIEL, N; DJIANE, J; DUFY, B			ROLE OF TYROSINE PHOSPHORYLATION IN POTASSIUM CHANNEL ACTIVATION - FUNCTIONAL ASSOCIATION WITH PROLACTIN RECEPTOR AND JAK2 TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RABBIT MAMMARY-GLAND; CELL-PROLIFERATION; PROTEIN; STIMULATION; PHOSPHATASE; CALCIUM; DEPHOSPHORYLATION; INHIBITION; LONG	Chinese hamster ovary (CHO) cells, stably transfected with the long form of the prolactin (PRL) receptor (PRL-R) cDNA, were used for PRL-R signal transduction studies, Patch-clamp technique in whole cell and cell-free configurations were employed. Exposure of transfected CHO cells to 5 nM PRL led to the increase of Ca2+- and voltage-dependent K+ channel (K-Ca) activity, The effect was direct as it was observed also in excised patch experiments, A series of tyrosine kinase inhibitors was studied to investigate the possible involvement of protein tyrosine kinases in K-Ca functioning and its stimulation by PRL, Genistein, lavendustin A, and herbimycin A decreased in a concentration and time-dependent manner the amplitude of the K-Ca current in whole cell and the open probability of K-Ca channels in cell-free experiments, The subsequent application of PRL was ineffective, The protein tyrosine phosphatase inhibitor orthovanadate (1 mM) stimulated K-Ca channel activity in excised patches, indicating that channels can be modulated in opposite directions by protein tyrosine kinase and protein tyrosine phosphatase. Moreover, in whole cell experiments as well as in excised patch recordings, anti-JAK2 tyrosine kinase antibody decreased the K-Ca conductance and the open probability of the K-Ca channels. Subsequent application of PRL was no longer able to stimulate K-Ca conductance. Immunoblotting studies using the same anti-JAK2 antibody, revealed the constitutive association of JAK2 kinase with PRL-R. Preincubation of anti-JAK2 antibody with the JAK2 Immunizing Peptide abolished the effects observed using anti-JAK2 antibody alone in both electrophysiological and immunoblotting studies. We conclude from these findings that these K-Ca channels are regulated through tyrosine phosphorylation/dephosphorylation; JAK2 tyrosine kinase, constitutively associated with PRL-R, is implicated in PRL stimulation of K-Ca channels.	INRA,MOLEC ENDOCRINOL UNIT,F-78352 JOUY EN JOSAS,FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay	PREVARSKAYA, NB (corresponding author), UNIV BORDEAUX 2,NEUROPHYSIOL LAB,CNRS,URA 1200,146 RUE LEO SAIGNAT,F-33076 BORDEAUX,FRANCE.		Vacher, Pierre/N-2243-2018	Prevarskaya, natacha/0000-0003-0316-197X; VACHER, Pierre/0000-0003-3503-7981				ABERCROMBIE RF, 1981, J GEN PHYSIOL, V78, P413, DOI 10.1085/jgp.78.4.413; AKIJAMA T, 1987, J BIOL CHEM, V262, P5592; ALEXANDER D R, 1990, New Biologist, V2, P1049; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIGNON C, 1993, BIOTECHNIQUES, V15, P243; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DJIANE J, 1985, J BIOL CHEM, V260, P1430; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ESQUERRA M, 1994, NATURE, V369, P563; FUH G, 1993, J BIOL CHEM, V268, P5376; GASSER F, 1985, IN VITRO CELL DEV B, V21, P588; GRAIER WF, 1993, BIOCHEM J, V291, P2653; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG Y, 1994, J BIOL CHEM, V269, P31183; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LESUEUR L, 1990, MOL CELL ENDOCRINOL, V71, P7; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MATSUNAGA H, 1994, AM J PHYSIOL, V267, pC456, DOI 10.1152/ajpcell.1994.267.2.C456; NESTER EJ, 1993, BASIC NEUROCHEMISTRY, V22, P449; NICOLL CS, 1980, FED PROC, V39, P2563; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P3537; OBINATA A, 1991, EXP CELL RES, V193, P36, DOI 10.1016/0014-4827(91)90535-3; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ONO K, 1994, NATURE, V370, P294; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PARANT MR, 1990, ANAL BIOCHEM, V184, P283, DOI 10.1016/0003-2697(90)90682-Y; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PEPPELENBOSCH MP, 1992, CELL, V162, P295; PREVARSKAYA N, 1994, AM J PHYSIOL, V267, pC554, DOI 10.1152/ajpcell.1994.267.2.C554; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; REPP H, 1993, P NATL ACAD SCI USA, V90, P3703; ROMERO L, 1993, PROSTATE, V22, P1, DOI 10.1002/pros.2990220102; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SCHWEIZER FE, 1989, NATURE, V339, P709; SHEN SH, 1990, NATURE, V352, P736; SKRYMA R, 1994, AM J PHYSIOL, V267, pC544, DOI 10.1152/ajpcell.1994.267.2.C544; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SYMS AJ, 1985, PROSTATE, V6, P145, DOI 10.1002/pros.2990060204; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VACHER P, 1994, ENDOCRINOLOGY, V134, P1213, DOI 10.1210/en.134.3.1213; VANDERKUUR JA, 1994, J BIOL CHEM, V34, P21709; WANG YF, 1993, ENDOCRINOLOGY, V133, P2156, DOI 10.1210/en.133.5.2156; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WATERS MJ, 1995, J BIOL CHEM, V270, P5136, DOI 10.1074/jbc.270.10.5136; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	62	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24292	24299		10.1074/jbc.270.41.24292	http://dx.doi.org/10.1074/jbc.270.41.24292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592639	Green Published, hybrid			2022-12-25	WOS:A1995TA21700067
J	SCHUMAKER, KS; GIZINSKI, MJ				SCHUMAKER, KS; GIZINSKI, MJ			1,4-DIHYDROPYRIDINE BINDING-SITES IN MOSS PLASMA-MEMBRANES - PROPERTIES OF RECEPTORS FOR A CALCIUM-CHANNEL ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL MEMBRANES; SKELETAL-MUSCLE; CHLAMYDOMONAS-REINHARDTII; ALPHA-1 SUBUNIT; CA2+ CHANNELS; MOLECULAR-PROPERTIES; H-3 AZIDOPINE; DIHYDROPYRIDINE; VERAPAMIL; FUNARIA	An increase in cytoplasmic calcium is an early event in hormone (cytokinin)-induced vegetative bud formation in the moss Physcomitrella patens, Whole cell and calcium transport studies have implicated 1,4-dihydropyridine-sensitive calcium channels in this increase in cellular calcium, To understand the molecular nature of the dihydropyridine-sensitive calcium channel, we have established conditions for the binding of the arylazide 1,4-dihydropyridine, [H-3]azidopine, to its receptor in moss plasma membranes, [H-3]Azidopine bound specifically in a saturable and reversible manner, The K-D for [H-3]azidopine binding was 5.2 nM and the B-max was 35.6 pmol/mg of protein, Association and dissociation of the receptor and [H-3]azidopine were temperature-dependent, and association varied as a function of pH, Binding was inhibited by dihydropyridine, phenylalkylamine, and benzothiazepine calcium channel blockers, bepridil, lanthanum, and N-ethylmaleimide. [H-3]Azidopine binding was stimulated by cations including calcium, strontium, manganese, and barium, [H-3]Azidopine binding was also stimulated by cytokinin with a K-m value for kinetin of 0.13 nM. These studies utilize a simple plant system to provide a biochemical framework for understanding calcium regulation during development and have implications for understanding mechanisms of signal transduction in plants.			SCHUMAKER, KS (corresponding author), UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721, USA.							ANDREJAUSKAS E, 1985, J BIOL CHEM, V260, P5411; BOLGER GT, 1982, BIOCHEM BIOPH RES CO, V104, P1604, DOI 10.1016/0006-291X(82)91436-X; Boyd PJ, 1988, METHODS BRYOLOGY, P47; BRANDES H, 1968, PLANT PHYSIOL, V43, P827, DOI 10.1104/pp.43.5.827; BUSH DS, 1993, PLANT PHYSIOL, V103, P7, DOI 10.1104/pp.103.1.7; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CONRAD PA, 1988, PLANT PHYSIOL, V86, P684, DOI 10.1104/pp.86.3.684; DOLLE R, 1988, J CELL SCI, V90, P457; DOLLE R, 1988, ARCH MICROBIOL, V149, P451, DOI 10.1007/BF00425587; EVANS DE, 1991, J EXP BOT, V42, P285, DOI 10.1093/jxb/42.3.285; FERRY DR, 1985, EMBO J, V4, P1933, DOI 10.1002/j.1460-2075.1985.tb03873.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FOSSET M, 1983, European Journal of Pharmacology, V86, P141; GALIZZI JP, 1986, J BIOL CHEM, V261, P1393; GELLI A, 1993, PLANT PHYSIOL, V102, P1139, DOI 10.1104/pp.102.4.1139; GILROY S, 1994, BIOESSAYS, V16, P677, DOI 10.1002/bies.950160914; GILROY S, 1992, P NATL ACAD SCI USA, V89, P3591, DOI 10.1073/pnas.89.8.3591; GLOSSMANN H, 1982, TRENDS PHARMACOL SCI, V3, P431, DOI 10.1016/0165-6147(82)91221-4; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GOTTWALD R, 1988, METHODS BRYOLOGY, P73; GOULD RJ, 1982, P NATL ACAD SCI-BIOL, V79, P3656, DOI 10.1073/pnas.79.11.3656; GRAZIANA A, 1988, BIOCHEMISTRY-US, V27, P764, DOI 10.1021/bi00402a041; GROTHA R, 1986, PLANTA, V169, P546, DOI 10.1007/BF00392105; HAHM SH, 1991, CELL CALCIUM, V12, P675, DOI 10.1016/0143-4160(91)90037-F; HARVEY HJ, 1989, BIOCHEM J, V257, P95, DOI 10.1042/bj2570095; HEPLER PK, 1992, INT REV CYTOL, V138, P239, DOI 10.1016/S0074-7696(08)61590-9; HETHERINGTON AM, 1984, PLANT SCI LETT, V35, P109, DOI 10.1016/0304-4211(84)90183-4; Hodges T K, 1974, Methods Enzymol, V32, P392; HSIEH WL, 1991, PLANT PHYSIOL, V97, P1535, DOI 10.1104/pp.97.4.1535; LEHTONEN J, 1984, PLANT SCI LETT, V33, P53, DOI 10.1016/0304-4211(84)90068-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAGAHASHI J, 1982, PROTOPLASMA, V112, P167, DOI 10.1007/BF01284090; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; NULTSCH W, 1986, ARCH MICROBIOL, V144, P393, DOI 10.1007/BF00409890; PALMGREN MG, 1990, PLANT PHYSIOL, V92, P871, DOI 10.1104/pp.92.4.871; PANTOJA O, 1992, SCIENCE, V255, P1567, DOI 10.1126/science.255.5051.1567; PIERSON ES, 1994, PLANT CELL, V6, P1815, DOI 10.1105/tpc.6.12.1815; PTASIENSKI J, 1985, BIOCHEM BIOPH RES CO, V129, P910, DOI 10.1016/0006-291X(85)91978-3; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; ROBERTS AW, 1992, PLANTA, V186, P586, DOI 10.1007/BF00198040; RUTH P, 1985, EUR J BIOCHEM, V150, P313, DOI 10.1111/j.1432-1033.1985.tb09023.x; SANDERS D, 1994, PLANT CELL, V6, P685; SAUNDERS MJ, 1982, SCIENCE, V217, P943, DOI 10.1126/science.217.4563.943; SAUNDERS MJ, 1983, DEV BIOL, V99, P41, DOI 10.1016/0012-1606(83)90252-X; SAUNDERS MJ, 1981, PLANTA, V152, P272, DOI 10.1007/BF00385156; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUMAKER KS, 1986, J BIOL CHEM, V261, P2172; SCHUMAKER KS, 1993, P NATL ACAD SCI USA, V90, P10937, DOI 10.1073/pnas.90.23.10937; SCHWEITZ H, 1973, BIOCHEMISTRY-US, V12, P2841, DOI 10.1021/bi00739a010; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1993, CELL PHYSIOL BIOCHEM, V3, P295, DOI 10.1159/000154695; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TRETYN A, 1990, PHYSIOL PLANTARUM, V78, P230, DOI 10.1111/j.1399-3054.1990.tb02086.x	56	17	17	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23461	23467		10.1074/jbc.270.40.23461	http://dx.doi.org/10.1074/jbc.270.40.23461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559508	hybrid			2022-12-25	WOS:A1995RY90900037
J	LI, JM; NICHOLS, MA; CHANDRASEKHARAN, S; XIONG, Y; WANG, XF				LI, JM; NICHOLS, MA; CHANDRASEKHARAN, S; XIONG, Y; WANG, XF			TRANSFORMING GROWTH-FACTOR-BETA ACTIVATES THE PROMOTER OF CYCLIN-DEPENDENT KINASE INHIBITOR P15(INK4B) THROUGH AN SP1 CONSENSUS SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; BINDING FACTOR; TATA BOX; PROTEIN; DNA	Transforming growth factor beta (TGF-beta) causes growth arrest in the G(1) phase in many cell types. One probable pathway for this growth inhibition is through the TGF-beta-mediated up-regulation of the cyclin-dependent kinase (CDK) inhibitor p15(INK4B), which specifically inhibits the enzymatic activities of CDK4 and CDKG6. An active cyclin D-CDK4/6 complex is required for pRb phosphorylation to allow the cell cycle to progress from G(1) to S phase, To study the molecular mechanism of the p15(INK4B) induction by TGF-beta, we isolated a 780-base pair promoter sequence of the human p15 gene and inserted this fragment upstream of a luciferase reporter gene, When this construct was transiently transfected into HaCaT cells, luciferase activity was induced more than 10-fold upon TGF-beta treatment, indicating that the induction of p15(INK4B) expression by TGF-beta is partly exerted at the transcription level, Promoter deletion analysis revealed that the sequence from -110 to -40 relative to the transcription start site is capable of conferring the 10-fold induction by TGF-beta. Within this region there are three Spl consensus sites. Mutation of one of these sites, GGGGCGGAG, substantially reduced both the induction by TGF-beta and the basal promoter activity, whereas mutations in the other two Spl sites and the spacer sequences had Little effect. In addition, gel mobility shift assay indicates that the transcription factors Spl and Sp3 bind to this Spl site. Taken together, these data suggest that a specific Spl consensus site is involved in the mediation of TGF-beta induction as well as the basal promoter activity of the p15 gene and that Sp1 and Sp3 transcription factors might be involved in this regulation.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27708 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NCI NIH HHS [CA 65572] Funding Source: Medline; NIDDK NIH HHS [DK45746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DATTO MB, 1995, IN PRESS J BIOL CHEM, V270; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NEVINS JR, 1992, SCIENCE, V258, P424; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; Sanger F, 1992, Biotechnology, V24, P104; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298	30	233	237	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26750	26753		10.1074/jbc.270.45.26750	http://dx.doi.org/10.1074/jbc.270.45.26750			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592908	hybrid			2022-12-25	WOS:A1995TE58300008
J	MEYERS, MB; PICKEL, VM; SHEU, SS; SHARMA, VK; SCOTTO, KW; FISHMAN, GI				MEYERS, MB; PICKEL, VM; SHEU, SS; SHARMA, VK; SCOTTO, KW; FISHMAN, GI			ASSOCIATION OF SORCIN WITH THE CARDIAC RYANODINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT CHINESE-HAMSTER; CALCIUM-BINDING PROTEIN; SARCOPLASMIC-RETICULUM; RELEASE CHANNELS; CELL-LINES; SKELETAL; MUSCLE; GENES; DNA; AMPLIFICATION	Sorcin is a 22 kDa calcium-binding protein initially identified in multidrug-resistant cells; however, its patterns of expression and function in normal tissues are unknown. Here we demonstrate that sorcin is widely distributed in rodent tissues, including the heart, where it was localized by immunoelectron microscopy to the sarcoplasmic reticulum. A > 500-kDa protein band immunoprecipitated from cardiac myocytes by sorcin antiserum was indistinguishable in size on gels from the 565-kDa ryanodine receptor/calcium release channel recognized by ryanodine receptor-specific antibody. Association of sorcin with a ryanodine receptor complex was confirmed by complementary co-immunoprecipitations of sorcin with the receptor antibody. Forced expression of sorcin in ryanodine receptor-negative Chinese hamster lung fibroblasts resulted in accumulation of the predicted 22-kDa protein as well as the unexpected appearance of ryanodine receptor protein. In contrast to the parental host fibroblasts, sorcin transfectants displayed a rapid and transient rise in intracellular calcium in response to caffeine, suggesting organization of the accumulated ryanodine receptor protein into functional calcium release channels. These data demonstrate an interaction between sorcin and the ryanodine receptor and suggest a role for sorcin in modulation of calcium release channel activity, perhaps by stabilizing the channel protein.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; UNIV ROCHESTER,MED CTR,DEPT PHARMACOL,ROCHESTER,NY 14642; MEM SLOAN KETTERING CANC CTR,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Cornell University; University of Rochester; Memorial Sloan Kettering Cancer Center	MEYERS, MB (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV CARDIOL,MOLEC CARDIOL SECT,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Sheu, Shey-Shing/Y-4009-2019	Sheu, Shey-Shing/0000-0003-3838-3601; Fishman, Glenn/0000-0002-2366-8527	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033333] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NHLBI NIH HHS [HL-33333] Funding Source: Medline; NIMH NIH HHS [MH-00078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; CROW MT, 1984, EXP BIOL MED, V9, P165; DEBRUIJN MHL, 1986, MOL CELL BIOL, V6, P4717, DOI 10.1128/MCB.6.12.4717; DELEON JR, 1994, J MOL CELL CARDIOL, V26, P379, DOI 10.1006/jmcc.1994.1047; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JONGSMA APM, 1987, CANCER RES, V47, P2875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LERANTH C, 1989, NEUROANATOMICAL TRAC, P129; Meyers M B, 1989, Cancer Commun, V1, P233; Meyers M. B., 1991, NOVEL CALCIUM BINDIN, P385, DOI 10.1007/978-3-642-76150-8_22; MEYERS MB, 1987, BIOCHEM PHARMACOL, V36, P2373, DOI 10.1016/0006-2952(87)90606-X; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1985, J CELL BIOL, V100, P588, DOI 10.1083/jcb.100.2.588; MEYERS MB, 1990, STIMULUS RESPONSE CO, P159; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; PETERSON RHF, 1983, CANCER RES, V43, P222; SALAMA G, 1992, CELL CALCIUM, V13, P635, DOI 10.1016/0143-4160(92)90074-3; SHARP AH, 1993, J NEUROSCI, V13, P3051; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL F, 1992, MOL CELL BIOL, V12, P1179, DOI 10.1128/MCB.12.3.1179; SU JY, 1984, PFLUG ARCH EUR J PHY, V400, P14, DOI 10.1007/BF00670530; TEAHAN CG, 1992, BIOCHEM J, V286, P549, DOI 10.1042/bj2860549; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; VIKSTROM KL, 1993, CELL MOTIL CYTOSKEL, V26, P192, DOI 10.1002/cm.970260303; WANG SL, 1995, BBA-GENE STRUCT EXPR, V1260, P285, DOI 10.1016/0167-4781(94)00206-I; WILLIFORD DJ, 1990, CIRC RES, V66, P241, DOI 10.1161/01.RES.66.1.241; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	35	127	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26411	26418		10.1074/jbc.270.44.26411	http://dx.doi.org/10.1074/jbc.270.44.26411			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592856	hybrid			2022-12-25	WOS:A1995TC97800063
J	VENEPALLY, P; WATERMAN, MR				VENEPALLY, P; WATERMAN, MR			2 SP1-BINDING SITES MEDIATE CAMP-INDUCED TRANSCRIPTION OF THE BOVINE CYP11A GENE THROUGH THE PROTEIN-KINASE-A SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN CLEAVAGE CYTOCHROME-P-450; CYCLIC-AMP; MAMMALIAN-CELLS; STEROID HYDROXYLASES; RESPONSE ELEMENT; PHORBOL ESTERS; P-450SCC GENE; SUBUNIT GENE; PROMOTER; EXPRESSION	Two sequence elements located at -111 to -100 base pairs and -70 to -50 base pairs in the 5'-flanking region of the bovine CYP11A gene and in closely related positions in CYP11A of other species contain G-rich regions that are similar to the consensus Sp1-binding site. These sequences bind the purified transcription factor Spl as well as nuclear proteins from mouse Y1 adrenal cells that interact with an antibody specific for Spl. Both of these CYP11A sequences support basal and cAMP-dependent transcription of reporter gene plasmids transfected into Y1 cells, and mutations within the G-rich -111/-100-base pair sequence that reduce or eliminate the binding of Sp1-related Y1 nuclear proteins also markedly reduce cAMP-induced transcription. cAMP-dependent transcription supported by both CYP11A sequence elements is mediated by protein kinase A at levels comparable to that promoted by different cAMP-response sequences and transcription factors in other genes involved in steroidogenesis. These results indicate that ACTH-dependent regulation of cholesterol side chain cleavage cytochrome P450 levels in the adrenal cortex which is mediated through cAMP involves the ubiquitous transcription factor Sp1.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P475; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GUO IC, 1994, J BIOL CHEM, V269, P6362; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; JOHN ME, 1984, P NATL ACAD SCI-BIOL, V81, P5628, DOI 10.1073/pnas.81.18.5628; JOHN ME, 1987, MOL CELL ENDOCRINOL, V50, P263, DOI 10.1016/0303-7207(87)90025-6; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V94, P235, DOI 10.1016/0303-7207(93)90172-G; LUND J, 1990, J BIOL CHEM, V265, P3304; LUND J, 1988, J BIOL CHEM, V263, P16195; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MIYAMOTO N, 1992, ENDOCRINOLOGY, V130, P3231, DOI 10.1210/en.130.6.3231; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OONK RB, 1990, J BIOL CHEM, V265, P22392; PESTELL RG, 1993, J MOL ENDOCRINOL, V10, P297, DOI 10.1677/jme.0.0100297; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; RICE DA, 1990, J BIOL CHEM, V265, P11713; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WOOD WM, 1989, J BIOL CHEM, V264, P14840	47	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25402	25410		10.1074/jbc.270.43.25402	http://dx.doi.org/10.1074/jbc.270.43.25402			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592707	hybrid			2022-12-25	WOS:A1995TB46600023
J	MCKAY, GA; WRIGHT, GD				MCKAY, GA; WRIGHT, GD			KINETIC MECHANISM OF AMINOGLYCOSIDE PHOSPHOTRANSFERASE TYPE IIIA - EVIDENCE FOR A THEORELL-CHANCE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; STAPHYLOCOCCUS-AUREUS; ACETYLTRANSFERASE; SEQUENCE; GENES	Bacterial resistance to aminoglycoside-aminocyclitol antibiotics is mediated primarily by covalent modification of the drugs by a variety of enzymes. One such modifying enzyme, the 3'-aminoglycoside phosphotransferase, which is produced by Gram-positive cocci such as Enterococcus and Streptococcus inactivates a broad range of aminoglycosides by ATP-dependent phosphorylation of specific hydroxyl residues on the antibiotics. Through the use of dead-end and product inhibitor studies, we present the first detailed examination of the kinetic mechanism for the 3'-aminoglycoside phosphotransferase-IIIa, Initial velocity patterns deduced from steady-state kinetics indicate a sequential mechanism with ordered binding of ATP first followed by aminoglycoside. Dead-end inhibition by AMP and adenylyl-imidodiphosphate is competitive versus ATP and noncompetitive versus kanamycin A. Dead-end inhibition by tobramycin, a kanamycin analogue lacking a 3'-OH, is competitive versus both kanamycin A and uncompetitive versus ATP, indicative of ordered substrate binding where ATP must add prior to aminoglycoside addition, Product inhibition by kanamycin phosphate is noncompetitive versus ATP when kanamycin A is held at subsaturating concentrations (K-m(kanA)), whereas no inhibition is observed when the concentration of kanamycin A is held at 10 K-m(kanA). This is consistent with kanamycin phosphate being the first product released followed by ADP release. The patterns of inhibition observed support a mechanism where ATP binding precedes aminoglycoside binding followed by a rapid catalytic step, Product release proceeds in an ordered fashion where kanamycin phosphate is released quickly followed by a slow release of ADP. Aminoglycoside substrates, such as kanamycin A, show substrate inhibition that is uncom petitive versus ATP. This indicates binding of the aminoglycosides to the slowly dissociating (E . ADP) complex at high drug concentrations. These experiments are consistent with a Theorell-Chance kinetic mechanism for 3'-aminoglycoside phosphotransferase-IIIa.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University			Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; Cleland W W, 1979, Methods Enzymol, V63, P500; DAVIES JE, 1991, ANTIBIOTICS LAB MED, P691; DAVIS BD, 1987, MICROBIOL REV, V51, P341, DOI 10.1128/MMBR.51.3.341-350.1987; Fromm H J, 1979, Methods Enzymol, V63, P467; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3826, DOI 10.1021/bi00410a046; GRAY GS, 1983, MOL BIOL EVOL, V1, P57; LEATHERBARROW RJ, 1992, GRAFIT 3 0 ERITHACUS; MARTEL A, 1983, EUR J BIOCHEM, V133, P515, DOI 10.1111/j.1432-1033.1983.tb07494.x; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; RADIKA K, 1984, J BIOL CHEM, V259, P2543; RADIKA K, 1984, ANAL BIOCHEM, V141, P413, DOI 10.1016/0003-2697(84)90063-0; RADIKA K, 1984, ANTIMICROB AGENTS CH, V25, P479, DOI 10.1128/AAC.25.4.479; Rudolph F B, 1979, Methods Enzymol, V63, P411; Segel I.H., 1975, ENZYME KINETICS; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; TRIEUCUOT P, 1983, GENE, V23, P331, DOI 10.1016/0378-1119(83)90022-7; Umezawa H., 1982, AMINOGLYCOSIDE ANTIB, P267; WILLIAMS JW, 1978, J BIOL CHEM, V253, P5902	19	70	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24686	24692		10.1074/jbc.270.42.24686	http://dx.doi.org/10.1074/jbc.270.42.24686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559583	hybrid			2022-12-25	WOS:A1995TB46500017
J	PLOCHOCKAZULINSKA, D; RASMUSSEN, G; RASMUSSEN, C				PLOCHOCKAZULINSKA, D; RASMUSSEN, G; RASMUSSEN, C			REGULATION OF CALCINEURIN GENE-EXPRESSION IN SCHIZOSACCHAROMYCES-POMBE - DEPENDENCE ON THE STE11 TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; FISSION YEAST; SEXUAL-DIFFERENTIATION; CALMODULIN; SUBUNIT; ENCODES; CLONING; MOTIF	Calmodulin and its target enzymes are important regulators of numerous cellular processes, including reversible protein phosphorylation. The calmodulin-dependent protein phosphatase (calcineurin) has been suggested to play roles in activation of T cells and in the mating response of yeast. Recently, studies have shown it to be the target of immunosuppressant drugs such as cyclosporin and FK-506. In this study, we have cloned the gene for the catalytic subunit of calcineurin, CnA, from the yeast Schizosaccharomyces pombe. The gene (named ppb1(+)) has been mapped to chromosome II by analysis of the hybridization of a genomic DNA probe to an ordered library. The gene produces a single mRNA species of 2.5 kilobases, which varies during the cell cycle in exponentially growing cells. In addition, expression of ppb1(+) mRA is induced by nitrogen starvation, a condition that favors mating in S. pombe. The ppb1(+) gene promoter contains a cis-acting element for the ste11 transcription factor, and we have shown that induction of the ppb1(+) mRNA during nitrogen starvation is dependent on the ste11 gene product. Together with earlier studies showing that disruption of the ppb1(+) gene in S. pombe results in sterility (Yoshida, T., Toda, T., and Yanagida, M. (1994) J. Cell Sci., 107, 1725-1735), our studies suggest that the ppb1(+) gene plays a role in the gene expression cascade that is essential for mating and sporulation in S. pombe.	UNIV ALBERTA, DEPT ANAT & CELL BIOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT ONCOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, NATL CTR INST CANADA MOLEC MECH, GROWTH CONTROL GRP, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta; University of Alberta; University of Alberta								ALFA C, 1992, EXPT FISSION YEAST L; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; EGEL R, 1990, TRENDS GENET, V6, P369, DOI 10.1016/0168-9525(90)90279-F; Egel R., 1989, MOL BIOL FISSION YEA, P31; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Maniatis T., 1982, MOL CLONING; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MIYAMOTO M, 1994, EMBO J, V13, P1873, DOI 10.1002/j.1460-2075.1994.tb06456.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OKAZAKI N, 1991, NUCLEIC ACIDS RES, V19, P7043, DOI 10.1093/nar/19.25.7043; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; SUGIYAMA A, 1994, EMBO J, V13, P1881, DOI 10.1002/j.1460-2075.1994.tb06457.x; THORNER J, 1981, MOL BIOL YEAST SACCH, P143; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; YOSHIDA T, 1994, J CELL SCI, V107, P1725	27	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24794	24799		10.1074/jbc.270.42.24794	http://dx.doi.org/10.1074/jbc.270.42.24794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559598	hybrid			2022-12-25	WOS:A1995TB46500032
J	WEDEL, B; HARTENECK, C; FOERSTER, J; FRIEBE, A; SCHULTZ, G; KOESLING, D				WEDEL, B; HARTENECK, C; FOERSTER, J; FRIEBE, A; SCHULTZ, G; KOESLING, D			FUNCTIONAL DOMAINS OF SOLUBLE GUANYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN; EXPRESSION; CONTAINS; PROTEIN; HEME	Soluble guanylyl cyclase is a heterodimer consisting of an alpha and beta subunit and stimulation occurs upon binding of NO to a prosthetic group. Little is known about the localization of catalytic and regulatory domains within the subunits of soluble guanylyl cyclase. We used deletion mutagenesis to identify the regions of alpha(1) and beta(1) subunits that are responsible for cGMP production or NO-heme-mediated activation. The amino terminus of the beta(1) subunit was necessary for NO stimulation since deletion of the 64 NH2-terminal amino acids resulted in a mutant with intact basal activity but complete loss of NO activation. The amino terminus of the alpha(1) subunit also appeared to be essential for NO sensitivity since deletion of 131 NH2-terminal amino acids of alpha(1) led to markedly reduced NO activation. These results suggest that NH2-terminal regions of alpha(1) and beta(1) are involved in NO-heme-mediated signal transduction. The NH2 terminally truncated beta(1) subunit exerted a dominant negative effect exclusively on the NO-stimulated activity of the wild type enzyme, further underlining that the regulatory domain is located within the NH2 terminus of the enzyme, Aside from the structural implications, the mutant represents a powerful tool to investigate nitric oxide-sensitive signaling pathways. Coexpression of the COOH-terminal halves of alpha(1) and beta(1) were sufficient for basal cGMP production while either of the halves expressed alone was inactive. Therefore the COOH-terminal regions appear to contain sufficient information for dimerization and basal enzymatic activity. Thus, we provide the first evidence that the regulatory and catalytic properties of soluble guanylyl cyclase can be attributed to different regions of the subunits and that the catalytic domain can be functionally expressed separately from the NH2-terminal regulatory domain. Taken together with findings on the membrane bound enzyme form, guanylyl cyclases, appear to resemble fusion proteins where different regulatory domains have been joined with a common cGMP-forming segment.	FREE UNIV BERLIN,INST PHARMAKOL,D-14195 BERLIN,GERMANY	Free University of Berlin								CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; GARBERS DL, 1992, CELL, V71, P1; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; THORPE DS, 1990, J BIOL CHEM, V265, P14717; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDCEL B, 1994, P NATL ACAD SCI USA, V91, P2592; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; YUEN PST, 1994, J BIOL CHEM, V269, P791	15	109	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24871	24875		10.1074/jbc.270.42.24871	http://dx.doi.org/10.1074/jbc.270.42.24871			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559610	hybrid			2022-12-25	WOS:A1995TB46500044
J	YAMAGUCHI, M; HAYASHI, Y; MATSUKAGE, A				YAMAGUCHI, M; HAYASHI, Y; MATSUKAGE, A			ESSENTIAL ROLE OF E2F RECOGNITION SITES IN REGULATION OF THE PROLIFERATING CELL NUCLEAR ANTIGEN GENE PROMOTER DURING DROSOPHILA DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; TRANSCRIPTION FACTOR; GROWTH-REGULATION; BUDDING YEAST; MELANOGASTER; EXPRESSION; PROTEIN; CYCLE; BINDING; CLONING	We have found sequences similar to the transcription factor E2F recognition site within the Drosophila proliferating cell nuclear antigen (PCNA) gene promoter. These sequences are located at positions -43 to -36 (site I) and -56 to -49 (site II) with respect to the cap site. Glutathione S-transferase (GST)-E2F and GST-DP fusion proteins cooperate and bind to the potential E2F sites in the PCNA promoter in vitro. A binding factor(s) to these sequences that has similar binding specificity to that of E2F was detected in nuclear extracts of Drosophila Kc cells. Furthermore, transient expression of E2F in Kc cells activated the PCNA promoter, and the target site for the activation coincided with the E2F sites. These results indicate that the PCNA gene is a likely target gene of E2F. Examination of lacZ expression from PCNA-lacZ fusion genes carrying mutations in either or both of two E2F sites introduced into flies by germ line transformation revealed that site II plays a major role in the PCNA promoter activity during embryogenesis and larval development, although both sites are required for optimal promoter activity. However, for maternal expression in ovaries, either one of the two sites is essentially sufficient to direct optimal promoter activity. These results demonstrate, for the first time, an essential role for E2F sites in regulation of PCNA promoter activity during development of a multicellular organism.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center								BAKKENIST CJ, 1994, J BIOL CHEM, V269, P26759; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BASERGA R, 1991, J CELL SCI, V98, P433; BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; COTTERILL S, 1992, NUCLEIC ACIDS RES, V20, P4325, DOI 10.1093/nar/20.16.4325; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI USA, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1994, J BIOL CHEM, V269, P2937; HIROSE F, 1993, J BIOL CHEM, V268, P2092; KARCH F, 1981, J MOL BIOL, V148, P219, DOI 10.1016/0022-2836(81)90536-2; Lee Hu-Hui, 1995, Gene Expression, V4, P95; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MATSUKAGE A, 1986, DEV BIOL, V117, P226, DOI 10.1016/0012-1606(86)90365-9; MATSUKAGE A, 1994, JPN J CANCER RES, V85, P1; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; Yamaguchi Masamitsu, 1995, Gene Expression, V4, P183; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; [No title captured]	39	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25159	25165		10.1074/jbc.270.42.25159	http://dx.doi.org/10.1074/jbc.270.42.25159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559650	hybrid			2022-12-25	WOS:A1995TB46500084
J	ROBEY, FA; KELSONHARRIS, T; ROLLER, PP; ROBERTGUROFF, M				ROBEY, FA; KELSONHARRIS, T; ROLLER, PP; ROBERTGUROFF, M			A HELICAL EPITOPE IN THE C4 DOMAIN OF HIV GLYCOPROTEIN-120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IMMUNODEFICIENCY-VIRUS TYPE-1; SYNTHETIC PEPTIDE POLYMERS; AUTOMATED SYNTHESIS; T4 MOLECULE; PROTEIN; RECEPTOR; GP120; CD4; RETROVIRUS; AFFINITY	The fourth conserved domain of the human immunodeficiency virus type 1 (HIV-1) envelope, the C4 region of glycoprotein 120 (gp120), is an amphipathic stretch of amino acids that, based on mutational analyses, constitutes a major component of the CD4 binding region in gp120. In the absence of crystallographic and NMR data on C4 in intact gp120, we sought to gain insight into C4's conformation and accessibility in gp120 by taking an immunochemical approach. In this study, a peptomer composed of a repeat peptide of C4 amino acids 419-436 from gp120 of HIV-1(MN) was synthesized for use as a conformationally constrained immunogen. Circular dichroism studies disclosed that the polymerized peptide, peptomer-(419-436), in 0.01 M Na2HPO4 buffer, pH 7.4, at 25 degrees C contained a dominant alpha-helical structure (53 +/- 1%) compared with 2 +/- 4% alpha-helical content for the monomeric peptide-(419-436). The peptomer in Ribi's adjuvant induced the production of rabbit antibodies that recognized recombinant and native gp120 but, consistent with the literature, the C4 peptide having no conformational constraints did not. The experimental results show that only those antibodies formed against a helical immunogen from C4 will recognize recombinant and native gp120, and, therefore, the results support the notion that C4 is an alpha-helix in gp120.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ROBEY, FA (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,PEPTIDE & IMMUNOCHEM UNIT,BLDG 30,RM 211,BETHESDA,MD 20892, USA.							CARDONNIER A, 1989, NATURE, V340, P571; CEASE KB, 1987, P NATL ACAD SCI USA, V47, P4249; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; KALYANARAMAN VS, 1990, AIDS RES HUM RETROV, V6, P371, DOI 10.1089/aid.1990.6.371; KENNEY JS, 1989, J IMMUNOL METHODS, V121, P157, DOI 10.1016/0022-1759(89)90156-7; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LINDNER W, 1987, INT J PEPT PROT RES, V30, P794; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; POLAND D, 1970, THEORY HELIX COIL TR; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Robey F A, 1994, Methods Mol Biol, V35, P73; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; ROBEY FA, 1992, CHIM OGGI, P27; ROBEY FA, 1992, CURRENT PROTOCOLS IM; SASTRY KJ, 1991, AIDS, V5, P699, DOI 10.1097/00002030-199106000-00009; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2	19	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23918	23921		10.1074/jbc.270.41.23918	http://dx.doi.org/10.1074/jbc.270.41.23918			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592582	hybrid			2022-12-25	WOS:A1995TA21700010
J	VANTHOF, W; RODRIGUEZBOULAN, E; MENON, AK				VANTHOF, W; RODRIGUEZBOULAN, E; MENON, AK			NONPOLARIZED DISTRIBUTION OF GLYCOSYLPHOSPHATIDYLINOSITOLS IN THE PLASMA-MEMBRANE OF POLARIZED MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; MDCK CELLS; GLYCOINOSITOL PHOSPHOLIPIDS; TRYPANOSOMA-BRUCEI; THY-1 GLYCOPROTEIN; PHOSPHATIDYLINOSITOL; ANCHOR; BIOSYNTHESIS; PROTEINS; GANGLIOSIDES	Glycosylphosphatidylinositols (GPIs) are ubiquitous in eukaryotes and serve to anchor a variety of proteins to the exoplasmic leaflet of cellular membranes, GPIs are synthesized in the endoplasmic reticulum (ER), in excess of the amount needed for protein modification. The fate of the excess GPIs is unknown, but they may be retained in the ER, transported to other membranes, and/or metabolized, In relation to this problem, we were interested in determining whether GPIs were transported to the plasma membrane and whether, like GPI-anchored proteins, their presence was confined to the apical plasma membrane domain in polarized epithelial cells. Polarized Madin-Darby canine kidney epithelial cell monolayers were incubated with [H-3]mannose or [H-3]ethanolamine to label GPIs and then infected with enveloped viruses, We used influenza virus (flu) and vesicular stomatitis virus (VSV) for these experiments as these viruses are assembled at the cell surface and acquire their envelope lipids from the plasma membrane, Furthermore, flu and VSV bud specifically from the apical and basolateral plasma membrane domains, respectively, Flu and VSV were isolated from the apical and basolateral media, respectively, and subjected to lipid analysis, Radiolabeled GPIs were found in both viruses, Moreover, the membrane concentration of GPIs (i.e, GPI radioactivity normalized to membrane mass) in the two viruses was essentially the same, These observations suggest that (i) non-protein-linked GPIs are located at the plasma membrane; (ii) since GPIs are synthesized in the ER, they must be transported from the ER to the plasma membrane; and (iii) transport of nonprotein-linked GPIs is not influenced by the sorting processes that target GPI-anchored proteins exclusively to the apical plasma membrane.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; CORNELL UNIV, COLL MED, DEPT ANAT & CELL BIOL, NEW YORK, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; Cornell University				Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107, R01GM041771] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28858] Funding Source: Medline; NIGMS NIH HHS [GM-34107, GM-41771, R01 GM034107] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CALAFAT J, 1983, J GEN VIROL, V64, P1241, DOI 10.1099/0022-1317-64-6-1241; DEEG MA, 1992, J BIOL CHEM, V267, P18581; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; HIROSE S, 1992, J BIOL CHEM, V267, P16968; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; LOW MG, 1985, NATURE, V318, P687, DOI 10.1038/318687a0; MAYOR S, 1992, J BIOL CHEM, V267, P754; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MENON AK, 1994, METHOD ENZYMOL, V230, P418; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; NICHOLS GE, 1988, J LIPID RES, V29, P1205; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; SPIEGEL S, 1988, BIOCHIM BIOPHYS ACTA, V938, P270, DOI 10.1016/0005-2736(88)90165-4; UDENFRIEND S, 1995, METHOD ENZYMOL, V250, P571; UEDA E, 1993, J BIOL CHEM, V268, P9998; VAN GENDEREN IL, 1994, VIROLOGY, V200, P831, DOI 10.1006/viro.1994.1252; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; WILSON JM, 1990, J CELL SCI, V96, P143	33	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24150	24155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592618				2022-12-25	WOS:A1995TA21700046
J	KANG, ME; DAHMUS, ME				KANG, ME; DAHMUS, ME			THE PHOTOACTIVATED CROSS-LINKING OF RECOMBINANT C-TERMINAL DOMAIN TO PROTEINS IN A HELA-CELL TRANSCRIPTION EXTRACT THAT COMIGRATE WITH TRANSCRIPTION FACTORS IIE AND IIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; LARGEST SUBUNIT; FUNCTIONAL INTERACTION; MAMMALIAN-CELLS; COMPLEX; FORM; COACTIVATORS; PROMOTER; INVITRO	The C-terminal domain (CTD) of RNA polymerase II (RNAP II) is essential for the assembly of RNAP II into preinitiation complexes on some promoters such as the dihydrofolate reductase (DHFR) promoter. In addition, during the transition from a preinitiation complex to a stable elongation complex, the CTD becomes heavily phosphorylated. In this report, interactions involving the CTD have been examined by protein-protein cross linking. As a prelude to the study of CTD interactions, the effect of recombinant CTD on in vitro transcription was examined. The presence of recombinant CTD inhibits in vitro transcription from both the DHFR and adenovirus 2 major late promoters, suggesting that the CTD is involved in essential interactions with a general transcription factor(s). Factors in the transcription extract that interact with the CTD were identified by protein-protein cross-linking. Recombinant CTD was phosphorylated at its casein kinase II site, at the C terminus of the CTD, in the presence of [S-35]adenosine 5'-O-(thiotriphosphate) and alkylated with azidophenacyl bromide, Incubation of azido-modified S-35 labeled CTD with a HeLa transcription extract followed by ultraviolet irradiation results in the covalent cross-linking of the CTD to proteins in contact with the CTD at the time of irradiation. Subsequent incubation with phenylmercuric acetate results in the transfer of S-35 from the CTD to the protein to which it was cross-linked. The two major photolabeled bands have a M(r) of 34,000 and 74,000. The specificity of CTD interactions was demonstrated by a reduction in photolabeling in the presence of unmodified CTD or RNAP II containing an intact CTD (RNAP IIA) but not in the presence of a CTD-less RNAP II (RNAP IIB). The S-35 labeled 34- and 74-kDa proteins comigrate on SDS-polyacrylamide gel electrophoresis with the beta subunit of transcription factor IIE and the 74-kDa subunit of transcription factor IIF, respectively. Moreover, some of the minor S-35-labeled bands comigrate with other subunits of the general transcription factors.	UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HANNA MM, 1983, BIOCHEMISTRY-US, V22, P3546, DOI 10.1021/bi00284a002; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	27	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23390	23397		10.1074/jbc.270.40.23390	http://dx.doi.org/10.1074/jbc.270.40.23390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559497	hybrid			2022-12-25	WOS:A1995RY90900026
J	NIELSEN, MS; NYKJAER, A; WARSHAWSKY, I; SCHWARTZ, AL; GLIEMANN, J				NIELSEN, MS; NYKJAER, A; WARSHAWSKY, I; SCHWARTZ, AL; GLIEMANN, J			ANALYSIS OF LIGAND-BINDING TO THE ALPHA(2)-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN - EVIDENCE THAT LIPOPROTEIN LIPASE AND THE CARBOXYL-TERMINAL DOMAIN OF THE RECEPTOR-ASSOCIATED PROTEIN BIND TO THE SAME SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN RECEPTOR; HEYMANN NEPHRITIS ANTIGEN; PLASMINOGEN-ACTIVATOR; CHYLOMICRON REMNANTS; MOLECULAR-CLONING; ESCHERICHIA-COLI; IN-VITRO; COMPLEXES; INHIBITOR; IDENTIFICATION	The endocytic alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha(2)MR/LRP) binds several classes of extracellular ligands at independent sites. In addition, alpha(2)MR/LRP can bind multiple copies of the 39-40-kDa receptor-associated protein (RAP). Both amino-terminal and carboxyl-terminal fragments of RAP exhibit affinity, and the fragments apparently bind to different sites on the receptor. RAP completely inhibits the binding of all presently known extracellular ligands, whereas several ligands such as alpha(2)-macroglobulin and tissue type plasminogen activator are poor inhibitors of RAP binding. Since RAP is largely an intracellular molecule that normally does not occupy alpha(2)MR/LRP at the cell surface, we hypothesized that an established extracellular ligand might bind to those sites on the receptor capable of binding the RAP fragments. We found complete cross competition between carboxyl-terminal RAP fragments and fragments of lipoprotein lipase containing the recently identified binding domain for alpha(2)MR/LRP (Nykjaer, A., Nielsen, M., Lookene, A., Meyer, N., Roigaard, H., Etzerodt, M., Beisiegel, U., Olivecrona, G., and Gliemann, J. (1994) J. Biol. Chem. 269, 31747-31755). Moreover, the lipoprotein lipase fragment completely inhibited the binding of several alpha(2)MR/LRP ligands in a pattern similar to that of carboxyl-terminal RAP fragments. On the other hand, the amino-terminal RAP fragment was a poor competitor of binding of the lipoprotein lipase fragment, whereas it competed effectively with pro-uPA for bind ing to the receptor. The results provide evidence that lipoprotein lipase binds to the site on alpha(2)MR/LRP also available for binding of the carboxyl terminal domain of RAP and suggest that pro-uPA may bind to or overlap the site available for the amino-terminal domain of RAP.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	NIELSEN, MS (corresponding author), AARHUS UNIV,DEPT MED BIOCHEM,OLE WORMS ALLE,BLDG 170,DK-8000 AARHUS C,DENMARK.		Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Nykjaer, Anders/0000-0001-6422-6736	NHLBI NIH HHS [HL52040, HL53280] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053280, R01HL052040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBATE M, 1993, EUR J CELL BIOL, V61, P139; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BENGTSSONOLIVEC.G, 1991, METHOD ENZYMOL, V197, P345; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BU GJ, 1994, J BIOL CHEM, V269, P29874; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HORN IR, 1995, J BIOL CHEM, V270, P11770, DOI 10.1074/jbc.270.20.11770; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JACKLE S, 1993, J LIPID RES, V34, P309; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LORENZEN N, 1993, J GEN VIROL, V74, P623, DOI 10.1099/0022-1317-74-4-623; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOESTRUP SK, 1994, ANN NY ACAD SCI, V737, P124, DOI 10.1111/j.1749-6632.1994.tb44306.x; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1994, ANN NY ACAD SCI, V737, P483, DOI 10.1111/j.1749-6632.1994.tb44346.x; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; REILLY TM, 1990, J BIOL CHEM, V265, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1995, FIBRINOLYSIS, V8, P204; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1994, ANN NY ACAD SCI, V737, P514, DOI 10.1111/j.1749-6632.1994.tb44357.x; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	55	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23713	23719		10.1074/jbc.270.40.23713	http://dx.doi.org/10.1074/jbc.270.40.23713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559542	hybrid			2022-12-25	WOS:A1995RY90900071
J	YANO, H; HAYASHI, K; MOMIYAMA, T; SAGA, H; HARUNA, M; SOBUE, K				YANO, H; HAYASHI, K; MOMIYAMA, T; SAGA, H; HARUNA, M; SOBUE, K			TRANSCRIPTIONAL REGULATION OF THE CHICKEN CALDESMON GENE - ACTIVATION OF GIZZARD-TYPE CALDESMON PROMOTER REQUIRES A CARG BOX-LIKE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CALMODULIN-BINDING PROTEIN; ALPHA-ACTIN GENE; MAMMALIAN-CELLS; C-FOS; EXPRESSION; ELEMENTS; ISOFORMS; FAMILY; CIS	Caldesmon, which plays a vital role in the actomyosin system, is distributed in smooth muscle and non-muscle cells, and its isoformal interconversion between a high M(r) form and low M(r) form is a favorable molecular event for studying phenotypic modulation of smooth muscle cells. Genomic analysis reveals two promoters, of which the gizzard-type promoter displays much higher activity than the brain-type promoter. Here, we have characterized transcriptional regulation of the gizzard-type promoter. Transient transfection assays in chick gizzard smooth muscle cells, chick embryo fibroblasts, mouse skeletal muscle cell line (C2C12), and HeLa cells revealed that the promoter activity was high in smooth muscle cells and fibroblasts, but was extremely low in other cells. Cell type-specific promoter activity depended on an element, CArG1, containing a unique CArG box-like motif (CCAAAAAAGG) at -315, while multiple E boxes were not directly involved in this event. Gel shift assays showed the specific interaction between the CArG1 and nuclear protein factors in smooth muscle cells and fibroblasts. These results suggest that the CArG1 is an essential cis element for cell type specific expression of caldesmon and that the function of CArG1 might be controlled under phenotypic modulation of smooth muscle cells.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT NEUROCHEM & NEUROPHARMACOL,SUITA,OSAKA 565,JAPAN	Osaka University								BIRUKOV KG, 1993, EXP CELL RES, V204, P46, DOI 10.1006/excr.1993.1007; BLANK RS, 1992, J BIOL CHEM, V267, P984; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DINGUS J, 1986, J CELL BIOL, V102, P1748, DOI 10.1083/jcb.102.5.1748; DRAEGER A, 1989, J CELL SCI, V94, P703; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARUNA M, 1993, BIOCHEM BIOPH RES CO, V197, P145, DOI 10.1006/bbrc.1993.2453; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P38; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HOSOYA M, 1989, J BIOCHEM, V105, P712, DOI 10.1093/oxfordjournals.jbchem.a122733; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KUROO M, 1989, J BIOL CHEM, V264, P18272; LAZARD D, 1993, P NATL ACAD SCI USA, V90, P999, DOI 10.1073/pnas.90.3.999; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; NABESHIMA Y, 1988, J MOL BIOL, V204, P497, DOI 10.1016/0022-2836(88)90350-6; NAKANO Y, 1991, GENE, V99, P285; NG SY, 1989, NUCLEIC ACIDS RES, V16, P601; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YANO H, 1994, BIOCHEM BIOPH RES CO, V201, P618, DOI 10.1006/bbrc.1994.1746	43	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23661	23666		10.1074/jbc.270.40.23661	http://dx.doi.org/10.1074/jbc.270.40.23661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559534	hybrid			2022-12-25	WOS:A1995RY90900063
J	OTTERSON, GA; KHLEIF, SN; CHEN, WD; COXON, AB; KAYE, FJ				OTTERSON, GA; KHLEIF, SN; CHEN, WD; COXON, AB; KAYE, FJ			CDKN2 GENE SILENCING IN LUNG-CANCER BY DNA HYPERMETHYLATION AND KINETICS OF P16(INK4) PROTEIN INDUCTION BY 5-AZA 2'DEOXYCYTIDINE	ONCOGENE			English	Article						P16(INK4); CDKN2; METHYLATION; 5-AZA 2'DEOXYCYTIDINE; LUNG CANCER	RETINOBLASTOMA GENE; MUTATION	Absent expression of the cyclin dependent kinase-inhibitor, p16(INK4), is observed in a wide range of primary human cancers. Although homozygous deletions and point mutations have been reported in a subset of these tumors, the molecular basis for absent p16(INK4) in other samples is unknown. We have examined 33 tumor cell lines and have shown that hypermethylation of a G:C-rich region within exon 1 of the CDKN2 gene was present in 100% of samples with wildtype RE expression and no detectable CDKN2 mutations. Treatment for at least 4 hours with the demethylating agent 5-aza 2'deoxycytidine, but not 5-azacytidine or 6-azacytidine, induces the prolonged expression of p16(INK4) protein each of these samples following a discrete 24-48 hour lag period, Consistent with the hypothesis that hypermethylation of the CDKN2 gene is a tumor-specific mechanism for gene inactivation, we observed hypomethylation at the exon 1 site exclusively in tumor lines that expressed p16(INK4) or that had sustained inactivating point mutations within the CDKN2 open reading frame, These findings demonstrate a link between DNA methylation and the p16(INK4):RB tumor suppressor pathway.	NCI,USN HOSP,ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA			kaye, frederic/E-2437-2011; CHEN, WEI-DONG/F-4521-2014	CHEN, WEI-DONG/0000-0003-2264-5515				FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAIRD PW, 1994, HUM MOL GENET, P1487; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; NAKAGAWA K, 1995, IN PRESS ONCOGENE; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Rideout W M 3rd, 1991, Princess Takamatsu Symp, V22, P207; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU E, 1994, ONCOGENE, V9, P2441; TAM SW, 1994, CANCER RES, V54, P5816; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	28	214	233	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1211	1216						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566983				2022-12-25	WOS:A1995RX18000026
J	ROUQUET, N; ALLEMAND, I; MOLINA, T; BENNOUN, M; BRIAND, P; JOULIN, V				ROUQUET, N; ALLEMAND, I; MOLINA, T; BENNOUN, M; BRIAND, P; JOULIN, V			FAS-DEPENDENT APOPTOSIS IS IMPAIRED BY SV40 T-ANTIGEN IN TRANSGENIC LIVER	ONCOGENE			English	Article						T-ANTIGEN; APOPTOSIS; FAS-RECEPTOR; CARCINOGENESIS	GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; MICE; ANTIBODY; GENE; PHOSPHORYLATION; EXPRESSION; DOMAIN; LENS	A transgenic mouse model for hepatocarcinoma has been previously produced by targeting SV40 T-antigen expression to the liver. To evaluate the perturbation of cell death occurring during hepatocarcinogenesis, we examined the Fas-induced apoptosis on hepatocytes expressing T-antigen. Whereas anti-Fas antibody induced apoptosis in primary cultured normal hepatocytes, they imparted a weak cytotoxicity on primary cultured hepatocytes expressing T-antigen. This resistance of hepatic Fas-mediated apoptosis appears to result in an enhancement of a protective mechanism involving the protein kinase C signaling pathway rather than in a down-regulation of Fas-antigen expression. We further demonstrated that anti-Fas antibody does not have as efficient a lethal effect in T-antigen transgenic mice as in wild-type mice, The livers of transgenic mice injected with anti-Fas mAbs showed large intact regions with a few scattered apoptotic bodies: these regions strictly corresponded with carcinoma nodules, expressing high level of T-antigen. Our results describe a novel function for SV40 T-antigen which could contribute to viral pathogenesis by protecting infected cells against the host apoptotic defense mechanism.	INST COCHIN GENET MOLEC, INSERM, U380, F-75014 PARIS, FRANCE; UNIV PARIS, RECH & HISTOPATHOL LAB, F-75006 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; allemand, isabelle/0000-0002-8861-7632; JOULIN, Virginie/0000-0003-1091-7819				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; CHEN JD, 1992, ONCOGENE, V7, P1167; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; GUO MW, 1994, BIOCHEM BIOPH RES CO, V203, P1438, DOI 10.1006/bbrc.1994.2346; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; LEIST M, 1995, J IMMUNOL, V154, P1307; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MEEK DW, 1992, BIOCHEM J, V287, P1; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SAMBROOK J, 1989, MOL CLONIGN LABORATO; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WONG GHW, 1994, J IMMUNOL, V152, P1751	39	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1061	1067						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566965				2022-12-25	WOS:A1995RX18000008
J	COWBURN, D; ZHENG, J; XU, QH; BARANY, G				COWBURN, D; ZHENG, J; XU, QH; BARANY, G			ENHANCED AFFINITIES AND SPECIFICITIES OF CONSOLIDATED LIGANDS FOR THE SRC HOMOLOGY (SH)3 AND SH2 DOMAINS OF ABELSON PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SOLID-PHASE SYNTHESIS; IDENTIFICATION; PEPTIDES; BINDING; DESIGN	The possible interrelationships between multiple domains of proteins involved in intracellular signal transduction are complex and not easily investigated. We have synthesized a series of bivalent consolidated ligands, which interact simultaneously with the SH2 and SH3 domain of Abelson kinase in a SH(32) dual domain construct, a portion of native Abelson kinase. Affinities were measured by quenching of intrinsic tryptophan fluorescence, Consolidated ligands have enhanced affinity and specificity compared to monovalent equivalents. Affinity is also dependent on the length of the linker joining the two parts, with an optimum distance similar to that expected from structural models of Abl (SH(32). These results suggest that consolidated ligands may be generally useful reagents for probing structural and functional activities of multidomain proteins.	UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	COWBURN, D (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, BOX 163, NEW YORK, NY 10021 USA.		Cowburn, David/A-8448-2008	Zheng, Jie/0000-0001-6524-6800; Cowburn, David/0000-0001-6770-7172	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042722, R01GM051628, R01GM047021] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-42722, GM-47021, GM-51628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERICIO F, 1990, J ORG CHEM, V55, P3730, DOI 10.1021/jo00299a011; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BYCROFT BW, 1993, J CHEM SOC CHEM COMM, P778, DOI 10.1039/c39930000778; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GILMER T, 1994, J BIOL CHEM, V269, P31711; GOSSER YQ, 1995, STRUCTURE, V3, P1075, DOI 10.1016/S0969-2126(01)00243-X; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; TURCK CW, 1992, PEPTIDE RES, V5, P156; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHU GC, 1994, ONCOGENE, V9, P1379	24	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26738	26741		10.1074/jbc.270.45.26738	http://dx.doi.org/10.1074/jbc.270.45.26738			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592905	hybrid			2022-12-25	WOS:A1995TE58300005
J	PETERS, JW; FISHER, K; NEWTON, WE; DEAN, DR				PETERS, JW; FISHER, K; NEWTON, WE; DEAN, DR			INVOLVEMENT OF THE P-CLUSTER IN INTRAMOLECULAR ELECTRON-TRANSFER WITHIN THE NITROGENASE MOFE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE NITROGENASE; AZOTOBACTER-VINELANDII; FE-PROTEIN; CRYSTALLOGRAPHIC STRUCTURE; HYDROGEN EVOLUTION; ATP HYDROLYSIS; ALPHA-SUBUNIT; CROSS-LINKING; COMPLEX	Nitrogenase is the catalytic component of biological nitrogen fixation, and it is comprised of two component proteins called the Fe protein and MoFe protein. The Fe protein contains a single Fe4S4 cluster, and the MoFe protein contains two metallocluster types called the P cluster (Fe8S8) and FeMo-cofactor (Fe7S9Mo-homocitrate), During turnover, electrons are delivered one at a time from the Fe protein to the MoFe protein in a reaction coupled to component-protein association dissociation and MgATP hydrolysis, Under conditions of optimum activity, the rate of component-protein dissociation is rate-limiting, The Fe protein's Fe4S4 cluster is the redox entity responsible for intermolecular electron delivery to the MoFe protein, and FeMo-cofactor provides the substrate reduction site, In contrast, the role of the P cluster in catalysis is not well understood although it is believed to be involved in accumulating electrons delivered from the Fe protein and brokering their intramolecular delivery to the substrate reduction site, A nitrogenase component-protein docking model, which is based on the crystallographic structures of the component proteins and which pairs the S-fold symmetric surface of the Fe protein with the exposed surface of the MoFe protein's pseudosymmetric cup interface, is now available, During component-protein interaction, this model places the P cluster between the Fe protein's Fe4S4 cluster and FeMo-cofactor, which implies that the P cluster is involved in mediating intramolecular electron transfer between the clusters, In the present study, evidence supporting this idea was obtained by demonstrating that it is possible to alter the rate of substrate reduction by perturbing the polypeptide environment between the P cluster and FeMo-cofactor without necessarily disrupting the metallocluster polypeptide environments or altering component-protein interaction.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University			Fisher, Karl/A-5956-2013	Fisher, Karl/0000-0003-3539-8939; Peters, John/0000-0001-9117-9568	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051962] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37255] Funding Source: Medline; NIGMS NIH HHS [GM51962] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; BRIGLE KE, 1987, P NATL ACAD SCI USA, V84, P7066, DOI 10.1073/pnas.84.20.7066; BURGESS BK, 1980, J BIOL CHEM, V255, P353; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; DILWORTH MJ, 1966, BIOCHIM BIOPHYS ACTA, V127, P285, DOI 10.1016/0304-4165(66)90383-7; FARID RS, 1993, CURR OPIN STRUC BIOL, V3, P225, DOI 10.1016/S0959-440X(05)80157-5; FISHER K, 1991, BIOCHEM J, V279, P81, DOI 10.1042/bj2790081; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOWARD JB, 1993, ACS SYM SER, V535, P271; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; IMAM S, 1980, FEBS LETT, V110, P35, DOI 10.1016/0014-5793(80)80016-0; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JENG DY, 1970, J BIOL CHEM, V245, P2809; Johnson M. K., 1988, METAL CLUSTERS PROTE, P326; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM CH, 1993, CURR PLANT SCI BIOT, V17, P105; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P33, DOI 10.1111/j.1432-1033.1986.tb09455.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V275, P93, DOI 10.1016/0005-2728(72)90027-8; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ORMEJOHNSON WH, 1977, IRON SULFUR PROTEINS, P15; PETERS JW, 1994, J BIOL CHEM, V269, P28076; Rees DC, 1993, ADV INORG CHEM, V40, P89; SCHOLLHORN R, 1967, P NATL ACAD SCI USA, V74, P3249; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SCOTT DJ, 1992, J BIOL CHEM, V267, P20002; SEEFELDT LC, 1994, PROTEIN SCI, V3, P2073, DOI 10.1002/pro.5560031120; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH BE, 1974, BIOCHEM J, V137, P169, DOI 10.1042/bj1370169; STEPHENS PJ, 1985, MOLYBDENUM ENZYMES, P117; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1993, ACS SYM SER, V535, P290; THORNELEY RNF, 1975, BIOCHEM J, V145, P391, DOI 10.1042/bj1450391; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATT GD, 1977, BIOCHEMISTRY-US, V16, P264, DOI 10.1021/bi00621a017; WATT GD, 1975, BIOCHEMISTRY-US, V14, P4266, DOI 10.1021/bi00690a019; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; WOLLE D, 1992, J BIOL CHEM, V267, P3667	47	70	72	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27007	27013		10.1074/jbc.270.45.27007	http://dx.doi.org/10.1074/jbc.270.45.27007			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592949	hybrid			2022-12-25	WOS:A1995TE58300049
J	STRIETER, RM; POLVERINI, PJ; KUNKEL, SL; ARENBERG, DA; BURDICK, MD; KASPER, J; DZUIBA, J; VANDAMME, J; WALZ, A; MARRIOTT, D; CHAN, SY; ROCZNIAK, S; SHANAFELT, AB				STRIETER, RM; POLVERINI, PJ; KUNKEL, SL; ARENBERG, DA; BURDICK, MD; KASPER, J; DZUIBA, J; VANDAMME, J; WALZ, A; MARRIOTT, D; CHAN, SY; ROCZNIAK, S; SHANAFELT, AB			THE FUNCTIONAL-ROLE OF THE ELR MOTIF IN CXC CHEMOKINE-MEDIATED ANGIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; NEUTROPHIL CHEMOTACTIC FACTOR; CAPILLARY ENDOTHELIAL-CELLS; TUMOR ANGIOGENESIS; ACTIVATES NEUTROPHILS; GENE-EXPRESSION; GROWTH-FACTOR; INHIBITION; INTERLEUKIN-8; CYTOKINES	In this study, we demonstrate that the CXC family of chemokines displays disparate angiogenic activity depending upon the presence or absence of the ELR motif. CXC chemokines containing the ELR motif (ELR-CXC chemokines) were found to be potent angiogenic factors, inducing both in vitro endothelial chemotaxis and in vivo corneal neovascularization. In contrast, the CXC chemokines lacking the ELR motif, platelet factor 4, interferon gamma-inducible protein 10, and monokine induced by gamma-interferon, not only failed to induce significant in vitro endothelial cell chemotaxis or in vivo corneal neovacularization but were found to be potent angiostatic factors in the presence of either ELR-CXC chemokines or the unrelated angiogenic factor, basic fibroblast growth factor, Additionally, mutant interleukin-g proteins lacking the ELR motif demonstrated potent angiostatic effects in the presence of either ELR-CXC chemokines or basic fibroblast growth factor, In contrast, a mutant of monokine induced by gamma-interferon containing the ELR motif was found to induce in vivo angiogenic activity, These findings suggest a functional role of the ELR motif in determining the angiogenic or angiostatic potential of CXC chemokines, supporting the hypothesis that the net biological balance between angiogenic and angiostatic CXC chemokines may play an important role in regulating overall angiogenesis.	UNIV MICHIGAN, MED CTR, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH DENT, ORAL PATHOL SECT, ANN ARBOR, MI 48109 USA; UNIV LOUVAIN, REGA INST, B-3000 LOUVAIN, BELGIUM; UNIV BERN, THEODOR KOCHER INST, CH-3000 BERN 9, SWITZERLAND; BAYER CORP, INST RES TECHNOL, W HAVEN, CT 06516 USA; BAYER CORP, DEPT MOLEC & CELLULAR BIOL, BERKELEY, CA 94701 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; KU Leuven; University of Bern; Bayer AG; Bayer AG	STRIETER, RM (corresponding author), UNIV MICHIGAN, MED CTR,SCH MED,DEPT INTERNAL MED, DIV PULM & CRIT CARE MED, BOX 0360, ANN ARBOR, MI 48109 USA.		Arenberg, Douglas/P-7251-2014; Polverini, Peter/AAJ-8392-2020	Arenberg, Douglas/0000-0001-7707-5092; 	NCI NIH HHS [CA66180] Funding Source: Medline; NHLBI NIH HHS [HL50057, 1P50HL46487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066180] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050057, P50HL046487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH R, 1981, LYMPHOKINES, V4; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; BREM H, 1975, J EXP MED, V141, P427, DOI 10.1084/jem.141.2.427; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CLARK RAF, 1993, J DERMATOL SURG ONC, V19, P693, DOI 10.1111/j.1524-4725.1993.tb00413.x; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FARBER JM, 1993, BIOCHEM BIOPH RES CO, V192, P223, DOI 10.1006/bbrc.1993.1403; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; FOLKMAN J, 1978, INT REV EXP PATHOL, V16, P207; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUSELLA GL, 1993, J IMMUNOL, V151, P2725; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOMANDBERG GA, 1986, BIOCHIM BIOPHYS ACTA, V874, P61, DOI 10.1016/0167-4838(86)90102-0; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; INGBER D, 1988, LAB INVEST, V59, P44; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A, 1983, SCIENCE, V221, P1185, DOI 10.1126/science.6193581; LEE K, 1987, CANCER RES, V47, P5021; Leibovich S J, 1988, Prog Clin Biol Res, V266, P131; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MARAGOUDAKIS ME, 1988, J PHARMACOL EXP THER, V244, P729; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEOTE K, 1993, J BIOL CHEM, V268, P12247; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PETERSON HI, 1986, ANTICANCER RES, V6, P251; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; PROOST P, 1993, J IMMUNOL, V150, P1000; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1987, J NATL CANCER I, V79, P1383; SCHNYDERCANDRIAN S, 1995, J LEUKOCYTE BIOL, V57, P929, DOI 10.1002/jlb.57.6.929; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SIDKY YA, 1987, CANCER RES, V47, P5155; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; STOUT AJ, 1993, INT J EXP PATHOL, V74, P79; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; STRIETER RM, 1992, AM J PATHOL, V141, P1279; TANNOCK IF, 1972, CANCER RES, V32, P77; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0	57	979	1055	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27348	27357		10.1074/jbc.270.45.27348	http://dx.doi.org/10.1074/jbc.270.45.27348			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592998	hybrid			2022-12-25	WOS:A1995TE58300098
J	TIAN, HC; KLAMBT, D; JONES, AM				TIAN, HC; KLAMBT, D; JONES, AM			AUXIN-BINDING PROTEIN-1 DOES NOT BIND AUXIN WITHIN THE ENDOPLASMIC-RETICULUM DESPITE THIS BEING THE PREDOMINANT SUBCELLULAR LOCATION FOR THIS HORMONE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZEA-MAYS-L; HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; MOLECULAR-CLONING; PLASMA-MEMBRANE; IMMUNOLOGICAL METHODS; COLEOPTILE MEMBRANES; MAIZE COLEOPTILES; SECRETORY PATHWAY; CORN COLEOPTILES	Auxin-binding protein 1 (ABP1) is a unique hormone receptor because it resides primarily in the lumen of the endoplasmic reticulum (ER); however, two lines of evidence presented here suggest that ABP1 does not bind auxin within the endoplasmic reticulum, despite its predominant location there, First, ABP1 cannot be photolabeled in intact cells that have accumulated the auxin and photolabeling reagent 5-[7-H-3]azidoindole-3-acetic acid, indicating either that auxin is excluded from the ER and is not available for photolabeling to ABP1 or that binding conditions within the ER lumen are insufficient for photolabeling, Second, at the pH of the ER lumen, auxin binding to ABP1 is not detectable. The pH estimate of the ER lumen is based on an indirect assay, which indicates that the pH is closer to pH 7 than to the binding optimum of pH 5.5. These results indicate that ABP1 does not bind auxin within the ER and point to a site of action that is post-ER, The effect of auxin on its trafficking from the ER was tested in an animal expression system, ABP1 expressed at high levels in COS7 cells is efficiently retained in the ER lumen and is not secreted even in the presence of 190 mu M indole-3-acetic acid, an auxin concentration that is 40 times above the K-d for indole-3-acetic acid binding to ABP1.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV BONN, INST BOT, W-5300 BONN, GERMANY	University of North Carolina; University of North Carolina Chapel Hill; University of Bonn								ABBATE M, 1993, EUR J CELL BIOL, V61, P139; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BARBIERBRYGOO H, 1991, PLANT J, V1, P83, DOI 10.1111/j.1365-313X.1991.00083.x; BARRIERBRYGOO H, 1989, P NATL ACAD SCI USA, V86, P891, DOI 10.1073/pnas.86.3.891; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BLATT MR, 1994, PLANT J, V5, P55, DOI 10.1046/j.1365-313X.1994.5010055.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JC, 1994, J BIOL CHEM, V269, P21136; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLELAND RE, 1976, PLANT PHYSIOL, V58, P210, DOI 10.1104/pp.58.2.210; CROSS JW, 1991, NEW BIOL, V3, P813; DIEKMANN W, 1995, P NATL ACAD SCI USA, V92, P3425, DOI 10.1073/pnas.92.8.3425; EDGERTON MD, 1994, PHYTOCHEMISTRY, V35, P1111, DOI 10.1016/S0031-9422(00)94807-6; GOLDSMITH MHM, 1993, P NATL ACAD SCI USA, V90, P11442, DOI 10.1073/pnas.90.24.11442; HERTEL R, 1972, PLANTA, V107, P325, DOI 10.1007/BF00386394; HESSE T, 1989, EMBO J, V8, P2453, DOI 10.1002/j.1460-2075.1989.tb08380.x; HOFFMANN B, 1992, PHYSIOL PLANTARUM, V84, P146, DOI 10.1111/j.1399-3054.1992.tb08777.x; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOHARA N, 1989, P NATL ACAD SCI USA, V86, P3564, DOI 10.1073/pnas.86.10.3564; JACOBS M, 1976, PLANT PHYSIOL, V58, P203, DOI 10.1104/pp.58.2.203; JONES AM, 1984, PLANT PHYSIOL, V74, P295, DOI 10.1104/pp.74.2.295; JONES AM, 1993, PLANT PHYSIOL, V101, P595, DOI 10.1104/pp.101.2.595; JONES AM, 1991, PLANT PHYSIOL, V97, P352, DOI 10.1104/pp.97.1.352; JONES AM, 1990, PLANT PHYSIOL, V93, P1154, DOI 10.1104/pp.93.3.1154; JONES AM, 1989, PLANTA, V179, P409, DOI 10.1007/BF00391088; JONES AM, 1989, P NATL ACAD SCI USA, V86, P6153, DOI 10.1073/pnas.86.16.6153; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; KLAMBT D, 1990, PLANT MOL BIOL, V14, P1045, DOI 10.1007/BF00019401; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LOBLER M, 1985, J BIOL CHEM, V260, P9848; MACDONALD H, 1994, PLANT PHYSIOL, V105, P1049, DOI 10.1104/pp.105.4.1049; MELHADO LL, 1982, PHYTOCHEMISTRY, V21, P2879, DOI 10.1016/0031-9422(80)85060-6; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; NAPIER RM, 1990, PLANTA, V182, P313, DOI 10.1007/BF00197128; NAPIER RM, 1992, J CELL SCI, V102, P261; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; PILARSKY C, 1992, EUR J CELL BIOL, V59, P275; RAY PM, 1977, PLANT PHYSIOL, V59, P594, DOI 10.1104/pp.59.4.594; RAY PM, 1977, PLANT PHYSIOL, V60, P585, DOI 10.1104/pp.60.4.585; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUCK A, 1993, PLANT J, V4, P41, DOI 10.1046/j.1365-313X.1993.04010041.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIMOMURA S, 1986, J BIOCHEM-TOKYO, V99, P1513, DOI 10.1093/oxfordjournals.jbchem.a135621; SHIMOMURA S, 1988, PLANTA, V175, P558, DOI 10.1007/BF00393079; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; THIEL G, 1993, P NATL ACAD SCI USA, V90, P11493, DOI 10.1073/pnas.90.24.11493; TILLMANN U, 1989, EMBO J, V8, P2463, DOI 10.1002/j.1460-2075.1989.tb08381.x; WANG XM, 1991, J BIOL CHEM, V266, P19981; WILSON DW, 1993, J BIOL CHEM, V268, P7465; YILLA M, 1993, J BIOL CHEM, V268, P19092; YOO SH, 1992, J BIOL CHEM, V267, P11236; ZIMMERMANN S, 1994, PLANT J, V6, P707, DOI 10.1046/j.1365-313X.1994.6050707.x	61	55	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26962	26969		10.1074/jbc.270.45.26962	http://dx.doi.org/10.1074/jbc.270.45.26962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592943	Green Published, hybrid			2022-12-25	WOS:A1995TE58300043
J	SAPORITOIRWIN, SM; VANNOSTRAND, WE				SAPORITOIRWIN, SM; VANNOSTRAND, WE			COAGULATION-FACTOR XIA CLEAVES THE RHDS SEQUENCE AND ABOLISHES THE CELL ADHESIVE PROPERTIES OF THE AMYLOID BETA-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; NEXIN-II; INHIBITOR DOMAIN; SECRETED FORMS; PURIFICATION; CDNA; FIBROBLASTS; EXPRESSION; CONTAINS	Amyloid beta-protein (A beta) is the major constituent of senile plaques and cerebrovascular amyloid deposits in Alzheimer's disease and is proteolytically derived from its transmembrane parent protein the amyloid beta-protein precursor (A beta PP). Although the physiological role(s) of secreted A beta PPs are not fully understood, several potential functions have been described including the regulation of hemostatic enzymes factors XIa and Ma and a role in cell adhesion. In the present study, we investigated the proteolytic processing of A beta PP by factor XIa (FXIa). Incubation of the human glioblastoma cell line U138 stably transfected to overexpress the 695 isoform of A beta PP with FXIa (2.55 nM) resulted in proteolytic cleavage of secreted A beta PP. Higher concentrations of FXIa (>25 nM) resulted in loss in cell adherence. Coin cubation of FXIa with purified, recombinant Kunitz protease inhibitor domain of A beta PP blocked both the proteolytic processing of A beta PP and the loss of cell adhesion. The RHDS cell adhesion site of A beta PP resides within residues 5-8 of the A beta domain. Incubation of synthetic AP(1-40) peptide with increasing concentrations of FXIa resulted in cleavage of A beta between Arg(5) and His(6) within the cell adhesion domain of the peptide. FXIa-digested A beta(1-40) or A beta PP695 lost their abilities to serve as cell adhesion substrates consistent with cleavage through this cell adhesion site, Together, these results suggest a new potential biological function for FXIa in the modulation of cell adhesion. In addition, we have shown that FXIa can proteolytically alter A beta and therefore possibly modify its physiological and perhaps pathological properties.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003229, R01HL049566] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03229, HL49566] Funding Source: Medline; NIA NIH HHS [AG00096-12] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHMAIER AH, 1995, BIOCHEMISTRY-US, V34, P1171, DOI 10.1021/bi00004a010; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, ANN NY ACAD SCI, V674, P243; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WANG R, 1991, J BIOL CHEM, V266, P16960	41	29	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26265	26269		10.1074/jbc.270.44.26265	http://dx.doi.org/10.1074/jbc.270.44.26265			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592834	hybrid			2022-12-25	WOS:A1995TC97800041
J	SARVAZYAN, NA; MODYANOV, NN; ASKARI, A				SARVAZYAN, NA; MODYANOV, NN; ASKARI, A			INTERSUBUNIT AND INTRASUBUNIT CONTACT REGIONS OF NA+/K+-ATPASE REVEALED BY CONTROLLED PROTEOLYSIS AND CHEMICAL CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; ACTIVATED ADENOSINE-TRIPHOSPHATASE; SPATIAL-ORGANIZATION; ALPHA-SUBUNIT; BETA-SUBUNIT; K+-ATPASE; CHYMOTRYPTIC CLEAVAGE; CATION OCCLUSION; MEMBRANE DOMAINS; SODIUM	To identify interfaces of alpha- and beta-subunits of Na+/K+- ATPase, and contact points between different regions of the same alpha-subunit, purified kidney enzyme preparations whose alpha-subunits were subjected to controlled proteolysis in different ways were solubilized with digitonin to disrupt intersubunit alpha,alpha-interactions, and oxidatively cross-linked. The following disulfide cross-linked products were identified by gel electrophoresis, staining with specific antibodies, and N-terminal analysis. 1) In the enzyme that was partially cleaved at Arg(438)-Ala(439), the cross-linked products were an alpha.beta-dimer, a dimer of N-terminal and C-terminal or fragments, and a trimer of beta and the two alpha fragments. 2) From an extensively digested enzyme that contained the 22-kDa C-terminal and several smaller fragments of or, two crosslinked products were obtained, One was a dimer of the 22-kDa C-terminal peptide and an 11-kDa N-terminal peptide containing the first two intramembrane helices of alpha (H-1-H-2). The other was a trimer of beta, the 11-kDa, and the 22-kDa peptides. 3) The cross-linked products of a preparation partially cleaved at Leu(266)-Ala(267) were an alpha,beta-dimer and a dimer of beta and the 83-bDa C-terminal fragment. Assuming the most likely 10-span model of alpha, these findings indicate that (a) the single intramembrane helix of beta is in contact with portions of H-8-H-10 intramembrane helices of alpha; and (b) there is close contact between N-terminal H1-H-2 and C-terminal H-8-H-10 segments of alpha; with the most probable interacting helices being the H-1,H-10-pair and the H-2,H-8-pair.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EFREMOV RG, 1992, J PROTEIN CHEM, V11, P699, DOI 10.1007/BF01024971; EFREMOV RG, 1992, J PROTEIN CHEM, V11, P665, DOI 10.1007/BF01024968; EFREMOV RG, 1993, J PROTEIN CHEM, V12, P143, DOI 10.1007/BF01026035; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; GIOTTA GJ, 1976, BIOCHEM BIOPH RES CO, V71, P776, DOI 10.1016/0006-291X(76)90898-6; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; HUANG WH, 1990, BIOCHIM BIOPHYS ACTA, V1030, P65, DOI 10.1016/0005-2736(90)90239-K; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; HUANG WH, 1979, BIOCHIM BIOPHYS ACTA, V578, P547, DOI 10.1016/0005-2795(79)90186-7; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JEAN DH, 1975, J BIOL CHEM, V250, P1035; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P1566; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; LEMAS MV, 1994, J BIOL CHEM, V269, P18651; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIANG SM, 1977, J BIOL CHEM, V252, P8278; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LO TN, 1978, J BIOL CHEM, V253, P4432; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; RHEE HM, 1975, BIOCHEM BIOPH RES CO, V63, P1139, DOI 10.1016/0006-291X(75)90687-7; SARVAZYAN N, 1994, FASEB J, V8, pA299; Sarvazyan N. A., 1995, Biophysical Journal, V68, pA308; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; XIE ZJ, 1994, SODIUM PUMP, P49; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	46	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26528	26532		10.1074/jbc.270.44.26528	http://dx.doi.org/10.1074/jbc.270.44.26528			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592871	hybrid			2022-12-25	WOS:A1995TC97800078
J	MERICKEL, A; ROSANDICH, P; PETER, D; EDWARDS, RH				MERICKEL, A; ROSANDICH, P; PETER, D; EDWARDS, RH			IDENTIFICATION OF RESIDUES INVOLVED IN SUBSTRATE RECOGNITION BY A VESICULAR MONOAMINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; BETA-ADRENERGIC-RECEPTOR; ESCHERICHIA-COLI; CHROMAFFIN GRANULES; SYNAPTIC VESICLES; AMINE TRANSPORTER; RESERPINE BINDING; TN10; RESISTANCE; SYSTEM	To identify the residues involved in substrate recognition by recently cloned vesicular monoamine transporters (VMAT1 and VMAT2), we have mutagenized the conserved residues in a cytoplasmic loop between transmembrane domains two and three of VMAT2. Although studies of related bacterial antibiotic resistance proteins indicate an important functional role for this region, we found no effect of these mutations on VMAT2 activity. However, replacement of aspartate 33 in the first predicted transmembrane domain with an asparagine (D33N) eliminates transport. D33N shows normal levels of expression and normal binding at equilibrium to the potent inhibitor reserpine. However, in contrast to wild-type VMAT2, serotonin inhibits reserpine binding to D33N very poorly, indicating a specific defect in substrate recognition. Replacement of three serine residues in transmembrane domain three with alanine (Stmd3A) shows a similarly selective but even more profound defect in substrate recognition. The results suggest that by analogy to receptors and plasma membrane transporters for monoamines, the cationic amino group of the ligand interacts with an aspartate in the first transmembrane domain of VMAT2 and hydroxyl groups on the catechol or indole ring interact with a group of serines in the third transmembrane domain. Importantly, D33N and Stmd3A retain coupling to the proton electrochemical gradient as measured by the Delta mu(H)+-induced acceleration of reserpine binding. This indicates that substrate recognition can be separated from coupling to the driving force.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, SCH MED, INTERDEPARTMENTAL PROGRAM NEUROSCI, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; GIROS B, 1994, J BIOL CHEM, V269, P15985; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P271, DOI 10.1006/abbi.1993.1422; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, J NEUROSCI, V15, P6179; RAMU A, 1983, P NATL ACAD SCI-BIOL, V80, P2107, DOI 10.1073/pnas.80.8.2107; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1988, EUR J PHARMACOL, V146, P359, DOI 10.1016/0014-2999(88)90317-2; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIRVAN A, 1994, FEBS LETT, V356, P145, DOI 10.1016/0014-5793(94)01252-0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490	49	61	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25798	25804		10.1074/jbc.270.43.25798	http://dx.doi.org/10.1074/jbc.270.43.25798			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592763	hybrid			2022-12-25	WOS:A1995TB46600080
J	WONG, P; HAMPTON, B; SZYLOBRYT, E; GALLAGHER, AM; JAYE, M; BURGESS, WH				WONG, P; HAMPTON, B; SZYLOBRYT, E; GALLAGHER, AM; JAYE, M; BURGESS, WH			ANALYSIS OF PUTATIVE HEPARIN-BINDING DOMAINS OF FIBROBLAST GROWTH-FACTOR-I - USING SITE-DIRECTED MUTAGENESIS AND PEPTIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; MITOGENIC ACTIVITY; RECEPTOR-BINDING; FACTOR FAMILY; ACIDIC FGF; PROTEINS; AFFINITY; RESIDUES; CELLS; INACTIVATION	The contribution of individual basic amino acids within three putative ''consensus sequences'' for heparin binding of fibroblast growth factor-1 have been examined by site-directed mutagenesis. The results indicate that a significant reduction in the apparent affinity of fibroblast growth factor-1 for heparin is only observed when basic residues in one of the three regions are mutated, Mutation in the other regions are without affect on heparin binding. The heparin binding properties of synthetic peptides based on the three ''consensus sequences'' paralleled the mutagenesis results. That is, synthetic peptides corresponding to regions of the protein that were affected by mutagenesis with respect to heparin binding exhibited a relatively high affinity for immobilized heparin, whereas those corresponding to regions of similar charge density that were unaffected by mutagenesis did not. In addition, amino acid substitution of a nonbasic residue in the heparin-binding peptide could abolish its heparin binding capacity. The heparin-binding peptide could antagonize the mitogenic activity of FGF-1, probably because of the heparin dependence of this activity. Together these data demonstrate that the heparin binding properties of fibroblast growth factor-1 are dictated by structural features more complex than clusters of basic amino acids. The results of these and other studies indicate that consensus motifs for heparin-binding require further definition. More importantly, the results provide a basis for the design of peptide-based inhibitors of FGF-1.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426	American Red Cross			Hampton, Brian/G-8427-2015	Hampton, Brian/0000-0003-4650-2869	NHLBI NIH HHS [HL35762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035762] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURGESS WH, 1995, REGULATION PROLIFERA, P155; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HATA A, 1993, J BIOL CHEM, V268, P8447; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAYE M, 1987, J BIOL CHEM, V262, P16612; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MEHLMAN T, 1990, ANAL BIOCHEM, V188, P159, DOI 10.1016/0003-2697(90)90545-K; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1991, ANN NY ACAD SCI, V638, P177, DOI 10.1111/j.1749-6632.1991.tb49028.x; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	38	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25805	25811		10.1074/jbc.270.43.25805	http://dx.doi.org/10.1074/jbc.270.43.25805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592764	hybrid			2022-12-25	WOS:A1995TB46600081
J	ATAMNA, H; GINSBURG, H				ATAMNA, H; GINSBURG, H			HEME DEGRADATION IN THE PRESENCE OF GLUTATHIONE - A PROPOSED MECHANISM TO ACCOUNT FOR THE HIGH-LEVELS OF NONHEME IRON FOUND IN THE MEMBRANES OF HEMOGLOBINOPATHIC RED-BLOOD-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE ERYTHROCYTE-MEMBRANES; LIPID-PEROXIDATION; OXIDATIVE DENATURATION; FERRIPROTOPORPHYRIN IX; ASSOCIATION; HEMOLYSIS; PROTEINS; RELEASE	Unstable hemoglobins and oxidative conditions tend to produce hemichromes which demonstrably release their heme to the erythrocyte membrane, with consequent lipid peroxidation and cell lysis. High levels of non-heme iron are also found in such circumstances, but the origin of this iron is uncertain. In the present work, we show that reduced glutathione (GSH) is able to degrade heme in solution with a pH optimum of 7. Degradation depended on the presence of oxygen and on heme and GSH concentrations. It was inhibited by catalase and superoxide dismutase, implicating the involvement of perferryl reactive species in the process of heme degradation. Heme degradation at pH 7 and 37 degrees C is rapid (t(1/2) = 70 s) and results in the release of iron from heme. Heme that was dissolved in red blood cell ghosts is also degraded by GSH with a concomitant increase in non-heme iron, most of which (75%) remains associated with the cell membrane. Loading of intact erythrocytes with heme was followed by time-dependent decrease of membrane-associated heme and caused an acceleration of the hexose monophosphate shunt due to the production of H2O2 and the oxidation of intracellular GSH. Most of the activation of the hexose monophosphate pathway was due to redox cycling of iron, since iron chelators inhibited it considerably. These results explain the origin of non-heme iron found in the membrane of sickle cells and the oxidative stress that is observed in these and other abnormal erythrocytes.	HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								AEBI H, 1982, METHOD ENZYMAT AN, V2, P673; Beutler E., 1984, RED CELL METABOLISM, P103; BROWN SB, 1968, T FARADAY SOC, V64, P999, DOI 10.1039/tf9686400999; CANNON JB, 1984, BIOCHEMISTRY-US, V23, P3715, DOI 10.1021/bi00311a022; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; CHIU D, 1989, SEMIN HEMATOL, V26, P128; CHIU D, 1989, SEMIN HEMATOL, V26, P257; CHOU AC, 1981, J CLIN INVEST, V68, P672, DOI 10.1172/JCI110302; GALARIS D, 1989, FREE RADICAL BIO MED, V6, P473, DOI 10.1016/0891-5849(89)90039-7; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1989, FREE RADICAL BIO MED, P129; HEBBEL RP, 1990, SEMIN HEMATOL, V27, P51; HEBBEL RP, 1989, SEMIN HEMATOL, V26, P136; JAROLIM P, 1990, BLOOD, V76, P2125; KREMER ML, 1989, EUR J BIOCHEM, V185, P651, DOI 10.1111/j.1432-1033.1989.tb15162.x; KUROSS SA, 1988, BLOOD, V71, P876; KUROSS SA, 1988, BLOOD, V72, P1278; LIU SC, 1988, BLOOD, V71, P1755; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; MUNDAY R, 1989, BIOCHEM PHARMACOL, V38, P4349, DOI 10.1016/0006-2952(89)90641-2; PESCARMONA GP, 1982, INT J BIOCHEM, V14, P243, DOI 10.1016/0020-711X(82)90146-X; PONKA P, 1994, CAN J PHYSIOL PHARM, V72, P659, DOI 10.1139/y94-093; PONKA P, 1985, J BIOL CHEM, V260, P4717; PONKA P, 1982, BIOCHIM BIOPHYS ACTA, V718, P151, DOI 10.1016/0304-4165(82)90213-6; REPKA T, 1991, BLOOD, V78, P2753; REPKA T, 1993, BLOOD, V82, P3204; Rice-Evans C., 1990, BLOOD CELL BIOCH, P429; ROSE MY, 1985, J BIOL CHEM, V260, P6632; SHINAR E, 1990, SEMIN HEMATOL, V27, P70; SHVIRO Y, 1987, BIOCHEM PHARMACOL, V36, P3801, DOI 10.1016/0006-2952(87)90441-2; SOLAR I, 1989, FEBS LETT, V256, P225, DOI 10.1016/0014-5793(89)81753-3; SUGIHARA T, 1992, J CLIN INVEST, V90, P2327, DOI 10.1172/JCI116121; SUGIOKA Y, 1987, FEBS LETT, V223, P251, DOI 10.1016/0014-5793(87)80299-5; SULLIVAN SG, 1992, BIOCHIM BIOPHYS ACTA, V1104, P38, DOI 10.1016/0005-2736(92)90129-A; WINTERBOURN CC, 1990, SEMIN HEMATOL, V27, P41	37	184	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24876	24883		10.1074/jbc.270.42.24876	http://dx.doi.org/10.1074/jbc.270.42.24876			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559611	hybrid			2022-12-25	WOS:A1995TB46500045
J	LAI, KS; JIN, Y; GRAHAM, DK; WITTHUHN, BA; IHLE, JN; LIU, ET				LAI, KS; JIN, Y; GRAHAM, DK; WITTHUHN, BA; IHLE, JN; LIU, ET			A KINASE-DEFICIENT SPLICE VARIANT OF THE HUMAN JAK3 IS EXPRESSED IN HEMATOPOIETIC AND EPITHELIAL CANCER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; EGF-RECEPTOR; BINDING-SITE; DOMAINS; FAMILY; IDENTIFICATION; GENE; SH2	Signal transduction of cytokine receptors is mediated by the JAK family of tyrosine kinases. Recently, the kinase partners for the interleukin (IL)-2 receptor have been identified as JAK1 and JAK3. In this study, we report the identification of splice variants that may modulate JAK3 signaling. Three splice variants were isolated from different mRNA sources: breast (B), spleen (S), and activated monocytes (M). Sequence analysis revealed that the splice variants contain identical NH2-terminal regions but diverge at the COOH termini. Analyses of expression of the JAK3 splice isoforms by reverse transcriptase-polymerase chain reaction on a panel of cell lines show splice preferences in different cell lines: the S-form is more commonly seen in hematopoietic lines, whereas the B- and M-forms are detected in cells both of hematopoietic and epithelial origins, Antibodies raised against peptides to the B-form splice variant confirmed that the 125-kDa JAK3B protein product is found abundantly in hematopoietic as well as epithelial cells, including primary breast cancers. The lack of subdomain XI in the tyrosine kinase core of the B-form JAK3 protein suggests that it is a defective kinase, This is supported by the lack of detected autokinase activity of the B-form JAK3. Intriguingly, both the S and B splice isoforms of JAK3 appear to co immunoprecipitate with the IL-2 receptor from HUT-78 cell lysates. This and the presence of multiple COOH-terminal splice variants coexpressed in the same cells suggest that the JAK3 splice isoforms are functional in JAK3 signaling and may enrich the complexity of the intracellular responses functional in IL-2 or cytokine signaling.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; St Jude Children's Research Hospital			Liu, Edison/C-4141-2008; witthuhn, bruce/GSE-3193-2022		NATIONAL CANCER INSTITUTE [P50CA058223] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58223-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HALEY J, 1987, ONCOGENE RES, V1, P375; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; RANE SG, 1994, ONCOGENE, V9, P2415; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	35	55	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25028	25036		10.1074/jbc.270.42.25028	http://dx.doi.org/10.1074/jbc.270.42.25028			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559633	hybrid, Green Published			2022-12-25	WOS:A1995TB46500067
J	UDDIN, S; CHAMDIN, A; PLATANIAS, LC				UDDIN, S; CHAMDIN, A; PLATANIAS, LC			INTERACTION OF THE TRANSCRIPTIONAL ACTIVATOR STAT-2 WITH THE TYPE-I INTERFERON RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IFN-ALPHA RECEPTOR; TYROSINE PHOSPHORYLATION; SUBUNIT; CELLS	Binding of interferon-alpha (IFN alpha) to the multisubunit type I IFN receptor (IFNR) induces activation of the Tyk-2 and Jak-1 kinases and tyrosine phosphorylation of multiple signaling elements, including the Stat proteins that form the ISGF3 alpha complex. Although Jak kinases are required for IFN alpha-dependent activation of Stats, the mechanisms by which Stats interact with these kinases are not known. We report that Stat-2 associates with beta(s) subunit of the type I IFN receptor in an interferon-dependent manner. This association is rapid, occurring within 1 min of interferon treatment of cells, and is inducible by various type I (alpha, beta, omega) but not type II (gamma) IFNs. The kinetics of Stat-2-IFNR association are similar to the kinetics of phosphorylation of Stat-2, suggesting that during its binding to the type I IFNR, Stat-2 acts as a substrate for interferon-dependent tyrosine kinase activity. These findings support the hypothesis that the type I IFNR acts as an adaptor, linking Stat proteins to Jak kinases, Interaction of Stat-2 with the beta(s) subunit of the type I IFNR may be a critical signaling event, required for the formation of the ISGF3 alpha complex and downstream transcription of interferon-stimulated genes.	LOYOLA UNIV,DEPT MED,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; EDWARD HINES JR VET ADM HOSP,HINES,IL 60141	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital				Uddin, Shahab/0000-0003-1886-6710				COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V8, P11411; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; PLATANIAS LC, 1992, BRIT J HAEMATOL, V82, P543; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3	24	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24627	24630		10.1074/jbc.270.42.24627	http://dx.doi.org/10.1074/jbc.270.42.24627			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559568	hybrid			2022-12-25	WOS:A1995TB46500002
J	DING, DXH; VERA, JC; HEANEY, ML; GOLDE, DW				DING, DXH; VERA, JC; HEANEY, ML; GOLDE, DW			N-GLYCOSYLATION OF THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR ALPHA-SUBUNIT IS ESSENTIAL FOR LIGAND-BINDING AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTORS; ASPARAGINE-LINKED OLIGOSACCHARIDES; INSULIN-RECEPTOR; BETA-SUBUNIT; EXPRESSION CLONING; CELL-LINE; AFFINITY; IDENTIFICATION; RECONSTITUTION; CARBOHYDRATE	The alpha subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein containing 11 potential N-glycosylation sites in the extracellular domain, We examined the role of N-glycosylation on alpha subunit membrane localization and function, Tunicamycin, an N-glycosylation inhibitor, markedly inhibited GM-CSF binding, GM-CSF-induced deoxyglucose uptake, and protein tyrosine phosphorylation in HL-60(eos) cells but did not affect cell surface expression of the alpha subunit as detected by an anti-alpha subunit monoclonal antibody, In COS cells expressing the alpha subunit and treated with tunicamycin, N-unglycosylated alpha subunit was expressed and transported to the cell surface but was not capable of binding GM-CSF. High affinity binding in COS cells expressing both alpha and beta subunits was also blocked by tunicamycin treatment. These studies indicate that N-linked oligosaccharides are essential for alpha subunit ligand binding and signaling by the human GM-CSF receptor.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01 CA30388, K11 CA01754] Funding Source: Medline; NHLBI NIH HHS [R01 HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030388, K11CA001754] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; CHIBA S, 1990, J BIOL CHEM, V265, P19777; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CHOCHOLA J, 1993, J BIOL CHEM, V268, P2312; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DAVIE SJ, 1992, DIABETES, V41, P167, DOI 10.2337/diabetes.41.2.167; DING DXH, 1994, P NATL ACAD SCI USA, V91, P2537, DOI 10.1073/pnas.91.7.2537; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FABIAN I, 1992, BLOOD, V80, P788; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JUBINSKY PT, 1994, BLOOD, V84, P4174, DOI 10.1182/blood.V84.12.4174.bloodjournal84124174; KANAKURA Y, 1991, BLOOD, V77, P243; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHANSKY K, 1987, BIOCHEMISTRY-US, V26, P4861, DOI 10.1021/bi00389a038; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAGAI AK, 1994, BBA-BIOMEMBRANES, V1193, P24, DOI 10.1016/0005-2736(94)90328-X; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LECONTE I, 1994, J BIOL CHEM, V269, P18062; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; MURATA Y, 1992, J EXP MED, V1765, P341; OHTA T, 1994, BIOCHEM BIOPH RES CO, V200, P1283, DOI 10.1006/bbrc.1994.1590; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V200, P1313, DOI 10.1006/bbrc.1994.1594; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAINES MA, 1992, BLOOD, V79, P3350; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; SEMMES OJ, 1992, INT J IMMUNOPHARMACO, V14, P583, DOI 10.1016/0192-0561(92)90119-6; SHIBUYA K, 1991, EUR J BIOCHEM, V198, P659, DOI 10.1111/j.1432-1033.1991.tb16064.x; SPIELHOLZ C, 1995, BLOOD, V85, P973, DOI 10.1182/blood.V85.4.973.bloodjournal854973; SZECOWKA J, 1990, ENDOCRINOLOGY, V126, P1834, DOI 10.1210/endo-126-4-1834; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; TOMONAGA M, 1986, BLOOD, V67, P1433; VERA JC, 1990, MOL CELL BIOL, V10, P743, DOI 10.1128/MCB.10.2.743	44	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24580	24584		10.1074/jbc.270.41.24580	http://dx.doi.org/10.1074/jbc.270.41.24580			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592677	hybrid			2022-12-25	WOS:A1995TA21700105
J	TINTUT, Y; WANG, JT; GRALLA, JD				TINTUT, Y; WANG, JT; GRALLA, JD			ABORTIVE CYCLING AND THE RELEASE OF POLYMERASE FOR ELONGATION AT THE SIGMA-54-DEPENDENT GLNAP2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI COMPONENTS; CORE RNA-POLYMERASE; TRANSCRIPTION INITIATION; KLEBSIELLA-PNEUMONIAE; TERNARY COMPLEXES; FACTOR SIGMA-54; PROTEIN; DNA; BINDING; ACTIVATION	Transcription initiation at the sigma 54-dependent glnAp2 promoter was studied to follow the state of polymerase as RNA synthesis begins. sigma 54 polymerase begins transcription in abortive cycling mode, i.e. after the first bond is made, approximately 75% of the time the short RNA is aborted and synthesis must be restarted. Polymerase is capable of abortive initiation until it reaches a position beyond +3 and before +7, at which stage polymerase is released from its promoter contacts and an elongation complex is formed. Initial elongation is accompanied by two transcription bubbles, one moving with the polymerase and the other remaining at the transcription start site, The sigma 54-associated polymerase shows an earlier and more efficient transition out of abortive initiation mode than prior studies of sigma 70-associated polymerase.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles	TINTUT, Y (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA.		Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NIGMS NIH HHS [GM35754, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARPOUSIS AJ, 1983, THESIS U CALIF, P70; Chamberlin M J, 1992, Harvey Lect, V88, P1; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; JACOB GA, 1994, J BIOL CHEM, V269, P3655; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MAGASANIK B, 1989, New Biologist, V1, P247; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MERRICK MJ, 1985, NUCLEIC ACIDS RES, V13, P7607, DOI 10.1093/nar/13.21.7607; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; TINTUT Y, 1994, P NATL ACAD SCI USA, V91, P2120, DOI 10.1073/pnas.91.6.2120; TINTUT Y, 1995, IN PRESS J BACTERIOL; TINTUT Y, 1995, IN PRESS GENES DEV; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24392	24398		10.1074/jbc.270.41.24392	http://dx.doi.org/10.1074/jbc.270.41.24392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592652	hybrid			2022-12-25	WOS:A1995TA21700080
J	KANETY, H; FEINSTEIN, R; PAPA, MZ; HEMI, R; KARASIK, A				KANETY, H; FEINSTEIN, R; PAPA, MZ; HEMI, R; KARASIK, A			TUMOR-NECROSIS-FACTOR-ALPHA INDUCED PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 (IRS-1) - POSSIBLE MECHANISM FOR SUPPRESSION OF INSULIN-STIMULATED TYROSINE PHOSPHORYLATION OF IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SIGNAL TRANSDUCTION; PROTEIN-KINASE-C; OKADAIC ACID; HEPATOMA-CELLS; INTERLEUKIN-1; GLUCOSE; PHOSPHATASE; RESISTANCE; EXPRESSION; ACTIVATION	Tumor necrosis factor-alpha (TNF) has been suggested to be the mediator of insulin resistance in infection, tumor cachexia, and obesity. We have previously shown that TNF diminishes insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1). The current work examines potential mechanisms that mediate this event. TNF effect on IRS-1 in Fao hepatoma cells was not associated with a significant reduction in insulin receptor tyrosine kinase activity as measured in vitro but impaired the association of IRS-1 with phosphatidylinositol 3-kinase, localizing TNF impact to IRS-1. TNF did not increase protein-tyrosine phosphatase activity and protein-tyrosine phosphatase inhibition by vanadate did not change TNF effect on IRS-1 tyrosine phosphorylation, suggesting that protein-tyrosine phosphatases are not involved in this TNF effect. In contrast, TNF increased IRS-1 phosphorylation on serine residues, leading to a decrease in its electrophoretic mobility. TNF effect on IRS-1 tyrosine phosphorylation was not abolished by inhibiting protein kinase C using staurosporine, while inactivation of Ser/Thr phosphatases by calyculin A and okadaic acid mimicked it. Our data suggest that TNF induces serine phosphorylation of IRS-1 through inhibition of serine phosphatases or activation of serine kinases other than protein kinase C. This increased serine phosphorylation interferes with insulin-induced tyrosine phosphorylation of IRS-1 and impairs insulin action.	SHEBA MED CTR, INST ENDOCRINOL, IL-52621 TEL HASHOMER, ISRAEL; SHEBA MED CTR, DEPT SURG, IL-52621 TEL HASHOMER, ISRAEL; BAR ILAN UNIV, DEPT LIFE SCI, IL-52900 RAMAT GAN, ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Bar Ilan University								BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KANETY H, 1994, P NATL ACAD SCI USA, V91, P1853, DOI 10.1073/pnas.91.5.1853; KLETZIEN RF, 1994, DIABETES, V43, pA82; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LANG CH, 1989, AM J PHYSIOL, V257, pE301, DOI 10.1152/ajpendo.1989.257.3.E301; MCCALL JL, 1992, BRIT J SURG, V79, P1361, DOI 10.1002/bjs.1800791240; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; OLD LJ, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P1; ROBINSON KA, 1993, AM J PHYSIOL, V265, pE36, DOI 10.1152/ajpendo.1993.265.1.E36; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHISHEVA A, 1991, ENDOCRINOLOGY, V129, P2279; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TOTPAL K, 1992, CANCER RES, V52, P2557; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VIETOR I, 1994, LYMPHOKINE CYTOK RES, V13, P315; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	41	344	357	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23780	23784		10.1074/jbc.270.40.23780	http://dx.doi.org/10.1074/jbc.270.40.23780			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559552	hybrid			2022-12-25	WOS:A1995RY90900081
J	GAJEWSKI, KM; SCHULZ, RA				GAJEWSKI, KM; SCHULZ, RA			REQUIREMENT OF THE ETS DOMAIN TRANSCRIPTION FACTOR D-ELG FOR EGG CHAMBER PATTERNING AND DEVELOPMENT DURING DROSOPHILA OOGENESIS	ONCOGENE			English	Article						CELL MIGRATION; DROSOPHILA OOGENESIS; MUTANT PHENOTYPE; TRANSCRIPTION FACTOR	BINDING-PROTEIN; GENE; RNA; LOCALIZATION; EMBRYO; DIFFERENTIATION; EMBRYOGENESIS; MELANOGASTER; CHROMOSOME; POLARITY	The D-elg gene encodes an ETS domain transcription factor that functions in Drosophila oogenesis. D-elg belongs to a small group of genes that are required for the formation of both the anteroposterior and dorsoventral axes of the egg chamber. During oogenesis in D-elg mutant females, the spatial localization of oskar and gurken mRNAs in the oocyte is disrupted and a follicle cell enhancer trap marker identifies dorsoventral polarity defects. Also, specialized follicle cells, called border cells, fail to migrate from their anterior location to a position adjacent to the developing oocyte. Consistent with these phenotypes, D-elg shows genetic interactions with two genes required for normal egg chamber differentiation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NICHD NIH HHS [T32 HD 07324] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007324] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BROWN T, 1992, GENE DEV, V6, P502; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CUPP MB, 1962, MOUSE NEWS LETT, V26, P51; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FORLANI S, 1993, MECH DEVELOP, V41, P109, DOI 10.1016/0925-4773(93)90041-U; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KIMBLE M, 1990, GENETICS, V126, P991; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; LU XY, 1993, DEVELOPMENT, P47; MANSEAU L, 1994, 35TH ANN DROS RES C; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PEIFER M, 1993, DEVELOPMENT, V118, P1191; ROTH S, 1994, DEVELOPMENT, V120, P2245; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; SCHULZ RA, 1993, ONCOGENE, V8, P3369; SCHUPBACH T, 1991, GENETICS, V129, P1119; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SPRADLING A, 1909, DEV DROSOPHILA MELAN, P1; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STJOHNSTON D, 1989, CELL, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644	36	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1033	1040						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566961				2022-12-25	WOS:A1995RX18000004
J	DAVEY, JC; BECKER, KB; SCHNEIDER, MJ; STGERMAIN, DL; GALTON, VA				DAVEY, JC; BECKER, KB; SCHNEIDER, MJ; STGERMAIN, DL; GALTON, VA			CLONING OF A CDNA FOR THE TYPE-II IODOTHYRONINE DEIODINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RANA-CATESBEIANA TADPOLES; THYROID-HORMONE; LIFE-CYCLE; EXPRESSION; GENE; ENZYME	Three types of iodothyronine deiodinase have been identified in vertebrate tissues. cDNAs for the types I and III have been cloned and shown to contain an in-frame TGA that codes for selenocysteine at the active site of the enzyme. We now report the cloning of a cDNA for a type II deiodinase using a reverse transcription/polymerase chain reaction strategy and RNA obtained from Rana catesbeiana tissues. This cDNA (RC5'DII) manifests limited but significant homology with other deiodinase cDNAs and contains a conserved in-frame TGA codon. Injection of capped in vitro synthesized transcripts of the cDNA into Xenopus laevis oocytes results in the induction of deiodinase activity with characteristics typical of a type II deiodinase. The levels of RC5'DII transcripts in R. catesbeiana tadpole tail and liver mRNA at stages XII and XXIII correspond well with that of type II deiodinase activity but not that of the type III activity in these tissues. These findings indicate that the amphibian type II 5'-deiodinase is a structurally unique member of the family of selenocysteine-containing deiodinases.	DARTMOUTH COLL SCH MED,DEPT PHYSIOL,LEBANON,NH 03756; DARTMOUTH COLL SCH MED,DEPT MED,LEBANON,NH 03756	Dartmouth College; Dartmouth College					NICHD NIH HHS [HD 27706, HD 09020] Funding Source: Medline; NIDDK NIH HHS [DK 07508] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027706, R01HD009020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007508] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER KB, 1995, ENDOCRINOLOGY, V136, P4424, DOI 10.1210/en.136.10.4424; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1992, ENDOCR REV, V13, P207, DOI 10.1210/er.13.2.207; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GALTON VA, 1987, ENDOCRINOLOGY, V121, P42, DOI 10.1210/endo-121-1-42; GALTON VA, 1988, ENDOCRINOLOGY, V122, P640; GALTON VA, 1991, ENDOCRINOLOGY, V129, P2298, DOI 10.1210/endo-129-5-2298; GALTON VA, 1988, ENDOCRINOLOGY, V122, P1746; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Kaplan MM, 1986, THYROID HORMONE META, P231; Leonard JL, 1986, THYROID HORMONE META, P189; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; MORENO M, 1994, FEBS LETT, V344, P143, DOI 10.1016/0014-5793(94)00365-3; SCHNEIDER MJ, 1993, ENDOCRINOLOGY, V133, P2488, DOI 10.1210/en.133.6.2488; SHARIFI J, 1992, J BIOL CHEM, V267, P12539; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P11282; STGERMAIN DL, 1989, MOL ENDOCRINOL, V3, P2049; TAYLOR AC, 1946, ANAT REC, V94, P7, DOI 10.1002/ar.1090940103; TOYODA N, 1994, J BIOL CHEM, V269, P20329; WANG Z, 1993, J BIOL CHEM, V268, P16270	23	176	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26786	26789		10.1074/jbc.270.45.26786	http://dx.doi.org/10.1074/jbc.270.45.26786			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592917	hybrid			2022-12-25	WOS:A1995TE58300017
J	CONTURSI, C; MINCHIOTTI, G; DINOCERA, PP				CONTURSI, C; MINCHIOTTI, G; DINOCERA, PP			IDENTIFICATION OF SEQUENCES WHICH REGULATE THE EXPRESSION OF DROSOPHILA-MELANOGASTER DOC ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; F-ELEMENTS; INTERNAL PROMOTER; MAMMALIAN LINES; START SITE; CONTAINS; RETROTRANSPOSITION; DOWNSTREAM; PROTEIN	Long interspersed nuclear elements (LINEs) are mobile DNA elements which propagate by reverse transcription of RNA intermediates. LINEs lack long terminal repeats, and their expression is controlled by promoters located inside to the transcribed region of unit-length DNA copies. Doc elements constitute one of the seven families of LINEs found in Drosophila melanogaster. Plasmids in which the chloramphenicol acetyltransferase (CAT) gene is preceded by DNA segments from different Doc family members were used as templates for transient expression assays in Drosophila S2 cells. Transcription is initiated at the 5' end of Doe elements within hexamers fitting the consensus (C/G)AYTCG and is regulated by a DNA region which is located similar to 20 base pairs (bp) downstream from the RNA start site(s). The region includes a sequence (RGACGTGY motif, or DE2) which stimulates transcription in other Drosophila LINEs, and two adjacent elements, DEI and DE3. Moving the downstream region either 4 bp away from, or 5 bp closer to the RNA start site region inhibited transcription. Sequences located similar to 200 bp downstream from the Doc 5' end repressed CAT expression in an orientation- and position-dependent manner. The inhibition reflects impaired translation of the CAT gene possibly consequent to the interaction of specific Doc RNA sequences with a cellular component.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,I-80131 NAPLES,ITALY; CNR,IST INT GENET & BIOFIS,NAPLES,ITALY	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)				Minchiotti, Gabriella/0000-0003-0225-9043				ARKHIPOVA IR, 1991, EMBO J, V10, P1169, DOI 10.1002/j.1460-2075.1991.tb08057.x; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; BUCHETON A, 1990, TRENDS GENET, V6, P1; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; CHEN HJ, 1994, MOL CELL BIOL, V14, P676, DOI 10.1128/MCB.14.1.676; CONTURSI C, 1993, J MOL BIOL, V234, P988, DOI 10.1006/jmbi.1993.1653; DINOCERA PP, 1988, NUCLEIC ACIDS RES, V16, P4041; DINOCERA PP, 1987, P NATL ACAD SCI USA, V84, P5843; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; Finnegan D J, 1986, Oxf Surv Eukaryot Genes, V3, P1; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; GRIMALDI G, 1988, P NATL ACAD SCI USA, V85, P5502, DOI 10.1073/pnas.85.15.5502; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; JAKUBCZAK JL, 1990, J MOL BIOL, V212, P37, DOI 10.1016/0022-2836(90)90303-4; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; LACHAUME P, 1992, DEVELOPMENT, V115, P729; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LIU CC, 1984, NATURE, V309, P82, DOI 10.1038/309082a0; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MCLEAN C, 1993, MOL CELL BIOL, V13, P1042, DOI 10.1128/MCB.13.2.1042; MCMILLAN JP, 1993, P NATL ACAD SCI USA, V90, P11533, DOI 10.1073/pnas.90.24.11533; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; MINCHIOTTI G, 1994, MOL GEN GENET, V245, P152, DOI 10.1007/BF00283262; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MIZROKHI LJ, 1990, P NATL ACAD SCI USA, V87, P9216, DOI 10.1073/pnas.87.23.9216; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; PASYUKOVA EG, 1993, MOL GEN GENET, V240, P302, DOI 10.1007/BF00277071; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; PRIIMAGI AF, 1988, GENE, V70, P253, DOI 10.1016/0378-1119(88)90197-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHALET AP, 1986, MUTAT RES, V163, P115, DOI 10.1016/0027-5107(86)90042-4; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; THUMMEL CS, 1989, GENE DEV, V3, P782, DOI 10.1101/gad.3.6.782; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823; [No title captured]	55	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26570	26576		10.1074/jbc.270.44.26570	http://dx.doi.org/10.1074/jbc.270.44.26570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592878	hybrid			2022-12-25	WOS:A1995TC97800085
J	SKOWYRA, D; WICKNER, S				SKOWYRA, D; WICKNER, S			GRPE ALTERS THE AFFINITY OF DNAK FOR ATP AND MG2+ - IMPLICATIONS FOR THE MECHANISM OF NUCLEOTIDE EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; REPA MONOMERIZATION; REPLICATION; CHAPERONES; BINDING; ORIGIN; GROEL	DnaK, DnaJ, and GrpE heat shock proteins of Escherichia coli activate site-specific DNA binding by the RepA replication initiator protein of plasmid P1 in a reaction dependent on ATP and Mg2+. We previously showed that GrpE is essential for in. vitro RepA activation specifically at about 1 mu m free Mg2+. In this paper, we demonstrate that GrpE lowers the requirement of DnaK ATPase for Mg2+, resulting in a large stimulation of ATP hydrolysis at about 1 mu M Mg2+ with and without DnaJ and RepA. In contrast to its effect on the Mg2+ requirement, GrpE increases the ATP requirement for DnaK ATPase and dramatically lowers the affinity of DnaK for ATP in the absence of Mg2+. We propose that GrpE not only lowers the affinity of DnaK for nucleotide but, by increasing affinity of DnaK for Mg2+, also weakens the interactions of Mg2+ with nucleotide prior to its release.			SKOWYRA, D (corresponding author), NCI, MOLEC BIOL LAB, BLDG 37, BETHESDA, MD 20892 USA.							BAKER TA, 1992, ANNU REV GENET, V26, P447; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MARTIN MT, 1988, METHOD ENZYMOL, V158, P15, DOI 10.1016/0076-6879(88)58044-8; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; SKOWYRA D, 1995, SEMIN VIROL, V6, P43, DOI 10.1016/S1044-5773(05)80008-3; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025	30	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26282	26285		10.1074/jbc.270.44.26282	http://dx.doi.org/10.1074/jbc.270.44.26282			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592837	hybrid			2022-12-25	WOS:A1995TC97800044
J	ZHAO, M; YONEDA, M; OHASHI, Y; KURONO, S; IWATA, H; OHNUKI, Y; KIMATA, K				ZHAO, M; YONEDA, M; OHASHI, Y; KURONO, S; IWATA, H; OHNUKI, Y; KIMATA, K			EVIDENCE FOR THE COVALENT BINDING OF SHAP, HEAVY-CHAINS OF INTER-ALPHA-TRYPSIN INHIBITOR, TO HYALURONAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; CDNA SEQUENCE; CUMULUS MASS; PROTEIN; ACID; SERUM; FAMILY; CD44; GLYCOPROTEIN	We previously showed that serum derived 85-kDa proteins (SHAPs, serum derived hyaluronan associated proteins) are firmly bound to hyaluronan (HA) synthesized sized by cultured fibroblasts. SHAPs were then identified to be the heavy chains of inter-alpha-trypsin inhibitor (ITI) (Huang, L., Yoneda, M., and Kimata, K. (1993) J. Biol. Chem. 268, 26725-26730). In this study, the SHAP . HA complex was isolated from pathological synovial fluid from human arthritis patients. The SHAP . HA complex was digested with thermolysin, followed by CsCl gradient centrifugation. The HA-containing fragments thus obtained were further digested with chondroitinase AC II and subjected to TSK gel high performance liquid chromatography (HPLC), Peptide-HA disaccharide-containing fractions (the SHAP . HA binding regions) were further purified by reverse phase HPLC. Major peaks were analyzed by protein sequencing and mass spectrometry (electrospray ionization mass spectrometry and collision induced dissociation-MS/MS). By comparison with the reported C-terminal sequences of the human ITI family, the peptides were found to correspond to tetrapeptides derived from the C termini of heavy chains 1 of and 2 of inter-alpha-trypsin inhibitor (HC1 and HC2), and heavy chain 3 of pre-alpha-trypsin inhibitor (HC3), respectively, and a heptapeptide from HC1, Mass spectrometric analyses suggested that the C-terminal Asp of each heavy chain was esterified to the CG-hydroxyl group of an internal N-acetylglucosamine of HA chain. This report is the first demonstration to give evidence for the covalent binding of proteins to HA.	AICHI MED UNIV, INST MOLEC SCI MED, NAGAKUTE, AICHI 48011, JAPAN; INST PHYS & CHEM RES, FRONTIER RES PROGRAM, GLYCOBIOL GRP, WAKO, SAITAMA 35101, JAPAN; NAGOYA UNIV, SCH MED, DEPT ORTHOPED SURG, NAGOYA, AICHI 466, JAPAN; SEIKAGAKU CORP, HIGASHIYAMATO, TOKYO 207, JAPAN	Aichi Medical University; RIKEN; Nagoya University; Seikagaku Corporation								ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BALAZS EA, 1965, AMINO SUGARS       A, V2, P401; BALDUYCK M, 1986, EUR J BIOCHEM, V158, P417, DOI 10.1111/j.1432-1033.1986.tb09769.x; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; DELPECH A, 1984, DEV BIOL, V101, P391, DOI 10.1016/0012-1606(84)90153-2; DELPECH B, 1985, ANAL BIOCHEM, V149, P555, DOI 10.1016/0003-2697(85)90613-X; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; GEBHARD W, 1988, BIOL CHEM H-S, V369, P19; GEBHARD W, 1986, PROTEINASE INHIBITOR, P375; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HUANG L, 1993, J BIOL CHEM, V268, P26725; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; ODUM L, 1992, INT J BIOCHEM, V24, P215, DOI 10.1016/0020-711X(92)90249-Z; PERIDES G, 1989, J BIOL CHEM, V264, P5981; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; ROUET P, 1992, BIOL CHEM H-S, V373, P1019, DOI 10.1515/bchm3.1992.373.2.1019; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SELLOUM L, 1987, BIOL CHEM H-S, V368, P47, DOI 10.1515/bchm3.1987.368.1.47; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUNDBLAD L, 1965, AMINO SUGARS       A, V2, P229; TENGBLAD A, 1986, BIOCHEM J, V236, P521, DOI 10.1042/bj2360521; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Toole BP, 1976, NEURONAL RECOGNITION, P275; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; UNDERHILL C, 1992, J CELL SCI, V103, P293; WEST DC, 1989, CIBA F SYMP, V143, P187; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YONEDA M, 1990, J BIOL CHEM, V265, P5247; YUKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1203, P298, DOI 10.1016/0167-4838(93)90098-C	49	146	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26657	26663		10.1074/jbc.270.44.26657	http://dx.doi.org/10.1074/jbc.270.44.26657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592891	hybrid			2022-12-25	WOS:A1995TC97800098
J	CHONN, A; SEMPLE, SC; CULLIS, PR				CHONN, A; SEMPLE, SC; CULLIS, PR			BETA-2-GLYCOPROTEIN-I IS A MAJOR PROTEIN ASSOCIATED WITH VERY RAPIDLY CLEARED LIPOSOMES IN-VIVO, SUGGESTING A SIGNIFICANT ROLE IN THE IMMUNE CLEARANCE OF NON-SELF PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID ASYMMETRY; LARGE UNILAMELLAR LIPOSOMES; PERFUSED RAT-LIVER; ANTICARDIOLIPIN ANTIBODIES; APOLIPOPROTEIN-H; SCAVENGER RECEPTOR; BLOOD COMPONENTS; UPTAKE MECHANISM; RECOGNITION; MACROPHAGES	Liposomes recovered from the blood of liposome-treated CD1 mice were previously reported to have a complex protein profile associated with their mem branes (Chonn, A., Semple, S. C., and Cullis, P. R. (1992) J. Biol. Chem. 267, 18759-18765). In this study, we have further characterized and identified the major proteins associated with very rapidly cleared large unilamellar vesicles. These liposomes contained phosphatidylcholine, cholesterol, and anionic phospholipids (phosphatidylserine, phosphatidic acid, or cardiolipin) that dramatically enhance the clearance rate of Liposomes hom the circulation. These anionic phospholipids are normally found exclusively in the interior of cells but become expressed when cells undergo apoptosis or programmed cell death, and thus, they are believed to be markers of cell senescence, Analysis of the proteins associated with these liposomes by SDS-polyacrylamide gel electrophoresis revealed that two of the major proteins associated with the liposome membranes are proteins with electrophoretic mobilities corresponding to M(r) of 66,000 and 50,000-55,000. The 66-kDa protein was identified to be serum albumin by immunoblot analysis. Using various biochemical and immunological methods, we have identified the 50-55-kDa protein as the murine equivalent of human beta(2)-glycoprotein I. beta 2-glycoprotein I has a strong affinity for phosphatidylserine, phosphatidic acid, and cardiolipin inasmuch as the levels of beta 2-glycoprotein I associated with these anionic liposomes approach or even exceed those of serum albumin, which is present in serum at a concentration 200-fold greater than beta 2-glycoprotein I. Further, we demonstrate that the amount of beta 2-glycoprotein I associated with liposomes, as quantitated by an enzyme-linked immunosorbent assay, is correlated with their clearance rates; moreover, the circulation residency time of cardiolipin-containing liposomes is extended in mice pretreated with anti-beta 2-glycoprotein I antibodies. These findings strongly suggest that beta 2-glycoprotein I plays a primary role in mediating the clearance of liposomes and, by extension, senescent cells and foreign particles.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER, BC V6P 6P2, CANADA	University of British Columbia								ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BONTE F, 1986, CHEM PHYS LIPIDS, V40, P359, DOI 10.1016/0009-3084(86)90079-4; BONTE F, 1987, BIOCHIM BIOPHYS ACTA, V900, P1, DOI 10.1016/0005-2736(87)90271-9; CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7; CHONN A, 1992, J BIOL CHEM, V267, P18759; CONNOR J, 1994, J BIOL CHEM, V269, P2399; FADOK VA, 1992, J IMMUNOL, V148, P2207; FINLAYSO.JS, 1967, BIOCHIM BIOPHYS ACTA, V147, P413, DOI 10.1016/0005-2795(67)90001-3; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARRIS EN, 1983, LANCET, V2, P1211; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JULIANO RL, 1980, LIPOSOMES IMMUNOBIOL, P49; KIWADA H, 1987, CHEM PHARM BULL, V35, P1189; KIWADA H, 1986, CHEM PHARM BULL, V34, P1249; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LEE NS, 1983, J BIOL CHEM, V258, P4765; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MCNEIL HP, 1989, BRIT J HAEMATOL, V73, P506, DOI 10.1111/j.1365-2141.1989.tb00289.x; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; NONAKA M, 1992, GENOMICS, V13, P1082, DOI 10.1016/0888-7543(92)90022-K; POLZ E, 1980, INT J BIOCHEM, V11, P265, DOI 10.1016/0020-711X(80)90229-3; POLZ E, 1979, FEBS LETT, V102, P183, DOI 10.1016/0014-5793(79)80955-2; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHLEGEL RA, 1985, J CELL PHYSIOL, V123, P215, DOI 10.1002/jcp.1041230210; SCHROIT AJ, 1984, BIOL CELL, V51, P227, DOI 10.1111/j.1768-322X.1984.tb00303.x; SENIOR JH, 1987, CRC CR REV THER DRUG, V3, P123; SOMMERMAN EF, 1986, THESIS U BRIT COLUMB; STEIN Y, 1980, FEBS LETT, V111, P104, DOI 10.1016/0014-5793(80)80771-X; WURM H, 1982, METABOLISM, V31, P484, DOI 10.1016/0026-0495(82)90238-4; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X	37	162	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25845	25849		10.1074/jbc.270.43.25845	http://dx.doi.org/10.1074/jbc.270.43.25845			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592769	hybrid			2022-12-25	WOS:A1995TB46600086
J	GRUGEL, S; FINKENZELLER, G; WEINDEL, K; BARLEON, B; MARME, D				GRUGEL, S; FINKENZELLER, G; WEINDEL, K; BARLEON, B; MARME, D			BOTH V-HA-RAS AND V-RAF STIMULATE EXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH-FACTOR IN NIH 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; B-RAF; PERMEABILITY FACTOR; FACTOR FAMILY; ONCOGENE; TRANSCRIPTION; ACTIVATION; SERUM; FOS; PHOSPHORYLATION	Stimulation of NIH 3T3 cells with platelet-derived growth factor (PDGF)-BB and 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances vascular endothelial growth factor (VEGF) gene expression. To address the question of whether Ras and Raf are involved in the induction of VEGF gene expression by PDGF and TPA, we examined the effects of both factors on NIH 3T3 cells stably transfected with v-Ha-ras or v-raf. In serum-starved NIH 3T3 cells, only low levels of mRNA expression can be detected, whereas both ras and raf transformed cell lines express enhanced levels of a 4.3-kilobase VEGF transcript. Stimulation with PDGF or TPA resulted in increased VEGF mRNA in all cell lines, with highest levels found in the transformed cells. Immunofluorescence studies confirmed that the elevated VEGF mRNA expression correlated with enhanced protein levels. Positive immunofluorescence signals could be detected in v-Ha-ras or v-raf transformed cell lines but not in unstimulated NIH 3T3 cells. VEGF from conditioned medium of v-raf transformed NIH 3T3 cells was partially purified by chromatography on heparin-Sepharose. Biological activity of this VEGF protein was demonstrated by competition with binding of recombinant I-125-VEGF(165) human umbilical vein endothelial cells and by its ability to stimulate proliferation of these cells.	TUMOR BIOL CTR,INST MOLEC MED,D-79106 FREIBURG,GERMANY									ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLENTON DJ, 1987, MOL CELL BIOL, V7, P3092; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; DELAGE S, 1993, CANCER RES, V53, P2762; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KIESER A, 1994, ONCOGENE, V9, P963; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Rapp U R, 1987, Haematol Blood Transfus, V31, P450; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, LUNG CANCER, V4, P162; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SENGER DR, 1986, CANCER RES, V46, P5629; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; ZHANG K, 1990, NATURE, V3346, P754; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	52	287	290	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25915	25919		10.1074/jbc.270.43.25915	http://dx.doi.org/10.1074/jbc.270.43.25915			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592779	hybrid			2022-12-25	WOS:A1995TB46600096
J	KAPAS, S; CATT, KJ; CLARK, AJL				KAPAS, S; CATT, KJ; CLARK, AJL			CLONING AND EXPRESSION OF CDNA-ENCODING A RAT ADRENOMEDULLIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HYPOTENSIVE PEPTIDE; MOLECULAR-CLONING; PROTEIN; GLOMERULOSA; FAMILY; LUNG	Adrenomedullin is a potent vasodilator peptide that exerts major effects on cardiovascular function. Its actions are mediated through an abundant class of specific binding sites that activate adenylyl cyclase through a G protein-coupled mechanism. We report here the identification of a cDNA clone for the adrenomedullin receptor that was originally isolated as an orphan receptor from rat lung. The cDNA encodes a polypeptide of 395 residues that contains seven transmembrane domains and has a general structural resemblance to other members of the G protein-linked receptor superfamily. When expressed in COS-7 cells, this receptor mediates a cAMP response to adrenomedullin with an EC(50) of 7 x 10(-9) M, and binds I-125-adrenomedullin with a K-D of 8.2 x 10(-9) M, properties that are consistent with those observed in cardiovascular and other target tissues. The receptor gene is expressed as several mRNA species of which the most prominent is a 1.8-kilobase transcript found in the Lung, adrenal, heart, spleen, cerebellum, and other sites. Identification of this receptor cDNA should facilitate further investigation of the cellular actions of adrenomedullin and its regulatory effects in normal and disordered states of cardiovascular function.	ST BARTHOLOMEWS HOSP,COLL MED,DEPT CHEM ENDOCRINOL,LONDON EC1A 7BE,ENGLAND; NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	University of London; Queen Mary University London; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AJL, 1992, MOL ENDOCRINOL, V6, P1889, DOI 10.1210/me.6.11.1889; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; EGUCHI S, 1994, FEBS LETT, V340, P226, DOI 10.1016/0014-5793(94)80143-6; EVA C, 1993, DNA CELL BIOL, V12, P393, DOI 10.1089/dna.1993.12.393; FINEBERG AP, 1983, ANAL BIOCHEM, V132, P6; HARRISON JK, 1993, FEBS LETT, V318, P17, DOI 10.1016/0014-5793(93)81318-T; ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014-5793(94)80106-1; ISHIYAMA Y, 1993, EUR J PHARMACOL, V241, P271, DOI 10.1016/0014-2999(93)90214-3; KANAZAWA H, 1994, BIOCHEM BIOPH RES CO, V205, P251, DOI 10.1006/bbrc.1994.2657; KAPAS S, 1992, J MOL ENDOCRINOL, V9, P47, DOI 10.1677/jme.0.0090047; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIPPTON H, 1994, J APPL PHYSIOL, V76, P2154, DOI 10.1152/jappl.1994.76.5.2154; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TC, 1995, ENDOCRINOLOGY, V136, P2459, DOI 10.1210/en.136.6.2459; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; OWJI AA, 1995, ENDOCRINOLOGY, V136, P2127, DOI 10.1210/en.136.5.2127; SAKATA J, 1993, BIOCHEM BIOPH RES CO, V195, P921, DOI 10.1006/bbrc.1993.2132; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON WK, 1995, ENDOCRINOLOGY, V136, P2349, DOI 10.1210/en.136.5.2349; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; YAMAGUCHI T, 1964, LIFE SCI, V56, P379	30	259	275	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25344	25347		10.1074/jbc.270.43.25344	http://dx.doi.org/10.1074/jbc.270.43.25344			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592696	hybrid			2022-12-25	WOS:A1995TB46600012
J	SPAIN, BH; KOO, D; RAMAKRISHNAN, M; DZUDZOR, B; COLICELLI, J				SPAIN, BH; KOO, D; RAMAKRISHNAN, M; DZUDZOR, B; COLICELLI, J			TRUNCATED FORMS OF A NOVEL YEAST PROTEIN SUPPRESS THE LETHALITY OF A G-PROTEIN ALPHA-SUBUNIT DEFICIENCY BY INTERACTING WITH THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; FACTOR RECEPTOR; MATING PHEROMONE; ADENYLYL CYCLASE; GAMMA-SUBUNITS; ADAPTIVE RESPONSE; SURFACE PROTEIN; CELL-FUSION	In Saccharomyces cerevisiae, the mating pheromone-initiated signal is transduced by a heterotrimeric G protein and normally results in transient cell cycle arrest and differentiation. A null allele of the G alpha (GPA1/SCG1) subunit results in cell death due to unchecked signaling from the G beta gamma (STE4, STE18, respectively) heterodimer, We have identified three high copy suppressors of gpa1 lethality, Two of these genes encode known transcription factors, Mat alpha 2p and Mcm1p, The third is a truncated form of a novel gene, SYG1, Overexpressed wild type SYG1 is a weak suppressor of gpa1. In contrast, the isolated mutant allele SYG1-1 is a strong suppressor that completely blocks the cell cycle arrest and differentiation phenotypes of gpa1 cells of both mating types, One deletion mutant (SYG1 Delta 340) can suppress the cell cycle arrest associated with gpa1, but the cells retain a differentiated morphology, SYG1-1 can suppress the effects of overexpressed wild type G beta but is not able to suppress the lethality of an activated G beta mutant (STE4(Hpl)). Consistent with these genetic observations, the suppressing form of Syg1p can interact with the STE4 gene product, as determined by a two-hybrid assay, SYG1-1 is also capable of promoting pheromone recovery in wild type cells, as judged by halo assay. The sequence of SYG1 predicts eight membrane-spanning domains, Deletion mutants of SYG1 indicate that complete gpa1 suppression requires removal of all of these hydrophobic regions, Interestingly, this truncated protein localizes to the same plasma membrane-enriched subcellular fraction as does full-length Syg1p. Three hypothetical yeast proteins, identified by their similarity to the SYG1 primary sequence within the gpa1 suppression domain, also appear to have related structures, The properties of Syg1p are consistent with those of a transmembrane signaling component that can respond to, or transduce signals through, G beta or G beta gamma.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, STRUCT BIOL & MOLEC MED LAB, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [R01 CA 56301] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CROSS FR, 1990, GENETICS, V126, P301; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GRISHIN AV, 1994, GENETICS, V138, P1081; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARE JF, 1994, J BIOL CHEM, V269, P5981; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIRSCH JP, 1992, BIOESSAYS, V14, P367, DOI 10.1002/bies.950140604; HIRSCH JP, 1993, GENETICS, V135, P943; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KONOPKA JB, 1993, MOL CELL BIOL, V13, P6876, DOI 10.1128/MCB.13.11.6876; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; PAPASAVVAS S, 1992, BIOCHEM BIOPH RES CO, V184, P1378, DOI 10.1016/S0006-291X(05)80035-X; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SIKORSKI RS, 1989, GENETICS, V122, P19; Sprague G F Jr, 1990, Adv Genet, V27, P33; SRINIVASA RT, 1994, J LEUKOCYTE BIOL, V55, P192; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; ZHANG M, 1993, MOL MICROBIOL, V9, P813, DOI 10.1111/j.1365-2958.1993.tb01740.x	63	83	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25435	25444		10.1074/jbc.270.43.25435	http://dx.doi.org/10.1074/jbc.270.43.25435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592711	hybrid			2022-12-25	WOS:A1995TB46600027
J	GERLACH, MS; KHARITONENKOV, A; VOGEL, W; ALI, S; ULLRICH, A				GERLACH, MS; KHARITONENKOV, A; VOGEL, W; ALI, S; ULLRICH, A			PROTEIN-TYROSINE-PHOSPHATASE 1D MODULATES ITS OWN STATE OF TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; BINDING-SITE; IRS-1; CELLS; ACTIVATION; DOMAINS; CLONING; SH-PTP2; KINASE	The insulin receptor-mediated signal transduction pathway involves insulin receptor substrate 1 and a variety of proteins containing Src homology-g (SH2) domains, such as phosphatidylinositol S-kinase, Grb2, and protein-tyrosine phosphatase 1D (PTP1D). Upon insulin stimulation of baby hamster kidney cells overexpressing the IR, the catalytically inactive mutant of PTP1D, C463A, becomes tyrosine-phosphorylated and coprecipitates with Grb2. Tyrosine phosphorylation of this mutant is significantly reduced when wild type PTP1D is coexpressed. Substitution of tyrosine residues 546 and 584 with phenylalanine abrogates tyrosine phosphorylation of the catalytically inactive mutant and abolishes its interaction with Grb2.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GUAN K, 1990, SCIENCE, V269, P553; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MAEGAWA H, 1994, BIOCHEM BIOPH RES CO, V199, P780, DOI 10.1006/bbrc.1994.1297; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P108; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	37	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24635	24637		10.1074/jbc.270.42.24635	http://dx.doi.org/10.1074/jbc.270.42.24635			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559570	hybrid			2022-12-25	WOS:A1995TB46500004
J	WHITE, T; BENNETT, EP; TAKIO, K; SORENSEN, T; BONDING, N; CLAUSEN, H				WHITE, T; BENNETT, EP; TAKIO, K; SORENSEN, T; BONDING, N; CLAUSEN, H			PURIFICATION AND CDNA CLONING OF A HUMAN UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLTRANSFERASE GENE FAMILY; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; HUMAN FIBRONECTIN; EXPRESSION; GALNAC; PROTEINS; GLYCOSYLATION; SPECIFICITY; TRANSFERASE	A UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase) from human placenta was purified to apparent homogeneity using a synthetic acceptor peptide as affinity ligand. The purified GalNAc-transferase migrated as a single band with an approximate molecular weight of 52,000 by reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Based on a partial amino acid sequence, the cDNA encoding the transferase was cloned and sequenced from a cDNA library of a human cancer cell line. The cDNA sequence has a 571-amino acid coding region in indicating a protein of 64.7 kDa with a type II domain structure. The deduced protein sequence showed significant similarity to a recently cloned bovine polypeptide GalNAc-transferase (Homa, F. L., Hollanders, T., Lehman, D. J., Thomsen, D. R., and Elhammer, Angstrom P. (1993) J. Biol. Chem, 268, 12609-12616), A polymerase chain reaction construct was expressed in insect cells using a baculovirus vector, Northern analysis of eight human tissues differed clearly from that of the bovine GalNAc-transferase. Polymerase chain reaction cloning and sequencing of the human version of the bovine transferase are presented, and 98% similarity at the amino acid level was found. The data suggest that the purified human GalNAc-transferase is a novel member of a family of polypeptide GalNAc-transferases, and a nomenclature GalNAc-T1 and GalNAc-T2 is introduced to distinguish the members.			WHITE, T (corresponding author), UNIV COPENHAGEN, SCH DENT, FAC HLTH SCI, DEPT ORAL DIAGNOST, NORRE ALLE 20, DK-2200 COPENHAGEN N, DENMARK.		Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021	Bennett, Eric/0000-0002-4976-0647; 				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENDIAK B, 1993, EUR J BIOCHEM, V216, P405, DOI 10.1111/j.1432-1033.1993.tb18158.x; BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; BIRKEN S, 1981, J BIOL CHEM, V256, P1816; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GUM JR, 1989, J BIOL CHEM, V264, P6480; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOMA FL, 1993, J BIOL CHEM, V268, P12609; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MANDEL U, 1994, APMIS, V102, P695, DOI 10.1111/j.1699-0463.1994.tb05222.x; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Ruegg U T, 1977, Methods Enzymol, V47, P111; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	40	183	223	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24156	24165		10.1074/jbc.270.41.24156	http://dx.doi.org/10.1074/jbc.270.41.24156			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592619	hybrid			2022-12-25	WOS:A1995TA21700047
J	ALBANESE, C; JOHNSON, J; WATANABE, G; EKLUND, N; VU, D; ARNOLD, A; PESTELL, RG				ALBANESE, C; JOHNSON, J; WATANABE, G; EKLUND, N; VU, D; ARNOLD, A; PESTELL, RG			TRANSFORMING P21(RAS) MUTANTS AND C-ETS-2 ACTIVATE THE CYCLIN D1 PROMOTER THROUGH DISTINGUISHABLE REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; STIMULATING FACTOR-I; C-JUN ACTIVITY; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; NUCLEAR-PROTEIN	Several different oncogenes and growth factors promote G(1) phase progression, Cyclin D1, the regulatory subunit of several cyclin dependent kinases, is required for, and capable of shortening, the G(1) phase of the cell cycle. The present study demonstrates that transforming mutants of p21(ras) (Ras Val-12, Ras Leu-61) induce the cyclin D1 promoter in human trophoblasts (JEG-3), mink lung epithelial (Mv1.Lu), and in Chinese hamster ovary fibroblast cell lines, Site-directed mutagenesis of AP-l-like sequences at -954 abolished p21(ras)-dependent activation of cyclin D1 expression. The AP-l-like sequences were also required for activation of the cyclin D1 promoter by c-Jun. In electrophoretic mobility shift assays using nuclear extracts from cultured cells and primary tissues, several AP-1 proteins (c-Jun, JunB, JunD, and c-Fos) bound the cyclin D1 -954 region. Cyclin D1 promoter activity was stimulated by overexpression of mitogen-activated protein kinase (p41(MAPK)) or c-Ets-2 through the proximal 22 base pairs. Expression of plasmids encoding either dominant negative MAPK (p41(MAPKi)) Or dominant negatives of ETS activation (Ets-LacZ), antagonized MAPK dependent induction of cyclin D1 promoter activity. Epidermal growth factor induction of cyclin D1 transcription, through the proximal promoter region, was antagonized by either p41(MAPKi) or Ets-LacZ, suggesting that ETS functions downstream of epidermal growth factor and MAPK in the context of the cyclin D1 promoter. The activation of cyclin D1 transcription by p21(ras) provides evidence for cross-talk between the p21(ras) and cell cycle regulatory pathways.	NORTHWESTERN UNIV,SCH MED,DIV ENDOCRINOL METAB & MOLEC MED,CHICAGO,IL 60611; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,ENDOCRINE ONCOL UNIT,BOSTON,MA 02114	Northwestern University; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NCI NIH HHS [CA55909, KO8 CA 620008-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1989, MOL IMMUNOL, V26, P985, DOI 10.1016/0161-5890(89)90117-X; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BUDRUG S, 1994, EMBO J, V13, P2124; CAI H, 1990, MOL CELL BIOL, V10, P5324; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COFFER P, 1994, ONCOGENE, V9, P911; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUBLER L, 1993, MOL CELL BIOL, V13, P6274, DOI 10.1128/MCB.13.10.6274; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JIANG W, 1993, ONCOGENE, V8, P3447; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KHOCHBIN S, 1988, CYTOMETRY, V9, P499, DOI 10.1002/cyto.990090516; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KROOK A, 1993, MOL CELL BIOL, V13, P1471, DOI 10.1128/MCB.13.3.1471; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LOVEC H, 1994, ONCOGENE, V9, P323; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAN BT, 1994, J BIOL CHEM, V269, P5968; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; PESTELL RG, 1995, MOL ENDOCRINOLOGY BA, P774; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SAMBROOK T, 1989, MOL CLONING LABORATO; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SETH A, 1992, J BIOL CHEM, V267, P24796; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH MJ, 1992, BLOOD, V79, P2107; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	90	762	771	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23589	23597		10.1074/jbc.270.40.23589	http://dx.doi.org/10.1074/jbc.270.40.23589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559524	hybrid			2022-12-25	WOS:A1995RY90900053
J	DEVERAUX, Q; JENSEN, C; RECHSTEINER, M				DEVERAUX, Q; JENSEN, C; RECHSTEINER, M			MOLECULAR CLONING AND EXPRESSION OF A 26-S-PROTEASE SUBUNIT ENRICHED IN DILEUCINE REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; UBIQUITIN; CYCLIN	The 26 S protease is a multisubunit enzyme required for ubiquitin-dependent proteolysis. Recently, we identified a 50-kDa subunit (S5) of this enzyme that binds ubiquitin polymers (Deveraux, Q., Ustrell, V., Pickart, C., and Rechsteiner, M. (1994) J. Biol. Chem. 269, 7059-7061). We have now isolated, sequenced, and expressed a cDNA encoding a novel 50-kDa subunit of the 26 S protease. The recombinant protein does not bind ubiquitin polymers. Two-dimensional electrophoresis reveals that two subunits of the 26 S protease have apparent molecular masses of 50 kDa. Antibodies specific for the recombinant protein recognize the more basic of the two subunits (S5b), whereas the more acidic subunit (S5a) binds ubiquitin chains. Thus, the 26 S protease contains at least two distinct subunits with apparent molecular masses of 50 kDa.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; MORI S, 1993, J BIOL CHEM, V268, P577; PICKART CM, 1992, J BIOL CHEM, V267, P14418; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065	17	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23726	23729		10.1074/jbc.270.40.23726	http://dx.doi.org/10.1074/jbc.270.40.23726			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559544	hybrid			2022-12-25	WOS:A1995RY90900073
J	ROSMARIN, AG; CAPRIO, DG; KIRSCH, DG; HANDA, H; SIMKEVICH, CP				ROSMARIN, AG; CAPRIO, DG; KIRSCH, DG; HANDA, H; SIMKEVICH, CP			GABP AND PU.1 COMPETE FOR BINDING, YET COOPERATE TO INCREASE CD18 (BETA(2) LEUKOCYTE INTEGRIN) TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS ONCOGENE; GENE-EXPRESSION; SUBUNIT CD18; PROMOTER; PROTEIN; DOMAIN; IDENTIFICATION; CLONING; MOTIFS	CD18 (beta(2) leukocyte integrin) is a leukocyte specific adhesion molecule that plays a crucial role in immune and inflammatory responses, A 79-nucleotide fragment of the CD18 promoter is sufficient to direct myeloid transcription, The CD18 promoter is bound by the B lymphocyte- and myeloid-restricted ets factor, PU.1, and disruption of the PU.1-binding sites significantly reduces promoter activity, However, PU.1 alone cannot fully account for the leukocyte-specific and myeloid-inducible transcription of CD18, We identified a ubiquitously expressed nuclear protein complex of extremely low electrophoretic mobility that also binds to this region of the CD18 promoter, This binding complex is a heterotetramer composed of GABP alpha, an ets factor, and GABP beta, a subunit with homology to Drosophila Notch, GABP alpha competes with the lineage restricted factor, PU.1, for the same critical CD18 ets sites, The CD18 promoter is activated in myeloid cells by transfection with both GABP alpha and GABP beta together, but not by either factor alone, Transfection of non-hematopoietic cells with the two GABP subunits together with PU.1 is sufficient to activate CD18 transcription in otherwise non-permissive cells, Thus, GABP and PU.1 compete for the same binding sites but cooperate to activate CD18 transcription.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, MIDORI KU, YOKOHAMA 2267, KANAGAWA, JAPAN	Tokyo Institute of Technology	ROSMARIN, AG (corresponding author), BROWN UNIV, MIRIAM HOSP, SCH MED, DIV HEMATOL, PROVIDENCE, RI 02906 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044728] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29 DK 44728] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGURA ED, 1992, BLOOD, V79, P602; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HROMAS R, 1993, BLOOD, V82, P2998; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSMARIN AG, 1989, BLOOD, V73, P131; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1992, BLOOD, V79, P2598; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WANG K, 1993, J BIOL CHEM, V268, P16052; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEITZMAN JB, 1991, FEBS LETT, V294, P97, DOI 10.1016/0014-5793(91)81351-8; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	36	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23627	23633		10.1074/jbc.270.40.23627	http://dx.doi.org/10.1074/jbc.270.40.23627			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559529	hybrid			2022-12-25	WOS:A1995RY90900058
J	SAITO, Y; OGAWA, K				SAITO, Y; OGAWA, K			WILD-TYPE P53 AND C-MYC COOPERATION IN GENERATING APOPTOSIS OF A RAT HEPATOCELLULAR-CARCINOMA CELL-LINE (FAA-HTC1)	ONCOGENE			English	Article						P53; C-MYC; APOPTOSIS; CELL GROWTH	MYELOID LEUKEMIC-CELLS; CANCER-CHEMOTHERAPY; MESSENGER-RNA; CYCLE; DEATH; INDUCTION; BCL-2; MUTATIONS; RADIATION; PROTEIN	p53 and c-myc are both known to be involved in apoptotic cell death as well as positive or negative regulation of cell proliferation, but it is not well established whether their functions are mechanistically correlated. We found that FAA-HTC1 cells, a rat hepatocellular carcinoma cell line, expressed c-myc independently of cell cycle and no detectable p53. To investigate possible co-operation between p53 and c-myc, the dexamethasone (Dex)-inducible wild type rat p53 was stably transfected into this cell line and c-myc expression was suppressed by treatment with c-myc antisense oligonucleotide (AS). p53 expression in the p53-introduced derivative resulted in apoptotic cell death, but it did not inhibit proliferative growth of the viable cells. On the other hand, when c-myc was suppressed in the p53-expressing cells, both apoptosis and cell growth were inhibited. These results indicate that p53 can act in the same cells either as a growth-inhibitor or apoptosis-inducer depending on the status of c-myc expression.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA 078,HOKKAIDO,JAPAN	Asahikawa Medical College								ASKEW DS, 1991, ONCOGENE, V6, P1915; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUKUDA I, 1992, CELL STRUCT FUNCT, V17, P427, DOI 10.1247/csf.17.427; FURUKAWA K, 1987, Tumor Research, V22, P71; HALDAR S, 1994, CANCER RES, V54, P2095; HARPER JW, 1993, CELL, V75, P805; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERRITT AJ, 1994, CANCER RES, V54, P614; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROBINSON WS, 1994, ANNU REV MED, V13, P711; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAETER G, 1990, Critical Reviews in Oncogenesis, V1, P437; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SOURCCI T, 1988, NUCLEIC ACIDS RES, V16, P11384; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	53	25	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1013	1018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566958				2022-12-25	WOS:A1995RX18000001
J	SASTRY, L; LIN, WH; WONG, WT; DIFIORE, PP; SCOPPA, CA; KING, CR				SASTRY, L; LIN, WH; WONG, WT; DIFIORE, PP; SCOPPA, CA; KING, CR			QUANTITATIVE-ANALYSIS OF GRB2-SOS1 INTERACTION - THE N-TERMINAL SH3 DOMAIN OF GRB2 MEDIATES AFFINITY	ONCOGENE			English	Article						GRB2; SOS1; BIACORE; SPR; KINETICS	RECEPTOR TYROSINE KINASES; BIOSPECIFIC INTERACTION ANALYSIS; NUCLEOTIDE EXCHANGE FACTOR; SURFACE-PLASMON RESONANCE; PHOSPHORYLATED PEPTIDES; SIGNAL TRANSDUCTION; RAS; PROTEIN; BINDS; ASSOCIATION	Grb2 is an adaptor protein that links receptor and cytoplasmic tyrosine kinases to the Ras signalling pathway by binding the Ras-specific guanine nucleotide exchange factor, Sos1, through its SH3 domains, The Grb2-SH3 domain binding has been localized to the carboxy-terminal two hundred amino acids of Sos1 (Sos1-c). By using real time biospecific interaction analysis (BIAcore), we studied the kinetic parameters and binding affinity of the Grb2-Sos1-c interaction, The binding of Grb2 to Sos1-c is a high affinity interaction with a moderate association rate (9.45 x 10(4) per M per s), a slow dissociation rate (13.8 x 10(-5) s), and an affinity constant of 1.48 nM. BIAcore measurements on isolated N-terminal and C-terminal SH3 domains (NSH3 and CSH3) further indicate that the high affinity Grb2-Sos1-c interaction is primarily mediated through the NSH3 domain (K-d=1.68 nM). The CSH3 domain shows substantially reduced binding to Sos1-c in these measurements, Inhibition studies with BIAcore using proline rich peptides derived from the C-terminus of Sos1 show that there is a single major binding site for Grb2 in Sos1, This binding site is contained within the peptide N20, which corresponds to amino acids 1143-1162 of Sos1, This peptide completely blocks the Grb2-Sos1-c and NSH3-Sos1-c interactions with IC50 values of 8 mu M and 4 mu M respectively, The discrete interaction between the NSH3 domain and the N20 peptide may be amenable for drug discovery through screening or peptidomimetic approaches.	ONCOL INC, GAITHERSBURG, MD 20878 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; FAC MED & CHIRURG, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRANZOW R, 1902, BIOTECHNOLOGY, V10, P390; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIKI H, 1994, J BIOL CHEM, V269, P5489; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; 1991, BIACORE SYSTEM MANUA	31	52	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1107	1112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566970				2022-12-25	WOS:A1995RX18000013
J	BROWN, LS; SASAKI, J; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK				BROWN, LS; SASAKI, J; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK			GLUTAMIC-ACID-204 IS THE TERMINAL PROTON RELEASE GROUP AT THE EXTRACELLULAR SURFACE OF BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE C-13; SCHIFF-BASE; VIBRATIONAL SPECTROSCOPY; STRUCTURAL-CHANGES; PHOTOCYCLE; TRANSLOCATION; MUTANTS; MECHANISM; ASP-96; ARG-82	We have measured proton release into the medium after proton transfer from the retinal Schiff base to Asp(85) in the photocycle and the C=O stretch bands of carboxylic acids in wild type bacteriorhodopsin and the E204Q and E204D mutants. In E204Q, but not in E204D, the normal proton release is absent. Consistent with this, a negative band in the Fourier transform infrared difference spectra at 1700 cm(-1) in the wild type, which we now attribute to depletion of the protonated E204, is also absent in E204Q, In E204D, this band is shifted to 1714 cm(-1), as expected from the higher frequency for a protonated aspartic than for a glutamic acid. Consistent with their origin from protonated carboxyls, the depletion bands in the wild type and E204D shift in D2O to 1690 and 1703 cm(-1), respectively. In the protein structure, Glu(204) seems to be connected to the Schiff base region by a chain of hydrogen-bonded water. As with other residues closer to the Schiff base, replacement of Glu(204) with glutamine changes the O-H stretch frequency of the bound water molecule near Asp(85) that undergoes hydrogen-bonding change in the photocycle. The results therefore identify Glu(204) as XH, the earlier postulated residue that is the source of the released proton during the transport, and suggest that its deprotonation is triggered by the protonation of Asp(85) through a network that contains water dipoles.	UNIV CALIF IRVINE, DEPT PHYSIOL & BIOPHYS, IRVINE, CA 92717 USA; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	University of California System; University of California Irvine; Kyoto University; Wayne State University			Brown, Leonid/A-1050-2008; Brown, Leonid/X-7445-2019; Lanyi, Janos/C-3808-2011	Brown, Leonid/0000-0002-5614-8317; Brown, Leonid/0000-0002-5614-8317; 	NIGMS NIH HHS [GM 29498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029498, R01GM029498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES JB, 1990, J AM CHEM SOC, V112, P9007, DOI 10.1021/ja00180a071; BALASHOV SP, 1993, BIOCHEMISTRY-US, V32, P10331, DOI 10.1021/bi00090a008; BALASHOV SP, 1992, COLLOQ INSE, V221, P111; BOUSCHE O, 1991, J BIOL CHEM, V266, P11063; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1994, BIOCHEMISTRY-US, V33, P1629, DOI 10.1021/bi00173a003; BROWN LS, 1994, BIOCHEMISTRY-US, V33, P12001, DOI 10.1021/bi00206a001; BROWN LS, 1993, BIOPHYS J, V65, P124, DOI 10.1016/S0006-3495(93)81064-6; BROWN LS, 1995, IN PRESS BIOPHYS J; CAO Y, 1993, BIOCHEMISTRY-US, V32, P10239, DOI 10.1021/bi00089a046; CAO Y, 1993, BIOCHEMISTRY-US, V32, P1981, DOI 10.1021/bi00059a015; DEGROOT HJM, 1990, BIOCHEMISTRY-US, V29, P6873, DOI 10.1021/bi00481a017; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; DER A, 1991, P NATL ACAD SCI USA, V88, P4751, DOI 10.1073/pnas.88.11.4751; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; EISENSTEIN L, 1987, J AM CHEM SOC, V109, P6860, DOI 10.1021/ja00256a055; FAHMY K, 1992, PHOTOCHEM PHOTOBIOL, V56, P1073, DOI 10.1111/j.1751-1097.1992.tb09731.x; FISCHER WB, 1994, BIOCHEMISTRY-US, V33, P12757, DOI 10.1021/bi00209a005; HEBERLE J, 1992, P NATL ACAD SCI USA, V89, P5996, DOI 10.1073/pnas.89.13.5996; HERZFELD J, 1990, BIOCHEMISTRY-US, V29, P5567, DOI 10.1021/bi00475a022; HUMPHREY W, 1994, BIOCHEMISTRY-US, V33, P3668, DOI 10.1021/bi00178a025; KANDORI H, 1995, J AM CHEM SOC, V117, P2118, DOI 10.1021/ja00112a036; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KONO M, 1993, FEBS LETT, V331, P31, DOI 10.1016/0014-5793(93)80291-2; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; MAEDA A, 1994, BIOCHEMISTRY-US, V33, P1713, DOI 10.1021/bi00173a013; MAEDA A, 1992, BIOCHEMISTRY-US, V31, P462, DOI 10.1021/bi00117a023; MARTI T, 1992, J BIOL CHEM, V267, P16922; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MCDERMOTT AE, 1991, BIOCHEMISTRY-US, V30, P8366, DOI 10.1021/bi00098a013; NEEDLEMAN R, 1991, J BIOL CHEM, V266, P11478; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; SASAKI J, 1994, BIOCHEMISTRY-US, V33, P3178, DOI 10.1021/bi00177a006; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SUBRAMANIAM S, 1993, EMBO J, V12, P1; THORGEIRSSON TE, 1991, BIOCHEMISTRY-US, V30, P9133, DOI 10.1021/bi00102a003; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; Tittor J, 1991, CURR OPIN STRUC BIOL, V1, P534, DOI 10.1016/S0959-440X(05)80074-0; VARO G, 1995, IN PRESS BIOCHEMISTR; YAMAZAKI Y, 1995, BIOCHEMISTRY-US, V34, P7088, DOI 10.1021/bi00021a021; ZIMANYI L, 1992, BIOCHEMISTRY-US, V31, P8535, DOI 10.1021/bi00151a022; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010	47	279	281	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27122	27126		10.1074/jbc.270.45.27122	http://dx.doi.org/10.1074/jbc.270.45.27122			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592966	hybrid			2022-12-25	WOS:A1995TE58300066
J	COLASANTI, M; PERSICHINI, T; MENEGAZZI, M; MARIOTTO, S; GIORDANO, E; CALDARERA, CM; SOGOS, V; LAURO, GM; SUZUKI, H				COLASANTI, M; PERSICHINI, T; MENEGAZZI, M; MARIOTTO, S; GIORDANO, E; CALDARERA, CM; SOGOS, V; LAURO, GM; SUZUKI, H			INDUCTION OF NITRIC-OXIDE SYNTHASE MESSENGER-RNA EXPRESSION - SUPPRESSION BY EXOGENOUS NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MECHANISMS; BINDING; RNA	The reactive nitrogen species, nitric oxide (NO), plays an important role in the pathogenesis of neurodegenerative diseases, The suppression of NO production may be fundamental for survival of neurons. Here, we report that pretreatment of human ramified microglial cells with nearly physiological levels of exogenous NO prevents lipopolysaccharide (LPS)/tumor necrosis factor alpha (TNF alpha)-inducible NO synthesis, because by affecting NF-kappa B activation it inhibits inducible Ca2+-independent NO synthase isoform (iNOS) mRNA expression. Using reverse transcriptase polymerase chain reaction, we have found that both NO donor sodium nitroprusside (SNP) and authentic NO solution are able to inhibit LPS/TNF alpha-inducible iNOS gene expression; this effect was reversed by reduced hemoglobin, a trapping agent for NO. The early presence of SNP during LPS/TNF alpha induction is essential for inhibition of iNOS mRNA expression. Furthermore, SNP is capable of inhibiting LPS/TNF alpha-inducible nitrite release, as determined by Griess reaction, Finally, using electrophoretic mobility shift assay, we have shown that SNP inhibits LPS/TNF alpha-elicited NF-kappa B activation, This suggests that inhibition of iNOS gene expression by exogenous NO may be ascribed to a decreased NF-kappa B availability.	UNIV ROME 3, DEPT BIOL, I-00154 ROME, ITALY; UNIV BOLOGNA, DEPT BIOCHEM, I-40126 BOLOGNA, ITALY; UNIV CAGLIARI, DEPT CYTOMORPHOL, I-09124 CAGLIARI, ITALY; UNIV VERONA, INST BIOL CHEM, I-37134 VERONA, ITALY	Roma Tre University; University of Bologna; University of Cagliari; University of Verona			mariotto, sofia/AAH-5473-2019; Giordano, Emanuele/AAH-6448-2021; Sogos, Valeria/B-5471-2012; COLASANTI, MARCO/A-5616-2010; Menegazzi, Marta/AAE-7079-2019	Giordano, Emanuele/0000-0002-8054-2875; Sogos, Valeria/0000-0002-4021-1043; COLASANTI, MARCO/0000-0002-5752-4943; Menegazzi, Marta/0000-0003-1310-9227; PERSICHINI, TIZIANA/0000-0001-8291-6706				BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLASANTI M, 1995, NEUROSCI LETT, V195, P45, DOI 10.1016/0304-3940(95)11778-U; COLASANTI M, 1995, IN PRESS NEUROSCI LE; DAWSON VL, 1993, J NEUROSCI, V13, P2651; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GOLDRING CEP, 1995, BIOCHEM BIOPH RES CO, V209, P73, DOI 10.1006/bbrc.1995.1472; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; MARIOTTO S, 1995, BRIT J PHARMACOL, V114, P1105, DOI 10.1111/j.1476-5381.1995.tb13320.x; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MONCADA S, 1991, PHARMACOL REV, V43, P109; NUNOKAWA Y, 1994, BIOCHEM BIOPH RES CO, V200, P802, DOI 10.1006/bbrc.1994.1522; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SUZUKI H, 1995, IN PRESS ADV NEUROIM; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	23	200	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26731	26733		10.1074/jbc.270.45.26731	http://dx.doi.org/10.1074/jbc.270.45.26731			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592903	hybrid			2022-12-25	WOS:A1995TE58300003
J	ELSON, A; LEDER, P				ELSON, A; LEDER, P			PROTEIN-TYROSINE-PHOSPHATASE-EPSILON - AN ISOFORM SPECIFICALLY EXPRESSED IN MOUSE MAMMARY-TUMORS INITIATED BY V-HA-RAS OR NEU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; GENE-PRODUCT; ONCOGENE; TRANSFORMATION; CLONING; FAMILY; MEMBER; ACID; OVEREXPRESSION; IDENTIFICATION	Transgenic mice that overexpress v-Ha-ras, c-myc, c-neu or int-2 proto-oncogenes in the mammary epithelium develop breast tumors with morphologies that are characteristic of each initiating oncogene, Since these morphological differences reflect distinctive patterns of tumor-specific gene expression, the identification of the products of these genes might shed light on the mechanisms of transformation and/or the identity of target cells that are transformed by specific classes of oncogenes, By focusing on the tyrosine phosphorylation pathway, we have found that the transmembranal protein-tyrosine phosphatase epsilon (PTP epsilon) is highly expressed in murine mammary tumors initiated by c-neu and v-Ha-ras, but not in mammary tumors initiated by c-myc or int-2. This difference is striking and occurs both in primary tumors and in epithelial cells cultured from them, Moreover, PTP epsilon overexpression appears to be mammary tumor-specific in that it is not found in other ras-based tumors and cell lines, These observations suggest that PTP epsilon either plays a role in ras- and neu-mediated transformation of mammary epithelium or marks mammary epithelial cells particularly susceptible to transformation by these oncogenes, Because of its distinctive expression in these mammary tumors, we have further characterized murine PTP epsilon, cloning and determining the complete structures of its cDNAs and showing that it is a glycoprotein that is N-glycosylated in a tissue-specific manner.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute				Elson, Ari/0000-0001-9808-9135	NATIONAL CANCER INSTITUTE [P20CA058203] Funding Source: NIH RePORTER; NCI NIH HHS [P20CA58203-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENALLAL M, 1994, EXPERIENTIA, V50, P664, DOI 10.1007/BF01952869; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOEHM T, 1993, ONCOGENE, V8, P1385; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DAUM G, 1994, J BIOL CHEM, V269, P10524; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUAN K, 1991, J BIOL CHEM, V266, P12964; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JANES PW, 1994, ONCOGENE, V9, P3601; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KARLUND JK, 1985, CELL, V41, P707; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MONGKOLSUK S, 1988, GENE, V70, P313, DOI 10.1016/0378-1119(88)90203-X; MORRISON BW, 1994, ONCOGENE, V9, P3417; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; REARDON DB, 1993, J BIOL CHEM, V268, P18136; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1991, BLOOD, V78, P2222; ZANDER NF, 1993, ONCOGENE, V8, P1175; ZHAI YF, 1993, CANCER RES, V53, P2272; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	46	84	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26116	26122		10.1074/jbc.270.44.26116	http://dx.doi.org/10.1074/jbc.270.44.26116			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592814	hybrid			2022-12-25	WOS:A1995TC97800021
J	NISHIMURA, M; UYEDA, K				NISHIMURA, M; UYEDA, K			PURIFICATION AND CHARACTERIZATION OF A NOVEL XYLULOSE 5-PHOSPHATE-ACTIVATED PROTEIN PHOSPHATASE CATALYZING DEPHOSPHORYLATION OF FRUCTOSE-6-PHOSPHATE,2-KINASE - FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CATALYTIC SUBUNIT; B-SUBUNIT; TYPE-2A; FORMS; PHOSPHORYLATION; SEQUENCE; KINASE; GLYCOLYSIS; QUANTITIES	We have shown previously (Nishimura, M., Fedorov, S., and Uyeda, K, (1994) (J, Biol, Chem, 269, 26100-26106) that the administration of high concentrations of glu cose stimulates dephosphorylation of Fru-6-P,a kinase: Fru-2,6-bisphosphatase in perfused liver, and xylulose (Xu) 5-P activates the dephosphorylation reaction, To characterize the protein phosphatase, we have purified the Xu Ei-P-activated protein phosphatase to homogeneity from livers of rats injected with high glucose, Several protein phosphatases in the livers were separated by DEAE cellulose chromatography, but only one peak of the enzyme was activated by Xu 5 P. The protein phosphatase was inhibited by okadaic acid (IC50 = 1-3 nM) and did not require Mg2+ or Ca2+, suggesting that the enzyme was type 2A, The enzyme was a heterotrimer (M(r) = 150,000) and consisted of structural (A, 65 kDa), catalytic (C, 36 kDa), and regulatory (B, 52 M)a) subunits, Amino acid sequences of five tryptic peptides derived from the B subunit showed similarity with those of the B alpha isoform of rat protein phosphatase 2A, but five out of 73 residues were different, The protein phosphatase catalyzed dephosphorylation of Fru-6-P,2-kinase:Fru-2,6-Pase, phosphorylase K-m and pyruvate kinase, and the K, values were 0.8 mu M, 3.7 mu M, and 2.2 mu M, respectively, Among these substrates dephosphorylation of only the bifunctional enzyme was activated by Xu 5-P, and the K-a value for Xu 5-P was 20 ELM. Xu 5 P was the only sugar phosphate which activated the PP2A among all the sugar phosphates examined. These results demonstrated the existence and isolation of a unique heterotrimeric protein phosphatase 2A in rat liver which catalyzed the dephosphorylation of Fru-6-P,2-kinase:Fru-2,6-Pase and was activated specifically by Xu 5-P, The Xu 5-P-activated protein phosphatase 2A explains the increased Fru 2,6-P-2 level in liver after high glucose administration.	DEPT VET AFFAIRS MED CTR, DALLAS, TX 75216 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASAZZA JP, 1986, BIOCHEM J, V236, P635, DOI 10.1042/bj2360635; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KOHL EA, 1976, ARCH BIOCHEM BIOPHYS, V176, P671, DOI 10.1016/0003-9861(76)90211-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PELECH S, 1984, EUR J BIOCHEM, V145, P39, DOI 10.1111/j.1432-1033.1984.tb08519.x; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; USUI H, 1988, J BIOL CHEM, V263, P3752; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; YUEDA K, 1991, CRC REV, V2, P445	36	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26341	26346		10.1074/jbc.270.44.26341	http://dx.doi.org/10.1074/jbc.270.44.26341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592845	hybrid			2022-12-25	WOS:A1995TC97800052
J	CREMASCHI, G; ZWIRNER, NW; GORELIK, G; MALCHIODI, EL; CHIARAMONTE, MG; FOSSATI, CA; STERINBORDA, L				CREMASCHI, G; ZWIRNER, NW; GORELIK, G; MALCHIODI, EL; CHIARAMONTE, MG; FOSSATI, CA; STERINBORDA, L			MODULATION OF CARDIAC PHYSIOLOGY BY AN ANTI-TRYPANOSOMA CRUZI MONOCLONAL-ANTIBODY AFTER INTERACTION WITH MYOCARDIUM	FASEB JOURNAL			English	Article						ADENYLATE CYCLASE; MYOCARDIOPATHY; CHAGAS DISEASE MUSCARINIC CHOLINERGIC RECEPTOR	CHAGAS-DISEASE; CHOLINERGIC RECEPTORS; SURFACE-ANTIGEN; ANTILAMININ IGG; INFECTED MICE; PROTEIN; BINDING; CONTRACTILITY; PARTICIPATION; CARDIOPATHY	Circulating antibodies from human and murine chagasic sera are able to interact with myocardium, activating neurotransmitter receptors, Here, we studied the effects of a monoclonal antibody (Mab CAK20.12), which recognizes a 150 kilodalton antigen of Trypanosoma cruzi and reacts with normal human and murine striated muscles and with cardiac tissue, The MAb CAK20.12 binds to purified cardiac membranes and interferes with the binding of beta-adrenergic receptor radioligand ([I-125]CYP) and muscarinic cholinergic receptor (mAChR) radioligand ([H-3]QNB) in a noncompetitive way, As a consequence of this interaction, beta-adrenergic receptor and mAChR were activated, leading to increased intracellular levels of cyclic AMP as a result of beta-adrenergic receptor-coupled adenylate cyclase triggering, When its sympathetic action was abrogated, it also induced an mAChR-mediated increase in cyclic GMP. Furthermore, cardiac physiology was modified by MAb CAK20.12, as it was able to increase cardiac contractility through beta-adrenoceptor activation and to decrease atrial frequency as a result of mAChR activation, The fact that this MAb modalates and modifies the mechanical and biochemical activity of normal murine heart established an important basis for future research and understanding of how the host's humoral immune response acts on the course and development of the chronic chagasic myocardiopathy.	CONSEJO NACL INVEST CIENT & TECN, CTR ESTUDIOS FARMACOL & BOT, RA-1414 BUENOS AIRES, DF, ARGENTINA; UNIV BUENOS AIRES, CONICET, INST ESTUDIOS INMUNIDAD HUMORAL, BUENOS AIRES, DF, ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires			Zwirner, Norberto/AAI-8961-2020	Zwirner, Norberto/0000-0001-7098-359X; Cremaschi, Graciela/0000-0002-1131-1723; Malchiodi, Emilio/0000-0001-7501-3330				ACOSTA AM, 1985, CIRCULATION, V71, P1255, DOI 10.1161/01.CIR.71.6.1255; ALCINA A, 1988, MOL BIOCHEM PARASIT, V29, P181, DOI 10.1016/0166-6851(88)90073-4; Andrade ZA, 1979, TRYPANOSOMA CRUZI DO, P199; BACMAN S, 1989, BRIT J PHARMACOL, V97, P377, DOI 10.1111/j.1476-5381.1989.tb11964.x; BACMAN S, 1990, CAN J PHYSIOL PHARM, V68, P539, DOI 10.1139/y90-078; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brener Z., 1980, Advances in Parasitology, V18, P247, DOI 10.1016/S0065-308X(08)60401-7; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; COSSIO PM, 1977, AM J PATHOL, V86, P533; COSSIO PM, 1974, CIRCULATION, V49, P13, DOI 10.1161/01.CIR.49.1.13; CREMASCHI G, 1990, BIOCHEM PHARMACOL, V39, P1861, DOI 10.1016/0006-2952(90)90602-H; CREMASCHI G, 1992, BIOCHEM PHARMACOL, V43, P2493, DOI 10.1016/0006-2952(92)90136-7; CUNNINGHAM DS, 1980, INFECT IMMUN, V30, P496; DEBRACCO MMD, 1984, CLIN EXP IMMUNOL, V55, P405; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7; GOLDBAUM FA, 1993, J CLIN MICROBIOL, V31, P2141, DOI 10.1128/JCM.31.8.2141-2145.1993; GOLL DE, 1967, J FOOD SCI, V32, P323, DOI 10.1111/j.1365-2621.1967.tb01322.x; GORELIK G, 1992, J MOL CELL CARDIOL, V24, P9, DOI 10.1016/0022-2828(92)91155-X; Hudson L., 1985, Parasitology Today, V1, P6, DOI 10.1016/0169-4758(85)90099-7; IOSA D, 1990, J AUTONOM NERV SYST, V30, pS83, DOI 10.1016/0165-1838(90)90107-T; KOBERLE F, 1961, Bol Oficina Sanit Panam, V51, P404; Koberle F., 1974, CIBA F SYMP, P137; MARGNI RA, 1982, IMMUNOLOGIA IMMUNOQU, P451; MARTIN JM, 1987, J PHARMACOL EXP THER, V240, P683; MIRKIN GA, 1994, CLIN IMMUNOL IMMUNOP, V73, P69, DOI 10.1006/clin.1994.1171; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PASCUAL J, 1986, BIOCHEM PHARMACOL, V35, P3839, DOI 10.1016/0006-2952(86)90673-8; PAULIN JJ, 1988, J PROTOZOOL, V35, P123, DOI 10.1111/j.1550-7408.1988.tb04091.x; SADIGURSKY M, 1982, AM J TROP MED HYG, V31, P934, DOI 10.4269/ajtmh.1982.31.934; SCHMUNIS G A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P287, DOI 10.1590/S0074-02761987000500011; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; SNARY D, 1983, CLIN EXP IMMUNOL, V54, P617; STERINBORDA L, 1990, FASEB J, V4, P1661, DOI 10.1096/fasebj.4.6.2156743; STERINBORDA L, 1988, CLIN EXP IMMUNOL, V74, P349; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8; SZARFMAN A, 1982, J EXP MED, V155, P1161, DOI 10.1084/jem.155.4.1161; VANVOORHIS WC, 1989, J EXP MED, V169, P641, DOI 10.1084/jem.169.3.641; ZWIRNER NW, 1994, INFECT IMMUN, V62, P2483, DOI 10.1128/IAI.62.6.2483-2489.1994	40	15	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1995	9	14					1482	1488		10.1096/fasebj.9.14.7589990	http://dx.doi.org/10.1096/fasebj.9.14.7589990			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TF678	7589990				2022-12-25	WOS:A1995TF67800013
J	BORSCHHAUBOLD, AG; KRAMER, RM; WATSON, SP				BORSCHHAUBOLD, AG; KRAMER, RM; WATSON, SP			CYTOSOLIC PHOSPHOLIPASE A(2) IS PHOSPHORYLATED IN COLLAGEN-STIMULATED AND THROMBIN-STIMULATED HUMAN PLATELETS INDEPENDENT OF PROTEIN-KINASE-C AND MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ARACHIDONIC-ACID; SELECTIVE INHIBITORS; SIGNAL-TRANSDUCTION; INOSITOL PHOSPHATES; MOLECULAR-CLONING; PHORBOL ESTERS; MAP KINASE; RELEASE; CALCIUM	Human platelets pretreated with indomethacin release arachidonic acid predominantly through the activity of cytosolic phospholipase A(2) (cPLA(2)), an 85-kDa protein. This enzyme is regulated by an increase in intracellular Ca2+, a necessary condition for arachidonic acid liberation, and by phosphorylation. Phosphorylation of cPLA(2) enhanced the Ca2+-induced arachidonic acid release in platelets stimulated by the ionophore A23187 and phorbol ester (phorbol 12,13-dibutyrate (PDBu)). In thrombin-stimulated platelets, however, phosphorylation appeared not to be necessary for arachidonic acid release since the latter response was not impaired in the presence of staurosporine, which inhibited phosphorylation. Collagen, thrombin, and PDBu induced phosphorylation of platelet cPLA(2) as well as activation of mitogen-activated protein kinase (MAPH; p42(maph) and p44(mapk)). cPLA(2) activation was not dependent on protein kinase C (PKC) in thrombin- and collagen-stimulated platelets, as preincubation with the PKC inhibitor Ro 31-8220 neither interfered with cPLA(2) phosphorylation nor reduced arachidonic acid release, However, collagen- and thrombin-induced activation of MAPK was inhibited by Ro 31-8220, indicating that PKC is necessary for MAPK stimulation in platelets. Although MAPH may underlie phosphorylation of cPLA(2) in PDBu-activated human platelets, our results provide evidence for PKC- and MAPK-independent phosphorylation of cPLA(2) in platelets stimulated by the physiological activators collagen and thrombin.	LILLY RES LABS,INDIANAPOLIS,IN 46285	Eli Lilly	BORSCHHAUBOLD, AG (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V342, P15, DOI 10.1016/0014-5793(94)80575-X; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FERBY IM, 1994, J BIOL CHEM, V269, P30485; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKASHIMA S, 1994, BIOCHEM BIOPH RES CO, V198, P497, DOI 10.1006/bbrc.1994.1073; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; POOLE AW, 1993, BRIT J PHARMACOL, V110, pP41; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RINK TJ, 1983, NATURE, V305, P317, DOI 10.1038/305317a0; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WATERMAN AH, 1995, BIOCHEM BIOPH RES CO, V209, P271; WATSON SP, 1995, MOL PHARMACOL, V47, P823; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WINITZ S, 1994, J BIOL CHEM, V269, P1889; XING MZ, 1994, J BIOL CHEM, V269, P3117; XING MZ, 1992, J BIOL CHEM, V267, P25966	61	115	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25885	25892		10.1074/jbc.270.43.25885	http://dx.doi.org/10.1074/jbc.270.43.25885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592775				2022-12-25	WOS:A1995TB46600092
J	LAEGREID, A; THOMMESEN, L; JAHR, TG; SUNDAN, A; ESPEVIK, T				LAEGREID, A; THOMMESEN, L; JAHR, TG; SUNDAN, A; ESPEVIK, T			TUMOR-NECROSIS-FACTOR INDUCES LIPOPOLYSACCHARIDE TOLERANCE IN A HUMAN ADENOCARCINOMA CELL-LINE MAINLY THROUGH THE TNF P55 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LPS BINDING-PROTEIN; MONOCLONAL-ANTIBODIES; CYTOKINE PRODUCTION; ACTIVATION; CD14; ALPHA; INTERLEUKIN-1; COMPLEXES; MONOCYTES	This study demonstrates that lipopolysaccharide (LPS) mediates induction of transcription factor NF kappa B and activation of the cytomegalovirus (CMV) promoter-enhancer in the SW480 cell Line. These cells do not express a functional membrane CD14. The LPS response in SW480 cells was weaker and markedly slower than the tumor necrosis factor (TNF) response. Pretreatment with TNF for 72 h inhibited both TNF, tumor necrosis factor receptor (TNFR) p55, TNFR p75, and LPS-mediated activation of nuclear factor -kappa B (NF kappa B), whereas pretreatment with LPS only inhibited the LPS response. TNFR p55 antibody pretreatment resulted in marked inhibition of the LPS response, while pretreatment with TNFR p75 antiserum only had a weak inhibitory effect. Flowcytometric analysis showed that LPS binding as well as expression of TNFR p55 and TNFR p75 were not affected by LPS or TNF pretreatment, indicating that the observed inhibition is not due to reduction of specific binding sites at the cell surface. The results suggest that LPS signaling in SW480 cells involves intracellular components which may be depleted or inactivated via TNFR p55, indicating that the LPS and TNFR p55 pathways overlap. We propose that TNFR p55 can mediate activation of NF kappa B and cytomegalovirus promoter-enhancer in SW480 cells via two distinct mechanisms, one which is activated only via TNFR p55 and leads to rapid activation of NF kappa B, and another which is overlapping with the LPS pathway.	UNIV TRONDHEIM,INST CANC RES & MOLEC BIOL,N-7005 TRONDHEIM,NORWAY; UNIV TRONDHEIM,CTR BIOL MOLEC,UNIGEN,N-7005 TRONDHEIM,NORWAY									BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; COUTURIER C, 1992, EUR J IMMUNOL, V22, P1461, DOI 10.1002/eji.1830220619; DAMAY BG, 1994, J BIOL CHEM, V269, P19687; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DING AH, 1988, J IMMUNOL, V141, P2407; ERROI A, 1993, INFECT IMMUN, V61, P4356, DOI 10.1128/IAI.61.10.4356-4359.1993; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GALLOWAY CJ, 1992, EUR J IMMUNOL, V22, P3045, DOI 10.1002/eji.1830221143; GENG Y, 1993, J IMMUNOL, V151, P6692; GODAMBE SA, 1994, J IMMUNOL, V153, P143; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HEITBROCK HWZ, 1993, J IMMUNOL, V151, P6986; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; JOHNS LD, 1994, J IMMUNOL, V152, P5877; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Kronke M, 1992, Immunol Ser, V56, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LIU J, 1994, J BIOL CHEM, V269, P3047; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MACHIAS S, 1994, P NATL ACAD SCI USA, V269, P13760; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEDRON T, 1994, J BIOL CHEM, V269, P2426; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WAAGE A, 1987, LANCET, V1, P355; WIEGMANN K, 1994, CELL, V8, P1005; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	48	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25418	25425		10.1074/jbc.270.43.25418	http://dx.doi.org/10.1074/jbc.270.43.25418			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592709	hybrid			2022-12-25	WOS:A1995TB46600025
J	MAGENDANTZ, M; HENRY, MD; LANDER, A; SOLOMON, F				MAGENDANTZ, M; HENRY, MD; LANDER, A; SOLOMON, F			INTERDOMAIN INTERACTIONS OF RADIXIN IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEINS; CYTOSKELETON; EZRIN; PURIFICATION; LOCALIZATION; COMPONENT; BINDING; CELLS	We have assayed the domains of the ERM protein radixin for binding activities in vitro. Affinity columns bearing the amino-terminal domain of radixin selectively bound a small subset of the proteins of the chicken erythrocyte cytoskeleton. Two of those proteins were identified as radixin itself and band 4.1. In contrast, the carboxyl-terminal domain of the molecule bound neither protein, and full-length radixin did not bind band 4.1 (binding of full-length radixin to itself was not evaluated). Columns bearing a mixture of the amino- and carboxyl-terminal domains of radixin also failed to bind radixin and band 4.1. These results suggested that the amino- and carboxyl-terminal sequences can interact with one another either in cis or in trans, and so interfere with radixin's interactions with other ligands. Using affinity co-electrophoresis, we confirmed a direct interaction in solution between the two radixin domains; the data are consistent with the formation of a 1:1 complex with a dissociation constant of similar to 5 x 10(-8) M. Competition between intramolecular and intermolecular interactions may help to explain the provocative and dynamic localization of ERM proteins within cells.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019	Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525; Henry, Michael/0000-0002-7871-245X	NATIONAL CANCER INSTITUTE [R01CA053395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER; NCI NIH HHS [CA53395] Funding Source: Medline; NINDS NIH HHS [NS26862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANDREOLI C, 1994, J CELL SCI, V107, P2509; BIRGBAUER E, 1991, J NEUROSCI RES, V30, P232; BIRGBAUER E, 1989, J CELL BIOL, V109, P1609, DOI 10.1083/jcb.109.4.1609; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1986, METHOD ENZYMOL, V134, P24; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; GRANGER BL, 1985, NATURE, V313, P238, DOI 10.1038/313238a0; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIM WA, 1991, METHOD ENZYMOL, V208, P196; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445	24	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25324	25327		10.1074/jbc.270.43.25324	http://dx.doi.org/10.1074/jbc.270.43.25324			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592691	hybrid, Green Published			2022-12-25	WOS:A1995TB46600007
J	PENG, H; MARIANS, KJ				PENG, H; MARIANS, KJ			THE INTERACTION OF ESCHERICHIA-COLI TOPOISOMERASE-IV WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME SEGREGATION; SALMONELLA-TYPHIMURIUM; NUCLEOID SEGREGATION; SUBUNIT STRUCTURE; NALIDIXIC-ACID; PBR322 DNA; GYRASE; REPLICATION; GENE; ENZYME	The two type II topoisomerases in Escherichia coli, DNA gyrase and topoisomerase (Topo) TV, share considerable amino acid sequence similarity, yet they have distinctive topoisomerization activities. Only DNA gyrase can supercoli relaxed DNA, whereas during oriC DNA replication in vitro, only Topo IV can support the final stages of replication, processing of the late inter mediate and decatenation of the daughter molecules. In order to develop an understanding for the basis of the differential activities of these two enzymes, we have initiated a characterization of Topo TV binding to DNA. We find that unlike gyrase, Topo IV neither constrains DNA in a positive supercoli when it binds nor protects a 150-base pair region of DNA from digestion with micrococcal nuclease. Consistent with this, DNase I footprinting experiments showed that Topo IV protected a 34-base pair region roughly centered about the topoisomerase induced cleavage site. In addition, Topo IV preferentially bound supercolied rather than relaxed DNA. Thus, the DNA binding characteristics of Topo IV are more akin to those of the type II eukaryotic enzymes rather than those of its prokaryotic partner.	CORNELL UNIV, GRAD SCH MED SCI, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Cornell University	PENG, H (corresponding author), MEM SLOAN KETTERING CANC CTR, MOLEC BIOL LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; GROSS WA, 1965, J BACTERIOL, V89, P1068; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HUSSAIN K, 1987, MOL MICROBIOL, V1, P259, DOI 10.1111/j.1365-2958.1987.tb01932.x; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1989, MOL GEN GENET, V217, P178, DOI 10.1007/BF00330959; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; RYAN MJ, 1976, BIOCHEMISTRY-US, V15, P3769, DOI 10.1021/bi00662a020; SCHMID MB, 1990, J BACTERIOL, V172, P5416, DOI 10.1128/jb.172.9.5416-5424.1990; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; STAUDENBAUER WL, 1976, EUR J BIOCHEM, V62, P491, DOI 10.1111/j.1432-1033.1976.tb10183.x; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; TRUCKSIS M, 1981, P NATL ACAD SCI-BIOL, V78, P2164, DOI 10.1073/pnas.78.4.2164; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0	44	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25286	25290		10.1074/jbc.270.42.25286	http://dx.doi.org/10.1074/jbc.270.42.25286			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559669	hybrid			2022-12-25	WOS:A1995TB46500103
J	SANCHEZALCAZAR, JA; HERNANDEZ, I; DELATORRE, MP; GARCIA, I; SANTIAGO, E; MUNOZYAGUE, M; SOLISHERRUZO, JA				SANCHEZALCAZAR, JA; HERNANDEZ, I; DELATORRE, MP; GARCIA, I; SANTIAGO, E; MUNOZYAGUE, M; SOLISHERRUZO, JA			DOWN-REGULATION OF TUMOR-NECROSIS-FACTOR RECEPTORS BY BLOCKADE OF MITOCHONDRIAL RESPIRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; MANGANOUS SUPEROXIDE-DISMUTASE; FACTOR-ALPHA; HYDROGEN-PEROXIDE; PHORBOL ESTERS; BINDING-CAPACITY; CELLS-INVITRO; GENERATION; PHOSPHORYLATION; ACTIVATION	We have studied the effect of blockade of mitochondrial respiration on the binding of human I-125-TNF alpha to L929 cell receptors. Specific TNF alpha binding was decreased to about 20-40% of controls by blocking mitochondrial respiration. This effect was dose- and time-related and was observed independently of the level at which the respiration was blocked (respiratory chain, proton backflow, ATPase, anaerobiosis). This blockade had no effect on the half-life of the specific TNF alpha binding, the internalization or degradation of TNF alpha-receptor complexes, or the number of TNF alpha-binding sites. Scatchard analysis of TNF alpha binding data indicated a 2-4-fold decrease in the affinity of these binding sites. These effects did not appear to be related to the protein kinase C activity or to reactive oxygen radicals, since they were not antagonized by pretreatment of cells with oxygen radical scavengers, deferoxamine, or inhibitors of protein kinase C. Decrease in TNF alpha binding capacity correlated significantly with cellular ATP content (r = 0.94; p < 0.01) and with the cytocidal activity of TNF alpha against L929 cells. These findings suggest that blockade of mitochondrial respiration down-regulates the binding of TNF alpha to cells, most likely by changing the affinity of receptors for this cytokine. This down-regulation may increase the resistance of cells to TNF alpha cytotoxicity.	UNIV COMPLUTENSE MADRID, HOSP 12 OCTUBRE, CTR INVEST, SERV GASTROENTEROL, E-28041 MADRID, SPAIN	Complutense University of Madrid; Hospital Universitario 12 de Octubre			García-Ruiz, Inmaculada/G-8204-2015; Sanchéz-Alcázar, José A. A/L-4925-2014	García-Ruiz, Inmaculada/0000-0003-4185-8524; Sanchéz-Alcázar, José A. A/0000-0001-9705-1469				ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; AGGARWAL BB, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P76; ALBERTS B, 1989, MOL BIOL CELL, P342; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BIDGA J, 1994, J EXP MED, V180, P445; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Boveris A., 1977, TISSUE HYPOXIA ISCHE, P67; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BURGERS JA, 1993, BIOCHEM J, V291, P157, DOI 10.1042/bj2910157; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COLTON T, 1979, ESTADISTICA MED; COSTLOW ME, 1982, J BIOL CHEM, V257, P9330; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HAHN T, 1985, P NATL ACAD SCI USA, V82, P3814, DOI 10.1073/pnas.82.11.3814; HELLER RA, 1992, CELL, V70, P47; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HERTEL C, 1988, MOL PHARMACOL, V44, P364; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; JOHNSON SE, 1988, J BIOL CHEM, V263, P5686; KAPLAN J, 1981, SCIENCE, V212, P14, DOI 10.1126/science.6259730; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KONSTANTINOV AA, 1987, BIOCHIM BIOPHYS ACTA, V894, P1, DOI 10.1016/0005-2728(87)90206-4; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LIAO JF, 1993, MOL PHARMACOL, V44, P364; LINGE C, 1993, GROWTH FACTORS PRACT, P201; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEURICH P, 1986, BIOCHEM BIOPH RES CO, V141, P855, DOI 10.1016/S0006-291X(86)80251-0; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STADLER J, 1992, ANN SURG, V216, P539, DOI 10.1097/00000658-199211000-00003; SVEC F, 1985, BIOCHIM BIOPHYS ACTA, V847, P147, DOI 10.1016/0167-4889(85)90167-3; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TRACEY KJ, 1989, LANCET, V1, P1122; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; WALLACH D, 1984, J IMMUNOL, V132, P2464; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WULFF K, 1985, METHOD ENZYMAT AN, V7, P357; YAMAUCHI N, 1989, CANCER RES, V49, P1671	60	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23944	23950		10.1074/jbc.270.41.23944	http://dx.doi.org/10.1074/jbc.270.41.23944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592589	Green Published, hybrid			2022-12-25	WOS:A1995TA21700017
J	WAYMAN, GA; HINDS, TR; STORM, DR				WAYMAN, GA; HINDS, TR; STORM, DR			HORMONE STIMULATION OF TYPE-III ADENYLYL-CYCLASE INDUCES CA2+ OSCILLATIONS IN HEK-293 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL TRISPHOSPHATE; CALCIUM MOBILIZATION; WHOLE CELLS; CALMODULIN; EXPRESSION; RECEPTOR; CLONING; PHOSPHORYLATION; ACTIVATION	Various forms of cross-talk between the Ca2+ and cAMP signal transduction systems can occur in animal cells depending upon the types of adenylyl cyclases present. Here, we report that Ca2+ oscillations can be generated by hormone stimulation of type III adenylyl cyclase expressed in HEK-293 cells. These Ca2+ oscillations are apparently due to the unique regulatory features of type III adenylyl cyclase, which is stimulated by hormones and inhibited by elevated Ca2+ in vivo. Ca2+ oscillations were generated by glucagon, isoproterenol, or forskolin stimulation of type III adenylyl cyclase and were dependent upon the activity of cAMP- and calmodulin-dependent protein kinases. Ca2+ oscillations were not solely dependent upon cAMP increases since dibutyryl cAMP or (S-p)-cAMP did not stimulate Ca2+ oscillations. We hypothesize that stimulation of type III adenylyl cyclase leads to increased cAMP, activation of inositol 1,4,5-trisphosphate receptors, and elevation of intracellular Ca2+. As free Ca2+ increases, type III adenylyl cyclase activity is attenuated by CaM kinase(s) and intracellular cAMP levels decrease. When cAMP levels drop below a threshold level, the inositol 1,4,5-trisphosphate receptor is dephosphorylated and Ca2+ is resequestered. This cycle is repeated if type III adenylyl cyclase is chronically exposed to an activator. This unique mechanism for generation of Ca2+ oscillations in cells is distinct from others documented in the literature.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BEAVO JA, 1990, TRENDS NEUROCHEM SCI, V13, P65; Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V256, P9583; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CAMPBELL MD, 1990, MOL PHARMACOL, V38, P282; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, ANN REV PHYSL, V55, P427; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; HOENEGGER M, 1993, BIOCHEM J, V296, P303; HORN VJ, 1991, MOL CELL BIOCHEM, V101, P43; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASTERS SB, 1985, BIOCHEM J, V227, P933, DOI 10.1042/bj2270933; NAKADE S, 1994, J BIOL CHEM, V269, P6735; RAPP PE, 1977, J THEOR BIOL, V66, P497, DOI 10.1016/0022-5193(77)90299-5; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SALOMON Y, 1979, ANAL BIOCHEM, V58, P541; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SUBERS EM, 1988, J MOL CELL CARDIOL, V20, P131, DOI 10.1016/S0022-2828(88)80026-9; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XU A, 1993, J BIOL CHEM, V268, P8394; YOSHIDA A, 1992, J BIOCH TOKYO; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	52	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24108	24115		10.1074/jbc.270.41.24108	http://dx.doi.org/10.1074/jbc.270.41.24108			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592612	hybrid			2022-12-25	WOS:A1995TA21700040
J	PIERSEN, CE; PRINCE, MA; AUGUSTINE, ML; DODSON, ML; LLOYD, RS				PIERSEN, CE; PRINCE, MA; AUGUSTINE, ML; DODSON, ML; LLOYD, RS			PURIFICATION AND CLONING OF MICROCOCCUS-LUTEUS ULTRAVIOLET ENDONUCLEASE, AN N-GLYCOSYLASE ABASIC LYASE THAT PROCEEDS VIA AN IMINO ENZYME-DNA INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; GENOMIC G+C CONTENT; ESCHERICHIA-COLI; PYRIMIDINE DIMERS; UV ENDONUCLEASE; CATALYTIC ACTIVITIES; BETA-ELIMINATION; CODON USAGE; MECHANISM; PROTEIN	Although Micrococcus luteus UV endonuclease has been reported to be an 18-kDa enzyme with possible homology to the 16-kDa endonuclease V from bacteriophage T4 (Gordon, L. K., and Haseltine, W. A. (1980) J. Biol, Chem, 255, 12047-12050; Grafstrom, R. H., Park, L., and Grossman, L. (1982) J. Biol, Chem, 257, 13465-13474), this study describes three independent purification schemes in which M. luteus UV damage-specific or pyrimidine dimer-specific nicking activity was associated with two proteins of apparent molecular masses of 31 and 32 kDa. An 18-kDa contaminant copurified with the doublet through many of the chromatographic steps, but it was determined to be a homolog of Escherichia coli ribosomal protein L6. Edman degradation analyses of the active proteins yielded identical NH2-terminal amino acid sequences, The corresponding gene (pdg, pyrimidine dimer glycosylase) was cloned, The protein bears strong sequence similarities to the E. coli repair proteins endonuclease III and MutY. Nonetheless, traditionally purified M. luteus protein acted exclusively on cis-syn thymine dimers; it was unable to cleave site-specific oligonucleotide substrates containing a trans-syn -I, (6-4), or Dewar thymine dimer, a 5,6-dihydrouracil lesion, or an A:G or A:C mismatch, The UV endonuclease incised cis-syn dimer-containing DNA in a dose-dependent manner and exhibited linear kinet ics within that dose range, Enzyme activity was inhibited by the presence of NaCN or NaBH4 with NaBH4 additionally being able to trap a covalent enzyme substrate product, These last findings confirm that the catalytic mechanism of M. luteus UV endonuclease, like those of other glycosylase/AP lyases, involves an imino intermediate.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston				Lloyd, R. Stephen/0000-0001-7273-372X; Piersen, Colleen/0000-0002-2913-4956	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES04091] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; CARRIER WL, 1970, J BACTERIOL, V102, P178, DOI 10.1128/JB.102.1.178-186.1970; CASH DJ, 1966, J BIOL CHEM, V241, P4290; CUNNINGHAM RP, 1994, ANN NY ACAD SCI, V726, P215, DOI 10.1111/j.1749-6632.1994.tb52818.x; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DIXON M, 1964, ENZYMES, P337; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FU WG, 1992, J BIOL CHEM, V267, P16135; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HAMILTON KK, 1992, NATURE, V356, P725, DOI 10.1038/356725a0; HAMILTON RW, 1989, J BIOL CHEM, V264, P17422; HAMILTON RW, 1990, THESIS VANDERBILT U, P26; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; KAPLAN JC, 1969, BIOCHEMISTRY-US, V63, P144; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; MANOHARAN, 1988, J AM CHEM SOC, V110, P2390; MANOHARAN M, 1989, J AM CHEM SOC, V111, P8029; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; NAKAYAMA H, 1971, BIOCHIM BIOPHYS ACTA, V228, P67, DOI 10.1016/0005-2787(71)90547-8; NAKAYAMA H, 1992, MUTAT RES, V273, P43, DOI 10.1016/0921-8777(92)90048-8; NAKAYAMA M, 1989, MOL GEN GENET, V218, P384, DOI 10.1007/BF00332399; NOLLING J, 1992, NUCLEIC ACIDS RES, V24, P6501; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OHAMA T, 1987, J BACTERIOL, V169, P4770, DOI 10.1128/jb.169.10.4770-4777.1987; OHAMA T, 1989, J MOL EVOL, V29, P381, DOI 10.1007/BF02602908; PIERRE J, 1980, BIOCHEMISTRY-US, V19, P5024, DOI 10.1021/bi00563a014; PIERRE J, 1980, BIOCHEMISTRY-US, V19, P5018, DOI 10.1021/bi00563a013; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; RIAZUDDIN S, 1977, J BIOL CHEM, V252, P6280; SCHALLER H, 1972, EUR J BIOCHEM, V26, P474, DOI 10.1111/j.1432-1033.1972.tb01789.x; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SHIOTA S, 1989, MOL GEN GENET, V217, P332, DOI 10.1007/BF02464901; SHIOTA S, 1988, MOL GEN GENET, V213, P21, DOI 10.1007/BF00333393; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779	51	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23475	23484		10.1074/jbc.270.40.23475	http://dx.doi.org/10.1074/jbc.270.40.23475			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559510	hybrid			2022-12-25	WOS:A1995RY90900039
J	UEDA, N; KURAHASHI, Y; YAMAMOTO, S; TOKUNAGA, T				UEDA, N; KURAHASHI, Y; YAMAMOTO, S; TOKUNAGA, T			PARTIAL-PURIFICATION AND CHARACTERIZATION OF THE PORCINE BRAIN ENZYME HYDROLYZING AND SYNTHESIZING ANANDAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID RECEPTOR AGONIST; CONSTITUENT; BINDING	Anandamide (arachidonylethanolamide) is known as an endogenous agonist for cannabinoid receptors. An amidohydrolase, which hydrolyzed anandamide, was solubilized from the microsomal fraction of porcine brain with 1% Triton X-100. The enzyme was partially purified by Phenyl-5PW hydrophobic chromatography to a specific activity of approximately 0.37 mu mol/min/mg of protein at 37 degrees C. As assayed with C-14-labeled substrates, the apparent K-m value for anandamide was 60 mu M, and anandamide was more active than ethanol-amides of linoleic, oleic, and palmitic acids. Ceramidase and protease activities were not detected in our enzyme preparation. The purified enzyme also synthesized anandamide from free arachidonic acid in the presence of a high concentration of ethanolamine with a specific activity of about 0.16 mu mol/min/mg of protein at 37 degrees C. On the basis of cochromatographies, pH dependence, heat inactivation, and effects of inhibitors such as arachidonyl trifluoromethyl ketone, p-chloromercuribenzoic acid, diisopropyl fluorophosphate, and phenylmethylsulfonyl fluoride, it was suggested that the anandamide amidohydrolase and synthase activities were attributable to a single enzyme protein.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,TOKUSHIMA 770,JAPAN; JAPAN TOBACCO INC,CENT PHARMACEUT RES INST,TAKATSUKI,OSAKA 569,JAPAN	Tokushima University; Japan Tobacco Inc.								ABADJI V, 1994, J MED CHEM, V37, P1889, DOI 10.1021/jm00038a020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILDERS SR, 1994, BIOCHEM PHARMACOL, V47, P711, DOI 10.1016/0006-2952(94)90134-1; CRAWLEY JN, 1993, PHARMACOL BIOCHEM BE, V46, P967, DOI 10.1016/0091-3057(93)90230-Q; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; HASSLER DF, 1993, ADV LIPID RES, V26, P49; JOHNSON DE, 1993, PROSTAG LEUKOTR ESS, V48, P429, DOI 10.1016/0952-3278(93)90048-2; KIDO H, 1993, J BIOL CHEM, V268, P13406; KOPACZYK KC, 1965, J LIPID RES, V6, P140; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; MACKIE K, 1993, MOL PHARMACOL, V44, P498; SATO T, 1994, SEIKAGAKU, V66, P802; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052	25	278	287	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23823	23827		10.1074/jbc.270.40.23823	http://dx.doi.org/10.1074/jbc.270.40.23823			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559559	hybrid			2022-12-25	WOS:A1995RY90900088
J	ZHANG, HL; MALPURE, S; DIGATE, RJ				ZHANG, HL; MALPURE, S; DIGATE, RJ			ESCHERICHIA-COLI DNA TOPOISOMERASE-III IS A SITE-SPECIFIC DNA-BINDING PROTEIN THAT BINDS ASYMMETRICALLY TO ITS CLEAVAGE SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME SEGREGATION; ENZYME; GYRASE; DECATENATION; REPLICATION; MECHANISM; DUPLEX; IV	The binding of DNA topoisomerase III (Topo III) to a single-stranded DNA substrate containing a strong cleavage site has been examined. The minimal substrate requirement for Topo III-catalyzed cleavage has been determined to consist of 7 bases: 6 bases 5' to the cleavage site and only 1 base 3' to the site. Nuclease P1 protection experiments indicate that the enzyme also binds to its substrate asymmetrically, protecting similar to 12 bases 5' to the cleavage site and only 2 bases 3' to the cleavage site. A catalytically inactive mutant of Topo III shows the same protection pattern as the active polypeptide, indicating that Topo III is a site-specific binding protein as well as a topoisomerase. Consistent with this view, an oligonucleotide containing a cleavage site is a more effective inhibitor and is bound more efficiently by Topo III than an oligonucleotide without a cleavage site.	UNIV MARYLAND,CELL & MOLEC BIOL PROGRAM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NIGMS NIH HHS [GM48445-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048445, R01GM048445] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; DEAN F, 1984, THESIS U CHICAGO; DEAN FB, 1985, J BIOL CHEM, V260, P4984; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DOMANICO PL, 1988, BIOCHEMISTRY-US, V27, P6365, DOI 10.1021/bi00417a026; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; HIASA H, 1994, J BIOL CHEM, V269, P32655; HIASA H, 1994, J BIOL CHEM, V269, P2093; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; PASTORCIC M, 1982, THESIS U CHICAGO; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; TSEDINH YC, 1983, NUCLEIC ACIDS RES, V11, P8691, DOI 10.1093/nar/11.24.8691; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZHANG HL, 1994, J BIOL CHEM, V269, P9052	20	26	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23700	23705		10.1074/jbc.270.40.23700	http://dx.doi.org/10.1074/jbc.270.40.23700			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559540	hybrid			2022-12-25	WOS:A1995RY90900069
J	REYMOND, A; BRENT, R				REYMOND, A; BRENT, R			P16 PROTEINS FROM MELANOMA-PRONE FAMILIES ARE DEFICIENT IN BINDING TO CDK4	ONCOGENE			English	Article						P16(INK4A); CDK4; CDK6; CKI, MELANOMA; 2-HYBRIDS	TRANSFORMATION	The tumor suppressor candidate p16(INK4) is a cyclin-dependent kinase inhibitor that inhibits cell proliferation, The p16 coding gene is often mutated in glioblastomas, pancreatic adenocarcinomas and melanoma-prone pedigrees, but, until recently, the significance of these allelic variants has remained unclear. Here, we used interaction mating and coprecipitation to measure interaction of seven p16 allelic variants detected in melanoma-prone pedigrees with Cyclin-dependent kinases (Cdks), We found that most variants were deficient in interaction with Cdk4 and Cdk6. One defective variant was found both in cancer prone families and in the control population and therefore previously defined as a common polymorphism. Another variant, which is weakly linked to familial cancer, is only slightly affected in interaction with Cdks. These results are consistent with the idea that p16 allelic variants that decrease Cdk interaction predispose individuals who carry them to an increased risk of cancer. Moreover, they suggest that determination of affinity between p16 mutants and partner proteins may help identify functionally-significant allelic variants not detected by classical human genetic techniques.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	REYMOND, A (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,50 BLOSSOM ST,BOSTON,MA 02114, USA.			Reymond, Alexandre/0000-0003-1030-8327				AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLEMIS E, 1992, MOL CELL BIOL, V8, P1614; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1993, NUCLEIC ACIDS RES, V21, P3615, DOI 10.1093/nar/21.16.3615; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	24	94	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1173	1178						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566978				2022-12-25	WOS:A1995RX18000021
J	HAWLEY, SA; SELBERT, MA; GOLDSTEIN, EG; EDELMAN, AM; CARLING, D; HARDIE, DG				HAWLEY, SA; SELBERT, MA; GOLDSTEIN, EG; EDELMAN, AM; CARLING, D; HARDIE, DG			5'-AMP ACTIVATES THE AMP-ACTIVATED PROTEIN-KINASE CASCADE AND CA2+/CALMODULIN ACTIVATES THE CALMODULIN-DEPENDENT PROTEIN-KINASE-I CASCADE, VIA 3 INDEPENDENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; RAT-BRAIN; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; P34(CDC2); P40(MO15)	ARIP-activated protein kinase (AMPK) and Ca2+/calmodulin (CaM) dependent protein kinase I (CaMKI) are protein kinases that are regulated both by allosteric activation (AMP and Ca2+/CaM, respectively) and by phosphorylation by upstream protein kinases (AMPK kinase (AMPKK) and CaMKI kinase (CaMKIK), respectively). We now report that AMPKK can activate CaMKI and that, conversely, CaMKIK can activate AMPK. CaMKIK is 68-fold more effective at activating CaMKI than AMPK, while AMPKK is 17-fold more effective at activating AMPK than CaMKI. Our results suggest that CaMKIK and AMPKK are distinct enzymes dedicated to their respective kinase targets but with some overlap in their substrate specificities. The availability of alternative substrates for AMPKK and CaMKIK allowed the unequivocal demonstration that AMP and Ca2+/calmodulin promote the activation of AMPK and CaMKI, respectively, via three independent mechanisms: 1) direct activation of AMPK and CaMKI, 2) activation of AMPKK and CaMKIK, and 3) by binding to AMPK and CaMKI, inducing exposure of their phosphorylation sites. Since AMP and Ca2+/calmodulin each has a triple effect in its respective system, in vivo, the two systems would be expected to be exquisitely sensitive to changes in concentration of their respective activating ligands.	SUNY BUFFALO,DEPT PHARMACOL & TOXICOL,BUFFALO,NY 14214; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOLEC MED GRP,LONDON W12 0NN,ENGLAND	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Dundee; Imperial College London			Carling, David/F-1943-2014; Hardie, David/Z-1979-2019	Carling, David/0000-0002-2316-1830; Hardie, Grahame/0000-0002-8373-7379	NIGMS NIH HHS [GM07145-20] Funding Source: Medline; NINDS NIH HHS [NS24738] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024738, R01NS024738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARLING D, 1994, J BIOL CHEM, V269, P11442; CARLING D, 1989, EUR J BIOCHEM, V185, P129; CLARKE PR, 1991, ADV PROT PHOSPHATASE, V6, P187; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DALE S, 1994, FEBS LETT, V361, P191; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FERRER A, 1985, BIOCHEM BIOPH RES CO, V132, P497, DOI 10.1016/0006-291X(85)91161-1; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; HARDIE DG, 1992, BIOESSAYS, V14, P699, DOI 10.1002/bies.950141011; HARIBABU B, 1995, EMBO J, V15, P3679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBBE JC, 1994, EMBO J, V13, P5155; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MOORE SK, 1990, DNA CELL BIOL, V9, P387, DOI 10.1089/dna.1990.9.387; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WEEKES J, 1993, FEBS LETT, V334, P335, DOI 10.1016/0014-5793(93)80706-Z; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x	38	347	361	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27186	27191		10.1074/jbc.270.45.27186	http://dx.doi.org/10.1074/jbc.270.45.27186			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592975	hybrid			2022-12-25	WOS:A1995TE58300075
J	KWAK, JY; LOPEZ, I; UHLINGER, DJ; RYU, SH; LAMBETH, JD				KWAK, JY; LOPEZ, I; UHLINGER, DJ; RYU, SH; LAMBETH, JD			RHOA AND A CYTOSOLIC 50-KDA FACTOR RECONSTITUTE GTP-GAMMA-S-DEPENDENT PHOSPHOLIPASE-D ACTIVITY IN HUMAN NEUTROPHIL SUBCELLULAR-FRACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; BINDING PROTEIN; REGULATORY PROTEIN; D ACTIVATION; RAS; PHOSPHOHYDROLASE; GRANULOCYTES; HYDROLYSIS; MEMBRANE; CALCIUM	Receptor activation of phospholipase D has been implicated in signal transduction in a variety of cells, Reconstitution of cell free guanosine 5'-O-(3-thiotriphosphate)(GTP gamma S)-dependent phospholipase D activity from human neutrophils requires protein factors in both the plasma membrane and the cytosol, We previously proposed that one of the factors is a Ras-family small molecular weight GTPase of the Rho subtype (Bowman, E.P., Uhlinger, D.J., and Lambeth, J.D. (1993) J, Biol, Chem. 268, 21509-21512), Herein, we have used RhoGDI (GDP dissociation inhibitor), an inhibitory Rho-binding protein, to selectively extract Rho-type GTPases from the plasma membrane, and have used immunoprecipitation as well as chromatographic methods to remove cytosolic Rho, Depletion of RhoA from either the plasma membrane or the cytosol re suited in a partial loss in GTP gamma S dependent activity, while removal of RhoA from both fractions resulted in a nearly complete loss in activity, Activity was nearly completely restored by adding purified recombinant RhoA, which showed an EC(50) of 52 nM, while Rad showed little activity, Cytosol fractionated using DEAE- cellulose chromatography separated ADP-ribosylation factor and Rho from the major activating fraction, Gel exclusion chromatography of this fraction revealed an activating factor of 50 KDa apparent molecular-mass, Using RhoA-depleted membranes, reconstitution of phospholipase D activity required both RhoA and the 50-kDa factor, Thus, RhoA along with a non-Rho, non-ADP-ribosylation factor 50-kDa cytosolic factor are both required to reconstitute GTP gamma S dependent phospholipase D activity by neutrophil plasma membranes.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA	Emory University				Ryu, Sung Ho/0000-0003-0913-3048	NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NCI NIH HHS [CA46508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HORWITZ J, 1992, J NEUROCHEM, V59, P1474, DOI 10.1111/j.1471-4159.1992.tb08463.x; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KUSNER DJ, 1994, BIOCHEM J, V304, P485, DOI 10.1042/bj3040485; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LAMBETH JD, 1994, PROTEIN KINASE C, P121; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PERRY DK, 1992, J IMMUNOL, V149, P2749; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1990, J BIOL CHEM, V265, P9373	31	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27093	27098		10.1074/jbc.270.45.27093	http://dx.doi.org/10.1074/jbc.270.45.27093			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592961	hybrid			2022-12-25	WOS:A1995TE58300061
J	ROY, K; MITSUGI, K; SIRLIN, S; SHANE, B; SIROTNAK, FM				ROY, K; MITSUGI, K; SIRLIN, S; SHANE, B; SIROTNAK, FM			DIFFERENT ANTIFOLATE-RESISTANT L1210 CELL VARIANTS WITH EITHER INCREASED OR DECREASED FOLYLPOLYGLUTAMATE SYNTHETASE GENE-EXPRESSION AT THE LEVEL OF MESSENGER-RNA TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANALOG TRANSPORT INWARD; METHOTREXATE RESISTANCE; FOLATE TRANSPORT; CYTO-TOXICITY; TUMOR-CELLS; BETA-ACTIN; MOUSE; POLYGLUTAMYLATION; POLYGLUTAMATES; NITROCELLULOSE	L1210 cell variants selected in the presence of the lipophilic dihydrofolate reductase inhibitor, metoprine, expressed increased levels of one-carbon, reduced folate transport inward (Sirotnak, F. M., Moccio, D. M., and Yang, C.-H, (1984) J. Biol. Chem, 259, 13139-13144), Growth of one of these variants (L1210/R69), with metoprine in the presence of decreasing concentrations of 1,L5-CHO-folateH(4) (natural diastereoisomer of B-formyltetrahydrofolate), resulted in the selection of other variants (L1210/R82, R83, and R84) with further reduction in one-carbon, reduced folate transport and in two cases (L1210/R83 and R84) with 3-8-fold increased folylpolyglutamate synthetase (FPGS) activity and folate compound polyglutamate formation in situ, Metoprine resistance was further increased, and the requirement for exogenous folate during growth was decreased as well in these variants, The increase in FPGS activity observed in L1210/R83 and R84 was characterized by 3-and 8-fold increases in value for V-max with no change in K-m and the same increase in a 60-61-kDa protein as shown by immunoblotting, Northern blotting revealed the same increases in these two variants in the level of a 2.3-kilobase FPGS mRNA when compared with control, while Southern blotting of genomic DNA did not reveal any increase in FPGS gene copy number or restriction polymorphisms. Also, no difference in stability of FPGS mRNA was found between parental and variant cells, In contrast, nuclear run-on assays revealed differences among these cell types in the rate of FPGS mRNA transcription that correlated with increased FPGS activity, protein, and mRNA level in the variants, Similar studies with a transport-defective, methotrexate resistant L1210 cell variant (L1210/R25) documented a 2-3-fold decrease in FPGS activity, protein, and mRNA levels that was accounted for by a decrease in FPGS mRNA transcription, These results provide the first examples of constituitively altered transcriptional regulation of FPGS activity associated with acquired resistance to antifolates.	MEM SLOAN KETTERING CANC CTR, MOLEC THERAPEUT LAB, PROGRAM MOLEC PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA; CORNELL UNIV, GRAD SCH MED SCI, NEW YORK, NY 10021 USA; UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	Memorial Sloan Kettering Cancer Center; Cornell University; University of California System; University of California Berkeley					NCI NIH HHS [CA08748, CA56517] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R35CA056517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BARREDO J, 1992, MOL PHARMACOL, V42, P687; BARRUECO JR, 1992, J BIOL CHEM, V267, P15356; CHELLO PL, 1982, BIOCHEM PHARMACOL, V31, P1527, DOI 10.1016/0006-2952(82)90376-8; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; Egan M. G., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P275; EGAN MG, 1995, J BIOL CHEM, V270, P5462, DOI 10.1074/jbc.270.10.5462; FABRE I, 1984, CANCER RES, V44, P3190; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HENDRICK SM, 1984, NATURE, V308, P149; HENGEN PN, 1992, BIOTECHNIQUES, V13, P56; JACKSON RC, 1984, FOLATE ANTAGONISTS T, V1, P290; KISLIUK RL, 1981, MOL CELL BIOCHEM, V39, P331, DOI 10.1007/BF00232583; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; POSER RG, 1981, CANCER RES, V41, P4441; RHEE MS, 1993, CANCER RES, V53, P2227; RUMBERGER BG, 1990, CANCER COMMUN, V2, P305; RUMBERGER BG, 1990, CANCER RES, V50, P4639; SAMUELS LL, 1986, CANCER RES, V46, P2230; SAMUELS LL, 1985, CANCER RES, V45, P1488; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANE B, 1989, VITAM HORM, V45, P263; SHEEHAN JC, 1965, J AM CHEM SOC, V87, P2492, DOI 10.1021/ja01089a034; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SIROTNAK FM, 1985, CANCER RES, V45, P4732; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1984, FOLATE ANTAGONISTS T, V2, P43; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG CH, 1988, J BIOL CHEM, V263, P9703	49	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26918	26922		10.1074/jbc.270.45.26918	http://dx.doi.org/10.1074/jbc.270.45.26918			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592937	hybrid			2022-12-25	WOS:A1995TE58300037
J	GANOZA, MC; CUNNINGHAM, C; GREEN, RM				GANOZA, MC; CUNNINGHAM, C; GREEN, RM			A NEW FACTOR FROM ESCHERICHIA-COLI AFFECTS TRANSLOCATION OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; TRANSLATION; TU; RECONSTRUCTION; PURIFICATION; TERMINATION; RIBOSOME; MODEL; GENE	Reconstitution of protein synthesis from purified translation factors on ribosomes from Escherichia coli has revealed the requirement for a protein, W, that affects chain elongation and is essential to reconstitute the process (Ganoza, M. C., Cunningham, C., and Green, R. M. (1985) Proc, Natl. Acad. Sci. U.S.A. 82, 1648-1652). We report that W has no effect on initiation complex formation by 30 or 70 S ribosomes or on the association of ribosomal subunits, peptide bond synthesis, or binding Ala-tRNA, which is the second amino acid of the coat protein of the MS2 RNA virion. W has a pronounced effect on tripeptide synthesis, and is obligatory for the synthesis of the coat protein or of the hexapeptide encoded by f2am3 RNA, Extracts from a temperature-sensitive mutant of the translocase, EF-G, were purified free of the W protein and were used to score for translocation defects, W is required for binding Ser-tRNA, the third N-terminal amino acid of the MS2 or f2 RNA coat protein to ribosomes bearing fMet-Ala-tRNA, as well as for the ejection of deacyl-tRNA from ribosomes, which occurred concomitant with the binding of the Ser-tRNA. We propose that W functions by ejecting tRNAs from ribosomes in a step that precedes the movement of mRNA during translocation.			GANOZA, MC (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO,ON M5G 1L6,CANADA.			GANOZA MELGAREJO, MICHAEL RICHARD/0000-0003-0196-8104				AOKI H, 1991, NUCLEIC ACIDS RES, V19, P6215, DOI 10.1093/nar/19.22.6215; ARAI KI, 1972, J BIOL CHEM, V247, P7029; CAPECHI M, 1967, BIOCHEM BIOPH RES CO, V28, P173; CHUNG DG, 1990, RIBOSOMES PROTEIN SY, P69; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; GANOZA MC, 1993, EUR J BIOCHEM, V217, P839, DOI 10.1111/j.1432-1033.1993.tb18312.x; GANOZA MC, 1984, J BIOL CHEM, V259, P4101; GANOZA MC, 1985, P NATL ACAD SCI USA, V82, P1648, DOI 10.1073/pnas.82.6.1648; GANOZA MC, 1976, EUR J BIOCHEM, V65, P613, DOI 10.1111/j.1432-1033.1976.tb10379.x; GANOZA MC, 1989, EUR J BIOCHEM, V178, P663, DOI 10.1111/j.1432-1033.1989.tb14496.x; GESTELAND RF, 1966, J MOL BIOL, V16, P67, DOI 10.1016/S0022-2836(66)80263-2; GORDON J, 1971, METHODS ENZYMOL    C, V20, P281; GREEN RH, 1985, BIOCHEM BIOPH RES CO, V126, P792, DOI 10.1016/0006-291X(85)90254-2; Hershey J W, 1979, Methods Enzymol, V60, P3; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V70, P4135; KALTSCHM.E, 1970, ANAL BIOCHEM, V36, P401, DOI 10.1016/0003-2697(70)90376-3; KUNG H, 1977, J BIOL CHEM, V252, P6889; KUNG HF, 1977, ARCH BIOCHEM BIOPHYS, V187, P457; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILJAS A, 1990, RIBOSOME, P309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCASLENARD J, 1974, ENZYMES, V10, P53; Miller D L, 1974, Methods Enzymol, V30, P219; MOAZED D, 1989, NATURE, V242, P142; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; PARKER J, 1989, MICROBIOL REV, V53, P273, DOI 10.1128/MMBR.53.3.273-298.1989; RYOJI M, 1981, J BIOL CHEM, V256, P5798; Sambrook J, 1989, MOL CLONING LABORATO; SUTTLE DP, 1973, BIOCHEM BIOPH RES CO, V51, P376, DOI 10.1016/0006-291X(73)91268-0; TOCCHINIVALENTI.GP, 1969, COLD SPRING HARB SYM, V34, P463; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WEISSBACH H, 1979, RIBOSOMES STRUCTURE, P357	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26377	26381		10.1074/jbc.270.44.26377	http://dx.doi.org/10.1074/jbc.270.44.26377			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592851	hybrid			2022-12-25	WOS:A1995TC97800058
J	WALTNER, M; WEINER, H				WALTNER, M; WEINER, H			CONVERSION OF A NONPROCESSED MITOCHONDRIAL PRECURSOR PROTEIN INTO ONE THAT IS PROCESSED BY THE MITOCHONDRIAL PROCESSING PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ALDEHYDE DEHYDROGENASE; TARGETING PEPTIDES; TRANSLATION SYSTEM; YEAST MITOCHONDRIA; SIGNAL PEPTIDES; BETA-SUBUNIT; IMPORT; PRESEQUENCE; CLEAVAGE	Mitochondrial processing peptidase (MPP) cleaves the signal sequence from a variety of mitochondrial pre cursor proteins. A subset of mitochondrial proteins, including rhodanese and 3-oxoacyl-CoA thiolase, are imported into the matrix space, yet are not processed. Rhodanese signal peptide and translated protein were recognized by MPP, as both were inhibitors of processing. The signal peptide of precursor aldehyde dehydrogenase consists of a helix-linker helix motif but when the RGP linker is removed, processing no longer occurs (Thornton, K., Wang, Y., Weiner, H., and Gorenstein, D. G. (1993) J. Biol. Chem. 268, 19906-19914). Disruption of the helical signal sequence of rhodanese by the addition of the RGP linker did not allow cleavage to occur. However, addition of a putative cleavage site allowed the protein to be processed. The same cleavage site was added to 3-oxoacyl-CoA thiolase, but this protein was still not processed, Thiolase and linker-deleted aldehyde dehydrogenase signal peptides were poor inhibitors of MPP. It can be concluded that both a processing site and the structure surrounding this site are important for MPP recognition.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005812, R37AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00028, AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARAKAWA H, 1990, J BIOCHEM-TOKYO, V107, P160, DOI 10.1093/oxfordjournals.jbchem.a123001; ARAKAWA H, 1987, EMBO J, V6, P1361, DOI 10.1002/j.1460-2075.1987.tb02376.x; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1103; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; GLICK B, 1991, ANNU REV GENET, V25, P21; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; KALOUSEK F, 1992, EMBO J, V8, P2803; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MILLER DM, 1991, J BIOL CHEM, V266, P4686; OU WJ, 1994, J BIOL CHEM, V269, P24673; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PAK YK, 1990, J BIOL CHEM, V265, P14298; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; ROISE D, 1988, J BIOL CHEM, V263, P4509; RYAN MT, 1994, FEBS LETT, V337, P152, DOI 10.1016/0014-5793(94)80263-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1995, BIOPHYS J, V68, P434, DOI 10.1016/S0006-3495(95)80205-5; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5; WANG Y, 1993, J BIOL CHEM, V268, P4759; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	42	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26311	26317		10.1074/jbc.270.44.26311	http://dx.doi.org/10.1074/jbc.270.44.26311			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592841	hybrid			2022-12-25	WOS:A1995TC97800048
J	KASHIWAGI, K; ENDO, H; KOBAYASHI, H; TAKIO, K; IGARASHI, K				KASHIWAGI, K; ENDO, H; KOBAYASHI, H; TAKIO, K; IGARASHI, K			SPERMIDINE-PREFERENTIAL UPTAKE SYSTEM IN ESCHERICHIA-COLI - ATP HYDROLYSIS BY POTA PROTEIN AND ITS ASSOCIATION WITH MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTRESCINE TRANSPORT-SYSTEM; HISTIDINE PERMEASE; NUCLEOTIDE-BINDING; MALTOSE TRANSPORT; PERIPLASMIC PERMEASES; POLYAMINE TRANSPORT; IDENTIFICATION; COMPONENTS; MUTANTS; GENE	PotA protein, one of the components of the spermidine-preferential uptake system in Escherichia coli, was purified to homogeneity, and some of its properties were examined, PotA protein showed Mg2+- and SH-dependent ATPase activity. The specific activity was approximately 400 nmol/min/mg of protein and the K-m value for ATP was 385 mu M. The nature of the ATP binding site was explored by identification of the amino acid residue photoaffinity-labeled with 8-azido-ATP. It was found that 8-azido-ATP was attached to cysteine 26. In the spermidine transport-deficient mutant E. coli NR1596, valine 135 of PotA protein, which is located between two consensus amino acid sequences for nucleotide binding (50-57 and 168-173), was replaced by methionine (Kashiwagi, K., Miyamoto, S., Nukui, E., Kobayashi, H., and Igarashi, It. (1993) J. Biol. Chem. 268, 19358-19363). This mutated PotA protein could be labeled with 8-azido-ATP, but showed very low ATPase activity. To identify which cysteine is involved in the function of potA protein, cysteines 26, 54, and 276 were replaced by alanine, threonine, and alanine, respectively. Among the three mutated PotA proteins, the mutated PotA protein C54T only lost both ATPase and spermidine uptake activities. The results taken together indicate that the adenine portion of ATP interacts with a domain close to the NH2-terminal end of PotA protein, and active centers of ATP hydrolysis are located both within and between the two consensus amino acid sequences for nucleotide binding. Association of PotA protein with membranes was strengthened by the existence of channel forming PotB and PotC proteins. ATPase of PotA protein was inhibited by spermidine, suggesting that uptake inhibition by spermidine may function during this process.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; INST PHYS & CHEM RES,DIV BIOMOLEC CHARACTERIZAT,WAKO,SAITAMA 35001,JAPAN	Chiba University; RIKEN				Igarashi, Kazuei/0000-0003-3751-3187				AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUNNINGHAMRUNDL.S, 1975, J BACTERIOL, V124, P791; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KASHIWAGI K, 1991, J BIOL CHEM, V26, P20922; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MUNRO GF, 1974, J BACTERIOL, V118, P952, DOI 10.1128/JB.118.3.952-963.1974; NEILSEN PJ, 1982, J BIOL CHEM, V257, P12316; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; PEGG AE, 1988, CANCER RES, V48, P759; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1966, J BIOL CHEM, V241, P3714; WALTER C, 1992, J BIOL CHEM, V267, P8863; WATANABE Y, 1981, BIOCH BIPHYS ACTA, V633, P87; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25377	25382		10.1074/jbc.270.43.25377	http://dx.doi.org/10.1074/jbc.270.43.25377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592703	hybrid			2022-12-25	WOS:A1995TB46600019
J	LLOYD, DB; THOMPSON, JF				LLOYD, DB; THOMPSON, JF			TRANSCRIPTIONAL MODULATORS AFFECT IN-VIVO PROTEIN FINDING TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; LEUCINE ZIPPER PROTEIN; BOX-BINDING-PROTEINS; A REDUCTASE; GENE-TRANSCRIPTION; MESSENGER-RNA; HEPG2 CELLS; IDENTIFICATION; SEQUENCE; SITE	Treatment of HepGa cells with known effecters of low density lipoprotein receptor (LDLR) gene expression altered the in vivo pattern of protein-DNA interactions in the promoter. The observed changes are consistent with proteins binding in vivo to the sterol regulatory element (SRE), to Sp1-like sites, as well as 60 other regions. Protein bound to the SRE in all conditions, but the nature of the dimethyl sulfate reactivity changed depending on the physiological state of the cell. Hypermethylation within the SRE of the low density lipoprotein receptor promoter was observed when cells were treated with cholesterol synthesis inhibitors, insulin, or phorbol 12-myristate 13-acetate, suggesting that the SRE regulates this promoter through sterol-independent as well as sterol-dependent mechanisms. No significant changes were observed in binding to the Sp1-like sites, suggesting that differential binding to these sites does not play a role in altered transcription levels. Analysis of the 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter also revealed protections that varied in a cell type-specific manner. Binding to the 3-hydroxy-3-methylglutaryl coenzyme A reductase SRE and putative nuclear factor 1 sites could be observed but varied little in different physiological conditions.	PFIZER INC,DIV CENT RES,DEPT MOLEC SCI,GROTON,CT 06340	Pfizer								AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHEN XR, 1994, ONCOGENE, V9, P3179; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; CUTHBERT JA, 1990, J LIPID RES, V31, P2067; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; ELLSWORTH JL, 1995, J LIPID RES, V36, P383; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIL G, 1988, J BIOL CHEM, V263, P19009; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOIVISTO UM, 1994, P NATL ACAD SCI USA, V91, P10526, DOI 10.1073/pnas.91.22.10526; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURAKAMI H, 1982, P NATL ACAD SCI-BIOL, V79, P1158, DOI 10.1073/pnas.79.4.1158; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; WADE DP, 1989, EUR J BIOCHEM, V181, P727, DOI 10.1111/j.1432-1033.1989.tb14784.x; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	42	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25812	25818		10.1074/jbc.270.43.25812	http://dx.doi.org/10.1074/jbc.270.43.25812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592765	hybrid			2022-12-25	WOS:A1995TB46600082
J	XU, P; ZOT, AS; ZOT, HG				XU, P; ZOT, AS; ZOT, HG			IDENTIFICATION OF ACAN125 AS A MYOSIN-I-BINDING PROTEIN PRESENT WITH MYOSIN-I ON CELLULAR ORGANELLES OF ACANTHAMOEBA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH3 DOMAINS; LOCALIZATION; ACTIN	We have discovered the first protein to bind to a nonfilamentous myosin, aside from actin. This protein, Acan125, is a 125-kDa protein from Acanthamoeba that associates with the SH3 domain of Acanthamoeba myosin-IC and not the SH3 domain of human fodrin. Antibodies raised against Acan125 recognize a single protein of 125 kDa hom a whole cell lysate of Acanthamoeba; antibodies to myosin-I (M1.7 and M1.8) do not recognize Acan125 on the same blot. Double labeling of Acanthamoeba show Acan125 and myosin-I to be present on the same intracellular organelle, most likely amoebastomes. Immunoprecipitation with either anti-myosin-I or anti-Acan125 antibodies coprecipitates both Acan125 and myosin-I from a lysate of Acanthamoeba, demonstrating that Acan125 interacts with native myosin-I.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; BAINES IC, 1989, J CELL BIOL, V111, P1895; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAGAN SJ, 1986, J CELL BIOL, V103, P2121; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MIKI H, 1994, J BIOL CHEM, V269, P5489; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; YONEMURA S, 1992, J CELL SCI, V102, P629; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	35	48	48	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25316	25319		10.1074/jbc.270.43.25316	http://dx.doi.org/10.1074/jbc.270.43.25316			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592689	hybrid			2022-12-25	WOS:A1995TB46600005
J	COUMAILLEAU, P; POELLINGER, L; GUSTAFSSON, JA; WHITELAW, ML				COUMAILLEAU, P; POELLINGER, L; GUSTAFSSON, JA; WHITELAW, ML			DEFINITION OF A MINIMAL DOMAIN OF THE DIOXIN RECEPTOR THAT IS ASSOCIATED WITH HSP90 AND MAINTAINS WILD-TYPE LIGAND-BINDING AFFINITY AND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RAT GLUCOCORTICOID RECEPTORS; LOOP-HELIX PROTEINS; AH-RECEPTOR; NUCLEAR RECEPTORS; ESCHERICHIA-COLI; HORMONE-BINDING; MR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPRESSION	The dioxin receptor is a cytoplasmic basic helix-loop-helix/Per-Arnt-Sim homology (bHLH/PAS) protein known to bind planar polycyclic ligands including polycyclic aromatic hydrocarbons, benzoflavones, heterocyclic amines, and halogenated aromatic hydrocarbons, e.g. dioxins. Ligand-induced activation of the dioxin receptor initiates a process whereby the receptor is transformed into a nuclear transcription factor complex with a specific bHLH/PAS partner protein, Arnt. In analogy to the glucocorticoid receptor, the latent dioxin receptor is found associated with the molecular chaperone hsp90. We have defined and isolated a minimal ligand binding domain of the dioxin receptor from the central PAS region, comprising of amino acids 230 to 421, and found this domain to interact with hsp90 in vitro. Expression of the minimal ligand binding domain in wheat germ lysates or bacteria, systems which harbor hsp90 homologs unable to interact with the glucocorticoid or dioxin receptors, resulted in non-ligand binding forms of this minimal 230 to 421 fragment. Importantly, affinity of the minimal ligand binding domain for dioxin was similar to the affinity inherent in the full-length dioxin receptor, and a profile of ligand structures which specifically bound the minimal ligand binding domain was found to be conserved between this domain and the native receptor. These experiments show that the minimal ligand binding domain maintains the quantitative and qualitative aspects of ligand binding exhibited by the full-length receptor, implying that the central ligand binding pocket may exist to accommodate all classes of specific dioxin receptor ligands, and that this pocket is critically dependent upon hsp90 for its ligand binding conformation.	KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, DEPT BIOSCI, S-14186 HUDDINGE, SWEDEN; KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, DEPT MED NUTR, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet; Karolinska Institutet			coumailleau, pascal/K-1697-2015					ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAAMANO CA, 1993, BIOCHEMISTRY-US, V32, P8589, DOI 10.1021/bi00084a028; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHENG L, 1994, J BIOL CHEM, V269, P18662; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; EMA M, 1994, J BIOL CHEM, V269, P27337; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; FRANKS RG, 1994, MECH DEVELOP, V45, P269, DOI 10.1016/0925-4773(94)90013-2; GILLNER M, 1993, MOL PHARMACOL, V44, P336; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRADIN K, 1994, J BIOL CHEM, V269, P23800; HANKINSON O, 1994, TRENDS ENDOCRIN MET, V5, P240, DOI 10.1016/1043-2760(94)P3082-I; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; JAIN S, 1994, J BIOL CHEM, V269, P31518; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LI H, 1994, J BIOL CHEM, V269, P28098; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OHARANEMOTO Y, 1990, J STEROID BIOCHEM, V37, P481, DOI 10.1016/0960-0760(90)90391-W; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Sambrook J, 1989, MOL CLONING LABORATO; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WHITLOCK JP, 1994, TRENDS ENDOCRIN MET, V5, P183, DOI 10.1016/1043-2760(94)90075-2; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	63	137	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25291	25300		10.1074/jbc.270.42.25291	http://dx.doi.org/10.1074/jbc.270.42.25291			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559670	hybrid			2022-12-25	WOS:A1995TB46500104
J	EASON, MG; LIGGETT, SB				EASON, MG; LIGGETT, SB			IDENTIFICATION OF A G(S) COUPLING DOMAIN IN THE AMINO-TERMINUS OF THE 3RD INTRACELLULAR LOOP OF THE ALPHA(2A)-ADRENERGIC RECEPTOR - EVIDENCE FOR DISTINCT STRUCTURAL DETERMINANTS THAT CONFER G(S) VERSUS G(I) COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; NUCLEOTIDE-BINDING PROTEINS; BETA-ADRENERGIC-RECEPTOR; HAMSTER OVARY CELLS; ALPHA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; PHOSPHATIDYLINOSITOL HYDROLYSIS; ALPHA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; ACTIVATION	alpha(2)-Adrenergic receptors (alpha(2)AR) functionally couple not only to Gi but also to G(5). We investigated the aminoterminal portion of the third intracellular loop of the human alpha(2A)R ((alpha 2)C10) for potential G(s) coupling domains using site directed mutagenesis and recombinant expression in several different cell types. A deletion mutant and four chimeric receptors consisting of the alpha(2A)R with the analogous sequence from the 5-HT1A receptor (a G(i)-coupled receptor) and the beta(2)AR (a G(s)-coupled receptor) were expressed in Chinese hamster ovary cells, Chinese hamster fibroblasts, or COS-7 cells and examined for their ability to mediate stimulation or inhibition of membrane adenylyl cyclase activity or whole cell cAMP accumulation. In stably expressing Chinese hamster ovary cells, deletion of amino acids 221-231, which are in close proximity to the fifth transmembrane domain, eliminated alpha(2)C10-mediated stimulation of adenylyl cyclase activity, while alpha(2)C10-mediated inhibition was only moderately affected. This suggested that this region is important for G(s) coupling, prompting construction of the chimeric receptor mutants. Substitution of amino acids 218-235 with 5-HT1A receptor sequence entirely ablated agonist-promoted G(s) coupling, as compared with a 338 +/- 29% stimulation of adenylyl cyclase activity observed with the wild-type alpha(2)C10. In contrast, G(i) coupling for this mutant remained fully intact (57 +/- 2% versus 52 +/- 1% inhibition for wild-type alpha(2)C10). Similar substitution with beta(2)AR sequence had no effect on G(i) coupling but did reduce G(s) coupling. Two additional mutated alpha(2)C10 containing smaller substitutions of the amino-terminal region with 5-HT1A receptor sequence at residues 218-228 or 229-235 were then studied. While G(i) coupling remained intact with both mutants, G(s) coupling was ablated in the former but not the latter mutant receptor. Similar results were obtained using transfected Chinese hamster fibroblasts (which exclusively display alpha(2)AR-G(i) coupling) and COS-7 cells (which exclusively display alpha(2)AR-G(s) coupling). Thus, a critical determinant for G(s) coupling is contained within 11 amino acids (218-228) of the amino-terminal region of the third intracellular loop localized directly adjacent to the fifth transmembrane domain. `	UNIV CINCINNATI,COLL MED,DEPT MED PULM,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496, HL53436] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL053436] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUML K, 1994, P NATL ACAD SCI USA, V269, P7980; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CRUCIANI RA, 1993, P NATL ACAD SCI USA, V90, P3019, DOI 10.1073/pnas.90.7.3019; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1994, MOL PHARMACOL, V45, P696; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HERSHBERGER RE, 1994, ENDOCRINOLOGY, V134, P1277, DOI 10.1210/en.134.3.1277; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; JONES SB, 1991, MOL PHARMACOL, V39, P239; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MALEK D, 1993, FEBS LETT, V325, P215; OCARROLL AM, 1994, MOL PHARMACOL, V46, P291; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PEPPERL DJ, 1993, MOL PHARMACOL, V44, P802; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; VANSANDE J, 1993, EUR J PHARM-MOLEC PH, V247, P177, DOI 10.1016/0922-4106(93)90075-K; VARRAULT A, 1994, J BIOL CHEM, V269, P16720; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V269, P6219; YAMADA M, 1994, MOL PHARMACOL, V46, P470	47	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24753	24760		10.1074/jbc.270.42.24753	http://dx.doi.org/10.1074/jbc.270.42.24753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559592	hybrid			2022-12-25	WOS:A1995TB46500026
J	GRUENKE, LD; KONOPKA, K; CADIEU, M; WASKELL, L				GRUENKE, LD; KONOPKA, K; CADIEU, M; WASKELL, L			THE STOICHIOMETRY OF THE CYTOCHROME P-450-CATALYZED METABOLISM OF METHOXYFLURANE AND BENZPHETAMINE IN THE PRESENCE AND ABSENCE OF CYTOCHROME B(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; NUCLEAR MAGNETIC-RESONANCE; RABBIT LIVER; CATALYTIC ACTIVITY; OXYGEN ACTIVATION; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; RAT-LIVER; HYDROXYLATION; OXIDATION	The complete stoichiometry of the metabolism of the cytochrome b(5) (cyt b(5))-requiring substrate, methoxyflurane, by purified cytochrome P-450 2B4 was compared to that of another substrate, benzphetamine, which does not require cyt b(5) for its metabolism. Cyt b(5) invariably improved the efficiency of product formation. That is, in the presence of cyt b(5) a greater percentage of the reducing equivalents from NADPH were utilized to generate substrate metabolites, primarily at the expense of the side product, superoxide. With methoxyflurane, cyt b(5) addition always resulted in an increased rate of product formation, while with benzphetamine the rate of product formation remained unchanged, increased or decreased. The apparently contradictory observations of increased reaction efficiency but decrease in total product formation for benzphetamine can be explained by a second effect of cyt b(5). Under some experimental conditions cyt b(5) inhibits total NADPH consumption. Whether stimulation, inhibition, or no change in product formation is observed in the presence of cyt b(5) depends on the net effect of the stimulatory and inhibitory effects of cyt b(5). When total NADPH consumption is inhibited by cyt b(5), the rapidly metabolized, highly coupled (congruent to 50%) substrate, benzphetamine, undergoes a net decrease in metabolism not counterbalanced by the increase in the efficiency (2-20%) of the reaction. In contrast, in the presence of the slowly metabolized, poorly coupled (congruent to 0.5-3%) substrate, methoxyflurane, inhibition of total NADPH consumption by cyt b(5) was never sufficient to overcome the stimulation of product formation due to an increase in efficiency of the reaction.	UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; VET ADM MED CTR,DEPT ANESTHESIA,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; ATKINS WM, 1987, J AM CHEM SOC, V109, P3754, DOI 10.1021/ja00246a038; BONFILS C, 1981, J BIOL CHEM, V256, P9457; BOSTERLING B, 1982, J BIOL CHEM, V257, P4375; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNSTROM A, 1980, BIOCHEM BIOPH RES CO, V95, P431, DOI 10.1016/0006-291X(80)90756-1; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CANOVADAVIS E, 1985, BIOCHEM PHARMACOL, V34, P1907, DOI 10.1016/0006-2952(85)90307-7; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; CAUSEY KM, 1990, MOL PHARMACOL, V38, P134; CHIANG JYL, 1981, ARCH BIOCHEM BIOPHYS, V211, P662, DOI 10.1016/0003-9861(81)90502-6; CINTI DL, 1972, BIOCHEM PHARMACOL, V21, P3249, DOI 10.1016/0006-2952(72)90089-5; COLLINS JR, 1988, J BIOL CHEM, V263, P3164; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIEDEMANN TE, 1957, METHOD ENZYMOL, V3, P414, DOI 10.1016/S0076-6879(57)03406-0; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GORSKY LD, 1986, DRUG METAB DISPOS, V14, P89; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HEINEMEYER G, 1980, N-S ARCH PHARMACOL, V314, P201, DOI 10.1007/BF00504539; HOFFMAN J, 1989, BRIT J ANAESTH, V63, P103, DOI 10.1093/bja/63.1.103; HOLADAY DA, 1970, ANESTHESIOLOGY, V33, P579, DOI 10.1097/00000542-197012000-00001; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; INGELMANSUNDBER.M, 1980, BIOCHEM BIOPH RES CO, V97, P582; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; KUTHAN H, 1978, FEBS LETT, V91, P343, DOI 10.1016/0014-5793(78)81206-X; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD TL, 1989, BIOCHEMISTRY-US, V28, P2071, DOI 10.1021/bi00431a016; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MORGAN ET, 1982, J BIOL CHEM, V257, P3951; MORGAN ET, 1984, DRUG METAB DISPOS, V12, P358; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NORDBLOM GD, 1977, ARCH BIOCHEM BIOPHYS, V180, P343, DOI 10.1016/0003-9861(77)90047-9; OKITA RT, 1981, J BIOL CHEM, V256, P5961; OMURA T, 1964, J BIOL CHEM, V239, P2370; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; OVENSTON TCJ, 1949, ANAL CHIM ACTA, V3, P277, DOI 10.1016/S0003-2670(00)87341-9; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PEYRONNEAU MA, 1992, EUR J BIOCHEM, V207, P109, DOI 10.1111/j.1432-1033.1992.tb17027.x; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; RAAG R, 1993, BIOCHEMISTRY-US, V32, P4571, DOI 10.1021/bi00068a013; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SCHWARZ D, 1984, BIOMED BIOCHIM ACTA, V43, P295; SELINSKY BS, 1988, MOL PHARMACOL, V33, P567; SELINSKY BS, 1988, MOL PHARMACOL, V33, P559; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; SWINNEY DC, 1994, BIOCHEMISTRY-US, V33, P2185, DOI 10.1021/bi00174a027; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TRETYACHENKOLAD.VG, 1993, BIOCHIM BIOPHYS ACTA, V1153, P163; VATSIS KP, 1982, J BIOL CHEM, V257, P1221; WASKELL L, 1982, ANESTH ANALG, V61, P609; WHITE RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P493, DOI 10.1016/0003-9861(84)90015-8; WHITE RE, 1986, J AM CHEM SOC, V108, P6024, DOI 10.1021/ja00279a059; WHITE RE, 1991, PHARMACOL THERAPEUT, V49, P21, DOI 10.1016/0163-7258(91)90020-M; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WINSTON GW, 1983, J BIOL CHEM, V258, P1508; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZHUKOV AA, 1982, BIOCHEM BIOPH RES CO, V109, P813, DOI 10.1016/0006-291X(82)92012-5	67	81	85	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24707	24718		10.1074/jbc.270.42.24707	http://dx.doi.org/10.1074/jbc.270.42.24707			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559586	hybrid			2022-12-25	WOS:A1995TB46500020
J	HERSHEY, JC; HAUTMANN, M; THOMPSON, MM; ROTHBLUM, LI; HAYSTEAD, TAJ; OWENS, GK				HERSHEY, JC; HAUTMANN, M; THOMPSON, MM; ROTHBLUM, LI; HAYSTEAD, TAJ; OWENS, GK			ANGIOTENSIN-II-INDUCED HYPERTROPHY OF RAT VASCULAR SMOOTH-MUSCLE IS ASSOCIATED WITH INCREASED 18S RIBOSOMAL-RNA SYNTHESIS AND PHOSPHORYLATION OF THE RIBOSOMAL-RNA TRANSCRIPTION FACTOR, UPSTREAM BINDING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RAT; ACTIN MESSENGER-RNA; GROWTH-FACTOR-BETA; CASEIN KINASE-II; PROTEIN-SYNTHESIS; DNA-BINDING; ALPHA-ACTIN; FACTOR HUBF; FACTOR UBF; CELLS	Hypertrophy of vascular smooth muscle cells (VSMC) is an important adaptive response of hypertension. Drug intervention studies have implicated a role for angiotensin II (A-II) in the mediation of VSMC hypertrophy in vivo, and A-II is a potent hypertrophic agent for VSMC in culture. Our laboratory has previously shown that A-II-induced hypertrophy of cultured VSMC is due in part to generalized increases in protein synthesis and increased content of rRNA. The aim of the present study was to determine if A-II stimulates rRNA gene synthesis and whether the rRNA transcription factor, upstream binding factor (UBF), is involved. Nuclear run-on analysis demonstrated that A-II induced a greater than 5-fold increase in rRNA gene synthesis within 6 h of stimulation. A-II also stimulated a rapid increase in UBF phosphorylation as well as nucleolar localization, but no changes in the content of UBF. Phosphoamino acid analysis showed that phosphorylation occurred only on serine residue(s). Results demonstrate that increased transcription of ribosomal DNA contributes to the A-II-induced increase in protein synthesis and VSMC hypertrophy, and suggest that an important regulatory event in this pathway may be the phosphorylation and/or nucleolar localization of UBF.	UNIV VIRGINIA, SCH MED, DEPT MOLEC PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA	University of Virginia; University of Virginia					NHLBI NIH HHS [P01 HL19242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALKJAER C, 1989, J HYPERTENS, V7, P305; AZUMA H, 1992, BRIT J PHARMACOL, V106, P665, DOI 10.1111/j.1476-5381.1992.tb14392.x; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1987, J BIOL CHEM, V262, P5057; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GARIEPY J, 1993, HYPERTENSION, V22, P111, DOI 10.1161/01.HYP.22.1.111; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; HAHN AWA, 1991, BIOCHEM BIOPH RES CO, V178, P1451, DOI 10.1016/0006-291X(91)91056-I; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; LICHTENSTEIN AH, 1986, HYPERTENSION, V8, P50; MONICAL PL, 1993, AM J PHYSIOL, V264, pC1466, DOI 10.1152/ajpcell.1993.264.6.C1466; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; OWENS GK, 1987, HYPERTENSION, V9, P178, DOI 10.1161/01.HYP.9.2.178; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1991, CELLULAR ASPECTS HYP; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROSE KM, 1981, P NATL ACAD SCI-BIOL, V78, P2833, DOI 10.1073/pnas.78.5.2833; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; ROUSSEL P, 1993, J CELL SCI, V104, P327; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; SMITH JB, 1984, P NATL ACAD SCI-BIOL, V81, P7812, DOI 10.1073/pnas.81.24.7812; STOUFFER GA, 1993, AM J PHYSIOL, V264, pC390, DOI 10.1152/ajpcell.1993.264.2.C390; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WOLINSKY H, 1970, CIRC RES, V26, P507, DOI 10.1161/01.RES.26.4.507	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25096	25101		10.1074/jbc.270.42.25096	http://dx.doi.org/10.1074/jbc.270.42.25096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559641	hybrid			2022-12-25	WOS:A1995TB46500075
J	KNUTSON, VP; DONNELLY, PV; BALBA, Y; LOPEZREYES, M				KNUTSON, VP; DONNELLY, PV; BALBA, Y; LOPEZREYES, M			INSULIN-RESISTANCE IS MEDIATED BY A PROTEOLYTIC FRAGMENT OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DOWN-REGULATION; SKELETAL-MUSCLE; TYROSINE KINASE; GENE; PHOSPHORYLATION; MUTATION; NIDDM; AUTOPHOSPHORYLATION; ADIPOCYTES; EXPRESSION	Insulin resistance is a common clinical feature of obesity and non-insulin-dependent diabetes mellitus, and is characterized by elevated serum levels of glucose, insulin, and lipids. The mechanism by which insulin resistance is acquired is unknown. We have previously demonstrated that upon chronic treatment of fibroblasts with insulin, conditions that mimic the hyperinsulinemia associated with insulin resistance, the membrane-associated insulin receptor beta subunit is proteolytically cleaved, resulting in the generation of a cytosolic fragment of the beta subunit, beta', and that the generation of beta' is inhibited by the thiol protease inhibitor E64 (Knutson, V. P. (1991) J. Biol. Chem. 266, 15656-15662). In this report, we demonstrate that in 3T3-L1 adipocytes: 1) cytosolic beta' is generated by chronic insulin administration to the cells, and that E64 inhibits the production of beta'; 2) chronic administration of insulin to the adipocytes leads to an insulin-resistant state, as measured by lipogenesis and glycogen synthesis, and E64 totally prevents the generation of this insulin-induced cellular insulin resistance; 3) E64 has no effect on the insulin-induced down-regulation of insulin receptor substrate-1, and therefore insulin resistance is not mediated by the down-regulation of insulin receptor substrate-1; 4) under in vitro conditions, partially purified beta' stoichiometrically inhibits the insulin-induced autophosphorylation of the insulin receptor beta subunit; and 5) administration of E64 to obese Zucker fatty rats improves the insulin resistance of the rats compared to saline-treated animals. These data indicate that beta' is a mediator of insulin resistance, and the mechanism of action of beta' is the inhibition of the insulin induced autophosphorylation of the beta subunit of the insulin receptor.			KNUTSON, VP (corresponding author), UNIV TEXAS, SCH MED, DEPT PHARMACOL, 6431 FANNIN, POB 20708, HOUSTON, TX 77225 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035397] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35397] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAR RS, 1976, J CLIN INVEST, V58, P1123, DOI 10.1172/JCI108565; BRILLON DJ, 1989, DIABETES, V38, P397, DOI 10.2337/diabetes.38.3.397; CAMA A, 1990, J CLIN ENDOCR METAB, V70, P1155, DOI 10.1210/jcem-70-4-1155; CARO JF, 1989, DIABETES METAB REV, V5, P665, DOI 10.1002/dmr.5610050804; COBB MH, 1989, J BIOL CHEM, V264, P18701; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; ELBEIN SC, 1991, DIABETOLOGIA, V34, P742, DOI 10.1007/BF00401521; ELLIS L, 1990, MOL ENDORCINOL, V1, P15; HARING HU, 1991, DIABETOLOGIA, V34, P848, DOI 10.1007/BF00400192; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156; IMANO E, 1991, DIABETES, V40, P548, DOI 10.2337/diabetes.40.5.548; Johnson, 1990, ILAR NEWS, V32, P4, DOI [DOI 10.1093/ILAR.32.3.4, 10.1093/ilar.32.3.4]; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KASISKE BL, 1992, HYPERTENSION, V19, pI110, DOI 10.1161/01.HYP.19.1_Suppl.I110; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KNUTSON VP, 1986, J BIOL CHEM, V261, P306; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KNUTSON VP, 1991, J BIOL CHEM, V266, P15656; KNUTSON VP, 1991, ARCH BIOCHEM BIOPHYS, V285, P197, DOI 10.1016/0003-9861(91)90349-N; KOSMAKOS FC, 1980, J BIOL CHEM, V255, P9860; KRIAUCIUNAS KM, 1988, J CLIN ENDOCR METAB, V67, P1284, DOI 10.1210/jcem-67-6-1284; KRUPP M, 1981, J BIOL CHEM, V256, P1689; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LONGO N, 1992, AM J HUM GENET, V50, P998; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MOLLER DE, 1989, DIABETES, V38, P1496, DOI 10.2337/diabetes.38.11.1496; MULLERWIELAND D, 1989, DIABETES, V38, P31, DOI 10.2337/diabetes.38.1.31; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; OJAMAA K, 1988, MOL ENDOCRINOL, V2, P242, DOI 10.1210/mend-2-3-242; ORAHILLY S, 1992, CLIN ENDOCRINOL, V36, P121, DOI 10.1111/j.1365-2265.1992.tb00945.x; ORAHILLY S, 1991, DIABETES, V40, P777, DOI 10.2337/diabetes.40.6.777; Peterson R.G., 1990, ILAR NEWS, V32, P16, DOI [10.1093/ilar.32.3.16, DOI 10.1093/ILAR.32.3.16, DOI 10.1093/ILAR.32.3.16)]; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SOLL AH, 1975, J CLIN INVEST, V56, P769, DOI 10.1172/JCI108155; SOWERS JR, 1992, J CLIN PHARMACOL, V32, P529, DOI 10.1177/009127009203200607; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAYLOR SI, 1991, ADV EXP MED BIOL, V293, P197; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	48	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24972	24981		10.1074/jbc.270.42.24972	http://dx.doi.org/10.1074/jbc.270.42.24972			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559625	hybrid			2022-12-25	WOS:A1995TB46500059
J	MANSER, E; CHONG, C; ZHAO, ZS; LEUNG, T; MICHAEL, G; HALL, C; LIM, L				MANSER, E; CHONG, C; ZHAO, ZS; LEUNG, T; MICHAEL, G; HALL, C; LIM, L			MOLECULAR-CLONING OF A NEW MEMBER OF THE P21-CDC42/RAC-ACTIVATED KINASE (PAK) FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; ACTIVATING PROTEIN; HUMAN HOMOLOG; IN-VITRO; GENE; RAS; CHIMAERIN; SEQUENCE; P21RAC; G25K	A number of ''target'' proteins for the Rho family of small GTP-binding proteins have now been identified, including the protein kinases ACK and p65(PAK) (Manser, E., Leung, T., Salihuddin, H., Zhao, Z.-S., and Lim, L. (1994) Nature 367, 40-46). The purified serine/threonine kinase p65(PAK) has been shown to be directly activated by GTP-Rac1 or GTP-Cdc42. Here we report the cDNA sequence encoding a new brain-enriched PAK isoform beta-PAK, which shares 79% amino acid identity with the previously described alpha-isoform. Their mRNAs are differentially expressed in the brain, with alpha-PAK mRNA being particularly abundant in motor-associated regions. In vitro translation products of the alpha- and beta-PAK cDNAs exhibited relative molecular masses of 68,000 and 65,000, respectively, by SDS-polyacrylamide analysis. A specific beta-PAK peptide sequence was obtained from rat brain-purified p65(PAK). Recombinant alpha- and beta-PAKs exhibited an increase in kinase activity mediated by GTP-p21 induced autophosphorylation. Cdc42 was a more potent activator in vitro of alpha-PAK kinase, and the fully activated enzyme is 300 times more active than the unphosphorylated form. Interestingly the down-regulation in the binding of p21s to recombinant beta-PAK and brain p65(PAK), which is observed upon kinase activation does not occur with recombinant alpha-PAK.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,GLAXO IMCB LAB,SINGAPORE 0511,SINGAPORE; INST NEUROL,DEPT NEUROCHEM,LONDON WC1N 1PJ,ENGLAND	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London			Hall, Christine/C-8390-2009; Manser, Edward/ABD-2301-2020					AHMED S, 1993, J BIOL CHEM, V268, P10709; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEEBURG PH, 1977, CELL, V12, P157, DOI 10.1016/0092-8674(77)90193-3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307	30	215	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25070	25078		10.1074/jbc.270.42.25070	http://dx.doi.org/10.1074/jbc.270.42.25070			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559638	hybrid			2022-12-25	WOS:A1995TB46500072
J	ZHOU, Y; ROVERE, C; KITABGI, P; LINDBERG, I				ZHOU, Y; ROVERE, C; KITABGI, P; LINDBERG, I			MUTATIONAL ANALYSIS OF PC1 (SPC3) IN PC12 CELLS - 66-KDA PC1 IS FULLY FUNCTIONAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTASE PC1; NEUROMEDIN-N; PROHORMONE; NEUROTENSIN; IDENTIFICATION; PRECURSOR; SEQUENCE; LINE; GENE; RNA	The proteinase mPC1, a neuroendocrine member of the mammalian family of subtilisin-like enzymes, has previously been shown to be converted to a carboxyl-terminally truncated 66-kDa form during transport through the secretory pathway. The cleavage site and the function of this carboxyl-terminal truncation event are unknown. We have performed site-directed mutagenesis of two paired basic sites in the mPC1 carboxyl-terminal tail and expressed these constructs in PC12 cells, a rat pheochromocytoma known to lack endogenous PC1. We found that the most likely site for the truncation event was at Arg(590)-Arg(591) since mutation of this site to Lys-His prevented processing of 87-kDa PC1. APC1 mutant carboxyl-terminally truncated at this site and expressed in PC12 cells was efficiently routed to the secretory pathway and stored in secretory granules, indicating that the carboxyl-terminal extension is not required for sorting of this enzyme. The function of the various PC1 constructs was assessed by analyzing proneurotensin cleavage to various forms. The carboxyl-terminally truncated PC1 mutant was found to perform most of the cleavages of this precursor as well as wild-type PC1; however, the blockade mutant processed proneurotensin much less efficiently, Differences between the site preferences of the various enzymes were noted. Our results support the notion that carboxyl terminal processing of PC1 serves to regulate PC1 activity.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70112 USA; CNRS, INST PHARMACOL, F-06560 VALBONNE, FRANCE	Louisiana State University System; Centre National de la Recherche Scientifique (CNRS)			Rovere-Jovene, Carole/O-4557-2016; Lindberg, Iris/Q-3825-2019	Rovere-Jovene, Carole/0000-0001-9400-7972; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA005084, DA 05084, R56 DA005084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; CARRAWAY RE, 1993, PEPTIDES, V14, P991, DOI 10.1016/0196-9781(93)90076-S; CHUN JY, 1994, NEURON, V12, P831, DOI 10.1016/0896-6273(94)90336-0; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P614, DOI 10.1006/mcne.1994.1075; Lindberg I., 1995, METH NEUROSCI, V23, P94; LOH YP, 1992, MECHANISMS INTRACELL, P181; MILGRAM SL, 1994, J CELL SCI, V107, P737; PALMER DJ, 1992, J BIOL CHEM, V267, P19806; ROTH WW, 1993, ENDOCRINOL J, V1, P131; ROVERE C, 1993, PEPTIDES, V14, P983, DOI 10.1016/0196-9781(93)90075-R; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SEIDAH NG, 1992, DNA CELL BIOL, V11, P283, DOI 10.1089/dna.1992.11.283; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhou A., 1994, Society for Neuroscience Abstracts, V20, P447; ZHOU Y, 1994, ZHOU, V269, P18408	27	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24702	24706		10.1074/jbc.270.42.24702	http://dx.doi.org/10.1074/jbc.270.42.24702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559585	hybrid			2022-12-25	WOS:A1995TB46500019
J	AHMED, MU; HAZEKI, K; HAZEKI, O; KATADA, T; UI, M				AHMED, MU; HAZEKI, K; HAZEKI, O; KATADA, T; UI, M			CYCLIC AMP-INCREASING AGENTS INTERFERE WITH CHEMOATTRACTANT INDUCED RESPIRATORY BURST IN NEUTROPHILS AS A RESULT OF THE INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE RATHER THAN RECEPTOR-OPERATED CA2+ INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; INDUCED TYROSINE PHOSPHORYLATION; GUINEA-PIG NEUTROPHILS; CHEMOTACTIC PEPTIDE; MAP KINASE; ADP-RIBOSYLATION; PERTUSSIS TOXIN; BINDING PROTEIN; HL-60 CELLS; CAMP	Superoxide anion and arachidonic acid were pro duced in guinea pig neutrophils in response to a chemotactic peptide formyl-methionyl leucyl-phenylalanine (fMLP). Both responses were markedly, but the former response to a phorbol ester was not at all, inhibited when the cellular cAMP level was raised by prostaglandin E(1) combined with a cAMP phosphodiesterase inhibitor. Increasing cAMP was also inhibitory to fMLP-induced activation of phosphatidylinositol (PI) 3-kinase and Ca2+ influx without any effect on the cation mobilization from intracellular stores. The fMLP-induced respiratory burst was abolished when PI 3-kinase was inhibited by wortmannin or LY294002, but was not affected when Ca2+ influx was inhibited. On the contrary, fMLP released arachidonic acid from the cells treated with the PI 3-kinase inhibitors as well as from nontreated cells, but it did not so when cellular Ca2+ uptake was prevented. The chemotactic peptide activated PI 3-kinase even in cells in which the receptor-mediated intracellular Ca2+ mobilization and respiratory burst were both abolished by exposure of the cells to a permeable Ca2+-chelating agent. Thus, stimulation of fMLP receptors gave rise to dual effects, activation of PI 3-kinase and intracellular Ca2+ mobilization; both effects were necessary for the fMLP-induced respiratory burst. Increasing cellular cAMP inhibited the respiratory burst and arachidonic acid release as a result of the inhibitions of PI 3-kinase and Ca2+ influx, respectively, in fMLP-treated neutrophils.	INST PHYS & CHEM RES,UI LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ASAHI M, 1993, J BIOL CHEM, V268, P23334; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DETOGNI P, 1984, BIOCHEM J, V224, P629, DOI 10.1042/bj2240629; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DONI MG, 1994, BIOCHEM J, V303, P599, DOI 10.1042/bj3030599; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; DUSI S, 1994, BIOCHEM J, V304, P243, DOI 10.1042/bj3040243; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LYNCH JW, 1994, J BIOL CHEM, V269, P8226; MONTERO M, 1993, J BIOL CHEM, V268, P26911; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; OHTA H, 1985, J BIOL CHEM, V260, P5771; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; PARK DG, 1993, J BIOL CHEM, V268, P4573; PYNE NJ, 1994, BIOCHEM J, V304, P611, DOI 10.1042/bj3040611; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UI M, 1986, RECEPTOR BIOCH METHO, P163; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG Y, 1994, J BIOL CHEM, V269, P18727	62	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23816	23822		10.1074/jbc.270.40.23816	http://dx.doi.org/10.1074/jbc.270.40.23816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559558	hybrid			2022-12-25	WOS:A1995RY90900087
J	DAMEN, JE; CUTLER, RL; JIAO, HY; YI, TL; KRYSTAL, G				DAMEN, JE; CUTLER, RL; JIAO, HY; YI, TL; KRYSTAL, G			PHOSPHORYLATION OF TYROSINE-503 IN THE ERYTHROPOIETIN RECEPTOR (EPR) IS ESSENTIAL FOR BINDING THE P85 SUBUNIT OF PHOSPHATIDYLINOSITOL (PI)-3-KINASE AND FOR EPR-ASSOCIATED PI-3-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; BOVINE BRAIN; CELL-LINE; PROTEIN; DOMAINS; EXPRESSION; FAMILY; GRB2; JAK2; SHC	We recently reported that phosphatidylinositol (PI) 3-kinase becomes associated with the activated erythropoietin receptor (EpR), most likely through the Src homology 2 (SH2) domains within the p85 subunit of PI-3 kinase and one or more phosphorylated tyrosines within the EpR, We have now investigated this interaction in more detail and have found, based on both blotting studies with glutathione S-transferase-p85-SH2 fusion proteins and binding of these fusion proteins to SDS-denatured EpRs, that this binding is direct, Moreover, both in vitro competition studies, involving phosphorylated peptides corresponding to the amino acid sequences flanking the eight tyrosines within the intracellular domain of the EpR, and in vivo studies with mutant EpRs bearing tyrosine to phenylalanine substitutions, indicate that phosphorylation of Tyr(503) within the EPR is essential for the binding of PI 3-kinase, The presence of PI 3-kinase activity in EpR immunoprecipitates from DA-3 cells infected with wild-type but not Y503F EpRs confirms this finding, Our results demonstrate that the SH2 domains of p85 can bind, in addition to their well established Tyr-Met/Val-X-Met consensus binding sequence, a Tyr-Val-Ala Cys motif that is present in the EpR, A comparison of erythropoietin-induced tyrosine phosphorylations and proliferation of wild-type and Y503F EpR-infected DA-3 cells revealed no differences, However, the PI-3 kinase inhibitor, wortmannin, markedly inhibited the erythropoietin-induced proliferation of both cell types, suggesting that PI 3-kinase is activated in Y503F EpR expressing cells, This was confirmed by carrying out PI 3-kinase assays with anti-phosphotyrosine immunoprecipitates from erythropoietin-stimulated Y503F EpR-infected DA-3 cells and suggested that PI 3-kinase has a role in regulating erythropoietin-induced proliferation, but at a site distinct from the EpR.	BRITISH COLUMBIA CANC RES CTR, TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA; CLEVELAND CLIN, RES INST, DEPT CANC BIOL, CLEVELAND, OH 44195 USA	British Columbia Cancer Agency; Cleveland Clinic Foundation				Krystal, Gerald/0000-0002-1961-6281				ANDREA AD, 1989, CELL, V57, P277; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOULD GW, 1994, J BIOL CHEM, V269, P26622; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARPUR AG, 1992, ONCOGENE, V7, P1347; HE TC, 1993, BLOOD, V82, P3530; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JAO R, 1995, SCIENCE, V267, P2003; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOMATSU N, 1992, BLOOD, V80, P53; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KRANTZ SB, 1991, BLOOD, V77, P419; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAM K, 1994, J BIOL CHEM, V269, P20648; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, J BIOL CHEM, V269, P614; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; POWIS G, 1994, CANCER RES, V54, P2419; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOGNUM AW, 1990, BLOOD, V76, P697; WOGNUM AW, 1992, BLOOD, V79, P642; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	115	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23402	23408		10.1074/jbc.270.40.23402	http://dx.doi.org/10.1074/jbc.270.40.23402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559499	hybrid			2022-12-25	WOS:A1995RY90900028
J	FOLKERS, GE; VANHEERDE, EC; VANDERSAAG, PT				FOLKERS, GE; VANHEERDE, EC; VANDERSAAG, PT			ACTIVATION FUNCTION-1 OF RETINOIC ACID RECEPTOR BETA-2 IS AN ACIDIC ACTIVATOR RESEMBLING VP16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR-TFIIB; HUMAN ESTROGEN-RECEPTOR; DOMAIN; PHOSPHORYLATION; PROTEIN; BINDING; IMMUNODETECTION; YEAST; ALPHA	The mechanisms underlying transcriptional activation are not very well understood, and knowledge is based on experiments with a small number of mostly viral activators. We have investigated the mechanism underlying transactivation by the activation domain present in the N-terminal part of retinoic acid receptor (RAR) beta 2 (AF-1), We show that RAR beta 2 phosphorylation is not crucial for its activity although it may modulate AF-1 activity, Sequential mutation of the negatively charged residues (Asp) resulted in a stepwise decrease in activity, while mutation of all aspartic acid residues resulted in complete loss of activity, Comparison of the critical region for activation with other activators revealed moderate homology with the viral activator VP16., The hydrophobic amino acids surrounding the negatively charged residues reported to be critical for activation by VP16 are all conserved in AF-1, The hydrophobic residues are required for AF-1, since mutation of these residues resulted in a decrease in activity, Furthermore, the activity of this activator, VP16 and TA(1) of RelA, is squelched by overexpression of an AF-1-containing expression construct, indicating that AF-1 is an acidic activator, Squelching experiments further indicate that AF-1 and AF-2 function by different mechanisms, Comparison of activation functions present in the AB region of other members of the steroid/thyroid hormone receptor family: RAR alpha 2, RAR gamma 2, and GR suggested that also these receptors contain an acidic activation domain, The mechanism underlying activation by AF-1 is discussed.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)			Folkers, Gert E/C-2863-2009	Folkers, Gert E/0000-0003-1070-0505				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DDAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P288; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HOEFFLER WK, 1994, NUCLEIC ACIDS RES, V22, P1305, DOI 10.1093/nar/22.7.1305; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INGLES CJ, 1991, NATURE, V365, P588; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KRUYT FAE, 1993, MOL ENDOCRINOL, V7, P604, DOI 10.1210/me.7.4.604; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MICHTELL PJ, 1989, SCIENCE, V345, P371; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SIEPEL K, 1994, BIOL CHEM HOPPESEYLE, V375, P463; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TONE Y, 1994, J BIOL CHEM, V269, P31157; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674	64	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23552	23559		10.1074/jbc.270.40.23552	http://dx.doi.org/10.1074/jbc.270.40.23552			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559520	hybrid			2022-12-25	WOS:A1995RY90900049
J	PORCELLINI, A; CIULLO, I; PANNAIN, S; FENZI, G; AVVEDIMENTO, E				PORCELLINI, A; CIULLO, I; PANNAIN, S; FENZI, G; AVVEDIMENTO, E			SOMATIC MUTATIONS IN THE VI-TRANSMEMBRANE SEGMENT OF THE THYROTROPIN RECEPTOR CONSTITUTIVELY ACTIVATE CAMP SIGNALING IN THYROID HYPERFUNCTIONING ADENOMAS	ONCOGENE			English	Article						THYROTROPIN RECEPTOR; CAMP-DEPENDENT TRANSCRIPTION PCR; MUTATIONS; NEOPLASMS GENETICS	PHOSPHATIDYLINOSITOL; ONCOGENE; TUMORS	We have discovered two somatic mutations in the VI transmembrane domain of the thyrotropin receptor gene in thyroid hyperfunctioning adenomas, The mutated amino acid residues are phenylalanine 631 (to cysteine) and threonine 632 (to isoleucine), Cloning and expression of the mutated versions of the receptor in COS cells increased significantly the basal and the TSH-induced cAMP levels compared to the wild type receptor, Moreover, the expression of a reporter gene under the control of the cAMP-inducible promoter, was likewise constitutively activated in cells expressing the 631 and 632 TSH receptor mutants relative to the wild type, These data indicate that the VI transmembrane segment in the TSH receptor and presumably in the other G-protein coupled receptors is a critical domain for the activation of G-protein signalling and that the mutations described here may be the cause of the thyroid hyperfunctioning adenoma.	UNIV REGGIO CALABRIA, FAC MED CATANZARO, DIPARTIMENTO MED SPERIMENTALE, CATANZARO, ITALY; UNIV NAPLES FEDERICO II, FAC MED, DIPARTIMENTO ENDOCRINOL, I-80131 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CTR ENDOCRINOL & ONCOL MOLEC, I-80131 NAPLES, ITALY	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; University of Naples Federico II; University of Naples Federico II			Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518				AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P109	22	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1089	1093						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566968				2022-12-25	WOS:A1995RX18000011
J	XUAN, JW; CHIN, JL; GUO, YZ; CHAMBERS, AF; FINKELMAN, MA; CLARKE, MW				XUAN, JW; CHIN, JL; GUO, YZ; CHAMBERS, AF; FINKELMAN, MA; CLARKE, MW			ALTERNATIVE SPLICING OF PSP94 (PROSTATIC SECRETORY PROTEIN OF 94 AMINO-ACIDS) MESSENGER-RNA IN PROSTATE TISSUE	ONCOGENE			English	Article						PROSTATE TUMOR; PSP94 (PROSTATIC SECRETORY PROTEIN OF 94 AMINO ACIDS); ALTERNATIVE SPLICING; CDNA SEQUENCE	INHIBIN-LIKE MATERIAL; HUMAN SEMINAL PLASMA; HUMAN BETA-MICROSEMINOPROTEIN; CARCINOMA CELL-LINES; MOLECULAR-CLONING; RHESUS-MONKEY; SEQUENCE; PEPTIDE; GENE; EXPRESSION	While performing reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of total mRNA from prostate cancer specimens, two forms of PSP94 cDNA were detected, RT-PCR products were analysed by Southern blotting and probing with exon-specific oligonucleotides, In the short form of PSP94 mRNA, designated as PSP57, exon III was found to be deleted, The two mRNA forms were confirmed by cloning and sequencing of the RT-PCR products and were found to result from alternative splicing, The alternatively spliced form, PSP57, was characterized by sequence analysis, PSP94 and PSP57 possess identical exons I and II, including identical secretion signal peptide and the 5' untranslated sequences, PSP57 has a frame-shifted exon IV and encodes a putative 57 amino acid protein with a navel, highly basic C-terminus of 41 amino acids, PSP57 mRNA was detected in other urogenital tissues (kidney, bladder) and in most tumor cell lines tested, but was not detectable in other tissues such as breast and lung, In prostate tumor cell lines, PSP57 mRNA was aberrantly spliced and localized in the nuclear fraction of the cell, Our results suggest the possible existence of a novel PSP protein that originates from alternative splicing of PSP94 mRNA in urogenital tissues.	UNIV WESTERN ONTARIO,DEPT SURG,DIV UROL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT ONCOL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,LONDON REG CANC CTR,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5C1,CANADA; PROCYON BIOPHARMA INC,LONDON,ON N6L 1A8,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; AKIYAMA K, 1985, BIOCHIM BIOPHYS ACTA, V829, P288, DOI 10.1016/0167-4838(85)90200-6; ALPERT G, 1992, J INFECT DIS, V165, P494, DOI 10.1093/infdis/165.3.494; BRAR A, 1988, J ANDROL, V99, P253; DOCTOR VM, 1986, BRIT J CANCER, V53, P547, DOI 10.1038/bjc.1986.85; DUBE JY, 1987, J UROLOGY, V138, P883, DOI 10.1016/S0022-5347(17)43408-2; DUBE JY, 1987, J ANDROL, V8, P182; FISHER CJ, 1994, CRIT CARE MED, V22, P553, DOI 10.1097/00003246-199404000-00008; FOA C, 1977, CANCER RES, V37, P3957; GARDE S, 1993, PROSTATE, V22, P225, DOI 10.1002/pros.2990220305; GARDE SV, 1993, CANCER LETT, V70, P159, DOI 10.1016/0304-3835(93)90226-Y; GREEN CB, 1990, BIOCHEM BIOPH RES CO, V167, P1184, DOI 10.1016/0006-291X(90)90648-7; HARA M, 1989, J LAB CLIN MED, V113, P541; KHARBANDA K, 1990, PROSTATE, V16, P163, DOI 10.1002/pros.2990160207; KHARBANDA K, 1991, PROSTATE, V18, P59, DOI 10.1002/pros.2990180106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG ZG, 1991, BIOCHEM BIOPH RES CO, V180, P356, DOI 10.1016/S0006-291X(05)81300-2; LIU AY, 1993, CANCER LETT, V74, P91, DOI 10.1016/0304-3835(93)90049-F; LOKESHWAR BL, 1993, CANCER RES, V53, P4855; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARRA MM, 1992, J IMMUNOL, V144, P662; MBIKAY M, 1987, DNA-J MOLEC CELL BIO, V6, P23, DOI 10.1089/dna.1987.6.23; MUNDLE SD, 1993, CELL BIOL INT, V17, P587, DOI 10.1006/cbir.1993.1103; MUTA T, 1987, J BIOCHEM-TOKYO, V101, P1321, DOI 10.1093/oxfordjournals.jbchem.a121999; NOLET S, 1991, GENOMICS, V9, P775, DOI 10.1016/0888-7543(91)90375-O; NOLET S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P247, DOI 10.1016/0167-4781(91)90016-F; PRICE JE, 1990, CANCER RES, V50, P717; SAMBROOK J, 1969, MOL CLONING LABORATO; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SEIDAH NG, 1984, FEBS LETT, V175, P349, DOI 10.1016/0014-5793(84)80766-8; SHETH AR, 1991, PERSPECTIVE PRIMATES, P235; SHETH AR, 1988, PROGR ENDOCRINOLOGY, P301; SHETH NA, 1987, CANCER LETT, V36, P93, DOI 10.1016/0304-3835(87)90106-6; SHETH NA, 1987, INHIBINS, V2, P109; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STARR L, 1992, BIOTECHNIQUES, V13, P612; TENI TR, 1988, CANCER LETT, V43, P9, DOI 10.1016/0304-3835(88)90205-4; ULVSBACK M, 1989, BIOCHEM BIOPH RES CO, V164, P1310, DOI 10.1016/0006-291X(89)91812-3; ULVSBACK M, 1991, GENOMICS, V11, P920, DOI 10.1016/0888-7543(91)90015-7; XUAN JW, 1994, GENOMICS, V20, P129, DOI 10.1006/geno.1994.1139; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213	41	32	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1041	1047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566962				2022-12-25	WOS:A1995RX18000005
J	ALLEN, RM; CHATTERJEE, R; LUDDEN, PW; SHAH, VK				ALLEN, RM; CHATTERJEE, R; LUDDEN, PW; SHAH, VK			INCORPORATION OF IRON AND SULFUR FROM NIFB COFACTOR INTO THE IRON-MOLYBDENUM COFACTOR OF DINITROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; INVITRO SYNTHESIS; NITROGENASE; PROTEIN; REDUCTASE; GENE; APODINITROGENASE; BIOSYNTHESIS; HOMOCITRATE	NifB-co is an iron- and sulfur-containing precursor to the iron-molybdenum cofactor (FeMo-co) of dinitrogenase. The synthesis of NifB-co requires at least the product of the nifB gene. Incorporation of Fe-55 and S-35 from NifB-co into FeMo-co was observed only when all components of the in vitro FeMo-co synthesis system were present. Incorporation of iron and sulfur from NifB-co into dinitrogenase was not observed in control experiments in which the apodinitrogenase (lacking FeMo-co) was initially activated with purified, unlabeled FeMo-co or in assays where NifB-co was oxygen-inactivated prior to addition to the synthesis system. These data clearly demonstrate that iron and sulfur from active NifB-co are specifically incorporated into FeMo-co of dinitrogenase and provide direct biochemical identification of an iron-sulfur precursor of FeMo-co. Under different in vitro FeMo-co synthesis conditions, iron and sulfur from NifB-co were associated with at least two other proteins (NIFNE and gamma) that are involved in the formation of active dinitrogenase. The results presented here suggest that multiple FeMo-co processing steps might occur on NIFNE and that FeMo-co synthesis is most likely completed prior to the association of FeMo-co with gamma.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,CTR STUDY NITROGEN FIXAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BRUMBY PE, 1965, J BIOL CHEM, V240, P2222; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HOMER MJ, 1995, J BIOL CHEM, V270, P24755; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; YOCH DC, 1966, J BACTERIOL, V168, P618; ZHENG LM, 1994, J BIOL CHEM, V269, P18723	29	79	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26890	26896		10.1074/jbc.270.45.26890	http://dx.doi.org/10.1074/jbc.270.45.26890			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592933	hybrid			2022-12-25	WOS:A1995TE58300033
J	BALL, HJ; SHINE, J; HERZOG, H				BALL, HJ; SHINE, J; HERZOG, H			MULTIPLE PROMOTERS REGULATE TISSUE-SPECIFIC EXPRESSION OF THE HUMAN NPY-Y1 RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-Y; TRANSCRIPTION; BRAIN; ELEMENTS; BINDING	Several cDNA clones encoding the human neuropeptide Y-Y1 receptor have been isolated that contain differing sequences at their 5'-ends. The divergence occurs at a splice junction in the 5'-untranslated region, suggesting that at least three forms of the neuropeptide Y-Y1 receptor transcript are generated by alternative splicing at this site, Genomic clones have been isolated that encompass the alternatively spliced 5'-exons. The exons are found 6.4, 18.4, and 23.9 kilobases upstream of exon 2, In the corresponding promoter regions of the various exons, possible response elements for the glucocorticoid receptor, as well as potential binding sites for the AP-1, AP-2, and NF-KB transcription factors are found.;Analysis of NPY-Y1 transcripts in various cell types demonstrates the tissue-specific activation of the three promoters.	ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Ball, Helen J/A-4242-2010; Herzog, Herbert/B-8294-2008	Ball, Helen J/0000-0003-3733-9748; 				AHUJA SK, 1994, J BIOL CHEM, V269, P26381; BLOMQVIST AG, 1995, BBA-GENE STRUCT EXPR, V1261, P439, DOI 10.1016/0167-4781(95)00051-H; CHENG HF, 1993, MOL PHARMACOL, V44, P533; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; HERZOG H, 1993, J BIOL CHEM, V268, P6703; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; JI RR, 1994, J NEUROSCI, V14, P6423; KALRA SP, 1992, ENDOCRINOLOGY, V130, P3323, DOI 10.1210/en.130.6.3323; LARSEN PJ, 1994, J NEUROENDOCRINOL, V6, P153, DOI 10.1111/j.1365-2826.1994.tb00566.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NUSING RM, 1993, J BIOL CHEM, V268, P25253; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PESQUERO JB, 1994, J BIOL CHEM, V269, P26920; PETITTO JM, 1994, J NEUROIMMUNOL, V54, P81, DOI 10.1016/0165-5728(94)90234-8; QUIRION R, 1990, ANN NY ACAD SCI, V611, P58; REN HZ, 1994, P NATL ACAD SCI USA, V91, P4864, DOI 10.1073/pnas.91.11.4864; REN HZ, 1994, J BIOL CHEM, V269, P3104; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STANLEY BG, 1984, LIFE SCI, V35, P2635, DOI 10.1016/0024-3205(84)90032-8; VALDENAIRE O, 1994, EUR J BIOCHEM, V220, P577, DOI 10.1111/j.1432-1033.1994.tb18658.x; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; WAHLESTEDT C, 1985, J PHARMACOL EXP THER, V234, P735; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WHARTON J, 1993, P NATL ACAD SCI USA, V90, P687, DOI 10.1073/pnas.90.2.687	33	52	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27272	27276		10.1074/jbc.270.45.27272	http://dx.doi.org/10.1074/jbc.270.45.27272			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592987	hybrid			2022-12-25	WOS:A1995TE58300087
J	GRILLI, M; RIBOLA, M; ALBERICI, A; VALERIO, A; MEMO, M; SPANO, PF				GRILLI, M; RIBOLA, M; ALBERICI, A; VALERIO, A; MEMO, M; SPANO, PF			IDENTIFICATION AND CHARACTERIZATION OF A KAPPA-B/REL BINDING-SITE IN THE REGULATORY REGION OF THE AMYLOID PRECURSOR PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; ALZHEIMERS-DISEASE; BRAIN; EXPRESSION; PROMOTER; CELLS; APP; INTERLEUKIN-1; NEURONS; DAMAGE	Several observations support the hypothesis that pathogenetic mechanisms of beta amyloid formation in Alzheimer's disease may involve alterations in amyloid precursor protein (APP) gene expression, In this regard, molecular dissection of the APP gene transcriptional regulation is of primary importance. We report evidence that members of the family of transcription factors NF kappa B/Rel can specifically recognize two identical sequences located in the 5'-regulatory region of APP, These sequences, which we refer to as APP kappa B sites, interact preferentially with p50-containing members of the family, In particular, p50 homodimers and p50/p65 and p50/c-Rel heterodimers act as transcriptional activators at the APP kappa B site, Finally, the nuclear complex specifically binding to the APP kappa B sites proves to be an integral part of neurons and lymphocytes.			GRILLI, M (corresponding author), UNIV BRESCIA, SCH MED, DEPT BIOMED SCI & BIOTECHNOL, DIV PHARMACOL, VIA VALSBBINA 19, I-25124 BRESCIA, ITALY.		Spano, Pier Franco A/E-7621-2010; Memo, Maurizio/AAK-7197-2020; Valerio, Alessandra/B-3413-2009; Spano, Pier Franco F/J-9944-2016; Memo, Maurizio/C-2555-2011; grilli, mariagrazia/ABF-1542-2020	Valerio, Alessandra/0000-0001-5844-2256; Spano, Pier Franco F/0000-0002-9906-0964; grilli, mariagrazia/0000-0001-9165-5827; MEMO, Maurizio/0000-0002-7543-0289				ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; CRENON I, 1993, ONCOGENE, V8, P867; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MONNING U, 1992, J BIOL CHEM, V267, P23950; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; TREJO J, 1994, J BIOL CHEM, V269, P21682; VANDENABEELE P, 1991, IMMUNOL TODAY, V12, P217, DOI 10.1016/0167-5699(91)90032-O; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	35	85	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26774	26777		10.1074/jbc.270.45.26774	http://dx.doi.org/10.1074/jbc.270.45.26774			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592914	hybrid			2022-12-25	WOS:A1995TE58300014
J	LIN, K; HWANG, PK; FLETTERICK, RJ				LIN, K; HWANG, PK; FLETTERICK, RJ			MECHANISM OF REGULATION IN YEAST GLYCOGEN-PHOSPHORYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; T-STATE; PURIFICATION; ACTIVATION; EVOLUTION; BINDING; GLUCOSE; SITES	The mechanism of yeast glycogen phosphorylase activation by covalent phosphorylation involves structural elements distinct from the mammalian homologs, To understand the role of the amino-terminal 39-residue extension in the phosphorylation control mechanism, mutants with 22 and 42 amino-terminal residues removed mere expressed in Escherichia coli, and their properties were compared with the wild-type (WT) enzyme. The unphosphorylated WT enzyme had a specific activity of 0.1 unit/mg and was not activated significantly by the substrate, glucose l-phosphate. Phosphorylation by protein kinase resulted in a 1300-fold activation, Glucose B-phosphate inhibited the unphosphorylated enzyme more effectively than the phosphorylated form, and inhibition of the latter was cooperative, Glucose was a poor inhibitor for both the unphosphorylated and phosphorylated WT enzyme with K-i > 300 mM. The rate of phosphorylation by protein kinase depended on substrates and interactions of the amino terminus. Maltoheptaose increased the rate of phosphorylation of the WT enzyme by yeast phosphorylase kinase 5-fold. The 22-residue deletion mutant (Nd22) had overall kinetic properties similar to the WT enzyme, except that Nd22 was a better substrate for the protein kinase and the rate of phosphorylation was unaffected by maltoheptaose. The 42-residue deletion mutant (Nd42), which lacks the phosphorylation site, was measurably active, although much less active than phosphorylated WT. Sedimentation equilibrium analysis indicated that the WT, Nd22, and Nd42 exist as tetramer, partially dissociated tetramer, and dimer, respectively, Phosphorylation of the WT and Nd22 converted both to dimer, The results indicated that the amino terminus affects quaternary structure and mediates activity regulation through conformational transition.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032822] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32822] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1966, METHOD ENZYMOL, V8, P116; BECKER JU, 1983, ARCH BIOCHEM BIOPHYS, V225, P667, DOI 10.1016/0003-9861(83)90078-4; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; CARNEY IT, 1978, ANAL BIOCHEM, V85, P321, DOI 10.1016/0003-2697(78)90309-3; FOSSET M, 1971, BIOCHEMISTRY-US, V10, P4105, DOI 10.1021/bi00798a015; GOLDSMITH EJ, 1987, J BIOL CHEM, V262, P1449; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1993, J MOL BIOL, V232, P253, DOI 10.1006/jmbi.1993.1380; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERCH K, 1975, BIOCHEMISTRY-US, V14, P2009, DOI 10.1021/bi00680a031; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; RATH VL, 1992, J MOL BIOL, V225, P1027, DOI 10.1016/0022-2836(92)90102-P; RATH VL, 1994, NAT STRUCT BIOL, V1, P681, DOI 10.1038/nsb1094-681; ROBERTSON JG, 1989, KINETASYST, V2; SAGARDIA F, 1971, BIOCHEM BIOPH RES CO, V42, P829, DOI 10.1016/0006-291X(71)90505-5; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1982, BIOCHEMISTRY-US, V21, P5364, DOI 10.1021/bi00264a038; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STALMANS W, 1970, EUR J BIOCHEM, V15, P9, DOI 10.1111/j.1432-1033.1970.tb00968.x; STULL JT, 1977, J BIOL CHEM, V252, P851; TANABE S, 1987, AGR BIOL CHEM TOKYO, V51, P2465; WINGENDERDRISSE.R, 1983, FEBS LETT, V163, P33	29	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26833	26839		10.1074/jbc.270.45.26833	http://dx.doi.org/10.1074/jbc.270.45.26833			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592925	hybrid			2022-12-25	WOS:A1995TE58300025
J	MINTZ, E; MATA, AM; FORGE, V; PASSAFIUME, M; GUILLAIN, F				MINTZ, E; MATA, AM; FORGE, V; PASSAFIUME, M; GUILLAIN, F			THE MODULATION OF CA2+ BINDING TO SARCOPLASMIC-RETICULUM ATPASE BY ATP ANALOGS IS PH-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CALCIUM-BINDING; FLUORESCEIN ISOTHIOCYANATE; CONFORMATIONAL TRANSITION; RAPID-FILTRATION; KINETIC EVIDENCE; CATALYTIC SITE; CA-2+; MECHANISM; PHOSPHORYLATION	Excess ATP is known to enhance Ca2+-ATPase activity and, among other effects, to accelerate the Ca2+ binding reaction, In previous work, we studied the pH dependence of this reaction and proposed a 3H(+)/2Ca(2+) exchange at the transport sites, in agreement with the H+/Ca2+ counter transport, Here we studied the effect of ADP and nonhydrolyzable ATP analogues on the Ca2+ binding reaction at various pH values. At pH 6, where Ca2+ binding is monophasic and slow, ADP, adenosine 5'-(beta,gamma-methylene)triphosphate (AMP-PCP), or adenyl-5'-yl imidodiphosphate (AMPPNP) increased the Ca2+ binding rate constant 20-fold, At pH 7 and 8, where Ca2+ binding is biphasic, the nucleotides induce fast and monophasic Ca2+ binding. At pH 7, AMP-PCP accelerated Ca2+ binding with an apparent dissociation constant of 10 mu M. At acidic pH, ADP, AMPPCP, or AMPPNP increased the equilibrium affinity of Ca2+ for ATPase, whereas at alkaline pH, these nucleotides had no effect, At pH 5.5, AMPPCP increased equilibrium Ca2+ binding with an apparent dissociation constant of 1 mu M.	CTR ETUDES SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,CNRS,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	MINTZ, E (corresponding author), CTR ETUDES SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,F-91191 GIF SUR YVETTE,FRANCE.		Mata, Ana M./J-8460-2014	Mata, Ana M./0000-0002-2887-7854				BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; FERNANDEZBELDA F, 1988, ARCH BIOCHEM BIOPHYS, V260, P118, DOI 10.1016/0003-9861(88)90431-6; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1993, EUR J BIOCHEM, V211, P117, DOI 10.1111/j.1432-1033.1993.tb19877.x; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MINTZ E, 1990, J BIOL CHEM, V265, P18762; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; NAKAMURA Y, 1982, J BIOENERG BIOMEMBR, V14, P307, DOI 10.1007/BF00743060; NEET KE, 1977, ARCH BIOCHEM BIOPHYS, V178, P588, DOI 10.1016/0003-9861(77)90230-2; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1305, DOI 10.1093/oxfordjournals.jbchem.a121837; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1982, J BIOL CHEM, V257, P6120; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526; YATES DW, 1976, BIOCHEM J, V159, P719, DOI 10.1042/bj1590719	38	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27160	27164		10.1074/jbc.270.45.27160	http://dx.doi.org/10.1074/jbc.270.45.27160			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592971	hybrid			2022-12-25	WOS:A1995TE58300071
J	GALLAGHER, PG; FORGET, BG				GALLAGHER, PG; FORGET, BG			STRUCTURE, ORGANIZATION, AND EXPRESSION OF THE HUMAN BAND 7.2B GENE, A CANDIDATE GENE FOR HEREDITARY HYDROCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; HEMOLYTIC-ANEMIA; MESSENGER-RNAS; STOMATOCYTOSIS; SEQUENCE; DNA; POLYADENYLATION; CONSERVATION; METABOLISM; EUKARYOTES	Band 7.2b is an integral membrane phosphoprotein absent from the erythrocyte membranes of patients with hereditary hydrocytosis, a hemolytic anemia inherited in an autosomal dominant fashion and characterized by stomatocytic red blood cells with abnormal permeability to Na+ and K+. The precise role of band 7.2b is unknown, but it may interact with other proteins of the junctional complex of the membrane skeleton. To gain additional insight into the structure and function of this protein and to provide the necessary tools for further genetic studies of hydrocytosis patients, we determined the sequence of the full-length human band 7.2b cDNA, characterized the genomic structure of the band 7.2b gene, studied its pattern of expression in different tissues, and characterized the promoter of the gene, The composite band 7.2b gene cDNA was 3047 base pairs in length, Northern blot analysis revealed a wide tissue distribution of expression of the band 7.2b gene, with utilization of alternative polyadenylation signals generating transcripts of 2.2 and 3.1 kilobases, Cloning of the band 7.2b chromosomal gene revealed that it is composed of seven exons distributed over 40 kilobases of DNA. The band 7.2b gene promoter was identified as a TATA-less, (G + C)-rich promoter with a typical InR recognition sequence and a single transcription initiation site. It directed high level expression of a reporter gene in both erythroid and nonerythroid cells, An imperfect simple sequence repeat polymorphism was identified in the 5'-flanking DNA, and an assay was developed for its analysis by PCR.	YALE UNIV, SCH MED, DEPT INTERNAL MED, HEMATOL SECT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Yale University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019482] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08HL02857] Funding Source: Medline; NIDDK NIH HHS [R37DK19482] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS JM, 1989, MOL CELL BIOL, V9, P620, DOI 10.1128/MCB.9.2.620; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1994, PROGRAM MANUAL WISCO; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; DACIE JV, 1985, HAEMOLYTIC ANAEMIA, P259; EBER SW, 1989, BRIT J HAEMATOL, V72, P452, DOI 10.1111/j.1365-2141.1989.tb07731.x; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; GALLAGHER PG, 1993, GENOMICS, V18, P167, DOI 10.1006/geno.1993.1449; GALLAGHER PG, 1995, BLOOD, V86, P359, DOI 10.1182/blood.V86.1.359.bloodjournal861359; GALLAGHER PG, 1994, BLOOD, V84, pA6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KANZAKI A, 1992, BRIT J HAEMATOL, V82, P133; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LABUDA D, 1989, NUCLEIC ACIDS RES, V17, P2477, DOI 10.1093/nar/17.7.2477; LANDE WM, 1985, CLIN HAEMATOL, V14, P89; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MASON P, 1993, GENE TRANSCRIPTION P, P47; MENTZER WC, 1975, BLOOD, V46, P659; MILLER DR, 1971, BLOOD-J HEMATOL, V38, P184, DOI 10.1182/blood.V38.2.184.184; MORLE L, 1989, BRIT J HAEMATOL, V71, P141, DOI 10.1111/j.1365-2141.1989.tb06288.x; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; OLIVIERI O, 1992, BRIT J HAEMATOL, V80, P258, DOI 10.1111/j.1365-2141.1992.tb08912.x; OSKI FA, 1969, NEW ENGL J MED, V280, P909, DOI 10.1056/NEJM196904242801701; RINCONLIMAS DE, 1991, MOL CELL BIOL, V11, P4157, DOI 10.1128/MCB.11.8.4157; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sinard J. H., 1994, Molecular Biology of the Cell, V5, p421A; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; ZARKOWSKY HS, 1968, NEW ENGL J MED, V278, P573, DOI 10.1056/NEJM196803142781101	43	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26358	26363		10.1074/jbc.270.44.26358	http://dx.doi.org/10.1074/jbc.270.44.26358			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592848	hybrid			2022-12-25	WOS:A1995TC97800055
J	LI, QQ; YOKOYAMA, S				LI, QQ; YOKOYAMA, S			INDEPENDENT REGULATION OF CHOLESTEROL INCORPORATION INTO FREE APOLIPOPROTEIN-MEDIATED CELLULAR LIPID EFFLUX IN RAT VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; MONOCYTE-DERIVED MACROPHAGES; LINE THP-1; INTRACELLULAR CHOLESTEROL; CULTURED FIBROBLASTS; SCAVENGER RECEPTOR; BINDING PROTEIN; HUMAN-PLASMA	Cholesterol was poorly available to free apolipoprotein (apo)A-I-mediated cellular lipid efflux from cholesterol-loaded rat vascular smooth muscle cells generating cholesterol-poorer pre-beta-HDL particles than those generated from macrophages by the same reaction (Li, a,, Komaba, k, and Yokoyama, S. (1993) Biochemistry 32, 4597-4603). The factors known to induce transformation of the smooth muscle cells into a macrophage-like stage were used in order to modulate this reaction, such as human platelet-derived growth factor, macrophage colony-stimulating factor, and phorbol 12-myristate-13-acetate (PMA). When the cells were stimulated by PMA following the pretreatment with platelet-derived growth factor plus macrophage colony-stimulating factor, cholesterol efflux mediated by free apoA-I increased 3-foId without changing phospholipid efflux, resulting in generation of pre-beta-HDL particles more rich in cholesterol. This treatment had only a little or no effect on apparent cellular cholesterol efflux to HDL or lipid microemulsion, respectively. Overall cellular free cholesterol pool size was unaffected by the treatment, and probing by extracellular cholesterol oxidase did not detect gross change in the cellular surface cholesterol. This specific enrichment of cholesterol in the apoA-I-mediated cellular lipid efflux was reversed by protein kinase C inhibitors. Measurement of intracellular cholesterol esterification suggested that PMA. induced translocation of intracellular cholesterol to a specific pool for apoA-I-mediated efflux, and a protein kinase C inhibitor reversed this effect.	UNIV ALBERTA,DEPT MED,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								BERNARD DW, 1992, 65TH SCI SESS AM HEA, P46; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CZARNECKA H, 1995, BIOCHEMISTRY-US, V34, P4385, DOI 10.1021/bi00013a030; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING PE, 1982, J CELL BIOL, V94, P350, DOI 10.1083/jcb.94.2.350; FORTE TM, 1993, J LIPID RES, V34, P317; FORTE TM, 1995, J LIPID RES, V36, P148; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HARA H, 1991, J BIOL CHEM, V266, P3080; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUME DA, 1988, J IMMUNOL, V141, P3405; INABA T, 1992, J BIOL CHEM, V267, P5693; INABA T, 1992, J BIOL CHEM, V267, P13107; INABA T, 1993, J CLIN INVEST, V92, P750, DOI 10.1172/JCI116646; INOUE I, 1992, ATHEROSCLEROSIS, V93, P245, DOI 10.1016/0021-9150(92)90261-E; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHII I, 1994, BBA-LIPID LIPID MET, V1212, P278, DOI 10.1016/0005-2760(94)90201-1; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; KOMABA A, 1992, J BIOL CHEM, V267, P17560; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LI Q, 1995, IN PRESS BIOCH BIOPH; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; LISCUM L, 1992, J LIPID RES, V33, P1239; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MENJU M, 1989, J BIOCHEM-TOKYO, V106, P505, DOI 10.1093/oxfordjournals.jbchem.a122882; MIIDA T, 1992, BIOCHEMISTRY-US, V31, P11112, DOI 10.1021/bi00160a022; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; MORI N, 1991, ARTERIOSCLER THROMB, V11, P1315, DOI 10.1161/01.ATV.11.5.1315; MURPHY JR, 1962, J LAB CLIN MED, V60, P86; NAKOINZ I, 1988, CELL IMMUNOL, V116, P331, DOI 10.1016/0008-8749(88)90235-3; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; RAY E, 1980, BIOCHIM BIOPHYS ACTA, V617, P318, DOI 10.1016/0005-2760(80)90174-5; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SHIMADA M, 1992, J BIOL CHEM, V267, P15455; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TAJIMA S, 1985, BIOCHEM BIOPH RES CO, V126, P526, DOI 10.1016/0006-291X(85)90637-0; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V986, P18, DOI 10.1016/0005-2736(89)90267-8; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; VOYNOYASENETSKA.TA, 1993, P NATL ACAD SCI USA, V90, P4256; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	61	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26216	26223		10.1074/jbc.270.44.26216	http://dx.doi.org/10.1074/jbc.270.44.26216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592827	hybrid			2022-12-25	WOS:A1995TC97800034
J	BENNETT, MK; LOPEZ, JM; SANCHEZ, HB; OSBORNE, TF				BENNETT, MK; LOPEZ, JM; SANCHEZ, HB; OSBORNE, TF			STEROL REGULATION OF FATTY-ACID SYNTHASE PROMOTER - COORDINATE FEEDBACK-REGULATION OF 2 MAJOR LIPID PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; MOLECULAR-CLONING; RECEPTOR PROMOTER; TRANSCRIPTION; GENE; IDENTIFICATION; SEQUENCE; DIFFERENTIATION; CHOLESTEROL	The gene encoding fatty acid synthase, the essential multi-functional enzyme of fatty acid biosynthesis, is shown to be regulated by cellular sterol levels similar to genes that encode important proteins of cholesterol metabolism. me show that expression of the endogenous FAS gene is repressed when regulatory sterols are included in the culture medium of HepG2 cells and that the FAS promoter is subject to similar regulation when fused to the luciferase reporter gene. Mutational studies demonstrate that sterol regulation is mediated by binding sites for the sterol regulatory element-binding protein (SREBP) and transcription factor Sp1, making it mechanistically similar to sterol regulation of the low density lipoprotein receptor gene. It is also demonstrated that SREBP and Sp1 synergistically activate the FAS promoter in Drosophila tissue culture cells, which lack endogenous Sp1. These experiments provide key molecular evidence that directly links the metabolism of fatty acids and cholesterol together.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Lopez, Jose M/D-1654-2011; Lopez, Jose/AAF-3798-2020	Lopez, Jose M/0000-0002-4104-6262; Lopez, Jose/0000-0002-4104-6262	NHLBI NIH HHS [HL48044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GLICKMAN RM, 1988, LIVER BIOL PATHOBIOL, P331; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Maxam A M, 1980, Methods Enzymol, V65, P499; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5329; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; Sambrook J, 1989, MOL CLONING LABORATO, P545; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WOOLLETT LA, 1992, J LIPID RES, V33, P77; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	28	322	330	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25578	25583		10.1074/jbc.270.43.25578	http://dx.doi.org/10.1074/jbc.270.43.25578			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592729	Green Published, hybrid			2022-12-25	WOS:A1995TB46600046
J	CHO, BK; SCHODIN, BA; KRANZ, DM				CHO, BK; SCHODIN, BA; KRANZ, DM			CHARACTERIZATION OF A SINGLE-CHAIN ANTIBODY TO THE BETA-CHAIN OF THE T-CELL RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CD3 MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; BINDING-AFFINITY; ESCHERICHIA-COLI; INTERACTION SITE; LYMPHOCYTES-T; V-BETA; RECOGNITION; THERAPY; COMPLEX	In this report the V-H and V-H genes of the anti-T cell receptor (TCR) antibody KJ16, which recognizes the TCR V beta 8.1 and V beta 8.2 regions in mice, were cloned and expressed as a single-chain antibody (scFv) in Escherichia coli. A 29-kDa protein was obtained after renaturation from inclusion bodies. The KJ16 scFv bad a relative affinity for the native TCR that was slightly higher than KJ16 Fab fragments. The scFv and Fab fragments of the KJ16 antibody, together with monovalent forms of two other anti-TCR antibodies, were evaluated as antagonists of the T cell-mediated recognition of a peptide-class I complex or of a superantigen. Staphylococcus enterotoxin B (SEB) bound to a class II product. Each of the anti-TCR antibodies was efficient at inhibiting the recognition of the SEE-class II complex. In contrast, only the clonotypic antibody, which binds to epitopes on both the V beta and V alpha regions, inhibited the recognition of peptide-class I complex. We conclude that the TCR binding site for the SEB-class II ligand encompasses a larger surface area than the TCR binding site for the peptide-class I ligand.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035990] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35990] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CHIOCCHIA G, 1991, EUR J IMMUNOL, V21, P2899, DOI 10.1002/eji.1830211202; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; DIGIUSTO DL, 1994, MOL IMMUNOL, V31, P693, DOI 10.1016/0161-5890(94)90179-1; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GAUR A, 1994, ADV IMMUNOL, V56, P219, DOI 10.1016/S0065-2776(08)60453-8; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P673; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HIRSCH R, 1989, J IMMUNOL, V142, P737; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; HOO WS, 1993, J IMMUNOL, V150, P4331; HOSAKA N, 1994, CLIN EXP IMMUNOL, V96, P500; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; JANEWAY CA, 1995, IMMUNOL TODAY, V16, P223, DOI 10.1016/0167-5699(95)80163-4; KANAGAWA O, 1991, J IMMUNOL, V147, P1307; KANG JS, 1994, J IMMUNOL, V152, P5305; KAPPLER J, 1994, P NATL ACAD SCI USA, V91, P8462, DOI 10.1073/pnas.91.18.8462; KASIBHATLA S, 1993, J IMMUNOL, V151, P3140; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PATTEN PA, 1993, J IMMUNOL, V150, P2281; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; ROJO JM, 1988, J IMMUNOL, V140, P1081; SCHODIN BA, 1993, J BIOL CHEM, V268, P25722; SEGAL DM, 1987, METHOD ENZYMOL, V150, P478; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P90, DOI 10.1016/0167-5699(95)80095-6; VACCHIO MS, 1992, J EXP MED, V175, P1405, DOI 10.1084/jem.175.5.1405; VOSS EW, 1984, FLUORESCEIN HAPTEN I, P18; WALDMANN TA, 1992, ANNU REV IMMUNOL, V10, P675, DOI 10.1146/annurev.immunol.10.1.675; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WOODLAND DL, 1993, J EXP MED, V177, P433, DOI 10.1084/jem.177.2.433; WOODLE ES, 1991, TRANSPLANTATION, V52, P361, DOI 10.1097/00007890-199108000-00034; YOON ST, 1994, IMMUNITY, V1, P563	48	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25819	25826		10.1074/jbc.270.43.25819	http://dx.doi.org/10.1074/jbc.270.43.25819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592766	hybrid			2022-12-25	WOS:A1995TB46600083
J	IVESSA, NE; DELEMOSCHIARANDINI, C; GRAVOTTA, D; SABATINI, DD; KREIBICH, G				IVESSA, NE; DELEMOSCHIARANDINI, C; GRAVOTTA, D; SABATINI, DD; KREIBICH, G			THE BREFELDIN A-INDUCED RETROGRADE TRANSPORT FROM THE GOLGI-APPARATUS TO THE ENDOPLASMIC-RETICULUM DEPENDS ON CALCIUM SEQUESTERED TO INTRACELLULAR STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; GTP-BINDING PROTEINS; METALLOENDOPROTEASE ACTIVITY; GUANINE-NUCLEOTIDE; HELA-CELLS; MEMBRANE; CA-2+-ATPASE; THAPSIGARGIN; INVOLVEMENT; INHIBITION	Ribophorin I is a type I transmembrane glycoprotein specific to the rough endoplasmic reticulum. We have previously shown that, when expressed in transfected HeLa cells, a carboxyl-terminally truncated form of ribophorin I that contains most of the luminal domain (RI(332)) is, like the native protein, retained in the endoplasmic reticulum (ER). Brefeldin A (BFA) treatment of these HeLa cells leads to O-glycosylation of RI(332) by glycosyltransferases that are redistributed from the Golgi apparatus to the ER (Ivessa, N. E., De Lemos-Chiarandini, C., Tsao, Y.-S., Takatsuki, A. Adesnik, M., Sabatini, D. D., and Kreibich, G. (1992) J. Cell Biol. 117, 949-958). Using the state of glycosylation of RI(332) as a measure for the BFA-induced backflow of enzymes of the Golgi apparatus to the ER, we now demonstrate that the retrograde transport is inhibited when cells are treated with various agents that affect intracellular Ca2+ concentrations, such as the dipeptide benzyloxy-carbonyl (Cbz)-Gly-Phe-amide, the Ca2+ ionophore A23187, and thapsigargin, an inhibitor of the Ca2+-transporting ATPase of the ER. These treatments prevent the BFA-induced O-glycosylation of RI(332). Immunofluorescence localization of the Golgi markers, MG-160 and galactosyltransferase, shows that when BFA is applied in the presence of Ca2+ modulating agents, the markers remain confined to the Golgi apparatus and are not redistributed to the ER, as is the case when BFA alone is used. Cbz-Gly-Phe-amide does not, however, interfere with the BFA-induced release of beta-COP from the Golgi apparatus. We conclude that the maintenance of a Ca2+ gradient between the cytoplasm and the lumen of the ER and the Golgi apparatus is required for the BFA-induced retrograde transport hom the Golgi apparatus to the ER to occur.	NYU, SCH MED, NEW YORK, NY 10016 USA; NYU, KAPLAN CANC CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University; New York University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1991, J BIOL CHEM, V266, P7037; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; CROUL S, 1990, J HISTOCHEM CYTOCHEM, V38, P957, DOI 10.1177/38.7.2355176; DEFIGUEIREDO P, 1995, MOL BIOL CELL, V6, P871, DOI 10.1091/mbc.6.7.871; DELEMOSCHIARANDINI C, 1992, EUR J CELL BIOL, V58, P187; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ECKSTEIN DJ, 1989, J CELL BIOL, V108, P2507, DOI 10.1083/jcb.108.6.2507; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; KELLY RB, 1995, CURR BIOL, V5, P257, DOI 10.1016/S0960-9822(95)00054-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LELKES PI, 1987, J BIOL CHEM, V262, P15496; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; LIPPINCOTTSCHWA.J, 1993, CELL, V3, P81; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MUNDY DI, 1985, CELL, V40, P645, DOI 10.1016/0092-8674(85)90213-2; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PITT A, 1991, EUR J CELL BIOL, V55, P328; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SABATINI DD, 1994, METABOLIC MOL BASES, V1, P459; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; STROUS GJ, 1988, J BIOL CHEM, V263, P18197; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TOOZE J, 1992, EUR J CELL BIOL, V58, P228; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335	51	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25960	25967		10.1074/jbc.270.43.25960	http://dx.doi.org/10.1074/jbc.270.43.25960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592786	hybrid			2022-12-25	WOS:A1995TB46600103
J	KOROMILAS, AE; CANTIN, C; CRAIG, AWB; JAGUS, R; HISCOTT, J; SONENBERG, N				KOROMILAS, AE; CANTIN, C; CRAIG, AWB; JAGUS, R; HISCOTT, J; SONENBERG, N			THE INTERFERON-INDUCIBLE PROTEIN-KINASE PKR MODULATES THE TRANSCRIPTIONAL ACTIVATION OF IMMUNOGLOBULIN-KAPPA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; BETA-INTERFERON; TYROSINE PHOSPHORYLATION; BINDING DOMAIN; P68 KINASE; B-LYMPHOMA; CELL-LINE; EXPRESSION; INDUCTION; LIPOPOLYSACCHARIDE	PKR is an interferon (IFN)-induced serine/threonine protein kinase that regulates protein synthesis through phosphorylation of eukaryotic translation initiation factor-2 (eIF-2). In addition to its demonstrated role in translational control, recent findings suggest that PKR plays an important role in regulation of gene transcription, as PKR phosphorylates I kappa B alpha upon double-stranded RNA treatment resulting in activation of NF-kappa B DNA binding in vitro (Kumar, A., Haque, J., Lacoste, J., Hiscott, J., and Williams, B. R. G. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 6288-6292). To further investigate the role of PKR in transcriptional signaling, we expressed the wild type human PKR and a catalytically inactive dominant negative PKR mutant in the murine pre-B lymphoma 70Z/3 cells. Here, we report that expression of wild type PKR had no effect on kappa-chain transcriptional activation induced by lipopolysaccharide or IFN-gamma. However, expression of the dominant negative PKR mutant inhibited kappa gene transcription independently of NF-kappa B activation. Phosphorylation of eIF-2 alpha was not increased by lipopolysaccharide or IFN-gamma, suggesting that PKR mediates kappa gene transcriptional activation without affecting protein synthesis. Our findings further support a transcriptional role for PKR and demonstrate that there are at least two distinct PKR-mediated signal transduction pathways to the transcriptional machinery depending on cell type and stimuli, NF-kappa B-dependent and NF-kappa B-independent.	MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA; CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; UNIV MARYLAND,INST BIOTECHNOL,CTR MARINE BIOTECHNOL,BALTIMORE,MD 21202; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3G 1A6,CANADA	McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; McGill University; University System of Maryland; University of Maryland Baltimore; McGill University			Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; BRISKIN M, 1988, SCIENCE, V242, P1036, DOI 10.1126/science.3143155; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAIGNEAULT L, 1992, NUCLEIC ACIDS RES, V20, P2749, DOI 10.1093/nar/20.11.2749; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; EILERS A, 1995, MOL CELL BIOL, V15, P3579; ELLIS MJC, 1994, NUCLEIC ACIDS RES, V22, P4489, DOI 10.1093/nar/22.21.4489; EMERY DW, 1989, MOL CELL BIOL, V9, P5231, DOI 10.1128/MCB.9.11.5231; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GUSELLA GL, 1995, IMMUNOLOGY, V154, P345; HANASH SM, 1993, GENE CHROMOSOME CANC, V8, P34, DOI 10.1002/gcc.2870080107; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARA H, 1990, INT IMMUNOL, V2, P691, DOI 10.1093/intimm/2.8.691; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HENRY C, 1980, SELECTED METHODS CEL, P138; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; ICELY PL, 1991, J BIOL CHEM, V266, P16073; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KOROMILAS A E, 1990, Technique (Philadelphia), V2, P189; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LASKY SR, 1982, J BIOL CHEM, V258, P11087; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MUERS EF, 1993, P NATL ACAD SCI USA, V90, P232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; NAKANO M, 1993, IMMUNOBIOLOGY, V187, P272, DOI 10.1016/S0171-2985(11)80344-X; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; OZES ON, 1993, J INTERFERON RES, V13, P283, DOI 10.1089/jir.1993.13.283; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RHODES LD, 1994, IMMUNOGENETICS, V40, P199, DOI 10.1007/BF00167080; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIEMANN T, 1994, J IMMUNOL, V155, P5740; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROONEY JW, 1990, IMMUNOGENETICS, V31, P65, DOI 10.1007/BF00661215; ROONEY JW, 1990, IMMUNOGENETICS, V31, P75; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; Sambrook J, 1989, MOL CLONING LABORATO; SEN GC, 1992, J BIOL CHEM, V267, P5017; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIGEKI M, 1994, P NATL ACAD SCI USA, V91, P5056; SUIRE J, 1993, GENOMICS, V16, P768; TSUDA M, 1978, J BIOCHEM-TOKYO, V84, P1285, DOI 10.1093/oxfordjournals.jbchem.a132247; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; WEEKS RS, 1988, J IMMUNOL, V140, P1312; WEEKS RS, 1984, J IMMUNOL, V133, P381; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	79	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25426	25434		10.1074/jbc.270.43.25426	http://dx.doi.org/10.1074/jbc.270.43.25426			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592710	hybrid			2022-12-25	WOS:A1995TB46600026
J	LAWRENCE, DA; GINSBURG, D; DAY, DE; BERKENPAS, MB; VERHAMME, IM; KVASSMAN, JO; SHORE, JD				LAWRENCE, DA; GINSBURG, D; DAY, DE; BERKENPAS, MB; VERHAMME, IM; KVASSMAN, JO; SHORE, JD			SERPIN-PROTEASE COMPLEXES ARE TRAPPED AS STABLE ACYL-ENZYME INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRYSTAL-STRUCTURE; INHIBITOR; MODEL; ALPHA-1-ANTITRYPSIN; ALPHA-2-ANTIPLASMIN; ANTITHROMBIN; CHYMOTRYPSIN; THROMBOSIS; MECHANISM	The serine protease inhibitors of the serpin family are an unusual group of proteins thought to have metastable native structures. Functionally, they are unique among polypeptide protease inhibitors, although their precise mechanism of action remains controversial, Conflicting results from previous studies have suggested that the stable serpin-protease complex is trapped in either a tight Michaelis-like structure, a tetrahedral intermediate, or an acyl-enzyme, In this report we show that, upon association with a target protease, the serpin reactive-center loop (RCL) is cleaved resulting in formation of an acyl-enzyme intermediate. This cleavage is coupled to rapid movement of the RCL into the body of the protein bringing the inhibitor closer to its lowest free energy state. From these data we suggest a model for serpin action in which the drive toward the lowest free energy state results in trapping of the protease-inhibitor complex as an acyl-enzyme intermediate.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; HENRY FORD HLTH SYST,DETROIT,MI 48202	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital	LAWRENCE, DA (corresponding author), AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.			Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [HL 49184, HL 45930A] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049184, R01HL045930] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; COHEN AB, 1977, P NATL ACAD SCI USA, V74, P4311, DOI 10.1073/pnas.74.10.4311; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; Fa M., 1994, Fibrinolysis, V8, P17; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	28	225	233	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25309	25312		10.1074/jbc.270.43.25309	http://dx.doi.org/10.1074/jbc.270.43.25309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592687	hybrid			2022-12-25	WOS:A1995TB46600003
J	MOUILLAC, B; CHINI, B; BALESTRE, MN; ELANDS, J; TRUMPPKALLMEYER, S; HOFLACK, J; HIBERT, M; JARD, S; BARBERIS, C				MOUILLAC, B; CHINI, B; BALESTRE, MN; ELANDS, J; TRUMPPKALLMEYER, S; HOFLACK, J; HIBERT, M; JARD, S; BARBERIS, C			THE BINDING-SITE OF NEUROPEPTIDE VASOPRESSIN V1A RECEPTOR - EVIDENCE FOR A MAJOR LOCALIZATION WITHIN TRANSMEMBRANE REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; ANTAGONIST; OXYTOCIN; AGONIST; EXPRESSION; RAT; IDENTIFICATION	To identify receptor functional domains underlying binding of the neurohypophysial hormones vasopressin (AVP) and oxytocin (OT), we have constructed a three-dimensional (3D) model of the V1a vasopressin receptor subtype and docked the endogenous ligand AVP, To verify and to refine the 3D model, residues likely to be involved in agonist binding were selected for site-directed mutagenesis, Our experimental results suggest that AVP, which is characterized by a cyclic structure, could be completely buried into a 15-20-Angstrom deep cleft defined by the transmembrane helices of the receptor and interact with amino acids located within this region, Moreover, the AVP-binding site is situated in a position equivalent to that described for the cationic neurotransmitters, Since all mutated residues are highly conserved in AVP and OT receptors, we propose that the same agonist-binding site is shared by all members of this receptor family, In contrast, the affinity for the antagonists tested, including those with a structure closely related to AVP, is not affected by mutations, This indicates a different binding mode for agonists and antagonists in the vasopressin receptor.	CNRS, INSERM, CTR PHARMACOL ENDOCRINOL, UNITE 401, F-34094 MONTPELLIER 05, FRANCE; MARION MERRELL DOW RES INST, F-67009 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673; Chini, Bice/0000-0002-1686-284X				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; BARBERIS C, 1993, VASOPRESSIN, P69; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FONG TM, 1992, J BIOL CHEM, V267, P25664; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HOFLACK J, 1993, 3D QSAR DRUG DESIGN, P355; HRUBY VJ, 1987, TRENDS PHARMACOL SCI, V8, P336, DOI 10.1016/0165-6147(87)90142-8; JARD S, 1988, INT CONGR SER, V799, P1183; JARD S, 1975, PHYSIOL REV, V55, P489, DOI 10.1152/physrev.1975.55.4.489; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAHLMANN S, 1994, P NATL ACAD SCI USA, V91, P1342, DOI 10.1073/pnas.91.4.1342; MANNING M, 1993, J RECEPTOR RES, V13, P195, DOI 10.3109/10799899309073655; MANNING M, 1984, NATURE, V308, P652, DOI 10.1038/308652a0; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TRUMPPKALLMEYER S, 1994, TACHYKININ RECEPTORS; ZIEGER G, 1991, MAGN RESON CHEM, V29, P580, DOI 10.1002/mrc.1260290608	45	205	206	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25771	25777		10.1074/jbc.270.43.25771	http://dx.doi.org/10.1074/jbc.270.43.25771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592759	hybrid			2022-12-25	WOS:A1995TB46600076
J	NG, SW; EDER, JP; SCHNIPPER, LE; CHAN, VTW				NG, SW; EDER, JP; SCHNIPPER, LE; CHAN, VTW			MOLECULAR-CLONING AND CHARACTERIZATION OF THE PROMOTER FOR THE CHINESE-HAMSTER DNA TOPOISOMERASE II-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE GENE; BOX-BINDING-PROTEINS; HUMAN-LEUKEMIC CELLS; 5'-FLANKING REGION; EXPRESSION; TRANSCRIPTION; RESISTANT; LOCALIZATION; CDNA; SEQUENCES	To investigate the mechanisms governing the expression of DNA topoisomerase II alpha, the Chinese hamster topoisomerase II alpha gene has been cloned and the promoter region analyzed. There are several transcriptional start sites clustered in a region of 30 base pairs, with the major one being 102 nucleotides upstream from the ATG translation initiation site. Sequencing data reveal one GC box and a total of five inverted CCAAT elements (ICEs) within a region of 530 base pairs upstream from the major transcription start site. Sequence comparison between the human and Chinese hamster topoisomerase II alpha gene promoter regions shows a high degree of homology centered at the ICEs and GC box. In vitro DNase I footprinting results indicate protection by binding proteins at and around each ICE on both DNA strands. However, no obvious protection was observed for the GC box, Competition gel mobility shift assays with oligonucleotides containing either the wild-type or mutated ICE sequences suggest that identical or similar proteins specifically bind at each ICE, although with different affinities for individual ICE sequences. Chloramphenicol acetyltransferase assays employing nested 5'-deletions of the 5'-flanking sequence of the gene demonstrate that the sequence between -186 and +102, which contains three proximal ICEs, is sufficient for near wild-type level of promoter activity. When these three ICEs were gradually replaced with sequences which do not interact with the binding proteins, reducing promoter activity of the resulted constructs was observed, In conjunction with results from footprinting and gel mobility shift studies, the transient gene expression finding suggests that the ICEs are functionally important for the transcriptional regulation of the topoisomerase II alpha gene.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,THORNDIKE LABS,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NCI NIH HHS [CA60154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; BECK WT, 1987, CANCER RES, V47, P5455; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; CARON PR, 1993, MOL BIOL DNA TOPOISO, P243; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DANKS MK, 1987, CANCER RES, V47, P1297; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FRY AM, 1991, CANCER RES, V51, P6592; GIACCONE G, 1992, CANCER RES, V52, P1666; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KAUFMANN SH, 1991, CANCER RES, V51, P3534; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MATSUO K, 1990, CANCER RES, V50, P5819; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXWELL A, 1985, ADV PROTEIN CHEM, V38, P69; MIRKOVITCH J, 1987, PHILOS T R SOC B, V317, P563, DOI 10.1098/rstb.1987.0081; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; POMMIER Y, 1986, CANCER RES, V46, P611; POMMIER Y, 1988, CANCER RES, V48, P512; POTMESIL M, 1988, CANCER RES, V48, P3537; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Sambrook J, 1989, MOL CLONING LABORATO; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANWIJNEN AJ, 1988, BIOCHEMISTRY-US, V27, P6534, DOI 10.1021/bi00417a051; WOESSNER RD, 1990, CANCER RES, V50, P2901	45	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25850	25858		10.1074/jbc.270.43.25850	http://dx.doi.org/10.1074/jbc.270.43.25850			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592770	hybrid			2022-12-25	WOS:A1995TB46600087
J	QU, YS; ISOM, LL; WESTENBROEK, RE; ROGERS, JC; TANADA, TN; MCCORMICK, KA; SCHEUER, T; CATTERALL, WA				QU, YS; ISOM, LL; WESTENBROEK, RE; ROGERS, JC; TANADA, TN; MCCORMICK, KA; SCHEUER, T; CATTERALL, WA			MODULATION OF CARDIAC NA+ CHANNEL EXPRESSION IN XENOPUS OOCYTES BY BETA-1 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; SODIUM-CHANNEL; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; BINDING-PROTEIN; ELECTROPHORUS-ELECTRICUS; SAXITOXIN BINDING; HUMAN BRAIN; TETRODOTOXIN; HEART	Voltage-gated Na+ channels consist of a large alpha subunit of 260 kDa associated with beta 1 and/or beta 2 subunits of 36 and 33 kDa, respectively. alpha subunits of rat cardiac Na+ channels (rH1) are functional when expressed alone in Xenopus oocytes or mammalian cells. beta 1 subunits are present in the heart, and localization of beta 1 subunit mRNA by in situ hybridization shows expression in the perinuclear cytoplasm of cardiac myocytes. Coexpression of beta 1 subunits with rH1 alpha subunits in Xenopus oocytes increases Na+ currents up to 6-fold in a concentration dependent manner. However, no effects of beta 1 subunit coexpression on the kinetics or voltage dependence of the rH1 Na+ current were detected. Increased expression of Na+ currents is not observed when an equivalent mRNA encoding a nonfunctional mutant beta 1 subunit is coexpressed. Our results show that beta 1 subunits are expressed in cardiac muscle cells and that they interact with alpha subunits to increase the expression of cardiac Na+ channels in Xenopus oocytes, suggesting that beta 1 subunits are important determinants of the level of excitability of cardiac myocytes in vivo.			QU, YS (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,BOX 357280,SEATTLE,WA 98195, USA.			Isom, Lori/0000-0002-9479-6729	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNEW WS, 1980, BIOCHEM BIOPH RES CO, V92, P860, DOI 10.1016/0006-291X(80)90782-2; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BAER M, 1976, NATURE, V263, P344, DOI 10.1038/263344a0; BARCHI RL, 1983, J NEUROCHEM, V40, P1377, DOI 10.1111/j.1471-4159.1983.tb13580.x; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BLACK JA, 1994, MOL BRAIN RES, V22, P275, DOI 10.1016/0169-328X(94)90056-6; BROWN AM, 1981, J PHYSIOL-LONDON, V318, P455; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; COHEN SA, 1993, CIRC RES, V73, P735, DOI 10.1161/01.RES.73.4.735; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KIMITSUKI T, 1990, AM J PHYSIOL, V258, pH247, DOI 10.1152/ajpheart.1990.258.1.H247; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KRANER SD, 1985, J BIOL CHEM, V260, P6341; KYLE JW, 1993, BIOPHYS J, V64, pA88; LOMBET A, 1984, EUR J BIOCHEM, V141, P651, DOI 10.1111/j.1432-1033.1984.tb08241.x; Makielski Jonathan C., 1995, Biophysical Journal, V68, pA157; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCCLATCHEY AI, 1993, HUM MOL GENET, V2, P745, DOI 10.1093/hmg/2.6.745; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; MILLER MA, 1989, METHODS NEUROSCIENCE, V1, P164; NORMAN RI, 1983, P NATL ACAD SCI-BIOL, V80, P4164, DOI 10.1073/pnas.80.13.4164; Nuss H. Bradley, 1995, Biophysical Journal, V68, pA133; OLEARY ME, 1994, J GEN PHYSIOL, V104, P507, DOI 10.1085/jgp.104.3.507; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; PATTON DE, 1994, J BIOL CHEM, V269, P17649; QU YS, 1994, P NATL ACAD SCI USA, V91, P3289, DOI 10.1073/pnas.91.8.3289; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SATIN J, 1992, J MEMBRANE BIOL, V130, P11; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SUTKOWSKI EM, 1990, J BIOL CHEM, V265, P12393; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; WHITE MM, 1991, MOL PHARMACOL, V39, P604; WOLLNER DA, 1988, NEURON, V1, P727, DOI 10.1016/0896-6273(88)90171-7; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7	45	108	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25696	25701		10.1074/jbc.270.43.25696	http://dx.doi.org/10.1074/jbc.270.43.25696			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592748	hybrid			2022-12-25	WOS:A1995TB46600065
J	BROSE, N; HOFMANN, K; HATA, Y; SUDHOF, TC				BROSE, N; HOFMANN, K; HATA, Y; SUDHOF, TC			MAMMALIAN HOMOLOGS OF CAENORHABDITIS-ELEGANS UNC-13 GENE DEFINE NOVEL FAMILY OF C-2-DOMAIN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE LEVELS; SYNAPTOTAGMIN; RECEPTOR; BINDING; MUTATIONS; SYNTAXIN; CLEAVAGE	The unc-13 gene in Caenorhabditis elegans is essential for normal presynaptic function and encodes a large protein with C-1- and C-2-domains. In protein kinase C and synaptotagmin, C-1- and/or C-2-domains are regulatory domains for Ca2+, phospholipids, and diacylglycerol, suggesting a role for unc-13 in regulating neurotransmitter release. To determine if a similar protein is a component of the presynaptic machinery for neurotransmitter release in vertebrates, we studied unc-13 homologues in rat. Molecular cloning revealed that three homologues of unc-13 called Munc13-1, -13-2, and -13-3 are expressed in rat brain. Munc13s are large, brain-specific proteins with divergent N termini but conserved C termini containing C-1- and C-2-domains. Specific antibodies demonstrated that Munc13-1 is a peripheral membrane protein that is enriched in synaptosomes and localized to plasma membranes but absent from synaptic vesicles. Our data suggest that the function of unc-13 in C. elegans is conserved in mammals and that Munc13s act as plasma membrane proteins in nerve terminals. The presence of C-1- and C-2-domains in these proteins and the phenotype of the C. elegans mutants raise the possibility that Munc13s may have an essential signaling role during neurotransmitter release.	UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; MAX PLANCK INST EXPTL MED,D-37075 GOTTINGEN,GERMANY; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Swiss Institute Experimental Cancer Research			Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083				AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; BRENNER S, 1974, GENETICS, V77, P71; BROSE N, 1993, J BIOL CHEM, V268, P22663; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFMANN K, 1995, FEBS LETT, V358, P153, DOI 10.1016/0014-5793(94)01415-W; HOSONO R, 1987, J NEUROCHEM, V49, P1820, DOI 10.1111/j.1471-4159.1987.tb02442.x; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; Jorgensen Erik M., 1995, Seminars in Developmental Biology, V6, P207, DOI 10.1016/S1044-5781(06)80030-7; KASANIETZ MG, 1995, J BIOL CHEM, V270, P10777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LUTHY R, 1994, PROTEIN SCI, V3, P139; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	40	318	332	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25273	25280		10.1074/jbc.270.42.25273	http://dx.doi.org/10.1074/jbc.270.42.25273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559667	hybrid			2022-12-25	WOS:A1995TB46500101
J	YAN, C; SEVER, Z; WHITSETT, JA				YAN, C; SEVER, Z; WHITSETT, JA			UPSTREAM ENHANCER ACTIVITY IN THE HUMAN SURFACTANT PROTEIN-B GENE IS MEDIATED BY THYROID TRANSCRIPTION FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HOMEODOMAIN; SITES	Surfactant protein B (SP-B) is selectively expressed in bronchiolar and alveolar epithelial cells of the lung. We identified an upstream enhancer located in the 5'-flanking region of the human SP-B gene (-439 to -331 base pair, hSP-B(-439/-331)) by deletion analysis of SP-B-luciferase constructs assessed in transfection assays in vitro. The element cis-activated the expression of an SV40 promoter-luciferase reporter gene in a human pulmunary adenocarcinoma cell line (H441-4). Three distinct binding sites for the nuclear transcription protein, thyroid transcription factor 1 (TTF-1), were identified, and the purified TTF-1 homeodomain was bound to the region of hSP-B(-439/-331). Co-transfection of H441-4 cells with the expression vector pCMV-TTF-1 trans-activated the native human SP-B promoter and the SV40 promoter fused with the SP-B enhancer. Mutations of the TTF-1 binding sites in the upstream enhancer blocked TTF-1 binding and transactivation activity. In summary, TTF-1 interacts with distinct proximal (-80 to -110) and distal (-439 to -331) cis-acting elements that regulate lung epithelial cell-specific transcription of the human SP-B gene.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038859, P01HL051832, R37HL038859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38859, HL51832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; GALANG CK, 1992, NEW BIOL, V4, P558; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; KELLY SE, 1995, AM J RESP CRIT CARE, V151, P163; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PTASHNE M, 1992, GENETIC SWITCH GENE, P114; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WHITSETT JA, 1995, IN PRESS PHYSL REV; YAN C, 1989, J BIOL CHEM, V265, P20188; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	25	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24852	24857		10.1074/jbc.270.42.24852	http://dx.doi.org/10.1074/jbc.270.42.24852			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559607	hybrid			2022-12-25	WOS:A1995TB46500041
J	ZHAO, TP; BETTELHEIM, FA				ZHAO, TP; BETTELHEIM, FA			ENTHALPY AND ENTROPY OF HYDRATION OF BOVINE CRYSTALLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ANALYSIS; FREEZABLE WATER-CONTENT; EYE-LENS; ALPHA-CRYSTALLIN; GAMMA-CRYSTALLIN; BETA-CRYSTALLIN; OSMOTIC-PRESSURE; TRANSPARENCY; RESOLUTION; STABILITY	Transparency of the lens of the eye is the result of a short range order in the packing of crystallin molecules within the fiber cells. Short range order depends on crystallin crystallin as well as water crystallin interactions. Light scattering measurements can provide information on the hydration of crystallins. Light scattering intensities were obtained as a function of scattering angle, concentration, and temperature on dilute solutions of beta(H),beta(L), and gamma fractions of bovine lens crystallins. The temperature dependence of the second virial coefficient was negative for the beta crystallin fractions and positive for the gamma fraction as well as that for alpha crystallin (Wang, X., and Bettelheim, F. A. (1989) Proteins Struct. Funct. Genet, 5, 166-169). The partial molar enthalpy values of the solutions were negative for the beta crystallin fractions, indicating a tendency for homo- and heterodimer and -oligomer association. The enthalpy values were positive for the alpha and gamma fractions. The negative values of the enthalpy of solutions differentiate the beta crystallins from the other crystallins. The partial molar entropy values of solutions of beta(L) and gamma fractions were identical, those of the oligomeric beta(H) fraction were higher, whereas those of alpha crystallin were a magnitude larger than those of the the smaller crystallin molecules.	ADELPHI UNIV,DEPT CHEM,GARDEN CITY,NY 11530	Adelphi University					NATIONAL EYE INSTITUTE [R01EY002571] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02571] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Bettelheim F. A., 1985, OCULAR LENS STRUCTUR, P265; BETTELHEIM FA, 1983, BIOPHYS J, V41, P29, DOI 10.1016/S0006-3495(83)84402-6; BETTELHEIM FA, 1986, CURR EYE RES, V5, P925, DOI 10.3109/02713688608995173; BETTELHEIM FA, 1990, EXP EYE RES, V50, P715, DOI 10.1016/0014-4835(90)90119-F; BETTELHEIM FA, 1986, INVEST OPHTH VIS SCI, V27, P122; BETTELHEIM FA, 1992, BIOCHEM BIOPH RES CO, V187, P39, DOI 10.1016/S0006-291X(05)81455-X; BETTELHEIM FA, 1991, EXP EYE RES, V52, P269, DOI 10.1016/0014-4835(91)90090-2; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P221; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; CASTORO JA, 1987, EXP EYE RES, V45, P191, DOI 10.1016/S0014-4835(87)80091-X; CHIRGADZE IN, 1986, DOKL AKAD NAUK SSSR+, V290, P492; FERNALD RD, 1983, NATURE, V301, P618, DOI 10.1038/301618a0; Flory PI, 1953, PRINCIPLES POLYM CHE, P495; HOPE JN, 1994, PROTEIN ENG, V7, P445, DOI 10.1093/protein/7.3.445; KENWORTHY AK, 1994, EXP EYE RES, V59, P11, DOI 10.1006/exer.1994.1077; LAHM D, 1985, INVEST OPHTH VIS SCI, V26, P1162; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; NAJMUDIN S, 1993, ACTA CRYSTALLOGR D, V49, P223, DOI 10.1107/S0907444992007601; SCHURTENBERGER P, 1991, BIOPOLYMERS, V31, P1229, DOI 10.1002/bip.360311011; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SLINGSBY C, 1990, BIOCHEMISTRY-US, V29, P6592, DOI 10.1021/bi00480a007; SLINGSBY C, 1985, TRENDS BIOCHEM SCI, V10, P281, DOI 10.1016/0968-0004(85)90088-X; TANFORD C, 1961, PHYSICAL CHEM MACROM, P200; THOMSON JA, 1989, CURR EYE RES, V8, P139, DOI 10.3109/02713688908995185; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; VERETOUT F, 1989, EUR BIOPHYS J BIOPHY, V17, P61, DOI 10.1007/BF00257103; WANG H, 1992, EXP EYE RES, V55, P387, DOI 10.1016/0014-4835(92)90110-E; WANG XW, 1989, PROTEINS, V5, P166, DOI 10.1002/prot.340050211; WHITE HE, 1989, J MOL BIOL, V207, P217, DOI 10.1016/0022-2836(89)90452-X; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1978, EXP EYE RES, V26, P537, DOI 10.1016/0014-4835(78)90063-5; ZIGLER JS, 1980, EXP EYE RES, V31, P41, DOI 10.1016/0014-4835(80)90089-5; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740	35	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24961	24964		10.1074/jbc.270.42.24961	http://dx.doi.org/10.1074/jbc.270.42.24961			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559623	hybrid			2022-12-25	WOS:A1995TB46500057
J	SCOTT, A; HAYSTEAD, CMM; HAYSTEAD, TAJ				SCOTT, A; HAYSTEAD, CMM; HAYSTEAD, TAJ			PURIFICATION OF A 12,020-DALTON PROTEIN THAT ENHANCES THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE BY MAP KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; TYROSINE KINASE; PHOSPHORYLATION; RAF; CELLS; MEK; PATHWAY; CLONING; INVITRO; COMPLEX	We have purified 3500-fold from rabbit skeletal muscle a 12,020-Da mitogen-activated protein kinase kinase (MEK)-enhancing factor (MEF) that stimulates both mitogen-activated protein kinase (MAPK) autophosphorylation and the rate (24-fold) at which the enzyme is phosphorylated by MEK in vitro. This was manifest by the finding that in the presence of MEF, molar equivalents of MEK to MAPK were sufficient to produce fully phosphorylated (2.1 +/- 0.4 mol/mol; S,D., n = 3) and activated MAPK, This contrasted with the 40:1 molar excess ratio of MEK to MAPK required to produce fully phosphorylated and activated MAPK in the absence of MEF. Phosphoamino acid analysis revealed that in the presence of MEF, phosphorylation of MAPK by MEK was ordered, with Tyr-185 phosphorylation preceding Thr-183 phosphorylation. However, the rate at which Thr-183 was phosphorylated relative to Tyr-185 was greatly increased, The finding that MEF stimulated MAPK autophosphorylation and increased its ability to be phosphorylated by MEK suggests a mechanism of action in which MEF interacts with MAPK to alter its conformation.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; CHOI KY, 1994, CELL, V78, P499; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ERREDA B, 1995, CURR OPIN CELL BIOL, V7, P197; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HAYSTEAD CMM, 1993, FEBS LETT, V317, P12, DOI 10.1016/0014-5793(93)81481-E; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; JAIWAL RK, 1994, MOL CELL BIOL, V14, P6944; KNIGHTON DR, 1991, SCIENCE, V407, P407; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MANSOUR SJ, 1994, SCIENCE, V265, P967; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SEGAR R, 1992, J BIOL CHEM, V267, P25628; SOLOMON MJ, 1991, CELL, V63, P1013; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1992, P NATL ACAD SCI USA, V90, P173; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHANG C, 1993, J BIOL CHEM, V268, P11435; ZHANG F, 1995, NATURE, V367, P704; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	61	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24540	24547		10.1074/jbc.270.41.24540	http://dx.doi.org/10.1074/jbc.270.41.24540			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592672	hybrid			2022-12-25	WOS:A1995TA21700100
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			SPHINGOSYLPHOSPHORYLCHOLINE RAPIDLY INDUCES TYROSINE PHOSPHORYLATION OF P125(FAK) AND PAXILLIN, REARRANGEMENT OF THE ACTIN CYTOSKELETON AND FOCAL CONTACT ASSEMBLY - REQUIREMENT OF P21(RHO) IN THE SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-KINASE-C; EXTRACELLULAR-MATRIX; ADHESION PROTEIN; ACTIVATION; BOMBESIN; VASOPRESSIN; CALCIUM; MOBILIZATION; STIMULATION	Sphingosylphosphorylcholine (SPC), a potent mitogen for Swiss 3T3 cells, rapidly induced tyrosine phosphorylation of multiple substrates including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000 in Swiss 3T3 cells, Focal adhesion kinase (p125(FAK)) and paxillin were identified as prominent substrates for SPC-stimulated tyrosine phosphorylation, An increase in tyrosine phosphorylation of p125(FAK) was detected as soon as 30 s after SPC stimulation, reaching a maximum after 2.5 min, SPC induced tyrosine phosphorylation of p125(FAK) in a concentration-dependent fashion; a half-maximum effect occurred at 250 nM. Tyrosine phosphorylation of p125(FAK) induced by SPC could be dissociated from both protein kinase C activation and Ca2+ mobilization from intracellular stores, SPC induced a unique pattern of reorganization of the actin cytoskeleton with a rapid appearance of actin microspikes at the plasma membrane that was followed by the formation of actin stress fibers, This pattern of cytoskeletal changes was clearly distinguishable from that induced by bombesin and 1-oleoyl-lysophosphatidic acid. Formation of microspikes and actin stress fibers were accompanied by striking assembly of focal adhesion plaques, Cytochalasin D, which disrupts the network of actin microfilaments, completely prevented SPC-induced tyrosine phosphorylation of p125(FAK), In addition, tyrosine phosphorylation of p125(FAK) was markedly inhibited in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that disrupts actin stress fibers, Finally, microinjection of Clostridium botulinum C3 exoenzyme, which inactivates p21(rho), prevented SPC-induced formation of actin stress fibers, focal adhesion assembly, and tyrosine phosphorylation, Thus, p21(rho) is upstream of both cytoskeletal reorganization and tyrosine phosphorylation in SPC-treated cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1991, EXP CELL RES, V192, P651, DOI 10.1016/0014-4827(91)90090-H; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1994, J CELL SCI, V107, P1583; VUORI K, 1993, J BIOL CHEM, V268, P21459; YULE D, 1994, J BIOL CHEM, V268, P12353; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	42	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24343	24351		10.1074/jbc.270.41.24343	http://dx.doi.org/10.1074/jbc.270.41.24343			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592646	hybrid			2022-12-25	WOS:A1995TA21700074
J	TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ				TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ			QUASI-NATIVE CHAPERONIN-BOUND INTERMEDIATES IN FACILITATED PROTEIN-FOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-COMPLEX POLYPEPTIDE-1; CYTOPLASMIC CHAPERONIN; ATP HYDROLYSIS; ALPHA-TUBULIN; IN-VIVO; GROEL; COOPERATIVITY; SUBUNITS; RING	Chaperonins are known to facilitate protein folding, but their mechanism of action is not well understood. The fact that target proteins are released from and rebind to different chaperonin molecules (''cycling'') during a folding reaction suggests that chaperonins function by unfolding aberrantly folded molecules, allowing them multiple opportunities to reach the native state in bulk solution. Here we show that the cycling of alpha-tubulin by cytosolic chaperonin (c-cpn) can be uncoupled from the action of cofactors required to complete the folding reaction. This results in the accumulation of folding intermediates which are chaperonin-bound, stable, and quasi-native in that they bind GTP nonex-changeably. We present evidence that these intermediates can be generated without the target protein leaving c-cpn. These data show that, in contrast to prevailing models, target proteins can maintain, and possibly acquire, significant native-like structure while chaperonin-bound.	NYU,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University								AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P12424; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9	27	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23910	23913		10.1074/jbc.270.41.23910	http://dx.doi.org/10.1074/jbc.270.41.23910			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592580	hybrid			2022-12-25	WOS:A1995TA21700008
J	RIES, A; ENGEL, J; LUSTIG, A; KUHN, K				RIES, A; ENGEL, J; LUSTIG, A; KUHN, K			THE FUNCTION OF THE NC1 DOMAINS IN TYPE-IV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; ALPHA-2 CHAINS; GENES; ORGANIZATION; AGGREGATION; MOLECULES; PROMOTER; NETWORK; REGION; MODEL	At its C terminus, the collagen IV molecule bears a globular NC1 domain, to which two functions have been assigned. In the macromolecular network of collagen IV, two molecules are connected via their NC1 domains, which form a hexameric complex, stabilized by intermolecular disulfide bonds. In addition, the NC1 domains are thought to be responsible for chain selection and assembly. In order to understand the role of the NC1 domains during these steps, hexameric complexes were isolated and further investigated. SDS-polyacrylamide gel electrophoresis and Western blot revealed disulfide-linked alpha 1(IV)NC1 and alpha 2(IV)NC1 homodimers but no heterodimers. The hexamers were dissociated at low pH, separated into monomers and dimers, and submitted to reconstitution experiments. Only alpha 1(IV)NC1 dimers were able to reconstitute a hexameric complex. alpha 1(IV)-NC1 and alpha 2(IV)NC1 monomers as well as the alpha 2(IV)NC1 dimers showed only a low tendency to form complexes. It is assumed that during formation of the collagen IV network, lateral aggregation of the molecules via the triple helical domains brings the C termini of two molecules into close vicinity and that subsequently the weak interactions observed between the NC1 subdomains provide the correct alignment for a disulfide exchange. It is, however, questionable whether the low affinity between the NC1 subdomains alone is sufficient for chain assembly and alignment of the alpha(IV) chains before molecule formation.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	Max Planck Society; University of Basel								BYERS PH, 1975, P NATL ACAD SCI USA, V72, P3009, DOI 10.1073/pnas.72.8.3009; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KUHN K, 1994, MATRIX BIOL, V14, P439; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LUKENS LN, 1976, J BIOL CHEM, V251, P3530; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MORRIS NP, 1975, J BIOL CHEM, V250, P5719; OBERBAUMER I, 1982, EMBO J, V7, P805; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; REGAN L, 1994, PROTEIN SCI, V3, P2419, DOI 10.1002/pro.5560031225; SCHOFIELD JD, 1974, BIOCHEMISTRY-US, V13, P1801, DOI 10.1021/bi00706a004; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; SOININEN R, 1988, J BIOL CHEM, V263, P17217; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	24	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23790	23794		10.1074/jbc.270.40.23790	http://dx.doi.org/10.1074/jbc.270.40.23790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559554	hybrid			2022-12-25	WOS:A1995RY90900083
J	TAHARA, H; KAMADA, K; SATO, E; TSUYAMA, N; KIM, JK; HARA, E; ODA, K; IDE, T				TAHARA, H; KAMADA, K; SATO, E; TSUYAMA, N; KIM, JK; HARA, E; ODA, K; IDE, T			INCREASE IN EXPRESSION LEVELS OF INTERFERON-INDUCIBLE GENES IN SENESCENT HUMAN-DIPLOID FIBROBLASTS AND IN SV40-TRANSFORMED HUMAN FIBROBLASTS WITH EXTENDED LIFE-SPAN	ONCOGENE			English	Article						SENESCENT CELLS; SV40-TRANSFORMED CELLS; INTERFERON; INTERFERON-INDUCIBLE GENES	GROWTH-FACTOR; DNA-SYNTHESIS; HUMAN-CELLS; SIMIAN VIRUS-40; MESSENGER-RNA; T-ANTIGEN; BETA; INHIBITION; INVITRO; SPAN	The normal human fibroblast line, TIG-3 which senesces at around 80 population doubling levels (PDLs), expressed interferon (IFN)-inducible genes such as 6-16, 2', 5'-oligoadenylate synthetase (2,5-A) and HLA B7 near the end of the proliferative lifespan. Other normal fibroblast line such as MRC-5 also expressed IFN-inducible genes when senesced. Clones transformed with SV40 T-antigen, which extended their proliferative lifespan by about 20-30 PDLs, also expressed IFN-inducible genes during their extended life. Anti-IFN-beta antibodies added in culture medium repressed the expression of IFN-inducible gene in both senescent and life-extended SV40-transformed IFN-beta repressed DNA synthesis in normal TIG-3 and induced IFN-inducible genes in both normal and SV40-transformed TIG-3. Conditioned medium recovered from life-extended SV40-transformed cells contained IFN-beta, but not IFN-alpha, IFN-gamma or TNF-alpha and possessed an activity that inhibited DNA synthesis of young TIG-3. Addition of anti-IFN-beta antibodies into the medium enhanced the serum-induced DNA synthesis of near senescent (91% lifespan completed) TIG-3, while it neither induced DNA synthesis in fully senescent TIG-3 nor extended the proliferative lifespan of TIG-3. These results suggest that normal and SV40-transformed human fibroblasts increase expression of IFN-beta with increasing proliferative age especially near the end of their lifespan resulting in induction of IFN-inducible genes and possibly in growth repression.	HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN	Hiroshima University; Tokyo University of Science								BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFINIS GJ, 1981, J GEN VIROL, V52, P169, DOI 10.1099/0022-1317-52-1-169; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRESCHERLINCOLN CK, 1984, EXP CELL RES, V153, P208, DOI 10.1016/0014-4827(84)90462-2; DRESCHERLINCOLN CK, 1983, EXP CELL RES, V144, P455, DOI 10.1016/0014-4827(83)90424-X; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ELEFTHERIOU CS, 1993, BIOCHIM BIOPHYS ACTA, V1180, P304, DOI 10.1016/0925-4439(93)90055-6; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FRIEDMAN RL, 1979, INTERFERON INTERACTI, V1; GERFAUX J, 1989, CANCER RES, V49, P1241; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1969, LANCET, V1, P424; GOLDSTEIN S, 1978, SCIENCE, V199, P781, DOI 10.1126/science.622567; GOLDSTEIN S, 1989, EXP GERONTOL, V24, P461, DOI 10.1016/0531-5565(89)90052-1; HARA E, 1993, ANAL BIOCHEM, V214, P58, DOI 10.1006/abio.1993.1456; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HERZOG H, 1990, NUCLEIC ACIDS RES, V18, P4600, DOI 10.1093/nar/18.15.4600; HISCOTT J, 1988, MOL CELL BIOL, V8, P3397, DOI 10.1128/MCB.8.8.3397; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; IWATA A, 1988, J BIOCHEM-TOKYO, V104, P247, DOI 10.1093/oxfordjournals.jbchem.a122451; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LALLEMAND C, 1992, ONCOGENE, V7, P1109; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OHASHI M, 1980, EXP GERONTOL, V15, P121, DOI 10.1016/0531-5565(80)90083-2; OLESZAK E, 1980, J INTERFERON RES, V1, P37, DOI 10.1089/jir.1980.1.37; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; TAHARA H, 1994, BIOCHEM BIOPH RES CO, V199, P1108, DOI 10.1006/bbrc.1994.1345; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WISTROM C, 1992, EXP CELL RES, V199, P355, DOI 10.1016/0014-4827(92)90445-E; YANISHEVSKY RM, 1980, EXP CELL RES, V126, P469, DOI 10.1016/0014-4827(80)90290-6; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	49	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1125	1132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566972				2022-12-25	WOS:A1995RX18000015
J	CONSTAM, DB; TOBLER, AR; RENSINGEHL, A; KEMLER, I; HERSH, LB; FONTANA, A				CONSTAM, DB; TOBLER, AR; RENSINGEHL, A; KEMLER, I; HERSH, LB; FONTANA, A			PUROMYCIN-SENSITIVE AMINOPEPTIDASE - SEQUENCE-ANALYSIS, EXPRESSION, AND FUNCTIONAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; ENKEPHALIN-DEGRADING AMINOPEPTIDASES; MATURATION-PROMOTING FACTOR; EPIDERMAL GROWTH-FACTOR; AMINO-ACID SEQUENCE; MULTICATALYTIC PROTEINASE; TAU-PROTEIN; NUCLEAR TRANSLOCATION; EMBRYONIC-DEVELOPMENT; MITOTIC-ARREST	Among the molecular mechanisms that control the cell division cycle, proteolysis has emerged as a key regulatory process enabling cells to pass critical check points. Such proteolysis involves a cascade of enzymes including a multisubunit complex termed 26S proteasome. Here we report on the analysis of a novel mouse cDNA encoding the puromycin-sensitive aminopeptidase (PSA) and on its expression in COS cells and 3T3 fibroblasts. PSA is 27-40% homologous to several known Zn2+-binding aminopeptidases including aminopeptidase N. Immunohistochemical analysis revealed that PSA is localized to the cytoplasm and to the nucleus and associates with microtubules of the spindle apparatus during mitosis. Furthermore, puromycin and bestatin both arrested the cell cycle, leading to an accumulation of cells in G(2)/M phase, and ultimately induced cells to undergo apoptosis at concentrations that inhibit PSA. Control experiments including cycloheximide further suggested that the induction of apoptosis by puromycin was not attributable to inhibition of protein synthesis. Taken together, these data favor the novel idea that PSA participates in proteolytic events essential for cell growth and viability.	UNIV ZURICH HOSP,DEPT INTERNAL MED,CLIN IMMUNOL SECT,CH-8044 ZURICH,SWITZERLAND; UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Zurich; University Zurich Hospital; University of Kentucky				Constam, Daniel B./0000-0002-6256-3891	NIDA NIH HHS [DA 02243] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AIZAWA H, 1989, J BIOL CHEM, V264, P5885; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; BARRY MA, 1993, CANCER RES, V53, P2349; BROWNLEES J, 1993, J NEUROCHEM, V60, P793, DOI 10.1111/j.1471-4159.1993.tb03223.x; CHAILLET P, 1983, EUR J PHARMACOL, V86, P329, DOI 10.1016/0014-2999(83)90181-4; DAVIDOFF AN, 1992, LEUKEMIA RES, V16, P1077, DOI 10.1016/0145-2126(92)90046-A; DAVIDOFF AN, 1993, EXP HEMATOL, V21, P456; DEERY WJ, 1984, J CELL BIOL, V98, P904, DOI 10.1083/jcb.98.3.904; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; DYER SH, 1990, J NEUROCHEM, V54, P547, DOI 10.1111/j.1471-4159.1990.tb01906.x; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HAMBROOK JM, 1976, NATURE, V262, P782, DOI 10.1038/262782a0; HERSH LB, 1980, NATURE, V286, P160, DOI 10.1038/286160a0; HERSH LB, 1981, J NEUROCHEM, V36, P171, DOI 10.1111/j.1471-4159.1981.tb02392.x; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUI KS, 1983, BIOCHEMISTRY-US, V22, P1062, DOI 10.1021/bi00274a010; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KAWAHARA H, 1992, DEV BIOL, V151, P27, DOI 10.1016/0012-1606(92)90210-8; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; Loewe Jan, 1995, Science (Washington D C), V268, P533; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MCLELLAN S, 1988, J NEUROCHEM, V51, P1552, DOI 10.1111/j.1471-4159.1988.tb01124.x; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PAL JK, 1988, J CELL SCI, V90, P555; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SOLHONNE B, 1987, NEUROSCIENCE, V22, P225, DOI 10.1016/0306-4522(87)90212-0; TAKAHASHI SI, 1985, J ANTIBIOT, V38, P1767, DOI 10.7164/antibiotics.38.1767; TAKAHASHI SI, 1989, EXP CELL RES, V183, P399, DOI 10.1016/0014-4827(89)90400-X; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	53	165	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26931	26939		10.1074/jbc.270.45.26931	http://dx.doi.org/10.1074/jbc.270.45.26931			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592939	hybrid			2022-12-25	WOS:A1995TE58300039
J	KOBAYASHI, K; MORITA, S; SAWADA, H; MIZUGUCHI, T; YAMADA, K; NAGATSU, I; HATA, T; WATANABE, Y; FUJITA, K; NAGATSU, T				KOBAYASHI, K; MORITA, S; SAWADA, H; MIZUGUCHI, T; YAMADA, K; NAGATSU, I; HATA, T; WATANABE, Y; FUJITA, K; NAGATSU, T			TARGETED DISRUPTION OF THE TYROSINE-HYDROXYLASE LOCUS RESULTS IN SEVERE CATECHOLAMINE DEPLETION AND PERINATAL LETHALITY IN MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DECARBOXYLASE; IMMUNO-CYTOCHEMICAL LOCALIZATION; DEPENDENT PROTEIN-KINASE; PRENATAL RAT-BRAIN; MANIC-DEPRESSION; MESSENGER-RNA; NORADRENERGIC PHENOTYPE; TRANSIENT EXPRESSION; TRANSGENIC MICE; ENTERIC NEURONS	Tyrosine 3-hydroxylase (TH, EC 1.14.16.2) catalyzes the first and rate-limiting step of the catecholamine biosynthetic pathway in the nervous and endocrine systems. The TH locus was disrupted in mouse embryonic stem cells by homologous recombination, Mice heterozygous for the TH mutation were apparently normal, In these mice, TH activity in the embryos and adult tissues was less than 50% of the wild-type values, but the catecholamine level was decreased only moderately in the developing animals and was maintained normally at adulthood, suggesting the presence of a regulatory mechanism for ensuring the proper catecholamine level during animal development, In contrast, the homozygous mutant mice died at a late stage of embryonic development or shortly after birth. Both TH mRNA and enzyme activity were lacking in the homozygous mutants, which thus explained the severe depletion of catecholamines. These changes, however, did not affect gross morphological development of the cells that normally express high catecholamine levels, Analysis of electrocardiograms of surviving newborn mutants showed bradycardia, suggesting an alteration of cardiac functions in the homozygous mice that may lead to the lethality of this mutation. In addition, transfer of a human TH transgene into the homozygous mice corrected the mutant phenotype, showing recovery of TH activity by expression of the human enzyme, These results indicate that TH is essential for survival of the animals during the late gestational development and after birth.	FUJITA HLTH UNIV, SCH MED, INST COMPREHENS MED SCI, TOYOAKE, AICHI 47011, JAPAN; FUJITA HLTH UNIV, SCH MED, DEPT ANAT, TOYOAKE, AICHI 47011, JAPAN; FUJITA HLTH UNIV, SCH MED, INST CARDIOVASC, TOYOAKE, AICHI 47011, JAPAN; CHUBU NATL HOSP, DEPT CLIN RES, AICHI 474, JAPAN	Fujita Health University; Fujita Health University; Fujita Health University				Kobayashi, Kazuto/0000-0002-7617-2939				ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P7713, DOI 10.1073/pnas.81.24.7713; ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; AXELROD J, 1966, PHARMACOL REV, V18, P95; AXELROD J, 1963, SCIENCE, V140, P499, DOI 10.1126/science.140.3566.499; BAETGE G, 1989, DEV BIOL, V132, P189, DOI 10.1016/0012-1606(89)90217-0; BAETGE G, 1990, DEV BIOL, V141, P353, DOI 10.1016/0012-1606(90)90391-U; BOHN MC, 1986, DEV BIOL, V114, P180, DOI 10.1016/0012-1606(86)90394-5; BOHN MC, 1982, DEV BIOL, V89, P299, DOI 10.1016/0012-1606(82)90319-0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUDNIK V, 1987, J NEUROGENET, V4, P309, DOI 10.3109/01677068709102351; Buijs R.M., 1992, HDB CHEM NEUROANATOM, P63; BYERLEY W, 1992, HUM HERED, V42, P259, DOI 10.1159/000154079; CHRISTENSON JG, 1970, ARCH BIOCHEM BIOPHYS, V141, P356, DOI 10.1016/0003-9861(70)90144-X; COCHARD P, 1979, DEV BIOL, V71, P100, DOI 10.1016/0012-1606(79)90085-X; DETERAWADLEIGH SD, 1987, NATURE, V325, P806, DOI 10.1038/325806a0; DUMAS S, 1990, J NEUROSCI RES, V25, P569, DOI 10.1002/jnr.490250415; EISENHOFER G, 1989, J CLIN ENDOCR METAB, V68, P247, DOI 10.1210/jcem-68-2-247; FAXELIUS G, 1983, ARCH DIS CHILD, V58, P262, DOI 10.1136/adc.58.4.262; GILL M, 1988, J MED GENET, V25, P634, DOI 10.1136/jmg.25.9.634; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; HODGKINSON S, 1987, NATURE, V325, P805, DOI 10.1038/325805a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; JAVOYAGID F, 1990, NEUROSCIENCE, V38, P245, DOI 10.1016/0306-4522(90)90389-L; JONAKAIT GM, 1984, DEV BIOL, V101, P51, DOI 10.1016/0012-1606(84)90116-7; Jones CT., 1980, BIOGENIC AMINES DEV, P63; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; KOBAYASHI K, 1992, P NATL ACAD SCI USA, V89, P1631, DOI 10.1073/pnas.89.5.1631; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KOBAYASHI K, 1994, J BIOL CHEM, V269, P29725; KOBAYASHI K, 1988, FEBS LETT, V238, P431, DOI 10.1016/0014-5793(88)80526-X; LAUWERYNS JM, 1988, J HISTOCHEM CYTOCHEM, V36, P1181, DOI 10.1177/36.9.2900264; LEBLANC GG, 1989, DEV BIOL, V131, P44, DOI 10.1016/S0012-1606(89)80037-5; LEBOYER M, 1990, LANCET, V335, P1219, DOI 10.1016/0140-6736(90)92738-4; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MELIGENI JA, 1982, J BIOL CHEM, V257, P2632; MILLS E, 1986, AM J PHYSIOL, V250, pR188, DOI 10.1152/ajpregu.1986.250.2.R188; NAGATSU I, 1993, TEC BEHAV N 1, V11, P151; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Nagatsu T, 1984, Adv Neurol, V40, P467; NECKAMEYER WS, 1993, J NEUROGENET, V8, P189, DOI 10.3109/01677069309083448; OLIVER RE, 1981, ARCH DIS CHILD, V56, P659, DOI 10.1136/adc.56.9.659; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PEARSE AGE, 1969, J HISTOCHEM CYTOCHEM, V17, P303, DOI 10.1177/17.5.303; RAHMAN MK, 1981, BIOCHEM PHARMACOL, V30, P645, DOI 10.1016/0006-2952(81)90139-8; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SEIDLER FJ, 1985, J PHYSIOL-LONDON, V358, P1; SILVER M, 1980, BIOGENIC AMINES DEV, P147; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; TEITELMAN G, 1978, BRAIN RES, V158, P229, DOI 10.1016/0006-8993(78)90021-5; TEITELMAN G, 1983, J NEUROSCI, V3, P1379; TEITELMAN G, 1987, CELL TISSUE RES, V250, P435; VULLIET PR, 1985, FEBS LETT, V182, P335, DOI 10.1016/0014-5793(85)80328-8; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215; ZIMLICHMAN R, 1988, CLIN SCI, V75, P515, DOI 10.1042/cs0750515	63	178	184	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27235	27243		10.1074/jbc.270.45.27235	http://dx.doi.org/10.1074/jbc.270.45.27235			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592982	hybrid			2022-12-25	WOS:A1995TE58300082
J	MARTIN, BL; SCHRADERFISCHER, G; BUSCIGLIO, J; DUKE, M; PAGANETTI, P; YANKNER, BA				MARTIN, BL; SCHRADERFISCHER, G; BUSCIGLIO, J; DUKE, M; PAGANETTI, P; YANKNER, BA			INTRACELLULAR ACCUMULATION OF BETA-AMYLOID IN CELLS EXPRESSING THE SWEDISH MUTANT AMYLOID PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMERS-DISEASE; MUTATION; PEPTIDE	beta-Amyloid (beta A) is a normal metabolic product of the amyloid precursor protein (APP) that accumulates in senile plaques in Alzheimer's disease. Cells that express the Swedish mutant APP (Sw-APP) associated with early onset Alzheimer's disease overproduce beta A, In this report, we show that expression of Sw-APP gives rise to cell-associated beta A, which is not detected in cells that express wild-type APP, Cell-associated beta A is rapidly generated, is trypsin-resistant, and is not derived from beta A uptake, indicating that it is generated from intracellular processing of Sw-APP, Intracellular and secreted beta A are produced with different kinetics, The generation of intracellular beta A is partially resistant to monensin and a 20 degrees C temperature block but is completely inhibited by brefeldin A, suggesting that it occurs in the Golgi complex, Monensin, brefeldin A, and a 20 degrees C temperature block almost completely inhibit beta A secretion without causing increased cellular retention of beta A, suggesting that secreted beta A is generated in a post-Golgi compartment, These results suggest that the metabolism of Sw-APP gives rise to intracellular and secreted forms of beta A through distinct processing pathways, Pathological conditions may therefore alter both the level and sites of accumulation of beta A It remains to be determined whether the intracellular form of beta A plays a role in the formation of amyloid plaques.	CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; SANDOZ RES INST,CH-3001 BERN,SWITZERLAND	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Novartis; Sandoz			Paganetti, Paolo/AAF-8039-2020	Paganetti, Paolo/0000-0003-1896-6324	NIA NIH HHS [AG09229] Funding Source: Medline; NINDS NIH HHS [NS30352] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG009229] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V359, P325; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; LO ACY, 1994, J BIOL CHEM, V269, P30966; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; PAGANETTI P, 1994, BRAIN RES, V633, P53, DOI 10.1016/0006-8993(94)91521-0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	20	88	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26727	26730		10.1074/jbc.270.45.26727	http://dx.doi.org/10.1074/jbc.270.45.26727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592902	hybrid			2022-12-25	WOS:A1995TE58300002
J	OBRIEN, LM; MEDVED, LV; FAY, PJ				OBRIEN, LM; MEDVED, LV; FAY, PJ			LOCALIZATION OF FACTOR IXA AND FACTOR VIIIA INTERACTIVE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; GAMMA-CARBOXYGLUTAMIC ACID; ACTIVATED PROTEIN-C; FACTOR-X ACTIVATION; A1/A3-C1-C2 DIMER; MONOCLONAL-ANTIBODIES; DOMAIN INTERACTIONS; A2 SUBUNIT; THROMBIN; BINDING	The contribution of the catalytic and noncatalytic domains of factor Ma to the interaction with its cofactor, factor VIIIa, was evaluated, Two proteolytic fragments of factor Ma, lacking some or all of the serine protease domain, failed to mimic the ability of factor Ma to enhance the reconstitution of factor VIIIa from isolated A1/A3-C1-C2 dimer and A2 subunit. Both fragments, however, inhibited this factor Ma-dependent activity, Selective thermal denaturation of the factor Ma serine protease domain eliminated its effect on factor Villa reconstitution, Modification of factor IXa with dansyl-Glu-Gly-Arg chloromethyl ketone (DEGR-IXa) stabilized this domain, and heat-treated DEGR-IXa retained its ability to enhance factor VIIIa reconstitution. These results indicate the importance of the serine protease do main as well as structures residing in the factor Ma light chain (gamma-carboxyglutamic acid and/or epidermal growth factor domains) for cofactor stabilizing activity, In the presence of phospholipid, the A1/A3-C1-C2 dimer produced a saturable increase in the fluorescence anisotropy of fluorescein-Phe-Phe-Arg chloromethyl ketone-modified factor IXa (F1-FFR-IXa), This effect was inhibited by a factor Ma fragment comprised of the gamma-carboxyglutamic acid and epidermal growth factor domains, The difference in F1-FFR-IXa anisotropy in the presence of A1/A3-C1-C2 dimer (Delta r = 0.043) compared with factor VIIIa (Delta r = 0.069) represented the contribution of the A2 subunit, A peptide corresponding to factor VIII A2 domain residues 558-565 decreased the factor Villa dependent anisotropy of F1-FFR-IXa to a value similar to that observed with the A1/A3-C1-C2 dimer, These results support a model of multiple interactive sites in the association of the enzyme-cofactor complex and localize sites for the A1/A3-C1-C2 dimer and the A2 subunit to the factor Ma light chain and serine protease domain, respectively.	UNIV ROCHESTER,SCH MED & DENT,MED CTR,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; AMER RED CROSS,HOLLAND LAB,ROCKVILLE,MD 20855	University of Rochester; University of Rochester; American Red Cross				Medved, Leonid/0000-0002-3665-9849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38199, HL 30616, HL-07152-20] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; CASILLAS G, 1971, COAGULATION, V4, P107; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FOSTER PA, 1990, BLOOD, V75, P1999; FRAZIER D, 1989, BLOOD, V74, P971; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAMAGUCHI N, 1994, BLOOD, V84, P1837, DOI 10.1182/blood.V84.6.1837.bloodjournal8461837; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LIN SW, 1990, J BIOL CHEM, V265, P144; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NOVOKHATNY VV, 1993, J BIOL CHEM, V268, P17211; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; THARAKAN J, 1990, VOX SANG, V58, P21, DOI 10.1111/j.1423-0410.1990.tb02050.x; TOOLE JJ, 1984, NATURE, V312, P330; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	43	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27087	27092		10.1074/jbc.270.45.27087	http://dx.doi.org/10.1074/jbc.270.45.27087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592960	hybrid			2022-12-25	WOS:A1995TE58300060
J	SCHWARTZ, ML; BRUCE, J; SHNEIDMAN, PS; SCHLAEPFER, WW				SCHWARTZ, ML; BRUCE, J; SHNEIDMAN, PS; SCHLAEPFER, WW			DELETION OF 3'-UNTRANSLATED REGION ALTERS THE LEVEL OF MESSENGER-RNA EXPRESSION OF A NEUROFILAMENT LIGHT SUBUNIT TRANSGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; GENE-EXPRESSION; UP-REGULATION; NF-L; MICE; CALIBER; PROTEINS; PROMOTER; SYSTEM; FAMILY	High levels of neurofilament (NF) mRNA expression are attained during early postnatal development and are a major determinant of axonal size. High level NF expression is also dependent upon axonal continuity since NF mRNA levels are down-regulated after nerve transection. This study shows that both postnatal upregulation and axotomy-induced down-regulation are altered by deletion of 3'-UTR from the mouse Light NF subunit (NF-L). Transgenes with (NF-L(+)) or without (NF-L(-)) 3'-UTR display similar patterns of neuron-specific expression but differ in their respective levels of expression. Whereas changes in the level of NF-L(+) mRNA parallel those of the endogenous mouse NF-L mRNA, changes in the level of NF-L(-) mRNA differ from the pattern of endogenous NP-L expression during postnatal up-regulation and axotomy-induced down-regulation. Specifically, the NF-L(-) transgene undergoes a 3-fold aberrant up-regulation between embryonic days 15 (E15) and 18 (E18) and has lost its susceptibility to axotomy-induced down-regulation. Studies of transfected P19 cells show that 3'-UTR deletion leads to a severalfold stabilization of NF-L mRNA and an increase in steady-state mRNA level. The findings support the working hypothesis that the 3'-UTR contains determinants that alter stability and that stabilization of NF-L mRNA regulates the levels of NF-L mRNA in neuronal tissues and cells.			SCHWARTZ, ML (corresponding author), UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, DIV NEUROPATHOL, 435 JOHNSON PAVIL, PHILADELPHIA, PA 19104 USA.				NINDS NIH HHS [R01 NS15722, T32 NS07064] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064, R01NS015722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1991, J CELL SCI, P85; COLE JS, 1994, J NEUROSCI, V14, P6956; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FRIEDE RL, 1972, J COMP NEUROL, V144, P233, DOI 10.1002/cne.901440207; GOLDSTEIN ME, 1988, MOL BRAIN RES, V3, P287, DOI 10.1016/0169-328X(88)90051-4; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HSIEH ST, 1994, J NEUROSCI, V14, P6392; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; MUMA NA, 1991, J NEUROCYTOL, V20, P844, DOI 10.1007/BF01191735; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PELTZ SW, 1993, CONTROL MRNA STABILI, P291; REEBEN M, 1993, BIOCHEM BIOPH RES CO, V192, P465, DOI 10.1006/bbrc.1993.1438; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SCHWARTZ ML, 1990, J NEUROSCI RES, V27, P193, DOI 10.1002/jnr.490270209; SCHWARTZ ML, 1994, MOL BRAIN RES, V27, P215, DOI 10.1016/0169-328X(94)90003-5; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P455, DOI 10.1093/nar/21.3.455	37	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26364	26369		10.1074/jbc.270.44.26364	http://dx.doi.org/10.1074/jbc.270.44.26364			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592849	hybrid			2022-12-25	WOS:A1995TC97800056
J	HIRAOKA, O; ANAGUCHI, H; ASAKURA, A; OTA, Y				HIRAOKA, O; ANAGUCHI, H; ASAKURA, A; OTA, Y			REQUIREMENT FOR THE IMMUNOGLOBULIN-LIKE DOMAIN OF GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR IN FORMATION OF A 2/1 RECEPTOR-LIGAND COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; EXPRESSION CLONING; DIMERIZATION; PURIFICATION; SUPERFAMILY; SECRETION; DESIGN	The extracellular portion of the granulocyte colony-stimulating factor (G-CSF) receptor has a mosaic structure of six domains (each approximately 100 amino acid residues) consisting of an immunoglobulin-like (Ig) domain, a cytokine receptor homologous region subdivided into amino-terminal (BN) and carboxyl-terminal (BC) domains, and three fibronectin type III repeats. In the present study, we expressed the Ig-BN and the BN-BC regions and purified them to homogeneity as monomers using G-CSF affinity column chromatography. Using gel filtration high performance liquid chromatography, we investigated the molecular composition of receptor-ligand complexes formed between G-CSF and purified BN-BC or Ig-BN domains. In contrast to the well characterized example of the human growth hormone (GH) receptor, in which the BN-BC . GH complex shows a 2:1 receptor-ligand complex stoichiometry, the BN-BC domain of the G-CSF receptor formed a 1:1 complex. The isolated Ig-BN domain also formed a 1:1 complex with G-CSF. However, in the presence of both Ig-BN and BN-BC domains, we detected a 1:1:1 Ig-BN . G-CSF . BN-BC complex corresponding to the 2:1 receptor: Ligand stoichiometry. These results suggest that 1) the Ig domain and both the BN and the BC domains are required for oligomerization of the G-CSF receptor, 2) G-CSF contains two binding sites for its receptor, and 3) there are two ligand binding sites on the G-CSF receptor, one site on the BN-BC domain and one on the Ig-BN domain.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; OTA Y, 1991, GENE, V106, P159, DOI 10.1016/0378-1119(91)90195-H; SETO Y, 1992, J IMMUNOL, V148, P259; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	29	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25928	25934		10.1074/jbc.270.43.25928	http://dx.doi.org/10.1074/jbc.270.43.25928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592781	hybrid			2022-12-25	WOS:A1995TB46600098
J	ANDERSEN, GR; KOCH, TJ; DOLMER, K; SOTTRUPJENSEN, L; NYBORG, J				ANDERSEN, GR; KOCH, TJ; DOLMER, K; SOTTRUPJENSEN, L; NYBORG, J			LOW-RESOLUTION X-RAY STRUCTURE OF HUMAN METHYLAMINE-TREATED ALPHA(2)-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; FLUORESCENCE ENERGY-TRANSFER; HUMAN ALPHA-2-MACROGLOBULIN; ELECTRON-MICROSCOPY; LIPOPROTEIN RECEPTOR; BAIT REGION; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; ALPHA-MACROGLOBULINS; COMPLEX-FORMATION	The structure of methylamine-treated human alpha(2)-macroglobulin (alpha(2)M-MA), a 720-kDa tetrameric inactivated proteinase inhibitor from plasma, has been determined to a resolution of 10 Angstrom. Data were collected with synchrotron radiation at 120 K, and phases were calculated by multiple isomorphous replacement and solvent flattening. A novel feature of the structure of alpha(2)M is present in its proteinase-binding cavity, dividing it into two compartments. The potential sites for proteinase entrap ment in these compartments are sterically restricted. The positions of the thiol groups appearing from the functional important thiol esters upon their cleavage have been determined. They are found at the walls of the compartments at the center of the structure. The overall structure of alpha(2)M-MA is much more sphere-like than previously inferred from electron microscopy studies. However, several aspects of the structure are well described by recent three-dimensional reconstructions. Possible models for the monomer, the disulfide bridged dimer, and native alpha(2)M are discussed.	AARHUS UNIV, DEPT CHEM, DK-8000 AARHUS C, DENMARK; AARHUS UNIV, DEPT MOLEC BIOL, DK-8000 AARHUS C, DENMARK	Aarhus University; Aarhus University			Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X; Andersen, Gregers Rom/0000-0001-6292-3319				ANDERSEN GR, 1994, ANN NY ACAD SCI, V737, P444, DOI 10.1111/j.1749-6632.1994.tb44335.x; ANDERSEN GR, 1994, ACTA CRYSTALLOGR D, V50, P298, DOI 10.1107/S0907444993013125; ANDERSEN GR, 1991, FEBS LETT, V292, P267, DOI 10.1016/0014-5793(91)80881-3; ANDERSEN GR, 1994, STRUCTURAL STUDIES A; ARAKAWA H, 1986, BIOCHEMISTRY-US, V25, P6785, DOI 10.1021/bi00370a009; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; BLOTH B, 1968, J EXP MED, V127, P749, DOI 10.1084/jem.127.4.749; BOISSET N, 1992, J STRUCT BIOL, V109, P39, DOI 10.1016/1047-8477(92)90065-I; BOISSET N, 1993, J MOL BIOL, V232, P522, DOI 10.1006/jmbi.1993.1408; BOISSET N, 1989, J BIOL CHEM, V264, P12046; BOISSET N, 1994, ANN NY ACAD SCI, V737, P229, DOI 10.1111/j.1749-6632.1994.tb44315.x; BOISSET N, 1992, J STRUCT BIOL, V108, P221, DOI 10.1016/1047-8477(92)90022-3; BOISSET N, 1991, J STRUCT BIOL, V106, P31, DOI 10.1016/1047-8477(91)90060-A; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; CHEN BJ, 1992, BIOCHEMISTRY-US, V31, P8960, DOI 10.1021/bi00152a036; DELAIN E, 1988, J BIOL CHEM, V263, P2981; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; DELAIN E, 1994, ANN NY ACAD SCI, V737, P202, DOI 10.1111/j.1749-6632.1994.tb44313.x; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; FUREY W, 1996, IN PRESS METHODS ENZ; GETTINS P, 1986, BIOCHEMISTRY-US, V25, P5011, DOI 10.1021/bi00366a007; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GETTINS P, 1990, BIOCHEMISTRY-US, V29, P7747, DOI 10.1021/bi00485a025; GETTINS PGW, 1993, FEBS LETT, V332, P211, DOI 10.1016/0014-5793(93)80633-6; GETTINS PGW, 1993, FEBS LETT, V325, P267, DOI 10.1016/0014-5793(93)81086-F; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IKAI A, 1990, FEBS LETT, V260, P291, DOI 10.1016/0014-5793(90)80126-4; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JACOBSON J, 1993, CLAVIER, V32, P20; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN J, 1981, J BIOL CHEM, V256, P7705; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LARQUET E, 1994, J STRUCT BIOL, V113, P87, DOI 10.1006/jsbi.1994.1034; MARSHALL LB, 1992, J BIOL CHEM, V267, P6347; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; PICKERSGILL RW, 1991, ACTA CRYSTALLOGR B, V47, P766, DOI 10.1107/S0108768191003191; POCHON F, 1989, BIOCHIM BIOPHYS ACTA, V996, P132, DOI 10.1016/0167-4838(89)90105-2; RUBENSTEIN DS, 1993, BIOCHEM J, V290, P85, DOI 10.1042/bj2900085; SCHNEIDER G, 1994, ACTA CRYSTALLOGR D, V50, P186, DOI 10.1107/S0907444993009679; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; SORENSEN AH, 1994, ACTA CRYSTALLOGR D, V50, P786, DOI 10.1107/S0907444994003689; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STOOPS JK, 1994, ANN NY ACAD SCI, V737, P212, DOI 10.1111/j.1749-6632.1994.tb44314.x; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STROTHKAMP KG, 1978, P NATL ACAD SCI USA, V75, P1181, DOI 10.1073/pnas.75.3.1181; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELINDER KG, 1984, J BIOL CHEM, V259, P8328; ZHAO BL, 1988, BIOCHEMISTRY-US, V27, P5304, DOI 10.1021/bi00414a053; 1979, SUITE PROGRAMS PROTE	71	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25133	25141		10.1074/jbc.270.42.25133	http://dx.doi.org/10.1074/jbc.270.42.25133			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559647	hybrid			2022-12-25	WOS:A1995TB46500081
J	DIZHOOR, AM; OLSHEVSKAYA, EV; HENZEL, WJ; WONG, SC; STULTS, JT; ANKOUDINOVA, I; HURLEY, JB				DIZHOOR, AM; OLSHEVSKAYA, EV; HENZEL, WJ; WONG, SC; STULTS, JT; ANKOUDINOVA, I; HURLEY, JB			CLONING, SEQUENCING, AND EXPRESSION OF A 24-KDA CA2+-BINDING PROTEIN ACTIVATING PHOTORECEPTOR GUANYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MOLECULAR-CLONING; RECOVERIN; TRANSDUCTION; MEMBRANES; TERMINUS; FAMILY	Two vertebrate photoreceptor-specific membrane guanylyl cyclases, RetGC-1 and RetGC-2, are activated by a soluble 24-kDa retinal protein, p24, in a Ca2+-sensitive manner (Dizhoor, A. M., Lowe, D. G., Olshevskaya, E. V., Laura, R. P., and Hurley, J. B. (1994) Neuron 12, 1345-1352; Lowe, D. G., Dizhoor, A. M., Liu, K., Gu, O., Laura, R., Lu, L., and Hurley, J. B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5535-5539). The primary structure of bovine p24 has been derived from peptide sequencing and from its cDNA. p24 is a new EF-hand-type Ca2+ binding protein, related but not identical to another guanylyl cyclase-activating protein, GCAP (Palczewski, K., Subbaraya, I., Gorczyca, W. A., Helekar, B. S., Ruiz, C. C., Ohguro, H. Huang, J., Zhao, X., Crabb, J. W., Johnson, R. S., Walsh, K. A., Gray-Keller, M. P., Detwiler, P. B., and Baehr, W. (1994) Neuron 13, 395-404) and other members of the recoverin family of Ca2+-binding proteins. Antibodies against a truncated fusion protein and against a p24-specific synthetic peptide specifically recognize retinal p24 on immunoblot. Both antibodies inhibit activation of photoreceptor membrane guanylyl cyclase by purified p24. p24 is found only in retina, and it copurifies with outer segment membranes. Immunocytochemical analysis shows that it is present in rod photoreceptor cells. An immobilized antibody column was used to purify p24 from a heat-treated retinal extract. Purified p24 appears on SDS-polyacrylamide gel electrophoresis as a homogenous protein not contaminated with GCAP, and it activates photoreceptor guanylyl cyclase in vitro at submicromolar concentrations. Ca2+ inhibits this activation with an EC(50) near 200 nM and a Hill coefficient of 1.7. Recombinant p24 expressed in 293 cells effectively stimulates photoreceptor guanylyl cyclase. These findings demonstrate that p24, like GCAP, imparts Ca2+ sensitivity to photoreceptor membrane guanylyl cyclase. We propose that p24 be referred to as GCAP-2 and that GCAP be referred to as GCAP-1.	UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; GENENTECH INC, S SAN FRANCISCO, CA 94080 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Roche Holding; Genentech				Dizhoor, Alexander/0000-0001-6770-9186; Henzel, William/0000-0003-2940-3797	NEI NIH HHS [EYO6641] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; Henzel William J., 1994, Methods (Orlando), V6, P239, DOI 10.1006/meth.1994.1026; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V196, P1017, DOI 10.1006/bbrc.1993.2351; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LI X, 1994, EXP EYE RES, V59, P761; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MARGULIS A, 1993, BIOCHEM BIOPH RES CO, V194, P855, DOI 10.1006/bbrc.1993.1900; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; STRYER L, 1991, J BIOL CHEM, V266, P10711; TENG DHF, 1994, J BIOL CHEM, V269, P31900; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	270	274	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25200	25206		10.1074/jbc.270.42.25200	http://dx.doi.org/10.1074/jbc.270.42.25200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559656	hybrid			2022-12-25	WOS:A1995TB46500090
J	ZHANG, SJ; HAN, JH; SELLS, MA; CHERNOFF, J; KNAUS, UG; ULEVITCH, RJ; BOKOCH, GM				ZHANG, SJ; HAN, JH; SELLS, MA; CHERNOFF, J; KNAUS, UG; ULEVITCH, RJ; BOKOCH, GM			RHO-FAMILY GTPASES REGULATE P38 MITOGEN-ACTIVATED PROTEIN-KINASE THROUGH THE DOWNSTREAM MEDIATOR PAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUTAGENESIS	The stress-activated p38 mitogen-activated protein (MAP) kinase defines a subgroup of the mammalian MAP kinases that appear to play a key role in regulating inflammatory responses. Co-expression of constitutively active forms of Rac and Cdc42 leads to activation of p38 while dominant negative Rac and Cdc42 inhibit the ability of interleukin-1 to increase p38 activity. p21-activated kinase 1 (Pak1) is a potential mediator of Rac/Cdc42 signaling, and we observe that Pak1 stimulates p38 activity. A dominant negative Pak1 suppresses both interleukin-1- and Rac/Cdc42-induced p38 activity. Rac and Cdc42 appear to regulate a protein kinase cascade initiated at the level of Pak and leading to activation of p38 and JNK.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Scripps Research Institute; Scripps Research Institute; Fox Chase Cancer Center			Chernoff, Jonathan/I-7631-2014; Ulevitch, Richard J/Q-3393-2017; Han, J/G-4671-2010	Chernoff, Jonathan/0000-0002-4803-7836; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V219, P470; DEIJARD B, 1995, SCIENCE, V267, P682; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QUI RG, 1995, NATURE, V374, P457; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639	25	653	666	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23934	23936		10.1074/jbc.270.41.23934	http://dx.doi.org/10.1074/jbc.270.41.23934			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592586	hybrid, Green Published			2022-12-25	WOS:A1995TA21700014
J	ALBERT, FG; BRONSON, EC; FITZGERALD, DJ; ANDERSON, JN				ALBERT, FG; BRONSON, EC; FITZGERALD, DJ; ANDERSON, JN			CIRCULAR STRUCTURES IN RETROVIRAL AND CELLULAR GENOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; SWINE FEVER VIRUS; GROUP-II INTRON; RECOMBINATIONAL ENHANCER ACTIVITY; SITE-SPECIFIC RECOMBINATION; INTEGRATION HOST FACTOR; CURVED DNA; KINETOPLAST DNA; NUCLEOTIDE-SEQUENCE; MULTIGENE FAMILIES	A computer program for predicting DNA bending from nucleotide sequence was used to identify circular structures in retroviral and cellular genomes, An 830-base pair circular structure was located in a control region near the center of the genome of the human immunodeficiency virus type I (HIV-I), This unusual structure displayed relatively smooth planar bending throughout its length, The structure is conserved in diverse isolates of HIV-I, HIV-II, and simian immunodeficiency viruses, which implies that it is under selective constraints, A search of all sequences in the GenBank data base was carried out in order to identify similar circular structures in cellular DNA, The results revealed that the structures are associated with a wide range of sequences that undergo recombination, including most known examples of DNA inversion and subtelomeric translocation systems, Circular structures were also associated with replication and transposition systems where DNA looping has been implicated in the generation of large protein-DNA complexes, Experimental evidence for the structures was provided by studies which demonstrated that two sequences detected as circular by computer preferentially formed covalently closed circles during ligation reactions in vitro when compared to nonbent fragments, bent fragments with noncircular shapes, and total genomic DNA, In addition, a single T --> C substitution in one of these sequences rendered it less planar as seen by computer analysis and significantly reduced its rate of ligase-catalyzed cyclization, These results permit us to speculate that intrinsically circular structures facilitate DNA looping during formation of the large protein-DNA complexes that are involved in site- and region-specific recombination and in other genomic processes.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER; NCI NIH HHS [1-T32-CA09634-01A1] Funding Source: Medline; NIGMS NIH HHS [R01 GM41208-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1985, P NATL ACAD SCI USA, V82, P5724, DOI 10.1073/pnas.82.17.5724; ALMENDRAL JM, 1990, J VIROL, V64, P2064, DOI 10.1128/JVI.64.5.2064-2072.1990; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; Barbour A G, 1993, Trends Microbiol, V1, P236, DOI 10.1016/0966-842X(93)90139-I; BARBOUR AG, 1991, INFECT IMMUN, V59, P390, DOI 10.1128/IAI.59.1.390-397.1991; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRONSON EC, 1994, J MOL EVOL, V38, P506, DOI 10.1007/BF00178851; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CONS BMG, 1990, BIOCHEM BIOPH RES CO, V171, P1064, DOI 10.1016/0006-291X(90)90792-L; Cox M. M., 1989, MOBILE DNA, P661; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; CUE D, 1993, P NATL ACAD SCI USA, V90, P9290, DOI 10.1073/pnas.90.20.9290; DECHASTONAY Y, 1990, GENE, V93, P199, DOI 10.1016/0378-1119(90)90225-G; DELAVEGA I, 1990, VIROLOGY, V179, P234, DOI 10.1016/0042-6822(90)90293-Z; DIEKMANN S, 1985, J MOL BIOL, V186, P1, DOI 10.1016/0022-2836(85)90251-7; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ECKDAHL TT, 1990, NUCLEIC ACIDS RES, V18, P1609, DOI 10.1093/nar/18.6.1609; ECKDAHL TT, 1987, NUCLEIC ACIDS RES, V15, P8531; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; FULKS KA, 1990, J BACTERIOL, V172, P310, DOI 10.1128/JB.172.1.310-316.1990; GLASGOW AC, 1989, MOBILE DNA, P637; GONZALEZ A, 1990, J VIROL, V64, P2073; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GORMAN C, 1985, DNA CLONING PRACTICA, P131; GRIFFITH J, 1986, CELL, V46, P717, DOI 10.1016/0092-8674(86)90347-8; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HARRINGTON RE, 1992, MOL MICROBIOL, V6, P2549, DOI 10.1111/j.1365-2958.1992.tb01431.x; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUBNER P, 1989, J MOL BIOL, V205, P493, DOI 10.1016/0022-2836(89)90220-9; HULL R, 1986, EMBO J, V5, P3083, DOI 10.1002/j.1460-2075.1986.tb04614.x; HUNGNES O, 1993, J MOL EVOL, V37, P198, DOI 10.1007/BF02407356; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; KABSCH W, 1982, NUCLEIC ACIDS RES, V10, P1097, DOI 10.1093/nar/10.3.1097; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KEMPKEN F, 1992, J MOL EVOL, V35, P502, DOI 10.1007/BF00160211; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIDANE GZ, 1984, GENE, V27, P265, DOI 10.1016/0378-1119(84)90071-4; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; KREMER W, 1993, EMBO J, V12, P4407, DOI 10.1002/j.1460-2075.1993.tb06125.x; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAUNDON CH, 1988, CELL, V52, P545, DOI 10.1016/0092-8674(88)90467-9; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LEVINGS CS, 1983, P NATL ACAD SCI-BIOL, V80, P4055, DOI 10.1073/pnas.80.13.4055; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MERKER P, 1993, COLD SPRING HARB SYM, V58, P505, DOI 10.1101/SQB.1993.058.01.057; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOHR G, 1993, NUCLEIC ACIDS RES, V21, P4991, DOI 10.1093/nar/21.22.4991; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; PAILLARD M, 1985, EMBO J, V4, P1125, DOI 10.1002/j.1460-2075.1985.tb03749.x; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PLOHL M, 1990, BIOCHIMIE, V72, P665, DOI 10.1016/0300-9084(90)90049-M; PROUS D, 1995, NUCLEIC ACIDS RES, V23, P1816; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RAY DS, 1986, NUCLEIC ACIDS RES, V14, P7953, DOI 10.1093/nar/14.20.7953; ROBERTSON BD, 1992, TRENDS GENET, V8, P422, DOI 10.1016/0168-9525(92)90325-X; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SANDMEIER H, 1991, NUCLEIC ACIDS RES, V19, P5831, DOI 10.1093/nar/19.21.5831; SCHLEIF R, 1988, SCIENCE, V240, P127, DOI 10.1126/science.3353710; SCHMIDT G, 1991, BIOCHIM BIOPHYS ACTA, V1088, P442, DOI 10.1016/0167-4781(91)90141-8; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SIEMEISTER G, 1990, MOL GEN GENET, V220, P425, DOI 10.1007/BF00391749; SILVER LE, 1986, CELL, V47, P537, DOI 10.1016/0092-8674(86)90618-5; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SZEKELY E, 1983, J BACTERIOL, V155, P74, DOI 10.1128/JB.155.1.74-81.1983; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; VANDERPLOEG LHT, 1992, TRENDS GENET, V8, P452, DOI 10.1016/0168-9525(92)90179-8; VANLINT C, 1991, J VIROL, V65, P7066, DOI 10.1128/JVI.65.12.7066-7072.1991; VANPUTTE P, 1992, TRENDS GENET, V8, P457; VANWYE JD, 1991, NUCLEIC ACIDS RES, V19, P5253, DOI 10.1093/nar/19.19.5253; VERDIN E, 1990, P NATL ACAD SCI USA, V87, P4874, DOI 10.1073/pnas.87.12.4874; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WANG Q, 1994, NUCLEIC ACIDS RES, V22, P5753, DOI 10.1093/nar/22.25.5753; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850	106	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23570	23581		10.1074/jbc.270.40.23570	http://dx.doi.org/10.1074/jbc.270.40.23570			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559522	hybrid			2022-12-25	WOS:A1995RY90900051
J	MAHDI, F; VANNOSTRAND, WE; SCHMAIER, AH				MAHDI, F; VANNOSTRAND, WE; SCHMAIER, AH			PROTEASE NEXIN-2 AMYLOID BETA-PROTEIN PRECURSOR INHIBITS FACTOR XA IN THE PROTHROMBINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; FACTOR-VA; CONFORMATIONAL CHANGE; FACTOR-IXA; ACTIVATION; DOMAIN; BINDING; PURIFICATION; FORMS; ALPHA	Protease nexin-2/amyloid beta-protein precursor (PN-2/A beta PP) is a Kunitz-type protease inhibitor which has been shown to be a tight-binding inhibitor of coagulation factors XIa and Ma. Here we show that PN-2/A beta PP and its KPI domain also inhibited isolated factor Xa with a K-i of 10(-8) M. On a solid phase binding assay, PN-2/A beta PP formed a complex with factor Xa. Incubation of molar excess factor Xa to PN-2/A beta PP produced a single cleavage within PN-2/A beta PP's heparin binding do main liberating a 8.2-kDa amino-terminal peptide. PN-2/A beta PP and its KPI domain equally inhibited factor Xa in the prothrombinase complex with a K-i of 1.9 x 10(-8) M and 1.3 x 10(-8) M, respectively. A beta PP695 which does not contain the KPI domain was a substrate of factor Xa but did not inhibit it, indicating the PN-2/A beta PP inhibition of factor Xa was not substrate inhibition. All of the factor Xa inhibition in the prothrombinase complex by PN-2/A beta PP and its KPI domain on the chromogenic assay was accounted for by inhibition of release of prothrombin fragment F-1+2 as determined on immunochemical assay, In the prothrombinase complex, PN-2/A beta PP inhibited factor Xa with a k(assoc) = 1.8 +/- 0.7 x 10(6) M(-1) min(-1) similar to antithrombin III and heparin inhibition (k(assoc) of 3.0 +/- 0.2 x 10(6) M(-1) min(-1)). These studies indicated that PN-2/A beta PP in the assembled prothrombinase complex inhibited factor Xa comparable to antithrombin III in the presence of heparin. PN-2/A beta PP's factor Xa inhibitory activity along with its known inhibition of factors XIa and Ma suggest that this protease inhibitor and related proteins could be regulators of hemostatic reactions on membranes of cells in the intravascular compartments.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,ANN ARBOR,MI 48109; UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of Michigan System; University of Michigan; University of California System; University of California Irvine			Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049566] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49566] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAUER KA, 1989, BLOOD, V74, P2007; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; ELLIS V, 1982, BIOCHIM BIOPHYS ACTA, V701, P24; GIGLI I, 1970, J IMMUNOL, V104, P574; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAU HK, 1979, J BIOL CHEM, V254, P8751; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PETERSEN LC, 1994, FEBS LETT, V338, P53, DOI 10.1016/0014-5793(94)80115-0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHMAIER AH, 1995, BIOCHEMISTRY-US, V34, P1171, DOI 10.1021/bi00004a010; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; VANNOSTRAND WE, 1991, BIOCHEM BIOPH RES CO, V175, P15, DOI 10.1016/S0006-291X(05)81193-3; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1994, BBA-PROTEIN STRUCT M, V1209, P165, DOI 10.1016/0167-4838(94)90180-5; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510	36	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23468	23474		10.1074/jbc.270.40.23468	http://dx.doi.org/10.1074/jbc.270.40.23468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559509	hybrid			2022-12-25	WOS:A1995RY90900038
J	MATSUI, C; WANG, CK; NELSON, CF; BAUER, EA; HOEFFLER, WK				MATSUI, C; WANG, CK; NELSON, CF; BAUER, EA; HOEFFLER, WK			THE ASSEMBLY OF LAMININ-5 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANES; SECRETION; PROTEINS; CELLS; CHAIN; GLYCOPROTEINS; BIOSYNTHESIS; FIBRINOGEN; EXPRESSION; VARIANT	Laminin-5 is a heterotrimer composed of alpha 3, beta 3, and gamma 2 chains, produced by keratinocytes and the human squamous cell carcinoma line (SCC-25), and is one of the candidate proteins for the genetic lesion in junctional epidermolysis bullosa, Two dimensional SDS-polyacrylamide gel electrophoresis (first dimension, nonreducing conditions; second dimension, reducing conditions) revealed that the immunoprecipitated laminin-5 from a SCC-25 cell fraction consisted of alpha 3, beta 3, and gamma 2 monomers, a beta 3 gamma 2 heterodimer, and an alpha 3 beta 3 gamma 2 heterotrimer. The presence of the beta 3 gamma 2 heterodimer, but not heterodimers containing an alpha 3 chain and any of the other chains, was suggestive of assembly of laminin-5 proceeding from a beta 3 gamma 2 heterodimer to an alpha 3 beta 3 gamma 2 heterotrimer. We showed, by cotransfection experiments using full-length recombinant beta 3 and gamma 2 chains in a human cell line devoid of endogenous laminin-5, that stable heterodimers can be formed in the absence of alpha 3 chain expression, In the SCC-25 cell fraction, the alpha 3 monomer pool was the smallest of the monomers. Pulse-chase experiments using the cell fraction also indicated that the heterotrimer was assembled after a 10-min pulse and was nearly absent after a 24-h chase, These results are consistent with the synthesis of alpha 3 being limiting for heterotrimer assembly, with rapid association of the alpha 3 chain with beta 3 gamma 2 heterodimers to form complete heterotrimers, Treatment with tunicamycin reduced the size of each of the laminin-5 subunits, indicating that all chains are glycosylated, but that N-linked glycosylation is not necessary for chain assembly and secretion.	STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305	Stanford University				Hoeffler, Warren/0000-0001-8656-6651	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019537, P01AR041045, R01AR019537] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR19537, AR41045-03] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; BAUDOIN C, 1994, J CLIN INVEST, V93, P862, DOI 10.1172/JCI117041; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DULIS BH, 1982, J BIOL CHEM, V257, P4369; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GOTTSCHLING C, 1993, EUR J BIOCHEM, V216, P293, DOI 10.1111/j.1432-1033.1993.tb18144.x; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HANOVER JA, 1981, ARCH BIOCHEM BIOPHYS, V211, P1, DOI 10.1016/0003-9861(81)90423-9; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUNTER I, 1992, J BIOL CHEM, V267, P6006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; NOMIZU M, 1994, J BIOL CHEM, V269, P30386; OHBA H, 1981, J BIOCHEM-TOKYO, V89, P901, DOI 10.1093/oxfordjournals.jbchem.a133273; OLDEN K, 1978, CELL, V13, P461, DOI 10.1016/0092-8674(78)90320-3; PETERS BP, 1985, J BIOL CHEM, V260, P4732; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; Sambrook J, 1989, MOL CLONING LABORATO; SMITH LT, 1993, ARCH DERMATOL, V129, P1578, DOI 10.1001/archderm.129.12.1578; SPETH C, 1993, EXP CELL RES, V204, P302, DOI 10.1006/excr.1993.1037; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; UTANI A, 1994, J BIOL CHEM, V269, P19167; VAILLY J, 1995, J INVEST DERMATOL, V104, P462, DOI 10.1111/1523-1747.ep12605898; VAILLY J, 1994, EUR J BIOCHEM, V216, P209; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2; VERRANDO P, 1991, LAB INVEST, V64, P85; WU CY, 1988, BIOCHEMISTRY-US, V27, P8780, DOI 10.1021/bi00424a014	33	114	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23496	23503		10.1074/jbc.270.40.23496	http://dx.doi.org/10.1074/jbc.270.40.23496			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559513	hybrid			2022-12-25	WOS:A1995RY90900042
J	VIGLIETTO, G; CHIAPPETTA, G; MARTINEZTELLO, FJ; FUKUNAGA, FH; TALLINI, G; RIGOPOULOU, D; VISCONTI, R; MASTRO, A; SANTORO, M; FUSCO, A				VIGLIETTO, G; CHIAPPETTA, G; MARTINEZTELLO, FJ; FUKUNAGA, FH; TALLINI, G; RIGOPOULOU, D; VISCONTI, R; MASTRO, A; SANTORO, M; FUSCO, A			RET/PTC ONCOGENE ACTIVATION IS AN EARLY EVENT IN THYROID CARCINOGENESIS	ONCOGENE			English	Note						RET PROTOONCOGENE; RET/PTC ONCOGENE; THYROID; OCCULT CARCINOMAS; RT-PCR	RET TYROSINE KINASE; PAPILLARY CARCINOMAS; PROTOONCOGENE	RET/PTC oncogene activation occurs in about 20% of human thyroid papillary carcinomas, However, it is not known yet whether it is an early or late event in the process of thyroid carcinogenesis, Here we demonstrate, by using a combined immunohistochemical and reverse-transcriptase-polymerase chain reaction based approach, that RET/PTC activation is present in 11 out of 26 occult thyroid papillary carcinomas analysed. Therefore, we conclude that it represents an early event in the process of thyroid cell transformation.	IST NAZL TUMORI,FDN SENATORE PASCALE,I-80131 NAPLES,ITALY; UNIV COMPLUTENSE MADRID,HOSP UNIV 12 OCTUBRE,DEPT PATHOL,E-28041 MADRID,SPAIN; KUAKINI MED CTR,HONOLULU,HI 96817; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; UNIV COMPLUTENSE MADRID,HOSP UNIV 12 OCTUBRE,SERV ENDOCRINOL,E-28041 MADRID,SPAIN; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	IRCCS Fondazione Pascale; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Yale University; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria			Tallini, Giovanni/F-7850-2013; Visconti, Roberta/C-5299-2009; Viglietto, Giuseppe/AAC-2852-2019	Tallini, Giovanni/0000-0003-0113-6682; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801				BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUKUNAGA FH, 1975, CANCER-AM CANCER SOC, V36, P1095, DOI 10.1002/1097-0142(197509)36:3<1095::AID-CNCR2820360338>3.0.CO;2-9; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; JACKSON DP, 1989, LANCET, V1, P1391; LANZI C, 1992, ONCOGENE, V7, P2189; MARTINEZTELLO FJ, 1993, CANCER-AM CANCER SOC, V71, P4022, DOI 10.1002/1097-0142(19930615)71:12<4022::AID-CNCR2820711236>3.0.CO;2-O; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509	16	221	233	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1207	1210						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566982				2022-12-25	WOS:A1995RX18000025
J	ADACHI, K; SABNEKAR, P; ADACHI, M; REDDY, LR; PANG, JA; REDDY, KS; SURREY, S				ADACHI, K; SABNEKAR, P; ADACHI, M; REDDY, LR; PANG, JA; REDDY, KS; SURREY, S			POLYMERIZATION OF RECOMBINANT HB S-KEMPSEY (DEOXY-R STATE) AND HB S-KANSAS (OXY-T STATE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOGLOBIN-KANSAS; AFFINITY VARIANT; GLOBIN STRUCTURE; GELATION; DEOXYHEMOGLOBIN; CRYSTALLIZATION; AGGREGATION; BINDING; HEME	In order to investigate the role of the R (relaxed) to T (tense) structural transition in facilitating polymerization of deoxy-Hb S, we have engineered and expressed two Hb S variants which destabilize either T state (Hb S-Kempsey, alpha(2) beta(2)(Val-6, Asn-99)). R State structures (Hb S-Kansas, alpha(2) beta(2)(Val-6, Thr-102)), Polymerization of deoxy-Hb S-Kempsey, which shows high oxygen affinity and increased dimer dissociation, required about 2- and Ci fold higher hemoglobin concentrations than deoxy-fm S for polymerization in low and high phosphate concentrations, and its kinetic pattern of polymerization was biphasic, In contrast, oxy- or CO Hb S-Kansas, which shows low oxygen affinity and increased dimer dissociation, polymerized at a slightly higher critical concentration than that required for polymerization of deoxy-Hb S in both low and high phosphate buffers, Polymerization of oxy- and CO Kb S Kansas was linear and showed no delay time, which is similar to oversaturated oxy- or CO Hb S, These results suggest that nuclei formation, which occurs during the delay time prior to deoxy-Hb S polymerization, does not occur in T state oxy-Hb S-Kansas, even though the critical concentration for polymerization of T state oxy-Hb S-Kansas is similar to that of T state deoxy Hb S.	UNIV PENN, DEPT BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	ADACHI, K (corresponding author), UNIV PENN, CHILDRENS HOSP, SCH MED, DIV HEMATOL, 34TH ST & CIVIC CTR BLVD, PHILADELPHIA, PA 19104 USA.		Adachi, Megumi/M-7746-2017	Adachi, Megumi/0000-0003-3404-6640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38632] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1979, J BIOL CHEM, V254, P2273; ADACHI K, 1981, J BIOL CHEM, V256, P1824; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ANDERSON L, 1975, J MOL BIOL, V94, P33, DOI 10.1016/0022-2836(75)90403-9; AROUS N, 1981, FEBS LETT, V126, P114, DOI 10.1016/0014-5793(81)81046-0; ATHA DH, 1979, J BIOL CHEM, V254, P2390; ATHA DH, 1976, J BIOL CHEM, V251, P5537; BLOUQUIT Y, 1981, HEMOGLOBIN, V5, P19, DOI 10.3109/03630268108996908; BONAVENTURA J, 1968, J BIOL CHEM, V243, P980; BUNN HF, 1974, J BIOL CHEM, V249, P7402; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P452; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P125; GIBSON QH, 1973, J BIOL CHEM, V248, P5976; GREER J, 1971, J MOL BIOL, V59, P99, DOI 10.1016/0022-2836(71)90415-3; HARRIS JW, 1950, P SOC EXP BIOL MED, V75, P197, DOI 10.3181/00379727-75-18144; HOFRICHTER J, 1976, P NATL ACAD SCI USA, V73, P3035, DOI 10.1073/pnas.73.9.3035; JONES RT, 1967, J CLIN INVEST, V46, P1840, DOI 10.1172/JCI105674; KIM HW, 1994, P NATL ACAD SCI USA, V91, P11547, DOI 10.1073/pnas.91.24.11547; LINDSTROM TR, 1973, BIOCHEMISTRY-US, V12, P4212, DOI 10.1021/bi00745a027; NAGAI K, 1982, BIOCHEMISTRY-US, V21, P842, DOI 10.1021/bi00534a005; NAGEL RL, 1976, NEW ENGL J MED, V295, P125, DOI 10.1056/NEJM197607152950302; OGAWA S, 1972, BIOCHEM BIOPH RES CO, V49, P1485, DOI 10.1016/0006-291X(72)90507-4; PERUTZ MF, 1971, COLD SPRING HARB SYM, V36, P295; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2174, DOI 10.1021/bi00707a027; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2163, DOI 10.1021/bi00707a026; REED CS, 1968, BLOOD, V31, P523, DOI 10.1182/blood.V31.5.623.623; RICHARD AJ, 1991, HEMOGLOBIN, V15, P125, DOI 10.3109/03630269109072493; ROCHETTE J, 1984, FEBS LETT, V32, P6411; RUCKNAGEL DL, 1967, CLIN RES, V15, P270; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; TAMAGNINI GP, 1991, HEMOGLOBIN, V15, P487, DOI 10.3109/03630269109027896; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WAJCMAN H, 1991, BLOOD, V78, P206; WEATHERALL DJ, 1977, BRIT J HAEMATOL, V35, P177, DOI 10.1111/j.1365-2141.1977.tb00575.x; YANASE H, 1995, PROTEIN SCI, V4, P21; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	38	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26857	26862		10.1074/jbc.270.45.26857	http://dx.doi.org/10.1074/jbc.270.45.26857			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592928	hybrid			2022-12-25	WOS:A1995TE58300028
J	TANG, DM; YEUNG, J; LEE, KY; MATSUSHITA, M; MATSUI, H; TOMIZAWA, K; HATASE, O; WANG, JH				TANG, DM; YEUNG, J; LEE, KY; MATSUSHITA, M; MATSUI, H; TOMIZAWA, K; HATASE, O; WANG, JH			AN ISOFORM OF THE NEURONAL CYCLIN-DEPENDENT KINASE-5 (CDK5) ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; BOVINE BRAIN; P34(CDC2); YEAST; PHASE; G1; PURIFICATION; P40(MO15)	Neuronal Cdc2-like kinase is a heterodimer of Cdk5 and a 25-kDa subunit that is derived from a 35-kDa brain- and neuron-specific protein called the neuronal Cdk5 activator (p35/p25(nck5a)) (Lew, J., Huang, Q.-Q., Qi, Z., Winkfein, R. J., Aebersold, R., Hunt, T., and Wang, J. H. (1994) Nature 371, 423-426; Tsai, L. H., Delalle, I., Caviness, V. S., Jr., Chae, T., and Harlow, E. (1994) Nature 371, 419-423). Upon screening of a human hippocampus library with a bovine Nck5a cDNA, we uncovered a distinct clone encoding a 39-kDa isoform of Nck5a. The isoform, designated the neuronal Cdk5 activator isoform (p39(nck5ai)), showed a high degree of sequence similarity to p35(nck5a) with 57% amino acid identity. Northern blot analysis detected its mRNA transcript in bovine and rat cerebrum and cerebellum, but not in any other rat tissues examined. In situ hybridization showed that Nck5ai was enriched in CA1 to CA3 of the hippocampus, but absent in the fimbria of hippocampal formation. Among seven cell lines in proliferating cultures, only PC12 and N2A, two cell lines capable of differentiating into neuron-like cells, were found to contain Nck5ai mRNA. A 30-kDa truncated form of Nck5ai expressed as a glutathione S-transferase fusion protein in Escherichia coli] was found to associate with Cdk5 to form an active Cdk5 kinase. Thus, the isoform shares many common characteristics with p35(nck5a), including Ckd5 activating activity and brain- and neuron-specific expression. Both proteins show limited sequence homology to cyclins, suggesting that they define a new family of cyclin-dependent kinase-activating proteins.	HONG KONG UNIV SCI & TECHNOL, DEPT BIOCHEM, KOWLOON, HONG KONG; UNIV CALGARY, DEPT MED BIOCHEM, MRC, SIGNAL TRANSDUCT GRP, CALGARY, AB T2N 4N1, CANADA; KAGAWA MED SCH, DEPT PHYSIOL, MIKI, KAGAWA 76107, JAPAN; OKAYAMA UNIV, SCH MED, DEPT PHYSIOL, OKAYAMA 700, JAPAN	Hong Kong University of Science & Technology; University of Calgary; Kagawa University; Okayama University			Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fantes P, 1989, CURR OPIN CELL BIOL, V1, P250, DOI 10.1016/0955-0674(89)90096-3; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; Hay R, 1992, AM TYPE CULTURE COLL; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; PINES J, 1993, CURR BIOL, V3, P544, DOI 10.1016/0960-9822(93)90053-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Sambrook J, 1989, MOL CLONING LABORATO; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	40	282	297	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26897	26903		10.1074/jbc.270.45.26897	http://dx.doi.org/10.1074/jbc.270.45.26897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592934	hybrid			2022-12-25	WOS:A1995TE58300034
J	TSUTAKAWA, SE; MEDZIHRADSZKY, KF; FLINT, AJ; BURLINGAME, AL; KOSHLAND, DE				TSUTAKAWA, SE; MEDZIHRADSZKY, KF; FLINT, AJ; BURLINGAME, AL; KOSHLAND, DE			DETERMINATION OF IN-VIVO PHOSPHORYLATION SITES IN PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; IDENTIFICATION; ACTIVATION; BOVINE; AUTOPHOSPHORYLATION; MULTIPLE; SEQUENCE; PEPTIDES; FAMILY; IONS	The primary structure of rat protein kinase C beta II was probed by high pressure liquid chromatography directly coupled to an electrospray ionization mass spectrometer and by high energy collision-induced dissociation analysis to identify in vivo phosphorylation sites, The N-terminal methionine was found to be cleaved post-translationally and replaced with an acetyl group, Four phosphopeptides were identified, Two peptides, Thr(500)-Lys(520) and Glu(490)-Lys(520), are phosphorylated at Thr(500) greater than 90%. Peptide His(636)-Arg(649) is phosphorylated about 75% at Thr(641). It is the only site that was previously identified during the in vitro autophosphorylation studies (Flint, A. J., Paladini, R. D., and Koshland, D. E., Jr. (1990) Science 249, 408-411). The fourth peptide Asn(650)-Lys(672) is phosphorylated at Thr(660). A discussion of the potential implication of these results follows.	UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory				Tsutakawa, Susan/0000-0002-4918-4571	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004705] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK09765] Funding Source: Medline; NIEHS NIH HHS [ES04705] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FALICK AM, 1990, RAPID COMMUN MASS SP, V4, P318, DOI 10.1002/rcm.1290040905; FALICK AM, 1995, ANAL CHEM, V58, P1308; Fisher E.H., 1955, J BIOL CHEM, V216, P121; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GIBSON BW, 1990, METHOD ENZYMOL, V193, P480, DOI 10.1016/0076-6879(90)93434-M; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMLING ME, 1990, BIOMED ENVIRON MASS, V19, P677, DOI 10.1002/bms.1200191107; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P137, DOI 10.1016/0168-1176(88)80060-0; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; Medzihradszky Katalin F., 1994, Methods (Orlando), V6, P284, DOI 10.1006/meth.1994.1030; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; PELECH SL, 1991, BIOCH CELL BIOL, V68, P1297; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SU LH, 1993, RECEPTOR CHANNEL, V1, P1; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; WALLS FC, 1993, 41ST P ASMS C MASS S; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	42	82	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26807	26812		10.1074/jbc.270.45.26807	http://dx.doi.org/10.1074/jbc.270.45.26807			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592921	hybrid			2022-12-25	WOS:A1995TE58300021
J	URBATSCH, IL; SANKARAN, B; BHAGAT, S; SENIOR, AE				URBATSCH, IL; SANKARAN, B; BHAGAT, S; SENIOR, AE			BOTH P-GLYCOPROTEIN NUCLEOTIDE-BINDING SITES ARE CATALYTICALLY ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; ADENOSINE-TRIPHOSPHATASE; VANADATE ION; MYOSIN; ATPASE; INHIBITION; RECONSTITUTION; GENE	The technique of vanadate trapping of nucleotide was used to study catalytic sites of P-glycoprotein (Pgp) in plasma membranes from multidrug-resistant Chinese hamster ovary cells. Vanadate trapping of Mg- or Co-8-azido-nucleotide (1 mol/mol of Pgp) caused complete inhibition of Pgp ATPase activity, with reactivation rates at 37 degrees C of 1.4 x 10(-3) s(-1) (t(1/2) = 8 min) or 3.3 x 10(-4) s(-1) (t(1/2) = 35 min), respectively. UV irradiation of the inhibited Pgp yielded permanent inactivation of ATPase activity and specific photolabeling of Pgp, Mild trypsin digestion showed that the two nucleotide sites were labeled in equal proportion. The results show that both nucleotide sites in Pgp are capable of nucleotide hydrolysis, that vanadate trapping of nucleotide at either site completely prevents hydrolysis at both sites, and that vanadate trapping of nucleotide in the N- or C-terminal nucleotide sites occurs non-selectively. A minimal scheme is presented to explain inhibition by vanadate trapping of nucleotide and to describe the normal catalytic pathway, The inhibited Pgp Mg-nucleotide vanadate complex is probably an analog of the catalytic transition state, implying that when one nucleotide site assumes the catalytic transition state conformation the other site cannot do so and suggesting that the two sites may alternate in catalysis.			URBATSCH, IL (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gros P, 1993, Int Rev Cytol, V137C, P169; LOO TW, 1994, J BIOL CHEM, V269, P7750; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1995, J BIOENERG BIOMEMBR, V27, P7, DOI 10.1007/BF02110325; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; SHIMIZU T, 1983, J BIOL CHEM, V258, P3833; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WOLODKO WT, 1983, J BIOL CHEM, V258, P4116; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	28	225	226	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26956	26961		10.1074/jbc.270.45.26956	http://dx.doi.org/10.1074/jbc.270.45.26956			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592942	hybrid			2022-12-25	WOS:A1995TE58300042
J	BIERHAUS, A; ZHANG, YM; DENG, YH; MACKMAN, N; QUEHENBERGER, P; HAASE, M; LUTHER, T; MULLER, M; BOHRER, H; GRETEN, J; MARTIN, E; BAEUERLE, PA; WALDHERR, R; KISIEL, W; ZIEGLER, R; STERN, DM; NAWROTH, PP				BIERHAUS, A; ZHANG, YM; DENG, YH; MACKMAN, N; QUEHENBERGER, P; HAASE, M; LUTHER, T; MULLER, M; BOHRER, H; GRETEN, J; MARTIN, E; BAEUERLE, PA; WALDHERR, R; KISIEL, W; ZIEGLER, R; STERN, DM; NAWROTH, PP			MECHANISM OF THE TUMOR-NECROSIS-FACTOR ALPHA-MEDIATED INDUCTION OF ENDOTHELIAL TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; FACTOR MESSENGER-RNA; NF-KAPPA-B; C-JUN; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL-ANALYSIS; GENE-EXPRESSION; MAMMALIAN-CELLS; PROTO-ONCOGENE; E-SELECTIN	This study examines the regulation of the human tissue factor (TF) promotor in vitro and in vivo. Transient transfections were performed in bovine aortic endothelial cells to investigate the role of two fundamentally different AP-1 sites and a closely located NF-kappa B site in the human TF promotor, The NF-kappa B site is functionally active, since overexpression of NF-kappa B(p65) resulted in induction of TF mRNA and activity, Promotor analysis showed that NF-kappa B induction was dependent on the integrity of the region from base pair -188 to -181. Overexpression of Jun/Fos resulted in TF induction of transcription and protein/activity. Functional studies revealed that the proximal AP-1 site, but not the distal, was inducible by Jun/Fos heterodimers. The distal AP-1 site, which has a G --> A switch at position 4, was inducible by Jun homodimers. Electrophoretic mobility shift assays, using extracts of tumor necrosis factor alpha (TNF alpha)-stimulated bovine aortic endothelial cells, demonstrated TNF alpha-inducible binding to the proximal AP-1 site, comprising JunD/Fos heterodimers. At the distal AP-1 site, only minor induction of binding activity, characterized as proteins of the Jun and ATF family, was observed. Consistently, this site only marginally participates in TNF alpha induction. Functional studies with TF promotor plasmids confirmed that deletion of the proximal AP-1 or the NF-kappa B site decreased TNF alpha-mediated TF induction to a higher extend than loss of the distal AP-1 site. However, integrity of both AP-1 sites and the NF-kappa B site was required for optimal TNF alpha stimulation. The relevance of these in vitro data was confirmed in vivo in a mouse tumor model. Expression plasmids for a dominant negative Jun mutant or I-KB were packaged in liposomes. When either mutated Jun or I-KB were injected intravenously 48 h before TNF alpha, a reduction in TNF alpha-mediated TF expression in the tumor endothelial cells was observed. Simultaneously, fibrin/fibrinogen deposition decreased and free blood flow could be re stored, Thus, TNF alpha-induced up-regulation of endothelial cell TF depends on a concerted action of members of the bZIP and NF-kappa B family.	UNIV HEIDELBERG, DEPT MED, D-69115 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT PATHOL, D-69115 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT ANESTHESIOL, D-69115 HEIDELBERG, GERMANY; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; TECH UNIV DRESDEN, DEPT PATHOL, D-01307 DRESDEN, GERMANY; INST BIOCHEM, D-79106 FREIBURG, GERMANY; UNIV NEW MEXICO, DEPT PATHOL, ALBUQUERQUE, NM 87131 USA; COLUMBIA UNIV, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Scripps Research Institute; Technische Universitat Dresden; University of New Mexico; Columbia University			Greten, Henry/A-3248-2012	Greten, Johannes/0000-0003-0196-4584				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BERGER I, 1991, ONCOGENE, V6, P561; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BIERHAUS A, 1995, THROMB HAEMOSTASIS, V73, P39; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CUNNINGHAM PR, 1990, BIOTECHNIQUES, V9, P713; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONOVANPALUSO O, 1994, J BIOL CHEM, V269, P1361; DRAKE TA, 1993, AM J PATHOL, V142, P1458; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; EDGINGTON TS, 1992, NOUV REV FR HEMATOLS, V34, P15; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAGEMEYER BM, 1993, EMBO J, V12, P3559; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HEMMER CJ, 1994, THROMB HAEMOSTASIS, V72, P457; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2675; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KONDO S, 1987, BLOOD, V70, P1947; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1993, AM J PATHOL, V143, P76; MANDECKI W, 1988, DNA-J MOLEC CELL BIO, V7, P57, DOI 10.1089/dna.1988.7.57; Maniatis T, 1989, DECONTAMINATION DILU; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P94; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAWROTH P, 1988, J EXP MED, V168, P637, DOI 10.1084/jem.168.2.637; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NAWROTH PP, 1985, THROMB RES, V40, P677, DOI 10.1016/0049-3848(85)90305-6; NAWROTH PP, 1984, BLOOD, V64, P801; NEMERSON Y, 1988, BLOOD, V71, P1; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PARRY GCN, 1994, FASEB J, V8, P5902; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; Solberg S, 1990, Blood Coagul Fibrinolysis, V1, P595; STERN DM, 1985, J EXP MED, V162, P1223, DOI 10.1084/jem.162.4.1223; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZHANG Y, 1995, IN PRESS J CLIN INVE; ZHANG YM, 1994, AM J PATHOL, V144, P51; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	80	128	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26419	26432		10.1074/jbc.270.44.26419	http://dx.doi.org/10.1074/jbc.270.44.26419			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592857	hybrid			2022-12-25	WOS:A1995TC97800064
J	ROSSAK, M; TIETJE, C; HEINZ, E; BENNING, C				ROSSAK, M; TIETJE, C; HEINZ, E; BENNING, C			ACCUMULATION OF UDP-SULFOQUINOVOSE IN A SULFOLIPID-DEFICIENT MUTANT OF RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLASTS; BIOSYNTHESIS	The sulfolipid 6-sulfo-alpha-D-quinovosyl diacylglycerol is found in the photosynthetic membranes of all plants and most photosynthetic bacteria. Progress toward the elucidation of the pathway for sulfolipid biosynthesis has been slow in the past. However, the recent isolation of three genes of the photosynthetic bacterium Rhodobacter sphaeroides known to be involved in sulfo-lipid biosynthesis provides promising new opportunities. Two of the genes flank an open reading frame predicted to encode a protein with amino acid sequence similarity to sugar nucleotide-dependent glycosyltransferases. The UDP-sulfoquinovose:diacylglycerol sulfoquinovosyltransferase thought to catalyze the last step of sulfolipid biosynthesis belongs to this group of glycosyltransferases. To test whether this open reading frame encodes the sulfoquinovosyltransferase of R. sphaeroides, it was inactivated by gene replacement avoiding polar mutagenesis. The resulting sulfolipid-deficient mutant defines a new gene, designated sqdD. Mutant cells grown in the presence of [S-35]sulfate accumulate a water-soluble S-35-labeled compound. The purified compound was tentatively identified by co-chromatography with standards and enzymatic conversion as UDP-sulfoquinovose, the final precursor of sulfolipid biosynthesis. This result strongly suggests that the inactivation of sqdD causes a metabolic block in the last step of sulfolipid biosynthesis.	INST GENBIOL FORSCH BERLIN GMBH,D-14195 BERLIN,GERMANY; UNIV HAMBURG,INST ALLGEMEINE BOT,D-22609 HAMBURG,GERMANY	University of Hamburg			Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667				BENNING C, 1992, J BACTERIOL, V174, P6479, DOI 10.1128/JB.174.20.6479-6487.1992; BENNING C, 1992, J BACTERIOL, V174, P2352, DOI 10.1128/JB.174.7.2352-2360.1992; BENSON AA, 1959, P NATL ACAD SCI USA, V45, P1582, DOI 10.1073/pnas.45.11.1582; BENSON AA, 1963, ADV LIPID RES, V1, P387; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; DALDAL F, 1986, P NATL ACAD SCI USA, V83, P2012, DOI 10.1073/pnas.83.7.2012; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; HAAS R, 1980, PLANTA, V148, P238, DOI 10.1007/BF00380033; Harwood J. L., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P301; HEINZ E, 1989, EUR J BIOCHEM, V184, P445, DOI 10.1111/j.1432-1033.1989.tb15037.x; HOCH M, 1989, CARBOHYD RES, V191, P21, DOI 10.1016/0008-6215(89)85043-8; IMHOFF JF, 1982, J BACTERIOL, V150, P1192, DOI 10.1128/JB.150.3.1192-1201.1982; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V2, P1190; SEIFERT U, 1992, BOT ACTA, V105, P197, DOI 10.1111/j.1438-8677.1992.tb00287.x; SHIBUYA ISAO, 1963, P627; Simon R., 1983, BIOTECHNOLOGY, V1, P37; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; van Niel CB, 1944, BACTERIOL REV, V8, P1	22	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25792	25797		10.1074/jbc.270.43.25792	http://dx.doi.org/10.1074/jbc.270.43.25792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592762	hybrid			2022-12-25	WOS:A1995TB46600079
J	ARGAUD, D; LANGE, AJ; BECKER, TC; OKAR, DA; ELMAGHRABI, MR; NEWGARD, CB; PILKIS, SJ				ARGAUD, D; LANGE, AJ; BECKER, TC; OKAR, DA; ELMAGHRABI, MR; NEWGARD, CB; PILKIS, SJ			ADENOVIRUS-MEDIATED OVEREXPRESSION OF LIVER 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE IN GLUCONEOGENIC RAT HEPATOMA-CELLS - PARADOXICAL EFFECT ON FRU-2,6-P(2) LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; MESSENGER-RNA; PYRUVATE-KINASE; HEPATOCYTES; INHIBITION; GLYCOLYSIS; METABOLISM; INSULIN	6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase has been postulated 60 be a metabolic signaling enzyme, which acts as a switch between glycolysis and gluconeogenesis in mammalian liver by regulating the level of fructose 2,6-bisphosphate, The effect of overexpressing the bifunctional enzyme was studied in FAO cells transduced with recombinant adenoviral constructs of either the wild-type enzyme or a double mutant that has no bisphosphatase activity or protein kinase phosphorylation site, With both constructs, the mRNA and protein were overexpressed by 150- and 40-fold, respectively, Addition of cAMP to cells overexpressing the wild-type enzyme increased the S-0.5 for fructose 6-phosphate of the kinase by 1.5 fold but had no effect on the overexpressed double mutant, When the wild-type enzyme was overexpressed, there was a decrease in fructose 2,6-bisphosphate levels, even though 6-phosphofructo-2-kinase maximal activity increased more than 22 fold and was in excess of fructose 2,6-bisphosphatase maximal activity, The kinase:bisphosphatase maximal activity ratio was decreased, indicating that the overexpressed enzyme was phosphorylated by cAMP-dependent protein kinase, Overexpression of the double mutant resulted in a 28-fold increase in kinase maximal activity and a 3-4 fold increase in fructose 2,6-bisphosphate levels, Overexpression of this form inhibited the rate of glucose production from dihydroxyacetone by 90% and stimulated the rate of lactate plus pyruvate production by 200%, In contrast, overexpression of the wild-type enzyme enhanced glucose production and inhibited lactate plus pyruvate production, These results provide direct support for fructose 2,6-bisphosphate as a regulator of gluconeogenic/glycolytic pathway flux and suggest that regulation of bifunctional enzyme activities by covalent modification is more important than the amount of the protein.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM & INTERNAL MED,DALLAS,TX 75235	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ARGAUD, D (corresponding author), UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354, R01DK046492, R37DK046492] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38354, DK-46492] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGAUD D, 1991, BIOCHEM J, V280, P663, DOI 10.1042/bj2800663; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Bergmeyer H., 1974, METHOD ENZYMAT AN, V3, P1125; BERTOLOTTI R, 1977, SOMAT CELL GENET, V3, P365, DOI 10.1007/BF01542966; CLAUS TH, 1984, BIOCHEM BIOPH RES CO, V125, P655, DOI 10.1016/0006-291X(84)90589-8; CLEVELAND DW, 1980, CELL, V20, P85; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DESCHATRETTE J, 1979, SOMAT CELL GENET, V5, P697, DOI 10.1007/BF01542636; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ESPINET C, 1993, BIOCHEM J, V293, P173, DOI 10.1042/bj2930173; EXTON JH, 1967, J BIOL CHEM, V242, P2622; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALESTRAP AP, 1986, HORMONAL CONTROL GLU, P31; HOD Y, 1984, J BIOL CHEM, V259, P5603; HOD Y, 1992, BIOTECHNIQUES, V13, P852; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; PROBST I, 1985, EUR J BIOCHEM, V153, P347, DOI 10.1111/j.1432-1033.1985.tb09309.x; RIOU JP, 1978, J BIOL CHEM, V253, P656; ROSA JL, 1995, IN PRESS BIOCH J; ROSELLA G, 1993, MOL ENDOCRINOL, V7, P1456, DOI 10.1210/me.7.11.1456; SCHAMHART DHJ, 1979, CANCER RES, V39, P1051; TAULER A, 1990, J BIOL CHEM, V265, P15617; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1990, FRUCTOSE 2 6 BISPHOS, P65; VARGAS AM, 1994, DIABETES, V43, P792, DOI 10.2337/diabetes.43.6.792; VENEZIALE CM, 1976, GLUCONEOGENESIS ITS, P463; WEINHOUSE S, 1972, CANCER RES, V32, P2007	47	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24229	24236		10.1074/jbc.270.41.24229	http://dx.doi.org/10.1074/jbc.270.41.24229			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592629	hybrid			2022-12-25	WOS:A1995TA21700057
J	BACOLLA, A; ULRICH, MJ; LARSON, JE; LEY, TJ; WELLS, RD				BACOLLA, A; ULRICH, MJ; LARSON, JE; LEY, TJ; WELLS, RD			AN INTRAMOLECULAR TRIPLEX IN THE HUMAN GAMMA-GLOBIN 5'-FLANKING REGION IS ALTERED BY POINT MUTATIONS ASSOCIATED WITH HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; SUPERCOILED PLASMID DNA; PURINE-PURINE TRIPLEX; SIMIAN VIRUS 40; MYOTONIC-DYSTROPHY; CTG REPEAT; B-DNA; GENE; STABILITY; HELIX	The properties of an intramolecular tripler formed in vitro at the 5'-flanking region of the human gamma-globin genes were studied by chemical and physical probes, Chemical modifications performed with osmium tetroxide, chloroacetaldehyde, and diethyl pyrocarbonate revealed the presence of non-paired nucleotides on the ''coding strand'' at positions -209 through -217, These reactivities were induced by negative supercoiling, low pH, and magnesium ions, Downstream point mutations associated with hereditary persistence of fetal hemoglobin (HPFH) altered the extent of the modifications and some of the patterns, Specifically, C-202 --> G and C-202 --> T significantly decreased the reactivities, whereas the patterns were increased and altered in the T-198 --> C, C-196 --> T and C-195 --> G caused local decreases in reactivity, Modifications at the upstream flanking duplex were modulated by the composition of the vector sequence, In summary, our data indicates the formation of an intramolecular tripler between nucleotides -209 to -217 of the ''non-coding strand'' and the downstream sequence containing the HPFH mutations, All of the HPFH point mutations altered the structure, More than one sequence alignment is possible for each of the triplexes, In addition, a consequence of some of the point mutations may be to facilitate slippage of the third strand relative to the Watson-Crick duplex.	TEXAS A&M UNIV,TEXAS MED CTR,INST BIOSCI & TECHNOL,HOUSTON,TX 77030; WASHINGTON UNIV,MED CTR,DEPT MED,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT GENET,ST LOUIS,MO 63110	Baylor College of Medicine; Texas A&M University System; Washington University (WUSTL); Washington University (WUSTL)			Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49786] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACOLLA A, 1991, NUCLEIC ACIDS RES, V19, P1639, DOI 10.1093/nar/19.7.1639; BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; BUCKLE M, 1991, METHOD ENZYMOL, V208, P236; CARBONNAUX C, 1991, BIOCHEMISTRY-US, V30, P5449, DOI 10.1021/bi00236a018; COCKELL M, 1994, NUCLEIC ACIDS RES, V22, P32, DOI 10.1093/nar/22.1.32; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; DITTRICH K, 1994, BIOCHEMISTRY-US, V33, P4111, DOI 10.1021/bi00180a003; DURLAND RH, 1994, NUCLEIC ACIDS RES, V22, P3233, DOI 10.1093/nar/22.15.3233; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; GIMBLE JM, 1988, BLOOD, V72, P606; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; HUISMAN THJ, 1992, HEMOGLOBIN, V16, P237, DOI 10.3109/03630269208998865; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG S, 1992, J BIOL CHEM, V267, P1259; KANG S, 1995, IN PRESS J BIOL CHEM; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KLYSIK J, 1995, J MOL BIOL, V245, P499, DOI 10.1006/jmbi.1994.0041; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE JS, 1989, GENE, V82, P191, DOI 10.1016/0378-1119(89)90044-9; LEONARD GA, 1990, NUCLEIC ACIDS RES, V18, P5617, DOI 10.1093/nar/18.19.5617; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LU GH, 1993, INT J BIOCHEM, V25, P1529, DOI 10.1016/0020-711X(93)90508-C; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MACAYA RF, 1991, SCIENCE, V254, P270, DOI 10.1126/science.1925581; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P585, DOI 10.1093/nar/21.3.585; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P105, DOI 10.1093/nar/21.1.105; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU M, 1994, J MOL BIOL, V235, P185, DOI 10.1016/S0022-2836(05)80025-7; SINDEN RR, 1994, DNA STRUCTURE FUNCTI, P134; STARCK J, 1994, BLOOD, V84, P1656; TATE VE, 1986, BLOOD, V68, P1389; TUNG CH, 1993, NUCLEIC ACIDS RES, V21, P5489, DOI 10.1093/nar/21.23.5489; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; WASHBROOK E, 1994, NUCLEIC ACIDS RES, V22, P3977, DOI 10.1093/nar/22.19.3977; WELLS RD, 1972, J BIOL CHEM, V247, P3405; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YAMAZOE M, 1994, J BIOL CHEM, V269, P15244; 1993, CELL, V72, P971	64	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24556	24563		10.1074/jbc.270.41.24556	http://dx.doi.org/10.1074/jbc.270.41.24556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592674	hybrid			2022-12-25	WOS:A1995TA21700102
J	DELL, A; MORRIS, HR; EASTON, RL; PANICO, M; PATANKAR, M; OEHNINGER, S; KOISTINEN, R; KOISTINEN, H; SEPPALA, M; CLARK, GF				DELL, A; MORRIS, HR; EASTON, RL; PANICO, M; PATANKAR, M; OEHNINGER, S; KOISTINEN, R; KOISTINEN, H; SEPPALA, M; CLARK, GF			STRUCTURAL-ANALYSIS OF THE OLIGOSACCHARIDES DERIVED FROM GLYCODELIN, A HUMAN GLYCOPROTEIN WITH POTENT IMMUNOSUPPRESSIVE AND CONTRACEPTIVE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL PROTEIN-14; LINKED OLIGOSACCHARIDES; MASS-SPECTROMETRY; CARBOHYDRATE-STRUCTURE; CELL ACTIVATION; ADHESION; CD22; RECOGNITION; PP14; PHYTOHEMAGGLUTININ	Glycodelin, also known as placental protein 14 (PP14) or progesterone-associated endometrial protein (PAEP), is a human glycoprotein with potent immunosuppressive and contraceptive activities. In this paper we report the first characterization of glycodelin-derived oligosaccharides. Using strategies based upon fast atom bombardment and electrospray mass spectrometry we have established that glycodelin is glycosylated at Asn-28 and Asn-63. The Asn-28 site carries high mannose, hybrid and complex-type structures, whereas the second site is exclusively occupied by complex-type glycans. The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-GGal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6GalNAc beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewis(x)), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewis(x)). It is possible that the oligosaccharides bearing sialylated lacNAc or lacdiNAc antennae may manifest immunosuppressive effects by specifically blocking adhesive and activation-related events mediated by CD22, the human B cell associated receptor. Oligosaccharides with fucosylated lacdiNAc antennae have previously been shown to potently block selectin-mediated adhesions and may perform the same function in glycodelin, The potent inhibitory effect of glycodelin on initial human sperm-zona pellucida binding is consistent with our previous suggestion that this cell adhesion event requires a selectin-like adhesion process. This result also raises the possibility that a convergence between immune and gamete recognition processes may have occurred in the types of carbohydrate ligands recognized in the human.	EASTERN VIRGINIA MED SCH, DEPT BIOCHEM, NORFOLK, VA 23501 USA; EASTERN VIRGINIA MED SCH, DEPT OBSTET & GYNECOL, NORFOLK, VA 23501 USA; UNIV HELSINKI, CENT HOSP, DEPT OBSTET & GYNECOL, SF-00290 HELSINKI, FINLAND	Eastern Virginia Medical School; Eastern Virginia Medical School; University of Helsinki; Helsinki University Central Hospital	DELL, A (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND.		Oehninger, Sergio/AAZ-8443-2020; Koistinen, Hannu/AGU-1279-2022; Seppala, Markku/AAT-6618-2021	Koistinen, Hannu/0000-0003-0926-3109; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; Bohn H, 1982, Placenta Suppl, V4, P67; BOLTON AE, 1987, LANCET, V1, P593; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLARK EA, 1993, J IMMUNOL, V150, P4715; CLARK GF, 1995, J ASSIST REPROD GEN, V12, P475; CLARK GF, 1995, IN PRESS HUM REPROD; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; DELL A, 1983, CARBOHYD RES, V115, P41, DOI 10.1016/0008-6215(83)88133-6; DELL A, 1994, METHOD ENZYMOL, V230, P108; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; GEDDES AJ, 1969, BIOCHEM J, V114, P695, DOI 10.1042/bj1140695; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; JULKUNEN M, 1986, FERTIL STERIL, V45, P47; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x; KAMARAINEN M, 1994, BLOOD, V84, P467; KHOO KH, 1993, CARBOHYD RES, V244, P205, DOI 10.1016/0008-6215(83)85002-2; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEMAIRE S, 1982, BIOCHEM BIOPH RES CO, V108, P51, DOI 10.1016/0006-291X(82)91830-7; LOCHNIT G, 1995, EUR J BIOCHEM, V228, P805, DOI 10.1111/j.1432-1033.1995.tb20326.x; MACEK MB, 1988, GAMETE RES, V20, P93, DOI 10.1002/mrd.1120200109; MAHONY MC, 1991, CONTRACEPTION, V44, P657, DOI 10.1016/0010-7824(91)90085-T; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; MILLER DJ, 1990, MOL REPROD DEV, V26, P184, DOI 10.1002/mrd.1080260213; MORRIS HR, 1971, BIOCHEM J, V125, P189, DOI 10.1042/bj1250189; MORRIS HR, 1983, BIOCHEM BIOPH RES CO, V117, P299, DOI 10.1016/0006-291X(83)91575-9; MORRIS HR, 1978, J BIOL CHEM, V253, P5155; MORROW DM, 1994, AM J PATHOL, V145, P1485; NAKATA N, 1993, BIOCHEMISTRY-US, V32, P4369, DOI 10.1021/bi00067a029; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OEHNINGER S, 1991, FERTIL STERIL, V55, P165; OKAMOTO N, 1991, AM J REPROD IMMUNOL, V26, P137, DOI 10.1111/j.1600-0897.1991.tb00713.x; Patankar M., 1993, Glycobiology, V3, P521; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; PEAKER CJG, 1994, CURR OPIN IMMUNOL, V6, P359, DOI 10.1016/0952-7915(94)90113-9; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POCKLEY AG, 1988, J REPROD IMMUNOL, V13, P31, DOI 10.1016/0165-0378(88)90046-0; POCKLEY AG, 1989, CLIN EXP IMMUNOL, V77, P252; POCKLEY AG, 1990, IMMUNOLOGY, V69, P277; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; RIITTINEN L, 1991, J IMMUNOL METHODS, V136, P85, DOI 10.1016/0022-1759(91)90253-C; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TOMIYA N, 1993, J BIOL CHEM, V268, P113; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	65	233	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24116	24126		10.1074/jbc.270.41.24116	http://dx.doi.org/10.1074/jbc.270.41.24116			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592613	hybrid			2022-12-25	WOS:A1995TA21700041
J	NAKAMURA, J; STRAUB, K; WU, J; LOU, L				NAKAMURA, J; STRAUB, K; WU, J; LOU, L			THE GLUTAMINE HYDROLYSIS FUNCTION OF HUMAN GMP SYNTHETASE - IDENTIFICATION OF AN ESSENTIAL ACTIVE-SITE CYSTEINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISMS	GMP synthetase (EC 6.3.5.2) is an amidotransferase that catalyzes the amination of xanthosine 5'-monophosphate to form GMP in the presence of glutamine and ATP, Glutamine hydrolysis produces the necessary amino group while ATP hydrolysis drives the reaction, Ammonia can also serve as an amino group donor, GMP synthetase contains two functional domains, which are well coordinated, The ''glutamine amide transfer'' or glutaminase domain is responsible for glutamine hydrolysis, The synthetase domain is responsible for ATP hydrolysis and GMP formation. Inorganic pyrophosphate inhibits the synthetase and uncouples the two domain functions by allowing glutamine hydrolysis to take place in the absence of ATP hydrolysis or GMP formation, Acivicin, a glutamine analog, selectively abolishes the glutaminase activity, It inhibits the synthetase activity only when glutamine is the amino do nor, When ammonia is used in place of glutamine, acivicin has no effect on the synthetase activity, Acivicin inhibits GRIP synthetase irreversibly by covalent modification. Enzyme inactivation is greatly facilitated by the presence of substrates. Acivicin labels GMP synthetase at a single site, and a tryptic peptide containing the modified residue was isolated, Mass spectrometry and Edman sequence analysis show that Cys(104) is the site of modification, This residue is conserved among GRIP synthetases and is located within a predicted glutamine amide transfer domain, These data suggest that Cys(104) is an essential residue involved in the hydrolysis of glutamine to produce an amino group and is not needed for the hydrolysis of ATP or amination of xanthosine 5'-monophosphate to produce GMP.	SYNTEX INC, DISCOVERY RES, INST BIOCHEM & CELL BIOL, PALO ALTO, CA 94303 USA; SYNTEX INC, DISCOVERY RES, INST ANALYT RES, PALO ALTO, CA 94303 USA	Syntex Corporation; Syntex Corporation								ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1760, DOI 10.1021/bi00173a019; Birchmeier W, 1977, Methods Enzymol, V46, P41; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3384; EUGUI EM, 1993, ANN NY ACAD SCI, V685, P309, DOI 10.1111/j.1749-6632.1993.tb35881.x; FUKUYAMA TT, 1966, J BIOL CHEM, V241, P4745; HAGER SE, 1967, J BIOL CHEM, V242, P5667; HIRAI K, 1987, J BIOCHEM, V102, P893, DOI 10.1093/oxfordjournals.jbchem.a122130; HIRST M, 1994, J BIOL CHEM, V269, P23830; LEE BH, 1974, BIOCHEM BIOPH RES CO, V60, P918, DOI 10.1016/0006-291X(74)90402-1; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3365, DOI 10.1021/bi00794a008; LOU L, 1995, PROTEIN EXPRES PURIF, V6, P487, DOI 10.1006/prep.1995.1065; LYONS SD, 1990, J BIOL CHEM, V265, P11377; MELOCHE HP, 1967, BIOCHEMISTRY-US, V6, P2273, DOI 10.1021/bi00860a002; MIZOBUCHI K, 1971, J BIOL CHEM, V243, P4853; NAKAMURA J, 1995, J BIOL CHEM, V270, P7347, DOI 10.1074/jbc.270.13.7347; PATEL N, 1975, J BIOL CHEM, V250, P2609; TRUITT CD, 1978, J BIOL CHEM, V253, P8470; TSO JY, 1980, J BIOL CHEM, V255, P6734; VONDERSAAL W, 1985, BIOCHEMISTRY-US, V24, P5343, DOI 10.1021/bi00341a011; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZALKIN H, 1977, J BIOL CHEM, V252, P5431	22	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23450	23455		10.1074/jbc.270.40.23450	http://dx.doi.org/10.1074/jbc.270.40.23450			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559506	hybrid			2022-12-25	WOS:A1995RY90900035
J	TARTAREDECKERT, S; SAWKAVERHELLE, D; MURDACA, J; VANOBBERGHEN, E				TARTAREDECKERT, S; SAWKAVERHELLE, D; MURDACA, J; VANOBBERGHEN, E			EVIDENCE FOR A DIFFERENTIAL INTERACTION OF SHC AND THE INSULIN-RECEPTOR SUBSTRATE-1 (IRS-1) WITH THE INSULIN-LIKE GROWTH-FACTOR-I (IGF-I) RECEPTOR IN THE YEAST 2-HYBRID SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SIGNAL TRANSDUCTION; PROTEIN; DOMAIN; PHOSPHORYLATION; ASSOCIATION; COMPLEXES; CELLS; GRB2	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1), We also mapped the specific domains of the IGF-IR and p52Shc participating in these interactions, Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-LR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the aminoterminal domain of p52Shc is required for its association with the IR and the IGF-IR, We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc, Finally, our data highlight the crucial role of the juxtamembrane domain in signaling by both the IR and the IGF-IR.			TARTAREDECKERT, S (corresponding author), INSERM,U145,AVE VALOMBROSE,F-06107 NICE 2,FRANCE.		TARTARE-DECKERT, Sophie/P-6057-2015	TARTARE-DECKERT, Sophie/0000-0001-8680-5720				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HARPER JW, 1993, CELL, V75, P805; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Miller J.H., 1972, EXPT MOL GENETICS; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, P125; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	43	96	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23456	23460		10.1074/jbc.270.40.23456	http://dx.doi.org/10.1074/jbc.270.40.23456			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559507	hybrid			2022-12-25	WOS:A1995RY90900036
J	ZHOU, BP; LEWIS, DA; KWAN, SW; ABELL, CW				ZHOU, BP; LEWIS, DA; KWAN, SW; ABELL, CW			FLAVINYLATION OF MONOAMINE-OXIDASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COVALENTLY-BOUND FLAVIN; MONOCLONAL-ANTIBODY; HUMAN-BRAIN; SEQUENCE; BINDING; POPULATIONS; PROTEINS	Monoamine oxidase B (MAO B) catalyzes the oxidative deamination of biogenic and xenobiotic amines. The oxidative step is coupled to the reduction of an obligatory cofactor, FAD, which is covalently linked to the enzyme at Cys(397). In this study, we developed a novel riboflavin-depleted (Rib(-)) COS 7 cell line to study the flavinylation of MAO B. ApoMAO B can be obtained by expressing MAO B cDNA in these cells. We found that MAO B is expressed equally in the presence or absence of FAD and that apoMAO B can be inserted into the outer mitochondrial membrane. Flavinylation of MAO B was achieved by introducing MAO B cDNA and different flavin derivatives simultaneously into Rib(-) COS-7 cells via electroporation. Since the addition of riboflavin, FMN, or FAD resulted in equal levels of MAO B activity, we conclude that the flavin which initially binds to apoMAO B is FAD. In our previous work, we used site-directed mutagenesis to show that Glu(34) in the dinucleotide binding motif of MAO B is essential for MAO B activity, and we postulated that this residue is involved in FAD binding. In this study, we tested the role of residue 34 in flavin binding by expressing wild-type or mutant MAO B cDNA in Rib(-) COS-7 cells with the addition of [C-14]FAD. We found that Glu(34) is essential for both FAD binding and catalytic activity. Thus, FAD binds to MAO B in a dual manner at Glu(34) noncovalently and Cys(397) covalently. We conclude that Glu(34) is critical for the initial noncovalent binding of FAD and is instrumental in delivering FAD to the covalent attachment site at Cys(397).	UNIV TEXAS, COLL PHARM, DIV MED CHEM, AUSTIN, TX 78712 USA; UNIV TEXAS, INST NEUROSCI, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024932] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24932] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL CW, 1994, HETEROCYCLES, V39, P933; [Anonymous], [No title captured]; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; DAPRADA M, 1989, J NEURAL TRANSM-GEN, P5; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENNEY RM, 1983, MOL PHARMACOL, V24, P60; DENNEY RM, 1982, SCIENCE, V215, P1400, DOI 10.1126/science.7063850; DOMBROWSKI JJ, 1981, INT J BIOCHEM, V13, P171, DOI 10.1016/0020-711X(81)90153-1; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; KOCHERSPERGER LM, 1985, J NEUROSCI, V5, P2874; KWAN SW, 1995, ARCH BIOCHEM BIOPHYS, V316, P385, DOI 10.1006/abbi.1995.1051; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MCCORMICK DB, 1970, J HETEROCYCLIC CHEM, V7, P447, DOI 10.1002/jhet.5570070240; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; NISHIKIMI M, 1994, BIOCHEM MOL BIOL INT, V33, P313; SINGER TP, 1956, ARCH BIOCHEM BIOPHYS, V60, P255, DOI 10.1016/0003-9861(56)90415-5; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; WALKER WH, 1971, EUR J BIOCHEM, V24, P328, DOI 10.1111/j.1432-1033.1971.tb19690.x; WATANABE K, 1980, BIOCHEM BIOPH RES CO, V94, P579, DOI 10.1016/0006-291X(80)91271-1; WESTLUND KN, 1988, NEUROSCIENCE, V25, P439, DOI 10.1016/0306-4522(88)90250-3; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WHITE HL, 1979, MONOAMINE OXIDASE ST, P129; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WU HF, 1993, MOL PHARMACOL, V43, P888; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; YEOMANSON KB, 1992, BIOCHIM BIOPHYS ACTA, V1116, P261, DOI 10.1016/0304-4165(92)90038-V; ZIMMERMANN U, 1982, J MEMBRANE BIOL, V67, P165, DOI 10.1007/BF01868659	36	30	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23653	23660		10.1074/jbc.270.40.23653	http://dx.doi.org/10.1074/jbc.270.40.23653			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559533	hybrid			2022-12-25	WOS:A1995RY90900062
J	ELOUAGARI, K; TEISSIE, J; BENOIST, H				ELOUAGARI, K; TEISSIE, J; BENOIST, H			GLYCOPHORIN A PROTECTS K562 CELLS FROM NATURAL-KILLER-CELL ATTACK - ROLE OF OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CYTO-TOXICITY; TRANSFERRIN RECEPTOR; SIALIC-ACID; NK SUSCEPTIBILITY; TARGET STRUCTURES; TUMOR-CELLS; LYSIS; GLYCOPROTEINS; EXPRESSION; RESISTANCE	Glycophorin A is a protein with an abundant glycosylation (60% carbohydrate by weight), and studies have suggested that resistance of target cells to natural killing may be correlated with the level of glycophorin A expression, To assess the role of glycophorin A and of its carbohydrates in sensitivity to lysis by natural killer (NK) cells, the glycoprotein was inserted into the membrane of K562 target cells using electropulsation. Peripheral blood lymphocytes were used as effector cells. When glycophorin A was inserted into the membrane, the level of resistance to NK cell attack increased with the number of glycophorin A molecules electroinserted. The resistance to lysis was not due to a defect in target cell effector cell binding, Electroassociation of glycophorin A did not cause a decrease in the expression of either ''positive signals'' for NK cells (such as CD71, CD15, and CD32 antigens) or cellular adhesion molecules (CD18, CD29, CD54, and CD58), Furthermore, electroinsertion of glycophorin A did not trigger any ''negative signals,'' such as class I HLA antigen expression. Finally, it was shown that the sialic acid and O-linked oligosaccharides of glycophorin A did not play any role in its effect against NK cells. Conversely, the unique N-linked oligosaccharide was shown to be essential for resistance to occur.	UNIV TOULOUSE 3,INSERM,U395,F-31024 TOULOUSE,FRANCE; DEPT GLYCOCONJUGUES & BIOMEMBRANES,CNRS,UPR 8221,F-31062 TOULOUSE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Teissie, Justin/AAA-5697-2019; Benoist, Hervé/P-2927-2014	Teissie, Justin/0000-0002-7588-8062; 				AHRENS PB, 1993, J BIOL CHEM, V268, P385; ALARCON B, 1985, J IMMUNOL, V134, P1286; ANDO I, 1987, INT J CANCER, V40, P12, DOI 10.1002/ijc.2910400104; ARORA DJS, 1984, J VIROL, V52, P839, DOI 10.1128/JVI.52.3.839-845.1984; BENOIST H, 1992, IMMUNOL LETT, V34, P45, DOI 10.1016/0165-2478(92)90026-K; BENOIST H, 1988, INT J CANCER, V42, P299, DOI 10.1002/ijc.2910420227; BEZOUSKA K, 1995, NATURE, V372, P150; DILL K, 1990, J PROTEIN CHEM, V9, P129, DOI 10.1007/BF01025303; DLUHY RA, 1983, BIOCHEMISTRY-US, V22, P1170, DOI 10.1021/bi00274a028; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; ELOUAGARI K, 1993, BIOCHIM BIOPHYS ACTA, V1151, P105, DOI 10.1016/0005-2736(93)90077-D; ELOUAGARI K, 1994, EUR J BIOCHEM, V219, P1031; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GRIMM E, 1979, J IMMUNOL, V123, P2861; HARRIS DT, 1994, SCAND J IMMUNOL, V39, P73, DOI 10.1111/j.1365-3083.1994.tb03342.x; KAPITZA HG, 1984, BIOPHYS J, V45, P577, DOI 10.1016/S0006-3495(84)84195-8; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; LAZARUS AH, 1985, CELL IMMUNOL, V96, P255, DOI 10.1016/0008-8749(85)90358-2; MCCOY J P JR, 1991, Glycobiology, V1, P321, DOI 10.1093/glycob/1.4.321; MORETTA L, 1992, IMMUNOL TODAY, V13, P300, DOI 10.1016/0167-5699(92)90042-6; PATARROYO M, 1991, CLIN IMMUNOL IMMUNOP, V60, P333, DOI 10.1016/0090-1229(91)90091-N; PERL A, 1986, J IMMUNOL, V136, P4714; QUILLET A, 1988, J IMMUNOL, V141, P17; QUILLETMARY A, 1991, INT J CANCER, V47, P473, DOI 10.1002/ijc.2910470328; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; TRINCHIERI G, 1992, NATURAL KILLER CELL, P42; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; WERKMEISTER JA, 1983, INT J CANCER, V32, P71, DOI 10.1002/ijc.2910320112; YOGEESWARAN G, 1981, INT J CANCER, V28, P517, DOI 10.1002/ijc.2910280419; YOKOYAMA WM, 1995, CURR OPIN IMMUNOL, V7, P110, DOI 10.1016/0952-7915(95)80036-0; ZARCONE D, 1987, CANCER RES, V47, P2674; ZEIRA M, 1991, P NATL ACAD SCI USA, V88, P4409, DOI 10.1073/pnas.88.10.4409	34	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26970	26975						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592944				2022-12-25	WOS:A1995TE58300044
J	OSTRANDER, DB; GORMAN, JA; CARMAN, GM				OSTRANDER, DB; GORMAN, JA; CARMAN, GM			REGULATION OF PROFILIN LOCALIZATION IN SACCHAROMYCES-CEREVISIAE BY PHOSPHOINOSITIDE METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; PHOSPHATIDYLINOSITOL SYNTHASE; PHOSPHOLIPASE-C; STRUCTURAL GENE; YEAST PROFILIN; HUMAN PLATELET; PURIFICATION; INOSITOL	Profilin is an actin- and phosphatidylinositol 4,5-bisphosphate binding protein that plays a role in the organization of the cytoskeleton and may be involved in growth factor signaling pathways. The subcellular localization of profilin was examined in the yeast Saccharomyces cerevisiae, Immunoblot analysis showed that profilin was localized in both the plasma membrane and cytosolic fractions of the cell. Actin was bound to the profilin localized in the cytosol. The association of profilin with the membrane was peripheral and mediated through interaction with phospholipid. The phospholipid dependence of profilin for membrane binding was examined in vitro using pure profilin and defined unilamellar phospholipid vesicles. The presence of phosphatidylinositol 4,5-bisphosphate in phospholipid vesicles was required for maximum profilin binding. Moreover, the binding of profilin to phospholipid vesicles was dependent on the surface concentration of phosphatidylinositol 4,5-bisphosphate. The subcellular localization of profilin was examined in vivo under growth conditions (i.e. inositol starvation of ino1 cells and glucose starvation of respiratory deficient cells) where plasma membrane levels of phosphatidylinositol 4,5-bisphosphate were depleted. Depletion of plasma membrane phosphatidylinositol 4,5-bisphosphate levels resulted in a translocation of profilin from the plasma membrane to the cytosolic fraction. Profilin translocated back to the membrane fraction from the cytosol under growth conditions where plasma membrane levels of phosphatidylinositol 4,5-bisphosphate were replenished. These results suggested that phosphoinositide metabolism played a role in the localization of profilin.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MICROBIAL MOLEC BIOL, PRINCETON, NJ 08543 USA	Rutgers State University New Brunswick; Bristol-Myers Squibb					NIGMS NIH HHS [GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECKER GW, 1977, J BIOL CHEM, V252, P8684; BELENDIUK G, 1978, J BIOL CHEM, V253, P4555; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CULBERTSON MR, 1975, GENETICS, V80, P23; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREEN PR, 1984, J BIOL CHEM, V259, P4688; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HAFFEY ML, 1988, J VIROL, V62, P4493, DOI 10.1128/JVI.62.12.4493-4498.1988; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARLOW E, 1988, ANTIBODIES LABORATOR; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; KILMARTIN JV, 1984, J CELL BIOL, V98, P933; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; METZLER WJ, 1994, J BIOL CHEM, V269, P4620; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; Rose MD., 1990, METHODS YEAST GENETI; SCHAAP AP, 1989, CLIN CHEM, V35, P1863; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	46	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27045	27050		10.1074/jbc.270.45.27045	http://dx.doi.org/10.1074/jbc.270.45.27045			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592954	hybrid			2022-12-25	WOS:A1995TE58300054
J	GERSTEN, KM; NATSUKA, S; TRINCHERA, M; PETRYNIAK, B; KELLY, RJ; HIRAIWA, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; LOWE, JB				GERSTEN, KM; NATSUKA, S; TRINCHERA, M; PETRYNIAK, B; KELLY, RJ; HIRAIWA, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; LOWE, JB			MOLECULAR-CLONING, EXPRESSION, CHROMOSOMAL ASSIGNMENT, AND TISSUE-SPECIFIC EXPRESSION OF A MURINE ALPHA-(1,3)-FUCOSYL-TRANSFERASE LOCUS CORRESPONDING TO THE HUMAN ELAM-1 LIGAND FUCOSYL-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; EMBRYONIC ANTIGEN SSEA-1; FULL-LENGTH CDNA; LEWIS-X; MONOCLONAL-ANTIBODIES; DETERMINES EXPRESSION; LEUKEMIA-VIRUS; MOUSE EMBRYOS	Terminal Fuc alpha 1-3GlcNAc moieties are displayed by mammalian cell surface glycoconjugates in a tissue-specific manner. These oligosaccharides participate in selectin-dependent leukocyte adhesion and have been implicated in adhesive events during murine embryogenesis. Other functions for these molecules remain to be defined, as do the tissue-specific expression patterns of the corresponding alpha-(1-3)-fucosyltransferase (alpha 1-3FT) genes. This report characterizes a murine alpha 1-3FT that shares 77% amino acid sequence identity with human ELAM ligand fucosyltransferase (ELFT, also termed Fuc-TIV). The corresponding gene maps to mouse chromosome 9 in a region of homology with the Fuc-TIV locus on human chromosome 11q. In vitro, the murine (alpha 1-3FT can efficiently fucosylate the trisaccharide Gal alpha 1-3Gal beta 1-4GlcNAc (apparent K-m of 0.71 mM) to form an unusual tetrasaccharide (Gal alpha 1-3Gal beta 1-4[Fuc alpha 1-3]GlcNAc) described in periimplantation mouse tissues. The enzyme can also form the Lewis x determinant from Gal beta 1-4GlcNAc (K-m = 2.05 mM), and the sialyl Lewis x determinant from NeuNAc alpha 2-3Gal beta 1-4GlcNAc (K-m = 1.78 mM). However, it does not yield sialyl Lewis x determinants when expressed in a mammalian cell line that maintains sialyl Lewis x precursors. Transcripts from this gene accumulate to low levels in hematopoietic organs, but are unexpectedly abundant in epithelia that line the stomach, small intestine, colon, and epididymus. Epithelial cell-specific expression of this gene suggests function(s) in addition to, and distinct from, its proposed role in selectin ligand synthesis.	UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT CELL & MOLEC BIOL PROGRAM, ANN ARBOR, MI 48109 USA; NCI, FREDERICK CANC RES & DEV CTR,ABL INC, BASIC RES PROGRAM,MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Natsuka, Shunji/L-9330-2018	Natsuka, Shunji/0000-0003-1726-8946	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NCRR NIH HHS [M01RR00042] Funding Source: Medline; NIGMS NIH HHS [1R01GM47455] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BERG EL, 1991, J BIOL CHEM, V266, P14869; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CHIA D, 1985, CANCER RES, V45, P435; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGGENS I, 1989, J BIOL CHEM, V264, P9476; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; Fitch W.M., 1970, EVOL BIOL, V4, P67; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALTON J, 1985, P117; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; Green EL, 1981, GENETICS PROBABILITY, P77; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAMANO T, 1983, J IMMUNOL, V130, P2027; HUMMEL M, 1987, J IMMUNOL, V138, P3539; ITO K, 1994, GLYCOCONJUGATE J, V11, P232, DOI 10.1007/BF00731223; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; JOZIASSE DH, 1993, BIOCHEM BIOPH RES CO, V194, P358, DOI 10.1006/bbrc.1993.1828; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOREN HS, 1975, J IMMUNOL, V114, P894; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maniatis T., 1982, MOL CLONING; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; OLD LJ, 1965, CANCER RES, V25, P813; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RALPH P, 1977, J IMMUNOL, V119, P950; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SINGER D, 1974, P NATL ACAD SCI USA, V71, P2668, DOI 10.1073/pnas.71.7.2668; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; SZULMAN AE, 1973, LAB INVEST, V28, P565; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; VALANILA RP, 1989, J BIOL CHEM, V19, P11158; VANKESSEL AG, 1984, J IMMUNOL, V133, P1265; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; 1972, SPECIFICATIONS CRITE	78	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25047	25056		10.1074/jbc.270.42.25047	http://dx.doi.org/10.1074/jbc.270.42.25047			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559635	hybrid			2022-12-25	WOS:A1995TB46500069
J	LI, C; DAVLETOV, BA; SUDHOF, TC				LI, C; DAVLETOV, BA; SUDHOF, TC			DISTINCT CA2+ AND SR2+ BINDING-PROPERTIES OF SYNAPTOTAGMINS - DEFINITION OF CANDIDATE CA2+ SENSORS FOR THE FAST AND SLOW COMPONENTS OF NEUROTRANSMITTER RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN; P65	Ca2+-dependent neurotransmitter release consists of at least two components: a major fast component that is insensitive to Sr2+ and a minor slow component that is potentiated by Sr2+ (Goda, Y., and Stevens, C. F. (1994) Proc. Natl. Acad. U. S. A. 91, 12942-12946). These results suggest that at least two Ca2+ sensors act in synaptic vesicle fusion with distinct Ca2+ and Sr2+ binding properties. We have now investigated the relative Ca2+ and Sr2+ binding activities of synaptotagmins to evaluate their potential roles as Ca2+ sensors for the fast and slow components. Our results demonstrate that the first C-2 domains of synaptotagmins I, II, III, V, and VII have very similar Ca2+ requirements for phospholipid binding (range of EC(50) = 2.6 mu M to 5.0 mu M), but distinct Sr2+ requirements (EC(50) range = 23 mu M to 133 mu M); synaptotagmin I and II had the lowest Sr2+ affinity, and synaptotagmin III the highest Sr2+ affinity. Purified synaptotagmin I from bovine brain exhibited similar properties as its recombinant first C-2 domain, suggesting that the first C-2 domain fully accounts for its Ca2+-dependent phospholipid binding properties. Sr2+ was unable to trigger syntaxin binding by synaptotagmin I at all concentrations tested, whereas it was effective for synaptotagmin III. These results suggest that different C-2 domains have distinct Sr2+ binding properties. They support the hypothesis that synaptotagmins localized on the same vesicle perform distinct functions, with synaptotagmins I and II serving as candidate Ca2+ sensors for the fast component in release and synaptotagmin III for the slow component.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; DAMER CK, 1994, J BIOL CHEM, V269, P31115; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; FUKUDA M, 1994, J BIOL CHEM, V269, P26206; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	132	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24898	24902		10.1074/jbc.270.42.24898	http://dx.doi.org/10.1074/jbc.270.42.24898			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559614	hybrid			2022-12-25	WOS:A1995TB46500048
J	LIANG, YZ; PATEL, SS; DEAN, DH				LIANG, YZ; PATEL, SS; DEAN, DH			IRREVERSIBLE BINDING-KINETICS OF BACILLUS-THURINGIENSIS CRYIA DELTA-ENDOTOXINS TO GYPSY-MOTH BRUSH-BORDER MEMBRANE-VESICLES IS DIRECTLY CORRELATED TO TOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTTERFLY PIERIS-BRASSICAE; BOMBYX-MORI; HELIOTHIS-VIRESCENS; MIDGUT; SPECIFICITY; PROTEINS; RECEPTORS; LEPIDOPTERA; INHIBITION; RESISTANCE	To examine the binding of Bacillus thuringiensis delta-endotoxins, CryIAa, CryIAb, and CryIAc, to Lymantria dispar (gypsy moth) brush border membrane vesicles (BBMV), saturation kinetic analyses were conducted according to a two-step interaction scheme [GRAPHICS] for delta-endotoxin binding to BBMV, rather than the one-step reversible binding presented in prior reports. The order of toxicity of the delta-endotoxins, as measured by the dose required for a 50% inhibition of weight gain (ID50), was CryIAa (77.3 ng) > CryIAb (157 ng) > CryIAc (187 ng). While both the maximum extent of binding, B-max and the half-maximum insertion rate concentration, K-1/2 was observed to be indirectly related to toxicity, the rate constant of irreversible binding, k(2), was found to be directly correlated to toxicity.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University					NIAID NIH HHS [R01 AI29092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELFIORE CJ, 1994, BIOCHEM BIOPH RES CO, V200, P359, DOI 10.1006/bbrc.1994.1456; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN XJ, 1993, P NATL ACAD SCI USA, V90, P9041, DOI 10.1073/pnas.90.19.9041; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; DENOLF P, 1993, APPL ENVIRON MICROB, V59, P1828, DOI 10.1128/AEM.59.6.1828-1837.1993; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HONEE G, 1993, ENTOMOL EXP APPL, V69, P145, DOI 10.1007/BF02380641; IHARA H, 1993, BIOSCI BIOTECH BIOCH, V57, P200, DOI 10.1271/bbb.57.200; JOHNSTON L, 1992, INT J SOCIOL LAW, V20, P1; KEENA M, 1993, P US DEP AGR INT GYP, P13; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P42; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; LEE MK, 1992, J BIOL CHEM, V267, P3115; LIANG Y, 1994, MOL MICROBIOL, V13, P569, DOI 10.1111/j.1365-2958.1994.tb00451.x; MACINTOSH SC, 1991, P NATL ACAD SCI USA, V88, P8930, DOI 10.1073/pnas.88.20.8930; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODDOU P, 1991, EUR J BIOCHEM, V202, P673, DOI 10.1111/j.1432-1033.1991.tb16422.x; ODDOU P, 1993, EUR J BIOCHEM, V212, P145, DOI 10.1111/j.1432-1033.1993.tb17644.x; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; VANFRANKENHUYZEN K, 1991, APPL ENVIRON MICROB, V57, P1650, DOI 10.1128/AEM.57.6.1650-1655.1991; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1991, J EXP BIOL, V161, P519; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475; WOLFERSBERGER MG, 1986, ZENTRALBL BAKTERIO S, V15, P237; WU D, 1992, J BIOL CHEM, V267, P2311; 1992, 28666X PIERC TECHN B	35	76	84	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24719	24724		10.1074/jbc.270.42.24719	http://dx.doi.org/10.1074/jbc.270.42.24719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559587	hybrid			2022-12-25	WOS:A1995TB46500021
J	BREUER, W; EPSZTEJN, S; CABANTCHIK, ZI				BREUER, W; EPSZTEJN, S; CABANTCHIK, ZI			IRON ACQUIRED FROM TRANSFERRIN BY K562 CELLS IS DELIVERED INTO A CYTOPLASMIC POOL OF CHELATABLE IRON(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; RETICULOCYTES; MOBILIZATION; METABOLISM; TRANSPORT; CHELATORS; PROTEIN; RNA	The release of iron from transferrin (Tf) in the acidic milieu of endosomes and its translocation into the cytosol are integral steps in the process of iron acquisition via receptor-mediated endocytosis (RME), The translocated metal is thought to enter a low molecular weight cytoplasmic pool, presumed to contain the form of iron which is apparently sensed by iron responsive proteins and is the direct target of iron chelators, The process of iron delivery into the cytoplasmic chelatable pool of K562 cells was studied in situ by continuous monitoring of the fluorescence of cells loaded with the metal-sensitive probe calcein, Upon exposure to Tf at 37 degrees C, intracellular fluorescence decayed, corresponding to an initial iron uptake of 40 nM/min, The Tf-mediated iron uptake was profoundly inhibited by weak, bases, the protonophore monensin, energy depletion, or low temperatures (<25 degrees C), all properties characteristic of RME, Cell iron levels were affected by the slowly permeating chelator desferrioxamine only after prolonged incubations, Conversely, rapidly penetrating, lipophilic iron(II) chelators such as 2,2'-bipyridyl, evoked swift increases in cell calcein fluorescence, equivalent to sequestration of 0.2-0.5 mu M cytosolic iron, depending on the degree of pre-exposure to Tf, Addition of iron(III) chelators to permeabilized 2,2'-bipyridyl-treated cells, failed to reveal significant levels of chelatable iron(III), The finding that the bulk of the in situ cell chelatable pool is comprised of iron(II) was corroborated by pulsing K562 cells with Tf-Fe-55, followed by addition of iron(II) and/or iron(III) chelators and extraction of chelator-Fe-55 complexes into organic solvent. Virtually all of the accumulated Fe-55 in the chelatable pool could be complexed by iron(II) chelators, The cytoplasmic concentration of iron(II) fluctuated between 0.3 and 0.5 mu M, and its mean transit time through the chelatable pool was 1-2 h, me conclude that after iron is translocated from the endosomes, it is maintained in the cytosol as a transit pool of chelatable iron(II), The ostensible absence of chelatable iron(III) implicates the intracellular operation of vigorous reductive mechanisms.			BREUER, W (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI020342, R01AI020342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER E, 1990, HEPATOLOGY, V15, P492; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BURKITT MJ, 1991, FREE RADICAL RES COM, V14, P107, DOI 10.3109/10715769109094123; CONRAD ME, 1990, J BIOL CHEM, V265, P5273; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; Crichton R.R, 1992, IRON HUMAN DIS, P23; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DEIGHTON N, 1989, BIOCHEM SOC T, V17, P490, DOI 10.1042/bst0170490; FONTECAVE M, 1991, BIOL MET, V4, P133, DOI 10.1007/BF01141302; HERSHKO C, 1988, CRC CR REV CL LAB SC, V26, P303, DOI 10.3109/10408368809105894; JACOBS A, 1977, BLOOD, V50, P4331; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAW FY, 1983, AM J PHYSIOL, V244, pC68, DOI 10.1152/ajpcell.1983.244.1.C68; LOYEVSKY M, 1993, J CLIN INVEST, V91, P218, DOI 10.1172/JCI116174; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCCORD JM, 1992, IRON HUMAN DISEASE, P509; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; NUNEZ MT, 1980, BLOOD, V55, P1051; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; POLLACK S, 1992, AM J HEMATOL, V39, P113, DOI 10.1002/ajh.2830390208; PONKA P, 1984, BIOCHIM BIOPHYS ACTA, V802, P477, DOI 10.1016/0304-4165(84)90367-2; ROBERTS S, 1988, J BIOL CHEM, V263, P19181; ROTHMAN RJ, 1992, MOL PHARMACOL, V42, P703; STPIERRE TG, 1992, BIOCHIM BIOPHYS ACTA, V1135, P154; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q; YOUNG SP, 1994, BIOCHEM J, V298, P165, DOI 10.1042/bj2980165	31	268	272	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24209	24215		10.1074/jbc.270.41.24209	http://dx.doi.org/10.1074/jbc.270.41.24209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592626	hybrid			2022-12-25	WOS:A1995TA21700054
J	SEABRA, MC; HO, YK; ANANT, JS				SEABRA, MC; HO, YK; ANANT, JS			DEFICIENT GERANYLGERANYLATION OF RAM/RAB27 IN CHOROIDEREMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; CDNA CLONING; COMPONENT-A; RAB; TRANSFERASE; GENE; TRANSPORT; PURIFICATION; INVITRO; HOMOLOG	Choroideremia, an X-linked form of retinal degeneration, results from defects in the Rab escort protein-1 (REP-1) gene. REP-1 and REP-2 assist in the attachment of geranylgeranyl groups to Rab GTPases, a modification essential for their action as molecular switches regulating intracellular vesicular transport. If Rabs that depend preferentially on REP-1 for prenylation exist, they will accumulate unprenylated in choroideremia cells. Using recombinant Rab geranylgeranyl transferase and REPs to label unprenylated cytosolic proteins, we identified one unprenylated protein in choroideremia lymphoblasts that was prenylated in vitro more efficiently by REP-1 than by REP-2. This protein was purified and identified as Ram (renamed Rab27), a previously cloned Rab of unknown function, Immunohistochemistry of rat retina showed that Ram/Rab27 is expressed in the pigment epithelium and choriocapillaris, the two retinal cell layers that degenerate earliest in choroideremia. These results raise the possibility that the retinal degeneration in choroideremia results from the deficient geranylgeranylation of Ram/Rab27 or a closely related protein.			SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Heckenlively JR, 1988, RETINITIS PIGMENTOSA, P176; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; NAGATA K, 1990, FEBS LETT, V275, P29, DOI 10.1016/0014-5793(90)81431-M; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REISS Y, 1991, J BIOL CHEM, V266, P10672; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	33	182	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24420	24427		10.1074/jbc.270.41.24420	http://dx.doi.org/10.1074/jbc.270.41.24420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592656	hybrid			2022-12-25	WOS:A1995TA21700084
J	LI, HH; MERCHANT, S				LI, HH; MERCHANT, S			DEGRADATION OF PLASTOCYANIN IN COPPER-DEFICIENT CHLAMYDOMONAS-REINHARDTII - EVIDENCE FOR A PROTEASE-SUSCEPTIBLE CONFORMATION OF THE APOPROTEIN AND REGULATED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID LUMEN PROTEINS; IRON-SULFUR PROTEIN; A-B PROTEIN; CRYSTAL-STRUCTURE; PEA-CHLOROPLASTS; TRANSCRIPTIONAL REGULATION; DIRECTED MUTAGENESIS; RAPID DEGRADATION; PHOTOSYSTEM-I; GREEN-ALGA	In the green alga Chlamydomonas reinhardtii, the copper-dependent accumulation of plastocyanin is effected via the altered stability of the protein in copper-deficient versus copper-sufficient medium (t(1/2)) < 20 min versus several hours), To understand the mechanism of plastocyanin degradation in vivo, the purified apoprotein was characterized relative to the holoprotein with respect to conformation and protease susceptibility. Circular dichroism spectroscopy revealed that the apoprotein in solution did not display the characteristic secondary structure displayed by the native or reconstituted holoprotein, The apoprotein was also susceptible to digestion in vitro by chymotrypsin whereas the holoprotein was resistant, High ionic conditions, which stabilize the folded structure of apoplastocyanin, also inhibit its degradation by chymotrypsin, These results suggest that one explanation for plastocyanin degradation in copper-deficient cells in vivo might be the increased susceptibility of the apo form to a lumenal protease, Since apoplastocyanin is a normal biosynthetic intermediate for the formation of holoplastocyanin, the increased susceptibility of apoplastocyanin to proteolysis implies that degradative and biosynthetic activities would compete for the same substrate. However, characterization of an apoplastocyanin-accumulating mutant suggests that a plastocyanin-degrading protease is active only in copper-deficient cells. Thus, apoplastocyanin is rapidly degraded in copper-deficient cells, whereas its major fate in copper-supplemented cells is holoplastocyanin formation.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles								ANDERSON CM, 1991, PLANT PHYSIOL, V96, P584, DOI 10.1104/pp.96.2.584; APEL K, 1980, PLANTA, V150, P426, DOI 10.1007/BF00390180; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BENNETT J, 1981, EUR J BIOCHEM, V118, P61, DOI 10.1111/j.1432-1033.1981.tb05486.x; BIEKMANN S, 1985, EUR J BIOCHEM, V152, P529, DOI 10.1111/j.1432-1033.1985.tb09228.x; BOVY A, 1992, MOL MICROBIOL, V6, P1507, DOI 10.1111/j.1365-2958.1992.tb00871.x; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BUSHNELL TP, 1993, PLANT PHYSIOL, V103, P585, DOI 10.1104/pp.103.2.585; CLINE K, 1992, J BIOL CHEM, V267, P2688; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DRAHEIM JE, 1986, BIOPHYS J, V49, P891, DOI 10.1016/S0006-3495(86)83717-1; ERICKSON JM, 1986, EMBO J, V5, P1745, DOI 10.1002/j.1460-2075.1986.tb04422.x; GARRETT TPJ, 1984, J BIOL CHEM, V259, P2822; GHASSEMIAN M, 1994, MICROBIOL-UK, V140, P1151, DOI 10.1099/13500872-140-5-1151; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRAY JC, 1990, PLANT MOL BIOL, V15, P947, DOI 10.1007/BF00039435; GROSSMAN AR, 1982, J BIOL CHEM, V257, P1558; GUSS JM, 1983, J MOL BIOL, V169, P521; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HARRISX EH, 1989, CHLAMYDOMANAS SOURCE; HOOBER JK, 1992, PLANT PHYSIOL, V99, P932, DOI 10.1104/pp.99.3.932; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KIM J, 1994, PLANT PHYSIOL, V104, P907, DOI 10.1104/pp.104.3.907; KIMATA Y, 1994, PLANT PHYSIOL, V104, P263, DOI 10.1104/pp.104.1.263; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KOIDE S, 1993, BIOCHEMISTRY-US, V32, P12299, DOI 10.1021/bi00097a005; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUMAR MA, 1992, BIOTECHNIQUES, V12, P198; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; KUWABARA T, 1990, PLANT CELL PHYSIOL, V31, P581; LI HH, 1992, J BIOL CHEM, V267, P9368; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; LIU XQ, 1984, FEBS LETT, V166, P248; LIU XQ, 1986, PLANT PHYSIOL, V81, P603, DOI 10.1104/pp.81.2.603; MANNAN RM, 1991, P NATL ACAD SCI USA, V88, P10168, DOI 10.1073/pnas.88.22.10168; MCLENDON G, 1978, J BIOL CHEM, V253, P6335; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MERCHANT S, 1996, IN PRESS METAL IONS; MISHKIND ML, 1985, CURR TOP PLANT BIOCH, V4, P34; MORAND LZ, 1994, MOL BIOL CYANOBACTER, P243; NAKAMURA M, 1992, J BIOCHEM, V111, P219, DOI 10.1093/oxfordjournals.jbchem.a123740; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; REDINBO MR, 1993, BIOCHEMISTRY-US, V32, P10560, DOI 10.1021/bi00091a005; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SCHMIDT GW, 1983, P NATL ACAD SCI-BIOL, V80, P2632, DOI 10.1073/pnas.80.9.2632; SLOVIN JP, 1982, PLANTA, V154, P465, DOI 10.1007/BF01267815; SMEEKENS S, 1988, PHOTOSYNTH RES, V16, P177, DOI 10.1007/BF00039492; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TAMILARASAN R, 1986, INORG CHEM, V25, P2037, DOI 10.1021/ic00232a025; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; ZHANG L, 1992, J BIOL CHEM, V267, P19054	65	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23504	23510		10.1074/jbc.270.40.23504	http://dx.doi.org/10.1074/jbc.270.40.23504			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559514	hybrid			2022-12-25	WOS:A1995RY90900043
J	LIANG, F; JASIN, M				LIANG, F; JASIN, M			STUDIES ON THE INFLUENCE OF CYTOSINE METHYLATION ON DNA RECOMBINATION AND END-JOINING IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; HOMOLOGOUS RECOMBINATION; GENE; REPLICATION; PROTEIN; REPAIR; MODEL; LOCI	To test the influence of cytosine methylation on homologous recombination and the rejoining of DNA double strand breaks in mammalian cells, we developed a sensitive and quantitative assay system using extrachromosomal substrates. First, methylation was introduced into substrates in vitro with the prokaryotic SssI methylase, which specifically methylates the C-5 position of cytosine bases within CpG dinucleotides, mimicking the mammalian DNA methyltransferase. Next, methylated substrates were incubated in mammalian cells for a sufficient length of time to recombine or rejoin prior to substrate recovery. Results from bacterial transformation of the substrates and from direct Southern analysis demonstrate that cytosine methylation has no detectable effect on either DNA end-joining or homologous recombination. Thus, the components of the protein machinery involved in these complex processes are unaffected by the major DNA modification in mammalian cells. These results leave open the possibility that methylation may modulate the accessibility of these components to chromosomal DNA by altering local chromatin structure.	SLOAN KETTERING INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [P30CA-08748-26] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; GILL JE, 1974, BIOCHIM BIOPHYS ACTA, V335, P330, DOI 10.1016/0005-2787(74)90157-9; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; JASIN M, 1985, CELL, V43, P695, DOI 10.1016/0092-8674(85)90242-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Maniatis T., 1982, MOL CLONING; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MONK M, 1987, DEVELOPMENT, V99, P371; MORISHIMA A, 1962, P NATL ACAD SCI USA, V48, P756, DOI 10.1073/pnas.48.5.756; MURCHIE AI, 1993, J MOL BIOL, V205, P593; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PUCHTA H, 1992, MOL CELL BIOL, V12, P3372, DOI 10.1128/MCB.12.8.3372; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SEIDMAN MM, 1987, MOL CELL BIOL, V7, P3561, DOI 10.1128/MCB.7.10.3561; SERGHINI MA, 1989, NUCLEIC ACIDS RES, V17, P3604, DOI 10.1093/nar/17.9.3604; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANI S, 1988, GENETIC RECOMBINATIO, P549; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VALANCIUS V, 1991, MOL CELL BIOL, V11, P4389, DOI 10.1128/MCB.11.9.4389; WILLARD HF, 1976, AM J HUM GENET, V28, P213; ZACHARIAS W, 1993, DNA METHYLATION MOL, P27	34	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23838	23844		10.1074/jbc.270.40.23838	http://dx.doi.org/10.1074/jbc.270.40.23838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559561	hybrid			2022-12-25	WOS:A1995RY90900090
J	BORHAN, B; JONES, AD; PINOT, F; GRANT, DF; KURTH, MJ; HAMMOCK, BD				BORHAN, B; JONES, AD; PINOT, F; GRANT, DF; KURTH, MJ; HAMMOCK, BD			MECHANISM OF SOLUBLE EPOXIDE HYDROLASE - FORMATION OF AN ALPHA-HYDROXY ESTER-ENZYME INTERMEDIATE THROUGH ASP-333	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED-HYDROLYSIS; MOUSE-LIVER; INHIBITION; HYDRATION; OXIDES; ACID; TRANS-3-PHENYLGLYCIDOLS; METABOLISM; HYDRASE	O-18-labeled epoxides of trans-1,3-diphenylpropene oxide (tDPPO) and cis-9,10-epoxystearic acid were synthesized and used to determine the regioselectivity of sEH. The nucleophilic nature of sEH catalysis was demonstrated by comparing the enzymatic and nonenzymatic hydrolysis products of tDPPO. The results from single turnover experiments with greater or equal molar equivalents of sEH:substrate were consistent with the existence of a stable intermediate formed by a nucleophilic amino acid attacking the epoxide group. Tryptic digestion of sEH previously subjected to multiple turnovers with tDPPO in (H2O)-O-18 resulted in the isolation and purification of a tryptic fragment containing Asp-333. Electrospray mass spectrometry of this fragment conclusively illustrated the incorporation of O-18. After complete digestion of the latter peptide it was shown that Asp-333 of sEH exhibited an increased mass. The attach by Asp-333 initiates enzymatic activity, leading to the formation of an alpha-hydroxyacyl-enzyme intermediate. Hydrolysis of the acyl enzyme occurs by the addition of an activated water to the carbonyl carbon of the ester bond, after which the resultant tetrahedral intermediate collapses, yielding the active enzyme and the diol product.	UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616; UNIV CALIF DAVIS,FACIL ADV INSTRUMENTAT,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis			Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R01ES002710, P30ES005707] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42 ES04699, R01 ES02710, P30 ES05707] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; ARMSTRONG RN, 1980, MICROSOMES DRUG OXID, P1119; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BELLUCCI G, 1989, J ORG CHEM, V54, P968, DOI 10.1021/jo00265a044; BELLUCCI G, 1982, J ORG CHEM, V47, P3105, DOI 10.1021/jo00137a015; BELLUCCI G, 1981, J ORG CHEM, V46, P5148, DOI 10.1021/jo00338a016; BORHAN B, 1994, J ORG CHEM, V59, P4316, DOI 10.1021/jo00094a054; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DANSETTE PM, 1978, ARCH BIOCHEM BIOPHYS, V187, P290, DOI 10.1016/0003-9861(78)90037-1; DIETZE EC, 1993, COMP BIOCHEM PHYS B, V104, P309, DOI 10.1016/0305-0491(93)90373-D; DIETZE EC, 1991, BIOCHEM PHARMACOL, V42, P1163, DOI 10.1016/0006-2952(91)90250-9; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; HALARNKAR PP, 1992, ARCH BIOCHEM BIOPHYS, V294, P586, DOI 10.1016/0003-9861(92)90729-G; HAMMOCK BD, 1980, LIFE SCI, V27, P1635, DOI 10.1016/0024-3205(80)90636-0; HAMMOCK BD, 1994, BIOCHEM BIOPH RES CO, V198, P850, DOI 10.1006/bbrc.1994.1121; IWASAWA N, 1988, CHEM LETT, P1721, DOI 10.1246/cl.1988.1721; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; JERINA DM, 1974, SCIENCE, V185, P573, DOI 10.1126/science.185.4151.573; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LEVIN W, 1977, ORIGINS HUMAN CANCER, P668; MEIJER J, 1988, CHEM-BIOL INTERACT, V64, P207, DOI 10.1016/0009-2797(88)90100-7; MIYAMOTO T, 1987, ARCH BIOCHEM BIOPHYS, V254, P203, DOI 10.1016/0003-9861(87)90096-8; MUMBY SM, 1979, PESTIC BIOCHEM PHYS, V11, P275, DOI 10.1016/0048-3575(79)90067-1; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PARKER RE, 1959, CHEM REV, P737; PINOT F, 1995, J BIOL CHEM, V270, P7968, DOI 10.1074/jbc.270.14.7968; PRESTWICH GD, 1985, ARCH BIOCHEM BIOPHYS, V242, P11, DOI 10.1016/0003-9861(85)90473-4; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; PRITCHAR.JG, 1973, J CHEM SOC PERK T 2, P452, DOI 10.1039/p29730000452; RIZEY JS, 1974, SYNTHETIC REAGENTS, V2, P65; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WATABE T, 1971, BIOCHEM BIOPH RES CO, V44, P199, DOI 10.1016/S0006-291X(71)80178-X; WATABE T, 1971, BIOCHEM PHARMACOL, V20, P912; WIXTROM RN, 1988, ANAL BIOCHEM, V169, P71, DOI 10.1016/0003-2697(88)90256-4; WIXTROM RN, 1985, BIOCH PHARM TOXICOLO, V1, P1; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402	39	84	85	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26923	26930		10.1074/jbc.270.45.26923	http://dx.doi.org/10.1074/jbc.270.45.26923			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592938	hybrid			2022-12-25	WOS:A1995TE58300038
J	DELEO, FR; NAUSEEF, WM; JESAITIS, AJ; BURRITT, JB; CLARK, RA; QUINN, MT				DELEO, FR; NAUSEEF, WM; JESAITIS, AJ; BURRITT, JB; CLARK, RA; QUINN, MT			A DOMAIN OF P47(PHOX) THAT INTERACTS WITH HUMAN NEUTROPHIL FLAVOCYTOCHROME B(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; NADPH OXIDASE; MICROBICIDAL OXIDASE; PLASMA-MEMBRANE; SUPEROXIDE PRODUCTION; CYTOSOLIC COMPONENTS; CYTOCHROME-B; BINDING SITE	The NADPH-dependent oxidase of human neutrophils is a multicomponent system including cytosolic and membrane proteins. Activation requires translocation of cytosolic proteins p47(phox), p67(phox) ,and Rac2 to the plasma membrane and association with the membrane flavocytochrome b to assemble a functioning oxidase. We report the location of a region in p47(phox) that mediates its interaction with flavocytochrome b. From a random peptide phage display Library, we used biopanning with purified flavocytochrome b to select phage peptides that mimicked potential p47(phox) binding residues. Using this approach, we identified a region of p47(phox) from residue 323 to 342 as a site of interaction with flavocytochrome b. Synthetic peptides (315)SRKRLSQD-AYRRNS(328), (323)AYRRNSVRFL(332) and (334)QRRRQARPG-PQSPG(347) inhibited superoxide (O-2(radical anion)) production in the broken cell system with IC, of 18, 57, and 15 mu M, respectively. (323)AYRRNSVRFL(332) and its derivative peptides inhibited phosphorylation of p47(phox). However, the functional importance of this peptide was independent of its effects on phosphorylation, since (323)AYRRNA-VRFL(332) inhibited O-2(radical anion) production, but had no effect on phosphorylation. None of the peptides blocked O-2(radical anion) production when added after enzyme activation, suggesting that they inhibited the assembly, rather than the activity, of the oxidase. Furthermore these peptides inhibited membrane association of p47(phox), the broken cell translocation assay and O-2(radical anion) production by electropermeabilized neutrophils, thereby supporting the interpretation that this region of p47(phox) interacts with flavocytochrome b.	MONTANA STATE UNIV,DEPT VET MOLEC BIOL,BOZEMAN,MT 59717; MONTANA STATE UNIV,DEPT MICROBIOL,BOZEMAN,MT 59717; UNIV IOWA,IOWA CITY,IA 52242; DEPT VET AFFAIRS MED CTR,DEPT MED,IOWA CITY,IA 52242; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital			Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619; Nauseef, William/0000-0003-4032-757X; DeLeo, Frank/0000-0003-3150-2516; Quinn, Mark/0000-0001-8114-5073; Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412, R01AI020866, R37AI020866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040929] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI020866, R37 AI020866, AI20866, AI28412] Funding Source: Medline; NIAMS NIH HHS [AR40929] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); BLRD VA		ABO A, 1991, J BIOL CHEM, V266, P23577; BADWEY JA, 1993, FASEB J, V7, P1004; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IYER SS, 1994, J BIOL CHEM, V269, P22405; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1994, J BIOL CHEM, V269, P18743; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; NAUSEEF WM, 1993, EUR J HAEMATOL, V51, P301; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1995, METHOD ENZYMOL, V255, P476; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sambrook J, 1989, MOL CLONING LABORATO; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	49	70	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26246	26251		10.1074/jbc.270.44.26246	http://dx.doi.org/10.1074/jbc.270.44.26246			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592831	hybrid			2022-12-25	WOS:A1995TC97800038
J	JANCIAUSKIENE, S; DE FRUTOS, PG; CARLEMALM, E; DAHLBACK, B; ERIKSSON, S				JANCIAUSKIENE, S; DE FRUTOS, PG; CARLEMALM, E; DAHLBACK, B; ERIKSSON, S			INHIBITION OF ALZHEIMER BETA-PEPTIDE FIBRIL FORMATION BY SERUM AMYLOID-P COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMPLEMENT C4B-BINDING PROTEIN; ASSOCIATION; DISEASE; PATHOGENESIS; DEPOSITS; SULFATE; BINDING; PATHWAY; HEPARIN	A 39-43-amino acid residue-long fragment (beta-peptide) from the amyloid precursor protein is the predominant component of amyloid deposits in the brain of individuals with Alzheimer's disease, Serum amyloid P component (SAP) is present in all types of amyloid, including that of Alzheimer's disease, We have used an in vitro model to study the effects of purified SAP on the fibril formation of synthetic Alzheimer beta-peptide 1-42, SAP was found to inhibit fibril formation and to increase the solubility of the peptide in a dose-dependent manner, At a 5:1 molar ratio of A beta 1-42 peptide to SAP, fibril formation was completely inhibited, and approximately 80% of the peptide remained in solution even after 4 days of incubation, At lower SAP concentrations, e,g, at peptide to SAP ratio of 1000:1, short fibrillar like structures, lacking amyloid characteristics, were formed, These structures frequently contained associated SAP molecules, suggesting that SAP binds to the polymerizing peptide in a reaction which prevented further fibril formation.	UNIV LUND HOSP, ELECTRONMICROSCOPY UNIT, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT MED, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT CLIN CHEM, S-22185 LUND, SWEDEN	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital			de Frutos, Pablo García/B-8594-2011	de Frutos, Pablo García/0000-0003-1547-1190; Dahlback, Bjorn/0000-0003-1546-0328				BREATHNACH SM, 1989, J EXP MED, V170, P1433, DOI 10.1084/jem.170.4.1433; BREATHNACH SM, 1981, NATURE, V293, P652, DOI 10.1038/293652a0; CHRISTNER RB, 1994, J BIOL CHEM, V269, P9760; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GALLO G, 1994, AM J PATHOL, V145, P526; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAMAZAKI H, 1995, J BIOL CHEM, V270, P10392, DOI 10.1074/jbc.270.18.10392; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HAMAZAKI H, 1989, BIOCHIM BIOPHYS ACTA, V998, P231, DOI 10.1016/0167-4838(89)90279-3; HICKS PS, 1992, J IMMUNOL, V149, P3689; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JANCIAUSKIENE S, 1995, BIOL CHEM H-S, V376, P415, DOI 10.1515/bchm3.1995.376.7.415; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1995, SAMTERS IMMUNOLOGIC, V2, P637; PERLMUTTER LS, 1995, J COMP NEUROL, V352, P92, DOI 10.1002/cne.903520107; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; RUBIO N, 1993, J BIOCHEM-TOKYO, V113, P277, DOI 10.1093/oxfordjournals.jbchem.a124039; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHWALBE RA, 1991, J BIOL CHEM, V266, P12896; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; STENSTAD T, 1993, CLIN EXP IMMUNOL, V94, P189; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P763; Thorell JL, 1978, RADIOIMMUNOASSAY REL; YING SC, 1993, J IMMUNOL, V150, P169	33	72	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26041	26044		10.1074/jbc.270.44.26041	http://dx.doi.org/10.1074/jbc.270.44.26041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592799	hybrid			2022-12-25	WOS:A1995TC97800006
J	MIYASHITA, T; KITADA, S; KRAJEWSKI, S; HORNE, WA; DELIA, D; REED, JC				MIYASHITA, T; KITADA, S; KRAJEWSKI, S; HORNE, WA; DELIA, D; REED, JC			OVEREXPRESSION OF THE BCL-2 PROTEIN INCREASES THE HALF-LIFE OF P21(BAX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL	Bcl-2 and Bax are homologous proteins which can heterodimerize with each other, These proteins have opposing effects on cell survival when overexpressed in cells, with Bcl-2 blocking and Bax promoting apoptosis, Here we demonstrate that gene transfer-mediated elevations in Bcl-2 protein levels result in a marked increase in the steady state levels of endogenous p21(Bax) protein as determined by immunoblotting in the Jurkat T-cell and 697 pre-B-cell leukemia cell lines, but not in several other cell lines including CEM T-cell leukemia, 32D.3 myeloid progenitor, PC12 pheochromocytoma, and NIH-3T3 fibroblasts. Steady-state levels of p21(Bax) protein were also elevated in the lymph nodes of Bcl-2 transgenic mice in which a BCL-2 transgene is expressed at high levels in B-cells. Northern blot analysis of BCL-2-transfected and control-transfected Jurkat and 697 leukemia cells revealed no Bcl-2-induced alterations in the steady-state levels of BAX mRNAs, In contrast, L-[S-35]methionine pulse-chase analysis indicated a marked increase in the half-life (t(1/2)) of the p21(Bax) protein in BCL-2-transfected 697 cells compared to control-transfected cells (t(1/2) > 24 h versus similar to 4 h), whereas the rate of Bax degradation was unaltered in Bcl-2-transfected CEM cells, The results demonstrate that levels of the proapoptotic p21(Bax) protein can be post-translationally regulated by Bcl-2, probably in a tissue-specific fashion, and suggest the existence of a feedback mechanism that may help to maintain the ratio of Bcl-2 to Bax protein in physiologically appropriate ranges.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; IDUN PHARMACEUT INC,SAN DIEGO,CA 92121; IST NAZL TUMORI,DIV OSA,I-20133 MILAN,ITALY	Sanford Burnham Prebys Medical Discovery Institute; Fondazione IRCCS Istituto Nazionale Tumori Milan					NCI NIH HHS [CA-60381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BEHL C, 1993, BIOCHEM BIOPH RES CO, V197, P949, DOI 10.1006/bbrc.1993.2571; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOYD JM, 1993, CELL, V79, P341; Exley M, 1991, Semin Immunol, V3, P283; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, IN PRESS J NEUROSCI; KRAJEWSKI S, 1995, IN PRESS CANCER RES; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1983, BLOOD, V81, P151; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REED JC, 1991, EXP CELL RES, V195, P277, DOI 10.1016/0014-4827(91)90374-4; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TORIGOE T, 1994, CANCER RES, V54, P4851; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	24	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26049	26052		10.1074/jbc.270.44.26049	http://dx.doi.org/10.1074/jbc.270.44.26049			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592801	hybrid			2022-12-25	WOS:A1995TC97800008
J	HAQUE, SJ; FLATI, V; DEB, A; WILLIAMS, BRG				HAQUE, SJ; FLATI, V; DEB, A; WILLIAMS, BRG			ROLES OF PROTEIN-TYROSINE PHOSPHATASES IN STAT1-ALPHA-MEDIATED CELL SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; INTERFERON-GAMMA; GENE-EXPRESSION; TRANSDUCTION PATHWAYS; INVITRO ACTIVATION; ALPHA-INTERFERON; VANADATE; KINASE; PHOSPHORYLATION; LINE	Different Stat proteins are activated through phosphorylation of unique tyrosine residues in response to different cytokines and growth factors. Interferon-gamma activates Stat1 molecules that form homodimers and bind cognate DNA elements. Here we show that treatment of permeabilized cells with 200-500 mu M peroxo-derivatives of vanadium, molybdenum, and tungsten results in the accumulation of constitutively phosphorylated Stat1 alpha molecules, In contrast, treatment of permeabilized cells with orthovanadate, vanadyl sulfate, molybdate, and tungstate at the same range of concentrations does not result in the accumulation of activated Stat1 alpha molecules in the absence of ligand. However, these compounds inhibit the inactivation of interferon-gamma-induced DNA-binding activity of Stat1 alpha. A 4-6-h exposure of the permeabilized cells to orthovanadate, molybdate, and tungstate, but not vanadyl sulfate, results in a ligand-independent activation of Stat1 alpha, which is blocked by the inhibition or depletion of NADPH oxidase activity in the cells, indicating that NADPH oxidase-catalyzed superoxide formation is required for the bioconversion of these metal oxides to the corresponding peroxo-compounds. Interestingly, Ligand-independent Stat1 alpha activation by peroxo-derivatives of these transition metals does not require Jak1, Jak2, or Tyk2 kinase activity, suggesting that other kinases can phosphorylate Stat1 alpha on tyrosine 701.			HAQUE, SJ (corresponding author), CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, RM NN1-12, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009; FLATI, VINCENZO/R-6231-2018	Williams, Bryan R. G./0000-0002-4969-1151; FLATI, VINCENZO/0000-0003-1014-297X	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; Cotton F.A., 1972, ADV INORGANIC CHEM, Vthird, P1145; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; ELBERG G, 1994, J BIOL CHEM, V269, P9521; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LAMB P, 1994, J INTERFERON RES, V14, P365, DOI 10.1089/jir.1994.14.365; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAI K, 1993, NATURE, V366, P508; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; XIAO S, 1994, J BIOL CHEM, V269, P21244; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	57	87	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25709	25714		10.1074/jbc.270.43.25709	http://dx.doi.org/10.1074/jbc.270.43.25709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592750	hybrid			2022-12-25	WOS:A1995TB46600067
J	HERBST, JJ; ANDREWS, GC; CONTILLO, LG; SINGLETON, DH; GENEREUX, PE; GIBBS, EM; LIENHARD, GE				HERBST, JJ; ANDREWS, GC; CONTILLO, LG; SINGLETON, DH; GENEREUX, PE; GIBBS, EM; LIENHARD, GE			EFFECT OF THE ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE BY A THIOPHOSPHOTYROSINE PEPTIDE ON GLUCOSE-TRANSPORT IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHYDROLYZABLE GTP ANALOGS; ALPHA-TOXIN; INSULIN; LOCALIZATION; MEMBRANE; RAT; TRANSLOCATION; KINASE; CELLS	Insulin causes the activation of phosphatidylinositol 3-kinase (PI 3-kinase) through complexation of tyrosine-phosphorylated YMXM motifs on insulin receptor substrate 1 with the Src homology 2 domains of PI 3-kinase. Previous studies with inhibitors have indicated that activation of PI 3-kinase is necessary for the stimulation of glucose transport in adipocytes. Here, we investigate whether this activation is sufficient for this effect. Short peptides containing two tyrosine-phosphorylated or thiophosphorylated YMXM motifs potently activated PI 3-kinase in the cytosol from 3T3-L1 adipocytes. Introduction of the phosphatase-resistant thiophosphorylated peptide into 3T3-L1 adipocytes through permeabilization with Staphylococcus aureus alpha-toxin stimulated PI 3-kinase as strongly as insulin. However, under the same conditions the peptide increased glucose transport into the permeabilized cells only 20% as well as insulin. Determination of the distribution of the glucose transporter isotype GLUT4 by confocal immunofluorescence showed that GLUT4 translocation to the plasma membrane can account for the effect of the peptide. These results suggest that one or more other insulin-triggered signaling pathways, besides the PI 3-kinase one, participate in the stimulation of glucose transport.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; PFIZER INC,PFIZER CENT RES,GROTON,CT 06340	Dartmouth College; Pfizer					NIDDK NIH HHS [DK 42816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042816, R01DK042816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BEUSCH JEB, 1995, J BIOL CHEM, V270, P2036; BIRNBAUM MJ, 1992, INT REV CYTOL, V137, P29; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GOULD GW, 1994, J BIOL CHEM, V269, P26622; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KITAS E, 1994, INT J PEPT PROT RES, V43, P146; KLARLUND JK, 1993, J BIOL CHEM, V268, P7646; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LAVAN BE, 1994, BIOCHEM SOC T, V22, P676, DOI 10.1042/bst0220676; LAZAR DF, 1995, DIABETES, V44, P206; OKADA T, 1994, J BIOL CHEM, V269, P3568; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; SHIBATA H, 1991, ARCH BIOCHEM BIOPHYS, V285, P97, DOI 10.1016/0003-9861(91)90333-E; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; TOKER A, 1994, J BIOL CHEM, V269, P32358; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	40	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					26000	26005		10.1074/jbc.270.43.26000	http://dx.doi.org/10.1074/jbc.270.43.26000			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592791	hybrid			2022-12-25	WOS:A1995TB46600108
J	HORI, O; BRETT, J; SLATTERY, T; CAO, R; ZHANG, JH; CHEN, JX; NAGASHIMA, M; LUNDH, ER; VIJAY, S; NITECKI, D; MORSER, J; STERN, D; SCHMIDT, AM				HORI, O; BRETT, J; SLATTERY, T; CAO, R; ZHANG, JH; CHEN, JX; NAGASHIMA, M; LUNDH, ER; VIJAY, S; NITECKI, D; MORSER, J; STERN, D; SCHMIDT, AM			THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) IS A CELLULAR-BINDING SITE FOR AMPHOTERIN - MEDIATION OF NEURITE OUTGROWTH AND COEXPRESSION OF RAGE AND AMPHOTERIN IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED GLYCOSYLATION; PLASMINOGEN ACTIVATION; PROTEIN AMPHOTERIN; GLUCOSE; COMPLICATIONS; LOCALIZATION; COLLAGEN; MEMBRANE; SEQUENCE; SURFACE	The receptor for advanced glycation end products (RAGE), a newly-identified member of the immunoglobulin superfamily, mediates interactions of advanced glycation end product (AGE)-modified proteins with endothelium and other cell types. Survey of normal tissues demonstrated RAGE expression in situations in which accumulation of AGEs would be unexpected, leading to the hypothesis that under physiologic circumstances, RAGE might mediate interaction with ligands distinct from AGEs. Sequential chromatography of bovine lung extract identified polypeptides with M(r) values of approximate to 12,000 (p12) and approximate to 23,000 (p23) which bound RAGE. NH2-terminal and internal protein sequence data for p23 matched that reported previously for amphoterin. Amphoterin purified from rat brain or recombinant rat amphoterin bound to purified sRAGE in a saturable and dose-dependent manner, blocked by anti-RAGE IgG or a soluble form of RAGE (sRAGE). Cultured embryonic rat neurons, which express RAGE, displayed dose-dependent binding of I-125-amphoterin which was prevented by blockade of RAGE using antibody to the receptor or excess soluble receptor (sRAGE). A functional correlate of RAGE-amphoterin interaction was inhibition by anti-RAGE F(ab')(2) and sRAGE of neurite formation by cortical neurons specifically on amphoterin-coated substrates. Consistent with a potential role for RAGE-amphoterin interaction in development, amphoterin and RAGE mRNA/antigen were co-localized in developing rat brain. These data indicate that RAGE has physiologically relevant ligands distinct from AGEs which are likely, via their interaction with the receptor, to participate in physiologic processes outside of the context of diabetes and accumulation of AGEs.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; BERLEX BIOSCI,RICHMOND,CA 94804	Columbia University; Columbia University; Columbia University					NHLBI NIH HHS [HL21006] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; HICKS M, 1988, BIOCHEM BIOPH RES CO, V151, P649, DOI 10.1016/S0006-291X(88)80330-9; Hunt J, 1990, DIABETES, V30, P1420; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOTZ I, 1984, J BIOL CHEM, V258, P11442; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; MOHANTY JG, 1989, COMP IMMUNOL MICROB, V12, P153, DOI 10.1016/0147-9571(89)90064-7; NEEPER M, 1992, J BIOL CHEM, V267, P14998; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1994, J BIOL CHEM, V269, P9882; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1994, FASEB J, V8, pA662; SCHMIDT AM, 1993, J CLIN INVEST, V92, P2155; SELL DR, 1989, J BIOL CHEM, V264, P21597; SLATTERY TK, 1992, TECHNIQUES PROTEIN C, V4; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; YAN SD, 1994, J BIOL CHEM, V269, P9889; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	33	968	1038	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25752	25761		10.1074/jbc.270.43.25752	http://dx.doi.org/10.1074/jbc.270.43.25752			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592757	hybrid			2022-12-25	WOS:A1995TB46600074
J	OSUSKY, M; TAYLOR, SJ; SHALLOWAY, D				OSUSKY, M; TAYLOR, SJ; SHALLOWAY, D			AUTOPHOSPHORYLATION OF PURIFIED C-SRC AT ITS PRIMARY NEGATIVE REGULATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-TRANSFORMING PROTEIN; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; PP60C-SRC; ACTIVATION; CSK; PP60V-SRC; P60C-SRC; KINASES	The phosphorylating and transforming activities of c-Src are negatively regulated by phosphorylation at Tyr-527 near its carboxyl terminus, Previous studies have indicated that c-Src preferentially autophosphorylates Tyr-416, a residue in the middle of the catalytic domain, in vitro, and that Tyr-527 is phosphorylated by the carboxyl-terminal Src kinase, Csk. However, indirect evidence suggests that c-Src may also autophosphorylate Tyr-527 as part of a negative feedback loop, While some in vivo evidence suggests that Tyr-527 can be autophosphorylated in an intermolecular interaction, it has not previously been possible to directly demonstrate significant autophosphorylation in vitro, Here we show that c-Src purified from recombinant bacteria can autophosphorylate Tyr-527 to high levels in vitro when incubated with sufficiently high concentrations of ATP (K-m(Mg2+/ATP) approximate to 20 mu M) that are well above those that have been used previously. In vitro Tyr-527 autophosphorylation can occur both as an intra- and intermolecular interaction; higher enzyme concentrations are required for intermolecular Tyr-527 phosphorylation than for Tyr-416 autophosphorylation, These results support the possibility that, Like G-proteins, c-Src can switch itself off in vivo by its own enzymatic activity.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FEDER D, 1990, J BIOL CHEM, V265, P8205; GILMER TM, 1982, P NATL ACAD SCI-BIOL, V79, P2152, DOI 10.1073/pnas.79.7.2152; GILMER TM, 1981, NATURE, V294, P771, DOI 10.1038/294771a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1993, ONCOGENE, V8, P117; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; REVISGUPTA S, 1991, P NATL ACAD SCI USA, V88, P5954, DOI 10.1073/pnas.88.14.5954; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SUGIMOTO Y, 1985, J BIOL CHEM, V260, P3838; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; ZHANG S, 1991, Cellular Physiology and Biochemistry, V1, P24, DOI 10.1159/000154590	23	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25729	25732		10.1074/jbc.270.43.25729	http://dx.doi.org/10.1074/jbc.270.43.25729			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592753	hybrid			2022-12-25	WOS:A1995TB46600070
J	DUAN, CM; CLEMMONS, DR				DUAN, CM; CLEMMONS, DR			TRANSCRIPTION FACTOR AP-2 REGULATES HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-5 GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; MYOBLAST DIFFERENTIATION; INDUCIBLE ENHANCER; RETINOIC ACID; CYCLIC-AMP; CLONING; CELLS; RAT; IDENTIFICATION; ACTIVATION	Insulin-like growth factor binding protein-5 (IGFBP-5) is an important modulator of IGF actions. IGFBP-5 mRNA is abundant in human fibroblasts and is regulated by cAMP. To understand the molecular mechanism underlying this cell type-specific expression and regulation, we isolated the 5'-flanking region of the human IGFBP-5 gene and fused it to a promoter-less reporter plasmid encoding luciferase. Transient transfection of the construct into fibroblasts displayed both constitutive and cAMP-induced promoter activity in an orientation-specific manner. Sequence analysis revealed the existence of distal and proximal consensus AP-2 recognition sites located 5' from the TATA box. Both sequences bound specifically to human AP-2 in vitro by gel shift mobility assay. The possible role of AP-2 was examined by cotransfection of AP-2-deficient HepG2 cells with the IGFBP-5 promoter construct and a human AP-2 expression construct. Cotransfection with AP-2 significantly elevated IGFBP-5 promoter activity. This trans-activation was IGFBP-5 promoter and AP-2 specific. In AP-2 abundant fibroblasts, expression of AP-2B, a dominant-negative inhibitor of AP-2, suppressed IGFBP-5 promoter activity. In HepG2 cells, AP-2B alone had no significant effect, but the AP a-induced activation of promoter activity was inhibited by AP-2B in a dose-dependent manner. The relative functional importance of the putative AP-2 binding sites was examined using a number of deletion mutants and point mutations. When the first two distal CCCCACCC-like putative AP-2 sites were deleted or mutated, there was no change in AP-2-induced trans-activation. Deletion or mutation of the proximal GCCNNNGGC-like sequences, however, abolished the AP-2-induced activation. These results suggest that AP-2 regulates the IGFBP-5 gene expression through the proximal GCCNNNGGC-like sequences. This AP-2-mediated trans-activation contributes at least in part to the constitutively high expression of IGFBP-5 in fibroblasts and to the cAMP responsiveness of this gene.			DUAN, CM (corresponding author), UNIV N CAROLINA,DEPT MED,CB 7170 MACNIDER,CHAPEL HILL,NC 27599, USA.				NIA NIH HHS [AG02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; ANDERSSON G, 1994, CELL GROWTH DIFFER, V5, P27; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BERNARDINI S, 1994, J NEUROENDOCRINOL, V6, P409, DOI 10.1111/j.1365-2826.1994.tb00601.x; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; FELDMAN EL, 1993, ANN NY ACAD SCI, V692, P262; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; KOU K, 1995, DNA CELL BIOL, V3, P241; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHEIKH MS, 1993, BIOCHEM BIOPH RES CO, V188, P1122; SHEMER J, 1993, J CLIN ENDOCR METAB, V77, P1246, DOI 10.1210/jc.77.5.1246; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; ZHU X, 1993, BIOCHEM BIOPH RES CO, V190, P1045, DOI 10.1006/bbrc.1993.1154	36	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24844	24851		10.1074/jbc.270.42.24844	http://dx.doi.org/10.1074/jbc.270.42.24844			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559606	Green Published, hybrid			2022-12-25	WOS:A1995TB46500040
J	FILATOV, D; THELANDER, L				FILATOV, D; THELANDER, L			ROLE OF A PROXIMAL NF-Y BINDING PROMOTER ELEMENT IN S-PHASE-SPECIFIC EXPRESSION OF MOUSE RIBONUCLEOTIDE REDUCTASE R2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; PROTEINS; DEOXYRIBONUCLEOTIDE; SUBUNITS; CLONING; TYPE-1	Cell cycle-regulated transcription of the R2 gene of mouse ribonucleotide reductase was earlier shown to be controlled at the level of elongation by an S phase-specific release from a transcriptional block. However, the R2 promoter is activated very early when quiescent cells start to proliferate, and this activation is dependent on three upstream sequences located nucleotide -672 to nucleotide -527 from the transcription start. In this study, we use R2-luciferase reporter gene constructs and gel shift assays to demonstrate that, in addition to the upstseam sequences, a proximal CCAAT element specifically binding the transcription factor NF-Y is required for continuous activity of the R2 promoter through the S phase. When the CCAAT element is deleted or mutated, promoter activity induced by the upstream elements decays before cells enter S phase, and the transcriptional block is released. This is a clear example of how changing of a proximal sequence element can alter not only the quantitative but also the qualitative response to upstream transcription activation domains.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	Umea University								ARCOT SS, 1989, J BIOL CHEM, V264, P2343; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BJORKLUND S, 1993, P NATL ACAD SCI USA, V90, P11322, DOI 10.1073/pnas.90.23.11322; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; MAIRE P, 1989, SCIENCE, V246, P343; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; NORDENSKJOLD BA, 1970, J BIOL CHEM, V245, P5360; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525	24	37	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25239	25243		10.1074/jbc.270.42.25239	http://dx.doi.org/10.1074/jbc.270.42.25239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559662	hybrid			2022-12-25	WOS:A1995TB46500096
J	LAMBALOT, RH; WALSH, CT				LAMBALOT, RH; WALSH, CT			CLONING, OVERPRODUCTION, AND CHARACTERIZATION OF THE ESCHERICHIA-COLI HOLO-ACYL CARRIER PROTEIN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PDXJ OPERON; PURIFICATION; SYNTHETASE; GENES	Holo-acyl carrier protein synthase (ACPS) transfers the 4'-phosphopantetheine (4'-PP) moiety from coenzyme A (CoA) to Ser-36 of acyl carrier protein (ACP) in Escherichia coli. This post-translational modification renders holo-ACP capable of acyl group activation via thioesterification of the cysteamine thiol of 4'-PP. We have purified E. coli ACPS to near homogeneity by exploiting the ability to refold ACPS and reconstitute its activity after elution from an apo-ACP affinity column under denaturing conditions. N-terminal sequencing of ACPS allowed us to identify dpj, an essential gene of previously unknown function, as the structural gene for ACPS. We report herein the 70,000-fold purification of wild-type ACPS and the overproduction and initial characterization of recombinant ACPS from E. coli.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, F32GM016583, R01GM020011] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20011, GM16583-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BALDWIN JE, 1991, J ANTIBIOT, V44, P241, DOI 10.7164/antibiotics.44.241; ELHUSSEIN SA, 1988, BIOCHEM J, V252, P39, DOI 10.1042/bj2520039; ELOVSON J, 1968, J BIOL CHEM, V243, P3603; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; GERNGROSS TU, 1994, BIOCHEMISTRY-US, V33, P9311, DOI 10.1021/bi00197a035; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; Jones A. Lesley, 1993, Biochemical Society Transactions, V21, p202S; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; MAJERUS PW, 1965, P NATL ACAD SCI USA, V53, P410, DOI 10.1073/pnas.53.2.410; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT B, 1992, FEBS LETT, V307, P355, DOI 10.1016/0014-5793(92)80712-P; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992	24	175	188	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24658	24661		10.1074/jbc.270.42.24658	http://dx.doi.org/10.1074/jbc.270.42.24658			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559576	hybrid			2022-12-25	WOS:A1995TB46500010
J	TANHAUSER, SM; LAIPIS, PJ				TANHAUSER, SM; LAIPIS, PJ			MULTIPLE DELETIONS ARE DETECTABLE IN MITOCHONDRIAL-DNA OF AGING MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN FUNCTION; DEGENERATIVE DISEASES; SKELETAL-MUSCLE; EXTERNAL OPHTHALMOPLEGIA; HUMAN BRAIN; SEQUENCE; MUTATION; TISSUES; ACCUMULATION; MYOPATHIES	Mutational damage to human mitochondrial DNA (mtDNA) can cause disorders in oxidative phosphorylation; speculation that such damage is involved in degenerative diseases and aging is common. We have detected deletions in mouse mtDNA which resemble those found in elderly humans or patients with certain mtDNA disorders. Five different mtDNA deletions, predicted from the positions of short, direct DNA repeats, were present in aged, but not young, mice. Deleted regions were surrounded by either exact or inexact repeats and occurred in both the major and minor regions of the mtDNA genome, The abundance of a particular deletion was generally related to the thermodynamic stability of the bounding repeat sequence. Deletions in aged mice were present at low levels (less than 0.01% of total mtDNA). However, in contrast to results from aged humans, deletions were more abundant in liver than in brain, heart, or skeletal muscle. These results make it possible to predict the location and relative abundance of deletions in any sequenced mtDNA, including inbred mouse strains differing in inherent natural lifespan. The inbred mouse model will allow a critical examination of the relationship between the presence and abundance of mtDNA deletions and the aging process.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NIGMS NIH HHS [GM33537] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033537] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ARNOLD FH, 1987, BIOCHEMISTRY-US, V26, P4068, DOI 10.1021/bi00387a049; BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3; BAUMER A, 1994, AM J HUM GENET, V54, P618; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLOCH W, 1992, AMPLIFICATIONS, V8, P1; BOURSOT P, 1987, MOL BIOL EVOL, V4, P46; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BROSSAS JY, 1994, BIOCHEM BIOPH RES CO, V202, P654, DOI 10.1006/bbrc.1994.1980; CHUNG SS, 1994, AGING-CLIN EXP RES, V6, P193, DOI 10.1007/BF03324239; COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U; CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DEGOUL F, 1991, NUCLEIC ACIDS RES, V19, P493, DOI 10.1093/nar/19.3.493; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; KATAYAMA M, 1991, BIOCHEM INT, V25, P47; LINNANE AW, 1992, MUTAT RES, V275, P195, DOI 10.1016/0921-8734(92)90023-I; LINNANE AW, 1990, BIOCHEM INT, V22, P1067; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MASORO EJ, 1992, LAB ANIM SCI, V42, P132; MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H; NEWSHOLME EA, 1983, BIOCH MED SCI, P146; PERITZ AE, 1991, BIOCHEMISTRY-US, V30, P6428, DOI 10.1021/bi00240a013; PIKO L, 1992, ANN NY ACAD SCI, V663, P450, DOI 10.1111/j.1749-6632.1992.tb38698.x; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; Sambrook J, 1989, MOL CLONING LABORATO; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V; SOONG NW, 1992, NAT GENET, V2, P318; SPROTT RL, 1991, NEUROBIOL AGING, V12, P635, DOI 10.1016/0197-4580(91)90113-X; SUGIYAMA S, 1991, BIOCHEM BIOPH RES CO, V180, P894, DOI 10.1016/S0006-291X(05)81149-0; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	49	124	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24769	24775		10.1074/jbc.270.42.24769	http://dx.doi.org/10.1074/jbc.270.42.24769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559594	hybrid			2022-12-25	WOS:A1995TB46500028
J	JOHNSON, EM; CHEN, PL; KRACHMAROV, CP; BARR, SM; KANOVSKY, M; MA, ZW; LEE, WH				JOHNSON, EM; CHEN, PL; KRACHMAROV, CP; BARR, SM; KANOVSKY, M; MA, ZW; LEE, WH			ASSOCIATION OF HUMAN PUR-ALPHA WITH THE RETINOBLASTOMA PROTEIN, RB, REGULATES BINDING TO THE SINGLE-STRANDED-DNA PUR-ALPHA RECOGNITION ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGEN; D-TYPE CYCLINS; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; REPLICATION ORIGIN; MOLECULAR-CLONING; EXPRESSION; SEQUENCE	The retinoblastoma protein, Rb, is detected in extracts of monkey CV-1 cells complexed with Pur alpha, a Sequence-specific single-stranded DNA-binding protein implicated in control of gene transcription and DNA replication, These complexes can be immunoextracted from cell lysates using monoclonal antibodies to either Pur alpha or Rb. The Pur alpha . Rb complexes contain a form of Pur alpha with extensive post-synthetic modification, as demonstrated following expression of Pur alpha cDNA fused to a 9-amino acid epitope tag. Human Pur alpha, expressed as a glutathione S-transferase fusion protein, specifically binds to the hypophosphorylated form of Rb with an affinity as high as that of SV40 large T-antigen, In the absence of DNA, glutathione S-transferase-Pur alpha binds to p56(RB), an NH2-terminal-truncated Rb protein purified from Escherichia coli, containing the T-antigen binding domain, to form multimeric complexes, The single-stranded DNA Pur alpha recognition element disrupts these complexes, Conversely, high concentrations of p56(RB) prevent Pur alpha binding to DNA, Through use of a series of deletion mutants, the DNA binding activity of Pur alpha is localized to a series of modular amino acid repeats, Rb binding involves a Pur alpha region with limited homology to the Rb-binding region of SV40 large T-antigen, Binding of Pur alpha to p56(RB), the COOH-terminal portion of Rb, is inhibited by a synthetic peptide containing the T-antigen Rb-binding motif.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health San Antonio	JOHNSON, EM (corresponding author), CUNY MT SINAI SCH MED,DEPT PATHOL,NEW YORK,NY 10029, USA.			Krachmarov, Chavdar/0000-0003-1100-5096	NATIONAL CANCER INSTITUTE [R01CA055219, R55CA055219] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [CA55219] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG CF, 1994, GENE, V148, P309; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOWDHURY M, 1993, ONCOGENE, V8, P887; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKDAHL TT, 1990, NUCLEIC ACIDS RES, V18, P1609, DOI 10.1093/nar/18.6.1609; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JACKS T, 1992, NATURE, V359, P328; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KILBOURNE ED, 1993, J GEN VIROL, V74, P1311, DOI 10.1099/0022-1317-74-7-1311; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LYNCH KJ, 1990, J VIROL, V64, P5812, DOI 10.1128/JVI.64.12.5812-5822.1990; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MA ZW, 1995, CYTOGENET CELL GENET, V71, P64, DOI 10.1159/000134065; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MAYOL X, 1993, ONCOGENE, V8, P2561; MORROW JS, 1983, METHOD ENZYMOL, V96, P298; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; PEDERSEN B, 1993, ANTICANCER RES, V13, P1913; SAVRANSKY E, 1994, LAB INVEST, V70, P676; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TODOROV IT, 1994, J CELL SCI, V107, P253; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VIRTAPEARLMAN VJ, 1993, MOL CELL BIOL, V13, P5931, DOI 10.1128/MCB.13.10.5931; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	60	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24352	24360		10.1074/jbc.270.41.24352	http://dx.doi.org/10.1074/jbc.270.41.24352			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592647	hybrid			2022-12-25	WOS:A1995TA21700075
J	WILSON, DM; BINDER, LI				WILSON, DM; BINDER, LI			POLYMERIZATION OF MICROTUBULE-ASSOCIATED PROTEIN-TAU UNDER NEAR-PHYSIOLOGICAL CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER NEUROFIBRILLARY TANGLES; NEUROPIL THREADS; ASSEMBLY INVITRO; DISEASE; BRAIN; TUBULIN; DEMENTIA; SENILE; PHOSPHORYLATION	Neurofibrillary tangles, which form in certain degenerating neurons in the brains of patients with Alzheimer's disease, are amassed from filaments having a straight or paired helical morphology. Solubilization of these filaments reveals that they are composed of the microtubule-associated protein tau. It has not previously been shown, however, that tan win assemble to form filaments of similar morphology under conditions representative of the intracellular environment. We have succeeded in forming such filaments using tau purified from porcine or rat microtubules. The filaments are relatively straight with narrowing at irregular intervals, and are about 10 nn wide, a morphology similar to that of straight filaments seen in Alzheimer's disease neurofibrillary tangles. At tau concentrations of 1-10 mu M, in vitro assembly occurs at physiological pH, ionic strength, temperature, and reducing potential, and each one of these factors modulates the reaction, Assembly is judged to be only slowly reversible by the exponential rather than normal distribution of filament lengths, and by the limited disassembly observed under conditions which inhibit polymerization. Tau purified directly from whole brain tissue rather than from microtubules does not polymerize under conditions described in this report.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIA NIH HHS [P01-AG06569, AG09031] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG009031] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; BERKOWITZ SA, 1977, BIOCHEMISTRY-US, V16, P5610, DOI 10.1021/bi00644a035; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; BUGIANI O, 1979, ACTA NEUROPATHOL, V45, P147, DOI 10.1007/BF00691893; BURNS RG, 1991, BIOCHEM J, V277, P231, DOI 10.1042/bj2770231; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DEGARCINI EM, 1986, BIOCHEM BIOPH RES CO, V141, P790, DOI 10.1016/S0006-291X(86)80242-X; DEGARCINI EM, 1987, J BIOCHEM-TOKYO, V102, P1415, DOI 10.1093/oxfordjournals.jbchem.a122187; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIRANO A, 1968, J NEUROPATH EXP NEUR, V27, P167, DOI 10.1097/00005072-196804000-00001; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IQBAL K, 1984, ACTA NEUROPATHOL, V62, P167, DOI 10.1007/BF00691849; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; METUZALS J, 1981, CELL TISSUE RES, V214, P455; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P375; PERRY G, 1987, J NEUROSCI, V7, P3736; PROBST A, 1989, ACTA NEUROPATHOL, V77, P430, DOI 10.1007/BF00687379; RUBEN GC, 1993, BRAIN RES, V602, P1, DOI 10.1016/0006-8993(93)90234-E; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; SANDOVAL IV, 1980, J BIOL CHEM, V255, P8952; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; SYMMONS MF, 1991, BIOCHEM J, V277, P245, DOI 10.1042/bj2770245; TELLEZNAGEL I, 1973, ARCH NEUROL-CHICAGO, V29, P324, DOI 10.1001/archneur.1973.00490290064007; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WISHIK CM, 1985, J CELL BIOL, V100, P1905; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008; WISNIEWSKI K, 1979, ANN NEUROL, V5, P288, DOI 10.1002/ana.410050311; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; YAGISHITA S, 1981, ACTA NEUROPATHOL, V54, P239, DOI 10.1007/BF00687747; YAMAGUCHI H, 1990, ACTA NEUROPATHOL, V80, P368, DOI 10.1007/BF00307689	59	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24306	24314		10.1074/jbc.270.41.24306	http://dx.doi.org/10.1074/jbc.270.41.24306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592641	hybrid			2022-12-25	WOS:A1995TA21700069
J	BUJO, H; LINDSTEDT, KA; HERMANN, M; DALMAU, LM; NIMPF, J; SCHNEIDER, WJ				BUJO, H; LINDSTEDT, KA; HERMANN, M; DALMAU, LM; NIMPF, J; SCHNEIDER, WJ			CHICKEN OOCYTES AND SOMATIC-CELLS EXPRESS DIFFERENT SPLICE VARIANTS OF A MULTIFUNCTIONAL RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; FAMILIAL HYPERCHOLESTEROLEMIA; BINDS; LIPASE; COMPLEXES; LIGANDS; VITELLOGENIN	An abundant 95-kDa protein belonging to the low density lipoprotein receptor supergene family is essential for chicken oocyte growth by mediating the uptake of multiple plasma-borne yolk precursors. This receptor harbors at the amino terminus a cluster of eight tandemly arranged repeats typical of the ligand binding domains of members of this family and is designated low density lipoprotein receptor relative with 8 repeats (LR8). Here, we demonstrate by reverse transcriptase-polymerase chain reaction, Northern, and Western blot analyses that the chicken expresses two forms of LR8, which are generated by differential splicing of an exon encoding a serine and threonine-rich region characteristic of LRs, termed O-linked sugar domain. The female germ cell of the chicken expresses extremely high levels of the short form of LR8 (LR8-), i.e. the 95-kDa protein; in contrast, somatic cells express lower but detectable levels of the form containing the O-linked sugar domain (LR8+). The main sites of LR8+ expression in the chicken are the heart and skeletal muscle, i.e. the same tissues where LR8 mRNAs predominate in mammals; in addition, in situ hybridization demonstrates that a significant amount of LR8+ is produced in the hen's ovarian follicular granulosa cells. We found no apparent functional difference between the two receptor forms; however, cell type specific targeting of the multiple ligands of these receptors possibly relates to their respective expression on the cell surface.	BIOCTR, DEPT MOLEC GENET, A-1030 VIENNA, AUSTRIA; UNIV VIENNA, A-1030 VIENNA, AUSTRIA	University of Vienna				Hermann, Marcela/0000-0003-2298-4269; Nimpf, Johannes/0000-0002-9273-3492				BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; FISCHER DG, 1993, SCIENCE, V262, P250, DOI 10.1126/science.8211145; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HO KJ, 1974, ARCH PATHOL, V98, P161; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; JONES DG, 1975, POULTRY SCI, V54, P1780; KAJINAMI K, 1988, ARTERIOSCLEROSIS, V8, P187, DOI 10.1161/01.ATV.8.2.187; KOIVISTO PVI, 1992, ARTERIOSCLER THROMB, V12, P584, DOI 10.1161/01.ATV.12.5.584; KOIVISTO PVI, 1993, ARTERIOSCLER THROMB, V13, P1680, DOI 10.1161/01.ATV.13.11.1680; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAMBROOK J, 1989, MOL CLONIGN LABORATO; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1990, J BIOL CHEM, V265, P882; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	51	83	86	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23546	23551		10.1074/jbc.270.40.23546	http://dx.doi.org/10.1074/jbc.270.40.23546			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559519	hybrid			2022-12-25	WOS:A1995RY90900048
J	YOKOKURA, H; PICCIOTTO, MR; NAIRN, AC; HIDAKA, H				YOKOKURA, H; PICCIOTTO, MR; NAIRN, AC; HIDAKA, H			THE REGULATORY REGION OF CALCIUM CALMODULIN-DEPENDENT PROTEIN-KINASE-I CONTAINS CLOSELY ASSOCIATED AUTOINHIBITORY AND CALMODULIN-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; SMOOTH-MUSCLE; PEPTIDE COMPLEX; RAT-BRAIN; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; SEQUENCE; RECOGNITION; CELLS	The mechanism for the regulation of Ca2+/calmodulin-dependent protein kinase I (CaM kinase I) was investigated using a series of COOH-terminal truncated mutants. These mutants were expressed in bacteria as fusion proteins with glutathione S-transferase and purified by affinity chromatography using glutathione Sepharose 4B. A mutant (residues 1-332) showed complete Ca2+/CaM-dependent activity. Truncation mutants (residues 1-321, 1-314, and 1-309) exhibited decreasing affinities for Ca2+/CaM and also exhibited decreasing Ca2+/CaM-dependent activities. Truncation mutants (residues 1-305 or 1-299) were unable to bind Ca2+/CaM and were inactive. In contrast, truncation mutants (residues 1-293 or 1-277) were constitutively active at a slightly higher level (a fold) than fully active CaM kinase I. These results indicate the location of the Ca2+/ CaM-binding domain on CaM kinase I (residues 294-321) and predict the existence of an autoinhibitory domain near, or overlapping, the Ca2+/CaM-binding domain. These conclusions were supported by studies which showed that a synthetic peptide (CaM kinase I(294-321)) corresponding to residues 294-321 of CaM kinase I inhibited the fully active kinase in a manner that was competitive with Ca2+/CaM and also inhibited the constitutively active mutant (residues 1-293) in a manner that was competitive with Syntide-2, a peptide substrate, (K-i = 1.2 mu M) but was non-competitive with ATP. Thus, these results suggest that CaM kinase I is regulated through an intrasteric mechanism common to other members of the family of Ca2+/CaM-dependent protein kinases.	NAGOYA UNIV, SCH MED, DEPT PHARMACOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN; INST PASTEUR, F-75724 PARIS, FRANCE; ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA	Nagoya University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Rockefeller University			Picciotto, Marina R./F-8747-2012	Picciotto, Marina R./0000-0002-4404-1280; Nairn, Angus/0000-0002-7075-0195				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; Beavo J A, 1974, Methods Enzymol, V38, P299; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell A.K, 1983, INTRACELLULAR CALCIU; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7519; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; ENDO T, 1981, J BIOL CHEM, V256, P2485; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GLENNEY JR, 1980, J BIOL CHEM, V255, P551; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INAGAKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P136, DOI 10.1016/0003-9861(87)90089-0; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; ITO T, 1994, BIOCHEM BIOPH RES CO, V201, P1561, DOI 10.1006/bbrc.1994.1882; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEARSON RB, 1984, FEBS LETT, V168, P108, DOI 10.1016/0014-5793(84)80216-1; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PICCIOTTO MR, 1995, J BIOL CHEM, V270, P10358; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	56	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23851	23859		10.1074/jbc.270.40.23851	http://dx.doi.org/10.1074/jbc.270.40.23851			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559563	hybrid			2022-12-25	WOS:A1995RY90900092
J	ZUCKER, S; CONNER, C; DIMASSMO, BI; ENDE, H; DREWS, M; SEIKI, M; BAHOU, WF				ZUCKER, S; CONNER, C; DIMASSMO, BI; ENDE, H; DREWS, M; SEIKI, M; BAHOU, WF			THROMBIN INDUCES THE ACTIVATION OF PROGELATINASE-A IN VASCULAR ENDOTHELIAL-CELLS - PHYSIOLOGICAL REGULATION OF ANGIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; IV COLLAGENASE; 72-KDA GELATINASE; MATRIX METALLOPROTEINASES; MEMBRANE; PROTEINASES; FIBROBLASTS; EXPRESSION; DOMAIN; PLASMA	Angiogenesis requires degradation of vascular base ment membrane prior to migration and proliferation of endothelial cells; proteinases are essential ingredients in this process. Because of thrombin's multiple effects on endothelium, we have examined its role in matrix metalloproteinase activation using human umbilical vein endothelial cells. Gelatin zymography of endothelial conditioned media revealed a prominent 72-kDa progelatinase A band. Addition of alpha-thrombin to endothelial cells resulted in the generation of 64 and 62 kDa gelatinolytic bands which is consistent with the activation of progelatinase A; thrombin had no effect in the absence of cells. This effect requires the proteolytic site of thrombin since progelatinase A activation was abolished by specific inhibitors of thrombin. Matrix metalloproteinase inhibitors diminished thrombin-induced activation of progelatinase A. Pretreatment of endothelial cells with excess tissue inhibitor of metalloproteinase-2 or a COOH-terminal fragment of progelatinase A abrogated thrombin mediated activation of progelatinase A presumably by competing with the COOH terminus of native progelatinase A for interaction with an activator site on endothelial plasma membranes. Although membrane-type matrix metalloproteinase was demonstrated in endothelial cells by Northern and Western blotting, the receptor function of this molecule in thrombin-induced activation of progelatinase A needs to be clarified. Progelatinase A activation did not require intracellular signal transduction events mediated by the thrombin receptor. These data demonstrate that 1) endothelial cells express a novel activation mechanism for progelatinase A, 2) proteolytically active thrombin regulates this activation mechanism, and 3) activation occurs independently of the functional thrombin receptor.	DEPT VET AFFAIRS MED CTR, DEPT MED, NORTHPORT, NY 11768 USA; DEPT VET AFFAIRS MED CTR, DEPT RES, NORTHPORT, NY 11768 USA; SUNY STONY BROOK, STONY BROOK, NY 11794 USA; KANAZAWA UNIV, CANC RES INST, KANAZAWA, ISHIKAWA 920, JAPAN	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Kanazawa University			Seiki, Motoharu/K-9443-2015		NHLBI NIH HHS [HL-02431, HL-49141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141, K08HL002431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; BELLONI PN, 1992, MICROVASC RES, V43, P20, DOI 10.1016/0026-2862(92)90004-9; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WT, 1990, CELL DIFFER DEV, V32, P329, DOI 10.1016/0922-3371(90)90047-Z; COOKSLEY S, 1990, MATRIX, V10, P285, DOI 10.1016/S0934-8832(11)80183-6; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; EMONARD HP, 1992, CANCER RES, V52, P5845; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FOLKMAN J, 1986, CANCER RES, V46, P467; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GALARDY RE, 1994, CANCER RES, V54, P4715; GARCIA JGN, 1990, J CELL PHYSIOL, V142, P186, DOI 10.1002/jcp.1041420123; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HUREWITZ AN, 1992, CHEST, V102, P1808, DOI 10.1378/chest.102.6.1808; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KLEINER DE, 1993, BIOCHEMISTRY-US, V32, P1583, DOI 10.1021/bi00057a024; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOUTSIAKIS D, 1992, CONNECT TISSUE RES, V28, P213, DOI 10.3109/03008209209015038; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; SALO T, 1991, J BIOL CHEM, V266, P11436; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TSOPANOGLOU NE, 1993, AM J PHYSIOL, V264, pC1302, DOI 10.1152/ajpcell.1993.264.5.C1302; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; ZUCKER S, 1992, INT J CANCER, V52, P366, DOI 10.1002/ijc.2910520307; ZUCKER S, 1994, CLIN EXP METASTAS, V12, P13, DOI 10.1007/BF01784329; ZUCKER S, 1987, CANCER RES, V47, P1608	45	173	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23730	23738		10.1074/jbc.270.40.23730	http://dx.doi.org/10.1074/jbc.270.40.23730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559545	hybrid			2022-12-25	WOS:A1995RY90900074
J	DELCOMMENNE, M; STREULI, CH				DELCOMMENNE, M; STREULI, CH			CONTROL OF INTEGRIN EXPRESSION BY EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MESSENGER-RNA; KERATINOCYTE ACTIVATION; FIBRONECTIN RECEPTOR; EPITHELIAL-CELLS; MELANOMA-CELLS; BETA-SUBUNIT; GROWTH; PROTEIN; TISSUE	Integrin-mediated interactions between cells and the extracellular matrix play a fundamental role in the development and function of a variety of tissues by triggering intracellular signals that regulate gene expression. In this study, mouse mammary epithelial cells plated on tissue culture plastic were shown to dramatically up-regulate the steady state levels of mRNA encoding the alpha(1), alpha(2), alpha(3), alpha(5), alpha(6), alpha(7), alpha(v), and beta(1) integrin subunits, in contrast to cells cultured on a basement membrane matrix or cells in vivo. This pattern of expression was also observed in a mouse mammary epithelial strain, CID-9 and in other mouse cell lines such as MMTE cells and K1735-M2 melanoma cells. The control of integrin expression was mediated at different levels in different cell types, In K1735-M2 cells, transcription of the beta(1) integrin gene was influenced by the substratum, although the levels of integrin protein remained similar. In mammary epithelial cells, the rates of beta(1) integrin gene transcription were similar, but mRNA and protein levels were higher in cells cultured on plastic than those on basement membrane. For both cell types, the rate of integrin protein turnover was nearly identical in cells cultured on either substratum. Our results demonstrate that extracellular matrix controls the expression of beta(1) integrin subunits and that this regulation is exerted at both transcriptional and post-transcriptional levels.	UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGGELER J, 1991, J CELL SCI, V99, P407; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHEN D, 1992, J BIOL CHEM, V267, P23502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304; ERLE DJ, 1991, AM J RESP CELL MOL, V5, P170, DOI 10.1165/ajrcmb/5.2.170; FALCIONI R, 1988, CANCER RES, V48, P816; FONG AM, 1994, J BIOL CHEM, V269, P18441; FULTON AB, 1993, J CELL SCI, V105, P867; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GRINNELL F, 1992, J CELL SCI, V101, P1; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; KIM LT, 1992, J CELL SCI, V103, P743; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOORADIAN DL, 1990, CANCER RES, V50, P273; NICOLSON GL, 1991, BIOESSAYS, V13, P337, DOI 10.1002/bies.950130706; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; RUCSLAHTI E, 1994, CELL, V77, P477; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1994, MOL CARCINOGEN, V10, P66, DOI 10.1002/mc.2940100203; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SONNENBERG A, 1988, NATURE, V367, P487; STREULI CH, 1990, J CELL BIOL, V110, P1405; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TOMINAGA S, 1988, FEBS LETT, V238, P315, DOI 10.1016/0014-5793(88)80503-9; TSUJI T, 1990, J BIOL CHEM, V265, P7016; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q	42	139	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26794	26801		10.1074/jbc.270.45.26794	http://dx.doi.org/10.1074/jbc.270.45.26794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592919	hybrid			2022-12-25	WOS:A1995TE58300019
J	DELUCA, M; DUNLOP, LC; ANDREWS, RK; FLANNERY, JV; ETTLING, R; CUMMING, DA; VELDMAN, M; BERNDT, MC				DELUCA, M; DUNLOP, LC; ANDREWS, RK; FLANNERY, JV; ETTLING, R; CUMMING, DA; VELDMAN, M; BERNDT, MC			A NOVEL COBRA VENOM METALLOPROTEINASE, MOCARHAGIN, CLEAVES A 10-AMINO ACID PEPTIDE FROM THE MATURE N-TERMINUS OF P-SELECTIN GLYCOPROTEIN LIGAND-RECEPTOR, PSGL-1, AND ABOLISHES P-SELECTIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MYELOID CELLS; LINKED OLIGOSACCHARIDES; MEMBRANE-GLYCOPROTEINS; CARBOHYDRATE LIGAND; SECRETORY PATHWAY; RECOGNITION; IDENTIFICATION; NEUTROPHILS; ADHESION; CLONING	Initial rolling of circulating neutrophils on a blood vessel wall prior to adhesion and transmigration to damaged tissue is dependent upon P-selectin expressed on endothelial cells and its specific neutrophil receptor, the P-selectin glycoprotein ligand-l (PSGL-1). Pretreatment of neutrophils, HL60 cells, or a recombinant fucosylated soluble form of PSGL-1 (sPSGL-1,T7) with the cobra venom metalloproteinase, mocarhagin, completely abolished binding to purified P-selectin in a time-dependent and EDTA- and diisopropyl fluorophosphate-inhibitable manner consistent with mocarhagin selectively cleaving PSGL-1. A polyclonal antibody against the N-terminal peptide Gln-1-Glu-15 of mature PSGL-1 immunoprecipitated sPSGL-1.T7 but not sPSGL-1.T7 treated with mocarhagin, indicating that the mocarhagin cleavage site was near the N terminus. A single mocarhagin cleavage site between Tyr-10 and Asp-ll of mature PSGL-1 was determined by N-terminal sequencing of mocarhagin fragments of sPSGL-1.T7 and is within a highly negatively charged amino acid sequence 1-QATEYEYLDY down arrow DFLPETEPPE, containing three tyrosine residues that are consensus sulfation sites. Consistent with a functional role of this region of PSGL-1 in binding P-selectin, an affinity-purified polyclonal antibody against residues Gln-1-Glu-15 of PSGL-1 strongly inhibited P-selectin binding to neutrophils, whereas an antibody against residues Asp-9-Arg-23 was noninhibitory, These combined data strongly suggest that the N-terminal anionic/sulfated tyrosine motif of PSGL-1 as well as downstream sialylated carbohydrate is essential for binding of P-selectin by neutrophils.	BAKER MED RES INST,VASC BIOL LAB,PRAHRAN,VIC 3181,AUSTRALIA; GENET INST INC,SMALL MOLEC DRUG DISCOVERY GRP,CAMBRIDGE,MA 02140	Baker Heart and Diabetes Institute			Berndt, Michael C/D-5580-2012					ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BERNDT MC, 1981, J BIOL CHEM, V256, P59; BOOTH WJ, 1984, J CLIN INVEST, V73, P291, DOI 10.1172/JCI111213; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHONG BH, 1994, BLOOD, V83, P1535; DONG JF, 1994, BIOCHEMISTRY-US, V38, P13946; FUKUDA M, 1984, J BIOL CHEM, V259, P925; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LEE N, 1990, J BIOL CHEM, V265, P20476; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WASLEY LC, 1993, J BIOL CHEM, V268, P8458	28	96	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26734	26737		10.1074/jbc.270.45.26734	http://dx.doi.org/10.1074/jbc.270.45.26734			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592904	hybrid			2022-12-25	WOS:A1995TE58300004
J	EARNEST, JP; SANTOS, GF; ZUERBIG, S; FOX, JEB				EARNEST, JP; SANTOS, GF; ZUERBIG, S; FOX, JEB			DYSTROPHIN-RELATED PROTEIN IN THE PLATELET MEMBRANE SKELETON - INTEGRIN-INDUCED CHANGE IN DETERGENT-INSOLUBILITY AND CLEAVAGE BY CALPAIN IN AGGREGATING PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; DUCHENNE MUSCULAR-DYSTROPHY; THROMBIN-STIMULATED PLATELETS; MUSCLE-CELLS; CA-2+-DEPENDENT PROTEASE; SUBCELLULAR-DISTRIBUTION; TERMINAL DOMAIN; ACTIN-FILAMENTS; PLASMA-MEMBRANE; CALCIUM-CHANNEL	The platelet membrane is lined with a membrane skeleton that associates with transmembrane adhesion receptors and is thought to play a role in regulating the stability of the membrane, distribution and function of adhesive receptors, and adhesive receptor-induced transmembrane signaling, When platelets are lysed with Triton X-100, cytoplasmic actin filaments can be sedimented by centrifugation at low g-forces (15,600 x g) but the membrane skeleton requires 100,000 x g. The present study shows that DRP (dystrophin-related protein) sediments from lysed platelets along with membrane skeleton proteins, Sedimentation results from association with the membrane skeleton because DRP was released into the detergent-soluble fraction when actin filaments were depolymerized, Interaction of fibrinogen with the integrin alpha(IIb)beta(3) induces platelet aggregation, transmembrane signaling, and the formation of integrin-rich cytoskeletal complexes that can be sedimented from detergent lysates at low g-forces. Like other membrane skeleton proteins, DRP redistributed from the high-speed pellet to the integrin-rich low-speed pellet of aggregating platelets, One of the signaling enzymes that is activated following alpha(IIb)beta(3)-ligand interactions in a platelet aggregate is calpain; DRP was cleaved by calpain to generate a similar to 140-kDa fragment that remained associated with the low-speed detergent-insoluble fraction. These studies show that DRP is part of the platelet membrane skeleton and indicate that DRP participates in the cytoskeletal reorganizations resulting from signal transmission between extracellular adhesive ligand and the interior of the cell.	CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA 94609; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL30657] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R01HL030657, R37HL030657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MS, 1992, TRENDS BIOCHEM SCI, V17, P289, DOI 10.1016/0968-0004(92)90437-E; ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BODENSTEINER JB, 1978, NEUROLOGY, V28, P439, DOI 10.1212/WNL.28.5.439; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COTTIN P, 1992, BIOCHIMIE, V74, P565, DOI 10.1016/0300-9084(92)90156-9; CULLEN MJ, 1990, PROC R SOC SER B-BIO, V240, P197, DOI 10.1098/rspb.1990.0034; DJAFFAR I, 1991, THROMB RES, V62, P127, DOI 10.1016/0049-3848(91)90187-2; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABBRIZIO E, 1994, J MUSCLE RES CELL M, V15, P595, DOI 10.1007/BF00121067; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FOX JEB, 1995, J CELL BIOCH B S, V19, pA136; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; FRANCO A, 1990, J PHYSIOL-LONDON, V427, P361, DOI 10.1113/jphysiol.1990.sp018176; FUJIMOTO T, 1991, J BIOL CHEM, V266, P16370; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JACKSON MJ, 1985, CLIN CHIM ACTA, V147, P215, DOI 10.1016/0009-8981(85)90202-5; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKONISHOK M, 1992, DEV BIOL, V152, P209, DOI 10.1016/0012-1606(92)90129-5; LANSMAN JB, 1991, J MUSCLE RES CELL M, V12, P409, DOI 10.1007/BF01738325; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MAN NT, 1991, J CELL BIOL, V115, P1695; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; RYBAK ME, 1988, BLOOD, V72, P714; SULTAN C, 1991, J BIOL CHEM, V266, P23554; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; YOSHIDA M, 1992, J BIOCHEM-TOKYO, V112, P433, DOI 10.1093/oxfordjournals.jbchem.a123918; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	71	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27259	27265		10.1074/jbc.270.45.27259	http://dx.doi.org/10.1074/jbc.270.45.27259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592985	hybrid			2022-12-25	WOS:A1995TE58300085
J	HARLOCKER, SL; BERGSTROM, L; INOUYE, M				HARLOCKER, SL; BERGSTROM, L; INOUYE, M			TANDEM BINDING OF 6 OMPR PROTEINS TO THE OMPF UPSTREAM REGULATORY SEQUENCE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ACTIVATOR PROTEIN; PORIN GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; 2-COMPONENT REGULATORS; TRANSMEMBRANE RECEPTOR; PHOSPHATASE-ACTIVITIES; SIGNAL-TRANSDUCTION; MYXOCOCCUS-XANTHUS; CANONICAL PROMOTER; POSITIVE REGULATOR	OmpR is a transcription factor in Escherichia coli whose function is modulated by phosphorylation in the presence of phosphorylated EnvZ, a transmembrane protein histidine kinase involved in osmosensing. Using a protein S-OmpR hybrid protein, we demonstrated that six OmpR molecules bind tandemly to the -100 to -39 sequence of ompF. This sequence consists of three 20-base pair units: F1, F2, and F3, each of which is bound by two OmpR proteins. Polymerase chain reaction selection of nine randomized base pairs within the F1 sequence revealed highly conserved C residues spaced 10 base pairs apart. Further mutational analysis of conserved bases indicated that two OmpR molecules bind tandemly to two direct repeats. Mobility shift assays showed that cooperative interactions play a role in enhancing binding of OmpR to lower affinity F2 and F3 sites. Activation and repression of ompF expression are thus regulated by a total of eight OmpR molecules, including two molecules that bind to a distal site (-380 to -361).	RUTGERS STATE UNIV,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIGMS NIH HHS [GM19043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; AIBA H, 1990, FEBS LETT, V261, P19, DOI 10.1016/0014-5793(90)80626-T; BAGBY S, 1994, P NATL ACAD SCI USA, V91, P4308, DOI 10.1073/pnas.91.10.4308; CARRA JH, 1993, EMBO J, V12, P35, DOI 10.1002/j.1460-2075.1993.tb05629.x; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; HUANG KJ, 1994, J BACTERIOL, V176, P1309, DOI 10.1128/jb.176.5.1309-1315.1994; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; INOUYE M, 1979, DEV BIOL, V68, P579, DOI 10.1016/0012-1606(79)90228-8; INOUYE S, 1981, J BACTERIOL, V148, P678, DOI 10.1128/JB.148.2.678-683.1981; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; KANAMARU K, 1990, J BIOCHEM-TOKYO, V108, P483, DOI 10.1093/oxfordjournals.jbchem.a123225; KASAHARA M, 1991, J BACTERIOL, V173, P549, DOI 10.1128/jb.173.2.549-558.1991; KAWAJI H, 1979, J BACTERIOL, V140, P843, DOI 10.1128/JB.140.3.843-847.1979; KIMURA S, 1989, MOL GEN GENET, V215, P374, DOI 10.1007/BF00427032; MAEDA S, 1988, J MOL BIOL, V202, P433, DOI 10.1016/0022-2836(88)90276-8; MAEDA S, 1988, J BIOL CHEM, V263, P14629; MAEDA S, 1991, J BIOCHEM-TOKYO, V110, P324, DOI 10.1093/oxfordjournals.jbchem.a123579; MAEDA S, 1990, J BACTERIOL, V172, P501, DOI 10.1128/JB.172.1.501-503.1990; MAKINO K, 1986, J MOL BIOL, V203, P85; MIZUNO T, 1988, J BIOL CHEM, V263, P1008; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; MIZUNO T, 1986, J BACTERIOL, V168, P86, DOI 10.1128/jb.168.1.86-95.1986; MIZUNO T, 1987, GENE, V54, P57, DOI 10.1016/0378-1119(87)90347-7; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; NORIOKA S, 1986, J BIOL CHEM, V261, P7113; OLIPHANT AR, 1987, NUCLEIC ACIDS RES, V16, P7673; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RAMPERSAUD A, 1989, J BIOL CHEM, V264, P18693; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SARMA V, 1977, J BACTERIOL, V132, P23, DOI 10.1128/JB.132.1.23-27.1977; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; SLAUCH JM, 1988, J BACTERIOL, V170, P439, DOI 10.1128/jb.170.1.439-441.1988; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSUNG K, 1989, J BIOL CHEM, V264, P10104; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	52	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26849	26856		10.1074/jbc.270.45.26849	http://dx.doi.org/10.1074/jbc.270.45.26849			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592927	hybrid			2022-12-25	WOS:A1995TE58300027
J	MCGREGOR, WG; MAH, MCM; CHEN, RH; MAHER, VM; MCCORMICK, JJ				MCGREGOR, WG; MAH, MCM; CHEN, RH; MAHER, VM; MCCORMICK, JJ			LACK OF CORRELATION BETWEEN DEGREE OF INTERFERENCE WITH TRANSCRIPTION AND RATE OF STRAND-SPECIFIC REPAIR IN THE HPRT GENE OF DIPLOID HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV-INDUCED MUTATIONS; EXCISION REPAIR; DIOL EPOXIDE; DNA ADDUCTS; PREFERENTIAL REPAIR; MAMMALIAN-CELLS; BENZO<A>PYRENE; INVITRO; RNA; 1-NITROSOPYRENE	The model that transcription coupled excision repair reflects the interference of DNA damage with the transcription process predicts that the rate of such excision repair will be related to the degree to which a particular type of lesion blocks transcription, We tested this by measuring the rate of excision repair of guanine adducts formed in the HPRT gene of diploid human fibroblasts and in the overall genome by two structurally related polycyclic carcinogens, l-nitrosopyrene (1-NOP) and N-acetoxy-2-acetylaminofluorene (N-AcO-AAF) and comparing the results with those we found previously using benzo[a]pyrene diol epoxide (BPDE). We also measured the degree of interference with in vitro transcription by these adducts. Our results showed that, although BPDE adducts are four times more effective than 1-NOP adducts in blocking transcription, the preferential and strand-specific repair of 1-NOP adducts was twice as fast as that of BPDE adducts. Excision repair of N-AcO-AAF adducts was significantly slower than that of BPDE adducts and was not strand-specific. The efficiency of blocking of transcription by deacetylated N-AcO-AAF adducts was similar to 1-NOP adducts. Therefore, the extent to which a particular lesion blocks transcription in vitro does not predict its rate of preferential or transcription-coupled excision repair.	MICHIGAN STATE UNIV,CTR CANC,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	MCGREGOR, WG (corresponding author), MICHIGAN STATE UNIV,DEPT MICROBIOL,CARCINOGENESIS LAB,FEE HALL,E LANSING,MI 48824, USA.				NATIONAL CANCER INSTITUTE [R01CA021253, K08CA001747, R01CA056796] Funding Source: NIH RePORTER; NCI NIH HHS [CA56796, K08 CA01747, CA21253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUST AE, 1984, MUTAT RES, V125, P95, DOI 10.1016/0027-5107(84)90036-8; BELAND FA, 1979, J CHROMATOGR, V174, P177, DOI 10.1016/S0021-9673(00)87048-X; BELAND FA, 1986, CARCINOGENESIS, V7, P1279, DOI 10.1093/carcin/7.8.1279; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BROYDE S, 1983, BIOPOLYMERS, V22, P2423, DOI 10.1002/bip.360221109; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; CHINAULT AC, 1984, PROG NUCLEIC ACID RE, V31, P295, DOI 10.1016/S0079-6603(08)60381-5; CHO BP, 1994, BIOCHEMISTRY-US, V33, P1373, DOI 10.1021/bi00172a013; CHOI DJ, 1994, BIOCHEMISTRY-US, V33, P780, DOI 10.1021/bi00169a020; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; HEFLICH RH, 1980, CHEM-BIOL INTERACT, V29, P43, DOI 10.1016/0009-2797(80)90085-X; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HINGERTY BE, 1986, J BIOMOL STRUCT DYN, V4, P365, DOI 10.1080/07391102.1986.10506355; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; LIN D, 1988, SOMAT CELL MOLEC GEN, V14, P261, DOI 10.1007/BF01534587; MAH MCM, 1989, CARCINOGENESIS, V10, P2321, DOI 10.1093/carcin/10.12.2321; MCCORMICK JJ, 1988, CARCINOGENESIS, V9, P2073, DOI 10.1093/carcin/9.11.2073; MCCORMICK JJ, 1981, DNA REPAIR LABORAT B, V1, P501; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NOLAN SJ, 1995, IN PRESS CARCINOGENE; PATTON JD, 1986, CARCINOGENESIS, V7, P89, DOI 10.1093/carcin/7.1.89; POIRIER MC, 1980, MOL PHARMACOL, V18, P581; ROSENKRANZ HS, 1982, MUTAT RES, V101, P1, DOI 10.1016/0165-1218(82)90159-8; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SINGH SB, 1991, CANCER RES, V51, P3482; SOSCHER DH, 1994, CARCINOGENESIS, V15, P1093; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TUNG BS, 1995, IN PRESS MUTATION RE; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; WANG YY, 1986, MUTAT RES, V175, P107, DOI 10.1016/0165-7992(86)90133-8; WATANABE M, 1985, MUTAT RES, V146, P285, DOI 10.1016/0167-8817(85)90070-7; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; YANG JL, 1988, MOL CELL BIOL, V8, P196; YANG LL, 1982, MUTAT RES, V94, P435, DOI 10.1016/0027-5107(82)90306-2	40	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27222	27227		10.1074/jbc.270.45.27222	http://dx.doi.org/10.1074/jbc.270.45.27222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592980	hybrid			2022-12-25	WOS:A1995TE58300080
J	HEATH, RJ; ROCK, CO				HEATH, RJ; ROCK, CO			ENOYL-ACYL CARRIER PROTEIN REDUCTASE (FABI) PLAYS A DETERMINANT ROLE IN COMPLETING CYCLES OF FATTY-ACID ELONGATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; INVIVO	The role of enoyl-acyl carrier protein (ACP) reductase (E.C, 1.3.1.9), the product of the fabI gene, was investigated in the type II, dissociated, fatty acid synthase system of Escherichia coli. All of the proteins required to catalyze one cycle of fatty acid synthesis from acetyl-CoA plus malonyl-CoA to butyryl-ACP in vitro were purified. These proteins were malonyl-CoA:ACP transacylase (fabD), beta-ketoacyl-ACP synthase III (fabH), beta-ketoacyl-ACP reductase (fabG), beta-hydroxydecanoyl-ACP dehydrase (fabA), and enoyl-ACP reductase (fabI). Unlike the other enzymes in the cycle, FabA did not efficiently convert its substrate beta-hydroxybutyryl-ACP to crotonyl-ACP, but rather the equilibrium favored formation of beta-hydroxybutyryl-ACP over crotonyl-ACP by a ratio of 9:1, The amount of butyryl-ACP formed depended on the amount of FabI protein added to the assay, Extracts from fabI(Ts) mutants accumulated beta-hydroxybutyryl-ACP, and the addition of FabI protein to the fabI(Ts) extract restored both butyryl-ACP and long-chain acyl-ACP synthesis. FabI was verified to be the only enoyl-ACP reductase required for the synthesis of fatty acids by demonstrating that purified FabI was required for the elongation of both long chain saturated and unsaturated fatty acids, These results were corroborated by analysis of the intracellular ACP pool composition in fabr(Ts) mutants that showed beta-hydroxybutyryl-ACP and crotonyl-ACP accumulated at the nonpermissive temperature in the same ratio found in the fabI(Ts) extracts and in the in vitro reconstruction experiments that lacked FabI. We conclude that FabI is the only enoyl-ACP reductase involved in fatty add synthesis in E, coli and that the activity of this enzyme plays a determinant role in completing cycles of fatty acid biosynthesis.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DORMANN P, 1995, ARCH BIOCHEM BIOPHYS, V316, P612, DOI 10.1006/abbi.1995.1081; EGAN AF, 1973, GENET RES, V21, P3603; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; MAGNUSON K, 1995, J BACTERIOL, V177, P3593, DOI 10.1128/jb.177.12.3593-3595.1995; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J. H., 1972, EXPT MOL GENETICS, P431; MOHAN S, 1994, J BIOL CHEM, V269, P32896; OHLROGGE J, 1995, ARCH BIOCHEM BIOPHYS, V317, P185, DOI 10.1006/abbi.1995.1152; PETTY KJ, 1994, CURRENT PROTOCOLS MO; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994; WEEKS G, 1968, J BIOL CHEM, V243, P1180	31	295	333	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26538	26542		10.1074/jbc.270.44.26538	http://dx.doi.org/10.1074/jbc.270.44.26538			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592873	hybrid			2022-12-25	WOS:A1995TC97800080
J	LAING, JG; BEYER, EC				LAING, JG; BEYER, EC			THE GAP JUNCTION PROTEIN CONNEXIN43 IS DEGRADED VIA THE UBIQUITIN PROTEASOME PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING ENZYME; DEGRADATION; PHOSPHORYLATION; LIVER; CARDIOMYOCYTES; RECEPTOR; INVITRO; E1	We investigated the degradation of the gap junction protein connexin43 in E36 Chinese hamster ovary cells and rat cardiomyocyte derived BWEM cells. Treatment of E36 cells with the lysosomotropic amine, primaquine, for 16 h doubled the amount of connexin43 detected by immunoblotting and modestly increased the half-life of connexin43 in pulse-chase studies, suggesting that the lysosome played a minor role in connexin43 proteolysis, In contrast, treatment with the proteasomal inhibitor N-acetyl-L-leucyl-L-leucinyl-norleucinal led to a B-fold accumulation of connexin43 and increased the half-life of connexin43 to similar to 9 h. The role of ubiquitin in connexin43 degradation was examined in an E36-derived mutant, ts20, which contains a thermolabile ubiquitin-activating enzyme, E1, E36 and ts20 cells grown at the permissive temperature contained similar amounts of connexin43 detectable by immunoblotting, Heat treatment dramatically reduced the amount of connexin43 detected in E36 cells, while connexin43 levels in heat-treated ts20 cells did not change, E36 cells that were heat-treated in the presence of N-acetyl-L-leucyl-L-leucinyl-norleucinal did not lose their connexin43. Pulse-chase experiments showed the reversibility of the block to connexin43 degradation in ts20 cells that were returned to the permissive temperature. Finally, sequential immunoprecipitation using anti-connexin43 and anti-ubiquitin antibodies demonstrated polyubiquitination of connexin43. These results indicate that ubiquitin mediated proteasomal proteolysis may be the major mechanism of degradation of connexin43.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Beyer, Eric/V-1317-2019	Beyer, Eric/0000-0001-8044-1356	NATIONAL EYE INSTITUTE [R29EY008368, R01EY008368] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045466] Funding Source: NIH RePORTER; NEI NIH HHS [EY08368] Funding Source: Medline; NHLBI NIH HHS [HL45466] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cole W.C., 1985, GAP JUNCTIONS, P215; DARROW BJ, 1995, CIRC RES, V76, P381, DOI 10.1161/01.RES.76.3.381; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; GINZBERG RD, 1979, DEV BIOL, V68, P110, DOI 10.1016/0012-1606(79)90247-1; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015; HILENSKI LL, 1992, J HISTOCHEM CYTOCHEM, V40, P1037, DOI 10.1177/40.7.1318894; HOU D, 1994, J BIOL CHEM, V269, P14244; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1994, J MEMBRANE BIOL, V139, P31; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LARSEN WJ, 1979, J CELL BIOL, V83, P576, DOI 10.1083/jcb.83.3.576; LENK SE, 1992, J CELL BIOL, V118, P301, DOI 10.1083/jcb.118.2.301; LUKE RA, 1991, J CLIN INVEST, V87, P1594, DOI 10.1172/JCI115173; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MANJUNATH CK, 1987, BIOCHEM BIOPH RES CO, V142, P228, DOI 10.1016/0006-291X(87)90475-X; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; RECHSTEINER M, 1988, CURRENT TRENDS STUDY, P235; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHWARTZ AL, 1986, J BIOL CHEM, V261, P5225; SEVERS NJ, 1989, CIRC RES, V65, P22, DOI 10.1161/01.RES.65.1.22; TOWBIN H, 1970, P NATL ACAD SCI USA, V76, P4350; TRAUB O, 1983, P NATL ACAD SCI-BIOL, V80, P755, DOI 10.1073/pnas.80.3.755; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	40	205	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26399	26403		10.1074/jbc.270.44.26399	http://dx.doi.org/10.1074/jbc.270.44.26399			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592854	hybrid			2022-12-25	WOS:A1995TC97800061
J	ROSE, T; SEBO, P; BELLALOU, J; LADANT, D				ROSE, T; SEBO, P; BELLALOU, J; LADANT, D			INTERACTION OF CALCIUM WITH BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI HEMOLYSIN HLYA; PROTEIN SECONDARY STRUCTURE; ESCHERICHIA-COLI; CIRCULAR-DICHROISM; ERYTHROCYTE-MEMBRANES; BINDING; PURIFICATION; ACTIVATION; SECRETION; DOMAINS	The adenylate intrinsic hemolytic activity that is independent hom the ATP cycling catalytic activity of the toxin, Both the cytotoxic and hemolytic activities are calcium-dependent. In this work, we have analyzed the calcium interacting properties of CyaA. We have shown that CyaA exposed to CaCl2 could retain membrane binding capability and hemolytic activity when it was further assayed in the presence of an excess of EGTA. Determination of the calcium content of CyaA exposed first to calcium and subsequently to EGTA indicated that some (3-5) calcium ions remained bound to the protein, suggesting the existence of Ca2+ binding sites of high affinity, finding of Ca2+ to these sites might be necessary for both the membrane binding capability and the hemolytic activity of the toxin. In addition, CyaA possesses a large number (about 45) of low affinity (K-D = 0.5-0.8 mM) Ca2+ binding sites that are located in the C terminus of the toxin, between amino acids 1007 and 1706. This region mainly consists of about 45 repeated sequences of the type GGXGXDXLX (where X represents any amino acid) that are characteristic of the RTX (Repeat: in ToXin) bacterial protein family. Our data suggest that each one can bind one calcium ion, Circular dichroism spectroscopy analysis showed that calcium binding to the low affinity sites induces a large conformational change of CyaA, as revealed by an important increase in the content of alpha-helical structures. This conformational change might be directly involved in the Ca2+-dependent translocation of the catalytic domain of CyaA through the plasma membrane of target cells.	INST PASTEUR, UNITE BIOCHIM REGULAT CELLULAIRES, F-75724 PARIS 15, FRANCE; INST PASTEUR, RESONANCE MAGNET NUCL LAB, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			SEBO, Peter/F-7423-2011; SEBO, Peter/N-2043-2019	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; ROSE, Thierry/0000-0001-8863-0207; LADANT, Daniel/0000-0003-1955-548X				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; DORMAN BP, 1973, P NATL ACAD SCI USA, V70, P255, DOI 10.1073/pnas.70.1.255; EHRMANN IE, 1992, FEBS LETT, V304, P51, DOI 10.1016/0014-5793(92)80587-7; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GLASER P, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P239; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LADANT D, 1995, J BIOL CHEM, V270, P3179; LADANT D, 1992, J BIOL CHEM, V267, P2244; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MASURE HR, 1987, MICROBIOL REV, V51, P60, DOI 10.1128/MMBR.51.1.60-65.1987; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Sambrook J, 1989, MOL CLONING LABORATO; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V24, P6323, DOI 10.1021/bi00344a001; SZABO G, 1994, J BIOL CHEM, V269, P22496; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	40	136	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26370	26376		10.1074/jbc.270.44.26370	http://dx.doi.org/10.1074/jbc.270.44.26370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592850	hybrid			2022-12-25	WOS:A1995TC97800057
J	BERVEN, LA; CROUCH, MF; KATSIS, F; KEMP, BE; HARLAND, LM; BARRITT, GJ				BERVEN, LA; CROUCH, MF; KATSIS, F; KEMP, BE; HARLAND, LM; BARRITT, GJ			EVIDENCE THAT THE PERTUSSIS-TOXIN-SENSITIVE TRIMERIC GTP-BINDING PROTEIN G(I2) IS REQUIRED FOR AGONIST-ACTIVATED AND STORE-ACTIVATED CA2+ INFLOW IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; RAT-LIVER; INHIBITION; PHOSPHORYLATION; THAPSIGARGIN; VASOPRESSIN; MESSENGER; MECHANISM; RELEASE	The role of a trimeric GTP-binding protein (G-protein) in the mechanism of vasopressin-dependent Ca2+ inflow in hepatocytes was investigated using both antibodies against the carboxyl termini of trimeric G-protein alpha subunits, and carboxyl-terminal alpha-subunit synthetic peptides. An anti-G(i1-2 alpha) antibody and a G(i2 alpha) peptide (G(i2 alpha) ILe(345)-Phe(355)), but not a Gi(3 alpha) peptide (G(i3 alpha) Ile(344)-Phe(354)), inhibited vasopressin- and thapsigargin-stimulated Ca2+ inflow, had no effect on vasopressin-stimulated release of Ca2+ from intracellular stores, and caused partial inhibition of thapsigargin-stimulated release of Ca2+. An anti-G(q alpha) antibody also inhibited vasopressin-stimulated Ca2+ inflow and partially inhibited vasopressin-induced release of Ca2+ from intracellular stores. Immunofluorescence measurements showed that G(i2 alpha) is distributed throughout much of the interior of the hepatocyte as well as at the periphery of the cell. By contrast, G(q/11 alpha) was found principally at the cell periphery. It is concluded that the trimeric G-protein, G(i2) is required for store-activated Ca2+ inflow in hepatocytes and acts between the release of Ca2+ from the endoplasmic reticulum (presumably adjacent to the plasma membrane) and the receptor-activated Ca2+ channel protein(s) in the plasma membrane.	FLINDERS UNIV S AUSTRALIA,SCH MED,DEPT MED BIOCHEM,ADELAIDE,SA 5001,AUSTRALIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV NEUROSCI,CANBERRA,ACT 2601,AUSTRALIA; ST VINCENTS INST MED RES,MELBOURNE,VIC 3065,AUSTRALIA	Flinders University South Australia; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research			Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; BERVEN LA, 1994, FEBS LETT, V346, P235, DOI 10.1016/0014-5793(94)00481-1; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; BUTTA N, 1993, J BIOL CHEM, V268, P6081; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CROUCH MF, 1993, CELL SIGNAL, V5, P41, DOI 10.1016/0898-6568(93)90006-8; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FERNANDO KC, 1994, BIOCHEM J, V303, P351, DOI 10.1042/bj3030351; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HOTH M, 1993, ANN NY ACAD SCI, V707, P198, DOI 10.1111/j.1749-6632.1993.tb38053.x; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; JENNER S, 1994, BIOCHEM J, V303, P337, DOI 10.1042/bj3030337; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; POBINER BF, 1991, MOL PHARMACOL, V40, P156; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; YANG LJ, 1993, J BIOL CHEM, V268, P3739	30	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25893	25897		10.1074/jbc.270.43.25893	http://dx.doi.org/10.1074/jbc.270.43.25893			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592776	hybrid			2022-12-25	WOS:A1995TB46600093
J	GOTOH, Y; MASUYAMA, N; DELL, J; SHIRAKABE, K; NISHIDA, E				GOTOH, Y; MASUYAMA, N; DELL, J; SHIRAKABE, K; NISHIDA, E			INITIATION OF XENOPUS OOCYTE MATURATION BY ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SOMATIC-CELLS; MAP KINASE; MEIOTIC MATURATION; SIGNAL-TRANSDUCTION; ONCOGENIC RAS; TYROSINE PHOSPHORYLATION; AMPHIBIAN OOCYTES; FROG OOCYTES; IN-VITRO; MOS	Mitogen-activated protein kinase (MAPK) and MAPK kinase (MAPKK) are activated during Xenopus oocyte maturation concomitant with the activation of maturation promoting factor (MPF). We reported previously that an anti-MAPKK neutralizing antibody inhibited progesterone- or Mos- induced initiation of oocyte maturation. Here, we show that injection of CL100 (also called MAPK phosphatase-1) into immature oocytes inhibited progesterone-induced oocyte maturation as well as MAPK activation and that injection of mRNA encoding a constitutively active MAPKK induced activation of histone H1 kinase and germinal vesicle breakdown in the absence of progesterone. Injection of recombinant STE11 protein (a yeast MAPKK kinase) also induced initiation of oocyte maturation. These data support the idea that the MAPKK/MAPK cascade plays an important role in oocyte maturation. Interestingly, injection of the active MAPKK mRNA or the STE11 protein resulted in induction and accumulation of Mos protein. Furthermore, in the presence of cycloheximide, the STE11-induced activation of MPF as well as the induction and accumulation of Mos was blocked, and the activation of MAPK was greatly reduced. The increase in Mos protein and the activation of MAPK by injecting cyclin A protein into immature oocytes were both blocked also by cycloheximide treatment. These results are consistent with an idea that there may exist a positive feedback loop consisting of Mos, the MAPKK/MAPK cascade, and MPF, which may be important for the initiation of oocyte maturation induced by progesterone.			GOTOH, Y (corresponding author), KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; ELETR M, 1979, SCIENCE, V205, P1297; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARDO, 1995, DEV BIOL, V168, P677; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MALLER JL, 1981, DEV BIOL, V85, P309, DOI 10.1016/0012-1606(81)90262-1; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Moon R. T., 1989, TECHNIQUE, V1, P76; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OPRESKO LK, 1990, P NATL ACAD SCI USA, V79, P2937; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	65	156	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25898	25904		10.1074/jbc.270.43.25898	http://dx.doi.org/10.1074/jbc.270.43.25898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592777	hybrid			2022-12-25	WOS:A1995TB46600094
J	OGO, A; WATERMAN, MR; KAMPS, MP; KAGAWA, N				OGO, A; WATERMAN, MR; KAMPS, MP; KAGAWA, N			PROTEIN-KINASE A-DEPENDENT TRANSACTIVATION BY THE E2A-PBX1 FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; PRE-B; DNA-BINDING; TRANSCRIPTION FACTOR; ADENOSINE-MONOPHOSPHATE; TRANSLOCATION PROTEIN; CAMP RESPONSIVENESS; GENE; E2A	The chimeric gene E2A-PBX1 is formed by the t(1;19) chromosomal translocation exclusively associated with pediatric pre-B cell acute lymphoblastic leukemia (pre-B ALL). The resultant fusion protein from this chimeric gene contains the DNA-binding homeodomain of Pbx1. The first and only functional Pbx1 binding site has been localized in bovine CYP17 to a sequence (CRS1) that participates in cAMP-dependent transcription of this gene encoding the steroid hydroxylase, 17 alpha-hydroxylase cytochrome P450. Because Pbx1 is not expressed in pre-B cells, it may be possible that the E2a-Pbx1 fusion protein expressed in pre-B cells having this translocation will activate, in response to cAMP, transcription of genes not normally expressed in these cells leading to arrest of differentiation at the pre-B cell stage. We have now shown that reporter genes comprising CRS1 are activated transcriptionally by protein kinase A (PKA) in the pre-B cell line 697, which endogenously expresses the fusion protein, and that overexpression of E2A-Pbx1 in additional cell lines enhances transcription of reporter genes in a PKA-dependent fashion. Thus, it seems plausible that arrest in the pre-B stage leading to pre-B ALL includes cAMP-dependent activation of E2A-Pbx1.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093	Vanderbilt University; University of California System; University of California San Diego					NIDDK NIH HHS [DK28350] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARKER PE, 1987, CANCER GENET CYTOGEN, V25, P379, DOI 10.1016/0165-4608(87)90204-4; BAUM C, 1994, BIOTECHNIQUES, V17, P1058; CARROLL AJ, 1984, BLOOD, V63, P721; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DENNIG D, 1991, LYMPHOKINE CYTOK RES, V10, P27; HOFFMANN MK, 1988, J IMMUNOL, V140, P580; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU QA, 1995, MOL CELL BIOL, V15, P3786; LUND J, 1990, J BIOL CHEM, V256, P3304; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	36	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25340	25343		10.1074/jbc.270.43.25340	http://dx.doi.org/10.1074/jbc.270.43.25340			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592695	hybrid			2022-12-25	WOS:A1995TB46600011
J	ROGERO, O; TEJEDOR, FJ				ROGERO, O; TEJEDOR, FJ			IMMUNOCHEMICAL CHARACTERIZATION AND DEVELOPMENTAL EXPRESSION OF SHAKER POTASSIUM CHANNELS FROM THE NERVOUS-SYSTEM OF DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; BINDING-PROPERTIES; XENOPUS-OOCYTES; PROTEINS; SUBUNIT; LOCUS; MELANOGASTER; BRAIN; GENE; CDNA	We have raised antisera against recombinant peptides expressed from cDNAs fragments common to all splicing variants generated at the Shaker locus of Drosophila and used them as a tool to biochemically characterize these channel proteins, This antisera succeeded in detecting the expression of multiple Shaker potassium channels (Sh Kch), proteins with variable molecular mass (65-85 kDa) and pi (5.5-7), Additionally, for first time, specific Sh proteins of 40-45 kDa most probably corresponding to some of the so called short Sh cDNAs previously isolated by others have been identified, Using genetic criteria, it has been determined that at least a good part of this variety of proteins is generated by alternative splicing, Developmental experiments show a double wave of Sh Hch channel expression with a first pick at the third instar larvae stage, a minimum at the beginning of puparation, and the highest plateau 36 h after hatching of adult flies, The pattern of Sh splice variants changes dramatically throughout development. A detergent-resistant fraction with about 50% of Sh Kch which seems to be anchored to submembranous structures has been found, Finally, other biochemical properties of Sh Kch, like membrane fractionation and glycosylation, are also described.	CSIC, INST CAJAL, E-28002 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)				Tejedor, Francisco J/0000-0003-1942-2580				ATTALI B, 1993, J BIOL CHEM, V268, P24283; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BARBAS JA, 1989, MOL BRAIN RES, V5, P171, DOI 10.1016/0169-328X(89)90008-9; BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; Breer H., 1985, Springer Series in Experimental Entomology, V1985, P125; BROADIE KS, 1993, J NEUROSCI, V13, P167; FERRUS A, 1990, GENETICS, V125, P383; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GISSELMANN G, 1989, EMBO J, V8, P2359, DOI 10.1002/j.1460-2075.1989.tb08364.x; HARDIE RC, 1991, NEURON, V6, P477, DOI 10.1016/0896-6273(91)90255-X; HARLOW E, 1988, ANTIBODIES LABORATOR; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KYTE J, 1983, ANAL BIOCHEM, V133, P515, DOI 10.1016/0003-2697(83)90118-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MOTTES JR, 1995, NEURON, V14, P613, DOI 10.1016/0896-6273(95)90318-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PASSAFARO M, 1994, NEURON, V12, P317, DOI 10.1016/0896-6273(94)90274-7; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, FEBS LETT, V247, P28, DOI 10.1016/0014-5793(89)81233-5; REHM H, 1984, J BIOL CHEM, V259, P6865; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Sambrook J, 1989, MOL CLONING LABORATO; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SANTAREN JF, 1986, EMBO J, V5, P877, DOI 10.1002/j.1460-2075.1986.tb04298.x; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; SHEN NV, 1993, NEURON, V11, P67; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; SUN TY, 1994, BIOCHEMISTRY-US, V33, P9992, DOI 10.1021/bi00199a024; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TSENGCRANK J, 1991, J NEUROGENET, V7, P229, DOI 10.3109/01677069109167435; Whittaker V P, 1965, Prog Biophys Mol Biol, V15, P39, DOI 10.1016/0079-6107(65)90004-0	49	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25746	25751		10.1074/jbc.270.43.25746	http://dx.doi.org/10.1074/jbc.270.43.25746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592756	hybrid			2022-12-25	WOS:A1995TB46600073
J	VONKOCH, CS; LAHIRI, DK; MAMMEN, AL; COPELAND, NG; GILBERT, DJ; JENKINS, NA; SISODIA, SS				VONKOCH, CS; LAHIRI, DK; MAMMEN, AL; COPELAND, NG; GILBERT, DJ; JENKINS, NA; SISODIA, SS			THE MOUSE APLP2 GENE - CHROMOSOMAL LOCALIZATION AND PROMOTER CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; ALZHEIMERS-DISEASE; REGULATORY ELEMENTS; MAMMALIAN-CELLS; MESSENGER-RNA; REGION; EXPRESSION; CDNA; DNA; IDENTIFICATION	Senile plaques are primarily comprised of deposits of the beta-amyloid protein derived from larger amyloid precursor proteins (APPs). APP is a member of a gene family, including amyloid precursor-like proteins APLP1 and APLP2. Using interspecific mouse backcross mapping, we localized the mouse APLP2 gene to the proximal region of mouse chromosome 9, syntenic with a region of human 11q. We cloned an similar to 1.2-kilobase mouse genomic fragment containing the APLP2 gene promoter. The APLP2 promoter lacks a typical TATA box, is CC-rich, and contains several sequences for transcription factor binding. S1 nuclease protection analysis revealed the presence of multiple transcription start sites. The lack of a TATA box, the presence of a high GC content, and multiple transcription start sites place the APLP2 promoter in the class of promoters of ''housekeeping genes.'' Regulatory regions within the promoter were assayed by transfection of mouse N2a and Ltk(-) cells with constructs containing progressive 5'-deletions of the APLP2 promoter fused to the bacterial chloramphenicol acetyl transferase (CAT) reporter gene. A minimal region that includes sequences 99 bp upstream of the predominant transcription start site of the APLP2 promoter was sufficient to direct high levels of CAT expression.	JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; INDIANA UNIV, SCH MED, DEPT PSYCHIAT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED & MOLEC GENET, INDIANAPOLIS, IN 46202 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Lahiri, Debomoy/AAZ-3322-2020; Mammen, Andrew/AAF-2885-2021		NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-46000] Funding Source: Medline; NIA NIH HHS [AG 05146] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERNAK JM, 1993, GENE, V133, P255, DOI 10.1016/0378-1119(93)90648-M; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Green EL, 1981, GENETICS PROBABILITY, P77; HANES J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P154, DOI 10.1016/0167-4781(93)90055-I; HOFFMAN PW, 1994, BIOCHEM BIOPH RES CO, V201, P610, DOI 10.1006/bbrc.1994.1745; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANNINEN I, 1993, BIOTECHNIQUES, V14, P174; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANDBRINK R, 1994, BBA-GENE STRUCT EXPR, V1219, P167, DOI 10.1016/0167-4781(94)90263-1; SANDBRINK R, 1994, J BIOL CHEM, V269, P14227; Sandbrink R, 1994, Neurobiol Dis, V1, P13, DOI 10.1006/nbdi.1994.0003; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; THINAKARAN G, 1995, IN PRESS J NEUROSCI; TREJO J, 1994, J BIOL CHEM, V269, P21682; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VONDERKAMMER H, 1994, GENOMICS, V20, P308, DOI 10.1006/geno.1994.1174; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; YANG-YEN H-F, 1990, New Biologist, V2, P351	40	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25475	25480		10.1074/jbc.270.43.25475	http://dx.doi.org/10.1074/jbc.270.43.25475			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592716	hybrid			2022-12-25	WOS:A1995TB46600032
J	CAO, L; WU, JM; GARDNER, DG				CAO, L; WU, JM; GARDNER, DG			ATRIAL-NATRIURETIC-PEPTIDE SUPPRESSES THE TRANSCRIPTION OF ITS GUANYLYL CYCLASE-LINKED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RAT RENAL GLOMERULI; DOWN-REGULATION; ENDOTHELIAL-CELLS; C-RECEPTOR; CLEARANCE RECEPTOR; ADENYLATE-CYCLASE; EXPRESSION; ANP; PROLIFERATION	Atrial natriuretic peptide (ANP) treatment of rat aortic smooth muscle cells suppressed both I-125-ANP binding and ANP dependent cGMP accumulation, suggesting reductions in the type C (NPR-C) and type A (NPR-A) natriuretic peptide receptor populations, respectively. NPR-A, but not NPR-C, mRNA levels were reduced in a dose-dependent fashion by ANP. The latter effect appeared to be due, at least in part, to suppression of NPR-A gene promoter activity. ANP effected a dose and time-dependent reduction in a transiently transfected NPR-A luciferase reporter (-1575LUC). Analysis of 5' deletion mutants of the NPR-A promoter demonstrated that the ANP-dependent sequence lies between -1575 and -1290 relative to the transcription start site. Inhibition of the ANP promoter was also effected by brain natriuretic peptide, type C natriuretic peptide, and 8-bromo-cGMP, but not by the NPR-C-selective ligand cANF. In the case of 8-bromo-cGMP, the responsive element(s) was localized to the same 285-base pair region linked to the ANP effect above. These findings indicate that ANP autoregulates its own receptors in these cells and, at least in the ease of NPR-A, it does so through suppression of receptor gene expression and receptor synthesis. This suppression may operate through a cGMP-dependent element located more than a kilobase upstream from the transcription start site.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 45637, HL 35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045637, R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; BALLERMANN BJ, 1985, J CLIN INVEST, V76, P2049, DOI 10.1172/JCI112207; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CACHOFEIRO V, 1989, AM J PHYSIOL, V256, pR1250, DOI 10.1152/ajpregu.1989.256.6.R1250; CAHILL PA, 1990, J BIOL CHEM, V265, P21896; CAO L, 1994, HYPERTENSION, V24, P329, DOI 10.1161/01.HYP.24.3.329; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUJIO N, 1994, HYPERTENSION, V23, P908, DOI 10.1161/01.HYP.23.6.908; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARDNER DG, 1986, P NATL ACAD SCI USA, V83, P6697, DOI 10.1073/pnas.83.18.6697; GAUQUELIN G, 1988, AM J PHYSIOL, V254, pF51, DOI 10.1152/ajprenal.1988.254.1.F51; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; HIRATA Y, 1987, EUR J PHARMACOL, V135, P439, DOI 10.1016/0014-2999(87)90697-2; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V128, P538, DOI 10.1016/0006-291X(85)90080-4; HIRATA Y, 1989, EUR J PHARMACOL, V164, P603, DOI 10.1016/0014-2999(89)90273-2; HUGHES RJ, 1987, AM J PHYSIOL, V253, pC809, DOI 10.1152/ajpcell.1987.253.6.C809; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; KATO J, 1993, EUR J PHARM-MOLEC PH, V244, P153, DOI 10.1016/0922-4106(93)90021-Z; KATO J, 1991, J BIOL CHEM, V266, P14681; KISHIMOTO I, 1993, AM J PHYSIOL, V265, pH1373, DOI 10.1152/ajpheart.1993.265.4.H1373; KISHIMOTO I, 1994, J BIOL CHEM, V269, P28300; KOHNO M, 1993, AM J PHYSIOL, V265, pE673, DOI 10.1152/ajpendo.1993.265.5.E673; LANIERSMITH KL, 1991, ENDOCRINOLOGY, V129, P2311, DOI 10.1210/endo-129-5-2311; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MARTIN ER, 1989, AM J PHYSIOL, V257, pF649, DOI 10.1152/ajprenal.1989.257.4.F649; PAUL RV, 1993, J BIOL CHEM, V268, P18205; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; ROUBERT P, 1987, BIOCHEM BIOPH RES CO, V148, P61, DOI 10.1016/0006-291X(87)91076-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFRIN EL, 1991, AM J PHYSIOL, V260, pH58, DOI 10.1152/ajpheart.1991.260.1.H58; SUGA SI, 1992, CIRC RES, V71, P34, DOI 10.1161/01.RES.71.1.34; TSUTAMOTO T, 1993, CIRCULATION, V87, P70, DOI 10.1161/01.CIR.87.1.70; WEI CM, 1993, AM J PHYSIOL, V264, pH71, DOI 10.1152/ajpheart.1993.264.1.H71; WINQUIST RJ, 1984, EUR J PHARMACOL, V102, P169, DOI 10.1016/0014-2999(84)90353-4; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314; ZHANG LM, 1993, AM J PHYSIOL, V264, pH1753, DOI 10.1152/ajpheart.1993.264.6.H1753	51	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24891	24897		10.1074/jbc.270.42.24891	http://dx.doi.org/10.1074/jbc.270.42.24891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559613	hybrid			2022-12-25	WOS:A1995TB46500047
J	CHAKRAVARTHY, BR; ISAACS, RJ; MORLEY, P; WHITFIELD, JF				CHAKRAVARTHY, BR; ISAACS, RJ; MORLEY, P; WHITFIELD, JF			CA2+-CALMODULIN PREVENTS MYRISTOYLATED ALANINE-RICH KINASE-C SUBSTRATE PROTEIN-PHOSPHORYLATION BY PROTEIN-KINASE CS IN C6 RAT GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING; MARCKS PROTEIN; DIFFERENTIATION; ACTIVATION; KERATINOCYTES; FAMILY; DOMAIN; IDENTIFICATION; NEUROMODULIN; GROWTH	Ionomycin stimulated membrane-associated protein kinase Cs (PKCs) activity in C6 rat glioma cells as much as the potent PKCs stimulator 12-O-tetradecanoyl phorbol 13-acetate (TPA). However, while TPA, as expected, powerfully stimulated the phosphorylation of the PKCs' 85-kDa myristoylated alanine-rich protein kinase C substrate (MARCKS) protein, ionomycin unexpectedly did not. Instead, ionomycin reduced the basal MARCKS phosphorylation. Pretreating the glioma cells with ionomycin prevented TPA-stimulated PKCs from phosphorylating the MARCKS protein. The stimulation of membrane PKCs activity and the prevention of MARCKS phosphorylation by ionomycin required external Ca2+ because they were both abolished by adding 5 mM EGTA to the culture medium, Recently (Chakravarthy, B. R., Isaacs, R. J., Morley, P., Durkin, J. P., and Whitfield, J. F. (1995) J, Biol. Chem, 270, 1362-1368), we proposed that Ca2+ calmodulin complexes block MARCKS phosphorylation by the activated PKCs in keratinocytes stimulated by raising the external Ca2+ concentration. In the present experiments calmodulin prevented MARCKS phosphorylation by TPA-stimulated PKCs in glioma cell lysates, and this blockade was lifted by a calmodulin antagonist, the calmodulin-binding domain peptide. But, physiologically more significant, pretreating intact glioma cells with a cell-permeable calmodulin antagonist, calmidazolium, prevented ionomycin from blocking MARCKS phosphorylation by PKCs in unstimulated and TPA-stimulated cells. The effect of ionomycin on MARCKS phosphorylation was not due to the stimulation of Ca2+ calmodulin-dependent phosphoprotein phosphatase, calcineurin, because cyclosporin A, a potent inhibitor of this phosphatase, did not stop ionomycin from preventing MARCKS phosphorylation. The ability of ionomycin to prevent TPA-stimulated PKCs hom phosphorylating MARCKS depended on whether ionomycin was added before, with, or after TPA. Maximum blockade occurred when ionomycin was added before TPA but was less effective when added with or after TPA. These results indicate that Ca2+ calmodulin can profoundly affect PKCs' signaling at the substrate level.			CHAKRAVARTHY, BR (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, BLDG M-54, MONTREAL RD CAMPUS, OTTAWA, ON K1A 0R6, CANADA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUELT MK, 1994, J BIOL CHEM, V269, P29367; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHAKRAVARTHY BR, 1992, BIOCHIM BIOPHYS ACTA, V1136, P83, DOI 10.1016/0167-4889(92)90088-S; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHAKRAVARTHY BR, 1994, BIOCHEM J, V304, P809, DOI 10.1042/bj3040809; CHIDA K, 1986, J BIOL CHEM, V261, P3013; FALCO JP, 1988, ONCOGENE, V2, P573; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WW, 1993, NEUROCHEM RES, V18, P681, DOI 10.1007/BF00966782; LIN WW, 1992, J NEUROSCI, V12, P1077; LIN WW, 1990, BIOCHEM BIOPH RES CO, V168, P512, DOI 10.1016/0006-291X(90)92351-Y; MORLEY P, 1993, J CELL PHYSIOL, V156, P219, DOI 10.1002/jcp.1041560202; MOSCAT J, 1989, J BIOL CHEM, V264, P11228; NAIRN AC, 1992, CIBA F SYMP, V164, P145; ORR JW, 1992, J BIOL CHEM, V267, P15263; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WEISSMANN BE, 1985, MOL CELL BIOL, V51, P3386; WHITFIELD JF, 1995, J CELL BIOCHEM, P74; WHITFIELD JF, 1992, J CELL PHYSIOL, V150, P299, DOI 10.1002/jcp.1041500212; WHITFIELD JF, 1995, CALCIUM CELL CYCLES; WILLIAMS RE, 1992, PEPTIDES CHEM BIOL, P923	42	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24911	24916		10.1074/jbc.270.42.24911	http://dx.doi.org/10.1074/jbc.270.42.24911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559616	hybrid			2022-12-25	WOS:A1995TB46500050
J	DURICK, K; YAO, VJ; BORRELLO, MG; BONGARZONE, I; PIEROTTI, MA; TAYLOR, SS				DURICK, K; YAO, VJ; BORRELLO, MG; BONGARZONE, I; PIEROTTI, MA; TAYLOR, SS			TYROSINES OUTSIDE THE KINASE CORE AND DIMERIZATION ARE REQUIRED FOR THE MITOGENIC ACTIVITY OF RET/PTC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEPENDENT PROTEIN-KINASE; REGULATORY SUBUNIT; SIGNAL TRANSDUCTION; RET; DNA; RECEPTOR; SEQUENCE; DOMAINS; CAMP	Defects in the c-ret proto-oncogene, a member of the protein tyrosine kinase receptor family, have recently been linked to two types of genetic syndromes, Hirschsprung's disease and the multiple endocrine neoplasia family of inherited cancers. RET/ptc2 is the product of a papillary thyroid carcinoma translocation event between the genes coding for c-ret and the type I alpha regulatory subunit of protein kinase A (RI alpha) (Lanzi, C., Borrello, M., Bongarzone, I., Migliazza, A., Fusco, A., Grieco, M., Santoro, M., Gambetta, R., Zunino, F., Della Porta, G., and Pierotti, M. (1992) Oncogene 7, 2189-2194). The resulting 596-residue protein contains the first two thirds of RI alpha and the entire tyrosine kinase domain of c-ret (RET(tk)). An in vivo assay of growth stimulatory effects was developed, which consisted of microinjecting a RET/ptc2 expression plasmid into the nuclei of 10T1/2 mouse fibroblasts and observing the incorporation of 5-bromodeoxyuridine. This assay was used to determine that only the dimerization domain of RI alpha fused to RET(tk) is required for RET/ptc2's mitogenic activity. In addition, all of the reported Hirschsprung's disease point mutations in the RET(tk) (S289P, R421Q, and R496G) inactivate RET/ptc2 in our assay, confirming that these are loss of function mutations. Two tyrosines outside the conserved kinase core were also identified that are essential for full mitogenic activity of RET/ptc2. These two tyrosines, Tyr-350 and Tyr-586, are potential sites for Src homology 2 and phosphotyrosine binding domain interactions.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY	University of California System; University of California San Diego; Fondazione IRCCS Istituto Nazionale Tumori Milan			Bongarzone, Italia/B-9544-2017; Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Bongarzone, Italia/0000-0003-2530-9170; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332	NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09523] Funding Source: Medline; NIDDK NIH HHS [DK0704417] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUBIS J, 1987, J BIOL CHEM, V262, P14961; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LANZI C, 1992, ONCOGENE, V7, P2189; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITE MF, 1988, J BIOL CHEM, V263, P2969	28	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24642	24645		10.1074/jbc.270.42.24642	http://dx.doi.org/10.1074/jbc.270.42.24642			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559572	hybrid			2022-12-25	WOS:A1995TB46500006
J	SHOJI, W; INOUE, T; YAMAMOTO, T; OBINATA, M				SHOJI, W; INOUE, T; YAMAMOTO, T; OBINATA, M			MIDA1, A PROTEIN ASSOCIATED WITH ID, REGULATES CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; GENE; DIFFERENTIATION; HSP70; TRANSCRIPTION; INHIBITION; EXPRESSION; SEQUENCE; FAMILY	We have isolated cDNA clone encoding a protein that can associate with Id, a helix-loop-helix (HLH) protein, This protein is named MIDA1 (mouse Id associate 1), and its predicted amino acid sequence consists of Zuotin (a putative Z-DNA binding protein in yeast) homology region and tryptophan-mediated repeats similar to c-Myb oncoprotein. MIDA1 associates with the HLH region of Id with the conserved region adjacent to eukaryotic DnaJ conserved motif within the Zuotin homology region, although it does not have any canonical HLH motif. The addition of antisense oligonucleotide of MIDA1 inhibited growth of murine erythroleukemia cells without interfering with erythroid differentiation, indicating that it regulates cell growth.	TOHOKU UNIV,INST DEV AGING & CANC,DEPT CELL BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University			Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233				BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAWE KM, 1990, EMBO J, V9, P161; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MILARSKI KL, 1989, J CELL BIOL, V108, P413, DOI 10.1083/jcb.108.2.413; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHOJI W, 1994, J BIOL CHEM, V268, P5078; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x	33	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24818	24825		10.1074/jbc.270.42.24818	http://dx.doi.org/10.1074/jbc.270.42.24818			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559602	hybrid			2022-12-25	WOS:A1995TB46500036
J	VENER, AV; VANKAN, PJM; GAL, A; ANDERSSON, B; OHAD, I				VENER, AV; VANKAN, PJM; GAL, A; ANDERSSON, B; OHAD, I			ACTIVATION DEACTIVATION CYCLE OF REDOX-CONTROLLED THYLAKOID PROTEIN-PHOSPHORYLATION - ROLE OF PLASTOQUINOL BOUND TO THE REDUCED CYTOCHROME BF COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; MAIZE MESOPHYLL CHLOROPLASTS; MEMBRANE POLYPEPTIDES; SPINACH-CHLOROPLASTS; EXCITATION-ENERGY; PHOTOSYSTEM-II; KINASE; STATE; PHOTOINHIBITION; INHIBITION	Signal transduction via light-dependent redox control of reversible thylakoid protein phosphorylation has evolved in plants as a unique mechanism for controlling events related to light energy utilization. Here we report for the first time that protein phosphorylation can be activated without light or the addition of reducing agents by a transient exposure of isolated thylakoid membranes to low pH in darkness. The activation of the kinase after incubation of dark-adapted thylakoids at pH 4.3 coincides with an increase in the plastoquinol: plastoquinone ratio up to 0.25. However, rapid plastoquinol reoxidation (<1 min) at pH 7.4 contrasts with the slow kinase deactivation (t(1/2) = 4 min), which indicates that the redox control is not directly dependent on the plastoquinone pool. Use of inhibitors and a cytochrome bf-deficient mutant of Lemna demonstrate the involvement of the cytochrome bf complex in the low-pH induced protein phosphorylation. EPR spectroscopy shows that subsequent to the transient low pH treatment and transfer of the thylakoids to pH 7.4, cytochrome f, the Rieske Fe-S center, and plastocyanin become reduced and are not reoxidized while the kinase is slowly deactivated. However, the deactivation correlates with a decrease of the EPR g(z) signal of the reduced Rieske Fe-S center, which is also affected by quinone analogues that inhibit the kinase. Our data point to an activation mechanism of thylakoid protein phosphorylation that involves the binding of plastoquinol to the cytochrome bf complex in the vicinity of the reduced Rieske Fe-S center.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	Stockholm University; Hebrew University of Jerusalem			Andersson, Bertil/C-9328-2009					ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Andersson B., 1994, P143; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1987, FEBS LETT, V210, P22, DOI 10.1016/0014-5793(87)81290-5; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BENNETT J, 1980, P NATL ACAD SCI-BIOL, V77, P5253, DOI 10.1073/pnas.77.9.5253; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; COUGHLAN SJ, 1986, J BIOL CHEM, V261, P14062; COUGHLAN SJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P413, DOI 10.1016/0005-2728(88)90076-X; EBBERT V, 1994, BBA-BIOENERGETICS, V1187, P335, DOI 10.1016/0005-2728(94)90007-8; ELICH TD, 1992, J BIOL CHEM, V267, P3523; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARCHAUS J, 1985, BIOCHIM BIOPHYS ACTA, V809, P17, DOI 10.1016/0005-2728(85)90162-8; FERNYHOUGH P, 1984, FEBS LETT, V176, P133, DOI 10.1016/0014-5793(84)80927-8; FRANK K, 1995, PHOTOCHEM PHOTOBIOL, V61, P2, DOI 10.1111/j.1751-1097.1995.tb09237.x; FRID D, 1992, J BIOL CHEM, V267, P25908; GAL A, 1988, J BIOL CHEM, V263, P7785; GAL A, 1987, FEBS LETT, V221, P205, DOI 10.1016/0014-5793(87)80926-2; GAL A, 1990, J BIOL CHEM, V265, P19742; GAL A, 1990, CURRENT RES PHOTOSYN, V2, P783; HALLIWELL B, 1981, CHLOROPLAST METABOLI, P1; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HORTON JP, 1981, FEBS LETT, V125, P193; HORTON P, 1990, BIOCHIM BIOPHYS ACTA, V1017, P160, DOI 10.1016/0005-2728(90)90147-V; HORTON P, 1985, PLANTA, V165, P37, DOI 10.1007/BF00392209; HOUCHINS JP, 1983, BIOCHIM BIOPHYS ACTA, V725, P138, DOI 10.1016/0005-2728(83)90233-5; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, FEBS LETT, V134, P1, DOI 10.1016/0014-5793(81)80537-6; HURT E, 1981, EUR J BIOCHEM, V117, P591; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; KRAMER DM, 1994, BBA-BIOENERGETICS, V1184, P251, DOI 10.1016/0005-2728(94)90230-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1984, FEBS LETT, V172, P255, DOI 10.1016/0014-5793(84)81136-9; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P69, DOI 10.1016/0005-2728(87)90213-1; MALKIN R, 1973, BIOCHIM BIOPHYS ACTA, V292, P169, DOI 10.1016/0005-2728(73)90261-2; MALKIN R, 1982, BIOCHEMISTRY-US, V21, P2945, DOI 10.1021/bi00541a022; MILLNER PA, 1982, J BIOL CHEM, V257, P1736; OXBOROUGH K, 1987, FEBS LETT, V221, P211, DOI 10.1016/0014-5793(87)80927-4; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REIDEL A, 1991, J BIOL CHEM, V266, P17838; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; SELAK MA, 1982, FEBS LETT, V150, P286, DOI 10.1016/0014-5793(82)80753-9; SHAHAK Y, 1976, PLANT PHYSIOL, V57, P577, DOI 10.1104/pp.57.4.577; SIEGENTHALER PA, 1976, EUR J BIOCHEM, V61, P573, DOI 10.1111/j.1432-1033.1976.tb10052.x; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; STAEHELIN LA, 1983, J CELL BIOL, V97, P1327, DOI 10.1083/jcb.97.5.1327; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V933, P85, DOI 10.1016/0005-2728(88)90058-8	54	90	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25225	25232		10.1074/jbc.270.42.25225	http://dx.doi.org/10.1074/jbc.270.42.25225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559660	hybrid			2022-12-25	WOS:A1995TB46500094
J	ZHOU, MY; WU, XJ; HUANG, LS; GINSBERG, HN				ZHOU, MY; WU, XJ; HUANG, LS; GINSBERG, HN			APOPROTEIN B100, AN INEFFICIENTLY TRANSLOCATED SECRETORY PROTEIN, IS BOUND TO THE CYTOSOLIC CHAPERONE, HEAT-SHOCK-PROTEIN-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; HEP G2 CELLS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; PAUSE TRANSFER; BIOSYNTHESIS; MICROSOMES; FRACTIONS; MEMBRANE; SEQUENCE	Apoprotein B100 (apoB) is a secretory protein that appears to be constitutively translated but inefficiently translocated into the lumen of the endoplasmic reticulum. Using several experimental approaches, we found that apoB is bound to the cytosolic chaperone protein, heat shock protein 72/73 (commonly referred to as Hsp7O). Similar to other chaperone-protein interactions, this binding was transient and ATP-sensitive. The binding of apoB to Hsp70 in HepG2 cells was decreased by treatment with oleic acid, which increases both translocation and secretion of apoB, and was increased by N-acetyl-leucyl-leucyl-norleucinal, a protease inhibitor which efficiently protects apoB from cellular degradation without affecting translocation. The N-terminal 16% of apoB, which is efficiently translocated into the endoplasmic reticulum lumen in stably transfected Chinese hamster ovary (CHO) cells, showed minimal, if any, binding to Hsp70. The N-terminal 50% of apoB, which is very poorly translocated in CHO cells, was found to bind significantly to Hsp7O. These results suggest that domains of nascent apoB localized on the C-terminal regions of the molecule are transiently exposed to the cytosol during translation and/or translocation, and that Hsp70 functions as a molecular chaperone to maintain apoB in a translocational competent conformation until translocation is completed.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36000, HL 21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V26, P10005; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIERKS T, 1993, PHILOS T ROY SOC B, V339, P335, DOI 10.1098/rstb.1993.0032; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GILMORE R, 1991, Current Opinion in Cell Biology, V3, P580, DOI 10.1016/0955-0674(91)90026-U; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEINEMANN T, 1994, J LIPID RES, V35, P2200; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P525, DOI 10.1073/pnas.79.2.525; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILKINSON J, 1993, J LIPID RES, V34, P815; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	35	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25220	25224		10.1074/jbc.270.42.25220	http://dx.doi.org/10.1074/jbc.270.42.25220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559659	hybrid			2022-12-25	WOS:A1995TB46500093
J	BORRAS, FE; LLOBERAS, J; MAKI, RA; CELADA, A				BORRAS, FE; LLOBERAS, J; MAKI, RA; CELADA, A			REPRESSION OF I-A-BETA GENE-EXPRESSION BY THE TRANSCRIPTION FACTOR PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY COMPLEX; INTERFERON-GAMMA; DNA-BINDING; REGULATES EXPRESSION; CD11B PROMOTER; NUCLEAR FACTOR; MICE LACKING; ETS ONCOGENE; CHAIN GENE; B-CELL	The PU.1 protein is an ets-related transcription factor that is expressed in macrophages and B lymphocytes. We present evidence that PU.1 binds to the promoter of the I-A beta gene, i.e. a PU box located next to the Y box. Transfection of PU.1 in B lymphocytes or in interferon-gamma-treated macrophages represses I-A beta gene expression. The inhibitory effect of PU.1 was obtained with the DNA binding domain of the protein, but not with the activation domain. Using the gel shift retardation assay we found that in vitro transcribed/translated NF-YA and NF-YB bind to the Y box of the I-A beta promoter. When PU.1 was added to the assay, a supershifted DNA band was found, indicating that PU.1 and NFY proteins bind to the same DNA molecule. We conclude that I-A beta gene expression is repressed by PU.1 binding to the PU box domain.	UNIV BARCELONA, FAC BIOL, DEPT FISIOL IMMUNOL, E-08028 BARCELONA, SPAIN; UNIV BARCELONA, FDN AUGUST PI & SUNYER, E-08028 BARCELONA, SPAIN; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Sanford Burnham Prebys Medical Discovery Institute			Celada, Antonio/I-1714-2016; Lloberas, Jorge/D-4303-2014; Borràs, Francesc E/P-2287-2017	Lloberas, Jorge/0000-0001-7075-4201; Borràs, Francesc E/0000-0003-4038-1912; Celada, Antonio/0000-0003-3883-2171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30656] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT SE, 1994, J EXP MED, V180, P233, DOI 10.1084/jem.180.1.233; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CELADA A, 1989, EUR J IMMUNOL, V19, P205, DOI 10.1002/eji.1830190134; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; CELADA A, 1988, J IMMUNOL, V140, P3995; CELADA A, 1989, MOL CELL BIOL, V9, P3097, DOI 10.1128/MCB.9.7.3097; CHEN HM, 1993, J BIOL CHEM, V268, P8230; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; FINN PW, 1990, J EXP MED, V171, P2159, DOI 10.1084/jem.171.6.2159; FINN PW, 1990, EMBO J, V9, P1543, DOI 10.1002/j.1460-2075.1990.tb08273.x; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; Griscelli C, 1989, Immunodefic Rev, V1, P135; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HROMAS R, 1993, BLOOD, V82, P2998; JACKSON ME, 1991, J CELL SCI, V100, P1; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KISHI F, 1993, GENE, V133, P243; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MORIMOTO R I, 1992, Current Opinion in Cell Biology, V4, P480, DOI 10.1016/0955-0674(92)90015-5; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OROURKE D, 1993, J VIROL, V67, P7201, DOI 10.1128/JVI.67.12.7201-7214.1993; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REITH W, 1994, J BIOL CHEM, V269, P20020; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Schwartz R H, 1986, Adv Immunol, V38, P31, DOI 10.1016/S0065-2776(08)60006-1; SHACKELFORD R, 1995, J IMMUNOL, V154, P1374; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STUART PM, 1989, CELL IMMUNOL, V122, P391, DOI 10.1016/0008-8749(89)90086-5; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VIVILLE S, 1991, J IMMUNOL, V146, P3211; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	56	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24385	24391		10.1074/jbc.270.41.24385	http://dx.doi.org/10.1074/jbc.270.41.24385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592651	hybrid			2022-12-25	WOS:A1995TA21700079
J	HORAN, T; WEN, J; ARAKAWA, T; LIU, NL; BRANKOW, D; HU, S; RATZKIN, B; PHILO, JS				HORAN, T; WEN, J; ARAKAWA, T; LIU, NL; BRANKOW, D; HU, S; RATZKIN, B; PHILO, JS			BINDING OF NEU DIFFERENTIATION FACTOR WITH THE EXTRACELLULAR DOMAIN OF HER2 AND HER3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR FAMILY; BREAST-CANCER; LIGAND; HEREGULIN; PROTEIN; MEMBER; HER4/P180(ERBB4); OVEREXPRESSION	The interaction of neu differentiation factor (NDF) with the extracellular domains of Her2 (sHer2) and Her3 (sHer3) have been studied using native gels, light scattering, and sedimentation equilibrium. The full-length NDF beta 2 was shown to bind sHer3 with a dissociation constant of 26 +/- 9 nM, while it showed a 1000-fold weaker binding to sHer2. Taken together, these results demonstrate that NDF is a high affinity ligand for Her3, but not for Hera. No increase in affinity of the NDF beta 2 for sHer3 was observed upon addition of sHer2 to the NDF beta 2-sHer3 mixture. Binding of NDF beta 2 to sHer3 did not induce receptor dimerization or oligomerization, the stoichiometry being one sHer3 per one NDF molecule. This finding suggests that transmembrane and/or intracellular domains of receptor family members or perhaps additional unidentified components may be involved in NDF induced dimerization and autophosphorylation, or alternatively, that dimerization is not the mechanism for Her3 autophosphorylation and signal transduction.			HORAN, T (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.		Philo, John S/A-8804-2009	Philo, John S/0000-0003-3418-0356				ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HARTMANN LC, 1994, CANCER, V74, P2956, DOI 10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PHILO J, 1994, J BIOL CHEM, V269, P27840; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TAKAGI T, 1990, J CHROMATOGR, V506, P409, DOI 10.1016/S0021-9673(01)91596-1; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WRIGHT C, 1989, CANCER RES, V49, P2087	26	64	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24604	24608		10.1074/jbc.270.41.24604	http://dx.doi.org/10.1074/jbc.270.41.24604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592681	hybrid			2022-12-25	WOS:A1995TA21700109
J	LI, SC; WU, YY; SUGIYAMA, E; TAKI, T; KASAMA, T; CASELLATO, R; SONNINO, S; LI, YT				LI, SC; WU, YY; SUGIYAMA, E; TAKI, T; KASAMA, T; CASELLATO, R; SONNINO, S; LI, YT			SPECIFIC RECOGNITION OF N-ACETYLNEURAMINIC ACID IN THE G(M2) EPITOPE BY HUMAN G(M2) ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS CALCULATIONS; ENZYMIC-HYDROLYSIS; GM2 GANGLIOSIDOSIS; HEXOSAMINIDASE-A; 3-DIMENSIONAL STRUCTURE; SULFATIDE ACTIVATOR; HUMAN-BRAIN; DEGRADATION; GENE; GLYCOLIPIDS	G(M2) Activator is a low molecular weight protein cofactor that stimulates the enzymatic conversion of G(M2) into G(M3) by human beta-hexosaminidase A and also the conversion of G(M2) into G(A2) by clostridial sialidase (Wu, Y.-Y., Lockyer, J. M., Sugiyama, E., Pavlova, N. V., Li, Y.-T., and Li, S.- C. (1994) J. Biol. Chem. 269, 16276-16283). Among the five known activator proteins for the enzymatic hydrolysis of glycosphingolipids, only G(M2) activator is effective in stimulating the hydrolysis of G(M2). However, the mechanism of action of G(M2) activator is still not well understood, Using a unique disialosylganglioside, GalNAc-G(D1a), as the substrate, we were able to show that in the presence of G(M2) activator, GalNAc-G(D1a) was specifically converted into GalNAc-G(M1a) by clostridial sialidase, while in the presence of saposin B, a nonspecific activator protein, GalNAc-G(D1a) was converted into both GalNAc-G(M1a) and GalNAc-G(M1b). individual products generated from GalNAc-G(D1a) by clostridial sialidase were identified by thin layer chromatography, negative secondary ion mass spectrometry, and immunostaining with a monoclonal IgM that recognizes the G(M2) epitope. Our results clearly show that G(M2) activator recognizes the G(M2) epitope in GalNAc-G(D1a). Thus, G(M2) activator may interact with the trisaccharide structure of the G(M2) epitope and render the GalNAc and NeuAc residues accessible to beta-hexosaminidase A and sialidase, respectively.	TOKYO MED & DENT UNIV,DEPT BIOCHEM,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,BIOMED ANAL LAB,TOKYO 113,JAPAN; UNIV MILAN,SCH MED,DEPT MED CHEM & BIOCHEM,I-20133 MILAN,ITALY	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Milan	LI, SC (corresponding author), TULANE UNIV,SCH MED,DEPT BIOCHEM,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.		Sonnino, Sandro/R-4154-2017	Sonnino, Sandro/0000-0001-8180-5908	NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACQUOTTI D, 1994, EUR J BIOCHEM, V225, P271, DOI 10.1111/j.1432-1033.1994.00271.x; ACQUOTTI D, 1990, J AM CHEM SOC, V112, P7772, DOI 10.1021/ja00177a043; ACQUOTTI D, 1991, CHEM PHYS LIPIDS, V59, P107, DOI 10.1016/0009-3084(91)90001-R; ANDO S, 1978, ANAL BIOCHEM, V89, P437, DOI 10.1016/0003-2697(78)90373-1; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CHRISTOMANOU H, 1985, BIOL CHEM H-S, V366, P245, DOI 10.1515/bchm3.1985.366.1.245; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; Corfield A.P., 1981, PERSPECTIVES INHERIT, V4, P3; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1982, PEDIATR RES, V16, P217, DOI 10.1203/00006450-198203000-00011; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; ILYAS AA, 1985, P NATL ACAD SCI USA, V82, P6697, DOI 10.1073/pnas.82.19.6697; INUI K, 1985, HUM GENET, V69, P197, DOI 10.1007/BF00293023; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1979, J BIOL CHEM, V254, P592; LI SC, 1981, J BIOL CHEM, V256, P6234; LI SC, 1976, J BIOL CHEM, V251, P1159; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; SIEBERT HC, 1992, BIOCHEMISTRY-US, V31, P6962, DOI 10.1021/bi00145a014; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAKI T, 1995, ANAL BIOCHEM, V225, P24, DOI 10.1006/abio.1995.1102; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU YY, 1994, J BIOL CHEM, V269, P16276; ZHOU B, 1989, J BIOL CHEM, V264, P12272	38	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24246	24251		10.1074/jbc.270.41.24246	http://dx.doi.org/10.1074/jbc.270.41.24246			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592631	hybrid			2022-12-25	WOS:A1995TA21700059
J	PURI, RN; KUMAR, A; CHEN, HY; COLMAN, RF; COLMAN, RW				PURI, RN; KUMAR, A; CHEN, HY; COLMAN, RF; COLMAN, RW			INHIBITION OF ADP-INDUCED PLATELET RESPONSES BY COVALENT MODIFICATION OF AGGREGIN, A PUTATIVE ADP RECEPTOR, BY 8-(4-BROMO-2,3-DIOXOBUTYLTHIO)ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; GLYCOPROTEIN-IIB-IIIA; BLOOD-PLATELETS; SHAPE CHANGE; ADENYLATE-CYCLASE; 8-<(4-BROMO-2,3-DIOXOBUTYL)THIO>ADENOSINE 5'-DIPHOSPHATE; BINDING-SITE; CYCLIC-AMP; ACTIVATION; AGGREGATION	ADP is an important platelet agonist which initiates platelet shape change, aggregation, exposure of fibrinogen receptors, and calcium mobilization. Because of the limitations of previously used affinity analogs and photolabeling studies as well as controversies surrounding the identity of an ADP receptor on platelets, we have used an affinity label capable of alkylating a putative exofacial receptor on platelets. We now report that 8-(4-bromo-2,3-dioxobutylthio)adenosine-5'-diphosphate (8-BDB-TADP), which is an analog of the natural ligand ADP, blocked ADP-induced platelet shape change, aggregation, exposure of fibrinogen-binding sites, secretion, and calcium mobilization. Following modification by 8-BDB-TADP, the rates of aggregation of platelets induced by thrombin, a calcium ionophore (A23187) or a stimulator of protein kinase C (phorbol myristate acetate) were minimally affected. However, the 8-BDB-TADP-modified platelets exhibited decreased rates of aggregation in response to ADP, as well as collagen and a thromboxane mimetic (U46619), both of which partially require ADP. Autoradiograms of the gels obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of solubilized platelets modified by either [beta-P-32]8-BDB-TADP, or 8-BDB-TADP and NaB[H-3](4) showed the presence of a single radiolabeled protein band at 100 kDa. The intensity of this band was reduced when platelets were preincubated with ADP, ATP, and 8-bromo-ADP prior to labeling by the radioactive 8-BDB-TADP. The results show that 8-BDB-TADP selectively and covalently labeled aggregin (100 kDa), a putative ADP receptor, resulting in a loss of ADP-induced platelet responses.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware	PURI, RN (corresponding author), TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140, USA.				NHLBI NIH HHS [HL 46431] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1978, J BIOL CHEM, V253, P7346; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BOYER JL, 1990, J BIOL CHEM, V265, P13515; BRASS LF, 1986, J BIOL CHEM, V263, P5210; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COLMAN RF, 1989, PROTEIN FUNCTION PRA, P77; COLMAN RF, 1994, BIOCHEMISTRY-US, V23, P3281; COLMAN RW, 1986, BLOOD, V68, P565; COLMAN RW, 1990, FASEB J, V4, P1425, DOI 10.1096/fasebj.4.5.2407587; COLMAN RW, 1992, NEWS PHYSIOL SCI, V7, P274; CRISTALLI G, 1993, BIOCHEM J, V291, P875, DOI 10.1042/bj2910875; DECAMP DL, 1988, BIOCHEMISTRY-US, V27, P7651, DOI 10.1021/bi00420a012; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; ELMAOTASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31; FIGURES WR, 1981, J BIOL CHEM, V258, P7789; GARRDER A, 1961, NATURE, V192, P531; GRECO NJ, 1991, J BIOL CHEM, V266, P13627; GRECO NJ, 1995, BBA-BIOMEMBRANES, V1236, P142, DOI 10.1016/0005-2736(95)00038-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haslam R. J., 1981, PURINERGIC RECEPTORS, P223; HOURANI SMO, 1991, PHARMACOL REV, V43, P243; HUANG Y, 1986, J BIOL CHEM, V261, P14100; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KALAMBAKAS SA, 1993, BLOOD, V81, P2652; KIKKAWA U, 1988, ADV CYCLIC NUCLEOTID, V17, P437; KOZARICH JW, 1973, BIOCHEMISTRY-US, V12, P4458, DOI 10.1021/bi00746a024; KUMAR A, 1994, ARCH BIOCHEM BIOPHYS, V308, P357, DOI 10.1006/abbi.1994.1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACFARLANE DE, 1982, BIOCHEMISTRY-US, V21, P544, DOI 10.1021/bi00532a020; MACFARLANE DE, 1983, J CLIN INVEST, V71, P420, DOI 10.1172/JCI110786; MAYINGER P, 1992, BIOCHIM BIOPHYS ACTA, V1137, P77, DOI 10.1016/0167-4889(92)90103-I; MILLS DCB, 1985, J BIOL CHEM, V260, P8078; MILLS DCB, 1972, ANN NY ACAD SCI, V201, P391, DOI 10.1111/j.1749-6632.1972.tb16312.x; MORINELLI TA, 1983, BLOOD, V61, P41; OZTURK DH, 1990, BIOCHEMISTRY-US, V29, P7112, DOI 10.1021/bi00482a024; OZTURK DH, 1991, BIOCHEMISTRY-US, V30, P7112; POWLING MJ, 1985, BLOOD, V66, P731; PURI RN, 1989, ARCH BIOCHEM BIOPHYS, V271, P346, DOI 10.1016/0003-9861(89)90284-1; PURI RN, 1991, ARCH BIOCHEM BIOPHYS, V286, P419, DOI 10.1016/0003-9861(91)90060-V; PURI RN, 1994, FASEB J, V8, pA1407; PURI RN, 1994, BLOOD S, V81, pA690; PURI RN, 1989, BLOOD, V77, P500; RAO AK, 1987, BLOOD, V70, P751; RINK TJ, 1984, TRENDS BIOCHEM SCI, V9, P215, DOI 10.1016/0968-0004(84)90067-7; SAVI P, 1994, THROMB RES, V76, P157, DOI 10.1016/0049-3848(94)90186-4; SCHIEVEN GL, 1993, J IMMUNOTHER, V14, P221, DOI 10.1097/00002371-199310000-00009; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SHI XP, 1995, THROMB RES, V77, P235, DOI 10.1016/0049-3848(95)91611-N; SUGATANI J, 1987, J BIOL CHEM, V262, P16995; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WHITE J G, 1974, American Journal of Pathology, V77, P135; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012	54	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24482	24488		10.1074/jbc.270.41.24482	http://dx.doi.org/10.1074/jbc.270.41.24482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592664	hybrid			2022-12-25	WOS:A1995TA21700092
J	DEBLANDRE, GA; MARINX, OP; EVANS, SS; MAJJAJ, S; LEO, O; CAPUT, D; HUEZ, GA; WATHELET, MG				DEBLANDRE, GA; MARINX, OP; EVANS, SS; MAJJAJ, S; LEO, O; CAPUT, D; HUEZ, GA; WATHELET, MG			EXPRESSION CLONING OF AN INTERFERON-INDUCIBLE 17-KDA MEMBRANE-PROTEIN IMPLICATED IN THE CONTROL OF CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUDI CELLS; GENE-EXPRESSION; MESSENGER-RNA; ANTIPROLIFERATIVE ANTIBODY; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; B-LYMPHOCYTES; ALPHA; LEU-13; ANTIGEN	Interferon-inducible membrane proteins of approximately 17 kDa have been suggested to play a role in the antiproliferative activity of interferons based on (1) their pattern of induction in interferon-sensitive and -resistant cell lines and (2) the ability of a membrane fraction enriched in 17-kDa proteins to inhibit cell growth. To gain insight into the nature of the proteins that mediate the antiproliferative activity of interferons, a monoclonal antibody, 13A5, was generated that reacted specifically with a 17-kDa interferon-inducible cell surface protein. The expression pattern of this 17-kDa protein by human cell lines correlated with sensitivity to the antiproliferative activity of interferons. To obtain information regarding the structure of this protein, the 13A5 antibody was used to screen COS cells transfected with a human cDNA expression library. Sequence analysis of a full-length cDNA clone revealed identity with the 9-27 cDNA, previously isolated on the basis of its interferon inducibility by differential screening. In addition, the 17-kDa protein encoded by the 9-27 gene was shown to be identical to the Leu-13 antigen. Leu-13 was previously identified as a 16-kDa interferon-inducible protein in leukocytes and endothelial cells and is a component of a multimeric complex involved in the transduction of antiproliferative and homotypic adhesion signals. These results suggest a novel level of cellular regulation by interferons involving a membrane protein, encoded by the interferon-inducible 9-27 gene, which associates with other proteins at the cell surface, forming a complex relaying growth inhibitory and aggregation signals.	SANOFI RECH,F-31676 LABEGE,FRANCE; ROSWELL PK CANC INST,BUFFALO,NY 14263; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Sanofi-Aventis; Sanofi France; Roswell Park Cancer Institute; Harvard University	DEBLANDRE, GA (corresponding author), FREE UNIV BRUSSELS,DEPT BIOL MOLEC,67 RUE CHEVAUX,B-1640 RHODE ST GENESE,BELGIUM.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN YX, 1984, J IMMUNOL, V133, P2496; DEBLANDRE GA, 1992, CYTOKINE, V4, P36, DOI 10.1016/1043-4666(92)90034-O; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; DRON M, 1983, J GEN VIROL, V64, P2641, DOI 10.1099/0022-1317-64-12-2641; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVANS SS, 1993, J IMMUNOL, V150, P736; EVANS SS, 1990, BLOOD, V76, P2583; FRANSSEN JD, 1981, PROTIDES BIOL FLUIDS, V29, P645; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GIL ML, 1992, J IMMUNOL, V148, P2826; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILLMAN MC, 1987, BIOCHEM BIOPH RES CO, V148, P140, DOI 10.1016/0006-291X(87)91087-4; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JAFFE EA, 1989, J IMMUNOL, V143, P3961; KNIGHT E, 1985, J INTERFERON RES, V5, P305, DOI 10.1089/jir.1985.5.305; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; LLOYD RE, 1983, SCIENCE, V221, P953, DOI 10.1126/science.6192500; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; MATTHEW WD, 1987, J IMMUNOL METHODS, V100, P73, DOI 10.1016/0022-1759(87)90174-8; MEURS E, 1988, EMBO J, V7, P1689, DOI 10.1002/j.1460-2075.1988.tb02997.x; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEN GC, 1992, J BIOL CHEM, V267, P5017; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x	42	146	158	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23860	23866		10.1074/jbc.270.40.23860	http://dx.doi.org/10.1074/jbc.270.40.23860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559564	hybrid			2022-12-25	WOS:A1995RY90900093
J	TSAO, PW; MOUSA, SA				TSAO, PW; MOUSA, SA			THROMBOSPONDIN MEDIATES CALCIUM MOBILIZATION IN FIBROBLASTS VIA ITS ARG-GLY-ASP AND CARBOXYL-TERMINAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; GLYCOPROTEIN-IIIA COMPLEX; HUMAN-ENDOTHELIAL-CELLS; HUMAN CARCINOMA-CELLS; SIGNAL TRANSDUCTION; INTRACELLULAR PH; BINDING DOMAIN; ADHESION; RECEPTOR; ATTACHMENT	Thrombospondin is a matrix glycoprotein found in various cells that can modulate cell attachment, migration, and proliferation. We now show that intact soluble thrombospondin causes a transient [Ca2+](i) increase in IMR-90 fibroblasts. This [Ca2+](i) increase is mediated partly by the RGD containing domain of thrombospondin that binds to the integrin alpha v beta 3 as demonstrated by inhibitor studies using anti-alpha v beta 3 antibody and RGD-containing peptides. A non-RGD and non-alpha v beta 3 component of this [Ca2+](i) increase is mediated by the carboxyl-terminal domain of thrombospondin through an unidentified receptor on fibroblasts as shown by the antibody to the carboxyl terminal of thrombospondin, C6.7. In addition, the carboxyl terminal derived peptide, RFYVVMWK, also triggers [Ca2+](i) increase in similar to 35% of fibroblasts. Both EGTA and Ni2+ block the entire [Ca2+](i) increase indicating that this is due to an influx of extracellular Ca2+. B6H12, an antibody to the integrin-associated protein, blocks this [Ca2+](i) increase by 50%, suggesting that some of the Ca2+ might be entering through an integrin-associated calcium channel. The current findings demonstrate that multiple domains on thrombospondin can trigger signal transduction events by increasing [Ca2+](i) through their interactions with different cell receptors.	DUPONT MERCK PHARMACEUT CO,EXPTL STN,DIV CARDIOVASC DIS,WILMINGTON,DE 19880	DuPont			Mousa, Shaker A/A-7151-2017	Mousa, Shaker A/0000-0002-9294-015X				ALESSIO M, 1993, BLOOD, V82, P3637; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLEZARDIN P, 1989, EUR J BIOCHEM, V181, P721, DOI 10.1111/j.1432-1033.1989.tb14783.x; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DARDIK R, 1987, EUR J BIOCHEM, V168, P347, DOI 10.1111/j.1432-1033.1987.tb13426.x; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GAO AG, 1994, J BIOL CHEM, V269, P29650; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NGSIKORSKI J, 1991, EXP CELL RES, V195, P204; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1988, CANCER RES, V48, P6785; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SHANKAR G, 1993, J CELL SCI, V105, P61; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; SMITH JW, 1994, J BIOL CHEM, V269, P960; STEINER B, 1989, J BIOL CHEM, V264, P13102; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TSAO PW, 1995, THROMB RES, V77, P543, DOI 10.1016/0049-3848(95)00029-1; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; WELDER CA, 1993, J IMMUNOL, V150, P2203; YABKOWITZ R, 1993, J CELL PHYSIOL, V157, P24, DOI 10.1002/jcp.1041570104; YABKOWITZ R, 1991, CANCER RES, V51, P3648; YABKOWITZ R, 1993, CANCER RES, V53, P378; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZIMOLO Z, 1994, AM J PHYSIOL, V266, pC376, DOI 10.1152/ajpcell.1994.266.2.C376	51	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23747	23753		10.1074/jbc.270.40.23747	http://dx.doi.org/10.1074/jbc.270.40.23747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559547	hybrid			2022-12-25	WOS:A1995RY90900076
J	LYMAN, SD; STOCKING, K; DAVISON, B; FLETCHER, F; JOHNSON, L; ESCOBAR, S				LYMAN, SD; STOCKING, K; DAVISON, B; FLETCHER, F; JOHNSON, L; ESCOBAR, S			STRUCTURAL-ANALYSIS OF HUMAN AND MURINE FLT3 LIGAND GENOMIC LOCI	ONCOGENE			English	Article						FLT3 LIGAND; GROWTH FACTORS; HEMATOPOIESIS; TYROSINE KINASE RECEPTORS	COLONY-STIMULATING FACTOR; MESSENGER-RNA PRECURSORS; CELL GROWTH-FACTOR; MOLECULAR-CLONING; HUMAN CSF-1; KIT-LIGAND; EXPRESSION; GENE; PROTEIN; FORMS	Both the murine and human genomic loci that encode flt3 ligand have been cloned, flt3 ligand is a hematopoietic growth factor that stimulates the proliferation of stem and progenitor cells, The portions of the murine and human flt3 ligand genomic loci encompassing the coding region of the protein are approximately 4.0 kb and 5.9 kb, respectively. The human genomic locus is larger as a result of the presence of repeated sequences within introns I, II, IV, V and VI, The transmembrane isoform of the murine and human flt3 ligand proteins are each encoded within seven exons (1-5+7 and 8), Analyses of flt3 ligand cDNA clones show that alternative splicing of a putative sixth exon results in the generation of a soluble form of the flt3 ligand protein, The sizes of each of the exons are well conserved between species, Murine and human flt3 genomic loci have a similar exon:intron structure compared to the genomic loci encoding Steel factor and colony stimulating factor 1. These proteins, which appear to be ancestrally related, are hematopoietic growth factors that stimulate cells via specific and structurally related tyrosine kinase receptors on the cell surface.			LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KAWASAKI ES, 1990, COLONY STIMULATING F, P155; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; Lyman S D, 1995, Curr Opin Hematol, V2, P177; LYMAN SD, 1995, ONCOGENE, V10, P149; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1994, STEM CELLS, V12, P99; MAJUMDAR MK, 1994, J BIOL CHEM, V269, P1237; MAKALOWSKI W, 1994, TRENDS GENET, V10, P98; MARASKOVSKY E, 1993, CELL, V75, P1157; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529	23	30	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1165	1172						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566977				2022-12-25	WOS:A1995RX18000020
J	GEORGE, KM; YUAN, Y; SHERMAN, DR; BARRY, CE				GEORGE, KM; YUAN, Y; SHERMAN, DR; BARRY, CE			THE BIOSYNTHESIS OF CYCLOPROPANATED MYCOLIC ACIDS IN MYCOBACTERIUM-TUBERCULOSIS - IDENTIFICATION AND FUNCTIONAL-ANALYSIS OF CMAS-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOMOLOGOUS SERIES; SMEGMATIS; SYNTHASE; ENZYME; CHROMATOGRAPHY; ORGANIZATION; MEMBRANES; CLONING; LIPIDS	The major mycolic acid produced by Mycobacterium tuberculosis contains two cis-cyclopropanes in the meromycolate chain. The gene whose product cyclopropanates the proximal double bond was cloned by homology to a putative cyclopropane synthase identified from the Mycobacterium leprae genome sequencing project. This gene, named cma2, was sequenced and found to be 52% identical to cma1 (which cyclopropanates the distal double bond) and 73% identical to the gene from M. leprae. Both cma genes were found to be restricted in distribution to pathogenic species of mycobacteria. Expression of cma2 in Mycobacterium smegmatis resulted in the cyclopropanation of the proximal double bond in the alpha(1), series of mycolic acids. Coexpression of both cyclopropane synthases resulted in cyclopropanation of both centers, producing a molecule structurally similar to the M; tuberculosis alpha-dicyclopropyl mycolates. Differential scanning calorimetry of purified cell walls and mycolic acids demonstrated that cyclopropanation of the proximal position raised the observed transition temperature by 3 degrees C. These results suggest that cyclepropanation contributes to the structural integrity of the cell wall complex.	NIAID,ROCKY MT LABS,INTRACELLULAR PARASITES LAB,TB RES UNIT,HAMILTON,MT 59840; PATHOGENESIS CORP,TB & MOLEC MICROBIOL LAB,SEATTLE,WA 98119	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Barry, III, Clifton/H-3839-2012; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BAESS I, 1978, ACTA PATH MICRO IM B, V86, P309; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; DANIELSON SJ, 1982, J BIOL CHEM, V257, P2196; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; DUFOURC EJ, 1983, CHEM PHYS LIPIDS, V33, P153, DOI 10.1016/0009-3084(83)90019-1; DUFOURC EJ, 1984, BIOCHEMISTRY-US, V23, P2300, DOI 10.1021/bi00305a033; EIGLMEIER K, 1993, MOL MICROBIOL, V7, P197, DOI 10.1111/j.1365-2958.1993.tb01111.x; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; GROGAN DW, 1984, J BACTERIOL, V158, P286, DOI 10.1128/JB.158.1.286-295.1984; GROGAN DW, 1986, J BACTERIOL, V166, P872, DOI 10.1128/jb.166.3.872-877.1986; HARLEY JB, 1978, J BACTERIOL, V134, P808, DOI 10.1128/JB.134.3.808-820.1978; Hopewell Philip C., 1994, P25; INGROSSO D, 1989, NIKAOL CHEM, V264, P20131; KANEDA K, 1986, J CLIN MICROBIOL, V24, P1060, DOI 10.1128/JCM.24.6.1060-1070.1986; KENNERLY DA, 1986, J CHROMATOGR, V363, P462, DOI 10.1016/S0021-9673(01)83775-4; LIU J, 1995, IN PRESS P NATL ACAD; MATHUR M, 1992, J BIOL CHEM, V267, P19388; Minnikin D.E., 1967, J CHEM SOC CHEM COMM, V33, P1172; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; QURESHI N, 1978, J BIOL CHEM, V253, P5411; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; SILVIUS JR, 1979, CHEM PHYS LIPIDS, V25, P125, DOI 10.1016/0009-3084(79)90062-8; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; TAKAYAMA K, 1984, MYCOBACTERIA SOURCEB, V15, P315; WANG AY, 1994, MOL MICROBIOL, V11, P1009, DOI 10.1111/j.1365-2958.1994.tb00379.x; WANG AY, 1992, BIOCHEMISTRY-US, V31, P11020, DOI 10.1021/bi00160a011; WINDER FG, 1982, BIOL MYCOBACTERIA, P353; WONG MYH, 1979, J BIOL CHEM, V254, P5741; WONG MYH, 1979, J BIOL CHEM, V254, P5734; YING Y, 1995, P NATL ACAD SCI USA, V92, P6630	34	145	152	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27292	27298		10.1074/jbc.270.45.27292	http://dx.doi.org/10.1074/jbc.270.45.27292			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592990	hybrid			2022-12-25	WOS:A1995TE58300090
J	KANG, SM; OHSHIMA, K; SHIMIZU, M; AMIRHAERI, S; WELLS, RD				KANG, SM; OHSHIMA, K; SHIMIZU, M; AMIRHAERI, S; WELLS, RD			PAUSING OF DNA-SYNTHESIS IN-VITRO AT SPECIFIC LOCI IN CTG AND CGG TRIPLET REPEATS FROM HUMAN HEREDITARY-DISEASE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; FRAGILE-X SYNDROME; MYOTONIC-DYSTROPHY; ESCHERICHIA-COLI; REPLICATION; TRACTS; TRANSCRIPTION; EXPANSION; MUTATIONS; PLASMIDS	Several human hereditary neuromuscular disease genes are associated with the expansion of CTG or CGG triplet repeats. The DNA syntheses of CTG triplets ranging from 17 to 180 and CGG repeats from 9 to 160 repeats in length were studied in vitro. Primer extensions using the Klenow fragment of DNA polymerase I, the modified T7 DNA polymerase (Sequenase), or the human DNA polymerase beta paused strongly at specific loci in the CTG repeats. The pausings were abolished by heating at 70 degrees C. As the length of the triplet repeats in duplex DNA, but not in single-stranded DNA, was increased, the magnitude of pausings increased. The location of the pause sites was determined by the distance between the site of primer hybridization and the beginning of the triplet repeats. CGG triplet repeats also showed similar, but not identical, patterns of pausings. These results indicate that appropriate lengths of the triplets adopt a non-B conformation(s) that blocks DNA polymerase progression; the resultant idling polymerase may catalyze slippages to give expanded sequences and hence provide the molecular basis for this non-Mendelian genetic process. These mechanisms, if present in human cells, may be related to the etiology of certain neuromuscular diseases such as myotonic dystrophy and Fragile X syndrome.	TEXAS A&M UNIV,TEXAS MED CTR,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System			Shimizu, Miho/Q-8522-2017; Shimizu, Miho/O-9903-2019	Shimizu, Miho/0000-0003-4070-8209; Shimizu, Miho/0000-0003-4070-8209	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG S, 1992, J BIOL CHEM, V267, P1259; KANG S, 1992, J BIOL CHEM, V267, P20889; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NELSON DL, 1993, GENOME ANAL, V7, P1; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PANYUTIN IG, 1992, J BIOL CHEM, V267, P5495; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1993, GENOME ANAL, V7, P107; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C; 1993, CELL, V72, P971	44	158	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27014	27021		10.1074/jbc.270.45.27014	http://dx.doi.org/10.1074/jbc.270.45.27014			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592950	hybrid			2022-12-25	WOS:A1995TE58300050
J	SEIDENBECHER, CI; RICHTER, K; RAUCH, U; FASSLER, R; GARNER, CC; GUNDELFINGER, ED				SEIDENBECHER, CI; RICHTER, K; RAUCH, U; FASSLER, R; GARNER, CC; GUNDELFINGER, ED			BREVICAN, A CHONDROITIN SULFATE PROTEOGLYCAN OF RAT-BRAIN, OCCURS AS SECRETED AND CELL-SURFACE GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE AGGREGATING PROTEOGLYCAN; GLYCOSYL-PHOSPHATIDYLINOSITOL; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; CORE PROTEIN; CARTILAGE; EXPRESSION; AGGRECAN; DOMAINS; BINDING	cDNA clones encoding proteins related to the aggrecan/versican family of proteoglycan core proteins have been isolated with antisera against rat brain synaptic junctions, Two sets of overlapping cDNAs have been characterized that differ in their 3'-terminal regions. Northern analyses with probes derived from unique regions of each set were found to hybridize with two brain-specific transcripts of 3.3 and 3.6 kilobases (kb), The 3.6-kb transcript encodes a polypeptide that exhibits 82% sequence identity with bovine brevican and is thought to be the rat ortholog of brevican, Interestingly, the polypeptide deduced from the open reading frame of the 3.3-kb transcript is truncated just carboxyl-terminal of the central domain of brevican and instead contains a putative glypiation signal, Antibodies raised against a bacterially expressed glutathione S-transferase-brevi can fusion protein have been used to show that both soluble:and membrane-bound brevican isoforms exist, Treatment of the crude membrane fraction and purified synaptic plasma membranes with phosphatidylinositol-specific phospholipase C revealed that isoforms of brevican are indeed glycosylphosphatidylinositol-anchored to the plasma membrane, Moreover, digestions with chondroitinase ABC have indicated that rat brevican, like its bovine ortholog, is a conditional chondroitin sulfate proteoglycan. Immunohistochemical studies have shown that brevican is widely distributed in the brain and is localized extracellularly, During postnatal development, amounts of both soluble and phosphatidylinositol:specific phospholipase C-sensitive isoforms increase, suggesting a role for brevican in the terminally differentiating and the adult nervous system.	FED INST NEUROBIOL, D-39778 MAGDEBURG, GERMANY; MAX PLANCK INST BIOCHEM, D-82752 MARTINSRIED, GERMANY; UNIV ALABAMA, NEUROBIOL RES CTR, BIRMINGHAM, AL 35294 USA	Max Planck Society; University of Alabama System; University of Alabama Birmingham				Garner, Craig/0000-0003-1970-5417; Seidenbecher, Constanze/0000-0002-7433-2716				BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; Brown Deborah A., 1992, Trends in Cell Biology, V2, P338; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; FULOP C, 1993, J BIOL CHEM, V268, P17377; GARNER CC, 1993, TANIG SYMP BRAIN SCI, P317; GORDONWEEKS PR, 1987, NEUROCHEMISTRY PRACT; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; IWATA M, 1993, J NEUROSCI, V13, P195; JAWORSKI DM, 1995, J NEUROSCI, V15, P1352; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P385; KISTNER U, 1993, J BIOL CHEM, V268, P4580; LECLERC N, 1989, J COMP NEUROL, V280, P197, DOI 10.1002/cne.902800204; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; NASO MF, 1994, J BIOL CHEM, V269, P32999; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; PURVES D, 1985, PRINCIPLES NEURAL DE; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; Sambrook J, 1989, MOL CLONING LABORATO; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; Steward O, 1987, PROG BRAIN RES <D>, V71, P267; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; STRIPP CS, 1994, J CELL BIOL, V124, P149; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WILLMOTT T, 1992, J NEUROCHEM, V58, P2037, DOI 10.1111/j.1471-4159.1992.tb10944.x; YAMADA H, 1994, J BIOL CHEM, V269, P10119; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZYSKIND JW, 1992, RECOMBINANT DNA LABO	43	118	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27206	27212		10.1074/jbc.270.45.27206	http://dx.doi.org/10.1074/jbc.270.45.27206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592978	hybrid			2022-12-25	WOS:A1995TE58300078
J	HARDY, DM; GARBERS, DL				HARDY, DM; GARBERS, DL			A SPERM MEMBRANE-PROTEIN THAT BINDS IN A SPECIES-SPECIFIC MANNER TO THE EGG EXTRACELLULAR-MATRIX IS HOMOLOGOUS TO VON-WILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACROSOME REACTION; ZONA-PELLUCIDA; HAMSTER SPERMATOZOA; EXPRESSION; AGGREGATION; RECEPTORS; SEQUENCE; CYCLASE	We have purified a sperm membrane protein, designated zonadhesin, that binds in a species-specific manner to the extracellular matrix (zona pellucida) of the egg, and cloned its cDNA, The cDNA encodes a novel protein with a single transmembrane segment separating a 36 amino acid, highly basic intracellular C terminus from a 2418 amino acid extracellular region. The extracellular sequence specifies a mosaic protein comprising a unique N-terminal domain, a mucin-like domain, and five tandem domains proximal to the membrane that are homologous to prepro von Willebrand factor. The N-terminal and mucin-like domains were absent from zonadhesin that bound to the egg extracellular matrix, suggesting that processing occurs during sperm maturation and/or capacitation, By Northern blotting and in situ hybridization, zonadhesin mRNA was detected only within the testis, where it was expressed primarily in haploid spermatids. The unique domain structure of zonadhesin suggests multiple functions, one of which is to mediate sperm adhesion to the zona pellucida.	UNIV TEXAS,SW MED SCH,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Hardy, Daniel/AAP-5823-2020	Hardy, Daniel/0000-0002-7297-3093				BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; BURKS DJ, 1995, SCIENCE, V269, P83, DOI 10.1126/science.7541556; CHANG MC, 1951, NATURE, V168, P697, DOI 10.1038/168697b0; CHERR GN, 1986, DEV BIOL, V114, P119, DOI 10.1016/0012-1606(86)90388-X; CHOMCZYNSKI P, 1988, ANAL BIOCHEM, V162, P156; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DUNBAR BS, 1980, BIOCHEMISTRY-US, V2, P356; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hardy Daniel M., 1994, Seminars in Developmental Biology, V5, P217, DOI 10.1006/sedb.1994.1029; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; PARRISH JJ, 1989, GAMETE RES, V24, P403, DOI 10.1002/mrd.1120240407; PETERSON RN, 1980, SCIENCE, V207, P73, DOI 10.1126/science.7188647; PRIMAKOFF P, 1988, NATURE, V335, P543, DOI 10.1038/335543a0; Ramarao Chodavarapu S., 1994, Seminars in Developmental Biology, V5, P265, DOI 10.1006/sedb.1994.1034; SALING PM, 1981, P NATL ACAD SCI-BIOL, V78, P6231, DOI 10.1073/pnas.78.10.6231; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUR BD, 1989, BIOCHIM BIOPHYS ACTA, V988, P389, DOI 10.1016/0304-4157(89)90012-9; SMITH TT, 1991, J REPROD FERTIL, V91, P567, DOI 10.1530/jrf.0.0910567; UTO N, 1988, J EXP ZOOL, V248, P113, DOI 10.1002/jez.1402480115; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; YANAGIMACHI R, 1976, J REPROD FERTIL, V46, P49; Yanagimachi R., 1981, FERTILIZATION EMBRYO, P81; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002	36	147	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26025	26028		10.1074/jbc.270.44.26025	http://dx.doi.org/10.1074/jbc.270.44.26025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592795	hybrid			2022-12-25	WOS:A1995TC97800002
J	CHOU, WY; TSAI, WP; LIN, CC; CHANG, GG				CHOU, WY; TSAI, WP; LIN, CC; CHANG, GG			SELECTIVE OXIDATIVE MODIFICATION AND AFFINITY CLEAVAGE OF PIGEON LIVER MALIC ENZYME BY THE CU2+-ASCORBATE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MESSENGER-RNA; EXPRESSION; MECHANISM; CLONING; COMPLEXES; PROTEINS; SITES; GENE	Pigeon liver malic enzyme was rapidly inactivated by micromolar concentration of Fe2+ in the presence of ascorbate at neutral pH. The inactivated enzyme was subsequently cleaved by the Fe2+-ascorbate system at the chemical bond between Asp(258) and Ile(259) (Wei, C. H., Chou, W. Y., Huang, S. M., Lin, C. C., and Chang, G. G. (1994) Biochemistry, 33, 7931-7936), which was confirmed by site-specific mutagenesis (Wei, C. H., Chou, W. Y., and Chang, G. G. (1995) Biochemistry 34, 7949-7954). In the present study, at neutral pH, Cu2+ was found to be more reactive in the oxidative modification of malic enzyme and the enzyme was cleaved in a similar manner as Fe2+ did. At acidic pH, however, Fe2+ was found to be ineffective in oxidative modification of the enzyme. Nevertheless, Cu2+ still caused enzyme inactivation and cleaved the enzyme at Asp(141)-Gly(142), Asp(194)-Pro(195), or Asp(464)-Asp(465). Mn2+ and L-malate synergistically protect the enzyme hom Cu2+ inactivation at acidic pH. Cu2+ is also a competitive inhibitor versus Mn2+ in the malic enzyme-catalyzed reaction with K-i value 70.3 +/- 5.8 mu M. The above results indicated that, in addition to the previously determined Asp(258) at neutral pH, Asp(141), Asp(194), and Asp(464) are also the coordination sites for the metal binding of malic enzyme. We suggest that the mechanism of affinity modification and cleavage of malic enzyme by the Cu2+-ascorbate system proceed in the following sequence. First, Cu2+ binds with the enzyme at the Mn2+ binding site and reduces to Cu+ by ascorbate. Next, the local oxygen molecules are reduced by Cu+, thereby generating superoxide or other reactive free radicals. These radicals interact with the susceptible essential amino acid residues at the metal-binding site, ultimately causing enzyme inactivation. Finally, the modified enzyme is cleaved into several peptide fragments, allowing the identification of metal site of the enzyme. The pH-dependent different specificities of metal-catalyzed oxidation system may be generally applicable for other enzymes or proteins.	ACAD SINICA,INST ZOOL,TAIPEI 100,TAIWAN	Academia Sinica - Taiwan	CHOU, WY (corresponding author), NATL DEF MED CTR,DEPT BIOCHEM,POB 90048,TAIPEI 100,TAIWAN.							BAGCHI S, 1987, J BIOL CHEM, V262, P1558; BORSCH D, 1990, FEBS LETT, V273, P111, DOI 10.1016/0014-5793(90)81063-T; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHANG GG, 1992, ARCH BIOCHEM BIOPHYS, V296, P468, DOI 10.1016/0003-9861(92)90599-R; CHANG JT, 1982, ANAL BIOCHEM, V121, P366, DOI 10.1016/0003-2697(82)90494-8; CHOU WY, 1994, ARCH BIOCHEM BIOPHYS, V310, P158, DOI 10.1006/abbi.1994.1152; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; HSU RY, 1992, BIOCHEM J, V284, P869, DOI 10.1042/bj2840869; HSU RY, 1976, J BIOL CHEM, V251, P6574; HSU RY, 1982, MOL CELL BIOCHEM, V43, P3; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; KOBAYASHI K, 1989, J BIOL CHEM, V264, P3200; KUFEL J, 1994, J MOL BIOL, V244, P511, DOI 10.1006/jmbi.1994.1749; KULKARNI G, 1993, ARCH BIOCHEM BIOPHYS, V300, P231, DOI 10.1006/abbi.1993.1032; LOEBER G, 1994, FEBS LETT, V344, P181, DOI 10.1016/0014-5793(94)00386-6; LOEBER G, 1991, J BIOL CHEM, V266, P3016; MAGNUSON MA, 1986, J BIOL CHEM, V261, P1183; MURRAY RK, 1990, HARPERS BIOCH, P682; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OLEARY MH, 1992, ENZYMES, V20, P236; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROTHERMEL BA, 1989, J BIOL CHEM, V264, P19587; SALLES JBV, 1950, J BIOL CHEM, V187, P849; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; Villafranca JJ., 1992, ENZYMES, V20, P63; WEI CH, 1994, BIOCHEMISTRY-US, V33, P7931, DOI 10.1021/bi00191a021; WEI CH, 1995, BIOCHEMISTRY-US, V34, P7949, DOI 10.1021/bi00024a020	33	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25935	25941		10.1074/jbc.270.43.25935	http://dx.doi.org/10.1074/jbc.270.43.25935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592782	hybrid			2022-12-25	WOS:A1995TB46600099
J	NIIMURA, Y; POOLE, LB; MASSEY, V				NIIMURA, Y; POOLE, LB; MASSEY, V			AMPHIBACILLUS XYLANUS NADH OXIDASE AND SALMONELLA-TYPHIMURIUM ALKYL-HYDROPEROXIDE REDUCTASE FLAVOPROTEIN COMPONENTS SHOW EXTREMELY HIGH SCAVENGING ACTIVITY FOR BOTH ALKYL HYDROPEROXIDE AND HYDROGEN-PEROXIDE IN THE PRESENCE OF SALMONELLA-TYPHIMURIUM ALKYL-HYDROPEROXIDE REDUCTASE 22-KDA PROTEIN-COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; ESCHERICHIA-COLI; DISULFIDE OXIDOREDUCTASES; SACCHAROMYCES-CEREVISIAE; LACKING CYTOCHROME; PURIFICATION; CATALASE; QUINONE; DISTINCT	The flavoprotein NADH oxidase from Amphibacillus xylanus consumes oxygen to produce hydrogen peroxide, The amino acid sequence of this flavoprotein shows 51.2% identity to the F-52a component, denoted AhpF, of the alkyl-hydroperoxide reductase hom Salmonella typhimurium, AhpF also catalyzes NADH-dependent hydrogen peroxide formation under aerobic conditions, albeit at a somewhat slower rate than the Amphibacillus protein. In the presence of the 22-kDa colorless component (AhpC) of tbe Salmonella alkyl-hydroperoxide reductase, both proteins catalyze the 4-electron reduction of oxygen to water. Both flavoproteins are active as AhpC reductases and mediate electron transfer, resulting in the NADH-dependent reduction of hydrogen peroxide and cumene hydroperoxide. Both enzymes' K-m values for hydrogen peroxide, cumene hydroperoxide, and NADH are so low that they could not be determined accurately, V-max values for hydrogen peroxide or cumene hydroperoxide reduction are >10,000 min(-1) at 25 degrees C, These values are almost the same as the reduction rate of the flavoprotein component by NADH. The involvement in catalysis of a redox-active disulfide of the A. xylanus flavoprotein was shown by construction of three mutant enzymes, C337S, C340S, and C337S/C340S. Very little activity for hydrogen peroxide or cumene hydroperoxide was found with the single mutants (C337S and C340S), and none with the double mutant (C337S/C340S). Analysis of the DNA sequence upstream of the Amphibacillus flavoprotein structural gene indicated the presence of a partial open reading frame homologous to the Salmonella ahpC structural gene (64.3% identical at the amino acid sequence level), suggesting that the NADH oxidase protein of A. xylanus is also part of a functional alkyl-hydroperoxide reductase system within these catalase-lacking bacteria.	WAKE FOREST UNIV, MED CTR, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	Wake Forest University; University of Michigan System; University of Michigan	NIIMURA, Y (corresponding author), TOKYO UNIV AGR, DEPT FOOD SCI & TECHNOL, 196 YASAKA, ABASHIRI, HOKKAIDO 09924, JAPAN.			Poole, Leslie/0000-0003-0334-7328	NIGMS NIH HHS [GM-50389, GM-11106, R01 GM050389] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050389, R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAUDIERE J, 1983, ARCH BIOCHEM BIOPHYS, V226, P448, DOI 10.1016/0003-9861(83)90314-4; COCCO D, 1988, EUR J BIOCHEM, V174, P267, DOI 10.1111/j.1432-1033.1988.tb14093.x; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; HIGUCHI M, 1993, J GEN MICROBIOL, V139, P2343, DOI 10.1099/00221287-139-10-2343; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KOIKE K, 1985, J BIOCHEM, V97, P1279, DOI 10.1093/oxfordjournals.jbchem.a135179; KOYAMA N, 1988, FEMS MICROBIOL LETT, V49, P123, DOI 10.1016/0378-1097(88)90113-9; LITTLE C, 1972, BIOCHIM BIOPHYS ACTA, V284, P375, DOI 10.1016/0005-2744(72)90133-7; NIIMURA Y, 1993, J BACTERIOL, V175, P7945, DOI 10.1128/JB.175.24.7945-7950.1993; NIIMURA Y, 1987, AGR BIOL CHEM TOKYO, V51, P2271; NIIMURA Y, 1990, INT J SYST BACTERIOL, V40, P297, DOI 10.1099/00207713-40-3-297; NIIMURA Y, 1989, FEMS MICROBIOL LETT, V61, P79, DOI 10.1016/S0378-1097(98)00072-X; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; OHNISHI K, 1995, J BIOL CHEM, V270, P5812, DOI 10.1074/jbc.270.11.5812; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; Poole LB, 1994, FLAVINS AND FLAVOPROTEINS 1993, P583; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; REINARDS R, 1981, EUR J BIOCHEM, V120, P329, DOI 10.1111/j.1432-1033.1981.tb05708.x; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SAEKI Y, 1985, J BIOCHEM-TOKYO, V98, P1433, DOI 10.1093/oxfordjournals.jbchem.a135411; SCHMIDT HL, 1986, EUR J BIOCHEM, V156, P149, DOI 10.1111/j.1432-1033.1986.tb09560.x; TAKAGI T, 1978, LIPIDS, V13, P147, DOI 10.1007/BF02533257; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; 1972, WORTHINGTON ENZYME M, P41	35	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25645	25650		10.1074/jbc.270.43.25645	http://dx.doi.org/10.1074/jbc.270.43.25645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592740	hybrid			2022-12-25	WOS:A1995TB46600057
J	SHASHKIN, P; KOSHKIN, A; LANGLEY, D; REN, JM; WESTERBLAD, H; KATZ, A				SHASHKIN, P; KOSHKIN, A; LANGLEY, D; REN, JM; WESTERBLAD, H; KATZ, A			EFFECTS OF CGS 9343B (A PUTATIVE CALMODULIN ANTAGONIST) ON ISOLATED SKELETAL-MUSCLE - DISSOCIATION OF SIGNALING PATHWAYS FOR INSULIN-MEDIATED ACTIVATION OF GLYCOGEN-SYNTHASE AND HEXOSE-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SOLEUS MUSCLE; GLUCOSE-TRANSPORT; DIABETES-MELLITUS; INDUCED INCREASE; PHOSPHORYLATION; INHIBITION; CELLS; STIMULATION; EPINEPHRINE; METABOLISM	The role of calmodulin in control of carbohydrate metabolism in the absence and presence of insulin in isolated mouse soleus muscle was investigated, The calmodulin antagonist CGS 9343B had no effect on basal glycogen synthase activity, the contents of high energy phosphates, glucose-6-P, or glycogen synthesis. However, CGS 9343B inhibited the basal rates of 2-deoxyglucose uptake and 3-O-methylglucose transport by 30% (p < 0.05) and 40% (p < 0.001), respectively, Insulin activated glycogen synthase by almost 40% (p < 0.01) and this increase was not altered in the presence of CGS 9343B. Insulin increased the muscle content of glucose-6-P (approximate to 2-fold), as well as glycogen synthesis (approximate to 8-fold), 2-deoxyglucose uptake (approximate to 3-fold), and 3-O-methylglucose transport (approximate to 2-fold), and these increases were inhibited by CGS 9343B, In additional experiments on isolated rat epitrochlearis muscle, it was found that the hypoxia-mediated activation of 3-O-methylglucose transport was also inhibited by CGS 9343B. These data demonstrate that: 1) hexose transport, both in the absence and presence of external stimuli (insulin and hypoxia), requires functional calmodulin; and 2) insulin-mediated activation of glycogen synthase does not require functional calmodulin, nor can it be accounted for by increases in glucose transport or glucose-6-P.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT SURG SCI,DIV CLIN PHYSIOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,S-17177 STOCKHOLM,SWEDEN; BAYER CORP,DIV PHARMACEUT,W HAVEN,CT 06516	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Bayer AG				Westerblad, Hakan/0000-0002-8180-3029				BEITNER R, 1993, INT J BIOCHEM, V25, P297, DOI 10.1016/0020-711X(93)90616-M; BOGARDUS C, 1990, NEW ENGL J MED, V322, P262, DOI 10.1056/NEJM199001253220409; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CHENZION M, 1992, INT J BIOCHEM, V24, P1661, DOI 10.1016/0020-711X(92)90185-4; CHIASSON JL, 1981, J CLIN INVEST, V68, P706, DOI 10.1172/JCI110306; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; GUARNER V, 1993, EUR J PHARMACOL, V237, P139, DOI 10.1016/0014-2999(93)90103-O; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; ISHIBASHI O, 1989, DIABETES RES CLIN PR, V6, P109, DOI 10.1016/0168-8227(89)90114-9; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KATZ A, 1995, BBA-GEN SUBJECTS, V1244, P229, DOI 10.1016/0304-4165(95)00050-L; KIPNIS DM, 1960, J BIOL CHEM, V235, P3070; LARNER J, 1960, ARCH BIOCHEM BIOPHYS, V86, P56, DOI 10.1016/0003-9861(60)90367-2; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LEMARCHANDBRUST.Y, 1981, BIOCHIM BIOPHYS ACTA, V677, P13; LEMARCHANDBRUST.Y, 1979, J CLIN INVEST, V64, P1505; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; NEUHAUS R, 1992, EUR J PHARM-MOLEC PH, V226, P183, DOI 10.1016/0922-4106(92)90182-U; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; ORON Y, 1980, MOL CELL BIOCHEM, V32, P153; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; REN JM, 1993, J BIOL CHEM, V268, P16113; SACKS DB, 1992, BIOCHEM J, V283, P21, DOI 10.1042/bj2830021; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHECHTER Y, 1984, P NATL ACAD SCI-BIOL, V81, P327, DOI 10.1073/pnas.81.2.327; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; TAN AWH, 1975, BIOCHIM BIOPHYS ACTA, V410, P45, DOI 10.1016/0005-2744(75)90206-5; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B; VITTONE L, 1994, MOL CELL BIOCHEM, V124, P33; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; XU A, 1994, J BIOL CHEM, V268, P8394; YOUN JH, 1994, AM J PHYSIOL-REG I, V267, pR888, DOI 10.1152/ajpregu.1994.267.4.R888; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	37	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25613	25618		10.1074/jbc.270.43.25613	http://dx.doi.org/10.1074/jbc.270.43.25613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592735	hybrid			2022-12-25	WOS:A1995TB46600052
J	CANTATORE, P; DADDABBO, L; FRACASSO, F; GADALETA, MN				CANTATORE, P; DADDABBO, L; FRACASSO, F; GADALETA, MN			IDENTIFICATION BY IN ORGANELLO FOOTPRINTING OF PROTEIN CONTACT SITES AND OF SINGLE-STRANDED-DNA SEQUENCES IN THE REGULATORY REGION OF RAT MITOCHONDRIAL-DNA - PROTEIN-BINDING SITES AND SINGLE-STRANDED-DNA REGIONS IN ISOLATED RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RNASE MRP; RIBOSOMAL-RNA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; INITIATION EVENTS; DISPLACEMENT LOOP; GENE ORGANIZATION; SENESCENT RAT; HEAVY-STRAND; IN-VIVO	Footprinting studies with the purine-modifying reagent dimethyl sulfate and with the single-stranded DNA probing reagent potassium permanganate were carried out in isolated mitochondria from rat liver. Dimethyl sulfate footprinting allowed the detection of protein-DNA interactions within the rat analogues of the human binding sites for the transcription termination factor mTERF and for the transcription activating factor mt-TFA. Although mTERF contacts were localized only at the boundary between the 16S rRNA/tRNA(UUR)(Leu) genes, multiple mtTFA contacts were detected, Contact sites were located in the light and the heavy strand promoters and, in agreement with in nitro footprinting data on human mitochondria, between the conserved sequence blocks (CSB) 1 and 2 and inside CSB-1. Potassium permanganate footprinting allowed detection of a 25-base pair region entirely contained in CSB-1 in which both strands were permanganate-reactive. No permanganate reactivity was associated with the other regions of the D-loop, including CSB-2 and -3, and with the mTERF contact site. We hypothesize that the single-stranded DNA at CSB-1 may be due to a profound helix distortion induced by mtTFA binding or be associated with a RNA polymerase pause site. In any case the location in CSB-1 of the 3' end of the most abundant replication primer and of the 5' end of the prominent D-loop DNA suggests that protein-induced DNA conformational changes play an important role in directing the transition from transcription to replication in mammalian mitochondria.	CNR,CTR STUDI MITOCONDRI & METAB ENERGET,I-70126 BARI,ITALY	Consiglio Nazionale delle Ricerche (CNR)	CANTATORE, P (corresponding author), UNIV BARI,DEPT BIOCHEM & MOLEC BIOL,VIA ORABONA 4A,I-70126 BARI,ITALY.							ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; [Anonymous], MITOCHONDRIAL DNA HU; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CAIRNS SS, 1986, J BIOL CHEM, V261, P8481; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CANTATORE P, 1988, CURR GENET, V14, P477, DOI 10.1007/BF00521272; CANTATORE P, 1987, INT REV CYTOL, V108, P149, DOI 10.1016/S0074-7696(08)61438-2; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1986, MOL CELL BIOL, V6, P294, DOI 10.1128/MCB.6.1.294; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; DESJARDINS P, 1990, J MOL BIOL, V212, P599, DOI 10.1016/0022-2836(90)90225-B; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; ENRIQUEZ JA, 1991, FEBS LETT, V280, P32, DOI 10.1016/0014-5793(91)80197-B; ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861; ENRIQUEZ JA, 1992, FEBS LETT, V304, P285, DOI 10.1016/0014-5793(92)80639-X; FABER S, 1993, J BIOL CHEM, V268, P24976; FERNANDEZSILVA P, 1991, BIOCHEM BIOPH RES CO, V176, P645, DOI 10.1016/S0006-291X(05)80233-5; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; GHIVIZZANI SC, 1993, J BIOL CHEM, V268, P8675; GHIVIZZANI SC, 1993, J MOL EVOL, V37, P36, DOI 10.1007/BF00170460; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KING TC, 1987, J BIOL CHEM, V262, P6204; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; Lawley P D, 1966, Prog Nucleic Acid Res Mol Biol, V5, P89, DOI 10.1016/S0079-6603(08)60232-9; LAWLEY PD, 1963, BIOCHEM J, V89, P127, DOI 10.1042/bj0890127; LI K, 1994, J CELL BIOL, V124, P871, DOI 10.1083/jcb.124.6.871; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; SACCONE C, 1991, J MOL EVOL, V33, P83, DOI 10.1007/BF02100199; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V84, P8934; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SHANG J, 1994, J BIOL CHEM, V269, P29112; SHISA E, 1990, CURR GENET, V17, P247; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; YANOFSKY C, 1988, J BIOL CHEM, V263, P609	72	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25020	25027		10.1074/jbc.270.42.25020	http://dx.doi.org/10.1074/jbc.270.42.25020			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559632	hybrid			2022-12-25	WOS:A1995TB46500066
J	LUCARELLI, E; KAPLAN, DR; THIELE, CJ				LUCARELLI, E; KAPLAN, DR; THIELE, CJ			SELECTIVE REGULATION OF TRKA AND TRKB RECEPTORS BY RETINOIC ACID AND INTERFERON-GAMMA IN HUMAN NEUROBLASTOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEURO-BLASTOMA; NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESSENGER-RNA; PROTOONCOGENE PRODUCT; EXPRESSION; DIFFERENTIATION; NGF; GENE	Trk receptors are a family of genes implicated in the survival, differentiation, and growth of certain neurons and tumors of the nervous system. A better understanding of the regulation of Trk receptors is relevant for developmental and oncological studies. Human neuroblastoma (NB) cell lines constitutively express low levels of TrkA mRNA, while TrkB mRNA is not readily detectable. Differentiation of NB cells is accompanied by a differential modulation of Trk expression in human NE cells. Nanomolar concentrations of RA induce a stable increase of TrkB mRNk. A transient induction of TrkA mRNA levels requires micromolar concentrations of RA. Induction of both TrkA and TrkB mRNA does not require new protein synthesis. However, RA-induced TrkB mRNA expression is transcriptionally regulated, while the transient RA-induced increase of TrkA mRNA is a consequence of extended mRNA stability. Interferon gamma (IFN-gamma) selectively increases TrkA mRNA without affecting TrkB mRNA levels. Similar to RA, IFN-gamma does not modify the transcriptional rate of TrkA mRNA, but rather increases TrkA mRNA stability. Thus, RA and IFN-gamma differentially regulate TrkA or TrkB expression in the same cell type by predominantly transcriptional (TrkB) or post transcriptional (TrkA) mechanisms. Such experiments indicate the complexity of Trk mRNA regulation and also indicate compounds that may affect neurotrophin responsiveness in developing neural cells.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOLEC MECHANISMS CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LUCARELLI, E (corresponding author), NCI, PEDIAT BRANCH,CELLULAR & MOLEC BIOL SECT,BLDG 10, ROOM 13C218, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Enrico, Lucarelli/G-3588-2015; Lucarelli, Enrico/AAF-1612-2021	Enrico, Lucarelli/0000-0002-6681-6374; Lucarelli, Enrico/0000-0002-6681-6374				BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BOSCO MC, 1994, BLOOD, V83, P537; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; DAVIES AM, 1994, CURR BIOL, V4, P273, DOI 10.1016/S0960-9822(00)00064-6; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HUNTER K, 1991, P NATL ACAD SCI USA, V88, P3666, DOI 10.1073/pnas.88.9.3666; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JELSMA TN, 1993, J NEUROBIOL, V24, P1207, DOI 10.1002/neu.480240907; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KRISHNAMURTHY S, 1963, J NUTR, V79, P503, DOI 10.1093/jn/79.4.503; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; LUCARELLI E, 1994, ADV NEUROBLASTOMA RE, V4, P185; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASANA Y, 1993, J NEUROSCI RES, V35, P468, DOI 10.1002/jnr.490350503; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MCCAFFERY P, 1993, ENZYMOLOGY MOL BIOL, V4, P181; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NAKAGAWARA A, 1995, GENOMICS, V25, P538, DOI 10.1016/0888-7543(95)80055-Q; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OKAZAWA H, 1994, ONCOGENE, V9, P1813; OLSSON T, 1994, EUR J IMMUNOL, V24, P308, DOI 10.1002/eji.1830240205; PASTOR R, 1994, ONCOGENE, V9, P1081; RADZIOCH D, 1991, MOL CELL BIOL, V11, P2718, DOI 10.1128/MCB.11.5.2718; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHIKATA A, 1994, JPN J CANCER RES, V85, P122, DOI 10.1111/j.1349-7006.1994.tb02070.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SOHRABJI F, 1994, J NEUROSCI, V14, P459; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; VILCEK J, 1994, INT ARCH ALLERGY IMM, V104, P311; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X	63	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24725	24731		10.1074/jbc.270.42.24725	http://dx.doi.org/10.1074/jbc.270.42.24725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559588	hybrid			2022-12-25	WOS:A1995TB46500022
J	RAO, PV; PUGAZHENTHI, S; KHANDELWAL, RL				RAO, PV; PUGAZHENTHI, S; KHANDELWAL, RL			THE EFFECTS OF STREPTOZOTOCIN-INDUCED DIABETES AND INSULIN SUPPLEMENTATION ON EXPRESSION OF THE GLYCOGEN-PHOSPHORYLASE GENE IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE; ENZYME-ACTIVITY; MESSENGER-RNA; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION; PARTICULATE FRACTIONS; GLUCOKINASE GENE; SKELETAL-MUSCLE; PYRUVATE-KINASE; PROTEIN-KINASE	We have previously observed that the chronic effects of streptozotocin-induced diabetes cause a decrease in the total hepatic glycogen phosphorylase activity with a corresponding reduction in the phosphorylase protein levels. These effects were normalized by insulin administration to diabetic rats. There was no change in the total glycogen synthase activity as a result of diabetes or insulin supplementation. These results are extended to examine the effects of diabetes and insulin administration to diabetic animals on the expression of phosphorylase and glycogen synthase enzymes. The expression (i.e. mRNA levels) of phosphorylase was down-regulated (45% of normal levels) in diabetic livers, and this was normalized by insulin supplementation to diabetic animals. Diabetes or insulin supplementation to diabetic rats showed no effect on the transcription rate of phosphorylase. As expected, diabetes (or insulin administration to diabetic animals) did not cause any alteration in the mRNA levels or in the transcription rate of hepatic glycogen synthase. The stability of phosphorylase mRNA was then examined using hepatocytes prepared from normal and diabetic rats. Diabetes caused a decrease in the half-life of phosphorylase mRNA from 14 h in normal hepatocytes to 6.5 h in diabetic hepatocyte. Insulin supplementation to the medium of diabetic hepatocytes increased the half-life of phosphorylase mRNA to a level comparable with normal values. This study indicates that the chronic effect of insulin on the activation of the total hepatic phosphorylase activity (and protein) is mediated through the stabilization of its mRNA levels.	UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON,SK S7N 5E5,CANADA	University of Saskatchewan								ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; BAHNAK BR, 1982, J BIOL CHEM, V257, P8775; BAI G, 1990, J BIOL CHEM, V265, P7843; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GABBAY RA, 1984, J BIOL CHEM, V259, P6052; GIFFIN BF, 1993, J HISTOCHEM CYTOCHEM, V41, P1849, DOI 10.1177/41.12.8245433; GORIN F, 1989, AM J PHYSIOL, V257, pC495, DOI 10.1152/ajpcell.1989.257.3.C495; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HOD Y, 1988, J BIOL CHEM, V263, P7747; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; KHANDELWAL RL, 1977, BIOCHEM J, V168, P541, DOI 10.1042/bj1680541; LARNER J, 1988, DIABETES, V37, P262, DOI 10.2337/diab.37.3.262; LAVOIE L, 1991, METABOLISM, V40, P1031, DOI 10.1016/0026-0495(91)90125-G; LEYLAND DM, 1991, BIOCHEM J, V278, P113, DOI 10.1042/bj2780113; MILLER TB, 1978, LIFE SCI, V23, P1083, DOI 10.1016/0024-3205(78)90670-7; MILLER TB, 1986, J IBOL CHEM, V261, P735; MOORE PS, 1989, MOL ENDOCRINOL, V3, P1724, DOI 10.1210/mend-3-11-1724; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NUTTALL FQ, 1989, ANAL BIOCHEM, V178, P311, DOI 10.1016/0003-2697(89)90644-1; OKUBO M, 1991, ARCH BIOCHEM BIOPHYS, V288, P126, DOI 10.1016/0003-9861(91)90173-G; PUGAZHENTHI S, 1990, BIOCHEM INT, V21, P651; PUGAZHENTHI S, 1993, MOL CELL BIOCHEM, V122, P77, DOI 10.1007/BF00925740; PUGAZHENTHI S, 1990, DIABETES, V39, P821, DOI 10.2337/diabetes.39.7.821; PUGAZHENTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1179, P271, DOI 10.1016/0167-4889(93)90082-Z; RAABO E, 1960, SCAND J CLIN LAB INV, V12, P402; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROESLER WJ, 1986, FEBS LETT, V195, P344, DOI 10.1016/0014-5793(86)80190-9; ROESLER WJ, 1986, ARCH BIOCHEM BIOPHYS, V244, P397, DOI 10.1016/0003-9861(86)90130-X; ROESLER WJ, 1990, MOL CELL BIOCHEM, V92, P99; ROESLER WJ, 1989, MOL CELL BIOCHEM, V87, P147; ROESLER WJ, 1987, ENDOCRINOLOGY, V121, P127; RULFS J, 1989, AM J PHYSIOL, V257, pE74, DOI 10.1152/ajpendo.1989.257.1.E74; SIDDLE K, 1973, BIOCHEM J, V132, P765, DOI 10.1042/bj1320765; STALFORS P, 1985, EUR J BIOCHEM, V149, P295; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; TAN AWH, 1975, BIOCHIM BIOPHYS ACTA, V410, P45, DOI 10.1016/0005-2744(75)90206-5; THOMAS JA, 1973, BIOCHIM BIOPHYS ACTA, V293, P84, DOI 10.1016/0005-2744(73)90378-1; van de Werve G, 1987, Diabetes Metab Rev, V3, P47	48	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24955	24960		10.1074/jbc.270.42.24955	http://dx.doi.org/10.1074/jbc.270.42.24955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559622	hybrid			2022-12-25	WOS:A1995TB46500056
J	TANIMURA, A; KURIHARA, K; RESHKIN, SJ; TURNER, RJ				TANIMURA, A; KURIHARA, K; RESHKIN, SJ; TURNER, RJ			INVOLVEMENT OF DIRECT PHOSPHORYLATION IN THE REGULATION OF THE RAT PAROTID NA+-K+-2CL(-) COTRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; K-CL COTRANSPORT; FLUID SECRETION; ACINAR-CELLS; BUMETANIDE-BINDING; NA/K/CL COTRANSPORTER; PROTEIN; PURIFICATION; INHIBITORS	We identify a 175-kDa membrane phosphoprotein (pp175) in rat parotid acini whose properties correlate well with the Na+-K+-2Cl(-) cotransporter previously characterized functionally and biochemically in this tissue. pp175 was the only phosphoprotein immunoprecipitated by an anti-Na+-K+-2Cl(-) cotransporter antibody and the only membrane protein whose phosphorylation state was conspicuously altered after a brief (45-s) exposure of acini to the beta-adrenergic agonist isoproterenol. Phosphopeptide mapping provided evidence for three phosphorylation sites on pp175, only one of which was labeled in response to isoproterenol treatment. The half-maximal effect of isoproterenol on phosphorylation of pp175 (approximate to 20 nM) was in excellent agreement with its previously demonstrated up regulatory effect on cotransport activity. Increased phosphorylation of pp175 was also seen following acinar treatment with a permeant cAMP analogue and with forskolin, conditions that have likewise been shown to up-regulate the cotransporter. Combined with earlier results from our laboratory, these data provide strong evidence that the up-regulation of the cotransporter by these agents is due to direct phosphorylation mediated by protein kinase A. ALF(4)(-) treatment, which results in an up regulation of cotransport activity comparable with that observed with isoproterenol (similar to 6-fold), caused a similar increase in phosphorylation of pp175. However, hypertonic shrinkage and treatment with the protein phosphatase inhibitor calyculin A, which also up-regulate the cotransporter (similar to 3-fold and similar to 6-fold, respectively) caused no change in the phosphorylation level. Furthermore, although acinar treatment with the muscarinic agonist carbachol results in a dramatic up-regulation of cotransport activity and a concomitant phosphorylation of pp175, no phosphorylation of pp175 was seen with the Ca2+-mobilizing agent thapsigargin, which is able to fully mimic the up-regulatory effect of carbachol on transport activity. Taken together, these results indicate that direct phosphorylation is only one of the mechanisms involved in secretagogue-induced regulation of the rat parotid Na+K+-2Cl(-) cotransporter.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Reshkin, Stephan/AAI-6680-2020	Reshkin, Stephan/0000-0001-9757-5908				CORCELLI A, 1991, J MEMBRANE BIOL, V120, P125, DOI 10.1007/BF01872395; Evans R. L., 1994, Molecular Biology of the Cell, V5, p116A; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; HAAS M, 1988, BIOCHIM BIOPHYS ACTA, V939, P131, DOI 10.1016/0005-2736(88)90054-5; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JOHNSON D A, 1987, P135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393, DOI 10.1152/ajpgi.1992.262.3.G393; MELVIN JE, 1987, BIOCHEM BIOPH RES CO, V145, P754, DOI 10.1016/0006-291X(87)91029-1; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; PAULAIS M, 1992, J BIOL CHEM, V267, P21558; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; RESHKIN SJ, 1993, J MEMBRANE BIOL, V136, P243, DOI 10.1007/BF02505766; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TORCHIA J, 1994, J BIOL CHEM, V269, P29778; TURNER RJ, 1993, ANN NY ACAD SCI, V694, P24, DOI 10.1111/j.1749-6632.1993.tb18339.x; TURNER RJ, 1990, J MEMBRANE BIOL, V113, P203, DOI 10.1007/BF01870072; TURNER RJ, 1988, J MEMBRANE BIOL, V102, P71, DOI 10.1007/BF01875354	23	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25252	25258		10.1074/jbc.270.42.25252	http://dx.doi.org/10.1074/jbc.270.42.25252			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559664	hybrid			2022-12-25	WOS:A1995TB46500098
J	ZHU, DH; CARDENAS, ME; HEITMAN, J				ZHU, DH; CARDENAS, ME; HEITMAN, J			MYRISTOYLATION OF CALCINEURIN-B IS NOT REQUIRED FOR FUNCTION OR INTERACTION WITH IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEXES IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CYCLOSPORINE-A; CATALYTIC SUBUNIT; GENE-PRODUCT; MOLECULAR CHARACTERIZATION; TYROSINE KINASES; BINDING SUBUNIT; AMINO TERMINUS; CYCLOPHILIN-A; SARCOMA-VIRUS	Calcineurin is a heterodimeric Ca2+/calmodulin-dependent protein phosphatase that regulates signal transduction and is the target of immunophilin-immunosuppressive drug complexes in T-lymphocytes and in yeast. Calcineurin is composed of a catalytic A subunit and a regulatory B subunit that is myristoylated at its amino terminus. We employed genetic and biochemical approaches to investigate the functional roles of myristoylation of calcineurin B (CNB1) in Saccharomyces cerevisiae, A calcineurin B mutant in which glycine 2 was substituted by alanine (CNB1-G2A) did not incorporate [H-3]myristate when expressed in yeast. Both wild-type calcineurin B and the CNB1-G2A mutant protein are partially associated with membranes and cytoskeletal structures; hence, myristoylation is not required for these associations. In several independent genetic assays of calcineurin functions (recovery from alpha-factor arrest, survival during cation stress, and viability of a calcineurin dependent strain), the nonmyristoylated CNB1-G2A mutant protein exhibited full biological activity. In vitro, both wild-type and CNB1-G2A mutant proteins formed complexes with both cyclophilin A-cyclosporin A (CsA) and FKBP12-FK506 that contained calcineurin A. Interestingly, expression of the nonmyristoylated CNB1-G2A mutant protein rendered yeast cells partially resistant to the immunosuppressant CsA, but not to FK506. This study demonstrates that calcineurin B myristoylation is not required for function, but may participate in inhibition by the cyclophilin A-CsA complex.	DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Heitman, Joseph/ABC-6006-2021					AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; ANGLISTER J, 1994, BIOCHEMISTRY-US, V33, P3540, DOI 10.1021/bi00178a010; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; BOSS MA, 1981, J VIROL, V40, P472, DOI 10.1128/JVI.40.2.472-481.1981; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; EGERTON M, 1993, YEAST, V9, P703, DOI 10.1002/yea.320090704; ENG WK, 1994, GENE, V151, P61, DOI 10.1016/0378-1119(94)90633-5; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOOR F, 1992, NATURE, V360, P682; FUKUI Y, 1989, ONCOGENE RES, V4, P283; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HADDY A, 1994, BIOCHEM BIOPH RES CO, V200, P1221, DOI 10.1006/bbrc.1994.1581; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HARLOW E, 1988, ANTIBODIES LABORATOR; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUSI H, 1994, J BIOL CHEM, V269, P14199; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONES DH, 1991, BIOTECHNIQUES, V10, P62; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JOTTE RM, 1994, J BIOL CHEM, V269, P16388; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LI W, 1993, J BIOL CHEM, V268, P14040; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; MANGER R, 1986, J VIROL, V59, P66, DOI 10.1128/JVI.59.1.66-72.1986; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; OLSON EN, 1986, J BIOL CHEM, V261, P2458; PAPADOPOULOS V, 1989, MOL CELL ENDOCRINOL, V63, P23, DOI 10.1016/0303-7207(89)90078-6; PAPADOPOULOS V, 1990, MOL CELL ENDOCRINOL, V74, P109, DOI 10.1016/0303-7207(90)90113-M; PARENT SA, 1993, J GEN MICROBIOL, V139, P2973, DOI 10.1099/00221287-139-12-2973; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; POLITINO M, 1990, J BIOL CHEM, V265, P7619; POLITINO M, 1987, J BIOL CHEM, V262, P10109; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UEKI K, 1993, J BIOL CHEM, V268, P6554; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; YE RR, 1992, EUR J BIOCHEM, V204, P713, DOI 10.1111/j.1432-1033.1992.tb16686.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	90	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24831	24838		10.1074/jbc.270.42.24831	http://dx.doi.org/10.1074/jbc.270.42.24831			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559604	hybrid			2022-12-25	WOS:A1995TB46500038
J	DEXAERDE, AD; SUPPLY, P; DUFOUR, JP; BOGAERTS, P; THINES, D; GOFFEAU, A; BOUTRY, M				DEXAERDE, AD; SUPPLY, P; DUFOUR, JP; BOGAERTS, P; THINES, D; GOFFEAU, A; BOUTRY, M			FUNCTIONAL COMPLEMENTATION OF A NULL MUTATION OF THE YEAST SACCHAROMYCES-CEREVISIAE PLASMA-MEMBRANE H+-ATPASE BY A PLANT H+-ATPASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTIANA-PLUMBAGINIFOLIA; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SHUTTLE VECTORS; EXPRESSION; PROLIFERATION; OVEREXPRESSION; IDENTIFICATION; CA-2+-ATPASE; MODULATION	In plants, the proton pump-ATPase (H+-ATPase) of the plasma membrane is encoded by a multigene family. The presence within an organ of several isoforms prevents a detailed enzymatic characterization of individual H+-ATPases. We therefore used the yeast Saccharomyces cerevisiae as a heterologous host for the expression of PMA2, an H+-ATPase isoform of Nicotiana plumbagini-folia. Yeast transformed by the plant pma2 was still able to grow under conditions where the yeast ATPase gene (PMA1) was either repressed or deleted. The transformed yeast strain was resistant to hygromycin, and its growth was prevented when the medium pH was lowered to 5.0. The N. plumbaginifolia PMA2 expressed in S. cerevisiae has unusual low K-m for ATP (23 mu M) and high pH optimum (6.8). Electron microscopic examination revealed PMA2 in internal structures of the karmellae type which proliferated when cell growth was arrested, either at a nonpermissive pH or at the stationary phase in a minimal medium. Under the latter conditions, subcellular fractionation on sucrose gradients revealed, in addition to the expected plant PMA2 peak linked to the plasma membrane fraction, a low density peak containing PMA2 and KAR2, an endoplasmic reticulum marker. These observations suggest that the partial internal accumulation of PMA2 occurs in membranes derived from the endoplasmic reticulum and largely depends on growth conditions.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain			de Kerchove d'Exaerde, Alban/R-6984-2019; Supply, Philip/A-9580-2019	de Kerchove d'Exaerde, Alban/0000-0002-0682-5877; Boutry, Marc/0000-0002-2315-6900; Supply, Philip/0000-0003-3690-3853				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BOUTRY M, 1989, BIOCHEM BIOPH RES CO, V162, P567, DOI 10.1016/0006-291X(89)92348-6; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; DEXAERDE AD, 1995, METHODS MOL GENETICS; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; HARRIS S, 1993, GENETICS, V135, P5; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MICHELET B, 1994, PLANT CELL, V6, P1375, DOI 10.1105/tpc.6.10.1375; MICHELET B, 1995, PLANT PHYSIOL, V108, P1, DOI 10.1104/pp.108.1.1; MORIAU L, 1993, PLANT MOL BIOL, V21, P955, DOI 10.1007/BF00023594; PALMGREN MG, 1988, PHYSIOL PLANTARUM, V74, P11, DOI 10.1111/j.1399-3054.1988.tb04934.x; PALMGREN MG, 1993, FEBS LETT, V317, P216, DOI 10.1016/0014-5793(93)81279-9; PALMGREN MG, 1994, J BIOL CHEM, V269, P3027; PEREZ C, 1992, J BIOL CHEM, V267, P1204; PETERS PH, 1978, PHYSIOL PLANTARUM, V46, P330; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; RAMOS RS, 1994, PLANT PHYSIOL, V105, P853, DOI 10.1104/pp.105.3.853; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; ROBERTS G, 1991, BIOCHIM BIOPHYS ACTA, V1064, P131, DOI 10.1016/0005-2736(91)90419-9; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TRECO DA, 1989, CURRENT PROTOCOLS MO; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	49	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23828	23837		10.1074/jbc.270.40.23828	http://dx.doi.org/10.1074/jbc.270.40.23828			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559560	hybrid			2022-12-25	WOS:A1995RY90900089
J	NAKAE, K; NAKAJIMA, K; INAZAWA, J; KITAOKA, T; HIRANO, T				NAKAE, K; NAKAJIMA, K; INAZAWA, J; KITAOKA, T; HIRANO, T			ERM, A PEA3 SUBFAMILY OF ETS TRANSCRIPTION FACTORS, CAN COOPERATE WITH C-JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; LONG TERMINAL REPEAT; AMP RESPONSE ELEMENT; DNA-BINDING; CYCLIC-AMP; ONCOGENE FAMILY; SOMATOSTATIN GENE; LEUKEMIA-VIRUS; NUCLEAR FACTOR; FACTOR P62TCF	A human cDNA clone for ERM, a member of the ets gene family, has been obtained by polymerase chain reaction with degenerate primers corresponding to highly conserved regions within an Ets DNA binding domain. ERM mRNA is expressed ubiquitously. The gene was mapped to chromosome 3q27. In in vivo transient-expression assays, ERM induced transcription more efficiently from a synthetic element containing both an ets-binding site (EBS) and a cyclic AMP response element (CRE) than from one containing an EBS alone. The activation of a synthetic EBS-CRE site by ERM was likely to involve a leucine zipper protein capable of dimerizing with CRE-BP1 leucine zipper. Indeed, ERM and c-Jun synergistically activated the EBS-CRE without making an apparent ternary complex. The synergy between c-Jun and ERM may be attributed to the enhancing effect of c-Jun on the transcription activity of ERM, because c Jun increased ERM transcription activity by more than 20-fold in an assay system using a variety of fusion proteins between a Ga14 DNA-binding domain and a portion of ERM. This enhancing effect of c-Jun required the amino-terminal portion of ERM.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT ONCOL,DIV MOLEC ONCOL,SUITA,OSAKA 565,JAPAN; KYOTO PREFECTURAL UNIV,DEPT HYG,KYOTO 602,JAPAN	Osaka University; Kyoto Prefectural University			Hirano, Toshio/C-8194-2009					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1993, ONCOGENE, V8, P3375; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIEDEN JM, 1993, ANNU REV IMMUNOL, V11, P539; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTE D, 1994, ONCOGENE, V9, P1397; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sambrook J, 1989, MOL CLONING LABORATO; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	67	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23795	23800		10.1074/jbc.270.40.23795	http://dx.doi.org/10.1074/jbc.270.40.23795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559555	hybrid			2022-12-25	WOS:A1995RY90900084
J	CASINI, T; GRAF, T				CASINI, T; GRAF, T			BICISTRONIC RETROVIRAL VECTOR REVEALS CAPACITY OF V-ERBA TO INDUCE ERYTHROLEUKEMIA AND TO COOPERATE WITH V-MYB	ONCOGENE			English	Article						BICISTRONIC RETROVIRUS; AVIAN ACUTE LEUKEMIA; VIRUS; THYROID HORMONE RECEPTOR; ERYTHROBLASTOSIS; ONCOGENE COOPERATIVITY	AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN ERYTHROID-CELLS; LEUKEMIA-VIRUS; THYROID-HORMONE; MONOCLONAL-ANTIBODIES; SELF-RENEWAL; DIFFERENTIATION; E26; ONCOGENES; GENE	Previous studies have shown that v-erbA and v-myb can induce the proliferation of avian erythroid cells in culture, To study the combined effects of v-erbA and v-myb, the two oncogenes were engineered into a retrovirus bicistronic vector with an internal ribosomal entry site (IRES) or into a vector with a splice acceptor (SPL), This allowed coexpression of the two proteins and a comparison with the same vector containing either v-erbA or v-myb only, Both the erbA IRES and the erbA/myb IRES virus constructs transformed erythroid cells after infection of bone marrow or blastoderm cultures. The erbA/myb IRES virus exhibited a 5-10-fold higher transformed colony forming efficiency than the erbA IRES virus in the blastoderm assay, Surprisingly, when injected into chicken embryos in the presence of helper virus, both viruses induced an erythroleukemia in about half of the animals, In contrast, no leukemia was observed with a myb IRES virus, with spliced vectors containing v-erbA alone or v-erbA in combination with v-myb nor with erbA IRES and erbA/myb IRES viruses produced in the absence of helper virus, The average latency of leukemia induction was shorter for the erbA/myb IRES virus (3.5 weeks) than for the erbA IRES virus (5 weeks), Nevertheless, for both leukemic blasts retained full factor growth, These results show that v-erbA is capable of inducing an erythroleukemia when expressed by a high titer bicistronic retrovirus under conditions of virus spreading and that its in vitro and in vivo transforming potential can be enhanced by v-myb.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; DAMM K, 1969, NATURE, V339, P593; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Frykberg L, 1988, Oncogene Res, V3, P313; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GOLDBERG Y, 1988, EMBO J, V7, P269; GRAESSER F A, 1991, Molecular and Cellular Biology, V11, P3987; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; KAHN P, 1986, CELL, V44, P349; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LUSCHER B, 1990, GENE DEV, V4, P2239; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER AW, 1992, MOL VIROLOGY PRACTIC; STOKER AW, 1909, J VIROL; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1019	1026						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566959				2022-12-25	WOS:A1995RX18000002
J	HILAIRE, N; SALVAYRE, R; THIERS, JC; BONNAFE, MJ; NEGRESALVAYRE, A				HILAIRE, N; SALVAYRE, R; THIERS, JC; BONNAFE, MJ; NEGRESALVAYRE, A			THE TURNOVER OF CYTOPLASMIC TRIACYLGLYCEROLS IN HUMAN FIBROBLASTS INVOLVES 2 SEPARATE ACYL-CHAIN LENGTH-DEPENDENT DEGRADATION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID STORAGE MYOPATHY; LYMPHOID-CELL LINES; FATTY-ACIDS; CULTURED FIBROBLASTS; WOLMANS DISEASE; LYSOSOMAL STORAGE; METABOLISM; CARBOXYLESTERASES; PROTEINS; PATIENT	Cultured fibroblasts from patients affected with the genetic metabolic disorder named neutral Lipid storage disease (NLSD) exhibit a dramatic accumulation of cytoplasmic triacylglycerols (Radom, J., Salvayre, R., Negre, A., Maret, A., and Douste-Blazy, L. (1987) Eur. J. Biochem, 164, 703-708), We compared here the metabolism of radiolabeled short-, medium- and long-chain fatty acids in these cells, Short/medium-chain fatty acids (C4-C10) were incorporated into polar lipids (60-80%) and triacylglycerols (20-40%) at a lower rate (5-10 times lower) than long-chain fatty acids, Pulse chase experiments allowed to evaluate the degradation rate of cytoplasmic triacylglycerols in normal and NLSD fibroblasts and to discriminate between two catabolic pathways of cytoplasmic triacylglycerols, Short/medium-chain (C4-C10) triacylglycerols were degraded at a normal rate in NLSD fibroblasts, whereas long-chain (C12 and longer) triacylglycerols remained undegraded, These data are confirmed by mass analysis, The use of diethylparanitrophenyl phosphate (E600) and parachloromercuribenzoate (PCMB) inhibitors allows to discriminate between the two triacylglycerol degradation pathways, E600 inhibited selectively the in situ degradation of short/medium-chain triacylglycerols without inhibition of the degradation of long-chain triacylglycerols, whereas PCMB inhibited selectively the in situ hydrolysis of long-chain triacylglycerols without affecting the degradation of long-chain triacylglycerols, This was correlated with the in vitro properties of cellular triacylglycerol-hydrolyzing enzymes characterized by their susbtrate specificity and their susceptibility to inhibitors; the neutral lipase specific to long-chain triacylglycerols is inhibited by PCMB, but not by E600, in contrast to short/medium-chain lipase, which is inhibited by E600 but not by PCMB. The data of in vitro and in situ experiments suggest the existence in fibroblasts of two separate acyl chain length-dependent pathways involved in the degradation of cytoplasmic triacylglycerols, one mediated by a neutral long chain lipase and another one mediated by a short/medium-chain lipase.	UNIV TOULOUSE 3,FAC MED,DEPT BIOCHEM,F-31054 TOULOUSE,FRANCE; UNIV TOULOUSE 3,FAC MED,INSERM,CJF9206,F-31054 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Negre-Salvayre, Anne/0000-0003-2136-5706				BECKER A, 1994, ARTERIOSCLER THROMB, V14, P1346, DOI 10.1161/01.ATV.14.8.1346; BELFRAGE P, 1969, J LIPID RES, V10, P341; BREMER J, 1982, J LIPID RES, V23, P243; BROCKERHOFF H, 1974, LIPOLYTIC ENZYMES, P83; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; CHEN PS, 1956, ANAL CHEM, V18, P1756; COHEN JA, 1967, METHOD ENZYMOL, V11, P687; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9731; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DIDONATO S, 1988, NEUROLOGY, V38, P1107; DIXON M, 1962, ENZYMES, P315; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FOLCH J, 1957, J BIOL CHEM, V226, P497; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GATT S, 1988, BIOCHIM BIOPHYS ACTA, V958, P130, DOI 10.1016/0005-2760(88)90254-8; GOLDSTEIN JL, 1979, ANN REV BIOCH, V46, P897; HILAIRE N, 1993, FEBS LETT, V328, P230, DOI 10.1016/0014-5793(93)80933-L; HILAIRE N, 1994, BIOCHEM J, V297, P467, DOI 10.1042/bj2970467; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; KASURINEN J, 1992, J BIOL CHEM, V267, P6563; LENGLE E, 1973, BIOCHIM BIOPHYS ACTA, V296, P411, DOI 10.1016/0005-2760(73)90099-4; LEVY E, 1981, BIOCHIM BIOPHYS ACTA, V664, P316, DOI 10.1016/0005-2760(81)90054-0; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORAND O, 1982, BIOCHIM BIOPHYS ACTA, V711, P539, DOI 10.1016/0005-2760(82)90070-4; MOSKOWITZ MS, 1967, LIPID METABOLISM TIS, P49; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; MYERS DK, 1960, ENZYMES, P475; NEGRE A, 1988, BIOCHIM BIOPHYS ACTA, V963, P340, DOI 10.1016/0005-2760(88)90300-1; NEGRE A, 1984, ENZYME, V31, P241, DOI 10.1159/000469533; NEGRE A, 1986, J INHERIT METAB DIS, V9, P193, DOI 10.1007/BF01799458; NEGRE A, 1986, ANAL BIOCHEM, V145, P398; NEGRE A, 1988, COMP BIOCH PHYSL, V91, P78; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PATRICK AD, 1973, LYSOSOMES STORAGE DI, P453; POWNALL HJ, 1989, CHEM PHYS LIPIDS, V50, P191, DOI 10.1016/0009-3084(89)90050-9; RADOM J, 1989, BIOCHIM BIOPHYS ACTA, V1005, P130, DOI 10.1016/0005-2760(89)90178-1; RADOM J, 1988, BIOL CELL, V62, P39; RADOM J, 1987, BIOCHIM BIOPHYS ACTA, V920, P131, DOI 10.1016/0005-2760(87)90252-9; RADOM J, 1990, BIOCHEM J, V269, P107, DOI 10.1042/bj2690107; RADOM J, 1987, EUR J BIOCHEM, V164, P703, DOI 10.1111/j.1432-1033.1987.tb11183.x; SALVAYRE R, 1989, FEBS LETT, V250, P35, DOI 10.1016/0014-5793(89)80679-9; SALVAYRE R, 1987, EUR J BIOCHEM, V170, P453, DOI 10.1111/j.1432-1033.1987.tb13721.x; SCHNEEBERGER EE, 1971, EXP CELL RES, V69, P193, DOI 10.1016/0014-4827(71)90325-9; WILLIAMS ML, 1991, BIOCHIM BIOPHYS ACTA, V1096, P162, DOI 10.1016/0925-4439(91)90055-E; YAN BF, 1994, J BIOL CHEM, V269, P29688	48	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27027	27034		10.1074/jbc.270.45.27027	http://dx.doi.org/10.1074/jbc.270.45.27027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592952	hybrid			2022-12-25	WOS:A1995TE58300052
J	LIU, JS; KUO, SR; BROKER, TR; CHOW, LT				LIU, JS; KUO, SR; BROKER, TR; CHOW, LT			THE FUNCTIONS OF HUMAN PAPILLOMAVIRUS TYPE-11 E1, E2, AND E2C PROTEINS IN CELL-FREE DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PAPILLOMAVIRUS; TRANSCRIPTIONAL ACTIVATOR; BINDING-SITES; TRANSIENT REPLICATION; T-ANTIGEN; ORIGIN; REQUIRES; ENHANCER; SEQUENCE; INVITRO	We examined the functions of human papillomavirus type 11 (HPV-11) El and E2 proteins purified from Sf9 cells infected with recombinant baculoviruses in cell-free HPV-11 origin (ori) replication. The El protein binds specifically to a wild type but not tb a mutated sequence in the ori spanning nucleotide position 1. It also has a relatively strong affinity for nonspecific DNA, A neutralizing antiserum directed against the amino-terminal one-third of the El protein totally abolishes initiation and elongation, suggesting that it functions as an initiator and a helicase at the replication fork. An antiserum against the carboxyl-terminal portion of El protein abolished replication only when added prior to initiation, Thus this portion of El is hidden in the replication complexes. The HPV-11 E2 protein appears not to be essential for elongation, but it must be present in the preinitiation complex for the El protein to recruit host DNA replication machinery to the ori. E2 antiserum added after preincubation in the absence of the cell extracts totally abolished replication, An identical conclusion is also reached for the bovine papillomavirus type 1 E2 protein. Finally, the HPV-11 E2C protein lacking the transacting domain of the full-length E2 protein partially inhibits E2-dependent ori replication.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; BLITZ IL, 1991, J VIROL, V65, P649, DOI 10.1128/JVI.65.2.649-656.1991; BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; BREAM GL, 1993, J VIROL, V67, P2655, DOI 10.1128/JVI.67.5.2655-2663.1993; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CHIANG CM, 1992, J VIROL, V66, P5224, DOI 10.1128/JVI.66.9.5224-5231.1992; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; CHIN MT, 1988, J VIROL, V62, P2994, DOI 10.1128/JVI.62.8.2994-3002.1988; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DELVECCHIO AM, 1992, J VIROL, V66, P5949, DOI 10.1128/JVI.66.10.5949-5958.1992; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, P99; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; FRATTINI MG, 1994, VIROLOGY, V204, P799, DOI 10.1006/viro.1994.1596; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; GOPALAKRISHNAN V, 1994, P NATL ACAD SCI USA, V91, P9597, DOI 10.1073/pnas.91.20.9597; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HEDGE RS, 1992, NATURE, V359, P505; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; HOLT SE, 1994, J VIROL, V68, P1094, DOI 10.1128/JVI.68.2.1094-1102.1994; HUGHES FJ, 1993, NUCLEIC ACIDS RES, V21, P5817, DOI 10.1093/nar/21.25.5817; KUO SR, 1994, J BIOL CHEM, V269, P24058; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; LUSKY M, 1993, J BIOL CHEM, V268, P15795; MACPHERSON P, 1994, VIROLOGY, V204, P403, DOI 10.1006/viro.1994.1544; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MCBRIDE AA, 1989, J BIOL CHEM, V266, P18411; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOSKALUK CA, 1989, VIROLOGY, V169, P236, DOI 10.1016/0042-6822(89)90062-7; MULLER F, 1994, J BIOL CHEM, V269, P17086; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; REMM M, 1992, NUCLEIC ACIDS RES, V20, P6015, DOI 10.1093/nar/20.22.6015; ROTENBERG MO, 1989, VIROLOGY, V172, P468, DOI 10.1016/0042-6822(89)90189-X; RUSSELL J, 1995, J VIROL, V69, P651, DOI 10.1128/JVI.69.2.651-660.1995; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SPALHOLZ BA, 1993, VIROLOGY, V193, P201, DOI 10.1006/viro.1993.1116; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STOLER MH, 1989, VIROLOGY, V172, P331, DOI 10.1016/0042-6822(89)90135-9; SVERDRUP F, 1995, J VIROL, V69, P1319, DOI 10.1128/JVI.69.2.1319-1323.1995; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	55	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27283	27291		10.1074/jbc.270.45.27283	http://dx.doi.org/10.1074/jbc.270.45.27283			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592989	hybrid			2022-12-25	WOS:A1995TE58300089
J	MIURA, Y; TAM, T; IDO, A; MORINAGA, T; MIKI, T; HASHIMOTO, T; TAMAOKI, T				MIURA, Y; TAM, T; IDO, A; MORINAGA, T; MIKI, T; HASHIMOTO, T; TAMAOKI, T			CLONING AND CHARACTERIZATION OF AN ATBF1 ISOFORM THAT EXPRESSES IN A NEURONAL DIFFERENTIATION-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; ZINC-FINGER; GENE-EXPRESSION; HOMEODOMAIN; DROSOPHILA; ZFH-2; REPLICATION; GENOMES; MOTIFS; BOX	The human ATBF1 cDNA reported previously, now termed ATBF1-B, encodes a 306-kDa protein containing 4 homeodomains and 18 zinc fingers including one pseudo zinc finger motif, Here, we report the isolation of a second ATBF1 cDNA, 12 kilobase pairs long, termed ATBF1-A. The deduced ATBF1-A protein is 404 kDa in size and differs from ATBF1-B by a 920-amino acid extention at the N terminus, Analysis of 5'-genomic sequences showed that the 5'-noneoding sequences specific to ATBF1-A and ATBF1-B transcripts were contained in distinct exons that could splice to a downstream exon common to the ATBF1-A and ATBF1-B mRNAs. The expression of ATBF1-A transcripts increased to high levels when P19 and NT2/D1 cells were treated with retinoic acid to induce neuronal. differentiation, Preferential expression of ATBF1-A transcripts was also observed in developing mouse brain. Transient transfection assays showed that the 5,5-kilobase pair sequence upstream of the ATBF1-A-specific exon (exon 2) supported expression of the linked chloramphenicol acetyltransferase gene in neuronal cells derived from P19 cells but not in undifferentiated P19 or in F9 cells, which do not differentiate into neurons. These results showed that ATBF1-A and ATBF1-B transcripts are generated by alternative promoter usage combined with alternative splicing and that the ATBF1-A-specific promoter is activated during neuronal differentiation.	UNIV CALGARY, FAC MED, DEPT MED BIOCHEM, CALGARY, AB T2N 4N1, CANADA; NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 1, NAGASAKI 852, JAPAN; SNOW BRAND MILK PROD CO LTD, LIFE SCI RES INST, ISHIBASHI, TOCHIGI 32905, JAPAN; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; HYOGO MED UNIV, DEPT GENET, NISHINOMIYA, HYOGO 659, JAPAN	University of Calgary; Nagasaki University; Snow Brand Milk Products Co., Ltd.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hyogo College of Medicine; University of Hyogo								ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASHIMOTO T, 1992, MECH DEVELOP, V39, P125, DOI 10.1016/0925-4773(92)90031-E; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; IDO A, 1994, DEV BIOL, V163, P184, DOI 10.1006/dbio.1994.1134; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J, 1989, MOL CLONING LABORATO; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395	26	75	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26840	26848		10.1074/jbc.270.45.26840	http://dx.doi.org/10.1074/jbc.270.45.26840			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592926	hybrid			2022-12-25	WOS:A1995TE58300026
J	PAGES, G; STANLEY, ER; LE GALL, M; BRUNET, A; POUYSSEGUR, J				PAGES, G; STANLEY, ER; LE GALL, M; BRUNET, A; POUYSSEGUR, J			THE MOUSE P44 MITOGEN-ACTIVATED PROTEIN-KINASE (EXTRACELLULAR SIGNAL-REGULATED KINASE-1) GENE - GENOMIC ORGANIZATION AND STRUCTURE OF THE 5'-FLANKING REGULATORY REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR GENE; INDUCED TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; PROMOTER REGION; BINDING ACTIVITY; MAP KINASES; 5' TERMINI; EXPRESSION; SEQUENCE; INSULIN	Mitogen-activated protein kinase (MAPK) or extracellular signal-regulated kinase are ubiquitous kinases conserved from fungi to mammals. Their activity is regulated by phosphorylation on both threonine and tyrosine, and they play a crucial role in the regulation of proliferation and differentiation. We report here the cloning of the murine p44 MAP kinase (extracellular signal-regulated kinase 1) gene, the determination of its intron/exon boundaries, and the characterization of its promoter. The gene spans approximately eight kilo-bases promoter. bases (kb) and can be divided into nine exons and eight introns, each coding region exon containing from one to three of the highly conserved protein kinase domains. Primer extension analysis reveals the existence of two major start sites of transcription located at -183 and -186 base pairs (bp) as well as four discrete start sites for transcription located at -178, -192, -273, and -292 bp of the initiation of translation. However, the start site region lacks TATA-like sequences but does contain initiator-like sequences proximal to the major start sites obtained by primer extension. 1 kb of the promoter region has been sequenced. It contains three putative TATA boxes far upstream of the main start sites region, one AP-1 box, one AP-2 box, one Malt box, one GAGA box, one half serum-responsive element, and putative binding sites for Spl (five), GC-rich binding factor (five), CTF-NF1 (one), Myb (one), p53 (two), Ets-1 (one), NF-IL6 (two), MyoD (two), Zeste (one), and hepatocyte nuclear factor-5 (one). To determine the sites critical for the function of the p44 MAPK promoter, we constructed a series of chimeric genes containing variable regions of the 5'-flanking sequence of p44 MAPK gene and the coding region for luciferase. Activity of the promoter, measured by its capacity to direct expression of a luciferase reporter gene, is strong, being comparable with the activity of the Rous sarcoma virus promoter. Progressive deletions of the similar to 1 kb (-1200/-78) promoter region allowed us to define a minimal region of 186 bp (-284/ -78) that has maximal promoter activity. Within this context, deletion of the AP-2 binding site reduces by 30-40% the activity of the promoter. Further deletion of this minimal promoter that removes the major start sites (-167/-78) surprisingly preserves promoter activity, This result implicates a major role of this region that contains the Spl sites. Finally, removal of the major start sites of transcription as well as the Spl sites reveals additional promoter activity at the upstream transcription minor start sites (-240/-167), an activity that is enhanced by the upstream cis-acting elements, In summary, our findings reveal a complex pattern of transcriptional of the mouse p44 MAPK promoter.			PAGES, G (corresponding author), CTR BIOCHIM, CNRS, UMR 134, PARC VALROSE, F-06108 NICE 2, FRANCE.		Stanley, Evan R/J-9154-2013; Pages, Gilles/N-7135-2017; Le Gall, Maude/W-2593-2019; Le Gall, Maude/C-3917-2017	Stanley, Evan R/0000-0002-2910-2065; Le Gall, Maude/0000-0002-5372-4585; Le Gall, Maude/0000-0002-5372-4585	NCI NIH HHS [CA 32551, CA 26504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026504, R01CA032551, R01CA026504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUNET A, 1994, ONCOGENE, V9, P3379; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LI L, 1994, ONCOGENE, V9, P647; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAZER S, 1986, J BIOL CHEM, V261, P4685; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VILA J, 1988, J CELL PHYSIOL, V135, P285, DOI 10.1002/jcp.1041350216; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514	61	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					26986	26992		10.1074/jbc.270.45.26986	http://dx.doi.org/10.1074/jbc.270.45.26986			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592946	hybrid			2022-12-25	WOS:A1995TE58300046
J	PIXLEY, FJ; LEE, PSW; DOMINGUEZ, MG; EINSTEIN, DB; STANLEY, ER				PIXLEY, FJ; LEE, PSW; DOMINGUEZ, MG; EINSTEIN, DB; STANLEY, ER			A HETEROMORPHIC PROTEIN-TYROSINE-PHOSPHATASE, PTP-PHI, IS REGULATED BY CSF-1 IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN-PLACENTA; SH2 DOMAIN; EXPRESSION; CLONING; CELL; RNA; PURIFICATION; DROSOPHILA; SEQUENCE	A novel protein-tyrosine phosphatase, PTP phi, was cloned from a murine macrophage cDNA library, As a result of alternative splicing, macrophage PTP phi mRNAs are predicted to encode two membrane-spanning molecules and a cytosolic enzyme with identical catalytic domains, The membrane spanning forms differ in the juxtamembrane region, while a start codon downstream of this region is utilized in the translation of the putative cytosolic form. Expression of PTP phi, mRNA is low and restricted to macrophage cell lines, macrophage-rich tissues, and brain, kidney, and heart. The mRNA in macrophages and heart is similar to 2.8 kilobases (kb), However, a similar to 5.5-kb transcript in brain and kidney indicates a fourth isoform encoding a large extracellular domain. The similar to 5.5-kb PTP phi brain mRNA encodes the mouse homolog of GLEPP1, a recently reported glomerular epithelial protein. The level of expression of the mRNA encoding the cytosolic form was very low, and only the membrane-spanning proteins (43 and 47 kDa) could be detected in macrophages. Following addition of colony stimulating factor-1 to quiescent BAC1.2F5 macrophages, PTP phi mRNA and protein were down-regulated. The restricted expression of the shorter isoforms of PTP phi and their regulation by colony stimulating factor-1 in macrophages suggest that PTP phi may play a role in mononuclear phagocyte survival, proliferation, and/or differentiation.	ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Stanley, Evan R/J-9154-2013; Pixley, Fiona/ABD-5567-2020	Stanley, Evan R/0000-0002-2910-2065; Pixley, Fiona/0000-0002-1571-2532	NATIONAL CANCER INSTITUTE [R01CA026504, R37CA026504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26504] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BOOCOCK CA, 1992, J LEUKOCYTE BIOL, V51, P535, DOI 10.1002/jlb.51.6.535; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HUME DA, 1984, ANAT REC, V210, P503, DOI 10.1002/ar.1092100311; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEI L, 1994, J BIOL CHEM, V269, P12254; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OUN SH, 1993, J BIOL CHEM, V268, P23964; PAN MG, 1993, J BIOL CHEM, V268, P19284; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1991, J BIOL CHEM, V266, P19688; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	47	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27339	27347		10.1074/jbc.270.45.27339	http://dx.doi.org/10.1074/jbc.270.45.27339			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7592997	hybrid			2022-12-25	WOS:A1995TE58300097
J	POLVERINO, A; FROST, J; YANG, PR; HUTCHISON, M; NIEMAN, AM; COBB, MH; MARCUS, S				POLVERINO, A; FROST, J; YANG, PR; HUTCHISON, M; NIEMAN, AM; COBB, MH; MARCUS, S			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE CASCADES BY P21-ACTIVATED PROTEIN-KINASES IN CELL-FREE-EXTRACTS OF XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAP KINASE; SIGNAL TRANSDUCTION; RAS; FAMILY; YEAST; CDNA	In the evolutionarily distant yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe, genetic evidence suggests that activation of pheromone induced mitogen-activated protein kinase (MAPK) cascades involves the function of the p21(cdc42/rac1)-activated protein kinases (PAKs) Ste20 and Shk1, respectively. In this report, we show that purified Ste20 and Shk1 were each capable of inducing p42(MAPK) activation in cell-free extracts of Xenopus laevis oocytes, while a mammalian Ste20/Shk1-related protein kinase, p65(pak) (Pak1), did not induce activation of p42(MAPK). In contrast to p42(MAPK), activation of JNK/SAPK in Xenopus oocyte ex tracts was induced by both the yeast Ste20 and Shk1 kinases, as well as by mammalian Pak1. Our results demonstrate that MAPK cascades that are responsive to PAKs are conserved in higher eukaryotes and suggest that distinct PAKs may regulate distinct MAPK modules.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; AMGEN INC,DEPT PROT STRUCT,THOUSAND OAKS,CA 91320; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of Texas System; UTMD Anderson Cancer Center; Amgen; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Frost, Jeffrey/0000-0001-9722-1536; Neiman, Aaron/0000-0002-6600-6996; Cobb, Melanie/0000-0003-0833-5473				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENGLISH JM, 1995, IN PRESS J BIOL CHEM, V270; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MAUSER E, 1994, NATURE, V367, P40; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rose MD., 1990, METHODS YEAST GENETI; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	41	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26067	26070		10.1074/jbc.270.44.26067	http://dx.doi.org/10.1074/jbc.270.44.26067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592806	hybrid			2022-12-25	WOS:A1995TC97800013
J	REDDY, SPM; CHUU, YJ; LAO, PN; DONN, J; ANN, DK; WU, R				REDDY, SPM; CHUU, YJ; LAO, PN; DONN, J; ANN, DK; WU, R			EXPRESSION OF HUMAN SQUAMOUS-CELL DIFFERENTIATION MARKER, SPR1, IN TRACHEOBRONCHIAL EPITHELIUM DEPENDS ON JUN AND TRE MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHORBOL ESTER; GENE-TRANSCRIPTION; DNA-BINDING; FOS; AP-1; COLLAGENASE; TPA; KERATINOCYTES; INDUCTION	Tracheobronchial epithelial (TBE) cells that normally do not express the squamous cell differentiation marker gene, SPR1, can be induced to produce it by 12-O-tetradecanoylphorbol-13-acetate (TPA), The regulation of SPR1 gene expression by TPA occurs, in part, at the transcriptional level in primary human and monkey TBE cells, Using a transient transfection assay, we observed that TPA stimulates the activity of the reporter gene, chloramphenicol acetyltransferase, by 2-4-fold in transfected TBE cells, However, this chloramphenicol acetyltransferase activity is cell type specific with significantly less activity in transformed epithelial cell lines and no activity in non-epithelial cell types, TPA-dependent stimulation can also be demonstrated by cotransfection with plasmid DNAs that overexpress the JUN family of proteins, especially c-JUN. Overexpression of c-JUN and TPA treatment synergistically stimulate the SPR1 promoter activity by more than 40-fold. Deletion analysis of the promoter region demonstrates that the DNA fragment of the first 98 base pairs of the 5'-flanking region contains the basal promoter activity, while the region between -162 and -96 contains the cis-enhancer elements for both the basal and TPA/c-JUN-stimulating promoter activities, This observation is supported by in vivo genomic footprinting studies that reveal persistent protections in the following motifs of this region: -141 TRE, -131 GT, -123 ETS-like, and -111 TRE-like motifs and in the enhanced protections in -141 TRE and -111 TRE-like motifs in cells after the TPA treatment. Site directed mutagenesis in this region demonstrates the involvement of both -141 TRE and -111 THE-like motifs in TPA/c-JUN-dependent stimulation as well as enhanced basal transcriptional activity, However, it is primarily the -111 TRE-like motif that is involved in the mediation of the enhanced basal promoter activity of the human SPR1 gene, These results are further supported by gel mobility shift assays that demonstrate the involvement of c-JUN and these TRE motifs in the formation of the DNA-protein complex.	UNIV CALIF DAVIS, CALIF REG PRIMATE RES CTR, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, SCH MED, DEPT INTERNAL MED, DAVIS, CA 95616 USA; UNIV SO CALIF, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Southern California					NHLBI NIH HHS [HL35635] Funding Source: Medline; NIDCR NIH HHS [DE10742] Funding Source: Medline; NIEHS NIH HHS [ES06230] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035635, R01HL035635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006230] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AN G, 1993, J CELL PHYSIOL, V157, P562, DOI 10.1002/jcp.1041570316; AN G, 1993, J BIOL CHEM, V268, P10977; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1991, MOL ASPECTS CELLULAR, V6, P295; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; HARRIS CC, 1972, JNCI-J NATL CANCER I, V48, P743; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; JETTEN AM, 1992, J NATL CANCER INVSTM, V18, P93; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; RADZIOCH D, 1987, MOL CELL BIOL, V7, P595, DOI 10.1128/MCB.7.2.595; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; ROBINSON CB, 1991, J TISSUE CULTURE MET, V13, P95; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TESFAIGZI J, 1995, J CELL PHYSIOL, V164, P571, DOI 10.1002/jcp.1041640315; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WU R, 1986, IN VITRO MODELS RESP, P1	42	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26451	26459		10.1074/jbc.270.44.26451	http://dx.doi.org/10.1074/jbc.270.44.26451			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592861	hybrid			2022-12-25	WOS:A1995TC97800068
J	SCHORK, SM; THUMM, M; WOLF, DH				SCHORK, SM; THUMM, M; WOLF, DH			CATABOLITE INACTIVATION OF FRUCTOSE-1,6-BISPHOSPHATASE OF SACCHAROMYCES-CEREVISIAE - DEGRADATION OCCURS VIA THE UBIQUITIN PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; CONJUGATING ENZYMES; PROTEIN-DEGRADATION; MULTIFUNCTIONAL PROTEINASE; INVIVO FUNCTION; CELL-SURVIVAL; YEAST; PROTEASOME; MUTANTS; COMPLEX	Catabolite inactivation of fructose-1,6-bisphosphatase (EBPase), a key enzyme in gluconeogenesis, is due to phosphorylation and subsequent degradation in the yeast Saccharomyces cerevisiae. The degradation process of the enzyme had been shown to depend on the action of the proteasome. Here we report that components of the ubiquitin pathway target FBPase to proteolysis. Upon glucose addition to yeast cells cultured on nonfermentable carbon sources FBPase is ubiquitinated in vivo. A multiubiquitin chain containing isopeptide linkages at Lys(48) of ubiquitin is attached to FBPase. Formation of a multiubiquitin chain is a prerequisite for the degradation of FBPase. Catabolite degradation of FBPase is dependent on the ubiquitin-conjugating enzymes Ubc1, Ubc4, and Ubc5. The 26 S proteasome is involved in the degradation process.	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY	University of Stuttgart			Thumm, Michael/A-8033-2015	Thumm, Michael/0000-0003-3238-4857				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CIECHANOVER A, 1994, BIOL CHEM H-S, V375, P565; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1992, MOL CELLULAR BIOL YE, P539; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; MAMROUDKIDRON E, 1994, FEBS LETT, V337, P239, DOI 10.1016/0014-5793(94)80199-1; MAZON MJ, 1982, J BIOL CHEM, V257, P1128; MOLANO J, 1974, EUR J BIOCHEM, V44, P213, DOI 10.1111/j.1432-1033.1974.tb03475.x; MULLER D, 1981, BIOCHEM BIOPH RES CO, V103, P926, DOI 10.1016/0006-291X(81)90899-8; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WOLF DH, 1979, EUR J BIOCHEM, V98, P375, DOI 10.1111/j.1432-1033.1979.tb13197.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZUBENKO GS, 1979, P NATL ACAD SCI USA, V76, P4581, DOI 10.1073/pnas.76.9.4581	49	95	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26446	26450		10.1074/jbc.270.44.26446	http://dx.doi.org/10.1074/jbc.270.44.26446			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592860	hybrid			2022-12-25	WOS:A1995TC97800067
J	LANGLOIS, WJ; SASAOKA, T; SALTIEL, AR; OLEFSKY, JM				LANGLOIS, WJ; SASAOKA, T; SALTIEL, AR; OLEFSKY, JM			NEGATIVE FEEDBACK-REGULATION AND DESENSITIZATION OF INSULIN-STIMULATED AND EPIDERMAL GROWTH FACTOR-STIMULATED P21(RAS) ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE EXCHANGE FACTOR; GUANINE-NUCLEOTIDES; TYROSINE KINASE; SUBSTRATE RECOGNITION; SIGNAL TRANSDUCTION; RAS; PROTEIN; RECEPTOR; GRB2; P21RAS	Insulin and epidermal growth factor receptors transmit signals for cell proliferation and gene regulation through formation of active GTP-bound p21(ras) mediated by the guanine nucleotide exchange factor Sos. Sos is constitutively bound to the adaptor protein Grb2 and growth factor stimulation induces association of the Grb2/Sos complex with She and movement of Sos to the plasma membrane location of p21(ras). Insulin or epidermal growth factor stimulation induces a rapid increase in p21(ras) levels, but after several minutes levels decline toward basal despite ongoing hormone stimulation. Here we show that deactivation of p21(ras) correlates closely with phosphorylation of Sos and dissociation of Sos from Grb2, and that inhibition of mitogen-activated protein (MAP) kinase kinase (also known as extracellular signal-related kinase (ERK) kinase, or MEK) blocks both events, resulting in prolonged p21(ras) activation. These data suggest that a negative feedback loop exists whereby activation of the Raf/MEK/MAP kinase cascade by p21(ras) causes Sos phosphorylation and, therefore, Sos/Grb2 dissociation, Limiting the duration of p21(ras) activation by growth factors. A serine/threonine kinase downstream of MEK (probably MAP kinase) mediates this desensitization feedback pathway.	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,RES SERV,SAN DIEGO,CA 92161; TOYAMA MED & PHARMACEUT UNIV,DEPT MED 1,TOYAMA 93001,JAPAN; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toyama; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1991, EMBO J, V5, P1103; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; DUDLEY DT, 1995, IN PRESS P NATL ACAD; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WATERS SB, 1995, MOL CELL BIOL, V15, P2791	36	161	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25320	25323		10.1074/jbc.270.43.25320	http://dx.doi.org/10.1074/jbc.270.43.25320			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592690	hybrid			2022-12-25	WOS:A1995TB46600006
J	HAGEN, G; DENNIG, J; PREISS, A; BEATO, M; SUSKE, G				HAGEN, G; DENNIG, J; PREISS, A; BEATO, M; SUSKE, G			FUNCTIONAL ANALYSES OF THE TRANSCRIPTION FACTOR SP4 REVEAL PROPERTIES DISTINCT FROM SP1 AND SP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; DNA-BINDING; GEL-ELECTROPHORESIS; MAMMALIAN-CELLS; ACTIVATION; DROSOPHILA; CLONING; DOMAINS; EXPRESSION; ELEMENT	Sp4 is a human sequence-specific DNA binding protein with structural features similar to those described for the transcription factors Sp1 and Sp3. These three proteins contain two glutamine-rich regions and a highly conserved DNA binding domain composed of three zinc fingers. Consistently, Sp1, Sp3, and Sp4 do have the same DNA binding specificities. In this report, we have embarked on a detailed analysis of the transcriptional properties of Sp4 in direct comparison to Sp1 and Sp3. Cotransfection experiments into Drosophila SL2 cells lacking endogenous Sp factors demonstrate that Sp4 is an activator protein like Sp1. However, in contrast to Sp1, Sp4 is not able to act synergistically through adjacent binding sites. The transactivation function of Sp4 resides, like that of Sp1, in the N-terminal glutamine-rich region. Sp4 can function as a target for the Sp1 activation domains in a superactivation assay, suggesting that the activation domains of Sp1 and Sp4 are functionally related. Furthermore, we show that Sp4-mediated transcriptional activation can be repressed by Sp3. Taken together, our results demonstrate that the transcription factor Sp4 exhibits specific functional properties distinct from Sp1 and Sp3.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222; Suske, Guntram/0000-0002-4807-0513				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1986, TRENDS BIOCHEM SCI, V11, P395, DOI 10.1016/0968-0004(86)90149-0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMATAKA H, 1992, EMBO J, V11, P3653; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Suske Guntram, 1992, Gene Expression, V2, P339	29	190	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24989	24994		10.1074/jbc.270.42.24989	http://dx.doi.org/10.1074/jbc.270.42.24989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559627	hybrid			2022-12-25	WOS:A1995TB46500061
J	HOE, MH; SLUSAREWICZ, P; MISTELI, T; WATSON, R; WARREN, G				HOE, MH; SLUSAREWICZ, P; MISTELI, T; WATSON, R; WARREN, G			EVIDENCE FOR RECYCLING OF THE RESIDENT MEDIAL/TRANS GOLGI ENZYME, N-ACETYLGLUCOSAMINYLTRANSFERASE-I, IN LDLD-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; O-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; CYTOPLASMIC DOMAIN; MANNOSIDASE-II; OKADAIC ACID; FREE SYSTEM; TRANSPORT; APPARATUS	ldlD cells, which lack the UDP-Gal/UDP-GalNAc 4-epimerase, were stably transfected with a Myc-tagged version of N-acetylglucosaminyltransferase I (Myc-Glc-NAc-T I). In the absence of GalNAc and Gal, newly synthesized GlcNAc-T I did not acquire O-linked oligosaccharides but was catalytically active and was transported to the Golgi region as defined using both immunofluorescence and immunoelectron microscopy. After addition of cycloheximide to prevent further synthesis, GalNAc and Gal were added, and the unglycosylated GlcNAc-T I was found to acquire mature, O-linked oligosaccharides with a half-time of about 150 min. The addition of these sugars was sensitive to N-ethylmaleimide and okadaic acid, both inhibitors of vesicle-mediated traffic. Together, these results suggest that Myc-GlcNAc-T I undergoes retrograde transport to the early part of the Golgi apparatus where the first O-linked sugar, GalNAc, is added followed by anterograde transport back to the Golgi stack, where addition of Gal and sialic acid occurs.	IMPERIAL CANC RES FUND, CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALCALDE J, 1994, J CELL BIOL, V124, P649, DOI 10.1083/jcb.124.5.649; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; CANAANI D, 1982, P NATL ACAD SCI-BIOL, V79, P5166, DOI 10.1073/pnas.79.17.5166; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JOHNSTON PA, 1994, J CELL SCI, V107, P529; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUCOCQ J, 1991, J CELL SCI, V100, P753; MISTELI T, 1995, J CELL SCI, V108, P2715; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; SOUTHERN PJ, 1981, IN VITRO, V18, P315; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; WERTZ GW, 1989, J VIROL, V63, P4767, DOI 10.1128/JVI.63.11.4767-4776.1989; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG SH, 1993, J BIOL CHEM, V268, P22853; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	67	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25057	25063		10.1074/jbc.270.42.25057	http://dx.doi.org/10.1074/jbc.270.42.25057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559636	hybrid			2022-12-25	WOS:A1995TB46500070
J	YAMADA, K; HARADA, N; HONDA, S; TAKAGI, Y				YAMADA, K; HARADA, N; HONDA, S; TAKAGI, Y			REGULATION OF PLACENTA-SPECIFIC EXPRESSION OF THE AROMATASE CYTOCHROME-P-450 GENE - INVOLVEMENT OF THE TROPHOBLAST-SPECIFIC ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; TISSUE-SPECIFIC EXPRESSION; HUMAN SKIN FIBROBLASTS; ADIPOSE STROMAL CELLS; MESSENGER-RNA; GRANULOSA-CELLS; MAMMALIAN-CELLS; ALTERNATIVE USE; PHORBOL ESTERS; CYCLIC-AMP	The aromatase (cytochrome P-450(AROM)) gene contains multiple untranslated exons I that are differentially transcribed in a tissue-specific manner. DNA sequences within the initial -301 upstream of placenta-specific exon I (exon Ia) are sufficient for placenta-specific expression of aromatase. In gel mobility shift assay, three separate domains in this region form specific binding complexes with proteins extracted from choriocarcinoma JEG-3 nuclei. A fragment containing these domains activates transcription driven by a heterologous promoter in a cell type-specific manner. Two of the binding domains that form major complexes in gel shift assay compete with each other and with a DNA fragment containing the trophoblast-specific element (TSE), which is derived from the enhancer region of the human chorionic gonadotropin alpha-subunit gene and is believed to confer placenta-specific expression of the gene. The core sequence RNCCTNNRG is sufficient for recognition of the TSE-binding protein, which is detected only in nuclear extracts prepared from placenta and choriocarcinoma. A mutation introduced in the distal TSE core in aromatase promoter resulted in marked reduction of transcriptional activity, although TSE region by itself did not show enhancer activity as that in human chorionic gonadotropin alpha-subunit gene.			YAMADA, K (corresponding author), FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV MOLEC GENET,TOYOAKE,AICHI 47011,JAPAN.							ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BERKOVITZ GD, 1992, J CLIN ENDOCR METAB, V74, P629, DOI 10.1210/jc.74.3.629; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROSS JC, 1994, MOL BIOL CELL S, V5, P453; DANIEL SAJ, 1980, ENDOCRINOLOGY, V107, P1027, DOI 10.1210/endo-107-4-1027; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DORRINGTON JH, 1975, P NATL ACAD SCI USA, V72, P2677, DOI 10.1073/pnas.72.7.2677; EVANS CT, 1987, J BIOL CHEM, V262, P6914; GARZO VG, 1984, AM J OBSTET GYNECOL, V148, P657, DOI 10.1016/0002-9378(84)90769-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P757; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HARADA N, 1988, J BIOCHEM-TOKYO, V103, P106, DOI 10.1093/oxfordjournals.jbchem.a122213; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HOLLENBERG AN, 1994, MOL CELL ENDOCRINOL, V106, P111, DOI 10.1016/0303-7207(94)90192-9; HONDA S, 1994, BIOCHEM BIOPH RES CO, V198, P1153, DOI 10.1006/bbrc.1994.1163; ITO A, 1990, BIOCHEM INT, V22, P235; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; KRASNOW JS, 1990, MOL ENDOCRINOL, V4, P13, DOI 10.1210/mend-4-1-13; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MENDELSON CR, 1982, ENDOCRINOLOGY, V111, P1077, DOI 10.1210/endo-111-4-1077; MENDELSON CR, 1986, ENDOCRINOLOGY, V118, P968, DOI 10.1210/endo-118-3-968; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NAFTOLIN F, 1972, ENDOCRINOLOGY, V90, P295, DOI 10.1210/endo-90-1-295; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; RITVOS O, 1992, ENDOCRINOLOGY, V130, P61, DOI 10.1210/en.130.1.61; ROSELLI CE, 1985, ENDOCRINOLOGY, V117, P2471, DOI 10.1210/endo-117-6-2471; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; TJAN R, 1994, CELL, V77, P5; TODA K, 1992, EUR J BIOCHEM, V205, P303, DOI 10.1111/j.1432-1033.1992.tb16781.x; TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; VALLADARES LE, 1979, P NATL ACAD SCI USA, V76, P4460, DOI 10.1073/pnas.76.9.4460; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YAMADA K, 1994, CYTOCHROME P450, P651	44	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25064	25069		10.1074/jbc.270.42.25064	http://dx.doi.org/10.1074/jbc.270.42.25064			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559637	hybrid			2022-12-25	WOS:A1995TB46500071
J	CHAKICHERLA, A; HANSEN, JN				CHAKICHERLA, A; HANSEN, JN			ROLE OF THE LEADER AND STRUCTURAL REGIONS OF PRELANTIBIOTIC PEPTIDES AS ASSESSED BY EXPRESSING NISIN-SUBTILIN CHIMERAS IN BACILLUS-SUBTILIS-168, AND CHARACTERIZATION OF THEIR PHYSICAL, CHEMICAL, AND ANTIMICROBIAL PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; ANTIBACTERIAL PEPTIDES; ANTIBIOTIC SUBTILIN; PRECURSOR; MECHANISMS; DEFENSINS; CECROPINS; BACTERIAL; VARIANT; CELLS	Biosynthesis of lantibiotics such as nisin and subtilin involves post-translational modifications, including dehydration of serines and threonines, formation of thioether cross-linkages, translocation, cleavage of a leader sequence, and release into the medium, We have studied the cellular machinery that performs the modifications by constructing and expressing nisin-subtilin chimeric prepeptides in a strain of Bacillus subtilis 168 that possesses all of the cellular machinery for making subtilin except for the presubtilin gene, The chimeras consisted of a normal subtilin leader region (SL), fused to nisin subtilin chimeric structural regions, one of which was S-L-Nis(1-11)-Sub(12-32), in which the N-terminal portion of the structural region was derived from nisin, and the C-terminal portion derived from subtilin, This chimera was accurately and efficiently converted to the corresponding mature lantibiotic, as established by reverse phase high performance liquid chromatography profiles, proton NMR spectroscopy, mass spectral analysis, and biological activity, A succinylated form of the chimera was also produced, Another chimera was in the reverse sense, with subtilin sequence at the N terminus and nisin sequence at the C terminus of the structural region (S,(L)-Sub(1-11)-Nis(12-34)). It was processed into a heterogeneous mixture of products, none of which had the characteristics of a correctly processed polypeptide, but did contain a minor component that was active, with a specific activity that considerably exceeded nisin itself. These results, together with results published earlier, establish that processing requires specific recognition between the prelantibiotic peptide and the processing machinery, and in order for the processing to occur correctly, there must be an appropriate combination of the N-terminal part of the leader region and the C-terminal part of the structural region of the prepeptide.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI024454, R01AI024454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24454] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BENZ R, 1991, NISIN NOVEL LANTIBIO, P359; BEVINS CL, 1994, CIBA F SYMP, V186, P250; BOMAN HG, 1985, DEV COMP IMMUNOL, V9, P551, DOI 10.1016/0145-305X(85)90018-7; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CHAN WC, 1993, BIOCHEM J, V291, P23, DOI 10.1042/bj2910023; Cuervo J H, 1988, Pept Res, V1, P81; FEENEY RE, 1948, ARCH BIOCHEM, V17, P435; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P810; GROSS E, 1978, ANTIBIOTICS ISOLATIO, P415; Gross E, 1975, PEPTIDES CHEM STRUCT, P31; HANSEN JN, 1993, ANNU REV MICROBIOL, V47, P535, DOI 10.1146/annurev.micro.47.1.535; HANSEN JN, 1994, CRIT REV FOOD SCI, V34, P69, DOI 10.1080/10408399409527650; Hansen JN, 1991, NISIN NOVEL LANTIBIO, P287; HAWKINS G, 1990, THESIS MARYLAND COLL; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; KORDEL M, 1989, FEBS LETT, V244, P99, DOI 10.1016/0014-5793(89)81171-8; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V3330, P23; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LEPAGE P, 1991, EUR J BIOCHEM, V196, P735, DOI 10.1111/j.1432-1033.1991.tb15872.x; LIU W, 1992, J BIOL CHEM, V267, P25078; LIU W, 1990, APPL ENVIRON MICROB, V56, P2551, DOI 10.1128/AEM.56.8.2551-2558.1990; LIU W, 1993, APPL ENVIRON MICROB, V59, P648, DOI 10.1128/AEM.59.2.648-651.1993; MARSH J, 1991, CIBA F S, V186; MORISHIMA I, 1990, COMP BIOCHEM PHYS B, V95, P551, DOI 10.1016/0305-0491(90)90019-P; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; MORRIS SL, 1984, J BIOL CHEM, V21, P13590; RINTALA H, 1993, BIOTECHNOL LETT, V15, P991, DOI 10.1007/BF00129923; SAHL HG, 1994, CIBA F SYMP, V186, P27; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULLER F, 1989, EUR J BIOCHEM, V182, P181, DOI 10.1111/j.1432-1033.1989.tb14815.x; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; VANDERMEER JR, 1994, J BIOL CHEM, V269, P3555; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	39	45	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23533	23539		10.1074/jbc.270.40.23533	http://dx.doi.org/10.1074/jbc.270.40.23533			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559517	hybrid			2022-12-25	WOS:A1995RY90900046
J	ROBACHEGALLEA, S; MORAND, V; BRUNEAU, JM; SCHOOT, B; TAGAT, E; REALO, E; CHOUAIB, S; ROMANROMAN, S				ROBACHEGALLEA, S; MORAND, V; BRUNEAU, JM; SCHOOT, B; TAGAT, E; REALO, E; CHOUAIB, S; ROMANROMAN, S			IN-VITRO PROCESSING OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL SERINE PROTEINASE; WEGENERS GRANULOMATOSIS; ANTICYTOPLASMIC ANTIBODIES; TARGET ANTIGEN; LEUKOCYTE PROTEINASE; PROTEASE INHIBITOR; FACTOR SECRETION; AUTOANTIBODIES; CLEAVAGE; CLONING	Tumor necrosis factor (TNF)-alpha is initially synthesized as a membrane-bound, cell-associated 26 kDa protein that is further cleaved to yield the soluble 17-kDa form. By using a radiolabeled in vitro translated TNF-alpha precursor we detected a serine proteinase processing activity present in crude membrane preparations of monocytic cells able to generate a 17-kDa active protein. A similar processing pattern was obtained using purified neutral serine proteinase proteinase 3 (PR-3). Moreover, while a secretory leukocyte proteinase inhibitor (a natural serine anti-proteinase) did not affect the in vitro TNF-alpha processing, IgG preparations containing high titers of anti-PR-3 autoantibodies completely blocked this activity. The NH2-terminal sequencing of the reaction products obtained with either membrane preparations or PR-3 showed that cleavage occurs in both cases between Val(77) and Arg(78). These results together with cellular expression and localization of PR-3 suggest a potential role for this enzyme as an accessory TNF-alpha processing enzyme.	ROUSSEL UCLAF, DOMAINE THERAPEUT IMMUNOL, F-93230 ROMAINVILLE, FRANCE; ROUSSEL UCLAF, RECH CENT, F-93230 ROMAINVILLE, FRANCE; INST GUSTAVE ROUSSY, INSERM, CJF 9411, F-94805 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy			Roman-Roman, Sergio/K-9993-2014; Chouaib, Salem/F-7939-2016	Roman-Roman, Sergio/0000-0001-6459-2613; 				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; BALLIEUX BEPB, 1994, EUR J IMMUNOL, V24, P3211, DOI 10.1002/eji.1830241245; BRAUN MG, 1991, AM J PATHOL, V139, P831; BRUBAKER MJ, 1992, BIOCHEM BIOPH RES CO, V188, P1318, DOI 10.1016/0006-291X(92)91375-Z; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHIDWICK K, 1994, ARTHRITIS RHEUM, V37, P1723, DOI 10.1002/art.1780371203; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; CSERNOK E, 1994, CLIN EXP IMMUNOL, V95, P244; CSERNOK E, 1990, AM J PATHOL, V137, P1113; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; HENSHAW TJ, 1994, ARTHRITIS RHEUM, V37, P104, DOI 10.1002/art.1780370116; JENNETTE JC, 1990, BLOOD, V75, P2263; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KIM KU, 1993, IMMUNOLOGY, V80, P134; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEID RW, 1993, EUR J IMMUNOL, V23, P2939, DOI 10.1002/eji.1830231132; LUDEMANN J, 1990, J EXP MED, V171, P357, DOI 10.1084/jem.171.1.357; MAYET WJ, 1993, BLOOD, V82, P1221; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; NIERORSTER M, 1990, BIOCHEM PHARMACOL, V40, P1601; NILES JL, 1989, BLOOD, V74, P1888; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RAO NV, 1991, J BIOL CHEM, V266, P9540; RAO NV, 1993, AM J RESP CELL MOL, V8, P612, DOI 10.1165/ajrcmb/8.6.612; RENESTO P, 1994, J IMMUNOL, V152, P4612; SCUDERI P, 1989, EUR J IMMUNOL, V19, P939, DOI 10.1002/eji.1830190523; SCUDERI P, 1989, J IMMUNOL, V143, P168; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VANDEWIEL BA, 1992, CLIN EXP IMMUNOL, V90, P409; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324	38	97	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23688	23692		10.1074/jbc.270.40.23688	http://dx.doi.org/10.1074/jbc.270.40.23688			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559538	hybrid			2022-12-25	WOS:A1995RY90900067
